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Preface 
Brain injury remains one of the most difficult and challenging problems facing many 
researchers, clinicians and experts involved in care of these patients. The present two
volume book “Brain Injury” is distinctive in its presentation and includes a wealth of
updated information for professionals on the high quality research on many aspects in
the field of brain injury as well as addresses the most difficult and challenging issues 
in the management and rehabilitation of brain injured patients. The Brain Injury - 
Pathogenesis, Monitoring, Recovery and Management  contains 5 sections and a total 
26 chapters devoted to pathogenesis of brain injury, concepts in cerebral blood flow
and metabolism, investigative approaches and monitoring of brain injured, different 
protective mechanisms and recovery and management approach to these individuals 
and Book Two contains (3 sections) 12 chapters devoted to functional and endocrine
aspects of brain injuries, approaches to rehabilitation of brain injured and preventive
aspects of traumatic brain injuries. 
Chapters in the book discus current understandings and experimental approaches, 
emerging role of innate and adaptive immunity, genetic effects among measures of
cognitive function,  compensatory neurogenesis in injured adult brain. Further the
issues discussed include effects of melatonin and Alzheimer’s factors on brain injury, 
lleukocyte response and immediate outcome in traumatic brain injury. Chapters 8 to
10 discuss the experimental models of ischemia, quantitative cerebral blood flow 
assessment and MRI characterization of progressive brain alterations after 
experimental traumatic brain injury. Chapters 11-14 address the issues in
neurointensive care monitoring, dynamic visualization technology in brain 
deceleration injury research, experimental technology on the brain impact injuries and
non-invasive bedside monitoring of cerebral blood flow and oxygen metabolism with 
near-infrared spectroscopy respectively. In Section IV protective mechanisms of
neuroprotection in ischemia/reperfusion Injury and the issues of recovery have been
discussed in details. Section V conservative as well operative management approaches
to treat brain injury have been discussed. The role of decompressive craniectomy
especially discussed in details.
I hope that collective contribution from experts in brain injury research area would be 
successfully conveyed to the readers and readers will find this book to be a valuable 
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 Part 1 
Understanding Pathogenesis 
 1 
Current Understanding and  
Experimental Approaches to the  
Study of Repetitive Brain Injury 
John T. Weber 
Memorial University of Newfoundland 
Canada 
1. Introduction 
Repetitive traumatic brain injury (TBI) occurs in a considerable number of individuals  
in the general population, such as athletes involved in contact sports (e.g. boxing, football, 
hockey and soccer), or child abuse victims. Repeated mild injuries, such as concussions, 
may cause cumulative damage to the brain and result in long-term cognitive dysfunction. 
The growing field of repetitive TBI research is reflected in the increased media attention 
given to reporting incidences of athletes suffering multiple blows to the head, and  
in several recent experimental studies of repeated mild TBI in vivo. Experimental reports 
generally demonstrate cellular and cognitive abnormalities after repetitive injury  
using rodent TBI models. In some cases, data suggests that the effects of a second mild 
TBI may be synergistic, rather than additive. In addition, some studies have found 
increases in cellular markers associated with Alzheimer’s disease after repeated mild 
injuries, which demonstrates a direct experimental link between repetitive TBI and 
neurodegenerative disease. To complement the findings from humans and in vivo 
experimentation, my laboratory group has investigated the effects of repeated trauma in 
cultured brain cells using an in vitro model of stretch-induced mechanical injury. In these 
studies, cells exhibit cumulative damage when receiving multiple mild injuries. 
Interestingly, the extent of damage to the cells is dependent on the time between repeated 
injuries. Although direct comparisons to the clinical situation are difficult to make, these 
types of repetitive, low-level, mechanical stresses may be similar to insults received  
by certain athletes, such as boxers, or hockey and soccer players. As this field of TBI 
research continues to evolve and expand, it is essential that experimental models  
of repetitive injury replicate injuries in humans as closely as possible. For example, it  
is important to appropriately model concussive episodes versus even lower-level injuries 
(such as those that might occur during boxing matches or by heading a ball repeatedly  
in soccer). Suitable inter-injury intervals are also important parameters to incorporate  
into studies. Additionally, it is essential to design and utilize proper controls, which  
can be more of a challenge than experimental approaches to single mild TBI. These issues, 
as well as an overview of findings from repeated TBI research, are discussed in  
this chapter. 
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2. Overview of TBI 
2.1 Occurrence and impact of TBI 
Traumatic brain injury (TBI) is an insult to the brain caused by an external physical force, 
resulting in functional disability. Falls and motor vehicle accidents are the primary causes of 
TBI, while sports, assaults and gunshot wounds also contribute significantly to these types 
of injuries (Centre for Disease Control, 2010). TBI is one of the leading causes of death and 
disability worldwide, including the developing world (Reilly, 2007). In the United Kingdom, 
an estimated 200-300 per 100,000 people are hospitalized every year due to a TBI (McGregor 
& Pentland, 1997) and the incidence is reported as even higher in southern Australia and 
South Africa (Hillier et al., 1997; Nell & Brown, 1991). Although it has been difficult to 
compile reliable statistics on the prevalence and incidence of TBI in Canada (Tator, 2010), 
estimates in the United States suggest that between 1.4 and 1.7 million Americans sustain a 
TBI each year, accounting for 50,000 deaths and 80,000 to 90,000 individuals who suffer from 
long-term disability (Centre for Disease Control, 2010; Thurman & Guerrero, 1999). In 
Europe, it is estimated that at least 11.5 million individuals are suffering long-term 
disabilities related to a TBI (Schouten, 2007). In addition, TBI is considered to be a robust 
risk factor for the further development of neurodegenerative diseases, such as Alzheimer’s 
disease (Slemmer et al., 2011), leading to additional dysfunction. Financially, the costs of TBI 
to society are no less distressing.  Over two decades ago, an estimated 37.8 billion dollars 
was spent on direct costs related to hospital care in the U.S., or on indirect costs related to 
work loss due to disability (Max et al. 1991), and this cost has likely increased substantially.  
Due to the enormous impact TBI has on human health and health care systems in general 
throughout the world, understanding the mechanics and pathophysiology involved in TBI 
is essential for developing successful acute and long-term therapeutic strategies. 
2.2 Repetitive mild TBI 
TBI is characterized as mild, moderate or severe. Mild TBI, i.e. concussion, accounts for 70-
90% of all TBI cases and 15-20% of individuals with a mild TBI have long-term dysfunction 
(Ryu et al, 2009). Although individuals who have experienced a moderate or severe TBI are 
certainly at risk of a second insult (Saunders et al., 2009), repetitive injuries occur in a 
considerable portion of individuals who have experienced a mild TBI. Child abuse victims, 
as well as victims of spousal abuse, are often subjected to multiple injuries to the head 
(Roberts et al., 1990; Shannon et al., 1998). Many injuries of these types go unreported, and it 
is difficult to assess how many insults a patient may have suffered. Arguably, athletes 
represent the largest group of patients that are at risk for experiencing repeated brain 
injuries, especially concussions (Guskiewicz et al., 2000; Kelly, 1999; Kelly & Rosenberg, 
1997; Powell and Barber-Foss, 1999). Also, in comparison to child or spousal abuse victims, 
there is generally better documentation of how many brain injuries an individual has 
sustained due to recreational or sports related activities, making this population easier to 
study.  
The idea that multiple head injuries in athletes could lead to clinical problems has long been 
suggested. For example, many clinicians believe that the development of dementia pugilistica 
in professional boxers is caused by the multiple hits to the head that a boxer endures over 
the course of their career (Jordan, 2000). Also, studies have shown that the number of 
concussions is inversely related to performance on several neuropsychological tests in soccer 
players (Matser et al., 1999; 2001), and jockeys that have experienced multiple concussions 
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generally display more cognitive dysfunctions than those who have had a single injury 
(Wall et al. 2006). An association between repetitive concussions and cognitive impairment, 
as well as clinical depression, has been demonstrated in professional football players in the 
United States (Guskiewicz et al., 2005; 2007). In Canada, the occurrence of concussion in ice 
hockey has been in the press substantially in recent months. The incidence of concussions in 
hockey appears to be on the rise not only in the National Hockey League, but also at the 
junior level (Ackery et al., 2009; Echlin et al., 2010). Many of these players have repeated 
concussions and suffer from post concussion symptoms such as memory impairment, 
headaches and depression (Ackery et al., 2009). As with boxers, there is evidence that 
repeated concussions may increase the risk of developing dementia later in life (De 
Beaumont et al., 2009). Therefore, it is important to understand the processes underlying the 
pathology of repetitive TBI. 
3. Experimental approaches to the study of repetitive TBI  
When studying repetitive brain trauma in athletes, we can gain much information about the 
pathology and progress of such injuries from the injured athletes themselves, e.g. by 
measuring changes in cognitive and motor performance. However, these injuries are 
generally at a mild level, and therefore, except in rare cases when athletes die as a result of 
the insult, we cannot assess the changes that have actually occurred in the brain at the 
cellular and sub-cellular levels. In order to compile this type of information, we must turn to 
experimental models of TBI.  
3.1 In vivo studies 
When discussing experimental studies of repetitive TBI in vivo, this does not include studies 
of secondary insults, such as a mechanical insult to the head followed by a defined duration 
of ischemia or glutamate exposure. Repeated TBI experimentation consists of an initial 
mechanical injury to the head followed by another mechanical insult to the head of the same 
or different degree. Based on these criteria, there were very few of these types of 
experiments conducted before the year 2000, with only a handful of repetitive injury studies 
being published (Kanayama et al., 1996; Olsson et al., 1976; Weitbrecht & Noetzel, 1976). 
Several additional in vivo studies of repeated injuries in rodents have now been conducted 
over the past decade (Allen et al., 2000; Conte et al., 2004; Creeley et al., 2004; DeFord et al., 
2002; Friess et al., 2009; Huh et al., 2007; Laurer et al., 2001; Longhi et al., 2005; Raghupathi et 
al., 2004; Shitaka et al., 2011; Uryu et al., 2002; Yoshiyama et al., 2005). All of these repeated 
mild injury studies were conducted using rodent models of TBI with the exception of the 
studies by Friess et al (2009) and Raghupathi et al (2004), which used a pediatric model of 
repeated injury in pigs.  
Repetitive TBI generally occurs at a mild level, therefore experimental models have been 
used which are minimally invasive and do not require a craniotomy, such as weight drop 
models or other forms of closed-skull TBI. The models must also be administered at a level 
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storage. Experimental and clinical data have demonstrated not only the importance of this 
brain region in learning and memory, but also that the hippocampus is uniquely vulnerable 
to injury, even after mild brain trauma (Lowenstein et al., 1992; Lyeth et al., 1990). In a study 
by DeFord et al. (2002), repeated mild injuries were administered to mice (four times every 
24 hr), followed by MWM testing and histological analysis. Significant learning deficits were 
found after repeated injuries, which were not evident after a single injury. These deficits 
occurred even in the absence of cell death within the cortex and hippocampus. Cognitive 
deficits after multiple mild TBIs (using MWM analysis) were demonstrated in a similar 
study using a weight drop model (Creeley et al., 2004). In a recent study, Shitaka et al. (2011) 
used a controlled cortical impact model in mice and found that animals receiving two 
injuries 24 hr apart displayed MWM deficits for several weeks. In addition, although no 
gross histological abnormalities were noted, mice that received two insults had damaged 
axons in various brain areas, which could underlie the cognitive abnormalities.  
In one of the early studies of repeated injury in vivo, Laurer et al. (2001) used an injury 
regimen that they described as “concussive”. This model was meant to mimic the type of 
insult that athletes may receive, and was also used for many subsequent studies (Conte et 
al., 2004; Longhi et al., 2005; Uryu et al., 2002). In an assessment of cognitive and motor 
function after repeated injury in mice, Laurer et al. (2001) found that the brain was more 
vulnerable to a second insult if the second injury occurred 24 hr after the first. Even though 
no cognitive deficits were demonstrated in mice receiving repeated injuries, there was a 
decrease in motor function and neuronal loss. The authors also stated that the effects of a 
second mTBI could be synergistic, rather than additive. To further analyze the effects of 
lengthening the inter-injury interval, Longhi et al. (2005) investigated repetitive injuries 
three, five and seven days apart. Animals that received repeated injuries three or five days 
apart exhibited cognitive dysfunction not evident in sham animals or those injured only 
once. However, no deficits were observed when the injury interval was extended to seven 
days. This experimental evidence demonstrating that the brain can recover from a first 
injury, given sufficient amount of time, is certainly alluring, especially in relation to 
establishing “return-to-play” guidelines for athletes. Overall, the evidence from these in vivo 
experimental models suggests that repetitive mild TBI causes more cognitive and cellular 
dysfunction than a single injury, if the brain is not given a sufficient amount of time to 
recover.  
Other in vivo studies have been conducted with a primary interest in discovering more 
about the pathology of inflicted repetitive brain injury in the pediatric population, such as 
‘shaken impact syndrome’ (Friess et al., 2009; Huh et al., 2007; Raghupathi et al., 2004). In a 
study by Raghupathi et al. (2004), neonatal pigs were subjected to rapid axial rotations of the 
head, either once, or twice within 15 minutes. Brains were analyzed at 6 hr post-injury and 
animals that had received double insults exhibited a wider distribution of injured axons 
than animals that were injured once. In another study in piglets (Friess et al., 2009), animals 
were injured (by axial head rotation) either once, twice one day apart, or twice one week 
apart. Animals injured one day apart had the highest mortality rate. Also, animals receiving 
two injuries had worse neuropathology and neurobehavioral outcome than those injured 
only once. Huh et al. (2007) conducted experiments in young rats (11 days old) and 
administered one, two or three injuries spaced only 5 minutes apart. Animals receiving 
multiple injuries generally displayed increased axonal damage, which was evident earlier 
after injury than a single impact. Overall, these studies suggest a graded response to 
repeated injury in the pediatric brain.  
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3.2 Studies conducted in vitro 
Several in vitro approaches have now been developed to study traumatic injury, which 
utilize dissociated brain cells or slices grown in culture (LaPlaca et al., 2005; Morrison et al., 
1998; Noraberg et al., 2005; Spaethling et al., 2007; Weber, 2004). For many years, my 
laboratory group has utilized an in vitro model of stretch-induced mechanical injury 
originally developed by Ellis et al. (1995). We have characterized this stretch injury model in 
cell cultures composed of neurons and glia from murine hippocampus (Slemmer et al., 2002; 
Slemmer & Weber, 2005), cortex (Engel et al., 2005), and cerebellum (Slemmer et al., 2004), 
and currently in cortical cultures from rat pups.  
We have previously conducted studies investigating the effects of repeated trauma on 
cultured hippocampal cells (Slemmer et al., 2002; Slemmer & Weber, 2005), which were 
intended to complement the findings from humans and in vivo experimentation. In these 
studies, we utilized a mild level of stretch injury that produces some measurable damage 
to cells when administered a single time. When mild stretch injuries were repeated at 
either 1-hr or 24-hr intervals, cells exhibited cumulative damage. For example, cultures 
that received a second insult displayed a significant loss of neurons not evident in 
cultures that received only one injury (see Figure 1).  Additionally, cultures injured twice 
released a significant level of neuron specific enolase (NSE), which was not observed in 
cultures injured a single time. Interestingly, the extent of damage to the cells was 
dependent on the time between repeated injuries. For example, cultures that received a 
second insult 1 hr after the first injury released more S-100B protein (a biomarker of injury 
commonly employed in the clinic) than cultures that received a second injury at 24 hr.  
Cultures injured 24 hr apart also exhibited less staining with the intravital dye, propidium 
iodide, than those injured 1 hr apart. As demonstrated in some in vivo studies, these 
findings suggest that a level of injury producing measurable damage or dysfunction on its 
own, may cause cumulative damage if repeated within a certain time frame (Laurer et al., 
2001; Longhi et al., 2005). 
We also investigated the effects of a very low level of stretch, which produces no overt cell 
damage (Slemmer and Weber, 2005). This “subthreshold” level of stretch did not cause 
significant damage or death, even when it was repeated at a 1 hr interval. However, this low 
level of stretch did induce cell damage when it was repeated several times at a short interval 
(every 2 min), indicated by increased propidium iodide staining (a marker of cellular 
injury), neuronal loss, and an increase in NSE release. Although direct comparisons to the 
clinical situation are difficult to make, these types of repetitive, low-level, mechanical 
stresses may be similar to the insults received by certain athletes, such as boxers, and hockey 
and soccer players (Jordan, 2000; Matser et al., 1998; Matser et al., 1999; Webbe & Ochs, 2003; 
Wennberg & Tator, 2003). This type of in vitro model may provide a reliable system in which 
to study the mechanisms underlying cellular dysfunction following repeated injuries. In 
addition, this approach could provide a means for rapid screening of potential therapeutic 
strategies for both single and repeated mild TBI. 
Another study of repeated injury in vitro used a model of axonal injury (Yuen et al., 2009). 
Low levels of strain to cortical axons in culture resulted in no obvious pathological 
changes. By 24 hr however, these axons exhibited increased sodium channel expression. 
When axons were stretched again at 24 hr, there was a significant increase in intracellular 
calcium, which led to degeneration of the axons. This finding suggests a possible 
mechanism underlying the susceptibility of the brain to a second impact within a certain 
temporal window. 
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Fig. 1. Effect of repeated stretch injury on hippocampal cells in culture. Cell injury was 
assessed using the two dyes fluorescein diacetate (FDA) and propidium iodide (PrI). FDA 
stains healthy, viable cells and fluoresces green, while PrI does not pass through intact 
cellular membranes. If membranes are damaged, however, cells lose their ability to retain 
FDA and PrI will enter the cell and bind to the nucleus, fluorescing red. (A) PrI uptake 
following mild stretch injury at 1 h post‐injury (B) A double mild insult increased PrI uptake 
when evaluated immediately after the second injury. Note that many cells also have beaded 
neurites. (A and B) Magnification: 100X. (C and D) Enlargements of A and B, respectively. 
Magnification: 200X. Modified from Slemmer et al. (2002). Reprinted with permission from 
Oxford Press, 2002. 
3.3 The preconditioning phenomenon 
Several studies have indicated that an initial, very mild insult to either cultured cells or to 
the brain itself, may provide some protection from a second, more severe insult, a finding 
that has been termed “preconditioning”. Ischemic preconditioning, in which a brief 
exposure to ischemia renders the brain more resistant to subsequent longer periods of 
ischemia, has been well described (for review, see Schaller & Graf, 2002). There is also 
evidence of preconditioning cross-tolerance. For example, brief ischemia lessens damage 
following TBI in vivo (Perez-Pinzon et al., 1999). More recently, several other types of 
pretreatments have been demonstrated to improve outcome and pathology after 
experimental TBI, such as a low dose of N-methyl-D-aspartate (Costa et al., 2010), exposure 
to lipopolysaccharide (Longhi et al., 2011) or glucagon (Fanne et al., 2011), hypothermia 
(Lotocki et al., 2006), as well as exposure to hyperbaric oxygen (Hu et al., 2008; 2010).  
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Another interesting phenomenon is that heat acclimation (chronic exposure to moderate 
heat) can also provide resistance to subsequent TBI (Shein et al. 2007; 2008; Umschwief et al., 
2010).  
In our in vitro studies using mechanical stretch, we observed a novel form of mechanical 
preconditioning. When hippocampal cultures were administered a subthreshold level of 
stretch 24 hr prior to a mild stretch, there was a significant decrease in released S-100B 
protein compared to cultures that were injured at a mild level alone (Slemmer & Weber, 
2005). This observation suggests some form of protection initiated by this low level of 
stretch. A similar finding in vivo was reported by Allen et al. (2000). In their study, rats 
received a series of mild injuries spaced three days apart using a weight drop model. Some 
of these animals received a severe injury after the repetitive mild injuries. Motor function 
deficits were evident in severely injured animals, but not in animals that received repeated 
mild injuries or repeated mild injuries followed by a severe injury. This last observation 
suggests a preconditioning effect. 
An important question is how do we utilize this information for beneficial means? One can 
imagine the ethical implications of suggesting to people that a mild insult to their brains 
may in fact protect them from worse insults in the future. We still have much to learn about 
preconditioning. For example, what is the threshold for mechanical insults between 
initiating protective versus damaging mechanisms in the brain? A clear understanding of 
the mechanisms by which this protection is elicited holds potential for the management of 
mild TBI. The fact that a wide variety of stressors can protect the brain from TBI (i.e. cross-
tolerance) suggests that the same, or similar mechanisms are responsible for the endogenous 
protection. Increasing the expression of these protective systems could not only be a reliable 
way for managing mild TBI, but could also provide resistance in individuals who may be at 
risk of sustaining an additional head injury, such as athletes. Both in vivo and in vitro models 
could provide reliable systems in which to study the mechanisms underlying the 
preconditioning phenomenon. 
4. Repetitive injury and neurodegenerative disease 
A correlation between the occurrence of TBI and the further development of 
neurodegenerative disease later in life has been recognized for several years, and TBI is 
considered to be one of the most robust risk factors for developing Alzheimer’s disease 
(AD; Szczygielski, et al., 2005; Slemmer et al., 2011). There is also evidence that genetic 
predisposition may increase one’s risk of developing AD, such as possession of the 
apolipoprotein E 4 allele (Isoniemi et al., 2006). A phenomenon known as chronic TBI 
occurs in a significant amount of professional boxers (Jordan, 2000), with the most serious 
form, the neurodegenerative disorder dementia pugilistica, resulting in severe cognitive 
and motor dysfunctions. A potential link between TBI and Parkinson’s disease has also 
been suggested (Masel and DeWitt, 2010). It is generally accepted that the pathology of 
AD and dementia pugilistica are quite similar (Geddes et al., 1999; Schmidt et al., 2001). 
Although epidemiological data linking TBI and neurogenerative diseases are quite strong, 
only a modest amount of experimental work has been conducted in order to achieve a 
mechanistic link between repeated mild TBI and the development of either AD or dementia 
pugilistica. 
In addition to cognitive symptoms, dementias such as dementia pugilistica and AD are 
associated with specific types of neuropathological markers. In fact, AD in humans can only 
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be fully confirmed post-mortem via the presence of extracellular senile plaques, which are 
abnormal amyloid β (Aβ) protein deposits, and abnormal tau protein aggregation in specific 
brain regions (Price et al., 1991). The tau protein is an important functional component of the 
cytoskeleton in healthy neurons, but it is also a predominant component of neurofibrillary 
plaques found in AD and dementia pugilistica (Schmidt et al., 2001). Therefore, the 
development of abnormal tau protein pathology is a potential molecular link between TBI 
and dementia. In a study by Kanayama et al (1996), rats were injured with a mild impact 
once a day for seven days. Analysis showed an increase in abnormal tau protein deposits by 
one month after injury. Yoshiyama et al. (2005) used a robust injury paradigm in an attempt 
to model human dementia pugilistica in transgenic mice expressing the shortest human tau 
isoform (T44). Mice were subjected to four injuries a day, once a week, for four weeks, 
resulting in each mouse receiving a total of 16 injuries, and surprisingly, they could find 
only one mouse that displayed pathology of dementia pugilistica at nine months of age. Partly 
for this reason, the vast majority of animal studies have focused on the deposition of Aβ, or 
the intracellular processing of amyloid precursor protein (APP), from which Aβ is derived. 
Although high levels of Aβ have clearly been demonstrated in AD patients, the exact 
function of amyloid protein has not been established. Interestingly, deposition of Aβ has not 
been observed in the majority of nontransgenic animal studies after trauma (Laurer et al., 
2001; Szczygielski, et al., 2005), and as a result, many of the current models used to 
investigate traumatic dementia are derived from transgenic rodents that were originally 
created to investigate AD. For example, the transgenic mouse Tg2576, which is characterized 
by AD-like amyloidosis by nine months of age, has been used in several investigations of 
repetitive mild TBI, and has become a popular animal model for traumatically-induced 
dementia. 
In a study by Uryu et al. (2002), Tg2576 transgenic mice subjected to repeated, but not to 
single mild TBI, displayed cognitive deficits and Aβ deposition. As shown in Figure 2, Aβ 
deposition did not occur in these mice at either 9 or 16 weeks post-sham injury. In contrast, 
brain slices from Tg2576 mice that underwent repeated mild TBI displayed evident Aβ 
deposition (in the form of senile plaques) at 16 weeks post-injury. The appearance of senile 
plaques followed a delayed time-scale, which is not surprising, as dementia is often 
manifested in humans long after TBI. This study also demonstrated that the transgenic 
background alone was not sufficient to induce marked amounts of Aβ deposition in these 
aged mice, which is in line with a “two-hit” hypothesis proposed by Nakagawa et al. (1999). 
In this case, the first-hit is the genetic predisposition, which enables an individual to 
produce high amounts of abnormal proteins such as Aβ, and the second-hit is the TBI.  
However, a single mild injury alone was not enough to produce AD-like pathology. It is 
therefore possible that more than one mild TBI is necessary to lead to dementia later in life, 
whereas a single moderate or severe TBI on its own may lead to dementia. Increased 
incidence of dementia in humans is obviously associated with increased age, and recent 
evidence links aging with the overproduction of free radicals via oxidative stress (Slemmer 
et al., 2008). TBI is also known to dramatically increase free radicals and reactive oxygen 
species (Slemmer et al., 2008, Weber, 2004). Repetitive, but not single mild TBI, has been 
previously shown to increase oxidative stress in Tg2576 mice (Uryu et al., 2002), which 
could be reduced by supplementing the rodent chow with vitamin E, a known antioxidant 
(Conte et al., 2004). Therefore, oxidative stress may be a major contributing factor leading to 
the development of neurodegenerative disease following TBI. 
 




Fig. 2. Amyloid deposition in Tg2576 mice with sham (A, B) or repetitive mild TBI (C, D) 
with 4G8 immunohistochemistry at 9 (A, C) and 16 (B, D) weeks after mild TBI. Senile 
plaques increased in an age-dependent manner in both sham and injured mice, but the 
largest number of Aβ-positive plaques are evident in the 16-week repetitive mild TBI mice 
(D). Modified from Uryu et al. (2002). Reprinted with permission from the Society for 
Neuroscience, 2002. 
The overall findings of these in vivo studies are quite significant, because they can 
demonstrate a direct experimental link between repeated mild TBI and the development of 
AD-like pathology, as well as other forms of dementia. Generally, it takes many years before 
the onset of symptoms of neurodegenerative disorders is evident, after an individual has 
experienced a TBI. Therefore, it requires an exceedingly long amount of time to gather this 
type of epidemiological data from the human population. This area of research, in 
particular, is where experimental models could truly help decipher the mechanisms by 
which neurodegenerative disease may be triggered by repetitive brain injury, and to 
identify potential therapeutic strategies. 
5. Future directions 
5.1 Potential new experimental directions  
The current lines of research in repetitive TBI should certainly be continued, such as 
attempting to firmly establish the link to neurodegenerative disease, as well as demonstrating 
appropriate recovery times after a mild injury. However, new avenues also need to be 
explored. For example, much experimental evidence suggests that animals demonstrate 
cognitive deficits and cellular dysfunction after repetitive mild TBI, even though the injury 
may not necessarily lead to cell death (DeFord et al., 2002; Kanayama et al., 1996). Therefore, 
rather than trying to prevent cells from dying after repeated injuries, it may be more useful to 
learn how to restore normal cellular physiology after a traumatic episode. Combining studies 
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at the cellular and behavioral levels is crucial for attaining this goal, and one area of potential 
interest is the evaluation of the effects of repeated TBI on synaptic plasticity in the cortex and 
hippocampus. The ability of neurons to undergo changes in synaptic strength, such as long-
term potentiation (LTP), is postulated to be a cellular correlate of learning and memory (Bliss 
& Collingridge, 1993; Malenka & Nicoll, 1999). Several studies have reported impaired 
hippocampal LTP after TBI in vivo (see Albensi, 2001; Weber, 2004). One area of future research 
could focus on restoring mechanisms of synaptic plasticity after injury (such as LTP), as well as 
correlated hippocampal-mediated behavioral tasks.  
The hippocampus shares neuronal projections with areas of the cerebral cortex, which 
undoubtedly also contributes to memory formation and storage. Indeed, alterations in 
synaptic plasticity may also occur directly in the cortex after repeated mild TBI. Therefore, 
although the hippocampus may play a central role in the cognitive dysfunction observed after 
mild TBI, it is important not to overlook contributions from other brain areas as well. Since 
some repeated injury studies demonstrate motor impairment, it may also be appropriate to 
investigate cellular physiology and synaptic plasticity in the cerebellum (see Hansel et al., 
2001; Weber et al., 2003; Slemmer et al., 2005) after repetitive TBI. These types of investigations 
could involve electrophysiology measurements as well as analysis of intracellular calcium 
dynamics. Intracellular calcium is extremely important to the normal function of neurons and 
can be considerably altered even in cells that do not go on to die (Weber, 2004; Yuen et al., 2009). 
5.2 Experimental design considerations 
Although deciding on appropriate research directions is of paramount importance to 
developing potential therapeutic strategies for repetitive TBI, the utilization of proper 
parameters for repeated injury studies may be just as crucial. For example, what are the best 
inter-injury interval, or intervals, to use? Although 24 hr between injuries is the most 
common (and perhaps practical) interval in the laboratory (Conte et al., 2004; Creeley et al., 
2004; DeFord et al., 2002; Friess et al., 2009; Kanayama et al., 1996; Laurer et al., 2001; Shitaka 
et al., 2011; Uryu et al., 2002; Weitbrecht & Noetzel, 1976; Yoshiyama et al., 2005), is it the 
most appropriate in mimicking what occurs in humans? Also, how many injuries should a 
researcher administer? If one is attempting to model concussive episodes, then two or three 
may be enough, as this may closely mimic a true situation, especially with athletes. 
However, when attempting to recreate dementia pugilistica (Yoshiyama et al., 2005), the 
number of injuries should certainly be increased, and perhaps be ‘subthreshold’ levels of 
injury, i.e. a level of injury which produces no overt damage on its own. 
The proper controls and endpoints to use for repeated injury studies also need to be carefully 
considered. For in vivo studies analyzing the effects of a single TBI, the issue of controls is fairly 
straightforward. Sham animals are treated at an equivalent time as injured animals, and the 
analysis, cellular or behavioral, is also performed at the same time-point. However, when 
comparing uninjured animals to animals that have received more than one injury, what is the 
proper comparison? For example, if an animal receives an injury on day one, and an additional 
injury on day two, and analysis takes place on day three, does one compare the data with 
sham animals from day one, or from day two (or both, see figure 3A)? The issue is further 
complicated when comparing repeatedly injured animals to animals that have received a 
single TBI. If the comparison concerns animals that undergo four injuries or a single injury, are 
the single insult animals injured at the same time as injury one in the repeated group, or at the 
same time as the fourth injury (see figure 3B)? This decision will affect the endpoint as well. 
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For example, if animals or tissue are analyzed one day after the fourth injury, then four days 
will have passed for the single injury group if those animals were injured on day one. This 
difference in time could affect the observations. One could argue that if a long enough period 
of time passes after the injuries, such as weeks or months, then the effect of when the single 
insult animals were injured will be negligible. Admittedly, this would be more proper for 
comparison to the human situation in which the effects of mild TBI can be manifested for 
weeks, months, or even years. However, this is often not practical for many laboratories, as the 
costs of housing animals for months can at times be prohibitive. Also, conducting long-term 
experiments in vitro is limited, since the cells generally remain viable for only a few weeks. 
This raises a critical point as to the relevance of repeated injury studies in vitro. I strongly 
believe that in vitro experiments can deliver information about the cellular mechanisms of 
repeated injury that are difficult to obtain in vivo, and that it is essential to combine data 
derived from in vitro experiments with those conducted with animals in vivo. However, I am 
unsure how to directly compare the data. For example, is a 24 hr injury interval in vitro 
equivalent to 24 hr in vivo? The greater consensus that exists on these issues with individuals 
who conduct repeated injury studies, the easier it will be to compare the data, and the stronger 
a case can be made for showing unequivocally, that repeated mild TBI could lead to long-term 
dysfunction in humans. 
 
 
Fig. 3. Issues for consideration when designing repeated TBI experiments (i.e. choosing 
proper timepoints for controls and behavioral/tissue analysis). T = time.  
From Weber (2007). Reprinted with permission from Elsevier, 2007. 
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5.3 Possible therapeutic interventions 
Perhaps one of the best, and most logical, therapeutic interventions that physicians can 
make especially when athletes are concerned is to not allow these individuals to return to 
play until they seem to have fully recovered from a mild injury/concussion. This would 
obviously stop the individual from being in a position of acquiring a second injury in a 
vulnerable period. Return to play and treatment guidelines have been established by a 
consensus statement on concussion in sport at the 3rd International Conference on 
concussion in sport in Zurich in November of 2008 (McCrory et al., 2009). Diagnosis of 
concussion and recovery involves a wide assessment of an individual including physical 
signs, behavioral abnormalities, balance, sleep and cognition (Echlin et al., 2010; McCrory et 
al., 2009). Neuropsychological assessments and tests such as the Sideline Concussion 
Assessment Tool 2 (SCAT2) and the Immediate Post-Concussion Assessment and Cognitive 
Test (ImPACT) should also be routinely used (Echlin et al., 2010; McCrory et al., 2009), and 
players should have no signs of neurological deficits or syndromes before returning to play 
(Ackery et al. 2009). There will likely still be players that will not comply with return to play 
advice, but these individuals need to be made aware that lack of compliance may put them 
at higher risk for experiencing another concussion as well as suffering potential permanent 
brain damage and disability (Ackery et al., 2009). 
Another potential type of intervention is genetic screening. As previously mentioned, 
individuals with the apolipoprotein E 4 allele generally show poorer outcome after injury 
than others without this genetic polymorphism (Isoniemi et al., 2006). Also, individuals with 
a genetic alteration in neprilysin, which is the enzyme that degrades Aβ protein, may be at 
greater risk of Aβ plaque formation after TBI as well as the development of AD (Johnson et 
al, 2009). At present, there are no specific therapeutic interventions that are routinely used 
for these individuals. However, these persons could at least be advised that they may be at a 
much higher risk of developing AD if they sustain a TBI or repetitive mild TBIs. Therefore, 
they could make an informed decision about whether they would participate in activities 
where they may be at high risk of experience a TBI, such as specific types of sports.  
TBI is known to increase free radicals and reactive oxygen species, leading to oxidative 
stress (Slemmer et al., 2008, Weber, 2004), and this may be a prevalent means of damage 
even after mild TBI. Therefore, specific agents that could be useful for treating mild TBI are 
antioxidants. In a study mentioned earlier (Conte et al., 2004), vitamin E, a known 
antioxidant, increased cognitive function and decreased Aβ deposition after repetitive 
concussive injury. In addition to supplementation, individuals could potentially increase the 
amount of antioxidant species in their body through diet, as several foods have high 
amounts of antioxidants (Ferrari & Torres, 2003). Of course, these compounds would have 
to cross the blood-brain barrier in order to provide protection from TBI. In fact, many of 
these species do cross into the brain. For example, Andres-Lacueva et al. (2005) 
demonstrated that compounds present in blueberries were found in rat brain cells after 
feeding them a diet with blueberry extract. In addition, Sweeney et al. (2002) showed that 
rats fed blueberries for six weeks were protected from stroke. This raises the possibility that 
an individual on a diet high in antioxidant species may be somewhat protected from a mild 
trauma and may have better outcome following a second mild TBI should it occur. 
Another interesting prospect in the field of treating repetitive mild TBI is the potential use of 
cognitive enhancers, such as ampakines, which were and still are touted as therapeutic 
agents for neurodegenerative conditions such as Alzheimer’s disease (Lynch and Gall, 2006). 
They are now gaining popularity as safe drugs to improve memory and concentration in 
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healthy individuals.  Ampakines positively modulate the AMPA-type of glutamate 
receptors in the brain (Lynch & Gall, 2006).  Glutamate receptors are known to be involved 
in a wide variety of processes in the nervous system, one of which is memory.  Their 
activation appears to be imperative for memory consolidation.  For example, the activation 
of AMPA receptors is known to facilitate LTP in the hippocampus. Ampakines are 
peripherally administered drugs known to cross the blood-brain barrier and can potently 
facilitate LTP, as demonstrated in rodents (Staubli et al., 1994). These drugs also improve 
memory performance in rodents and humans (Lynch, 1998; Lynch & Gall, 2006). 
Ampakines have now been evaluated in clinical trials in humans. One of these drugs in 
particular (CX516) has demonstrated enhanced memory and cognitive performance in 
healthy young adults (Ingvar et al., 1997; Lynch et al., 1996). Similar positive cognitive 
effects were found with CX516 in healthy elderly subjects (Lynch et al., 1997).  In these 
studies, no changes in heart rate, mood or motor performance were found.  Another study 
in healthy elderly volunteer subjects with another ampakine (farampator) showed 
improvements with short-term memory (Wezenberg et al., 2007).  At higher doses, 
farampator caused side effects such as nausea, headache and drowsiness.  Overall, these 
drugs produce cognitive enhancement with either no, or very mild side effects.  This raises 
the possibility of treating athletes with these drugs after they have sustained a concussion, 
as well as treating child and spousal abuse victims who have repetitive injuries. 
6. Conclusions 
Repetitive mild TBI constitutes a significant portion of all TBI cases and the incidence of 
repeated TBI appears to be on the rise. Overall, there has been surprisingly little attention 
given to experimental repetitive TBI studies. However, more researchers have conducted 
studies in this field in recent years. Research involving both in vivo and in vitro 
experimentation holds promise for unraveling the pathology of repetitive mild TBI, which 
may differ from that of single TBI at various levels. A greater understanding of how long the 
brain takes to recover after a mild injury will aid in determining return to play guidelines 
for athletes. In addition, further experimentation and monitoring of mild TBI sufferers will 
assist in developing treatment strategies for decreasing damage should a second injury 
occur. 
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Another potential type of intervention is genetic screening. As previously mentioned, 
individuals with the apolipoprotein E 4 allele generally show poorer outcome after injury 
than others without this genetic polymorphism (Isoniemi et al., 2006). Also, individuals with 
a genetic alteration in neprilysin, which is the enzyme that degrades Aβ protein, may be at 
greater risk of Aβ plaque formation after TBI as well as the development of AD (Johnson et 
al, 2009). At present, there are no specific therapeutic interventions that are routinely used 
for these individuals. However, these persons could at least be advised that they may be at a 
much higher risk of developing AD if they sustain a TBI or repetitive mild TBIs. Therefore, 
they could make an informed decision about whether they would participate in activities 
where they may be at high risk of experience a TBI, such as specific types of sports.  
TBI is known to increase free radicals and reactive oxygen species, leading to oxidative 
stress (Slemmer et al., 2008, Weber, 2004), and this may be a prevalent means of damage 
even after mild TBI. Therefore, specific agents that could be useful for treating mild TBI are 
antioxidants. In a study mentioned earlier (Conte et al., 2004), vitamin E, a known 
antioxidant, increased cognitive function and decreased Aβ deposition after repetitive 
concussive injury. In addition to supplementation, individuals could potentially increase the 
amount of antioxidant species in their body through diet, as several foods have high 
amounts of antioxidants (Ferrari & Torres, 2003). Of course, these compounds would have 
to cross the blood-brain barrier in order to provide protection from TBI. In fact, many of 
these species do cross into the brain. For example, Andres-Lacueva et al. (2005) 
demonstrated that compounds present in blueberries were found in rat brain cells after 
feeding them a diet with blueberry extract. In addition, Sweeney et al. (2002) showed that 
rats fed blueberries for six weeks were protected from stroke. This raises the possibility that 
an individual on a diet high in antioxidant species may be somewhat protected from a mild 
trauma and may have better outcome following a second mild TBI should it occur. 
Another interesting prospect in the field of treating repetitive mild TBI is the potential use of 
cognitive enhancers, such as ampakines, which were and still are touted as therapeutic 
agents for neurodegenerative conditions such as Alzheimer’s disease (Lynch and Gall, 2006). 
They are now gaining popularity as safe drugs to improve memory and concentration in 
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healthy individuals.  Ampakines positively modulate the AMPA-type of glutamate 
receptors in the brain (Lynch & Gall, 2006).  Glutamate receptors are known to be involved 
in a wide variety of processes in the nervous system, one of which is memory.  Their 
activation appears to be imperative for memory consolidation.  For example, the activation 
of AMPA receptors is known to facilitate LTP in the hippocampus. Ampakines are 
peripherally administered drugs known to cross the blood-brain barrier and can potently 
facilitate LTP, as demonstrated in rodents (Staubli et al., 1994). These drugs also improve 
memory performance in rodents and humans (Lynch, 1998; Lynch & Gall, 2006). 
Ampakines have now been evaluated in clinical trials in humans. One of these drugs in 
particular (CX516) has demonstrated enhanced memory and cognitive performance in 
healthy young adults (Ingvar et al., 1997; Lynch et al., 1996). Similar positive cognitive 
effects were found with CX516 in healthy elderly subjects (Lynch et al., 1997).  In these 
studies, no changes in heart rate, mood or motor performance were found.  Another study 
in healthy elderly volunteer subjects with another ampakine (farampator) showed 
improvements with short-term memory (Wezenberg et al., 2007).  At higher doses, 
farampator caused side effects such as nausea, headache and drowsiness.  Overall, these 
drugs produce cognitive enhancement with either no, or very mild side effects.  This raises 
the possibility of treating athletes with these drugs after they have sustained a concussion, 
as well as treating child and spousal abuse victims who have repetitive injuries. 
6. Conclusions 
Repetitive mild TBI constitutes a significant portion of all TBI cases and the incidence of 
repeated TBI appears to be on the rise. Overall, there has been surprisingly little attention 
given to experimental repetitive TBI studies. However, more researchers have conducted 
studies in this field in recent years. Research involving both in vivo and in vitro 
experimentation holds promise for unraveling the pathology of repetitive mild TBI, which 
may differ from that of single TBI at various levels. A greater understanding of how long the 
brain takes to recover after a mild injury will aid in determining return to play guidelines 
for athletes. In addition, further experimentation and monitoring of mild TBI sufferers will 
assist in developing treatment strategies for decreasing damage should a second injury 
occur. 
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1. Introduction 
Traumatic brain injury (TBI) has long been recognized as a leading cause of mortality and 
permanent neurological disability worldwide and has been described as a silent epidemic of 
modern societies. It is most common amongst young individuals, in their productive years 
of life, thereby causing a significant social and financial burden for them, their families and 
the public health system (Maas et al., 2008). 
The pathophysiology of TBI is complex and multifactorial with several pathways involved 
in the damage of the brain. TBI has been classified into primary and secondary injury. The 
primary injury is the result of the external mechanical force at the moment of trauma 
leading to skull fractures, brain contusions, lacerations, diffuse axonal injuries, vascular 
tearing and intracranial hemorrhages (Maas et al., 2008). The initial impact damages directly 
the neuronal tissue via excitatory amino acids release and massive ionic influx referred to as 
traumatic depolarization (Katayama et al., 1995).  
Secondary neuronal damage is induced immediately after primary injury and is mediated 
through several pathophysiologic mechanisms including raised intracranial pressure, 
disruption of blood brain barrier, brain edema, decreased cerebral blood flow, altered tissue 
perfusion, cerebral hypoxia, ischemia and reperfusion injury (Graham et al., 2000). 
Furthermore, a cascade of molecular, neurochemical, cellular and immune processes 
contribute to secondary damage such as disruption of calcium homeostasis, oxidative stress, 
excitatory mediators release, cytoskeletal and mitochondrial dysfunction, Ab-peptide 
deposition, inflammatory cell infiltration and neuronal cell apoptosis and death (Greve & 
Zink, 2009). Gene expression studies have demonstrated that several genes are implicated in 
the pathophysiology of secondary brain damage (Lei et al., 2009). Secondary cascade of 
events were found to dramatically aggregate primary neuronal damage and given that 
primary injury is unavoidable and irreversible, secondary processes are the targets of 
current therapeutic strategies and trials on neuroprotective agents (Jain, 2008).  
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1. Introduction 
Traumatic brain injury (TBI) has long been recognized as a leading cause of mortality and 
permanent neurological disability worldwide and has been described as a silent epidemic of 
modern societies. It is most common amongst young individuals, in their productive years 
of life, thereby causing a significant social and financial burden for them, their families and 
the public health system (Maas et al., 2008). 
The pathophysiology of TBI is complex and multifactorial with several pathways involved 
in the damage of the brain. TBI has been classified into primary and secondary injury. The 
primary injury is the result of the external mechanical force at the moment of trauma 
leading to skull fractures, brain contusions, lacerations, diffuse axonal injuries, vascular 
tearing and intracranial hemorrhages (Maas et al., 2008). The initial impact damages directly 
the neuronal tissue via excitatory amino acids release and massive ionic influx referred to as 
traumatic depolarization (Katayama et al., 1995).  
Secondary neuronal damage is induced immediately after primary injury and is mediated 
through several pathophysiologic mechanisms including raised intracranial pressure, 
disruption of blood brain barrier, brain edema, decreased cerebral blood flow, altered tissue 
perfusion, cerebral hypoxia, ischemia and reperfusion injury (Graham et al., 2000). 
Furthermore, a cascade of molecular, neurochemical, cellular and immune processes 
contribute to secondary damage such as disruption of calcium homeostasis, oxidative stress, 
excitatory mediators release, cytoskeletal and mitochondrial dysfunction, Ab-peptide 
deposition, inflammatory cell infiltration and neuronal cell apoptosis and death (Greve & 
Zink, 2009). Gene expression studies have demonstrated that several genes are implicated in 
the pathophysiology of secondary brain damage (Lei et al., 2009). Secondary cascade of 
events were found to dramatically aggregate primary neuronal damage and given that 
primary injury is unavoidable and irreversible, secondary processes are the targets of 
current therapeutic strategies and trials on neuroprotective agents (Jain, 2008).  
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Extensive research has indicated that cellular and humoral inflammation after TBI play a 
key role in the extent of brain injury and repair processes. The initiation, progression and 
resolution of inflammation in TBI is multifaceted involving leukocyte infiltration, activation 
of resident immune cells and secretion of inflammatory mediators such as pro- and anti-
inflammatory cytokines, chemokines, adhesion molecules, complement factors, reactive 
oxygen species and other factors. Several lines of evidence support a dual role for the 
neuroinflammation either detrimental or beneficial depending on the extent, time and site of 
induction. Elucidation of the inflammatory cascade in the injured brain would offer the 
possibility of novel therapies. 
The present article will focus on the TBI induced neuroinflammation and on the current 
knowledge regarding the involvement of innate and adaptive immune system in the 
inflammation and repair following TBI.  
2. Neuroinflammation  
The normal central nervous system (CNS) limits the entry of immune components and is 
traditionally regarded as an immune privileged organ separated from the peripheral immune 
system by the blood-brain-barrier (BBB). However, this concept of limited immune 
intervention in the CNS has been questioned, since under physiological conditions, resident 
brain cells are capable of immune surveillance and expression of immune mediators within the 
CNS. In addition, T-lymphocytes are known to enter the healthy brain parenchyma to perform 
surveillance in the absence of inflammatory stimulus (Hickey, 1999; Becher et al., 2000). During 
inflammatory brain insults the immune privileged status is compromised with an activation of 
innate immune cells and mobilization of specific adaptive immune responses.  
A growing body of evidence suggests a pivotal role of TBI induced cerebral inflammation, 
including activation of resident cells, migration and recruitment of leukocytes and release of 
inflammatory mediators, in the extent of neuronal injury and repair. Inflammation after TBI 
is believed to be triggered by several factors such as extravasated blood products, tissue 
debris, intracellular components, complement fragments, prostaglandins, reactive oxygen 
and nitrogen species. The BBB is disrupted after TBI resulting in invasion of neutrophils, 
monocytes and lymphocytes from the periphery and activation of microglia and other 
resident cells and thus initiating a potent inflammatory response. A biphasic BBB 
breakdown after TBI has been reported with a first opening occurring immediately after the 
primary impact reaching a maximum permeability within a few hours and then being 
declined. A second-delayed opening as a result of secondary injury cascades was found to 
peak around 3-7 days following TBI and can last from days to years (Baskaya et al., 1997; 
Shlosberg et al., 2010). 
The accumulation of leukocytes into the injured brain area is crucial to the extent of 
inflammation and secondary brain damage. Leukocytes migrate out of blood vessels into the 
injured brain parenchyma via binding to the endothelial selectins P and E and the 
intercellular adhesion molecules (ICAMs). Chemokines from the injured brain tissue 
contribute to the expression of these endothelial molecules in the local vasculature. 
Chemokines are produced by resident cells including microglia, astrocytes and neurons in 
response to local inflammation (Ransohoff, 2002). For instance, the chemokine CXCL8 (IL8) 
interacts with leukocytes, triggering the activation of the integrins LFA-1 and CR3 (Mac-1) 
in the surface of leukocytes. These integrins consequently interact with endothelial ICAM-1 
and ICAM-2 leading to a firm adhesion, conformational changes and extravasation of 
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leukocytes between endothelial cells. Finally, these leukocytes migrate along the 
concentration gradient of chemokines to the site of TBI. Neutrophil accumulation peaks 
within 2 days after TBI whereas monocytes accumulate slightly later (Rhodes, 2011).  
Leukocytes are believed to be important in the initiation and progression of inflammation 
following TBI because they contain and release a significant number of inflammatory 
mediators that injure neurons. Increased leukocyte infiltration has been linked to increased 
brain damage. Leukocytes release pro-inflammatory cytokines, proteases, prostaglandins, 
complement factors, free oxygen and nitrogen species which damage neuronal population and 
brain microvasculature and contribute to the disruption of BBB and formation of vasogenic 
edema (Nguyen et al., 2007). Studies in vitro have shown that mixed cultures of hippocampal 
neurons and neutrophils contributed to increased neuronal loss and excitotoxic damage 
(Dinkel et al., 2004). Also, leukocyte accumulation seemed to mediate the detrimental effects of 
chemokines. It was shown that increased intrathecal levels of CXCL8 were correlated to the 
extent of posttraumatic BBB dysfunction and mortality (Kossmann et al., 1997; Whalen et al., 
2000). However, these effects were attenuated by prior depletion of the circulating leukocytes 
(Bell et al., 1996). Leukocytes also contribute to oxidative damage in the injured brain tissue. 
Free oxygen radicals released by leukocytes induce lipid and protein peroxidation, 
mitochondrial and DNA damage and neuronal apoptosis (Tyurin et al., 2000).   
It has been hypothesized that inhibition of neutrophil function or migration would reduce 
the injury size and improve the functional outcome after TBI. This notion has already been 
proved in experimental models of ischemic brain injury. However, the beneficial role of 
leukocyte inhibition is less convincing in TBI experiments. Studies in animal models and 
humans with severe TBI have shown increased expression of the adhesion molecules 
selectin E and ICAM-1 in the early period following TBI (Carlos et al., 1997; McKeating et al., 
1998; Pleines et al., 1998) indicating that these molecules are important in the neutrophil 
recruitment in the injured brain. Administration of monoclonal antibodies directed against 
the leukocyte adhesion molecules CD11b (aM subunit of integrin CR3) and ICAM-1 resulted 
in decreased neutrophil migration (Carlos et al., 1997; Weaver et al., 2000; Knoblach & 
Faden, 2002) and better clinical recovery (Knoblach & Faden, 2002) after experimental brain 
trauma. However, in the latter study the beneficial effect of anti-ICAM-1 treatment was also 
achieved, although to a lesser extent, with the administration of a nonspecific IgG, 
indicating that part of the effects may be attributed to the general properties of the 
antibodies. Moreover, ICAM-1 gene deficient mice with TBI did not demonstrate evidence 
of improved neurological function, reduced lesion volume or neutrophil accumulation 
compared to wild type control mice (Whalen et al., 1999), suggesting that other adhesion 
molecules may also play a significant role in the recruitment of neutrophils. Inhibition of 
neutrophil infiltration was also tested by blocking chemokine expression. Mice deficient in 
CXC receptor 2 which interacts with chemokines CXCL8, CXCL1 and CXCL2 and mediates 
the neutrophil transmigration across the BBB were reported to demonstrate significant 
attenuation of neutrophil infiltration, reduced tissue damage and neuronal loss, especially in 
the delayed phase post injury (Semple et al., 2010a). In a similar study, deletion of monocyte 
chemokine CCL2 gene resulted in improved neurological function, delayed reduction in 
lesion volume and macrophage accumulation (Semple et al., 2010b). Both the latter studies 
support the notion that late inhibition of leukocyte recruitment in TBI may be beneficial for 
the extent of brain trauma and the clinical outcome. These results were not achieved when 
neutrophil depletion was applied early in the course of TBI (Whalen et al., 1999), indicating 
that leukocyte infiltration in the early phase post injury may mediate some beneficial 
 
Brain Injury – Pathogenesis, Monitoring, Recovery and Management 
 
24
Extensive research has indicated that cellular and humoral inflammation after TBI play a 
key role in the extent of brain injury and repair processes. The initiation, progression and 
resolution of inflammation in TBI is multifaceted involving leukocyte infiltration, activation 
of resident immune cells and secretion of inflammatory mediators such as pro- and anti-
inflammatory cytokines, chemokines, adhesion molecules, complement factors, reactive 
oxygen species and other factors. Several lines of evidence support a dual role for the 
neuroinflammation either detrimental or beneficial depending on the extent, time and site of 
induction. Elucidation of the inflammatory cascade in the injured brain would offer the 
possibility of novel therapies. 
The present article will focus on the TBI induced neuroinflammation and on the current 
knowledge regarding the involvement of innate and adaptive immune system in the 
inflammation and repair following TBI.  
2. Neuroinflammation  
The normal central nervous system (CNS) limits the entry of immune components and is 
traditionally regarded as an immune privileged organ separated from the peripheral immune 
system by the blood-brain-barrier (BBB). However, this concept of limited immune 
intervention in the CNS has been questioned, since under physiological conditions, resident 
brain cells are capable of immune surveillance and expression of immune mediators within the 
CNS. In addition, T-lymphocytes are known to enter the healthy brain parenchyma to perform 
surveillance in the absence of inflammatory stimulus (Hickey, 1999; Becher et al., 2000). During 
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resident cells and thus initiating a potent inflammatory response. A biphasic BBB 
breakdown after TBI has been reported with a first opening occurring immediately after the 
primary impact reaching a maximum permeability within a few hours and then being 
declined. A second-delayed opening as a result of secondary injury cascades was found to 
peak around 3-7 days following TBI and can last from days to years (Baskaya et al., 1997; 
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contribute to the expression of these endothelial molecules in the local vasculature. 
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leukocytes between endothelial cells. Finally, these leukocytes migrate along the 
concentration gradient of chemokines to the site of TBI. Neutrophil accumulation peaks 
within 2 days after TBI whereas monocytes accumulate slightly later (Rhodes, 2011).  
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following TBI because they contain and release a significant number of inflammatory 
mediators that injure neurons. Increased leukocyte infiltration has been linked to increased 
brain damage. Leukocytes release pro-inflammatory cytokines, proteases, prostaglandins, 
complement factors, free oxygen and nitrogen species which damage neuronal population and 
brain microvasculature and contribute to the disruption of BBB and formation of vasogenic 
edema (Nguyen et al., 2007). Studies in vitro have shown that mixed cultures of hippocampal 
neurons and neutrophils contributed to increased neuronal loss and excitotoxic damage 
(Dinkel et al., 2004). Also, leukocyte accumulation seemed to mediate the detrimental effects of 
chemokines. It was shown that increased intrathecal levels of CXCL8 were correlated to the 
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2000). However, these effects were attenuated by prior depletion of the circulating leukocytes 
(Bell et al., 1996). Leukocytes also contribute to oxidative damage in the injured brain tissue. 
Free oxygen radicals released by leukocytes induce lipid and protein peroxidation, 
mitochondrial and DNA damage and neuronal apoptosis (Tyurin et al., 2000).   
It has been hypothesized that inhibition of neutrophil function or migration would reduce 
the injury size and improve the functional outcome after TBI. This notion has already been 
proved in experimental models of ischemic brain injury. However, the beneficial role of 
leukocyte inhibition is less convincing in TBI experiments. Studies in animal models and 
humans with severe TBI have shown increased expression of the adhesion molecules 
selectin E and ICAM-1 in the early period following TBI (Carlos et al., 1997; McKeating et al., 
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recruitment in the injured brain. Administration of monoclonal antibodies directed against 
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Faden, 2002) and better clinical recovery (Knoblach & Faden, 2002) after experimental brain 
trauma. However, in the latter study the beneficial effect of anti-ICAM-1 treatment was also 
achieved, although to a lesser extent, with the administration of a nonspecific IgG, 
indicating that part of the effects may be attributed to the general properties of the 
antibodies. Moreover, ICAM-1 gene deficient mice with TBI did not demonstrate evidence 
of improved neurological function, reduced lesion volume or neutrophil accumulation 
compared to wild type control mice (Whalen et al., 1999), suggesting that other adhesion 
molecules may also play a significant role in the recruitment of neutrophils. Inhibition of 
neutrophil infiltration was also tested by blocking chemokine expression. Mice deficient in 
CXC receptor 2 which interacts with chemokines CXCL8, CXCL1 and CXCL2 and mediates 
the neutrophil transmigration across the BBB were reported to demonstrate significant 
attenuation of neutrophil infiltration, reduced tissue damage and neuronal loss, especially in 
the delayed phase post injury (Semple et al., 2010a). In a similar study, deletion of monocyte 
chemokine CCL2 gene resulted in improved neurological function, delayed reduction in 
lesion volume and macrophage accumulation (Semple et al., 2010b). Both the latter studies 
support the notion that late inhibition of leukocyte recruitment in TBI may be beneficial for 
the extent of brain trauma and the clinical outcome. These results were not achieved when 
neutrophil depletion was applied early in the course of TBI (Whalen et al., 1999), indicating 
that leukocyte infiltration in the early phase post injury may mediate some beneficial 
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physiologic processes and only delayed and prolonged leukocyte recruitment may be 
deleterious to the neuronal survival.  
Apart from leukocyte infiltration, the humoral components of neuroinflammation were also 
found to play an important role in the initiation, maintenance and resolution of 
inflammation following TBI. The primary traumatic impact and the ensuing injury triggers 
the release of several cytokines which facilitate the migration of inflammatory cells, the 
activation of resident cells, the expression of vascular endothelial molecules and 
chemokines. Cellular sources of cytokines include leukocytes, lymphocytes, microglia, 
astrocytes, endothelial cells and neurons. Cytokines are induced shortly after primary insult 
and this early increase is mediated by resident brain cells. Cytokines have multiple actions 
and targets, and often overlapping biological effects. Cytokines exert their function either 
through binding to their receptors, which are expressed by both glial and neuronal cells, or 
through diverse pathways such as modulation of neurotransmitter receptor function, 
induction of nitric oxide synthase, secretion of chemokines and proteolytic enzymes (Allan 
& Rothwell, 2001). 
Interleukin-1 (IL-1) is a pro-inflammatory cytokine that has been identified as an important 
mediator of the inflammation following TBI. The IL-1 family has three main members: the pro-
inflammatory cytokines IL-1a and IL-1b, which exert their action by binding to the cell surface 
receptor IL-1RI, and the anti-inflammatory cytokine IL-1 receptor antagonist (IL-1ra) (Rothwell 
& Luheshi, 2000). The pro-inflammatory cytokines IL-1a and IL-1b have pleiotropic effects 
which are mediated by binding to the IL-1RI. IL-1 triggers inflammatory reactions, leads to 
recruitment of leukocytes, disruption of BBB and formation of edema, induces other 
interleukins, prostagladins, histamine, thromboxane, chemokines and adhesion molecules and 
exerts multiple effects in neuronal, glial and endothelial cells (Hopkins & Rothwell, 1995; 
Rothwell & Hopkins, 1995). IL-1ra is a naturally occurring competitive and highly selective 
inhibitor of IL-1a and IL-1b which binds to the IL-1RI without initiating signal transduction. 
IL-1ra plays an important role in the regulation of the inflammatory response and the balance 
between proinflammatory and anti-inflammatory cytokines (Arend, 1991; Dinarello, 1991).  
In experimental TBI a rapid induction of IL-1b (mRNA expression and protein levels) was 
observed in the very early period following TBI (Fan et al., 1995; Wang & Shuaib, 2002). 
Similarly, IL-1ra was upregulated in response to head injury but shortly after the induction 
of IL-1b (Gabellec et al., 1999).  Elevated levels of IL-1b were also detected intrathecally in 
patients with head injury (Winter et al., 2002). Moreover, these elevated levels were 
correlated to poorer clinical outcome (Chiaretti et al., 2005; Shiozaki et al., 2005).  The 
proinflammatory cytokines IL-1a and IL-1b are believed to initiate inflammation and to 
contribute to neurodegeneration after various brain insults including TBI, whereas IL-1ra 
seemed to be neuroprotective. In experimental animal models, intracerebral or 
intraventricular administration of exogenous IL-1b markedly exacerbates brain injury (Patel 
et al., 2003). In contrast, administration or overexpression of IL-1ra significantly attenuates 
neuronal damage and inflammation (Toulmond & Rothwell, 1995; Sanderson et al., 1999; 
Tehranian et al., 2002). Apart from acute neuroinflammation, TBI induces long-term and 
persistent inflammation with elevation of IL-1 and other cytokines and increased expression 
of beta-amyloid protein and phosphorylated tau protein. This long-term inflammation may 
be the causative link between TBI and traumatic dementia (Hoshino et al., 1998; Holmin & 
Mathiesen, 1999). These data highlight the important role of IL-1 in the acute and chronic 
neuroinflammation following TBI and the possibility of beneficial effects that may ensue 
after its therapeutic inhibition. However, many studies have underlined the complexity of 
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inflammatory processes, the lack of meaningful effects after blocking a single inflammatory 
mediator and the duality of inflammation which means that inflammation may have either 
detrimental or beneficial effects depending on the site, the time of induction, the 
concentration of mediators and the microenvironment (Morganti-Kossmann et al., 2002). 
This duality was demonstrated for IL-1 which aside from its pro-inflammatory effects also 
seems to participate in tissue repair processes, especially when induced at later stages, via 
stimulation of neurotrophic factors synthesis (Spranger et al., 1990; DeKosky et al., 1994; 
Herx et al., 2000), astrocyte proliferation (Appel et al., 1997) and involvement in synaptic 
plasticity (Fagan & Gage, 1990; Bellinger et al., 1993; Ide et al., 1996). 
IL-6 is another cytokine that has been studied in TBI. IL-6 was found to have also a dual role in 
inflammation with either regulatory, anti-inflammatory or inflammatory effects depending on 
the time course and extent of expression (Allan & Rothwell, 2001; Morganti-Kossmann et al., 
2002). The neurotrophic properties of IL-6 are mediated by inhibition of TNFa synthesis, 
induction of IL-1ra and nerve growth factor and attenuation of oxidative stress (Morganti-
Kossmann et al., 2001). On the contrary, IL-6 promotes inflammatory processes by stimulating 
the production of chemokines and adhesion molecules and the recruitment of leukocytes 
(Romano et al., 1997). Elevated levels of IL-6 were observed in the cerebrospinal fluid (CSF) 
and in the serum of patients with TBI and this increase was correlated with a favorable 
neurological outcome (Singhal et al., 2002; Chiaretti et al., 2008). In contrast, other studies 
demonstrated that IL-6 levels were correlated to the clinical severity of TBI patients (Arand et 
al., 2001; Minambres et al., 2003). Studies in animal models provide evidence for a 
neuroprotective effect of IL-6. IL-6 was found at elevated levels in experimental TBI (Shohami 
et al., 1994). Mice deficient for IL-6 had increased numbers of apoptotic neurons, increased 
oxidative stress and delayed healing of the tissue (Penkowa et al., 2000), whereas the same 
group demonstrated that IL-6 transgenic mice exhibited increased reduction of oxidative stress 
and apoptotic cell death after a cryogenic brain injury (Penkowa et al., 2003). 
Tumor necrosis factor-a (TNFa) is another cytokine with a well-documented role in TBI. 
TNFa mRNA and protein is elevated in the early period after experimental TBI and before 
the infiltration of leukocytes suggesting that the early source of TNFa production are the 
resident cells (Riva-Depaty et al., 1994). Elevated levels were also observed in the clinical 
setting of TBI patients (Goodman et al., 1990; Csuka et al., 1999). TNFa has pro-
inflammatory properties similar to that of IL-1 and exacerbates inflammation and secondary 
brain damage after TBI (Allan & Rothwell, 2001). Early upregulation of neuronal TNFa 
expression after TBI was found to contribute to subsequent neurological dysfunction 
(Knoblach et al., 1999). Inhibition of TNFa by the HU-211 compound (a novel TNFa 
production inhibitor), pentoxyfilline and TNF-binding protein resulted in improved 
neurological outcome after closed head injury (Shohami et al., 1997). However, in a phase III 
clinical trial, administration of the HU-211 compound in patients with TBI failed to show 
improved outcome 6 months after the injury, compared to the placebo group (Maas et al., 
2006). These data indicate that neurodegeneration is mediated through various pathological 
pathways and neuroprotection cannot be achieved by blocking a single mediator as other 
alternative pathways may be activated leading to neuronal loss. Furthermore, as reported 
with IL-1, TNFa also has neuroprotective effects and can enhance recovery processes. In a 
very interesting study, knockout mice for the TNFa gene exhibited milder behavioral 
deficits compared to the wild-type mice during the acute period post-injury. However, in 
the long term period (4 weeks post-injury) knockout mice did not recover as well as the 
wild-type mice, had persistent motor deficits and greater cortical tissue loss (Scherbel et al., 
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physiologic processes and only delayed and prolonged leukocyte recruitment may be 
deleterious to the neuronal survival.  
Apart from leukocyte infiltration, the humoral components of neuroinflammation were also 
found to play an important role in the initiation, maintenance and resolution of 
inflammation following TBI. The primary traumatic impact and the ensuing injury triggers 
the release of several cytokines which facilitate the migration of inflammatory cells, the 
activation of resident cells, the expression of vascular endothelial molecules and 
chemokines. Cellular sources of cytokines include leukocytes, lymphocytes, microglia, 
astrocytes, endothelial cells and neurons. Cytokines are induced shortly after primary insult 
and this early increase is mediated by resident brain cells. Cytokines have multiple actions 
and targets, and often overlapping biological effects. Cytokines exert their function either 
through binding to their receptors, which are expressed by both glial and neuronal cells, or 
through diverse pathways such as modulation of neurotransmitter receptor function, 
induction of nitric oxide synthase, secretion of chemokines and proteolytic enzymes (Allan 
& Rothwell, 2001). 
Interleukin-1 (IL-1) is a pro-inflammatory cytokine that has been identified as an important 
mediator of the inflammation following TBI. The IL-1 family has three main members: the pro-
inflammatory cytokines IL-1a and IL-1b, which exert their action by binding to the cell surface 
receptor IL-1RI, and the anti-inflammatory cytokine IL-1 receptor antagonist (IL-1ra) (Rothwell 
& Luheshi, 2000). The pro-inflammatory cytokines IL-1a and IL-1b have pleiotropic effects 
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recruitment of leukocytes, disruption of BBB and formation of edema, induces other 
interleukins, prostagladins, histamine, thromboxane, chemokines and adhesion molecules and 
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Rothwell & Hopkins, 1995). IL-1ra is a naturally occurring competitive and highly selective 
inhibitor of IL-1a and IL-1b which binds to the IL-1RI without initiating signal transduction. 
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between proinflammatory and anti-inflammatory cytokines (Arend, 1991; Dinarello, 1991).  
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Similarly, IL-1ra was upregulated in response to head injury but shortly after the induction 
of IL-1b (Gabellec et al., 1999).  Elevated levels of IL-1b were also detected intrathecally in 
patients with head injury (Winter et al., 2002). Moreover, these elevated levels were 
correlated to poorer clinical outcome (Chiaretti et al., 2005; Shiozaki et al., 2005).  The 
proinflammatory cytokines IL-1a and IL-1b are believed to initiate inflammation and to 
contribute to neurodegeneration after various brain insults including TBI, whereas IL-1ra 
seemed to be neuroprotective. In experimental animal models, intracerebral or 
intraventricular administration of exogenous IL-1b markedly exacerbates brain injury (Patel 
et al., 2003). In contrast, administration or overexpression of IL-1ra significantly attenuates 
neuronal damage and inflammation (Toulmond & Rothwell, 1995; Sanderson et al., 1999; 
Tehranian et al., 2002). Apart from acute neuroinflammation, TBI induces long-term and 
persistent inflammation with elevation of IL-1 and other cytokines and increased expression 
of beta-amyloid protein and phosphorylated tau protein. This long-term inflammation may 
be the causative link between TBI and traumatic dementia (Hoshino et al., 1998; Holmin & 
Mathiesen, 1999). These data highlight the important role of IL-1 in the acute and chronic 
neuroinflammation following TBI and the possibility of beneficial effects that may ensue 
after its therapeutic inhibition. However, many studies have underlined the complexity of 
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inflammatory processes, the lack of meaningful effects after blocking a single inflammatory 
mediator and the duality of inflammation which means that inflammation may have either 
detrimental or beneficial effects depending on the site, the time of induction, the 
concentration of mediators and the microenvironment (Morganti-Kossmann et al., 2002). 
This duality was demonstrated for IL-1 which aside from its pro-inflammatory effects also 
seems to participate in tissue repair processes, especially when induced at later stages, via 
stimulation of neurotrophic factors synthesis (Spranger et al., 1990; DeKosky et al., 1994; 
Herx et al., 2000), astrocyte proliferation (Appel et al., 1997) and involvement in synaptic 
plasticity (Fagan & Gage, 1990; Bellinger et al., 1993; Ide et al., 1996). 
IL-6 is another cytokine that has been studied in TBI. IL-6 was found to have also a dual role in 
inflammation with either regulatory, anti-inflammatory or inflammatory effects depending on 
the time course and extent of expression (Allan & Rothwell, 2001; Morganti-Kossmann et al., 
2002). The neurotrophic properties of IL-6 are mediated by inhibition of TNFa synthesis, 
induction of IL-1ra and nerve growth factor and attenuation of oxidative stress (Morganti-
Kossmann et al., 2001). On the contrary, IL-6 promotes inflammatory processes by stimulating 
the production of chemokines and adhesion molecules and the recruitment of leukocytes 
(Romano et al., 1997). Elevated levels of IL-6 were observed in the cerebrospinal fluid (CSF) 
and in the serum of patients with TBI and this increase was correlated with a favorable 
neurological outcome (Singhal et al., 2002; Chiaretti et al., 2008). In contrast, other studies 
demonstrated that IL-6 levels were correlated to the clinical severity of TBI patients (Arand et 
al., 2001; Minambres et al., 2003). Studies in animal models provide evidence for a 
neuroprotective effect of IL-6. IL-6 was found at elevated levels in experimental TBI (Shohami 
et al., 1994). Mice deficient for IL-6 had increased numbers of apoptotic neurons, increased 
oxidative stress and delayed healing of the tissue (Penkowa et al., 2000), whereas the same 
group demonstrated that IL-6 transgenic mice exhibited increased reduction of oxidative stress 
and apoptotic cell death after a cryogenic brain injury (Penkowa et al., 2003). 
Tumor necrosis factor-a (TNFa) is another cytokine with a well-documented role in TBI. 
TNFa mRNA and protein is elevated in the early period after experimental TBI and before 
the infiltration of leukocytes suggesting that the early source of TNFa production are the 
resident cells (Riva-Depaty et al., 1994). Elevated levels were also observed in the clinical 
setting of TBI patients (Goodman et al., 1990; Csuka et al., 1999). TNFa has pro-
inflammatory properties similar to that of IL-1 and exacerbates inflammation and secondary 
brain damage after TBI (Allan & Rothwell, 2001). Early upregulation of neuronal TNFa 
expression after TBI was found to contribute to subsequent neurological dysfunction 
(Knoblach et al., 1999). Inhibition of TNFa by the HU-211 compound (a novel TNFa 
production inhibitor), pentoxyfilline and TNF-binding protein resulted in improved 
neurological outcome after closed head injury (Shohami et al., 1997). However, in a phase III 
clinical trial, administration of the HU-211 compound in patients with TBI failed to show 
improved outcome 6 months after the injury, compared to the placebo group (Maas et al., 
2006). These data indicate that neurodegeneration is mediated through various pathological 
pathways and neuroprotection cannot be achieved by blocking a single mediator as other 
alternative pathways may be activated leading to neuronal loss. Furthermore, as reported 
with IL-1, TNFa also has neuroprotective effects and can enhance recovery processes. In a 
very interesting study, knockout mice for the TNFa gene exhibited milder behavioral 
deficits compared to the wild-type mice during the acute period post-injury. However, in 
the long term period (4 weeks post-injury) knockout mice did not recover as well as the 
wild-type mice, had persistent motor deficits and greater cortical tissue loss (Scherbel et al., 
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1999). These results suggest that the time, concentration and the site of TNFa induction may 
determine the driving of inflammatory processes towards neurodegeneration or 
neuroprotection.  
3. Innate immunity   
Microglia, the brain's resident macrophages, are the main cell type of the innate immune 
system of the brain. Microglia, although debatable, seem to originate from bone marrow 
monocytic cells which invade the CNS during embryonic development (Chan et al., 2007). 
Microglia provide a first line of regional defense in the CNS against various pathological 
insults. They are scattered throughout the CNS although some regional differences in their 
localization have been reported as they are more densely distributed in the gray than in the 
white matter and in structures like hippocampus, basal ganglia and substantia nigra (Block 
et al., 2007).  
While resting, microglia have a highly ramified morphology with symmetrically extended, 
motile processes that form a network, which continuously monitor the local 
microenvironment of the brain parenchyma being the most susceptible sensors of brain 
pathology (Nimmerjahn et al., 2005; Kettenmann et al., 2011). In physiological conditions they 
provide surveillance of the CNS homeostasis and they sense neuronal and astrocytic activity 
and other physiological changes such as pH shifts, ion currents and neurotransmitter release 
(Farber & Kettenmann, 2005). This is achieved by the expression of numerous receptors by the 
microglia establishing a delicate neuron-microglia communication (McCluskey & Lampson, 
2000). In an in vitro study the normal neuronal activity was found to inhibit the effects of 
microglia activators such as interferon-γ  signifying the importance of cell to cell interactions 
(Neumann et al., 1996).  
Various brain insults including bacterial lipopolysaccharide (LPS), cytokines, b-amyloid 
peptide and damaged tissue can result in activation of microglia (Nakamura, 2002). Upon 
activation, the cell size increases and the morphology dramatically changes to an amoeboid 
structure which facilitates the migration of microglial cells towards the lesion site and the 
phagocytosis of cellular debris and toxic substances (Raivich, 2005). In response to noxious 
stimuli microglia also proliferate and migrate to the lesion site. The rapidly chemotactic 
convergence to the site of injury is mediated by ATP, glutamate and other chemotactic agents 
released by the injured cells (Davalos et al., 2005; Liu et al., 2009). At this point the morphology 
of activated microglia cannot be discriminated from that of infiltrating macrophages using 
standard immunohistochemical techniques (Streit et al., 1999; Loane & Byrnes, 2010).  
A significant part in the activation of microglia after inflammatory stimuli is the expression 
of constitutive and inducible surface receptors. Activated microglia express pattern 
recognition receptors, cytokine and chemokine receptors, phagocytic receptors, Fc and 
complement receptors, receptors for glutamate, growth factors and several other molecules 
(Gebicke-Haerter et al., 1996; Cho et al., 2006; Kettenmann et al., 2011). Activated microglia 
also express on their surface MHC class I and II molecules, making them able to present 
antigenic peptides and thus modulating T cell responses (Aloisi, 2001).   
The specific profile of the surface receptors determine the phenotype of microglia and their 
functional properties. In line with macrophages phenotype, activated microglia may be 
neurotoxic (M1) due to the secretion of pro-inflammatory cytokines and reactive oxygen and 
nitrogen species. In contrast, activation of microglia may enable them to maintain and 
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enhance neuronal survival (M2) through the release of anti-inflammatory cytokines and 
neurotrophic factors. However, it is possible that M1 and M2 phenotypes may represent the 
two extremes of a wide spectrum of phenotypes that microglia can have in response to the 
type, intensity, persistence of the stimuli and the microenvironment interactions (Mantovani 
et al., 2004). In fact, microglia have plastic properties and at different stages of the disease 
can acquire diverse phenotypes and functions that can be either detrimental or beneficial.  
The activation process begins when resting microglia detect the noxious stimuli or the sub-
products of tissue damage. Microglia become activated, release inflammatory mediators, 
express surface molecules and remove cellular debris by phagocytosis. Once the toxic factors 
are eliminated and under the influences of the invading immune cells and the normal CNS 
cells activated microglia acquire a neurotrophic phenotype and release anti-inflammatory 
cytokines and neurotrophic factors. After a certain period of time inflammation is resolved 
and the activating microglia return to a resting-surveying state retaining some kind of 
memory of the processes. However, under not fully elucidated conditions, this delicate 
balance between activation-termination and neurotoxic-neurotrophic phenotype can be 
disrupted leading to excessive, uncontrolled or prolonged activation of microglia with 
destructive consequences in neuronal survival. Excessive and dysregulated microglia 
activation were elicited after intense and severe CNS insults. Moreover, insufficient 
recruitment of systemic immune cells to the CNS site of lesion may result in an inability to 
suppress and terminate the microglia activation or to turn them into a neuroprotective 
phenotype (Kempermann & Neumann, 2003; Hanisch & Kettenmann, 2007; Popovich & 
Longbrake, 2008; Rivest, 2009; Schwartz & Shechter, 2010). Thus, dysregulation of the innate 
or adaptive immune system may mediate excessive inflammatory damage following brain 
insults. It is obvious that a better understanding of the interaction mechanisms between 
immune cells may facilitate the introduction of novel therapies.  
Several studies have investigated the microglia function after TBI. The release of various 
mediators in the extracellular space after the injured site alters the expression profile of local 
microglia. In a very interesting imaging study of fluorescent labeled microglia it was shown 
that microglia from the intact brain that are nearby the injured site extend their processes 
which reach the damaged site. There the processes and without cell body movement, 
converge and fuse together to form a spherical area of containment that separate the healthy 
from the injured tissue. In other words fused microglial processes act as a barrier that 
contains the tissue debris. This highly dynamic movement of microglial processes is under 
the chemotactic influence of extracellular ATP (Davalos et al., 2005).   
The time of induction and the duration of microglia activation after TBI were found to be 
different from other brain insults such as cerebral ischemia. Studies in humans with TBI 
have revealed a striking delay of microglial activation and proliferation. Markers of 
microglial activation and proliferation were not detected until 3 days post TBI (Beschorner 
et al., 2000; Engel et al., 2000) whereas the same markers were expressed early in cerebral 
ischemia (Postler et al., 1997). This observation although in line with some findings in 
experimental models (Aihara et al., 1995; Holmin et al., 1997) cannot be fully understood. It 
is possible to reflect different activation cascades of microglia after TBI compared to other 
brain insults. However this window delay of microglial activation after TBI may provide a 
therapeutic opportunity when the target would be the microglial activation.  
Several studies in TBI have also demonstrated that inflammation can persist for long period 
of time after the primary traumatic brain insult. Studies in rodents have revealed reactive 
astrocytosis for over a year following brain injury resulting in chronic progressive neuronal 
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1999). These results suggest that the time, concentration and the site of TNFa induction may 
determine the driving of inflammatory processes towards neurodegeneration or 
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system of the brain. Microglia, although debatable, seem to originate from bone marrow 
monocytic cells which invade the CNS during embryonic development (Chan et al., 2007). 
Microglia provide a first line of regional defense in the CNS against various pathological 
insults. They are scattered throughout the CNS although some regional differences in their 
localization have been reported as they are more densely distributed in the gray than in the 
white matter and in structures like hippocampus, basal ganglia and substantia nigra (Block 
et al., 2007).  
While resting, microglia have a highly ramified morphology with symmetrically extended, 
motile processes that form a network, which continuously monitor the local 
microenvironment of the brain parenchyma being the most susceptible sensors of brain 
pathology (Nimmerjahn et al., 2005; Kettenmann et al., 2011). In physiological conditions they 
provide surveillance of the CNS homeostasis and they sense neuronal and astrocytic activity 
and other physiological changes such as pH shifts, ion currents and neurotransmitter release 
(Farber & Kettenmann, 2005). This is achieved by the expression of numerous receptors by the 
microglia establishing a delicate neuron-microglia communication (McCluskey & Lampson, 
2000). In an in vitro study the normal neuronal activity was found to inhibit the effects of 
microglia activators such as interferon-γ  signifying the importance of cell to cell interactions 
(Neumann et al., 1996).  
Various brain insults including bacterial lipopolysaccharide (LPS), cytokines, b-amyloid 
peptide and damaged tissue can result in activation of microglia (Nakamura, 2002). Upon 
activation, the cell size increases and the morphology dramatically changes to an amoeboid 
structure which facilitates the migration of microglial cells towards the lesion site and the 
phagocytosis of cellular debris and toxic substances (Raivich, 2005). In response to noxious 
stimuli microglia also proliferate and migrate to the lesion site. The rapidly chemotactic 
convergence to the site of injury is mediated by ATP, glutamate and other chemotactic agents 
released by the injured cells (Davalos et al., 2005; Liu et al., 2009). At this point the morphology 
of activated microglia cannot be discriminated from that of infiltrating macrophages using 
standard immunohistochemical techniques (Streit et al., 1999; Loane & Byrnes, 2010).  
A significant part in the activation of microglia after inflammatory stimuli is the expression 
of constitutive and inducible surface receptors. Activated microglia express pattern 
recognition receptors, cytokine and chemokine receptors, phagocytic receptors, Fc and 
complement receptors, receptors for glutamate, growth factors and several other molecules 
(Gebicke-Haerter et al., 1996; Cho et al., 2006; Kettenmann et al., 2011). Activated microglia 
also express on their surface MHC class I and II molecules, making them able to present 
antigenic peptides and thus modulating T cell responses (Aloisi, 2001).   
The specific profile of the surface receptors determine the phenotype of microglia and their 
functional properties. In line with macrophages phenotype, activated microglia may be 
neurotoxic (M1) due to the secretion of pro-inflammatory cytokines and reactive oxygen and 
nitrogen species. In contrast, activation of microglia may enable them to maintain and 
 
Traumatic Brain Injury and Inflammation: Emerging Role of Innate and Adaptive Immunity 
 
29 
enhance neuronal survival (M2) through the release of anti-inflammatory cytokines and 
neurotrophic factors. However, it is possible that M1 and M2 phenotypes may represent the 
two extremes of a wide spectrum of phenotypes that microglia can have in response to the 
type, intensity, persistence of the stimuli and the microenvironment interactions (Mantovani 
et al., 2004). In fact, microglia have plastic properties and at different stages of the disease 
can acquire diverse phenotypes and functions that can be either detrimental or beneficial.  
The activation process begins when resting microglia detect the noxious stimuli or the sub-
products of tissue damage. Microglia become activated, release inflammatory mediators, 
express surface molecules and remove cellular debris by phagocytosis. Once the toxic factors 
are eliminated and under the influences of the invading immune cells and the normal CNS 
cells activated microglia acquire a neurotrophic phenotype and release anti-inflammatory 
cytokines and neurotrophic factors. After a certain period of time inflammation is resolved 
and the activating microglia return to a resting-surveying state retaining some kind of 
memory of the processes. However, under not fully elucidated conditions, this delicate 
balance between activation-termination and neurotoxic-neurotrophic phenotype can be 
disrupted leading to excessive, uncontrolled or prolonged activation of microglia with 
destructive consequences in neuronal survival. Excessive and dysregulated microglia 
activation were elicited after intense and severe CNS insults. Moreover, insufficient 
recruitment of systemic immune cells to the CNS site of lesion may result in an inability to 
suppress and terminate the microglia activation or to turn them into a neuroprotective 
phenotype (Kempermann & Neumann, 2003; Hanisch & Kettenmann, 2007; Popovich & 
Longbrake, 2008; Rivest, 2009; Schwartz & Shechter, 2010). Thus, dysregulation of the innate 
or adaptive immune system may mediate excessive inflammatory damage following brain 
insults. It is obvious that a better understanding of the interaction mechanisms between 
immune cells may facilitate the introduction of novel therapies.  
Several studies have investigated the microglia function after TBI. The release of various 
mediators in the extracellular space after the injured site alters the expression profile of local 
microglia. In a very interesting imaging study of fluorescent labeled microglia it was shown 
that microglia from the intact brain that are nearby the injured site extend their processes 
which reach the damaged site. There the processes and without cell body movement, 
converge and fuse together to form a spherical area of containment that separate the healthy 
from the injured tissue. In other words fused microglial processes act as a barrier that 
contains the tissue debris. This highly dynamic movement of microglial processes is under 
the chemotactic influence of extracellular ATP (Davalos et al., 2005).   
The time of induction and the duration of microglia activation after TBI were found to be 
different from other brain insults such as cerebral ischemia. Studies in humans with TBI 
have revealed a striking delay of microglial activation and proliferation. Markers of 
microglial activation and proliferation were not detected until 3 days post TBI (Beschorner 
et al., 2000; Engel et al., 2000) whereas the same markers were expressed early in cerebral 
ischemia (Postler et al., 1997). This observation although in line with some findings in 
experimental models (Aihara et al., 1995; Holmin et al., 1997) cannot be fully understood. It 
is possible to reflect different activation cascades of microglia after TBI compared to other 
brain insults. However this window delay of microglial activation after TBI may provide a 
therapeutic opportunity when the target would be the microglial activation.  
Several studies in TBI have also demonstrated that inflammation can persist for long period 
of time after the primary traumatic brain insult. Studies in rodents have revealed reactive 
astrocytosis for over a year following brain injury resulting in chronic progressive neuronal 
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tissue loss (Smith et al., 1997; Holmin & Mathiesen, 1999). In primates, microglia activation 
was found to persist for at least 12 months (Nagamoto-Combs et al., 2007). Post-mortem 
studies in humans have shown persistent elevated microglial activity several years after TBI 
(Gentleman et al., 2004). In addition, a recent PET imaging study in humans using a ligand 
that binds to activated microglia revealed increased microglial activation for up to 17 years 
after TBI (Ramlackhansingh et al., 2011). Persistent microglial activation is believed to 
underline both chronic neuroprotective and destructive processes. The precise mechanisms 
for the persistence of inflammatory processes after TBI are not fully understood. It is 
believed that a severe initial neuronal injury with excessive cytokine signals may lead to 
enhanced activation of microglia that further aggravate brain damage feeding a self-
sustaining and self-propelling prolonged vicious circle of neurotoxicity and progressive 
degeneration (Gao & Hong, 2008). This dysregulated and uncontrolled microglial activation 
may be the key for chronic, long-lived and destructive inflammatory processes. The long-
term microglia activation may also provide insights into a potential causative link between 
head injury and Alzheimer’s disease. 
4. Adaptive immunity  
Adaptive immunity refers to an antigen-specific response either cell-mediated or humoral 
aiming at elimination of pathogenic factors. Adaptive immunity is mediated by B and T 
lymphocytes. In experiment TBI, T cells were found to infiltrate the brain parenchyma in a 
biphasic manner: immediately after the primary impact as a result of disruption of BBB and 
in a delayed phage with increased numbers of T cells which represents an active infiltration 
of specific targeting T-cells (Czigner et al., 2007). In other studies it was shown that T cell 
infiltration in the damaged tissue occurred 3-14 days after CNS trauma and persisted for 6 
months (Kigerl et al., 2006; Beck et al., 2010). In post-mortem human studies CD4+ and CD8+ 
were identified in the injured tissue after spinal cord injury (Fleming et al., 2006).  
It is known that the transformation of naive T cells into effector T cells requires an initial 
antigen presentation in secondary lymphoid organs and a re-activation after re-exposure to 
their antigen. However, the exact mechanics of adaptive immune response after brain injury 
have not been fully elucidated and some aspects remain obscure. It is known that naive T 
cells against CNS antigens are circulating in the periphery. After brain insults the cerebral 
auto-antigens are exposed to the peripheral blood cells. The activation of naive T cells can 
take place in the peripheral lymph nodes as a result of BBB disruption and release of 
cerebral antigens into the bloodstream alone or in conjunction with the brain APCs 
(Lenzlinger et al., 2001; Ling et al., 2003; Karman et al., 2004). After activation, T cells traffic 
to the CNS under the influence of chemokine gradient. Microglia are already activated as a 
result of brain tissue damage and release of inflammatory mediators. Activated microlgia 
release at the site of injury cytokines and chemokines, express various surface molecules 
including complement components and induce the expression of adhesion molecules by the 
endothelial cells. These alterations induce the recruitment of the T cells into the injury site. 
Within the CNS, T cells become re-activated against their antigen which is presented to 
them by local microglia and macrophages.  
As already mentioned MHC expression is almost absent in normal brain parenchyma. 
After brain trauma activated microglia upregulate the expression of MHC class I and class 
II and the expression of adhesion molecules and costimulatory factors. Activated 
microglia can act as antigen-presenting cells to T cells by phagocytosis of the tissue debris, 
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processing of the relevant antigen and its subsequent presentation on class I or class II 
MHC (Ankeny et al., 2006).  
Another hypothesis that has been introduced is that the initial activation of T cells takes 
place within CNS. However, data have shown that the interaction between microglia and T 
cells is incomplete and insufficient to support a full activation and proliferation of T cells. In 
an ex vivo study this interaction resulted in increased T cell apoptosis which may reflect a 
regulatory function of microglia upon T cell responses (Ford et al., 1996). It seems possible 
that activated microglia may influence the function and maintenance of auto-reactive T cells 
in the CNS either directly by presenting the antigen causing re-activation of the T cells or 
indirectly by determining the local inflammatory/anti-inflammatory microenvironment and 
the recruitment of T cells.  
The peripheral activation of T cells against cerebral antigens is supported by a number of 
studies. Several studies have provided evidence for a traveling of the antigen from the CNS 
to the peripheral lymph nodes. Fluorescent substances injected into the CNS of animal 
models were detected in the cervical lymph nodes in a few hours after the injection. In 
addition, intracerebrally infused protein antigen was found to elicit the accumulation of 
antigen-specific CD8+ T cells 3 days after the injection (Ling et al., 2003). Moreover, 
experimental and human studies of CNS trauma have revealed the presence of auto-reactive 
T cells against cerebral antigens. Isolated T cells from an animal model of spinal cord injury 
when injected intravenously into naive recipients were found to induce spinal cord 
neuroinflammation and transient hind limb paralysis and ataxic gait (Popovich et al., 1996). 
Additionally auto-reactive T cells against myelin basic protein were found in increased 
frequencies in patients with spinal cord injury compared to multiple sclerosis patients and 
normal controls (Kil et al., 1999).  
Adaptive immunity may mediate either pathogenic or reparative processes based of the 
inflammatory conditions of the microenvironment during activation of T-cells. It has been 
hypothesized that Th1 immune response may aggravate brain damage by pro-inflammatory 
actions whereas Th2 response may alleviate brain damage by anti-inflammatory and 
neurotrophic effects. In a study of freeze cerebral injury activated T cells were found to 
exacerbate brain damage when transferred to rats 24h before the injury (Fee et al., 2003). In 
contrast, in an very intriguing study in animals with injury in the optic nerve it was shown 
that intraperitoneally injected anti-myelin basic protein specific T cells prevented the 
secondary degeneration of retinal ganglion cells (Moalem et al., 1999). These significant data 
were also replicated in an animal model of spinal cord injury. It was shown that 
autoreactive T cells against myelin basic protein or active immunization with myelin basic 
protein improved the recovery by promoting neuroprotective and regenerative processes 
(Hauben et al., 2000). Furthermore, it was showed that Th2 cells specific for myelin basic 
protein had protective effects on neuronal survival. This neuroprotective effect of the 
antigen-specific T cells was influenced by the extent of non-specific activation of the T cells 
(Wolf et al., 2002). In another study of peripheral facial nerve injury CD4+ T cells were found 
to mediate facial motor neurons survival (Serpe et al., 2003).  
These observations of beneficial effects of autoreactive T cells led to the introduction of the 
term “protective autoimmunity” implying that the recognition of an exposed self antigen by 
T cells can result in protection, repair and maintenance of the functional integrity of a tissue 
rather than the initiation of an autoimmune process. (Schwartz et al., 2003; Schwartz & 
Shechter, 2010). Regulatory T cells (CD4+CD25+Foxp3+) that suppress autoimmune activity 
seem to play a central role in protective autoimmunity. The concept of protective 
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tissue loss (Smith et al., 1997; Holmin & Mathiesen, 1999). In primates, microglia activation 
was found to persist for at least 12 months (Nagamoto-Combs et al., 2007). Post-mortem 
studies in humans have shown persistent elevated microglial activity several years after TBI 
(Gentleman et al., 2004). In addition, a recent PET imaging study in humans using a ligand 
that binds to activated microglia revealed increased microglial activation for up to 17 years 
after TBI (Ramlackhansingh et al., 2011). Persistent microglial activation is believed to 
underline both chronic neuroprotective and destructive processes. The precise mechanisms 
for the persistence of inflammatory processes after TBI are not fully understood. It is 
believed that a severe initial neuronal injury with excessive cytokine signals may lead to 
enhanced activation of microglia that further aggravate brain damage feeding a self-
sustaining and self-propelling prolonged vicious circle of neurotoxicity and progressive 
degeneration (Gao & Hong, 2008). This dysregulated and uncontrolled microglial activation 
may be the key for chronic, long-lived and destructive inflammatory processes. The long-
term microglia activation may also provide insights into a potential causative link between 
head injury and Alzheimer’s disease. 
4. Adaptive immunity  
Adaptive immunity refers to an antigen-specific response either cell-mediated or humoral 
aiming at elimination of pathogenic factors. Adaptive immunity is mediated by B and T 
lymphocytes. In experiment TBI, T cells were found to infiltrate the brain parenchyma in a 
biphasic manner: immediately after the primary impact as a result of disruption of BBB and 
in a delayed phage with increased numbers of T cells which represents an active infiltration 
of specific targeting T-cells (Czigner et al., 2007). In other studies it was shown that T cell 
infiltration in the damaged tissue occurred 3-14 days after CNS trauma and persisted for 6 
months (Kigerl et al., 2006; Beck et al., 2010). In post-mortem human studies CD4+ and CD8+ 
were identified in the injured tissue after spinal cord injury (Fleming et al., 2006).  
It is known that the transformation of naive T cells into effector T cells requires an initial 
antigen presentation in secondary lymphoid organs and a re-activation after re-exposure to 
their antigen. However, the exact mechanics of adaptive immune response after brain injury 
have not been fully elucidated and some aspects remain obscure. It is known that naive T 
cells against CNS antigens are circulating in the periphery. After brain insults the cerebral 
auto-antigens are exposed to the peripheral blood cells. The activation of naive T cells can 
take place in the peripheral lymph nodes as a result of BBB disruption and release of 
cerebral antigens into the bloodstream alone or in conjunction with the brain APCs 
(Lenzlinger et al., 2001; Ling et al., 2003; Karman et al., 2004). After activation, T cells traffic 
to the CNS under the influence of chemokine gradient. Microglia are already activated as a 
result of brain tissue damage and release of inflammatory mediators. Activated microlgia 
release at the site of injury cytokines and chemokines, express various surface molecules 
including complement components and induce the expression of adhesion molecules by the 
endothelial cells. These alterations induce the recruitment of the T cells into the injury site. 
Within the CNS, T cells become re-activated against their antigen which is presented to 
them by local microglia and macrophages.  
As already mentioned MHC expression is almost absent in normal brain parenchyma. 
After brain trauma activated microglia upregulate the expression of MHC class I and class 
II and the expression of adhesion molecules and costimulatory factors. Activated 
microglia can act as antigen-presenting cells to T cells by phagocytosis of the tissue debris, 
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processing of the relevant antigen and its subsequent presentation on class I or class II 
MHC (Ankeny et al., 2006).  
Another hypothesis that has been introduced is that the initial activation of T cells takes 
place within CNS. However, data have shown that the interaction between microglia and T 
cells is incomplete and insufficient to support a full activation and proliferation of T cells. In 
an ex vivo study this interaction resulted in increased T cell apoptosis which may reflect a 
regulatory function of microglia upon T cell responses (Ford et al., 1996). It seems possible 
that activated microglia may influence the function and maintenance of auto-reactive T cells 
in the CNS either directly by presenting the antigen causing re-activation of the T cells or 
indirectly by determining the local inflammatory/anti-inflammatory microenvironment and 
the recruitment of T cells.  
The peripheral activation of T cells against cerebral antigens is supported by a number of 
studies. Several studies have provided evidence for a traveling of the antigen from the CNS 
to the peripheral lymph nodes. Fluorescent substances injected into the CNS of animal 
models were detected in the cervical lymph nodes in a few hours after the injection. In 
addition, intracerebrally infused protein antigen was found to elicit the accumulation of 
antigen-specific CD8+ T cells 3 days after the injection (Ling et al., 2003). Moreover, 
experimental and human studies of CNS trauma have revealed the presence of auto-reactive 
T cells against cerebral antigens. Isolated T cells from an animal model of spinal cord injury 
when injected intravenously into naive recipients were found to induce spinal cord 
neuroinflammation and transient hind limb paralysis and ataxic gait (Popovich et al., 1996). 
Additionally auto-reactive T cells against myelin basic protein were found in increased 
frequencies in patients with spinal cord injury compared to multiple sclerosis patients and 
normal controls (Kil et al., 1999).  
Adaptive immunity may mediate either pathogenic or reparative processes based of the 
inflammatory conditions of the microenvironment during activation of T-cells. It has been 
hypothesized that Th1 immune response may aggravate brain damage by pro-inflammatory 
actions whereas Th2 response may alleviate brain damage by anti-inflammatory and 
neurotrophic effects. In a study of freeze cerebral injury activated T cells were found to 
exacerbate brain damage when transferred to rats 24h before the injury (Fee et al., 2003). In 
contrast, in an very intriguing study in animals with injury in the optic nerve it was shown 
that intraperitoneally injected anti-myelin basic protein specific T cells prevented the 
secondary degeneration of retinal ganglion cells (Moalem et al., 1999). These significant data 
were also replicated in an animal model of spinal cord injury. It was shown that 
autoreactive T cells against myelin basic protein or active immunization with myelin basic 
protein improved the recovery by promoting neuroprotective and regenerative processes 
(Hauben et al., 2000). Furthermore, it was showed that Th2 cells specific for myelin basic 
protein had protective effects on neuronal survival. This neuroprotective effect of the 
antigen-specific T cells was influenced by the extent of non-specific activation of the T cells 
(Wolf et al., 2002). In another study of peripheral facial nerve injury CD4+ T cells were found 
to mediate facial motor neurons survival (Serpe et al., 2003).  
These observations of beneficial effects of autoreactive T cells led to the introduction of the 
term “protective autoimmunity” implying that the recognition of an exposed self antigen by 
T cells can result in protection, repair and maintenance of the functional integrity of a tissue 
rather than the initiation of an autoimmune process. (Schwartz et al., 2003; Schwartz & 
Shechter, 2010). Regulatory T cells (CD4+CD25+Foxp3+) that suppress autoimmune activity 
seem to play a central role in protective autoimmunity. The concept of protective 
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autoimmunity raises some interesting therapeutics options. A vaccination with weak CNS 
specific antigens or a modulation of regulatory T cells activity that enhance protective 
autoimmunity would be a novel approach for neuroprotection and repair after CNS trauma 
(Schwartz et al., 2009).  
In conclusion, neuroinflammation seems to play a key role in the pathophysiology of brain 
damage following TBI. A complex interaction between several components and mediators 
of the innate and adaptive immunity appear to determine the extent of inflammation and its 
nature, either destructive or reparative. A better understanding of these mechanisms that 
are implicated in the initiation, progression and termination of the inflammation and the 
communication between immune cells is required for the development of new and effective 
therapeutic strategies.   
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1. Introduction 
The aging process influences cognitive and physical functioning through a variety of 
biological mechanisms.  Multiple facets of cognitive function decline with age, including 
executive function, memory, language, visuomotor coordination, and information 
processing speed.  Strong epidemiological trends show that areas of brain injury due to 
ischemic damage also increase with age.  Areas of ischemic damage known as leukoaraiosis 
appear as hyperintense spots on MRI of the white matter of the brain.  Leukoaraiosis is a 
strong predictor of ischemic stroke and vascular dementia, independent of other known risk 
factors (Markus et al., 2005).  It is also strongly associated with cognitive impairment and 
cognitive decline in individuals who have not yet progressed to dementia (Pantoni et al., 
2007; Schmidt et al., 2007). 
Few studies have examined the genetic contribution to later-age cognitive changes in 
relationship to markers of subclinical ischemic brain injury such as leukoaraiosis.  After 
increasing age, the main risk factors for leukoaraiosis are elevated blood pressure and lack 
of hypertension control (van Dijk et al., 2004). However, there is a significant amount of 
inter-individual variation in leukoaraiosis among subjects with similar duration and 
severity of hypertension (Schmidt et al., 2004; Szolnoki & Melegh, 2006).  Cognitive 
functioning is also highly variable, and it is likely that genetic variability accounts for a 
significant portion of the variation in both structural characteristics of the brain such as 
leukoaraiosis and measures of cognitive function (Deary et al., 2004). 
In this chapter, we present a review of the biological mechanisms that influence 
leukoaraiosis and cognitive function, discuss the public health implications of the clinical 
manifestations of cerebrovascular disease, and explore the broad genetic attributes that 
explain inter-individual variation and covaraition (i.e., pleiotropy) among these brain traits. 
1.1 Biological mechanisms that influence leukoaraiosis and cognitive function 
1.1.1 Physiology and pathology of cerebrovascular disease and leukoaraiosis 
The human brain is composed of gray matter (the cerebral cortex) that is responsible for 
consciousness, movement, and cognition and white matter that consists of nerve fibers that 
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increasing age, the main risk factors for leukoaraiosis are elevated blood pressure and lack 
of hypertension control (van Dijk et al., 2004). However, there is a significant amount of 
inter-individual variation in leukoaraiosis among subjects with similar duration and 
severity of hypertension (Schmidt et al., 2004; Szolnoki & Melegh, 2006).  Cognitive 
functioning is also highly variable, and it is likely that genetic variability accounts for a 
significant portion of the variation in both structural characteristics of the brain such as 
leukoaraiosis and measures of cognitive function (Deary et al., 2004). 
In this chapter, we present a review of the biological mechanisms that influence 
leukoaraiosis and cognitive function, discuss the public health implications of the clinical 
manifestations of cerebrovascular disease, and explore the broad genetic attributes that 
explain inter-individual variation and covaraition (i.e., pleiotropy) among these brain traits. 
1.1 Biological mechanisms that influence leukoaraiosis and cognitive function 
1.1.1 Physiology and pathology of cerebrovascular disease and leukoaraiosis 
The human brain is composed of gray matter (the cerebral cortex) that is responsible for 
consciousness, movement, and cognition and white matter that consists of nerve fibers that 
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transmit impulses among cerebral areas and to the central nervous system. Leukoaraiosis is 
visible as bright spots in the white matter on T2-weighted MRIs (Markus, 2008; O'Sullivan, 
2008). Leukoaraiosis ranges in severity from small, distinct areas of white matter 
hyperintensity (punctuate lesions) to large regions of white matter hyperintensity (early 
confluent or confluent lesions) (O'Sullivan, 2008). Leukoaraiosis is thought to be a marker of 
cerebral small vessel disease (cerebrovascular disease) in the long, narrow penetrating 
arterioles that supply the white matter with blood (Markus, 2008). This type of small vessel 
disease is defined by areas of diffuse arteriolosclerosis with deposits of a proteinaceous 
substance that includes fibrin, amyloid, and collagen, which results in thickening of the 
vessel and chronic ischemia that leads to demyelination, axonal loss, and gliosis (Markus, 
2008; O'Sullivan, 2008). It occurs in regions of the brain that have low perfusion pressure, 
such as the deep white matter, and results in chronic ischemia and multiple diffuse 
infarctions due to small vessel occlusions (lacunar infarctions), both of which are visible as 
hyperintensity on MRIs (Markus, 2008). In regions of leukoaraiosis, there appears to be 
decreased blood flow (hypoperfusion) and impaired ability to regulate blood flow 
(autoregulation) (Markus, 2008).  
Recently, it has been suggested that endothelial dysfunction, characterized by the inability 
of endothelial cells to perform tasks such as mediation of coagulation, platelet adhesion, and 
immune response, may be the intermediate process between hypertension and the 
alterations in blood flow observed in areas of leukoaraiosis (Hassan et al., 2003; Markus, 
2008). Circulating endothelial markers may show a pro-coagulant pattern of endothelial 
function (e.g. higher circulating levels of thrombomodulin (TM) and lower circulating levels 
of tissue factor pathway inhibitor (TFPI)) that is specific to leukoaraiosis (Hassan et al., 2003) 
and may be related to progression of leukoaraiosis (Markus et al., 2005). Further support for 
endothelial dysfunction comes from the strong association between leukoaraiosis and 
elevated homocysteine level, which is hypothesized to be a mediator of endothelial damage 
(Hassan et al., 2004). 
1.1.2 Hypertension as a predictor of leukoaraiosis 
Development of leukoaraiosis is thought to be a marker of one of the major mechanistic 
pathways between hypertension and clinical endpoints such as ischemic stroke and vascular 
dementia, and is a known risk factor for both of these endpoints (Markus et al., 2005; 
O'Sullivan, 2008). Inadequately controlled hypertension gives rise to ischemic damage of the 
brain that is thought to be the manifestation of underlying cerebrovascular disease (Turner 
& Boerwinkle, 2000). Several studies have also demonstrated an association between 
hypertension in midlife and cognitive decline in later life (Launer et al., 2000), and it has 
been hypothesized that this is due to the cumulative effects of subclinical damage due to 
small vessel disease (Knopman et al., 2001) with leukoaraiosis as a detectable sign of one of 
the main mechanistic pathways implicated (Sierra & Coca, 2006). Hypertension is a leading 
risk factor for ischemic stroke (Roger et al., 2011) and for cognitive decline leading to 
vascular dementia (Launer et al., 2000). Hypertension affects approximately 1 in 3 American 
adults (76.4 million people), and accounts for $43.5 billion in yearly direct and indirect costs 
in the United States (Roger et al., 2011).  
1.1.3 The relationship between leukoaraiosis and cognitive function 
In a review of studies pertaining to leukoaraiosis and cognition, Pantoni et al. (2007) 
conclude that despite different study characteristics, there is almost invariably evidence of 
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an effect of leukoaraiosis on cognition. In particular, leukoaraiosis is more strongly 
associated with decreasing executive function than memory and is also associated with a 
decline in motor performance such as gait disturbances (Pantoni et al., 2007; Schmidt et al., 
2007). The rate of progression of leukoaraiosis over time is also related to cognitive decline, 
and the severity of leukoaraiosis at baseline is a significant predictor of progression 
(Schmidt et al., 2007). It is also important to keep in mind, however, that other factors may 
affect the association between leukoaraiosis and cognitive decline such as brain atrophy and 
stroke (Pantoni et al., 2007; Schmidt et al., 2007). 
1.1.4 Cognitive decline and vascular dementia 
Dementia is a heterogeneous group of disorders with variable etiology that involves 
impairment in cognitive domains such as memory, executive function, and language as well 
as specific physical impairments such as gait abnormalities that cause significant 
impairment in social or occupational function and represent a decline from a previous level 
of functioning (American Psychiatric Association, 2000). The differential diagnosis of 
vascular dementia (VaD), incorporates the underlying vascular cause as well as the 
cognitive and physical symptomology (Pohjasvaara et al., 2000), specifically “focal 
neurological signs and symptoms or laboratory evidence indicative of cerebrovascular 
disease (multiple infarctions involving cortex and underlying white matter) that are judged 
to be etiologically related to the disturbance“ (American Psychiatric Association, 2000). 
Leukoaraiosis and multiple lacunar (small vessel) strokes, both caused by cerebrovascular 
disease, are the primary markers of VaD (Geldmacher & Whitehouse, 1997) and are thought 
to be contributors to cognitive impairment in individuals who have not yet progressed to 
dementia (Pantoni et al., 2007; Schmidt et al., 2007). Several studies have also shown that 
leukoaraiosis is predictive of incident VaD (Prins et al., 2004). 
1.1.5 Complexity in the inter-relationships among clinical outcomes and sub-clinical 
measures 
A complex relationship exists among hypertension, leukoaraiosis, cognitive decline, 
dementia, and stroke. The figure below illustrates what is currently known about the inter-
relationships among these clinical outcomes and subclinical measures, including: 
 Leukoaraiosis is thought to be a manifestation (sub-clinical marker) of cerebrovascular 
disease. 
 Hypertension is a primary risk factor for leukoaraiosis. 
 Leukoaraiosis is a risk factor for cognitive decline and ischemic stroke. 
 Leukoaraiosis, ischemic stroke, and cognitive decline are included in the clinical criteria 
for the diagnosis of vascular dementia. 
 Ischemic stroke (without additional evidence of leukoaraiosis) is a risk factor for 
cognitive decline. 
1.2 Public health implications of the clinical manifestations of cerebrovascular 
disease 
The clinical outcomes that are associated with cerebrovascular disease have large public 
health implications. Ischemic stroke accounts for 87% of all strokes, a leading cause of 
morbidity, mortality, and economic burden in the US (Roger et al., 2011). Stroke is the 
second most common cause of death and disability-adjusted life-years in industrialized 
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an effect of leukoaraiosis on cognition. In particular, leukoaraiosis is more strongly 
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2007). The rate of progression of leukoaraiosis over time is also related to cognitive decline, 
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impairment in social or occupational function and represent a decline from a previous level 
of functioning (American Psychiatric Association, 2000). The differential diagnosis of 
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to be contributors to cognitive impairment in individuals who have not yet progressed to 
dementia (Pantoni et al., 2007; Schmidt et al., 2007). Several studies have also shown that 
leukoaraiosis is predictive of incident VaD (Prins et al., 2004). 
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measures 
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 Ischemic stroke (without additional evidence of leukoaraiosis) is a risk factor for 
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disease 
The clinical outcomes that are associated with cerebrovascular disease have large public 
health implications. Ischemic stroke accounts for 87% of all strokes, a leading cause of 
morbidity, mortality, and economic burden in the US (Roger et al., 2011). Stroke is the 
second most common cause of death and disability-adjusted life-years in industrialized 
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countries (Lopez et al., 2001) and the third most common cause of death in the US, 
accounting for approximately 1 in 18 deaths in 2007 (Roger et al., 2011). Over 7 million 
Americans currently living with the cognitive and physical consequences of stroke (Roger et 
al., 2011), and it has been estimated that stroke account for approximately 4% of all direct 
health care costs in the US (Donnan et al., 2008). The risk of first-ever stroke is almost twice 
as high for African Americans as for white Americans, which may in part be due to the 
higher prevalence of hypertension in this group (Roger et al., 2011).  
 
 
Fig. 1. Relationship between subclinical measures and clinical outcomes. Dark blue arrows 
represent risk factor relationships, and dashed blue lines represent clinical criteria. 
Dementia is also an important public health burden in the U.S. and abroad (Haan & 
Wallace, 2004), and the World Health Organization predicts that there will be approximately 
29 million people affected by all forms of dementia by the year 2020 (Essink-Bot et al., 2002). 
Alzheimer’s disease (AD) and other dementias affect over 5.2 million Americans, including 
between 200,000 and 500,000 people under the age of 65. Dementias place a heavy economic 
burden on the health care system, with each Medicare patient with dementia accounting for 
more than three times as much spending than the average beneficiary (Alzheimer’s 
Association, 2008). The aging population of the U.S. is expected to dramatically increase the 
prevalence of dementia, which is thought to affect 3%-11% of people older than 65 and 25%-
47% of people older than 85 (Boustani et al., 2003). Older African Americans are about twice 
as likely to develop AD and other dementias as older white Americans, which may in part 
be due to the higher prevalences of hypertension and diabetes and lower average 
socioeconomic status of this group (Alzheimer’s Association, 2010). 
1.3 Role of genetics in leukoaraiosis and cognitive function 
Genetic factors are likely to account for a significant amount of the inter-individual variation 
in cognitive functioning and brain structure (Deary et al., 2004). Heritability studies, 
candidate gene studies, and genome-wide association studies are beginning to shed light on 
the biological processes involved in the progression from hypertension to the development 
of leukoaraiosis and cognitive decline that are indicators of increased risk of stroke and 
dementia.  
1.3.1 Genetics of leukoaraiosis and cognitive function 
Estimates of heritability for leukoaraiosis range from 0.45-0.71, indicating that genetic 
factors account for a large proportion of the inter-individual variation in this trait (Atwood 
et al., 2004; Carmelli et al., 1998; Turner et al., 2004). Candidate gene studies for 
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leukoaraiosis have primarily concentrated on genes in pathways known to be involved in 
hypertension, vasculature, and endothelial damage. Although initial findings have been 
encouraging, no specific genetic factors have been unequivocally shown to be associated 
with this trait (Paternoster et al., 2009). Genome-wide association studies (GWAS) for this 
trait have also been limited, but are currently being conducted in several ethnic groups. To 
date, the most promising evidence for association is with a region on chromosome 17q25 in 
European Americans (Fornage et al., 2011). 
For cognitive decline, the most promising candidate genes include those that are associated 
with hypertension, leukoaraiosis, Alzheimer’s Disease (AD), normal cognitive functioning, 
cardiovascular function, oxidative stress, and inflammation (Deary et al., 2004), though 
candidate gene studies have not yet established any specific genetic factors that definitively 
affect cognitive decline. GWAS for a variety of cognitive traits are currently underway. 
GWASs that examine the change of cognitive traits over time in multiple cohorts will be 
particularly useful for identifying genetic factors associated with cognitive decline. 
1.3.2 Role of pleiotropy 
Pleiotropy is most simply defined as the condition in which variation in a single gene affects 
multiple traits (Hodgkin, 1998). Defined in this manner, pleiotropic genes range from those 
that encode proteins involved in a single biological pathway that influences multiple disease 
processes and/or organ systems to those that play entirely different roles in multiple biological 
pathways. In some instances, pleiotropy is “the phenomenon in which a single gene controls 
several distinct, seemingly unrelated, phenotypic effects” (Zou et al., 2008). A well-known 
example of pleiotropy in humans is the 4 allele of the apolioprotein E (APOE) gene (Dickstein 
et al., 2010). APOE is a plasma cholesterol transport molecule that resides primarily on very 
low density lipoproteins, and the 4 allele has been shown to be a risk factor for coronary heart 
disease and stroke through mechanisms related directly to lipid transport. However, the 4 
alelle is also a risk factor for AD and cognitive decline, with those carrying the allele having a 
younger age of onset as well as an accelerated pace of cognitive decline. Though the precise 
mechanism by which 4 leads to cognitive decline is not known, the main hypotheses are 
through pathways not directly related or only tangentially related to lipid transport. APOE 
appears to affect brain traits through its role as a chaperone for the amyloid beta protein 
and/or mediation of the phosphorylation of the tau protein.  
The study of pleiotropy in model organisms and humans serves several functions. In model 
organisms, it serves to further the understanding and elucidation of the complex biological 
pathways that regulate the development of traits, providing information about normal 
cellular function, normal development and function at the organismal level, connections 
between previously unrecognized biological processes, and increased predictive ability in 
breeding programs (Hodgkin, 1998). It also it provides insight into the mechanisms of 
evolution, as effects on multiple traits due to a single genetic variant may pose severe 
evolutionary constraints (Cheverud et al., 2004). The findings from pleiotropy studies in 
model organisms, particularly the high degree of connectivity among transcriptional 
modules, have strong implications for understanding the pleiotropic genetic mechanisms 
that are also operating in humans. A greater understanding of the underlying pleiotropic 
mechanisms contributing to human health and disease has the potential to allow for earlier 
identification of individuals at increased risk for disease, the development of more 
efficacious treatments, and the tailoring of particular treatments to people most likely to 
respond positively. 
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countries (Lopez et al., 2001) and the third most common cause of death in the US, 
accounting for approximately 1 in 18 deaths in 2007 (Roger et al., 2011). Over 7 million 
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al., 2011), and it has been estimated that stroke account for approximately 4% of all direct 
health care costs in the US (Donnan et al., 2008). The risk of first-ever stroke is almost twice 
as high for African Americans as for white Americans, which may in part be due to the 
higher prevalence of hypertension in this group (Roger et al., 2011).  
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as likely to develop AD and other dementias as older white Americans, which may in part 
be due to the higher prevalences of hypertension and diabetes and lower average 
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in cognitive functioning and brain structure (Deary et al., 2004). Heritability studies, 
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the biological processes involved in the progression from hypertension to the development 
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efficacious treatments, and the tailoring of particular treatments to people most likely to 
respond positively. 
 
Brain Injury – Pathogenesis, Monitoring, Recovery and Management 
 
44
1.3.3 Bivariate variance component analysis to assess pleiotropy 
Studies of pleiotropy in humans have generally consisted of bivariate genetic analysis using 
variance decomposition techniques and linkage analysis in biologically related groups of 
traits. Variance decomposition techniques are used to parse the total phenotypic correlation 
in a pair of traits into the correlation due to genetic influences (genetic correlation) and the 
correlation due to environmental influences (environmental correlation) using family 
relationships.  
Bivariate variance decomposition techniques have been used to study pleiotropy in humans 
for a variety of purposes. Comuzzie et al. (1994) estimated the genetic and environmental 
correlations among eight measures of skinfolds in order to inform epidemiologic studies 
that examine these measures as risk factors for heart disease and diabetes. The authors 
argue that studying pleiotropy in risk factors is important because shared genetic or 
environmental effects may confound analyses using these traits if these effects are 
unrecognized. Bivariate genetic analysis is has also been used to identify measureable 
endophenotypes that can be used to study the genetic underpinnings of complex diseases 
with multiple etiologies. For example, Charlesworth et al. (2010) examined the genetic 
correlations between several quantitative characteristics of the eye and primary open-angle 
glaucoma in order to determine the most appropriate endophenotypes to focus on in genetic 
association studies. 
1.4 Motivation for studying pleiotropy of leukoaraiosis and cognitive function 
In this chapter, we focus on estimating the heritabilities, genetic correlations, and 
environmental correlations between leukoaraiosis and seven measures of neurocognitive 
function. In a sample of 759 whites and 720 African Americans, we examine patterns of 
pleiotropy using a bivariate variance components approach. Findings of this work help 
inform the understanding of the genetic relationships among leukoaraiosis and measures of 
cognitive function. A deeper understanding the genetics of leukoaraiosis development and 
its impact on cognitive decline in individuals free of overt neurocognitive disorders may 
help to inform pharmacogenomic drug development and preventive strategies for 
identifying individuals at increased risk of stroke and dementia. Research into the genetic 
architecture of leukoaraiosis and cognitive function in samples that are presymptomatic is 
particularly important because preventive interventions for dementia would need to start 
early, preferably before any brain damage occurs (DeKosky & Marek, 2003). 
2. Methods 
2.1 Sample 
The National Heart, Lung and Blood Institute established the Family Blood Pressure 
Program (FBPP) in 1996 from four existing research networks that were investigating the 
genetics of hypertension and its sequelae (FBPP Investigators, 2002), including The Genetic 
Epidemiology Network of Arteriopathy (GENOA). GENOA recruited hypertensive sibships 
from Rochester, Minnesota and Jackson, Mississippi for linkage and association studies to 
investigate the genetic underpinnings of hypertension and target organ damage related to 
hypertension (Daniels et al., 2004). 
In the initial phase of the GENOA study (Phase I: 1996-2001), all members of sibships 
containing ≥ 2 individuals with essential hypertension clinically diagnosed before age 60 
were invited to participate, including both hypertensive and normotensive siblings (1,583 
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non-Hispanic whites and 1,841 African Americans). The diagnosis of essential hypertension 
was established based on blood pressure levels measured at the study visit (>140 mmHg 
average systolic BP or >90 mmHg average diastolic BP) or a prior diagnosis of hypertension 
and current treatment with antihypertensive medications. Exclusion criteria were secondary 
hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent diabetes mellitus, or 
active malignancy. In the second phase of the GENOA study (Phase II: 2000-2004), 1,241 
white and 1,482 African American participants were successfully re-recruited to measure 
potential target organ damage due to hypertension. Phase I and II GENOA data consist of 
demographic information, medical history, clinical characteristics, lifestyle factors, and 
blood samples for genotyping and biomarker assays. Written informed consent was 
obtained from all subjects and approval was granted by participating institutional review 
boards. All reported phenotype and covariate data used for this analysis was collected 
during the Phase II exam. 
The Genetics of Microangiopathic Brain Injury (GMBI) study (2001-2006) is an ancillary 
study of GENOA undertaken to investigate susceptibility genes for ischemic brain injury. 
Phase II GENOA participants that had a sibling willing and eligible to participate in  
the GMBI study underwent a neurocognitive testing battery to assess several domains  
of cognitive function including learning, memory, attention, concentration, and language. 
Ischemic brain damage to the subcortical and periventricular white matter (leukoaraiosis) 
was quantified by magnetic resonance imaging (MRI) in subjects who had no history  
of stroke or neurological disease and no implanted metal devices. Participants  
were excluded from this analysis if they were less than 45 years of age or had evidence of 
silent stroke (transient ischemic attack) upon examination of their MRI. The analysis 
sample was comprised of 762 whites in 378 sibships and 720 African Americans in  
413 sibships. 
2.2 Leukoaraiosis 
Leukoaraiosis volume (cm3) was obtained via MRI in a separate clinical visit. All MRI scans 
were performed on identically equipped Signa 1.5 T MRI scanners (GE Medical Systems, 
Waukesha, WI, USA) and images were centrally processed at the Mayo Clinic. Symmetric 
head positioning with respect to orthogonal axes was verified by a series of short scout 
scans. Total intracranial volume (head size) was measured from T1-weighted spin echo 
sagittal images, each set consisting of 32 contiguous 5 mm thick slices with no interslice gap, 
field of view = 24 cm, matrix = 256 x 192, obtained with the following sequence: scan  
time = 2.5 min, echo time = 14 ms, repetitions = 2, replication time = 500 ms (Jack et al., 
1989). Total brain and leukoaraiosis volumes were determined from axial fluid-attenuated 
inversion recovery (FLAIR) images, each set consisting of 48 contiguous 3-mm interleaved 
slices with no interslice gap, field of view = 22 cm, matrix = 256 x 160, obtained with the 
following sequence: scan time = 9 min, echo time = 144.8 ms, inversion time = 2,600 ms, 
repetition time = 26,002 ms, bandwidth = +/- 15.6 kHz, one signal average. A FLAIR image 
is a T2-weighted image with the signal of the cerebrospinal fluid nulled, such that brain 
pathology appears as the brightest intracranial tissue. Interactive imaging processing steps 
were performed by a research associate who had no knowledge of the subjects’ personal or 
medical histories or biological relationships. A fully automated algorithm was used to 
segment each slice of the edited multi-slice FLAIR sequence into voxels assigned to one of 
three categories: brain, cerebrospinal fluid, or leukoaraiosis. The mean absolute error of this 
method is 1.4% for brain volume and 6.6% for leukoaraiosis volume, and the mean test-
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1.3.3 Bivariate variance component analysis to assess pleiotropy 
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early, preferably before any brain damage occurs (DeKosky & Marek, 2003). 
2. Methods 
2.1 Sample 
The National Heart, Lung and Blood Institute established the Family Blood Pressure 
Program (FBPP) in 1996 from four existing research networks that were investigating the 
genetics of hypertension and its sequelae (FBPP Investigators, 2002), including The Genetic 
Epidemiology Network of Arteriopathy (GENOA). GENOA recruited hypertensive sibships 
from Rochester, Minnesota and Jackson, Mississippi for linkage and association studies to 
investigate the genetic underpinnings of hypertension and target organ damage related to 
hypertension (Daniels et al., 2004). 
In the initial phase of the GENOA study (Phase I: 1996-2001), all members of sibships 
containing ≥ 2 individuals with essential hypertension clinically diagnosed before age 60 
were invited to participate, including both hypertensive and normotensive siblings (1,583 
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non-Hispanic whites and 1,841 African Americans). The diagnosis of essential hypertension 
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obtained from all subjects and approval was granted by participating institutional review 
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The Genetics of Microangiopathic Brain Injury (GMBI) study (2001-2006) is an ancillary 
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was quantified by magnetic resonance imaging (MRI) in subjects who had no history  
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head positioning with respect to orthogonal axes was verified by a series of short scout 
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sagittal images, each set consisting of 32 contiguous 5 mm thick slices with no interslice gap, 
field of view = 24 cm, matrix = 256 x 192, obtained with the following sequence: scan  
time = 2.5 min, echo time = 14 ms, repetitions = 2, replication time = 500 ms (Jack et al., 
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retest coefficient of variation is 0.3% for brain volume and 1.4% for leukoaraiosis volume 
(Jack et al., 2001). White matter hyperintensities in the corona-radiata and periventricular 
zone, as well as central gray infarcts (ie, lacunes) were included in the global leukoaraiosis 
measurements. Brain scans with cortical infarctions were excluded from the analyses 
because of the distortion of the leukoaraiosis volume estimates that would be introduced in 
the automated segmentation algorithm. 
2.3 Neuropsychological testing battery 
Neuropsychological tests were conducted in a private room that was free of noise and other 
distractions by trained interviewers. In order to assure accuracy and comparability in test 
administrator performance, a portion (approximately 5%) of all interviews were tape 
recorded and evaluated for accuracy to provide feedback to test administrators. The 
neuropsychological outcome measures used for this analysis are presented in Table 1 along 
with the cognitive functions assessed.  
 
Neurocognitive Test Outcome Measure Cognitive Functions 
Rey’s Auditory Verbal 





Vulnerability to interference 
Rey’s Auditory Verbal 





Digit Symbol Substitution 




Controlled Oral Word 
Association Test (COWA) COWA FAS 
Language 
Verbal fluency (phonetic association) 
Controlled Oral Word 




Category fluency (semantic association) 
Stroop Color Word Test Stroop color word 
Concentration effectiveness 
Ability to shift perceptual sets in 
response to novel stimuli 
Stroop Color Word Test Stroop interference 
Ability to shift perceptual sets in 
response to novel stimuli 
Table 1. Measures of cognitive function 
2.3.1 Rey’s Auditory Verbal Learning Test (RAVLT) 
Rey’s Auditory Verbal Learning Test (RAVLT) is a brief test that assesses learning and 
memory through multiple learning trials and a 30-minute delayed recall (Rey, 1964). 
Specifically, the measure assesses immediate memory span, new learning, vulnerability to 
interference in learning, and recognition memory. RAVLT testing norms for individuals 
aged 55 and older were developed through Mayo’s Older Americans Normative Studies 
(MOANS), and the testing procedure followed in GMBI was identical to that used in 
MOANS (Ivnik et al., 1992). 
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The examiner begins by reading a list of 15 common words aloud, and participants are 
asked to recall as many of the words as possible in any order. The same procedure is 
repeated four more times using the same list of 15 words. The total number of words that 
the participant remembers correctly over the five trials is recorded and forms the basis of the 
RAVLT total learning outcome measure for this analysis, which assesses immediate 
memory. Delayed recall is assessed by asking the participant to again name as many words 
as he/she remembers after a 30-minute delay, forming the basis of the RAVLT delayed 
learning outcome measure for this analysis. During the 30-minute interim, an interference 
task is performed in which the interviewer reads another set of words aloud, and the 
participant is asked to recall them. Thus, the delayed learning outcome assesses both 
delayed memory as well as vulnerability to interference. 
2.3.2 Wechsler Adult Intelligence Scale Revised (WAIS-R) Digit Symbol  
Substitution Task (DSST) 
The Digit Symbol Substitution task (DSS) from the Wechsler Adult Intelligence Scale 
Revised (WAIS-R) (Wechsler, 1981) is a timed translation test designed to measure complex 
visual attention, sustained and focused concentration, response speed, and visuomotor 
coordination (Lezak, 1995). In this test, participants are given a key in which each number 
corresponds to a special symbol. The task consists of filling in empty boxes below a series of 
random numbers with the symbol corresponding to the appropriate number (translating the 
numbers to symbols). After a practice session to ensure that the participant understands the 
task, participants were given a 90 second time limit to complete as many items as possible. 
The DSST outcome measure for this analysis was the number of correct symbols completed 
in 90 seconds.  
2.3.3 Controlled Oral Word Association Test (COWA) of the Multilingual Aphasia 
Examination 
The Multilingual Aphasia Examination was developed to diagnose the presence of aphasic 
disorders (any type of acquired language impairment), and the Controlled Oral Word 
Association Test (COWA) is a subset of this examination designed to measure verbal fluency 
(Lezak, 1995). Two measures of verbal fluency were used as outcomes for the present study, 
one of letter fluency (Word Fluency Test (WFT)) and one of category fluency (Animal Naming). 
The Word Fluency Test of the COWA assesses letter fluency (phonetic association) by asking 
subjects to generate words orally that begin with a specific letter of the alphabet (“F”, “A”, 
and “S”) for a period of 60 seconds. These letters were chosen because they have been 
demonstrated to allow more vocabulary choices overall than other letters. Scoring of this 
test consisted of adding the total number of admissible words generated for each of the 
three letters. Inadmissable words include proper nouns as well as variations, plurals, and 
repetitions of previously stated words. 
The Animal Naming portion of the COWA assesses category fluency (semantic association) by 
asking subjects to name as many animals as possible in a period of 60 seconds (Lezak, 1995). 
Scoring of this test is the sum of all admissible animals. Inadmissable animals include extinct, 
imaginary, or magical animals, proper names, and variations of previously stated animals. 
2.3.4 Stroop Color Word (CW) Test 
The Stroop Color Word (CW) Test is primarily a measure of concentration effectiveness, 
specifically the ability to shift perceptual sets to correspond with changing demands and the 
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retest coefficient of variation is 0.3% for brain volume and 1.4% for leukoaraiosis volume 
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the automated segmentation algorithm. 
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with the cognitive functions assessed.  
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Rey’s Auditory Verbal Learning Test (RAVLT) is a brief test that assesses learning and 
memory through multiple learning trials and a 30-minute delayed recall (Rey, 1964). 
Specifically, the measure assesses immediate memory span, new learning, vulnerability to 
interference in learning, and recognition memory. RAVLT testing norms for individuals 
aged 55 and older were developed through Mayo’s Older Americans Normative Studies 
(MOANS), and the testing procedure followed in GMBI was identical to that used in 
MOANS (Ivnik et al., 1992). 
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The examiner begins by reading a list of 15 common words aloud, and participants are 
asked to recall as many of the words as possible in any order. The same procedure is 
repeated four more times using the same list of 15 words. The total number of words that 
the participant remembers correctly over the five trials is recorded and forms the basis of the 
RAVLT total learning outcome measure for this analysis, which assesses immediate 
memory. Delayed recall is assessed by asking the participant to again name as many words 
as he/she remembers after a 30-minute delay, forming the basis of the RAVLT delayed 
learning outcome measure for this analysis. During the 30-minute interim, an interference 
task is performed in which the interviewer reads another set of words aloud, and the 
participant is asked to recall them. Thus, the delayed learning outcome assesses both 
delayed memory as well as vulnerability to interference. 
2.3.2 Wechsler Adult Intelligence Scale Revised (WAIS-R) Digit Symbol  
Substitution Task (DSST) 
The Digit Symbol Substitution task (DSS) from the Wechsler Adult Intelligence Scale 
Revised (WAIS-R) (Wechsler, 1981) is a timed translation test designed to measure complex 
visual attention, sustained and focused concentration, response speed, and visuomotor 
coordination (Lezak, 1995). In this test, participants are given a key in which each number 
corresponds to a special symbol. The task consists of filling in empty boxes below a series of 
random numbers with the symbol corresponding to the appropriate number (translating the 
numbers to symbols). After a practice session to ensure that the participant understands the 
task, participants were given a 90 second time limit to complete as many items as possible. 
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in 90 seconds.  
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disorders (any type of acquired language impairment), and the Controlled Oral Word 
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one of letter fluency (Word Fluency Test (WFT)) and one of category fluency (Animal Naming). 
The Word Fluency Test of the COWA assesses letter fluency (phonetic association) by asking 
subjects to generate words orally that begin with a specific letter of the alphabet (“F”, “A”, 
and “S”) for a period of 60 seconds. These letters were chosen because they have been 
demonstrated to allow more vocabulary choices overall than other letters. Scoring of this 
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ability to inhibit a customary response to stimulus in favor of a more novel one (Lezak, 1995; 
Stroop, 1935). Administration and scoring of the test to GMBI participants followed 
procedures outlined in the standardized version of the CW test developed by Golden 
(Golden, 1978).  
This test consists of three pages: the word page, the color page, and the color-word page. The 
word page consists of the words “RED”, “GREEN”, and “BLUE” arranged randomly and 
printed in black ink. The color page consists of sets of “XXXX” printed in red, green, or blue 
ink. The color-word page consists of the words from the word page printed in the colors on the 
color page, but no word matches the color in which it is printed (for example, the word “RED” 
is printed in either green or blue ink). For this study, the participant was first asked to read the 
word page as fast as he/she could for 45 seconds, and the total number of correct words was 
recorded. If the participant stated an incorrect word, the interviewer said, “No,” and the 
participant was instructed to read the same word again to correct their error. The same 
procedure was followed for naming the colors on the color page. The participant was then 
asked to state the colors of the words on the color-word page as fast as he/she could in 45 
seconds, and the total number of correctly stated colors were recorded.  
Two measures from this test are used as outcomes in the present study. The color-word 
(CW) score is the total number of correctly stated colors out of 100 from the color-word 
page. The Stroop interference score is the difference in scores between the color page and 
the color-word page.   
2.4 Statistical analysis 
2.4.1 Descriptive statistics 
Data management and statistical analyses were conducted primarily in R version 2.8.0 (R 
Core Development Team, 2008). Distributional plots indicated that the measures of 
leukoaraiosis volume are severely right-skewed, so this variable was transformed by taking 
the natural log of (leukoaraiosis + 1). The cognitive traits appeared to have relatively normal 
distributions; thus, no variable transformations were applied to these variables. T-tests were 
conducted for the outcome measures to test whether there were significant differences in the 
white and African American study participants.  
2.4.2 Covariates 
Biometrical modeling of leukoaraiosis and cognitive function included age at cognitive 
testing, gender, and education as covariates. Relative performance on cognitive tests is 
determined using age- and gender-specific population-based norms, since both of these 
variables are known to affect cognitive function. Age is also a very strong independent 
predictor for leukoaraiosis. Education affects performance on some cognitive tests, as people 
with higher educational attainment tend to perform better (Valenzuela & Sachdev, 2006). 
For this analysis, education was categorized as follows: 0) less than high school, 1) 
completed high school (GED), 2) some college, and 3) completed college (4+ years). To 
account for differences in brain size, intracranial volume was also included in models of 
leukoaraiosis. We conducted multivariable linear mixed models with covariates as predictor 
variables for each outcome measure to explore the relationships between these variables and 
each outcome of interest in GENOA whites and African Americans.  
2.4.3 Biometrical genetic modeling 
The expected covariance of a trait between a pair of individuals can be modeled as a 
function of the variance parameters and the expected correlation between the individuals 
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for genetic effects, based on family relationships (Sing et al., 1987). In this study, SOLAR 
(Sequential Oligogenic Linkage Analysis Routines) (Almasy & Blangero, 1998) was used to 
implement a variance component regression based on maximum likelihood estimation to 
estimate the proportion of phenotypic variance that is due to additive genetic effects, giving 
an estimate of heritability. Shared residual (non-genetic) effects are assumed to be zero 
because the siblings in this study are all adults and have reported living in separate 
households.  
Heritabilities were estimated for the outcome variables (all cognitive traits and 
ln(leukoaraiosis+1)) both with and without covariates (age, sex, education, and TIV) 
included in the biometric models. When covariates are included in the model, the 
heritability estimate is given by [(1-proportion of variance explained by covariates)*h2]*100, 
and represents the hertiability the residual variance of the trait that is not accounted for by 
the covariates. 
The heritability of the traits were tested for significance by comparing the log-likelihood of 
the model in which heritability is estimated to that of the model in which heritability is fixed 
to 0. The null distribution of the likelihood ratio test statistic is a 50:50 mixture of a Chi-
square distribution with one degree of freedom and a point mass at zero.  
2.4.4 Phenotypic, genetic, and environmental correlations 
The phenotypic, genetic, and environmental correlations among all pairs of traits in both 
ethnic groups were estimated in SOLAR, both with and without covariates included in the 
biometric models. The estimated genetic and environmental correlations, ρg and ρe, were 
tested for significance by comparing the log-likelihood of the model in which the parameter 
of interest is estimated to that of the model in which the parameter is fixed to 0.  
The test for pleiotropy, or evidence of shared genetic influences, is as follows: Ho: ρg = 0 vs. 
Ha: ρg  ≠ 0. The null distribution of the likelihood ratio test statistic statistic is a Chi-square 
distribution with one degree of freedom. Rejection of the null hypothesis provides evidence 
of pleiotropy.  
The presence of shared environmental influences (non-genetic influences beyond the 
covariates included in the model) is tested similarly: Ho: ρe = 0 vs. Ha: ρe  ≠ 0. The null 
distribution of the likelihood ratio test statistic statistic is a Chi-square distribution with one 
degree of freedom. Rejection of the null hypothesis provides evidence that there are shared 
environmental influences on the traits. 
3. Results 
3.1 Descriptive statistics 
Descriptive statistics of the outcome measures and covariates for the 762 white and 720 
African American participants, as well as T-tests comparing the samples, are presented in 
Tables 2 and 3. GENOA whites are 58.1% female, have a mean age at the time of cognitive 
testing of 61.3 years (range= 45-84 years), and have a mean leukoaraiosis volume of 8.11cm3 
(range=1.2-62 cm3). GENOA African Americans have a much larger percentage of females 
(72.6%), have a higher mean age of cognitive testing (63.3 years, range = 45-91 years)), and 
have a higher mean volume of leukoaraiosis with greater variability (9.56cm3, range=2.0-126 
cm3). Approximately half of both whites and African Americans attended at least some 
college; however, only 5.2% of white participants did not graduate from high school or 
obtain a GED while this was true for 28.3% of African American participants. The mean 
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with higher educational attainment tend to perform better (Valenzuela & Sachdev, 2006). 
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for genetic effects, based on family relationships (Sing et al., 1987). In this study, SOLAR 
(Sequential Oligogenic Linkage Analysis Routines) (Almasy & Blangero, 1998) was used to 
implement a variance component regression based on maximum likelihood estimation to 
estimate the proportion of phenotypic variance that is due to additive genetic effects, giving 
an estimate of heritability. Shared residual (non-genetic) effects are assumed to be zero 
because the siblings in this study are all adults and have reported living in separate 
households.  
Heritabilities were estimated for the outcome variables (all cognitive traits and 
ln(leukoaraiosis+1)) both with and without covariates (age, sex, education, and TIV) 
included in the biometric models. When covariates are included in the model, the 
heritability estimate is given by [(1-proportion of variance explained by covariates)*h2]*100, 
and represents the hertiability the residual variance of the trait that is not accounted for by 
the covariates. 
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the model in which heritability is estimated to that of the model in which heritability is fixed 
to 0. The null distribution of the likelihood ratio test statistic is a 50:50 mixture of a Chi-
square distribution with one degree of freedom and a point mass at zero.  
2.4.4 Phenotypic, genetic, and environmental correlations 
The phenotypic, genetic, and environmental correlations among all pairs of traits in both 
ethnic groups were estimated in SOLAR, both with and without covariates included in the 
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tested for significance by comparing the log-likelihood of the model in which the parameter 
of interest is estimated to that of the model in which the parameter is fixed to 0.  
The test for pleiotropy, or evidence of shared genetic influences, is as follows: Ho: ρg = 0 vs. 
Ha: ρg  ≠ 0. The null distribution of the likelihood ratio test statistic statistic is a Chi-square 
distribution with one degree of freedom. Rejection of the null hypothesis provides evidence 
of pleiotropy.  
The presence of shared environmental influences (non-genetic influences beyond the 
covariates included in the model) is tested similarly: Ho: ρe = 0 vs. Ha: ρe  ≠ 0. The null 
distribution of the likelihood ratio test statistic statistic is a Chi-square distribution with one 
degree of freedom. Rejection of the null hypothesis provides evidence that there are shared 
environmental influences on the traits. 
3. Results 
3.1 Descriptive statistics 
Descriptive statistics of the outcome measures and covariates for the 762 white and 720 
African American participants, as well as T-tests comparing the samples, are presented in 
Tables 2 and 3. GENOA whites are 58.1% female, have a mean age at the time of cognitive 
testing of 61.3 years (range= 45-84 years), and have a mean leukoaraiosis volume of 8.11cm3 
(range=1.2-62 cm3). GENOA African Americans have a much larger percentage of females 
(72.6%), have a higher mean age of cognitive testing (63.3 years, range = 45-91 years)), and 
have a higher mean volume of leukoaraiosis with greater variability (9.56cm3, range=2.0-126 
cm3). Approximately half of both whites and African Americans attended at least some 
college; however, only 5.2% of white participants did not graduate from high school or 
obtain a GED while this was true for 28.3% of African American participants. The mean 
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values for all outcome measures were significantly different in whites and African 
Americans except for Stroop interference. Leukoaraiosis was strongly right skewed in both 
populations, but had a relatively normal distribution after taking the natural logarithm.  
 
  Whites  
African Americans 
 
Trait Category N Percentage N Percentage 
Education 0 (Less than HS) 40 5.2% 204 28.3% 
 1 (HS/GED) 329 43.2% 205 28.5% 
 2 (Some College) 246 32.3% 127 17.6% 
 3 (Grad/Professional) 147 19.3% 184 25.6% 
Gender Male 319 41.9% 197 27.4% 
 Female 443 58.1% 523 72.6% 
Table 2. Descriptive characteristics of the samples 
 
 Whites African Americans  





Leukoaraiosis volume, cm3 714 8.11 (6.83) 574 9.56 (9.89) 0.0028 
Ln (leukoaraiosis+1) 714 2.06 (0.05) 574 2.16 (0.55) 0.0002 
RAVLT delayed recall  758  9.08 (3.27) 708 6.80 (3.36) <2.2E-16 
RAVLT total learning  759  47.7 (9.8)  712 40.1 (9.4) <2.2E-16 
DSST  758  50.2 (12.4)  697 32.9 (13.6) <2.2E-16 
COWA FAS 760  32.4  (13.6) 687 28.6 (11.7) 1.96E-08 
COWA animals 762  19.3  (4.9) 716 14.9 (4.5) <2.2E-16 
Stroop color word 740  34.5 (9.3)  648 22.3 (10.1) <2.2E-16 
Stroop interference 740  32.8 (9.3)  648 33.6 (11.8) 0.4450 
a T-test p-value for a test of equality of trait means in whites and African Americans.  
Table 3. Comparison of outcome measures  
3.2 Associations between covariates and outcome measures 
In order to explore the relationship between covariates and each outcome of interest, we 
conducted multivariable linear mixed models with covariates as predictor variables for each 
outcome measure. In both whites and African Americans, age, gender, and education were 
significant predictors for all cognitive measures except that education was not a significant 
predictor of Stroop interference in whites and gender was not a significant predictor of 
Stroop color word in African Americans after accounting for the other covariates. As 
expected, increasing age was associated with lower cognitive scores, while increasing 
education was associated with higher cognitive scores. Female gender also showed a trend 
of being associated with higher cognitive scores. In both groups, increasing age and total 
intracranial volume were associated with increasing leukoaraiosis volume, while gender 
and education were not associated with this measure.  
The amount of variance explained by the covariates, as measured by R2, showed a consistent 
pattern between the two groups. R2 was lowest for Stroop interference (0.018 in whites and 
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0.074 in African Americans) and highest for DSST (0.411 in whites and 0.529 in African 
Americans). The amount of variance explained by covariates in the remainder of the 
cognitive measures ranged from 0.122 to 0.309 in whites and from 0.207 to 0.294 in African 
Americans. Variance of ln(leukoaraiosis+1) explained by covariates was higher in whites 
(0.309) than in African Americans (0.213). 
3.3 Genetic variance (heritability) 
In order to examine the contribution of genetic factors to the observed variation in the traits, 
we used a biometrical approach to estimate the proportion of variance in the traits explained 
by genetic factors (heritabilities) both with and without inclusion of covariates in the models 
(Table 4). Heritabilities of all traits were highly significant in both whites and African 
Americans (p-value<0.001) with the exception of Stroop interference in African Americans 
that showed only a marginally significant heritability, illustrating that all of the traits under 
study are influenced by genetic factors. Similar patterns of heritability were observed 
between the two groups, though African Americans tended to have lower heritabilities than 
whites for most traits. 
 
Trait 


















Whites     
Ln(leukoaraiosis+1) 0.656*** 0.529*** 0.311 36.45 
RAVLT delayed recall  0.602*** 0.526*** 0.222 40.92 
RAVLT total learning  0.627*** 0.516*** 0.308 35.71 
DSST  0.774*** 0.843*** 0.403 50.33 
COWA FAS 0.441*** 0.366*** 0.139 31.51 
COWA animals 0.503*** 0.349*** 0.152 29.60 
Stroop color word 0.586*** 0.429*** 0.276 31.06 
Stroop interference 0.302*** 0.275*** 0.023 26.87 
 
African Americans     
Ln(leukoaraiosis+1) 0.485*** 0.432*** 0.217 33.83 
RAVLT delayed recall  0.494*** 0.390*** 0.203 31.08 
RAVLT total learning  0.560*** 0.440*** 0.279 31.72 
DSST  0.810*** 0.556*** 0.525 26.41 
COWA FAS 0.710*** 0.536*** 0.300 37.52 
COWA animals 0.551*** 0.329*** 0.260 24.35 
Stroop color word 0.532*** 0.440*** 0.232 33.79 
Stroop interference 0.135*** 0.154* 0.075 14.25 
a [(1 – Proportion of variance explained by adjustment covariates)*h2]*100 
For all traits modeled with covariates, biometric models included age, sex, and education. The biometric 
model for ln(leukoaraiosis+1) also included TIV. 
Null hypothesis of tests: h2 = 0 
* 0.01 < p-value < 0.05,  ** 0.001 < p-value < 0.01,  *** p-value < 0.001 
Table 4. Trait heritabilities 
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values for all outcome measures were significantly different in whites and African 
Americans except for Stroop interference. Leukoaraiosis was strongly right skewed in both 
populations, but had a relatively normal distribution after taking the natural logarithm.  
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Education 0 (Less than HS) 40 5.2% 204 28.3% 
 1 (HS/GED) 329 43.2% 205 28.5% 
 2 (Some College) 246 32.3% 127 17.6% 
 3 (Grad/Professional) 147 19.3% 184 25.6% 
Gender Male 319 41.9% 197 27.4% 
 Female 443 58.1% 523 72.6% 
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Leukoaraiosis volume, cm3 714 8.11 (6.83) 574 9.56 (9.89) 0.0028 
Ln (leukoaraiosis+1) 714 2.06 (0.05) 574 2.16 (0.55) 0.0002 
RAVLT delayed recall  758  9.08 (3.27) 708 6.80 (3.36) <2.2E-16 
RAVLT total learning  759  47.7 (9.8)  712 40.1 (9.4) <2.2E-16 
DSST  758  50.2 (12.4)  697 32.9 (13.6) <2.2E-16 
COWA FAS 760  32.4  (13.6) 687 28.6 (11.7) 1.96E-08 
COWA animals 762  19.3  (4.9) 716 14.9 (4.5) <2.2E-16 
Stroop color word 740  34.5 (9.3)  648 22.3 (10.1) <2.2E-16 
Stroop interference 740  32.8 (9.3)  648 33.6 (11.8) 0.4450 
a T-test p-value for a test of equality of trait means in whites and African Americans.  
Table 3. Comparison of outcome measures  
3.2 Associations between covariates and outcome measures 
In order to explore the relationship between covariates and each outcome of interest, we 
conducted multivariable linear mixed models with covariates as predictor variables for each 
outcome measure. In both whites and African Americans, age, gender, and education were 
significant predictors for all cognitive measures except that education was not a significant 
predictor of Stroop interference in whites and gender was not a significant predictor of 
Stroop color word in African Americans after accounting for the other covariates. As 
expected, increasing age was associated with lower cognitive scores, while increasing 
education was associated with higher cognitive scores. Female gender also showed a trend 
of being associated with higher cognitive scores. In both groups, increasing age and total 
intracranial volume were associated with increasing leukoaraiosis volume, while gender 
and education were not associated with this measure.  
The amount of variance explained by the covariates, as measured by R2, showed a consistent 
pattern between the two groups. R2 was lowest for Stroop interference (0.018 in whites and 
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0.074 in African Americans) and highest for DSST (0.411 in whites and 0.529 in African 
Americans). The amount of variance explained by covariates in the remainder of the 
cognitive measures ranged from 0.122 to 0.309 in whites and from 0.207 to 0.294 in African 
Americans. Variance of ln(leukoaraiosis+1) explained by covariates was higher in whites 
(0.309) than in African Americans (0.213). 
3.3 Genetic variance (heritability) 
In order to examine the contribution of genetic factors to the observed variation in the traits, 
we used a biometrical approach to estimate the proportion of variance in the traits explained 
by genetic factors (heritabilities) both with and without inclusion of covariates in the models 
(Table 4). Heritabilities of all traits were highly significant in both whites and African 
Americans (p-value<0.001) with the exception of Stroop interference in African Americans 
that showed only a marginally significant heritability, illustrating that all of the traits under 
study are influenced by genetic factors. Similar patterns of heritability were observed 
between the two groups, though African Americans tended to have lower heritabilities than 
whites for most traits. 
 
Trait 


















Whites     
Ln(leukoaraiosis+1) 0.656*** 0.529*** 0.311 36.45 
RAVLT delayed recall  0.602*** 0.526*** 0.222 40.92 
RAVLT total learning  0.627*** 0.516*** 0.308 35.71 
DSST  0.774*** 0.843*** 0.403 50.33 
COWA FAS 0.441*** 0.366*** 0.139 31.51 
COWA animals 0.503*** 0.349*** 0.152 29.60 
Stroop color word 0.586*** 0.429*** 0.276 31.06 
Stroop interference 0.302*** 0.275*** 0.023 26.87 
 
African Americans     
Ln(leukoaraiosis+1) 0.485*** 0.432*** 0.217 33.83 
RAVLT delayed recall  0.494*** 0.390*** 0.203 31.08 
RAVLT total learning  0.560*** 0.440*** 0.279 31.72 
DSST  0.810*** 0.556*** 0.525 26.41 
COWA FAS 0.710*** 0.536*** 0.300 37.52 
COWA animals 0.551*** 0.329*** 0.260 24.35 
Stroop color word 0.532*** 0.440*** 0.232 33.79 
Stroop interference 0.135*** 0.154* 0.075 14.25 
a [(1 – Proportion of variance explained by adjustment covariates)*h2]*100 
For all traits modeled with covariates, biometric models included age, sex, and education. The biometric 
model for ln(leukoaraiosis+1) also included TIV. 
Null hypothesis of tests: h2 = 0 
* 0.01 < p-value < 0.05,  ** 0.001 < p-value < 0.01,  *** p-value < 0.001 
Table 4. Trait heritabilities 
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Heritabilities in traits modeled without covariates were lowest for Stroop interference (0.302 
in whites, 0.135 in African Americans) and highest for DSST (0.774 in whites, 0.81 in African 
Americans), with the majority of heritabilities in the range of 0.45 to 0.6. Leukoaraiosis had a 
higher heritability in whites (0.656) than in African Americans (0.485). After including 
covariates in the biometric models, heritabilities for the traits were generally lower but 
remained highly significant. Again, Stroop interference had the lowest heritability in both 
groups (0.275 in whites, 0.154 in African Americans) and DSST had the highest (0.843 in 
whites, 0.556 in African Americans), with the remaining traits ranging between 0.33 and 
0.54. Leukoaraiosis still showed higher heritability in whites (0.529) than in African 
Americans (0.432).  
The proportion of the observed trait variance accounted for by covariates estimated with 
biometric modeling mirrored the relationships we observed in multivariate linear mixed 
modeling, described above. The lowest proportion of variance explained was for Stroop 
interference (0.023 in whites, 0.075 in African Americans) and the highest was for DSST 
(0.403 in whites, 0.525 in African Americans). For the remainder of the traits, the proportion 
of variance explained by covariates ranged from 0.139 (COWA FAS) to 0.311 (leukoaraiosis) 
in whites and from 0.203 (RAVLT delayed recall) to 0.3 (COWA FAS) in African Americans.  
In order to determine the proportion of variation in the traits explained by genetic factors, 
we multiplied the proportion of variation not explained by the covariates by the heritability. 
Expressed as a percentage of total variation, genetic factors explain the lowest amount of 
variation in Stroop interference in both groups (26.87% in whites, 14.25% in African 
Americans). The largest amount of variation explained by genetic factors in whites was for 
DSST (50.33%) followed by RAVLT delayed recall (40.92%) and leukoaraiosis (36.45%).  
In African Americans, genetic factors explained the largest percentage of variation in 
COWA FAS (37.52%) followed by leukoaraiosis (33.83%) and Stroop color word (33.79%). 
For the majority of traits, the amount of variation explained by genetic factors was lower in 
African Americans than in whites, but most traits in both groups had at least 25% of 
variation explained by genetic factors, showing that genetics has an important influence on 
these traits.   
3.4 Phenotypic correlations between trait pairs 
The patterns observed in the correlations estimated biometrically in SOLAR are presented in 
Table 5. The strongest correlation in the traits modeled with covariates was between the two 
RAVLT measures (0.755 in whites, 0.729 in African Americans), and the weakest correlations 
were between leukoaraiosis and all cognitive traits (ranging from -0.001 to -0.083). In general, 
multiple measures from the same test exhibited stronger correlations than measures across 
tests, which is intuitive since measures from the same test are assessing different but closely 
related cognitive functions. Patterns of correlation in whites and African Americans were very 
similar, though whites generally tended to exhibit somewhat stronger correlations. 
3.5 Genetic and environmental correlations between trait pairs 
In order to begin to understand the extent to which pleiotropic genetic effects may be 
contributing to each pair of traits, we used a biometrical approach to estimate genetic and 
environmental correlations (Table 6). Overall, there were far more significant genetic 
correlations (pleiotropic effects) between trait pairs than environmental correlations, 
indicating that shared genetic effects were more common in these pairs of traits than shared  
 













Whites         
Leuko 0.529***  -0.253 -0.295 -0.294 -0.072 -0.174 -0.232 -0.110 
RAV-DR -0.083 0.526*** 0.816 0.442 0.274 0.373 0.376 0.052 
RAV-TL -0.063 0.755 0.516***  0.523 0.346 0.429 0.441 0.147 
DSST -0.064 0.213 0.269 0.843***  0.376 0.334 0.600 0.268 
C-FAS -0.023 0.163 0.234 0.265 0.366***  0.440 0.345 0.160 
C-AN -0.039 0.261 0.311 0.175 0.367 0.349***  0.309 0.134 
Str-CW 0.003 0.186 0.226 0.424 0.262 0.160 0.429***  -0.134 
Str-Int -0.071 -0.010 0.089 0.228 0.128 0.107 -0.233 0.275***  
 
African Americans 
Leuko 0.432***  -2.10 -0.281 -0.270 -0.213 -0.172 -0.197 -0.108 
RAV-DR -0.007 0.390***  0.790 0.416 0.307 0.285 0.275 0.153 
RAV-TL -0.079 0.729 0.440***  0.492 0.401 0.358 0.308 0.257 
DSST -0.075 0.188 0.220 0.556***  0.557 0.489 0.534 0.311 
C-FAS -0.081 0.136 0.020 0.298 0.536***  0.540 0.347 0.311 
C-AN -0.031 0.143 0.188 0.245 0.395 0.329***  0.357 0.204 
Str-CW -0.056 0.145 0.132 0.332 0.170 0.161 0.440***  -0.189 
Str-Int -0.021 0.046 0.139 0.194 0.219 0.129 -0.339 0.154*  
Leuko = Ln(leukoaraios+1), RAV-DR = RAVLT delayed recall, RAV-TL = RAVLT total learning, C-FAS 
= COWA FAS, C-AN = COWA animals, Str-CW = Stroop color word, Str-Int = Stroop interference 
Above diagonal: phenotypic correlations, p, for traits modeled without covariates 
Below diagonal: phenotypic correlations, p, for traits modeled with covariates 
Diagonal: heritabilities from polygenic analysis, h2, for traits modeled with covariates 
For all traits modeled with covariates, biometric models included age, sex, and education. The biometric 
model for ln(leukoaraiosis+1) also included TIV. 
Null hypothesis of tests: h2 = 0 (diagonal) 
* 0.01 < p-value < 0.05, ** 0.001  < p-value < 0.01,  *** p-value < 0.001 
Table 5. Biometrically derived phenotypic correlations among traits 
environmental effects. For all estimates of genetic and environmental correlations, 
adjustment covariates were included in the biometric models. 
The majority of significant genetic correlations observed were in whites. In whites, 
significant genetic correlations ranged from 0.263 (RAVLT total learning and DSST) to 0.918 
(RAVLT total learning and RAVLT delayed recall). Other highly significant genetic 
correlations (p-value<0.001) were between DSST and Stroop color word (0.7) and between 
RAVLT total learning and COWA animals (0.55). Many of the pairs involving RAVLT, 
COWA, and DSST also showed significant genetic correlations, ranging from 0.263 to 0.476. 
Leukoaraiosis and RAVLT had a marginally significant negative genetic correlation (-0.28), 
indicating that genes shared between these two traits have opposite effects on the traits (for 
example, a certain genetic variation may increase leukoaraiosis volume while decreasing 
learning scores). No other evidence of pleiotropic effects was found between leukoaraiosis 
and cognitive measures.  
In contrast to the relative abundance of genetic correlations between these measures, there 
were very few significant environmental correlations in whites. The most significant 
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Heritabilities in traits modeled without covariates were lowest for Stroop interference (0.302 
in whites, 0.135 in African Americans) and highest for DSST (0.774 in whites, 0.81 in African 
Americans), with the majority of heritabilities in the range of 0.45 to 0.6. Leukoaraiosis had a 
higher heritability in whites (0.656) than in African Americans (0.485). After including 
covariates in the biometric models, heritabilities for the traits were generally lower but 
remained highly significant. Again, Stroop interference had the lowest heritability in both 
groups (0.275 in whites, 0.154 in African Americans) and DSST had the highest (0.843 in 
whites, 0.556 in African Americans), with the remaining traits ranging between 0.33 and 
0.54. Leukoaraiosis still showed higher heritability in whites (0.529) than in African 
Americans (0.432).  
The proportion of the observed trait variance accounted for by covariates estimated with 
biometric modeling mirrored the relationships we observed in multivariate linear mixed 
modeling, described above. The lowest proportion of variance explained was for Stroop 
interference (0.023 in whites, 0.075 in African Americans) and the highest was for DSST 
(0.403 in whites, 0.525 in African Americans). For the remainder of the traits, the proportion 
of variance explained by covariates ranged from 0.139 (COWA FAS) to 0.311 (leukoaraiosis) 
in whites and from 0.203 (RAVLT delayed recall) to 0.3 (COWA FAS) in African Americans.  
In order to determine the proportion of variation in the traits explained by genetic factors, 
we multiplied the proportion of variation not explained by the covariates by the heritability. 
Expressed as a percentage of total variation, genetic factors explain the lowest amount of 
variation in Stroop interference in both groups (26.87% in whites, 14.25% in African 
Americans). The largest amount of variation explained by genetic factors in whites was for 
DSST (50.33%) followed by RAVLT delayed recall (40.92%) and leukoaraiosis (36.45%).  
In African Americans, genetic factors explained the largest percentage of variation in 
COWA FAS (37.52%) followed by leukoaraiosis (33.83%) and Stroop color word (33.79%). 
For the majority of traits, the amount of variation explained by genetic factors was lower in 
African Americans than in whites, but most traits in both groups had at least 25% of 
variation explained by genetic factors, showing that genetics has an important influence on 
these traits.   
3.4 Phenotypic correlations between trait pairs 
The patterns observed in the correlations estimated biometrically in SOLAR are presented in 
Table 5. The strongest correlation in the traits modeled with covariates was between the two 
RAVLT measures (0.755 in whites, 0.729 in African Americans), and the weakest correlations 
were between leukoaraiosis and all cognitive traits (ranging from -0.001 to -0.083). In general, 
multiple measures from the same test exhibited stronger correlations than measures across 
tests, which is intuitive since measures from the same test are assessing different but closely 
related cognitive functions. Patterns of correlation in whites and African Americans were very 
similar, though whites generally tended to exhibit somewhat stronger correlations. 
3.5 Genetic and environmental correlations between trait pairs 
In order to begin to understand the extent to which pleiotropic genetic effects may be 
contributing to each pair of traits, we used a biometrical approach to estimate genetic and 
environmental correlations (Table 6). Overall, there were far more significant genetic 
correlations (pleiotropic effects) between trait pairs than environmental correlations, 
indicating that shared genetic effects were more common in these pairs of traits than shared  
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Table 5. Biometrically derived phenotypic correlations among traits 
environmental effects. For all estimates of genetic and environmental correlations, 
adjustment covariates were included in the biometric models. 
The majority of significant genetic correlations observed were in whites. In whites, 
significant genetic correlations ranged from 0.263 (RAVLT total learning and DSST) to 0.918 
(RAVLT total learning and RAVLT delayed recall). Other highly significant genetic 
correlations (p-value<0.001) were between DSST and Stroop color word (0.7) and between 
RAVLT total learning and COWA animals (0.55). Many of the pairs involving RAVLT, 
COWA, and DSST also showed significant genetic correlations, ranging from 0.263 to 0.476. 
Leukoaraiosis and RAVLT had a marginally significant negative genetic correlation (-0.28), 
indicating that genes shared between these two traits have opposite effects on the traits (for 
example, a certain genetic variation may increase leukoaraiosis volume while decreasing 
learning scores). No other evidence of pleiotropic effects was found between leukoaraiosis 
and cognitive measures.  
In contrast to the relative abundance of genetic correlations between these measures, there 
were very few significant environmental correlations in whites. The most significant 
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environmental correlation was between the trait pair that also had the highest genetic 
correlation, RAVLT total learning and RAVLT delayed recall (0.586), although the 
environmental correlation was substantially less than the genetic correlation. This indicates 
that for this trait pair, shared genetic effects have a stronger influence than shared 
environmental effects, though both contribute to the observed strong phenotypic 
correlation. The only other highly significant environmental correlation was between Stroop 
color word and Stroop interference (-0.427). This correlation is negative since poor cognitive 
performance is indicated by a low score on Stroop color word but by a high score on Stroop 
interference. Only two other trait pairs exhibited even marginally significant environmental 
correlations in whites. Leukoaraiosis had a negative environmental correlation with Stroop 
interference (-0.274) and the two measures from the COWA had a positive environmental 












Whites         
Leuko 0.529*** 0.078 0.178 -0.008 -0.092 -0.136 -0.066 -0.274* 
RAV-DR -0.233 0.526*** 0.586*** -0.015 -0.072 0.185 0.087 -0.024 
RAV-TL -0.280* 0.918*** 0.516*** 0.354 0.149 0.142 0.128 0.092 
DSST -0.092 0.329** 0.263* 0.843*** 0.107 0.015 0.021 0.276 
C-FAS 0.062 0.476** 0.350* 0.418** 0.366*** 0.293* 0.163 0.185 
C-AN 0.084 0.372* 0.550** 0.310* 0.495* 0.349*** 0.023 0.157 
Str-CW 0.078 0.296 0.336* 0.700*** 0.413* 0.371* 0.429*** -0.427*** 
Str-Int 0.230 0.010 0.091 0.280 0.007 -0.004 0.146 0.275*** 
 
African Americans 
Leuko 0.432*** -0.161 -0.261 -0.232 -0.169 -0.127 -0.194 0.130 
RAV-DR 0.215 0.390*** 0.596*** 0.327* 0.167 0.166 0.040 0.035 
RAV-TL 0.158 0.915*** 0.440*** 0.401** 0.322* 0.128 0.017 0.035 
DSST 0.078 0.036 0.045 0.556*** 0.442** 0.270* -0.005 0.237 
C-FAS 0.010 0.102 0.075 0.179 0.536*** 0.313* -0.019 0.113 
C-AN 0.124 0.101 0.286 0.228 0.533** 0.329*** 0.158 0.020 
Str-CW 0.128 0.293 0.278 0.698*** 0.363* 0.167 0.440*** -0.541*** 
Str-Int -0.422 0.010 0.432 0.164 0.507 0.522 0.099 0.154* 
Leuko = Ln(leukoaraios+1), RAV-DR = RAVLT delayed recall, RAV-TL = RAVLT total learning, C-FAS 
= COWA FAS, C-AN = COWA animals, Str-CW = Stroop color word, Str-Int = Stroop interference 
Above diagonal: environmental correlations, e 
Below diagonal: genetic correlations, g 
Diagonal: heritabilities from univariate polygenic analysis, h2, for adjusted traits 
For all adjusted traits, biometric models included age, sex, and education. The biometric model for 
ln(leukoaraiosis+1) also included TIV. 
Null hypothesis of tests: e = 0 (above diagonal) 
Null hypothesis of tests: g = 0 (below diagonal) 
Null hypothesis of tests: h2 = 0 (diagonal) 
* 0.01 < p-value < 0.05,  ** 0.001 < p-value < 0.01,  *** p-value < 0.001 
Table 6. Genetic and enviromental correlations among traits 
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The overall patterns of genetic and environmental correlations in African Americans were 
strikingly similar to the patterns observed in whites. However, many of the genetic 
correlations in African Americans did not reach statistical significance due to larger standard 
errors in their estimates, and there was slightly more evidence of shared environmental effects. 
Two of the four highly significant genetic correlations observed in whites were also observed 
in African Americans. RAVLT total learning and RAVLT delayed recall were the most 
strongly genetically correlated (0.915) followed by DSST and Stroop color word (0.698). The 
only other significant genetic correlations were between the two measures of COWA (0.533) 
and between COWA FAS and Stroop color word (0.363). There were no significant genetic 
correlations between leukoaraiosis and any of the cognitive traits. 
As with whites, the most highly significant environmental correlation was between the two 
measures of RAVLT (0.596) and between Stroop color word and Stroop interference (-0.541). 
The direction and magnitudes of the correlations for these traits were also the same in 
African Americans as they were in whites. The other strongly significant environmental 
correlations observed in African Americans were between DSST and RAVLT total learning 
(0.401) and DSST and COWA FAS (0.442). Four additional pairs of traits also exhibited 
marginally significant environmental correlations, including the two COWA measures 
(0.313) that also showed a marginally significant environmental correlation in whites.  
4. Discussion 
4.1 Heritability of leukoaraiosis 
In our study, the heritability of leukoaraiosis was 0.529 in whites and 0.432 in African 
Americans, after adjustment for age, sex, and total intracranial volume. This finding is 
consistent with heritability estimates from comparable studies.  Heritability was estimated 
to be 0.71 in study of white male twins (mean age 73 years) after adjustment for age and 
head size (Carmelli et al., 1998) and 0.55 in a sample of stroke- and dementia-free subjects 
(mean age 61.0 years) after adjustment for sex, age, age2, and total cranial volume (Atwood 
et el., 2004). Turner et al. (2004) showed that leukoaraiosis has a consistently high 
heritability even after adjustment for blood pressure. These high heritabilities imply that 
much of the inter-individual differences in variation of leukoaraiosis are due to differences 
in genetics. 
4.2 Heritability of cognitive function  
Our study estimates that the majority of heritabilities of seven measures of cognitive 
function in whites and African Americans are between ~0.35 and ~0.55. Previous studies of 
the heritability of cognitive functioning has been conducted primarily in twin studies that 
use factor analysis to identify a common factor to act as a proxy for overall cognitive 
function, and the findings point to a higher heritability for this measure than was estimated 
in our study. For example, McGue and Christensen (2002) estimated the heritability of 
general cognitive function as measured by five cognitive tasks comprised of fluency, digit 
span, and recall to be 0.70. Finkel et al. (1995) peformed quantitative genetic analysis on four 
measures of cognitive function (verbal, spatial, perceptual speed, and memory) and showed 
that heritability for a general cognitive factor was between 0.54 and 0.81 in two samples 
across several age groups of adults (from young to elderly). 
Our results show that there are differences in heritability across cognitive measures, with 
processing speed having the highest heritability in whites (0.843) and African Americans 
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environmental correlation was between the trait pair that also had the highest genetic 
correlation, RAVLT total learning and RAVLT delayed recall (0.586), although the 
environmental correlation was substantially less than the genetic correlation. This indicates 
that for this trait pair, shared genetic effects have a stronger influence than shared 
environmental effects, though both contribute to the observed strong phenotypic 
correlation. The only other highly significant environmental correlation was between Stroop 
color word and Stroop interference (-0.427). This correlation is negative since poor cognitive 
performance is indicated by a low score on Stroop color word but by a high score on Stroop 
interference. Only two other trait pairs exhibited even marginally significant environmental 
correlations in whites. Leukoaraiosis had a negative environmental correlation with Stroop 
interference (-0.274) and the two measures from the COWA had a positive environmental 
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The overall patterns of genetic and environmental correlations in African Americans were 
strikingly similar to the patterns observed in whites. However, many of the genetic 
correlations in African Americans did not reach statistical significance due to larger standard 
errors in their estimates, and there was slightly more evidence of shared environmental effects. 
Two of the four highly significant genetic correlations observed in whites were also observed 
in African Americans. RAVLT total learning and RAVLT delayed recall were the most 
strongly genetically correlated (0.915) followed by DSST and Stroop color word (0.698). The 
only other significant genetic correlations were between the two measures of COWA (0.533) 
and between COWA FAS and Stroop color word (0.363). There were no significant genetic 
correlations between leukoaraiosis and any of the cognitive traits. 
As with whites, the most highly significant environmental correlation was between the two 
measures of RAVLT (0.596) and between Stroop color word and Stroop interference (-0.541). 
The direction and magnitudes of the correlations for these traits were also the same in 
African Americans as they were in whites. The other strongly significant environmental 
correlations observed in African Americans were between DSST and RAVLT total learning 
(0.401) and DSST and COWA FAS (0.442). Four additional pairs of traits also exhibited 
marginally significant environmental correlations, including the two COWA measures 
(0.313) that also showed a marginally significant environmental correlation in whites.  
4. Discussion 
4.1 Heritability of leukoaraiosis 
In our study, the heritability of leukoaraiosis was 0.529 in whites and 0.432 in African 
Americans, after adjustment for age, sex, and total intracranial volume. This finding is 
consistent with heritability estimates from comparable studies.  Heritability was estimated 
to be 0.71 in study of white male twins (mean age 73 years) after adjustment for age and 
head size (Carmelli et al., 1998) and 0.55 in a sample of stroke- and dementia-free subjects 
(mean age 61.0 years) after adjustment for sex, age, age2, and total cranial volume (Atwood 
et el., 2004). Turner et al. (2004) showed that leukoaraiosis has a consistently high 
heritability even after adjustment for blood pressure. These high heritabilities imply that 
much of the inter-individual differences in variation of leukoaraiosis are due to differences 
in genetics. 
4.2 Heritability of cognitive function  
Our study estimates that the majority of heritabilities of seven measures of cognitive 
function in whites and African Americans are between ~0.35 and ~0.55. Previous studies of 
the heritability of cognitive functioning has been conducted primarily in twin studies that 
use factor analysis to identify a common factor to act as a proxy for overall cognitive 
function, and the findings point to a higher heritability for this measure than was estimated 
in our study. For example, McGue and Christensen (2002) estimated the heritability of 
general cognitive function as measured by five cognitive tasks comprised of fluency, digit 
span, and recall to be 0.70. Finkel et al. (1995) peformed quantitative genetic analysis on four 
measures of cognitive function (verbal, spatial, perceptual speed, and memory) and showed 
that heritability for a general cognitive factor was between 0.54 and 0.81 in two samples 
across several age groups of adults (from young to elderly). 
Our results show that there are differences in heritability across cognitive measures, with 
processing speed having the highest heritability in whites (0.843) and African Americans 
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(0.556). Other studies have also shown that processing speed has the strongest genetic 
influence among measures of executive function (Carmelli et al., 2002). The heritability of 
executive function generally tends to be higher than that of memory, with heritabilities for 
executive functions between 0.34-0.70 (Carmelli et al., 2002; Sleegers et al., 2007) and 
heritabilities for memory function closer to 0.2-0.4 (McGue & Christensen, 2001; Plomin et 
al., 1994; Sleegers et al., 2007). In GENOA whites, memory measures (RAVLT) had slightly 
higher heritabilities than most of the executive function tests except for DSST. However, in 
African Americans, heritability of memory measures tended to be similar to those of 
executive funtion.  
While existing research supports true differences in the heritabilities of cognitive domains, a 
portion of the observed differences may be due to the nature of the tests and scoring 
procedures. More complex tests such as Stroop may be more susceptible to measurement 
error than less complex tests such as DSST, and test scores that are mathematically 
manipulated (e.g., Stroop interference) are particularly susceptible to this type of error. 
Increased measurement error may lead to lower heritability estimations as well as weaker 
genetic and environmental correlations among trait pairs. 
4.3 Bivariate variance component analysis in leukoaraiosis and cognitive traits  
We found that in GENOA whites, measures of cognitive function exhibit substantial 
evidence of genetic correlation (pleiotropy), with measures of similar tests showing stronger 
genetic correlation. Evidence of phenotypic correlation due to shared environment was 
largely limited to a smaller number of cognitive trait pairs in African Americans. However, 
we detected no evidence of genetic or environmental correlations between measures of 
cognitive function and leukoaraiosis.  
The lack of evidence of genetic correlation between leukoaraiosis and cognitive function 
in this study stands in contrast to a study conducted by Carmelli, et al. (2002), which used 
maximum likelihood nested modeling techniques to estimate the proportion of variance 
in leukoaraiosis and executive control function due to genetic, shared environmental, and 
non-shared environmental effects in 142 pairs of elderly twins (mean age = 73 years). The 
total phenotypic correlation between leukoaraiosis and executive function was -0.20, and 
they found that 70% of the total phenotypic correlation was accounted for by shared genes 
while 30% was accounted for by shared environments. While this is substantial, the 
contribution of overlapping genes (genes shared between the executive control factor and 
leukoaraiosis) to the genetic variance in executive function was only 8% due to the 
relatively low phenotypic correlation. The lack of detecting shared genetic or 
enviornmental effects between leukoaraiosis and measures of cognitive function in the 
GENOA study was partially due to the very low phenotypic correlations among 
leukoaraiosis and the measures of cognitive function, which may be a function of the 
younger average age of GENOA participants. 
Other studies of the shared genetic components of cognitive traits tend to focus on change in 
cognition over time. Variance components analysis of the relationship between cognitive 
change and perception speed in a study of 292 twins aged 40-84 revealed that 90% of the 
age-related variance and 70% of the genetic variance in cognitive function was shared with 
perception speed, demonstrating that there is a genetic component to processing speed 
which also influences general cognitive functioning (Finkel & Pedersen, 2000). This finding 
was supported by the GENOA study, as processing speed (DSST) exhibited genetic 
correlation with nearly all of the other cognitive measures in whites. Although GENOA 
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African Americans showed little evidence for genetic correlation among cognitive traits, a 
significant genetic correlation was found for DSST and Stroop color word. 
4.4 Differences in the genetic parameters for whites and African Americans 
Heritabilities of leukoaraiosis and cognitive measures showed a consistent pattern in whites 
and African Americans. DSST had the highest heritability (0.883 in whites, 0.556 in African 
Americans), Stroop interference had the lowest heritability (0.275 in whites, 0.154 in African 
Americans), and leukoaraiosis and the other cognitive measures had mid-range heritabilities 
(0.35-0.53 in whites, 0.33-0.54 in African Americans). However, heritabilities showed a clear 
trend of being lower in African Americans, with COWA FAS being the only notable 
exception (heritability = 0.366 in whites, 0.536 in African Americans). A similar trend was 
observed for overall phenotypic correlations and genetic correlations, with African 
Americans showing a similar but weaker correlational structure. 
There are several reasons that could account for the lower observed heritabilities in African 
Americans. Since heritability is the fraction of the total variability of the trait accounted for 
by additive genetic factors, lower heritabilities could result from greater trait variation (a 
larger denominator) or from a smaller contribution from additive genetic effects (a smaller 
numerator). Differences in either the numerator or the demoninator could be due to true 
population differences between whites and African Americans, or they could simply be 
artefacts of the GENOA samples, such as differences in age or family structure. We 
examined the possibility that age or family structure may be responsible for the differences 
in heritability by re-estimating heritabilities in sub-samples of each ethnic group that were 
of equivalent age or had equivalent family compositions (data not shown). Trends in the 
heritabilities remained consistent across sub-samples, so we concluded that the lower 
heritabilities observed in the African American GENOA sample reflect a true difference in 
the population parameters of the groups studied and is not an artefact of the GENOA 
sample structure. However, it is possible that the same factors hypothesized to contribute to 
variability in test scores among ethnic groups (e.g., cultural variability in familiarity with 
testing response sets, motivation and attitudes toward test-taking) may have increased the 
measurement error of the cognitive function tests in the African American sample, resulting 
in lower heritability estimates for this group. 
Lower heritabilities of leukoaraiosis and the seven cognitive traits as well as differences in 
the genetic and environmental correlations between GENOA whites and African Americans 
suggest that non-genetic factors have a greater effect in African Americans than in whites 
for all of the brain traits studied. Though similar patterns were observed in whites and 
African Americans, genetic correlations (evidence of shared genetic effects) among cognitive 
traits tended to be higher and more significant in whites. While very little evidence of 
environmental correlation (shared environmental effects) between cognitive traits was 
observed in whites, eight of the 21 pairs of cognitive traits (38%) had evidence of significant 
environmental correlation in African Americans. Therefore, it is likely that non-genetic 
factors are indeed playing a larger role in affecting variation in brain traits in African 
American GENOA sample. 
4.5 The effect of age on genetic parameter estimation 
Most studies of the genetic and environmental factors associated with leukoaraiosis have 
had samples composed of individuals who have already experienced clinical endpoints such 
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(0.556). Other studies have also shown that processing speed has the strongest genetic 
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higher heritabilities than most of the executive function tests except for DSST. However, in 
African Americans, heritability of memory measures tended to be similar to those of 
executive funtion.  
While existing research supports true differences in the heritabilities of cognitive domains, a 
portion of the observed differences may be due to the nature of the tests and scoring 
procedures. More complex tests such as Stroop may be more susceptible to measurement 
error than less complex tests such as DSST, and test scores that are mathematically 
manipulated (e.g., Stroop interference) are particularly susceptible to this type of error. 
Increased measurement error may lead to lower heritability estimations as well as weaker 
genetic and environmental correlations among trait pairs. 
4.3 Bivariate variance component analysis in leukoaraiosis and cognitive traits  
We found that in GENOA whites, measures of cognitive function exhibit substantial 
evidence of genetic correlation (pleiotropy), with measures of similar tests showing stronger 
genetic correlation. Evidence of phenotypic correlation due to shared environment was 
largely limited to a smaller number of cognitive trait pairs in African Americans. However, 
we detected no evidence of genetic or environmental correlations between measures of 
cognitive function and leukoaraiosis.  
The lack of evidence of genetic correlation between leukoaraiosis and cognitive function 
in this study stands in contrast to a study conducted by Carmelli, et al. (2002), which used 
maximum likelihood nested modeling techniques to estimate the proportion of variance 
in leukoaraiosis and executive control function due to genetic, shared environmental, and 
non-shared environmental effects in 142 pairs of elderly twins (mean age = 73 years). The 
total phenotypic correlation between leukoaraiosis and executive function was -0.20, and 
they found that 70% of the total phenotypic correlation was accounted for by shared genes 
while 30% was accounted for by shared environments. While this is substantial, the 
contribution of overlapping genes (genes shared between the executive control factor and 
leukoaraiosis) to the genetic variance in executive function was only 8% due to the 
relatively low phenotypic correlation. The lack of detecting shared genetic or 
enviornmental effects between leukoaraiosis and measures of cognitive function in the 
GENOA study was partially due to the very low phenotypic correlations among 
leukoaraiosis and the measures of cognitive function, which may be a function of the 
younger average age of GENOA participants. 
Other studies of the shared genetic components of cognitive traits tend to focus on change in 
cognition over time. Variance components analysis of the relationship between cognitive 
change and perception speed in a study of 292 twins aged 40-84 revealed that 90% of the 
age-related variance and 70% of the genetic variance in cognitive function was shared with 
perception speed, demonstrating that there is a genetic component to processing speed 
which also influences general cognitive functioning (Finkel & Pedersen, 2000). This finding 
was supported by the GENOA study, as processing speed (DSST) exhibited genetic 
correlation with nearly all of the other cognitive measures in whites. Although GENOA 
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African Americans showed little evidence for genetic correlation among cognitive traits, a 
significant genetic correlation was found for DSST and Stroop color word. 
4.4 Differences in the genetic parameters for whites and African Americans 
Heritabilities of leukoaraiosis and cognitive measures showed a consistent pattern in whites 
and African Americans. DSST had the highest heritability (0.883 in whites, 0.556 in African 
Americans), Stroop interference had the lowest heritability (0.275 in whites, 0.154 in African 
Americans), and leukoaraiosis and the other cognitive measures had mid-range heritabilities 
(0.35-0.53 in whites, 0.33-0.54 in African Americans). However, heritabilities showed a clear 
trend of being lower in African Americans, with COWA FAS being the only notable 
exception (heritability = 0.366 in whites, 0.536 in African Americans). A similar trend was 
observed for overall phenotypic correlations and genetic correlations, with African 
Americans showing a similar but weaker correlational structure. 
There are several reasons that could account for the lower observed heritabilities in African 
Americans. Since heritability is the fraction of the total variability of the trait accounted for 
by additive genetic factors, lower heritabilities could result from greater trait variation (a 
larger denominator) or from a smaller contribution from additive genetic effects (a smaller 
numerator). Differences in either the numerator or the demoninator could be due to true 
population differences between whites and African Americans, or they could simply be 
artefacts of the GENOA samples, such as differences in age or family structure. We 
examined the possibility that age or family structure may be responsible for the differences 
in heritability by re-estimating heritabilities in sub-samples of each ethnic group that were 
of equivalent age or had equivalent family compositions (data not shown). Trends in the 
heritabilities remained consistent across sub-samples, so we concluded that the lower 
heritabilities observed in the African American GENOA sample reflect a true difference in 
the population parameters of the groups studied and is not an artefact of the GENOA 
sample structure. However, it is possible that the same factors hypothesized to contribute to 
variability in test scores among ethnic groups (e.g., cultural variability in familiarity with 
testing response sets, motivation and attitudes toward test-taking) may have increased the 
measurement error of the cognitive function tests in the African American sample, resulting 
in lower heritability estimates for this group. 
Lower heritabilities of leukoaraiosis and the seven cognitive traits as well as differences in 
the genetic and environmental correlations between GENOA whites and African Americans 
suggest that non-genetic factors have a greater effect in African Americans than in whites 
for all of the brain traits studied. Though similar patterns were observed in whites and 
African Americans, genetic correlations (evidence of shared genetic effects) among cognitive 
traits tended to be higher and more significant in whites. While very little evidence of 
environmental correlation (shared environmental effects) between cognitive traits was 
observed in whites, eight of the 21 pairs of cognitive traits (38%) had evidence of significant 
environmental correlation in African Americans. Therefore, it is likely that non-genetic 
factors are indeed playing a larger role in affecting variation in brain traits in African 
American GENOA sample. 
4.5 The effect of age on genetic parameter estimation 
Most studies of the genetic and environmental factors associated with leukoaraiosis have 
had samples composed of individuals who have already experienced clinical endpoints such 
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as stroke or severe cognitive decline. The relatively young age range of our sample provided 
the unique opportunity to examine the relationships between leukoaraiosis and cognitive 
phenotypes in asymptomatic individuals, at a time when preventive treatment would be 
most effective. However, the young age of our sample also imposed constraints, including 
the limited variability in the leukoaraiosis phenotype. In addition, it has been shown that 
heritabilities of cognitive traits tend to vary with age (Knopman et al., 2001; Mattay, 2008). 
Since this study was cross-sectional, we did not have the ability to examine how 
heritabilities and genetic correlations change over time. Differential heritabilities across age 
groups also implies that there may be genetic factors that show age-related changes in 
penetrance with respect to cognitive traits. It is therefore plausible that the genetic 
correlations between leukoaraiosis and cognitive traits may also change with age. 
5. Conclusion  
The complex relationship between subclinical measures and clinical outcomes underscores 
the importance of studying leukoaraiosis and cognitive decline as the predecessors of stroke 
and dementia in order to better elucide the shared and unique contributions of genetic 
factors to the disease pathologies that result from hypertension and other risk factors. This 
study illustrates that the genetic and environmental influences on the subclinical measures 
of stroke and dementia vary substantially between measures of structural injury 
(leukoaraiosis) and performance on cognitive tests, and that unique patterns of genetic and 
environmental correlation exist across cognitive domains (memory vs. executive function).  
All of the traits studied demonstrate significant heritability, indicating that genetic factors 
account for a substantial portion of the variability in leukoaraiosis as well as multiple 
measures of cognitive function. Some of the cognitive measures, particularly those that 
assessed similar cognitive domains, demonstrated a significant degree of shared genetic 
effects, while others demonstrated a greater degree of shared environmental effects. 
Leukoaraiosis, while heritable, does not share any genetic or environmental influences with 
the cognitive measures. Patterning of heritability and genetic/environmental correlations 
showed definitive trends that were consistent across ethic groups, but one clear difference 
was that cognitive measures tended to have more shared genetic effects in whites and more 
shared enviornmental effects in African Americans. These results indicate that the 
environmental and genetic factors that predispose individuals to leukoaraiosis and 
cognitive decline are likely to be best understood and studied at the family and community 
levels. Integrating genetic information with family history and cultural or socio-economic 
stressors and supports is likely to contribute to new knowledge of the unique and shared 
risk factors for these traits, and thus lead to more effective preventive strategies. 
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as stroke or severe cognitive decline. The relatively young age range of our sample provided 
the unique opportunity to examine the relationships between leukoaraiosis and cognitive 
phenotypes in asymptomatic individuals, at a time when preventive treatment would be 
most effective. However, the young age of our sample also imposed constraints, including 
the limited variability in the leukoaraiosis phenotype. In addition, it has been shown that 
heritabilities of cognitive traits tend to vary with age (Knopman et al., 2001; Mattay, 2008). 
Since this study was cross-sectional, we did not have the ability to examine how 
heritabilities and genetic correlations change over time. Differential heritabilities across age 
groups also implies that there may be genetic factors that show age-related changes in 
penetrance with respect to cognitive traits. It is therefore plausible that the genetic 
correlations between leukoaraiosis and cognitive traits may also change with age. 
5. Conclusion  
The complex relationship between subclinical measures and clinical outcomes underscores 
the importance of studying leukoaraiosis and cognitive decline as the predecessors of stroke 
and dementia in order to better elucide the shared and unique contributions of genetic 
factors to the disease pathologies that result from hypertension and other risk factors. This 
study illustrates that the genetic and environmental influences on the subclinical measures 
of stroke and dementia vary substantially between measures of structural injury 
(leukoaraiosis) and performance on cognitive tests, and that unique patterns of genetic and 
environmental correlation exist across cognitive domains (memory vs. executive function).  
All of the traits studied demonstrate significant heritability, indicating that genetic factors 
account for a substantial portion of the variability in leukoaraiosis as well as multiple 
measures of cognitive function. Some of the cognitive measures, particularly those that 
assessed similar cognitive domains, demonstrated a significant degree of shared genetic 
effects, while others demonstrated a greater degree of shared environmental effects. 
Leukoaraiosis, while heritable, does not share any genetic or environmental influences with 
the cognitive measures. Patterning of heritability and genetic/environmental correlations 
showed definitive trends that were consistent across ethic groups, but one clear difference 
was that cognitive measures tended to have more shared genetic effects in whites and more 
shared enviornmental effects in African Americans. These results indicate that the 
environmental and genetic factors that predispose individuals to leukoaraiosis and 
cognitive decline are likely to be best understood and studied at the family and community 
levels. Integrating genetic information with family history and cultural or socio-economic 
stressors and supports is likely to contribute to new knowledge of the unique and shared 
risk factors for these traits, and thus lead to more effective preventive strategies. 
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1. Introduction 
The occurrence of neurogenesis, defined as the generation of new neurons, has become well 
established in the adult mammalian brain, including the human brain over the last two 
decades.  Neurogenesis in the adult brain can be divided into four phases: (a) progenitor cell 
proliferation; (b) migration of progenitor cells towards a target area; (c) terminal 
differentiation into a specific phenotype, and; (d) integration into established networks.  
Neural stem/progenitor cells generate neurons throughout life in the mammalian forebrain 
subventricular zone (SVZ)–olfactory bulb (OB) pathway and the hippocampal dentate gyrus 
[for review see (Whitman, et al., 2009)]. Neural progenitor cells can be isolated from these 
two regions and cultured in vitro as self-renewable neurospheres in epidermal growth factor 
(EGF) and fibroblast growth factor-2 (FGF2) containing media (Reynolds, et al., 1992, 
Reynolds, et al., 1996).  Upon withdrawal of growth factors, they differentiate into the three 
main neural lineages; neurons, astrocytes and oligodendrocytes (Reynolds & Weiss, 1996). 
There are four major cell types within the adult SVZ-OB pathway; ependymal cells, Type B, 
Type C and Type A cells (Doetsch, et al., 1997). The true neural stem cells in this region are 
the Type B cells which have the characteristics of radial glial cells, including the expression 
of GFAP (Doetsch, et al., 1997, Doetsch, et al., 1999). Type B cells proliferate slowly to 
generate Type C cells, which are the most rapidly proliferating cell type in the SVZ. The 
bipotent Type C cells are able to divide either symmetrically or asymmetrically to generate 
glial or neural precursor cells. The SVZ-OB pathway is organized as an extensive network of 
chains of migrating neural precursor cells (neuroblasts; Type A cells) that travel through 
glial tubes formed by GFAP positive radial glial-like cells (Lois, et al., 1994, Doetsch, et al., 
1996, Lois, et al., 1996, Doetsch, et al., 1997).  SVZ- derived neuroblasts migrate long 
distances via a restricted forebrain pathway known as the rostral migratory stream (RMS) to 
their final destination in the olfactory bulb. This is achieved through a unique form of 
tangential chain migration.  Migrating neuroblasts (Type A cells) in the SVZ – OB pathway 
can be identified by their expression of characteristic markers such as the polysialylated 
form of neural cell adhesion molecule (PSA-NCAM), neuron-specific βIII-tubulin and 
doublecortin (Dcx). Once the neuroblasts reach the subependymal region of the olfactory 
bulb, they disperse radially and differentiate into granule and periglomerular neurons 
(Luskin, 1993, Lois&Alvarez-Buylla, 1994, Lois, et al., 1996, Thomas, et al., 1996, Curtis, et al., 
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2007). Studies have shown that olfactory granule and periglomerular cells are continuously 
added to the olfactory bulb to both increase total cell number over time in these layers as 
well as replace pre-existing cells (Lagace, et al., 2007, Imayoshi, et al., 2008). The function of 
persistent olfactory bulb neurogenesis is largely unknown, but increasing evidence supports 
a role for the new neurons in olfactory memory and odour discrimination (Gheusi, et al., 
2000, Petreanu, et al., 2002, Rochefort, et al., 2002).        
In contrast to the extensive migration undertaken by neurons destined for the olfactory 
bulb, dentate gyrus granule neurons are born locally in the subgranular zone (SGZ), a 
germinal layer between the dentate gyrus and the hilus (Altman, et al., 1965, Kaplan, et al., 
1977, Eriksson, et al., 1998, Kornack, et al., 1999, Gould, et al., 2001).  Within the SGZ, GFAP 
positive cells (Type B cells) divide to give rise to immature Type D cells, which then 
generate granule neurons (Palmer, et al., 2000, Seri, et al., 2001). Interestingly, Type D cells 
divide less frequently and are more differentiated than the transit amplifying Type C cells in 
the SVZ.  SGZ-derived neural progenitor cells generate new neurons that make and receive 
functional synapses (Palmer, et al., 2000, Song, et al., 2002, Van Praag, et al., 2002).  Ongoing 
hippocampus neurogenesis is known to facilitate long-term potentiation and stimulate 
learning and memory (Van Praag, et al., 1999, Wang, et al., 2005, Imayoshi, et al., 2008) with 
ablation of adult-born dentate granule cells impairing certain forms of hippocampal-
dependent learning (Dupret, et al., 2008, Imayoshi, et al., 2008, Clelland, et al., 2009).   
Adult neurogenesis is not static, but its rate may fluctuate in response to environmental 
change.  Evidence from in vitro and in vivo studies have demonstrated that neurogenesis can 
be regulated by a range of growth and neurotrophic factors, neurotransmitters and 
hormones [for review see (Parent, 2003, Lie, et al., 2004)].  Neurogenesis has also been shown 
to be altered by the presence of cell death induced by brain injury or disease [for review see 
(Peterson, 2002, Parent, 2003, Lie, et al., 2004, Goldman, 2005)]. A critical issue of 
neurogenesis, both during development and in adulthood, is the appropriate integration  
of different cell types to form mature neural cells.  This means that progenitor cells need  
to migrate from their places of birth to their final positions. Such a highly regulated process 
is mediated by a number of environmental cues like substrates, chemoattractive/ 
chemorepulsive factors, and detachment/stop signals.  Although some of these factors have 
been identified, many remain to be discovered [for review see (Cayre, et al., 2009)].  
Progenitor cell migration is most extensive in the developing and immature brain. In the 
adult brain, neural cell migration still continues, although in a more limited capacity with 
the most extensive region of migration observed in the SVZ-OB pathway. It is not yet clear 
why new neurons are not born in the place they need to reside. While the maintenance of 
stem cell niches in the adult brain may provide a potential source of cells for brain repair 
and cell replacement, these regions may be costly for the organism and may also require 
specific features that restrict the structures where they can persist. As a result, in both 
normal and pathological conditions cells need to be able to migrate from these discrete 
niches to their final destination. During pathological processes, such as brain injury, the 
brain demonstrates spontaneous attempts at repair and regeneration. These processes result 
in a distinct profile of cell proliferation and migration not observed in the normal adult 
brain, which appear to be mediated by an independent set of environmental cues. This 
chapter will discuss what is known about the response of endogenous adult neural 
progenitor cells to brain injury including stroke, traumatic brain injury, epilepsy and 
excitotoxic injury, the mechanisms by which this response may occur, and how this 
knowledge may be translated to effective therapeutic strategies. 
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2. The response of progenitor cells to the injured brain 
2.1 Temporal lobe epilepsy 
Epilepsy, characterized by periodic and unpredictable occurrence of seizure activity, 
affects ~50 million people worldwide and temporal lobe epilepsy (TLE) is among the most 
frequent types of intractable epilepsy. Abnormal hippocampal neurogenesis has emerged 
as an important pathophysiology of TLE over the past decade [for review see (Kuruba, et 
al., 2009)].  Initial studies on neurogenesis in animal models of TLE by Parent and 
colleagues (Parent, et al., 1997, Parent, et al., 1998) and Bengzon and colleagues (Bengzon, 
et al., 1997) provided the first evidence for increased hippocampal neurogenesis following 
acute seizures. In these studies, an increase in the production of new cells was observed in 
the SGZ of the dentate gyrus following pilocarpine-induced status epilepticus (SE) 
(Parent, et al., 1997, Gray, et al., 1998) or kindling stimulations (Bengzon, et al., 1997, 
Parent, et al., 1998).  However, by 3-4 weeks after seizure induction, neurogenesis 
returned to baseline levels. In normal animals, proliferating cells labeled with the mitotic 
marker bromodeoxyuridine (BrdU) are restricted to the SGZ of the hippocampus. In 
contrast, following seizure activity BrdU+ cells were found extensively in the dentate 
hilus and/or dentate molecular layer of the hippocampus, indicating aberrant migration 
of dividing cells in response to seizure-induced cell loss (Parent, et al., 1997, Scharfman, et 
al., 2000, Scharfman, et al., 2002, Scharfman, et al., 2003, Parent, et al., 2006). Similarly, 
displaced granule cells have been observed in hippocampal tissues obtained from patients 
with TLE (Houser, 1990, Thom, et al., 2002, Liu, et al., 2008). This suggests that acute 
seizure-induced dentate gyrus neurogenesis promotes aberrant circuitry development, 
which likely contributes to the evolution of initial seizure-induced hippocampal injury 
into chronic epilepsy (Kuruba, et al., 2009).  
In addition to the neurogenic response observed in the hippocampus, progenitor cells in the 
SVZ also respond to seizure activity in the adult rodent brain. Within 1-2 weeks following 
pilocarpine-induced seizure activity, Parent and colleagues (Parent, et al., 2002) observed an 
increase in BrdU labeling and Nissl staining in the RMS. These changes were associated 
with an increase in expression of the Type A neuroblast marker Dcx 2 – 3 weeks following 
prolonged seizures.  At these same time points the RMS expanded and contained more 
proliferating cells and immature neurons.  BrdU labeling and retroviral tracing showed that 
prolonged seizures also increased neuroblast migration to the olfactory bulb. Importantly, a 
large number of labeled cells were found adjacent to the RMS instead of within its realms 
(most prominent at 14 days following seizure induction), indicating that seizure activity 
induces aberrant migration of SVZ-derived progenitor cells into surrounding regions of the 
brain (Parent, et al., 2002). 
Increased neurogenesis observed following acute seizure activity returns to baseline by 
about 2 months after the initial seizure episode in rats. The extent of neurogenesis has then 
been shown to decline significantly in the chronic phase of epilepsy when significant 
numbers of spontaneous seizures manifest [for review see (Hattiangady, et al., 2008)]. A 64-
81% decrease in neurogenesis was reported at 5 months post-SE with an inverse relationship 
evident between the frequency of spontaneous seizures and the extent of neurogenesis 
(Hattiangady, et al., 2004).  The severe reduction in hippocampal neurogenesis observed in 
chronic TLE is not however associated with either decreased production of new cells or 
reduced survival of newly born cells in the dentate gyrus.  Rather, it is due to a decline in 
the neuronal fate-choice decision of newly generated cells with the majority of newly born 
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cells differentiating to a glial rather than a neuronal lineage in response to chronic TLE 
(Hattiangady, et al., 2010). Thus, diminished hippocampal neurogenesis might contribute to 
the persistence of spontaneous seizures, learning and memory deficits, and depression 
prevalent in chronic TLE.  
2.2 Traumatic brain injury 
Traumatic brain injury (TBI) is characterized by both neuronal and white matter loss, with 
resultant brain atrophy and functional neurological impairment.  Injury may be in the form 
of focal damage, or it may be diffuse with widespread delayed neuronal loss.  In addition to 
local neuronal loss resulting from the mechanical primary insult, TBI also induces a cascade 
of delayed secondary events that contribute to neuronal death, including ischemia, 
Wallerian degeneration secondary to diffuse axonal injury, excitotoxicity, dysregulation of 
calcium homeostasis, mitochondrial dysfunction and free radical-mediated damage.  
Among the diffuse injury sites, the hippocampus is known to be especially vulnerable in 
humans and shows the earliest evidence of TBI-induced degeneration in experimental 
models. The most frequently used experimental models of TBI include the controlled 
cortical impact (CCI) and lateral fluid percussion (FPI) models (Wang, et al., 2010). The 
lateral FPI model can reproduce multiple types of human TBI, including focal contusion, 
intraparenchymal and subarachnoid hemorrhage, tissue tears and axonal damage, and has 
been widely adopted as a combined model of focal and diffuse brain injury. The CCI model 
generally has been found to produce a more focused injury compared to lateral FPI; the 
severity of injury is also significantly greater in the gray matter relative to the underlying 
white matter. In both injury models there is an acute neurogenic response with an increase 
in hippocampal progenitor cell proliferation observed from 24hr to 1-2 weeks following TBI 
(Dash, et al., 2001, Chirumamilla, et al., 2002, Emery, et al., 2005). Newly generated neurons 
in the dentate gyrus integrate into the existing hippocampal circuitry following TBI, 
potentially resulting in cognitive recovery (Sun, et al., 2005). Transgenic approaches have 
demonstrated that following TBI, the nestin-expressing progenitor cells are first activated by 
injury, whereas the later Dcx-expressing committed neuroblasts appear to be eliminated 
(Miles, et al., 2008, Yu, et al., 2008). Later, the Dcx-expressing cells within the dentate gyrus 
reemerge and are likely contributors to stable neurogenesis (Yu, et al., 2008).    
Adult SVZ neurogenesis has also been investigated in the CCI model of TBI (Goings, et al., 
2002, Ramaswamy, et al., 2005).  In these studies, SVZ progenitor cell proliferation was 
observed either to be reduced (Goings, et al., 2002), or to exhibit a delayed increase in 
proliferation (Ramaswamy, et al., 2005) following TBI. In the lateral FPI model, an increase 
in SVZ progenitor cell incorporation of BrdU was observed between 2 – 8 days post injury 
(Chirumamilla, et al., 2002).  Interestingly, in the CCI model progenitor cell migration within 
the SVZ - OB pathway, as demonstrated by PSA-NCAM expression, was not enhanced until 
25-35 days post TBI (Goings, et al., 2002).  Retroviral labeling of SVZ progenitor cells and 
examination of the location of labeled cells at 4 days and 3 weeks post injury in adult mice 
determined that very few cells migrated into the cerebral cortex in the normal brain, 
whereas a large number of labeled cells migrated into the lesioned area following cortical 
impact (Goings, et al., 2004). Migration of progenitor cells into the lesioned cortex appeared 
to be at the expense of migration to the olfactory bulb; in control animals approximately half 
of the labeled SVZ cells were found in the olfactory bulb, whereas only a quarter of labeled 
cells migrated there following cortical injury (Goings, et al., 2004). However, the majority of 
adult-born cells located in the lesioned area appear to be newly generated glial cells, with 
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limited to no neuronal differentiation observed (Chirumamilla, et al., 2002, Goings, et al., 
2004). Finally, an increase in proliferative markers and the number of proliferative neural 
progenitor cells was recently observed to be increased in the perilesion cortex of the human 
brain following TBI (Zheng, et al., 2011), indicating that TBI may also induce compensatory 
neurogenesis in the human brain. Thus, it appears that TBI results in compensatory 
neurogenesis in response to both hippocampal and cortical damage, with progenitor cell 
migration focused on recruitment to areas of neural injury. Further studies however are 
required to determine the fate and survival of adult-born cells in areas of TBI-induced injury. 
2.3 Focal ischemia 
Ischemic stroke involves an interruption in blood supply to the brain and results in the 
death of neural cells and corresponding loss of brain function.  Focal ischemia is generated 
through the blockage of blood vessels which supply specific regions of the brain, and is 
commonly modeled by the occurrence of transient middle cerebral artery occlusion 
(tMCAo) which results in damage to the cortex and striatum. Studies of experimental stroke 
in rodents over the past decade indicate that focal ischemia potently stimulates SVZ cell 
proliferation and neurogenesis (Jin, et al., 2001, Zhang, et al., 2001, Arvidsson, et al., 2002, 
Parent, et al., 2002, Ohab, et al., 2006). Although initial studies suggested that the increase in 
SVZ neurogenesis after stroke is transient (Arvidsson, et al., 2002, Parent, et al., 2002), more 
recent work indicates that it persists for at least 4 months after ischemia (Thored, et al., 2006). 
SVZ progenitor cells have also been observed to migrate in chains into the ischemic striatum 
and cortex (Arvidsson, et al., 2002, Parent, et al., 2002, Jin, et al., 2003, Ohab, et al., 2006, 
Yamashita, et al., 2006, Zhang, et al., 2009). As with TBI, this appears to be at the expense of 
olfactory bulb migration. Recent evidence suggests that a similar long-distance migration of 
neuroblasts may occur in peri-infarct tissue in human stroke (Jin, et al., 2006). Although a 
large number of neuroblasts reach regions of striatal damage after stroke, few of them 
differentiate into mature neurons.  Most adult-born neurons appear to die (Arvidsson, et al., 
2002, Parent, et al., 2002), perhaps from a failure to integrate or due to inflammatory milieu.  
However, the persistence of SVZ neuroblast migration to the injured striatum for up to a 
year after ischemia (Thored, et al., 2006) suggests that the SVZ may serve as a constant 
reservoir of  new neurons that offers an extended window for therapeutic manipulation.  In 
most stroke models, many of the surviving cells differentiate into neurons, but the precise 
nature of the neurons that persist long term in the striatum is controversial. The generation 
of neurons expressing markers of the striatal medium spiny neurons including DARPP-32 
and calbindin after tMCAo in adult rats has been reported by two groups (Arvidsson, et al., 
2002, Parent, et al., 2002). More recently however, Liu and colleagues (Liu, et al., 2009) used 
retroviral reporters to label SVZ progenitor cells prior to inducing stroke in adult rats and 
found that adult-born neurons exclusively differentiated into calretinin-expressing 
interneurons. This may be due to differences in the location and extent of focal ischemic 
injury, selectivity of ischemic-induced neural cell loss, or alternatively the response of the 
specific population of neural progenitor cells investigated (Lledo, et al., 2008). Further 
research is also required to determine the potential for adult-born neurons to integrate into 
the surrounding parenchyma following focal ischemic injury.         
2.4 Excitotoxic brain injury 
Striatal injection of the neurotoxin quinolinic acid (QA) generates the selective loss of the 
GABAergic medium spiny neurons in the striatum. This model has been used to investigate 
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cells differentiating to a glial rather than a neuronal lineage in response to chronic TLE 
(Hattiangady, et al., 2010). Thus, diminished hippocampal neurogenesis might contribute to 
the persistence of spontaneous seizures, learning and memory deficits, and depression 
prevalent in chronic TLE.  
2.2 Traumatic brain injury 
Traumatic brain injury (TBI) is characterized by both neuronal and white matter loss, with 
resultant brain atrophy and functional neurological impairment.  Injury may be in the form 
of focal damage, or it may be diffuse with widespread delayed neuronal loss.  In addition to 
local neuronal loss resulting from the mechanical primary insult, TBI also induces a cascade 
of delayed secondary events that contribute to neuronal death, including ischemia, 
Wallerian degeneration secondary to diffuse axonal injury, excitotoxicity, dysregulation of 
calcium homeostasis, mitochondrial dysfunction and free radical-mediated damage.  
Among the diffuse injury sites, the hippocampus is known to be especially vulnerable in 
humans and shows the earliest evidence of TBI-induced degeneration in experimental 
models. The most frequently used experimental models of TBI include the controlled 
cortical impact (CCI) and lateral fluid percussion (FPI) models (Wang, et al., 2010). The 
lateral FPI model can reproduce multiple types of human TBI, including focal contusion, 
intraparenchymal and subarachnoid hemorrhage, tissue tears and axonal damage, and has 
been widely adopted as a combined model of focal and diffuse brain injury. The CCI model 
generally has been found to produce a more focused injury compared to lateral FPI; the 
severity of injury is also significantly greater in the gray matter relative to the underlying 
white matter. In both injury models there is an acute neurogenic response with an increase 
in hippocampal progenitor cell proliferation observed from 24hr to 1-2 weeks following TBI 
(Dash, et al., 2001, Chirumamilla, et al., 2002, Emery, et al., 2005). Newly generated neurons 
in the dentate gyrus integrate into the existing hippocampal circuitry following TBI, 
potentially resulting in cognitive recovery (Sun, et al., 2005). Transgenic approaches have 
demonstrated that following TBI, the nestin-expressing progenitor cells are first activated by 
injury, whereas the later Dcx-expressing committed neuroblasts appear to be eliminated 
(Miles, et al., 2008, Yu, et al., 2008). Later, the Dcx-expressing cells within the dentate gyrus 
reemerge and are likely contributors to stable neurogenesis (Yu, et al., 2008).    
Adult SVZ neurogenesis has also been investigated in the CCI model of TBI (Goings, et al., 
2002, Ramaswamy, et al., 2005).  In these studies, SVZ progenitor cell proliferation was 
observed either to be reduced (Goings, et al., 2002), or to exhibit a delayed increase in 
proliferation (Ramaswamy, et al., 2005) following TBI. In the lateral FPI model, an increase 
in SVZ progenitor cell incorporation of BrdU was observed between 2 – 8 days post injury 
(Chirumamilla, et al., 2002).  Interestingly, in the CCI model progenitor cell migration within 
the SVZ - OB pathway, as demonstrated by PSA-NCAM expression, was not enhanced until 
25-35 days post TBI (Goings, et al., 2002).  Retroviral labeling of SVZ progenitor cells and 
examination of the location of labeled cells at 4 days and 3 weeks post injury in adult mice 
determined that very few cells migrated into the cerebral cortex in the normal brain, 
whereas a large number of labeled cells migrated into the lesioned area following cortical 
impact (Goings, et al., 2004). Migration of progenitor cells into the lesioned cortex appeared 
to be at the expense of migration to the olfactory bulb; in control animals approximately half 
of the labeled SVZ cells were found in the olfactory bulb, whereas only a quarter of labeled 
cells migrated there following cortical injury (Goings, et al., 2004). However, the majority of 
adult-born cells located in the lesioned area appear to be newly generated glial cells, with 
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limited to no neuronal differentiation observed (Chirumamilla, et al., 2002, Goings, et al., 
2004). Finally, an increase in proliferative markers and the number of proliferative neural 
progenitor cells was recently observed to be increased in the perilesion cortex of the human 
brain following TBI (Zheng, et al., 2011), indicating that TBI may also induce compensatory 
neurogenesis in the human brain. Thus, it appears that TBI results in compensatory 
neurogenesis in response to both hippocampal and cortical damage, with progenitor cell 
migration focused on recruitment to areas of neural injury. Further studies however are 
required to determine the fate and survival of adult-born cells in areas of TBI-induced injury. 
2.3 Focal ischemia 
Ischemic stroke involves an interruption in blood supply to the brain and results in the 
death of neural cells and corresponding loss of brain function.  Focal ischemia is generated 
through the blockage of blood vessels which supply specific regions of the brain, and is 
commonly modeled by the occurrence of transient middle cerebral artery occlusion 
(tMCAo) which results in damage to the cortex and striatum. Studies of experimental stroke 
in rodents over the past decade indicate that focal ischemia potently stimulates SVZ cell 
proliferation and neurogenesis (Jin, et al., 2001, Zhang, et al., 2001, Arvidsson, et al., 2002, 
Parent, et al., 2002, Ohab, et al., 2006). Although initial studies suggested that the increase in 
SVZ neurogenesis after stroke is transient (Arvidsson, et al., 2002, Parent, et al., 2002), more 
recent work indicates that it persists for at least 4 months after ischemia (Thored, et al., 2006). 
SVZ progenitor cells have also been observed to migrate in chains into the ischemic striatum 
and cortex (Arvidsson, et al., 2002, Parent, et al., 2002, Jin, et al., 2003, Ohab, et al., 2006, 
Yamashita, et al., 2006, Zhang, et al., 2009). As with TBI, this appears to be at the expense of 
olfactory bulb migration. Recent evidence suggests that a similar long-distance migration of 
neuroblasts may occur in peri-infarct tissue in human stroke (Jin, et al., 2006). Although a 
large number of neuroblasts reach regions of striatal damage after stroke, few of them 
differentiate into mature neurons.  Most adult-born neurons appear to die (Arvidsson, et al., 
2002, Parent, et al., 2002), perhaps from a failure to integrate or due to inflammatory milieu.  
However, the persistence of SVZ neuroblast migration to the injured striatum for up to a 
year after ischemia (Thored, et al., 2006) suggests that the SVZ may serve as a constant 
reservoir of  new neurons that offers an extended window for therapeutic manipulation.  In 
most stroke models, many of the surviving cells differentiate into neurons, but the precise 
nature of the neurons that persist long term in the striatum is controversial. The generation 
of neurons expressing markers of the striatal medium spiny neurons including DARPP-32 
and calbindin after tMCAo in adult rats has been reported by two groups (Arvidsson, et al., 
2002, Parent, et al., 2002). More recently however, Liu and colleagues (Liu, et al., 2009) used 
retroviral reporters to label SVZ progenitor cells prior to inducing stroke in adult rats and 
found that adult-born neurons exclusively differentiated into calretinin-expressing 
interneurons. This may be due to differences in the location and extent of focal ischemic 
injury, selectivity of ischemic-induced neural cell loss, or alternatively the response of the 
specific population of neural progenitor cells investigated (Lledo, et al., 2008). Further 
research is also required to determine the potential for adult-born neurons to integrate into 
the surrounding parenchyma following focal ischemic injury.         
2.4 Excitotoxic brain injury 
Striatal injection of the neurotoxin quinolinic acid (QA) generates the selective loss of the 
GABAergic medium spiny neurons in the striatum. This model has been used to investigate 
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the effect of excitotoxic striatal injury on SVZ-derived neurogenesis. QA lesioning results in 
a significant increase in progenitor cell proliferation at days 1 – 14 following injury 
(Tattersfield, et al., 2004, Collin, et al., 2005). In addition, both expansion of the RMS and 
aberrant migration of SVZ-derived Dcx-expressing progenitor cells into the lesioned 
striatum has been demonstrated following QA-induced striatum cell loss (Tattersfield, et al., 
2004, Collin, et al., 2005, Gordon, et al., 2007). In order to elucidate the temporal profile of 
progenitor cell migration in response to QA-induced striatal cell loss, Gordon and 
colleagues (Gordon, et al., 2007) used retroviral tracing to label SVZ-derived progenitor cells 
and track their migratory profile. This study demonstrated that SVZ-derived progenitor cell 
migration was significantly enhanced in the RMS of QA lesioned animals immediately 
following, and up to 30 days following QA-induced striatal cell loss. This was in contrast to 
the migratory response observed in both TBI and ischemic stroke, and demonstrated that 
recruitment of SVZ-derived progenitor cells into the QA lesioned striatum was not at the 
expense of olfactory bulb migration.  In addition, Gordon and colleagues (Gordon, et al., 
2007) identified that aberrant migration of SVZ-derived progenitor cells into the QA 
lesioned striatum is transient, with progenitor cell recruitment predominantly observed by 
cells labeled either 2 days prior or up to 3 days following QA lesioning. Interestingly, a 
change in the morphology of the recruited SVZ-derived progenitor cells was observed over 
time. SVZ-derived progenitor cells labeled either 2 days prior, or on the day of QA lesioning 
predominantly exhibited a bipolar morphology and expressed Dcx. In contrast, the majority 
of progenitor cells labeled from the day of QA lesioning up to 3 days following lesioning 
displayed a multipolar morphology and did not express Dcx (Gordon, et al., 2007). This 
indicates that striatal cell loss induces an expansion of the SVZ progenitor cell population, in 
which a sub-population of SVZ-derived progenitor cells are responsive to recruitment into 
the lesioned area.  In addition, the novel observation of a temporal change in the 
morphological profile of progenitor cells recruited into the QA lesioned striatum is of great 
interest, and warrants further investigation. This alteration in progenitor cell morphology 
may be in response to changes in environmental cues present in the lesioned striatum. 
Following recruitment into the QA-lesioned striatum, about 80% of adult-born neurons 
survive up to 6 weeks, when they express the mature neuronal marker NeuN and 
phenotypic markers of striatal medium spiny neurons (DARPP-32) and interneurons 
(parvalbumin or neuropeptide Y) (Tattersfield, et al., 2004, Collin, et al., 2005). However, 
similar to the observations made in models of ischemic stroke, relatively few adult-born 
neurons survive long term. The low level of adult-born cell survival in models of both focal 
ischemia and excitotoxic striatal cell loss indicates that further investigation is required in 
both injury models to determine the effect of the environment of cell fate, integration and 
long-term survival.  
3. Factors modulating compensatory neurogenesis 
The precise mechanisms underlying injury-induced compensatory neurogenesis in the adult 
brain are unclear. However, several potential mechanisms have been proposed. First it is 
believed that the release of mitogenic factors from dying neurons and reactive glia probably 
increases the proliferation of neural progenitor cells and the survival of newly generated 
neurons. Expression of mitogenic factors can also alter transcriptional signaling pathways in 
neural progenitor cells, redirecting neurogenic processes from a normal physiological role 
(Bath, et al., 2010, Hodge, et al., 2011, Jones, et al., 2011). Increased expression of cytokines 
 
Compensatory Neurogenesis in the Injured Adult Brain 69 
and chemokines from reactive microglia and blood vessels are also involved in directing the 
migration of neural progenitor cells to areas of neuronal loss and injury, as well as 
controlling adult-born neuron survival (Gonzalez-Perez, et al., 2010). Angiogenesis and the 
expression of pro-angiogenic factors appear to play an important role both in progenitor cell 
proliferation and survival as well as migration (Xiong, et al., 2010, Yang, et al., 2011). In 
addition, alteration in neurochemical signaling, such as GABAergic and glutamtergic 
transmission, and neuronal activity have been shown to modulate neurogenesis following 
brain injury (Deisseroth, et al., 2004, Ge, et al., 2007). Thus, it appears multiple mechanisms 
underlie the regulation of compensatory neurogenesis following brain injury; these will be 
summarized in the following section.            
3.1 Potential mechanisms of increased hippocampal neurogenesis after  
seizure activity 
Multiple studies have demonstrated that several factors known to promote neural 
progenitor cell proliferation and neuron survival such as nerve growth factor (NGF), brain-
derived neurotrophic factor (BDNF), fibroblast growth factor-2 (FGF2), vascular endothelial 
growth factor (VEGF) and sonic hedgehog (Shh) are all up-regulated in the hippocampus 
after acute seizures (Lowenstein, et al., 1993, Gall, et al., 1994, Riva, et al., 1994, Gómez-
Pinilla, et al., 1995, Shetty, et al., 2003, Croll, et al., 2004, Shetty, et al., 2004, Banerjee, et al., 
2005). Increased levels of GABA in the dentate gyrus during the early post-seizure period 
may also positively regulate hippocampal neurogenesis, as studies show that GABA  
has crucial roles in regulating various steps of adult neurogenesis, including progenitor  
cell proliferation, migration and differentiation of neuroblasts, and synaptic integration of 
adult-born neurons (Ge, et al., 2007). Further, increased levels of neuropeptide Y (NPY) 
found typically after acute seizures may enhance the proliferation of neural progenitor cells 
in the dentate gyrus, as studies have shown that neural progenitor cells increase 
neurogenesis in the presence of NPY (Howell, et al., 2003, Howell, et al., 2005, Howell, et al., 
2007, Rodrigo, et al., 2010).   
3.2 Abnormal migration of adult-born cells after acute seizure activity 
As discussed in Section 2.1, aberrant migration of progenitor cells is observed in response to 
seizure-induced cell loss. The precise reason for aberrant migration of adult-born granule 
cells is still being examined. However, it has been shown that acute seizures do not 
significantly influence the proliferation of nestin-expressing neural stem cells but rather 
stimulate the division of Dcx-expressing transient amplifying cells and immature neurons 
(Jessberger, et al., 2005). Based on this, it has been proposed that delayed proliferation 
during the process of neurogenesis interferes with migration, leading to a significant 
dispersion of Dcx-positive cells away from the granule cell layer into the dentate hilus and 
the molecular layer.  In addition, recent evidence suggests that a loss of the migration 
guidance cue Reelin due to seizure activity may lead to aberrant chain migration of newly 
born dentate granule cells (Gong, et al., 2007). Interneuron subsets typically lost in human 
and experimental TLE express Reelin, and dentate granule progenitor cells express the 
downstream Reelin signaling molecule Disabled 1 (Dab1).  Prolonged seizure activity has 
been shown to decrease Reelin expression in the adult rat dentate gyrus and increase Dab1 
expression in hilar ectopic neuroblasts. Further, exogenous Reelin increased detachment of 
chain-migrating neuroblasts in dentate gyrus explants, and blockade of Reelin signaling 
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the effect of excitotoxic striatal injury on SVZ-derived neurogenesis. QA lesioning results in 
a significant increase in progenitor cell proliferation at days 1 – 14 following injury 
(Tattersfield, et al., 2004, Collin, et al., 2005). In addition, both expansion of the RMS and 
aberrant migration of SVZ-derived Dcx-expressing progenitor cells into the lesioned 
striatum has been demonstrated following QA-induced striatum cell loss (Tattersfield, et al., 
2004, Collin, et al., 2005, Gordon, et al., 2007). In order to elucidate the temporal profile of 
progenitor cell migration in response to QA-induced striatal cell loss, Gordon and 
colleagues (Gordon, et al., 2007) used retroviral tracing to label SVZ-derived progenitor cells 
and track their migratory profile. This study demonstrated that SVZ-derived progenitor cell 
migration was significantly enhanced in the RMS of QA lesioned animals immediately 
following, and up to 30 days following QA-induced striatal cell loss. This was in contrast to 
the migratory response observed in both TBI and ischemic stroke, and demonstrated that 
recruitment of SVZ-derived progenitor cells into the QA lesioned striatum was not at the 
expense of olfactory bulb migration.  In addition, Gordon and colleagues (Gordon, et al., 
2007) identified that aberrant migration of SVZ-derived progenitor cells into the QA 
lesioned striatum is transient, with progenitor cell recruitment predominantly observed by 
cells labeled either 2 days prior or up to 3 days following QA lesioning. Interestingly, a 
change in the morphology of the recruited SVZ-derived progenitor cells was observed over 
time. SVZ-derived progenitor cells labeled either 2 days prior, or on the day of QA lesioning 
predominantly exhibited a bipolar morphology and expressed Dcx. In contrast, the majority 
of progenitor cells labeled from the day of QA lesioning up to 3 days following lesioning 
displayed a multipolar morphology and did not express Dcx (Gordon, et al., 2007). This 
indicates that striatal cell loss induces an expansion of the SVZ progenitor cell population, in 
which a sub-population of SVZ-derived progenitor cells are responsive to recruitment into 
the lesioned area.  In addition, the novel observation of a temporal change in the 
morphological profile of progenitor cells recruited into the QA lesioned striatum is of great 
interest, and warrants further investigation. This alteration in progenitor cell morphology 
may be in response to changes in environmental cues present in the lesioned striatum. 
Following recruitment into the QA-lesioned striatum, about 80% of adult-born neurons 
survive up to 6 weeks, when they express the mature neuronal marker NeuN and 
phenotypic markers of striatal medium spiny neurons (DARPP-32) and interneurons 
(parvalbumin or neuropeptide Y) (Tattersfield, et al., 2004, Collin, et al., 2005). However, 
similar to the observations made in models of ischemic stroke, relatively few adult-born 
neurons survive long term. The low level of adult-born cell survival in models of both focal 
ischemia and excitotoxic striatal cell loss indicates that further investigation is required in 
both injury models to determine the effect of the environment of cell fate, integration and 
long-term survival.  
3. Factors modulating compensatory neurogenesis 
The precise mechanisms underlying injury-induced compensatory neurogenesis in the adult 
brain are unclear. However, several potential mechanisms have been proposed. First it is 
believed that the release of mitogenic factors from dying neurons and reactive glia probably 
increases the proliferation of neural progenitor cells and the survival of newly generated 
neurons. Expression of mitogenic factors can also alter transcriptional signaling pathways in 
neural progenitor cells, redirecting neurogenic processes from a normal physiological role 
(Bath, et al., 2010, Hodge, et al., 2011, Jones, et al., 2011). Increased expression of cytokines 
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and chemokines from reactive microglia and blood vessels are also involved in directing the 
migration of neural progenitor cells to areas of neuronal loss and injury, as well as 
controlling adult-born neuron survival (Gonzalez-Perez, et al., 2010). Angiogenesis and the 
expression of pro-angiogenic factors appear to play an important role both in progenitor cell 
proliferation and survival as well as migration (Xiong, et al., 2010, Yang, et al., 2011). In 
addition, alteration in neurochemical signaling, such as GABAergic and glutamtergic 
transmission, and neuronal activity have been shown to modulate neurogenesis following 
brain injury (Deisseroth, et al., 2004, Ge, et al., 2007). Thus, it appears multiple mechanisms 
underlie the regulation of compensatory neurogenesis following brain injury; these will be 
summarized in the following section.            
3.1 Potential mechanisms of increased hippocampal neurogenesis after  
seizure activity 
Multiple studies have demonstrated that several factors known to promote neural 
progenitor cell proliferation and neuron survival such as nerve growth factor (NGF), brain-
derived neurotrophic factor (BDNF), fibroblast growth factor-2 (FGF2), vascular endothelial 
growth factor (VEGF) and sonic hedgehog (Shh) are all up-regulated in the hippocampus 
after acute seizures (Lowenstein, et al., 1993, Gall, et al., 1994, Riva, et al., 1994, Gómez-
Pinilla, et al., 1995, Shetty, et al., 2003, Croll, et al., 2004, Shetty, et al., 2004, Banerjee, et al., 
2005). Increased levels of GABA in the dentate gyrus during the early post-seizure period 
may also positively regulate hippocampal neurogenesis, as studies show that GABA  
has crucial roles in regulating various steps of adult neurogenesis, including progenitor  
cell proliferation, migration and differentiation of neuroblasts, and synaptic integration of 
adult-born neurons (Ge, et al., 2007). Further, increased levels of neuropeptide Y (NPY) 
found typically after acute seizures may enhance the proliferation of neural progenitor cells 
in the dentate gyrus, as studies have shown that neural progenitor cells increase 
neurogenesis in the presence of NPY (Howell, et al., 2003, Howell, et al., 2005, Howell, et al., 
2007, Rodrigo, et al., 2010).   
3.2 Abnormal migration of adult-born cells after acute seizure activity 
As discussed in Section 2.1, aberrant migration of progenitor cells is observed in response to 
seizure-induced cell loss. The precise reason for aberrant migration of adult-born granule 
cells is still being examined. However, it has been shown that acute seizures do not 
significantly influence the proliferation of nestin-expressing neural stem cells but rather 
stimulate the division of Dcx-expressing transient amplifying cells and immature neurons 
(Jessberger, et al., 2005). Based on this, it has been proposed that delayed proliferation 
during the process of neurogenesis interferes with migration, leading to a significant 
dispersion of Dcx-positive cells away from the granule cell layer into the dentate hilus and 
the molecular layer.  In addition, recent evidence suggests that a loss of the migration 
guidance cue Reelin due to seizure activity may lead to aberrant chain migration of newly 
born dentate granule cells (Gong, et al., 2007). Interneuron subsets typically lost in human 
and experimental TLE express Reelin, and dentate granule progenitor cells express the 
downstream Reelin signaling molecule Disabled 1 (Dab1).  Prolonged seizure activity has 
been shown to decrease Reelin expression in the adult rat dentate gyrus and increase Dab1 
expression in hilar ectopic neuroblasts. Further, exogenous Reelin increased detachment of 
chain-migrating neuroblasts in dentate gyrus explants, and blockade of Reelin signaling 
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increased chain migration (Gong, et al., 2007). These observations suggest that Reelin 
modulates dentate gyrus progenitor cell migration and loss of Reelin expression in the 
epileptic adult hippocampus may contribute to ectopic chain migration and aberrant 
integration of newborn granule cells.       
3.3 Potential mechanisms underlying decreased neurogenesis in chronic TLE 
The precise mechanisms underlying decreased neurogenesis in chronic TLE are unknown, 
however several explanations have been proposed [for review see (Kuruba, et al., 2009)].  
While a role for chronic inflammation is an attractive hypothesis, this has been ruled out as 
only minimal density of activated microglia have been observed in the hippocampus during 
chronic epilepsy (Hattiangady, et al., 2004). One potential mechanism may be a reduction in 
mitogenic factors such as FGF-2, BDNF and insulin-like growth factor 1 (IGF-1) in the 
epileptic hippocampus resulting in an unfavourable neurogenic environment (Hattiangady, 
et al., 2004, Shetty, et al., 2004). As neuronal differentiation rather than progenitor cell 
number and proliferation is predominantly affected in chronic TLE, the presence of an 
unfavourable hippocampal milieu due to reduction of mitogenic factors currently remains 
the most plausible mechanism (Altar, et al., 2004, Chan, et al., 2008).   
3.4 Potential mechanisms of increased neurogenesis after TBI 
Several studies have shown that neurotrophic factor expression is significantly altered after 
TBI.  Some neurotrophic factors such as NGF and BDNF are up-regulated, while others such 
as neurotrophic factor-3 (NT-3) have been shown to be down-regulated (Yang, et al., 1996, 
Hicks, et al., 1997, Oyesiku, et al., 1999, Truettner, et al., 1999).  Interestingly, BDNF levels 
after TBI have been reported to be increased to a greater extent in older rather than younger 
animals (Shah, et al., 2006), despite the well known fact that older age is correlated with a 
worse outcome after TBI. Results from the CCI model also suggest that FGF-2 is up-
regulated, potentially stimulating post-traumatic neurogenesis (Yoshimura, et al., 2003). In 
addition, up-regulation of VEGF has been observed following both CCI (Sköld, et al., 2005, 
Lu, et al., 2011) and lateral FPI (Lee, et al., 2010), and may be involved in enhancing 
neurogenesis and promoting migration following TBI as observed in rodent models of focal 
ischemia.  
3.5 Potential mechanisms of increased neurogenesis after stroke 
Potential mediators of stroke-induced cell proliferation and neurogenesis are beginning to 
be identified (Yan, et al., 2006, Zhang, et al., 2008, Leker, et al., 2009, Luo, 2011). Through 
infusion studies, a range of growth factors have been identified to play a role in regulating 
SVZ neurogenesis following focal ischemia. Factors such as GDNF, VEGF, EGF, 
transforming growth factor-α (TGF-α) and IGF-1 have all been shown to increase progenitor 
cell proliferation in the ipsilateral SVZ following ischemic damage (Jin, et al., 2002, Sun, et al., 
2003, Schänzer, et al., 2004, Kobayashi, et al., 2006, Ninomiya, et al., 2006, Yan, et al., 2006, 
Leker, et al., 2009, Guerra-Crespo, et al., 2010). VEGF was shown not only to increase 
progenitor cell proliferation, but to also increase the survival of adult-born neurons and 
induce neurite outgrowth in newborn cells (Wang, et al., 2009, Zheng, et al., 2010). Another 
study (Ninomiya, et al., 2006) demonstrated that EGF infusion into the ischemic brain caused 
the number of Type C transient amplifying cells to increase and the number of neuroblasts 
to decrease. However, 6 weeks after the discontinuation of EGF infusion, a significant 
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increase in the number of neuroblasts was found, both in the ischemic striatum and SVZ.  
Co-administration of EGF and FGF2 into the lateral ventricle for 5 days in a rodent model of 
global cerebral ischemia has been shown to increase the proliferative rate and differentiation 
of newly generated hippocampal neurons (Nakatomi, et al., 2002). The newborn neurons 
exhibited histological markers of young and maturing neurons, appropriate connectivity 
and synapse formation as well as electrophysiological characteristics of young neurons.  
Further, memory deficits were resolved in EGF and FGF2 treated rats within 90 days. 
Erythropoietin (EPO) also plays a role in regulating compensatory SVZ neurogenesis 
following ischemic injury. EPO stimulates the maturation, differentiation and survival of 
hematopoietic progenitor cells and promotes angiogenesis. While EPO and its receptor are 
only weakly expressed in normal adult brain, expression of EPO and its receptor is greatly 
increased in neurons, neural progenitor cells, glia and cerebrovascular endothelial cells in 
response to brain injury.  Infusion of EPO into the adult lateral ventricles results in a 
decrease in the number of neural progenitor cells in the SVZ, an increase in neural precursor 
cells migrating to the olfactory bulb and an increase in the generation of new olfactory bulb 
neurons (Shingo, et al., 2001). Further, delivery of EPO for 7 days following 7 days of EGF 
treatment has been shown to enhance SVZ neurogenesis and direct progenitor cell 
migration to the ischemic cortex, resulting in cortical regeneration and functional recovery 
(Kolb, et al., 2006). It is thought that EPO might affect the number of daughter cells that stay 
in cell cycle and promote cell cycle exit and terminal differentiation with preference towards 
neuronal differentiation (Shingo, et al., 2001). Systemic administration of BDNF has also 
been shown to induce neurogenesis and improve sensorimotor function in a rodent model 
of ischemic injury (Schabitz, et al., 2007).  In addition, a range of signaling pathways appear 
to be important in regulating compensatory neurogenesis following ischemic injury.  These 
include notch, retinoid, bone morphogenic protein, tumor necrosis factor-alpha (TNF-α) and 
Shh pathways (Androutsellis-Theotokis, et al., 2006, Chou, et al., 2006, Iosif, et al., 2008, 
Plane, et al., 2008, Zhang, et al., 2008, Sims, et al., 2009, Wang, et al., 2009). 
3.6 The role of chemoattractants in regulating neural progenitor cell migration 
following brain injury 
A fundamental issue concerning progenitor cell migration in the adult brain is to 
understand the extracellular cues and mechanisms that allow the persistence of normal 
migratory pathways, as well as the recruitment of progenitor cells into the areas of neural 
damage.  Increasing evidence indicates the involvement of developmental signals that are 
maintained in restricted regions of the adult brain, including factors such as extracellular 
matrix molecules, Eph-Ephrin interactions, neuregulins, and a range of chemoattractant and 
chemorepulsive molecules [for review see (Cayre, et al., 2009)]. In addition, several 
mechanisms and migratory tracks have been proposed for the guidance of migrating 
progenitor cells towards regions of neural damage. These include migration along: 1) 
myelinated fiber tracks; 2) radial processes; and 3) blood vessels [for review see (Cayre, et al., 
2009)]. Besides these mechanisms, inflammation-induced chemoattraction plays a major role 
in progenitor cell migration following neural cell loss. Upon insult or infection, the brain 
exhibits a profound innate response, characterised predominantly by robust activation of 
microglia (resident macrophages of the CNS).  Activated microglia play a dual role, 
scavenging the damaged and dying neurons as well as initiating a prompt local 
inflammatory reaction. The inflammatory response involves production of pro-
inflammatory cytokines and chemokines, as well as various reactive nitrogen and oxygen 
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increased chain migration (Gong, et al., 2007). These observations suggest that Reelin 
modulates dentate gyrus progenitor cell migration and loss of Reelin expression in the 
epileptic adult hippocampus may contribute to ectopic chain migration and aberrant 
integration of newborn granule cells.       
3.3 Potential mechanisms underlying decreased neurogenesis in chronic TLE 
The precise mechanisms underlying decreased neurogenesis in chronic TLE are unknown, 
however several explanations have been proposed [for review see (Kuruba, et al., 2009)].  
While a role for chronic inflammation is an attractive hypothesis, this has been ruled out as 
only minimal density of activated microglia have been observed in the hippocampus during 
chronic epilepsy (Hattiangady, et al., 2004). One potential mechanism may be a reduction in 
mitogenic factors such as FGF-2, BDNF and insulin-like growth factor 1 (IGF-1) in the 
epileptic hippocampus resulting in an unfavourable neurogenic environment (Hattiangady, 
et al., 2004, Shetty, et al., 2004). As neuronal differentiation rather than progenitor cell 
number and proliferation is predominantly affected in chronic TLE, the presence of an 
unfavourable hippocampal milieu due to reduction of mitogenic factors currently remains 
the most plausible mechanism (Altar, et al., 2004, Chan, et al., 2008).   
3.4 Potential mechanisms of increased neurogenesis after TBI 
Several studies have shown that neurotrophic factor expression is significantly altered after 
TBI.  Some neurotrophic factors such as NGF and BDNF are up-regulated, while others such 
as neurotrophic factor-3 (NT-3) have been shown to be down-regulated (Yang, et al., 1996, 
Hicks, et al., 1997, Oyesiku, et al., 1999, Truettner, et al., 1999).  Interestingly, BDNF levels 
after TBI have been reported to be increased to a greater extent in older rather than younger 
animals (Shah, et al., 2006), despite the well known fact that older age is correlated with a 
worse outcome after TBI. Results from the CCI model also suggest that FGF-2 is up-
regulated, potentially stimulating post-traumatic neurogenesis (Yoshimura, et al., 2003). In 
addition, up-regulation of VEGF has been observed following both CCI (Sköld, et al., 2005, 
Lu, et al., 2011) and lateral FPI (Lee, et al., 2010), and may be involved in enhancing 
neurogenesis and promoting migration following TBI as observed in rodent models of focal 
ischemia.  
3.5 Potential mechanisms of increased neurogenesis after stroke 
Potential mediators of stroke-induced cell proliferation and neurogenesis are beginning to 
be identified (Yan, et al., 2006, Zhang, et al., 2008, Leker, et al., 2009, Luo, 2011). Through 
infusion studies, a range of growth factors have been identified to play a role in regulating 
SVZ neurogenesis following focal ischemia. Factors such as GDNF, VEGF, EGF, 
transforming growth factor-α (TGF-α) and IGF-1 have all been shown to increase progenitor 
cell proliferation in the ipsilateral SVZ following ischemic damage (Jin, et al., 2002, Sun, et al., 
2003, Schänzer, et al., 2004, Kobayashi, et al., 2006, Ninomiya, et al., 2006, Yan, et al., 2006, 
Leker, et al., 2009, Guerra-Crespo, et al., 2010). VEGF was shown not only to increase 
progenitor cell proliferation, but to also increase the survival of adult-born neurons and 
induce neurite outgrowth in newborn cells (Wang, et al., 2009, Zheng, et al., 2010). Another 
study (Ninomiya, et al., 2006) demonstrated that EGF infusion into the ischemic brain caused 
the number of Type C transient amplifying cells to increase and the number of neuroblasts 
to decrease. However, 6 weeks after the discontinuation of EGF infusion, a significant 
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increase in the number of neuroblasts was found, both in the ischemic striatum and SVZ.  
Co-administration of EGF and FGF2 into the lateral ventricle for 5 days in a rodent model of 
global cerebral ischemia has been shown to increase the proliferative rate and differentiation 
of newly generated hippocampal neurons (Nakatomi, et al., 2002). The newborn neurons 
exhibited histological markers of young and maturing neurons, appropriate connectivity 
and synapse formation as well as electrophysiological characteristics of young neurons.  
Further, memory deficits were resolved in EGF and FGF2 treated rats within 90 days. 
Erythropoietin (EPO) also plays a role in regulating compensatory SVZ neurogenesis 
following ischemic injury. EPO stimulates the maturation, differentiation and survival of 
hematopoietic progenitor cells and promotes angiogenesis. While EPO and its receptor are 
only weakly expressed in normal adult brain, expression of EPO and its receptor is greatly 
increased in neurons, neural progenitor cells, glia and cerebrovascular endothelial cells in 
response to brain injury.  Infusion of EPO into the adult lateral ventricles results in a 
decrease in the number of neural progenitor cells in the SVZ, an increase in neural precursor 
cells migrating to the olfactory bulb and an increase in the generation of new olfactory bulb 
neurons (Shingo, et al., 2001). Further, delivery of EPO for 7 days following 7 days of EGF 
treatment has been shown to enhance SVZ neurogenesis and direct progenitor cell 
migration to the ischemic cortex, resulting in cortical regeneration and functional recovery 
(Kolb, et al., 2006). It is thought that EPO might affect the number of daughter cells that stay 
in cell cycle and promote cell cycle exit and terminal differentiation with preference towards 
neuronal differentiation (Shingo, et al., 2001). Systemic administration of BDNF has also 
been shown to induce neurogenesis and improve sensorimotor function in a rodent model 
of ischemic injury (Schabitz, et al., 2007).  In addition, a range of signaling pathways appear 
to be important in regulating compensatory neurogenesis following ischemic injury.  These 
include notch, retinoid, bone morphogenic protein, tumor necrosis factor-alpha (TNF-α) and 
Shh pathways (Androutsellis-Theotokis, et al., 2006, Chou, et al., 2006, Iosif, et al., 2008, 
Plane, et al., 2008, Zhang, et al., 2008, Sims, et al., 2009, Wang, et al., 2009). 
3.6 The role of chemoattractants in regulating neural progenitor cell migration 
following brain injury 
A fundamental issue concerning progenitor cell migration in the adult brain is to 
understand the extracellular cues and mechanisms that allow the persistence of normal 
migratory pathways, as well as the recruitment of progenitor cells into the areas of neural 
damage.  Increasing evidence indicates the involvement of developmental signals that are 
maintained in restricted regions of the adult brain, including factors such as extracellular 
matrix molecules, Eph-Ephrin interactions, neuregulins, and a range of chemoattractant and 
chemorepulsive molecules [for review see (Cayre, et al., 2009)]. In addition, several 
mechanisms and migratory tracks have been proposed for the guidance of migrating 
progenitor cells towards regions of neural damage. These include migration along: 1) 
myelinated fiber tracks; 2) radial processes; and 3) blood vessels [for review see (Cayre, et al., 
2009)]. Besides these mechanisms, inflammation-induced chemoattraction plays a major role 
in progenitor cell migration following neural cell loss. Upon insult or infection, the brain 
exhibits a profound innate response, characterised predominantly by robust activation of 
microglia (resident macrophages of the CNS).  Activated microglia play a dual role, 
scavenging the damaged and dying neurons as well as initiating a prompt local 
inflammatory reaction. The inflammatory response involves production of pro-
inflammatory cytokines and chemokines, as well as various reactive nitrogen and oxygen 
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species. Cytokines released by microglia subsequently activate resident astrocytes, which 
again release cytokines. Peripheral macrophages are recruited into the brain by chemotaxis 
in response to a superfamily of cytokines called chemokines.  Chemokines are small, 
secreted proteins that play crucial roles in leukocyte migration under normal conditions as 
well as during neuroinflammatory responses.  Following injury to the adult brain, a range of 
cytokines and chemokines have been shown to be up-regulated in the region of neural cell 
death, including GRO-α, IL-8, IP-10, MCP-1, MCP-2, MIP-1α , RANTES ,  SDF-1α , and TNF-
α (Mcmanus, et al., 1998, Das, et al., 2008, Gordon, et al., 2009, Whitney, et al., 2009). In 
addition, chemokine receptors, including CXCR1, CXCR2, CXCR4, CXCR7, CCR1, CCR2, 
CCR3 and CCR5, are widely expressed on neural progenitor cells (Ji, et al., 2004, Tran, et al., 
2004, Gordon, et al., 2009). The expression of chemokine receptors on neural progenitor cells 
signifies the crucial roles played by chemokines in guiding progenitor cell migration and the 
influence these factors have in the recovery process in the injured CNS.  
While a number of cytokines and chemokines involved in the inflammatory process have 
been demonstrated to play a role in directing progenitor cell migration, MCP-1 and SDF-1α 
and their receptors have been the most widely examined and clearly regulate the directed 
migration of endogenous neural progenitor cells from the SVZ to the injured brain following 
either ischemic or excitotoxic neural cell loss (Imitola, et al., 2004, Belmadani, et al., 2006, 
Robin, et al., 2006, Yan, et al., 2006, Gordon, et al., 2009). The SDF-1α receptors CXCR4 and 
CXCR7 are highly expressed on neural progenitor cells. SDF-1α expression is highly up-
regulated in reactive astrocytes, microglia and endothelial cells in the ischemic striatum 
during several weeks after focal ischemic injury (Thored, et al., 2006) and has been shown to 
induce the migration of progenitor cells in vitro (Peng, et al., 2004) and in vivo to areas of 
hypoxic-ischemic-induced inflammation via CXCR4 signalling pathways (Imitola, et al., 
2004, Robin, et al., 2006). The chemokine MCP-1 is also up-regulated in response to 
inflammation and induces the migration of neural progenitor cells.  The MCP-1 receptor 
CCR2 is expressed by neural progenitor cells and MCP-1 recruits progenitor cells to the site 
of brain inflammation by binding to CCR2 and inducing their migration (Widera, et al., 2004, 
Belmadani, et al., 2006, Gordon, et al., 2009). These studies clearly indicate that 
neuroinflammation and the resulting expression of cytokines and chemokines play a major 
role in directing the migration of progenitor cells in the injured brain.  However, 
inflammatory cues involved in directing the migration of progenitor cells can also contribute 
to decreased survival of these migrating cells, creating juxtaposition between regeneration 
and ongoing cell loss and highlighting the complexity of the neuroinflammatory 
environment: on one hand it is useful for attracting progenitor cells to the appropriate 
region for neural replacement, but on the other hand it prevents efficient cell replacement by 
affecting the survival abilities of the migrating precursor cells (Whitney, et al., 2009).  The 
opposing properties of neuroinflammation therefore complicates the development of 
therapeutic strategies involving the use of cytokines or chemokines. 
4. Therapeutic strategies 
4.1 Chronic TLE 
The major issue associated with chronic TLE is the observed reduction in hippocampal 
neurogenesis and potential contribution this plays to the persistence of spontaneous 
seizures, learning and memory deficits, and depression prevalent in chronic TLE. Based on 
studies in animal models of brain disease and injury, the following strategies may provide 
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mechanisms by which to increase hippocampal neurogenesis in chronic epilepsy; 
administration of neurotrophic factors, physical exercise, exposure to an enriched 
environment and antidepressant therapy [for review see (Kuruba, et al., 2009)]. 
Administration of neurotrophic factors is relevant as many factors that promote 
neurogenesis (e.g: BDNF, FGF-2, IGF-1) are reduced in chronic epilepsy (Hattiangady, et al., 
2004, Shetty, et al., 2004). Supporting this, a range of studies have demonstrated that 
administration of neurotrophic factors to both the normal and injured adult rodent brain can 
enhance hippocampal neurogenesis (Lichtenwalner, et al., 2001, Yoshimura, et al., 2001, Jin, 
et al., 2003, Scharfman, et al., 2005, Rai, et al., 2007, Paradiso, et al., 2009, Paradiso, et al., 2011). 
Performing physical exercise and environmental enrichment have also been shown to 
enhance hippocampal neurogenesis, potentially through increased expression of a range of 
mitogenic factors such as BDNF, FGF2, NGF, IGF-1 and VEGF as well as phosphorylation of 
cAMP-response binding protein (CREB) (Nithianantharajah, et al., 2006, Van Praag, 2008, 
Llorens-Martín, et al., 2009, 2010, Lafenetre, et al., 2011) and may provide an appealing non-
invasive therapeutic approach for the treatment of chronic TLE (Dhanushkodi, et al., 2008, 
Arida, et al., 2009). Antidepressant therapy in chronic TLE is another interesting approach 
for increasing neurogenesis and reducing cognitive impairments, as antidepressant therapy 
enhances hippocampal neurogenesis probably via increases in levels of serotonin, 
noradrenaline, BDNF, CREB and a range of other mitogenic factors  (Sahay, et al., 2007, 
Thomas, et al., 2008, Lanni, et al., 2009). In particular, a recent study demonstrated that 
repeated administration of the antidepressant agent citalopram counteracted kainic acid-
induced neuronal loss and dispersion of PSA-NCAM-positive cells within the granule cell 
layer of the hippocampus (Jaako, et al., 2011). Citalopram also counteracted the 
downregulation of Reelin on both mRNA and protein levels. As decreased neurogenesis, 
cognitive impairment and depression coexist in chronic epilepsy, prolonged antidepressant 
treatment may provide an effective strategy for easing these problems.   
4.2 Traumatic brain injury 
For TBI, it remains unclear whether compensatory neurogenesis contributes at all to 
functional recovery. However, several studies have examined the effect of administering 
neurogenic agents to rodent models of TBI to assess the effect on neuronal replacement and 
functional recovery. Administration of EGF or FGF-2 into the lateral ventricles following FPI 
has been shown to increase the rate of memory recovery in the Morris Water Maze, and 
produce a concomitant increase in the number of new hippocampal neurons co-labeled with 
BrdU and NeuN (Sun, et al., 2009, Sun, et al., 2010).  Interestingly, intraventricular 
administration of the calcium-binding protein S100β following TBI has also been shown to 
increase the percentage of newly generated hippocampal neurons expressing NeuN and 
improve cognitive recovery in the Morris water Maze [for review see (Kleindienst, et al., 
2007)]. This is in conflict with clinical data in which an increase in CSF levels of S100β is 
correlated with poor prognosis in patients with TBI. Delivery of VEGF to the lateral FPI 
model has been shown to significantly increase the number of BrdU labeled adult-born 
neurons in the adult hippocampus, but does not change the number of BrdU labeled 
newborn cells per se (Lee&Agoston, 2010) suggesting that in the hippocampus VEGF 
predominantly mediates survival of adult-born neurons rather than progenitor cell 
proliferation. In contrast, Thau-Zuchman and colleagues (Thau-Zuchman, et al., 2010) 
observed an increase in the number of proliferating cells in the SVZ and the perilesion 
cortex following infusion of VEGF into the lateral ventricles of mice after TBI. Further, while 
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species. Cytokines released by microglia subsequently activate resident astrocytes, which 
again release cytokines. Peripheral macrophages are recruited into the brain by chemotaxis 
in response to a superfamily of cytokines called chemokines.  Chemokines are small, 
secreted proteins that play crucial roles in leukocyte migration under normal conditions as 
well as during neuroinflammatory responses.  Following injury to the adult brain, a range of 
cytokines and chemokines have been shown to be up-regulated in the region of neural cell 
death, including GRO-α, IL-8, IP-10, MCP-1, MCP-2, MIP-1α , RANTES ,  SDF-1α , and TNF-
α (Mcmanus, et al., 1998, Das, et al., 2008, Gordon, et al., 2009, Whitney, et al., 2009). In 
addition, chemokine receptors, including CXCR1, CXCR2, CXCR4, CXCR7, CCR1, CCR2, 
CCR3 and CCR5, are widely expressed on neural progenitor cells (Ji, et al., 2004, Tran, et al., 
2004, Gordon, et al., 2009). The expression of chemokine receptors on neural progenitor cells 
signifies the crucial roles played by chemokines in guiding progenitor cell migration and the 
influence these factors have in the recovery process in the injured CNS.  
While a number of cytokines and chemokines involved in the inflammatory process have 
been demonstrated to play a role in directing progenitor cell migration, MCP-1 and SDF-1α 
and their receptors have been the most widely examined and clearly regulate the directed 
migration of endogenous neural progenitor cells from the SVZ to the injured brain following 
either ischemic or excitotoxic neural cell loss (Imitola, et al., 2004, Belmadani, et al., 2006, 
Robin, et al., 2006, Yan, et al., 2006, Gordon, et al., 2009). The SDF-1α receptors CXCR4 and 
CXCR7 are highly expressed on neural progenitor cells. SDF-1α expression is highly up-
regulated in reactive astrocytes, microglia and endothelial cells in the ischemic striatum 
during several weeks after focal ischemic injury (Thored, et al., 2006) and has been shown to 
induce the migration of progenitor cells in vitro (Peng, et al., 2004) and in vivo to areas of 
hypoxic-ischemic-induced inflammation via CXCR4 signalling pathways (Imitola, et al., 
2004, Robin, et al., 2006). The chemokine MCP-1 is also up-regulated in response to 
inflammation and induces the migration of neural progenitor cells.  The MCP-1 receptor 
CCR2 is expressed by neural progenitor cells and MCP-1 recruits progenitor cells to the site 
of brain inflammation by binding to CCR2 and inducing their migration (Widera, et al., 2004, 
Belmadani, et al., 2006, Gordon, et al., 2009). These studies clearly indicate that 
neuroinflammation and the resulting expression of cytokines and chemokines play a major 
role in directing the migration of progenitor cells in the injured brain.  However, 
inflammatory cues involved in directing the migration of progenitor cells can also contribute 
to decreased survival of these migrating cells, creating juxtaposition between regeneration 
and ongoing cell loss and highlighting the complexity of the neuroinflammatory 
environment: on one hand it is useful for attracting progenitor cells to the appropriate 
region for neural replacement, but on the other hand it prevents efficient cell replacement by 
affecting the survival abilities of the migrating precursor cells (Whitney, et al., 2009).  The 
opposing properties of neuroinflammation therefore complicates the development of 
therapeutic strategies involving the use of cytokines or chemokines. 
4. Therapeutic strategies 
4.1 Chronic TLE 
The major issue associated with chronic TLE is the observed reduction in hippocampal 
neurogenesis and potential contribution this plays to the persistence of spontaneous 
seizures, learning and memory deficits, and depression prevalent in chronic TLE. Based on 
studies in animal models of brain disease and injury, the following strategies may provide 
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mechanisms by which to increase hippocampal neurogenesis in chronic epilepsy; 
administration of neurotrophic factors, physical exercise, exposure to an enriched 
environment and antidepressant therapy [for review see (Kuruba, et al., 2009)]. 
Administration of neurotrophic factors is relevant as many factors that promote 
neurogenesis (e.g: BDNF, FGF-2, IGF-1) are reduced in chronic epilepsy (Hattiangady, et al., 
2004, Shetty, et al., 2004). Supporting this, a range of studies have demonstrated that 
administration of neurotrophic factors to both the normal and injured adult rodent brain can 
enhance hippocampal neurogenesis (Lichtenwalner, et al., 2001, Yoshimura, et al., 2001, Jin, 
et al., 2003, Scharfman, et al., 2005, Rai, et al., 2007, Paradiso, et al., 2009, Paradiso, et al., 2011). 
Performing physical exercise and environmental enrichment have also been shown to 
enhance hippocampal neurogenesis, potentially through increased expression of a range of 
mitogenic factors such as BDNF, FGF2, NGF, IGF-1 and VEGF as well as phosphorylation of 
cAMP-response binding protein (CREB) (Nithianantharajah, et al., 2006, Van Praag, 2008, 
Llorens-Martín, et al., 2009, 2010, Lafenetre, et al., 2011) and may provide an appealing non-
invasive therapeutic approach for the treatment of chronic TLE (Dhanushkodi, et al., 2008, 
Arida, et al., 2009). Antidepressant therapy in chronic TLE is another interesting approach 
for increasing neurogenesis and reducing cognitive impairments, as antidepressant therapy 
enhances hippocampal neurogenesis probably via increases in levels of serotonin, 
noradrenaline, BDNF, CREB and a range of other mitogenic factors  (Sahay, et al., 2007, 
Thomas, et al., 2008, Lanni, et al., 2009). In particular, a recent study demonstrated that 
repeated administration of the antidepressant agent citalopram counteracted kainic acid-
induced neuronal loss and dispersion of PSA-NCAM-positive cells within the granule cell 
layer of the hippocampus (Jaako, et al., 2011). Citalopram also counteracted the 
downregulation of Reelin on both mRNA and protein levels. As decreased neurogenesis, 
cognitive impairment and depression coexist in chronic epilepsy, prolonged antidepressant 
treatment may provide an effective strategy for easing these problems.   
4.2 Traumatic brain injury 
For TBI, it remains unclear whether compensatory neurogenesis contributes at all to 
functional recovery. However, several studies have examined the effect of administering 
neurogenic agents to rodent models of TBI to assess the effect on neuronal replacement and 
functional recovery. Administration of EGF or FGF-2 into the lateral ventricles following FPI 
has been shown to increase the rate of memory recovery in the Morris Water Maze, and 
produce a concomitant increase in the number of new hippocampal neurons co-labeled with 
BrdU and NeuN (Sun, et al., 2009, Sun, et al., 2010).  Interestingly, intraventricular 
administration of the calcium-binding protein S100β following TBI has also been shown to 
increase the percentage of newly generated hippocampal neurons expressing NeuN and 
improve cognitive recovery in the Morris water Maze [for review see (Kleindienst, et al., 
2007)]. This is in conflict with clinical data in which an increase in CSF levels of S100β is 
correlated with poor prognosis in patients with TBI. Delivery of VEGF to the lateral FPI 
model has been shown to significantly increase the number of BrdU labeled adult-born 
neurons in the adult hippocampus, but does not change the number of BrdU labeled 
newborn cells per se (Lee&Agoston, 2010) suggesting that in the hippocampus VEGF 
predominantly mediates survival of adult-born neurons rather than progenitor cell 
proliferation. In contrast, Thau-Zuchman and colleagues (Thau-Zuchman, et al., 2010) 
observed an increase in the number of proliferating cells in the SVZ and the perilesion 
cortex following infusion of VEGF into the lateral ventricles of mice after TBI. Further, while 
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functional outcome was significantly improved in mice treated with VEGF compared to 
vehicle treated animals following TBI, fate analysis demonstrated that most newborn cells 
differentiated into astrocytes and oligodendroglia, and only a few cells differentiated into 
neurons (Thau-Zuchman, et al., 2010).       
The effect of mitogen support on hippocampal neurogenesis following TBI has also been 
examined using transgenic models.  FGF-2(-/-) mice subjected to CCI injury exhibit a 
reduction in the number of both BrdU-positive cells and BrdU-positive neurons when 
compared to FGF-2(+/+) mice.  In contrast, over-expression of FGF-2 by intracerebral 
injection of herpes simplex virus-1 amplicon vectors encoding for this factor increased both 
the number of dividing cells and BrdU-positive neurons (Yoshimura, et al., 2003). This 
suggests that FGF-2 up-regulates neurogenesis and protects the survival of adult-born 
neurons in the adult hippocampus after TBI. BDNF has also been shown to play a role in 
regulating the survival of adult-born immature neurons in the hippocampus following TBI, 
with the level of adult-born immature neuron death in the dentate gyrus significantly 
increased in BDNF conditional knockout mice following TBI.        
A number of studies have demonstrated that the injured brain can be stimulated to promote 
angiogenesis and neurogenesis, which are coupled restorative processes that contribute to 
functional recovery in both TBI and stroke [for review see (Xiong, et al., 2010)]. Studies have 
demonstrated that intraperitoneal administration of EPO post-TBI significantly increases 
BDNF expression and enhances hippocampal neurogenesis with subsequent improvement 
in sensorimotor and spatial learning functions (Meng, et al., Lu, et al., 2005, Xiong, et al., 
2008, Xiong, et al., 2010). Statins also show neurorestorative effects in animal models of TBI 
through the induction of angiogenesis and neurogenesis. Simvastatin treatment provides 
long-lasting (3 month) functional improvement after TBI in rats. This was coupled with 
increased expression of VEGF and BDNF and enhanced in the dentate gyrus of rats 
following TBI (Lu, et al., 2007, Wu, et al., 2008). Clinical trials investigating the use of either 
EPO or CEPO, or the use of statins for the treatment of TBI are currently being undertaken 
[for review see (Xiong, et al., 2010)].     
4.3 Stroke 
A range of therapeutic strategies promoting regeneration in stroke are being investigated.  
However, some of the most interesting approaches are based around the use of statins and 
the phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil (Xiong, et al., 2010). Statins 
have been shown to induce angiogenesis, neurogenesis and synaptogenesis, and to enhance 
functional recovery after stroke in rats (Chen, et al., 2003). It is thought that expression of 
BDNF, VEGF and VEGFR2, and regulation of Notch signaling activity contribute to these 
regenerative processes (Chen, et al., 2005, Chen, et al., 2008). Clinical trials for both lovastatin 
and simvastatin in stroke patients are currently being undertaken [for review see (Xiong, et 
al., 2010)]. Given the wide use of statins, their favourable safety profile, rare serious adverse 
effects and the extensive preclinical data showing neuroprotection and neurorestoration in 
rodent models of stroke, further clinical studies investigating the potential use of statins to 
promote neuroregeneration following stroke are warranted. The PDE5 inhibitor sildenafil 
has also been shown to promote neurogenesis and reduce functional deficits when 
administered to rats either 2 or 24 hours after ischemic injury (Zhang, et al., 2002), or for 7 
consecutive days starting 7 days following focal ischemia (Zhang, et al., 2006). Further, 
treatment of ischemic stroke with a long-acting PDE5 inhibitor tadalafil improves functional 
recovery, which is associated with increases in brain cGMP levels and enhanced 
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angiogenesis and neurogenesis (Zhang, et al., 2006). Treatment of ischemic stroke with EPO 
is also under investigation, with additional studies examining the use of nonhematopoietic 
EPO analogues such as CEPO. As discussed in Section 4.2, EPO has been shown to promote 
both neurogenesis and angiogenesis, resulting in functional recovery in rodent models of 
focal ischemic injury. Clinical trials investigating the therapeutic application of EPO or 
CEPO for the treatment of stroke are currently being undertaken [for review see (Xiong, et 
al., 2010)].    
5. Conclusions 
The presence of both neural and glial progenitor cells in the adult central nervous system 
(CNS), and the capacity of these cells to migrate through this mature structure to areas of 
pathological damage and injury raises hope for the development of new therapeutic 
strategies to treat brain injury. Although at present time the compensatory neurogenesis 
described after various types of brain injuries appears to be modest, the development of a 
strategy promoting the proliferation, directed mobilization and phenotypic induction of 
endogenous progenitor cells to areas of neural cell loss remains of high interest. However, 
the development of novel neuroregenerative strategies focusing on the promotion of 
compensatory adult neurogenesis will only be achieved once we fully understand the 
mechanisms promoting the response of endogenous progenitor cells to neural injury and 
cell loss. An important factor that needs to be addressed when investigating therapeutic 
strategies by which to enhance compensatory neurogenesis following brain injury is 
whether adult-born cells become functional and integrate appropriately into existing 
circuitry and contribute to the recovery process, or whether they just enhance or restore the 
functionality and survival of existing dysfunctional cells. While striving to identify potential 
factors or the redirected use of current pharmaceuticals to promote compensatory 
neurogenesis for the treatment of brain injury, caution must also be taken. Post-traumatic 
epilepsy is a fairly common morbidity associated with both stroke and TBI and one 
postulated mechanism for this is that aberrant neurogenesis serves as the epileptic focus 
(Parent, et al., 2008). Therefore, any strategy aimed at enhancing neurogenesis may 
inadvertently result in this and other unwanted side effects.  In addition, since many 
strategies aimed towards enhancing neurogenesis promote cell growth, it remains a 
possibility that increasing proliferation may result in potentially unwanted tumour growth. 
Thus, while enhancing compensatory neurogenesis for the treatment of brain injury remains 
an exciting and potentially revolutionary therapeutic strategy, many issues regarding 
specificity, mechanism and potential toxicity need to be thoroughly investigated before 
meaningful clinical intervention can occur. 
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angiogenesis and neurogenesis (Zhang, et al., 2006). Treatment of ischemic stroke with EPO 
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CEPO for the treatment of stroke are currently being undertaken [for review see (Xiong, et 
al., 2010)].    
5. Conclusions 
The presence of both neural and glial progenitor cells in the adult central nervous system 
(CNS), and the capacity of these cells to migrate through this mature structure to areas of 
pathological damage and injury raises hope for the development of new therapeutic 
strategies to treat brain injury. Although at present time the compensatory neurogenesis 
described after various types of brain injuries appears to be modest, the development of a 
strategy promoting the proliferation, directed mobilization and phenotypic induction of 
endogenous progenitor cells to areas of neural cell loss remains of high interest. However, 
the development of novel neuroregenerative strategies focusing on the promotion of 
compensatory adult neurogenesis will only be achieved once we fully understand the 
mechanisms promoting the response of endogenous progenitor cells to neural injury and 
cell loss. An important factor that needs to be addressed when investigating therapeutic 
strategies by which to enhance compensatory neurogenesis following brain injury is 
whether adult-born cells become functional and integrate appropriately into existing 
circuitry and contribute to the recovery process, or whether they just enhance or restore the 
functionality and survival of existing dysfunctional cells. While striving to identify potential 
factors or the redirected use of current pharmaceuticals to promote compensatory 
neurogenesis for the treatment of brain injury, caution must also be taken. Post-traumatic 
epilepsy is a fairly common morbidity associated with both stroke and TBI and one 
postulated mechanism for this is that aberrant neurogenesis serves as the epileptic focus 
(Parent, et al., 2008). Therefore, any strategy aimed at enhancing neurogenesis may 
inadvertently result in this and other unwanted side effects.  In addition, since many 
strategies aimed towards enhancing neurogenesis promote cell growth, it remains a 
possibility that increasing proliferation may result in potentially unwanted tumour growth. 
Thus, while enhancing compensatory neurogenesis for the treatment of brain injury remains 
an exciting and potentially revolutionary therapeutic strategy, many issues regarding 
specificity, mechanism and potential toxicity need to be thoroughly investigated before 
meaningful clinical intervention can occur. 
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1. Introduction  
Organophosphates (OP) are potent toxic substances used in agriculture as insecticide and 
pesticides, and in warfare. Over 200,000 cases of accidental toxic exposure to OPs are 
reported annually (Jyaratnam, 1999).   
OPs inhibit acetylcholine esterase (ACE), an enzyme which breaks down acetylcholine in 
cholinergic synapses in the peripheral nervous system (PNS) and central nervous system 
(CNS). Thus OP intoxication is characterized by findings related to hyperstimulation of 
cholinergic synapses in the PNS and CNS. Hyper-stimulation of cholinergic synapses in CNS 
may result in rapid blackout attacks and inhibition of respiratory center in medulla oblongata 
(Marrs, 2007). In animal studies of OPs used as chemical warfare agents, status epilepticus 
occurs rapidly due to severe brain damage, which is demonstrated on both electrophysiologic 
and histopathologic studies (McDonough et al, 1998). Pharmacological treatment of OP 
intoxication includes anticholinergic agents like atropine sulfate to block postsynaptic 
cholinergic receptors, oximes to reactivate inhibited enzymes, and antiepileptics to control 
seizure activity (Marrs, 2007). 
In previous studies, oxidative stress caused by OPs was demonstrated in humans and rats. 
Lipid peroxidation in rat brain and human erythrocytes caused by OPs was confirmed as 
well (Abdollahi et al, 2004). Melatonin removes the potent hydroxyl radical secreted from 
pineal gland. Blood can easily pass the brain barrier and provides oxidative protection in the 
brain. At the same time, it also removes other reactive molecules such as hydrogen peroxide, 
singlet oxygen, peroxynitrite, and nitric oxide. Melatonin decreases oxidative stress by 
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occurs rapidly due to severe brain damage, which is demonstrated on both electrophysiologic 
and histopathologic studies (McDonough et al, 1998). Pharmacological treatment of OP 
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2.1 Experimental methods 
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Research Center. Twenty (12 male, 8 female, weight range 2500-4000 g) New Zealand rabbits 
were used. The subjects were divided into three groups: a sham group (n=8), a pralidoxime 
(PAM) plus atropine group (n=6), and a melatonin plus PAM plus atropine group (n=6). 
Subjects were anaesthetized with 50 mg/kg IM ketamine and 15 mg/kg IM xylazine HCL. 
The central ear artery and marginal ear vein were catheterized. Blood was drawn in EDTA 
tubes to measure baseline plasma ACE, nitric oxide (NO), and plasma and erythrocyte 
malondialdehyde (MDA).  
Orogastric feeding tubes were inserted and 50 mg/kg (LD50=50 mg/kg) dichlorvos was 
administered. One hour later, when signs of toxicity (hypersalivation, bronchospasm, 
fasciculations, convulsions) appeared, venous blood samples were taken again in order to 
measure plasma ACE, nitric oxide (NO), and plasma and erythrocyte MDA.  
In the sham group, no treatment was given. Venous blood samples were taken at 12 hours 
after OP administration hour to measure plasma ACE, nitric oxide (NO), and plasma and 
erythrocyte MDA. In the PAM+atropine group, 0.05 mg/kg IV atropine was given and this 
dose was administered again as needed. In addition, a 30 mg/kg IV bolus of PAM was 
given, then 15 mg/kg IV PAM was given every 4 hours. In the melatonin plus PAM-
atropine group, 10 mg/kg IV melatonin was administered, as well as PAM and atropine as 
in the PAM-atropine group. Blood samples were taken from the subjects in PAM-atropine 
and melatonin-PAM-atropine groups at 12 and 24 hours after intoxication in order to 
measure plasma ACE, nitric oxide (NO), and plasma and erythrocyte MDA.  
At 24 hours post-intoxication, craniotomy was performed and liver samples were taken after 
laparotomy to evaluate ACE, NO and MDA levels. At the end of the study, subjects were 
sacrificed by administering a high dose of ketamine. 
2.2 Biochemical methods  
2.2.1 Measurement of plasma ACE activity 
Plasma was separated from erythrocytes by centrifuging for 15 minutes at 3000 rpm. The 
following were placed into a 10 mL test tube: 3 mL of distilled water, 0.2 mL of plasma, and 
3 mL of barbital phosphate (pH 8.1). The pH (pH1) of the mixture was measured with a glass 
electrode pH meter. Then, 0.1 ml of 7.5% acetylcholine iodide solution was added to the 
reaction mixture and incubated for 20 min at 37° C. At the end of incubation period, the pH 
of the reaction mixture was measured (pH2). ACE activity was calculated using the 
following formula:  
ACE activity (ΔpH/20 minutes) = pH1 – pH2 – (Δ pH of the blank) 
2.2.2 Measurement of ACE activity in brain tissue 
To measure brain ACE activity, a brain tissue sample was homogenized (at 25% of  
the maximum speed) in barbital phosphate (pH 8.1) to weigh 3 ml/100 mg when wet. 
Homogenization was performed in an ice bath and brain homogenate was preserved  
in ice before cholinesterase determination. For determining brain ACE activity, 0.2 mL of  
tissue homogenate was used. ACE activity was calculated using the same formula as shown 
above.   
2.2.3 Measurement of NO in plasma and brain tissue 
To measure NO in plasma and brain tissue homogenate, the Nitric Oxide Synthase Assay 
Kit (Colorimetric) (Merck Chemicals, Darmstadt, Germany) was used.  
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2.2.4 Measurement of MDA in brain tissue 
A brain tissue sample (0.5 g) was taken and preserved at -80° C. Using a cold 150 mM KCL 
solution, the tissue sample was homogenized to make a 10% homogenate, and was then 
centrifuged at 10,000 rpm for 10 minutes. The following substances were mixed: 0.1 ml of 
the homogenate, 0.2 mL of 8.1% sodium dodecyl sulfate (SDS) solution, 1.5 mL of 20% acetic 
acid solution (sodium hydroxide was added to this mixture for adjust pH>3), and 1.5 ml of 
0.8% thiobarbituric acid liquid; this mixture was then stirred with a vortex. The mixture was 
then boiled in distilled water at 95° C for 60 minutes. Then it was cooled, and the following 
were added to the mixture: 1 mL of distilled water, 5 mL of n-butanol and pyridine (15:l, 
v/v) were added, and the mixture was rinsed. The resulting mixture was spun at 4,000 rpm 
for 10 minutes. A sample was from the upper layer of the mixture was taken, and 
absorbance at 532 nm was measured spectrophotometrically. MDA concentrations were 
derived with the following formula: 
C = Measured absorbance x 320.5 x dilution factor / microprotein of homogenate= 
nmol/mg tissue  
2.2.4 Measurement of MDA in erythrocytes 
Blood was centrifuged and the plasma was separated. After being washed with normal 
saline solution once, 1.5 mL was taken from the erythrocyte plug and 1.5 mL of buffered 
sodium azide was added. 50 mL was taken from this hemolizate and 12.5 mL of Drabkin 
solution was added and the Hb was measured. 5 mL was taken from this mixture and 5 mL 
of 35% H2O2 was added and this mixture was incubated for 2 hours at 37° C with tubes 
open. After this was cooled, 3 mL was taken and 2 mL of trichloroacetic acid-arsenide 
solution was added and the mixture was then centrifuged at 2,500 rpm. 3 mL was taken 
from this supernatant and 1 mL of thiobarbituric acid was added and then the mixture was 
boiled for 15 min. After it cooled, absorbance at 532 nm was measured 
spectrophotometrically and the results were calculated for each gram of hemoglobin. 
2.3 Statistical methods 
Statistical analyses were performed using SPSS for Windows 13.0 (SPSS, Inc., Chicago, 
USA). Between group comparisons were made by repeated measurements with variance 
analysis (ANOVA). For significant values, Bonferroni one-way variance analysis as a post 
hoc test, and then the Tukey HSD test was applied. Comparisons with a P value of less than 
0.05 were regarded as statistically significant. When comparing intra-group repeated 
measurements, the student t test was used. Means of each group’s values were calculated 
and reported as a table. To compare tissue ACE and tissue MDA values, one-way ANOVA 
and then Tukey HSD tests were performed. 
3. Results 
All sham group animals died before 24 hours after intoxication, therefore no blood sample 
was collected from those subjects at 24 hours. 
No significant differences between groups in erythrocyte ACE levels were found. At 12 
hours after treatment, the mean erythrocyte ACE level of the melatonin+PAM+atropine 
group was not significantly different from that of the PAM+atropine group, but it was 
significantly higher than that of the sham group (p=0.023). The mean erythrocyte ACE level 
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solution, the tissue sample was homogenized to make a 10% homogenate, and was then 
centrifuged at 10,000 rpm for 10 minutes. The following substances were mixed: 0.1 ml of 
the homogenate, 0.2 mL of 8.1% sodium dodecyl sulfate (SDS) solution, 1.5 mL of 20% acetic 
acid solution (sodium hydroxide was added to this mixture for adjust pH>3), and 1.5 ml of 
0.8% thiobarbituric acid liquid; this mixture was then stirred with a vortex. The mixture was 
then boiled in distilled water at 95° C for 60 minutes. Then it was cooled, and the following 
were added to the mixture: 1 mL of distilled water, 5 mL of n-butanol and pyridine (15:l, 
v/v) were added, and the mixture was rinsed. The resulting mixture was spun at 4,000 rpm 
for 10 minutes. A sample was from the upper layer of the mixture was taken, and 
absorbance at 532 nm was measured spectrophotometrically. MDA concentrations were 
derived with the following formula: 
C = Measured absorbance x 320.5 x dilution factor / microprotein of homogenate= 
nmol/mg tissue  
2.2.4 Measurement of MDA in erythrocytes 
Blood was centrifuged and the plasma was separated. After being washed with normal 
saline solution once, 1.5 mL was taken from the erythrocyte plug and 1.5 mL of buffered 
sodium azide was added. 50 mL was taken from this hemolizate and 12.5 mL of Drabkin 
solution was added and the Hb was measured. 5 mL was taken from this mixture and 5 mL 
of 35% H2O2 was added and this mixture was incubated for 2 hours at 37° C with tubes 
open. After this was cooled, 3 mL was taken and 2 mL of trichloroacetic acid-arsenide 
solution was added and the mixture was then centrifuged at 2,500 rpm. 3 mL was taken 
from this supernatant and 1 mL of thiobarbituric acid was added and then the mixture was 
boiled for 15 min. After it cooled, absorbance at 532 nm was measured 
spectrophotometrically and the results were calculated for each gram of hemoglobin. 
2.3 Statistical methods 
Statistical analyses were performed using SPSS for Windows 13.0 (SPSS, Inc., Chicago, 
USA). Between group comparisons were made by repeated measurements with variance 
analysis (ANOVA). For significant values, Bonferroni one-way variance analysis as a post 
hoc test, and then the Tukey HSD test was applied. Comparisons with a P value of less than 
0.05 were regarded as statistically significant. When comparing intra-group repeated 
measurements, the student t test was used. Means of each group’s values were calculated 
and reported as a table. To compare tissue ACE and tissue MDA values, one-way ANOVA 
and then Tukey HSD tests were performed. 
3. Results 
All sham group animals died before 24 hours after intoxication, therefore no blood sample 
was collected from those subjects at 24 hours. 
No significant differences between groups in erythrocyte ACE levels were found. At 12 
hours after treatment, the mean erythrocyte ACE level of the melatonin+PAM+atropine 
group was not significantly different from that of the PAM+atropine group, but it was 
significantly higher than that of the sham group (p=0.023). The mean erythrocyte ACE level 
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in the melatonin+PAM+atropine group was significantly higher (p=0.031) than that of the 
PAM+atropine group (Table 1). 
 
Treatment group 1 hour 12 hours 24 hours 
Sham 1.75±1.0 1.45±1.1  
Pralidoxime + atropine 1.89±0.8 1.79±1.7 1.85±2.0 
Melatonin+pralidoxime+ 
atropine 2.10±1.2 2.31±1.3 2.95±1.8 
p value p>0.05 p<0.01 p<0.05 
Table 1. Mean erythrocyte acetylcholine esterase levels (U/L) at various times after 
intoxication with dichlorvos in the three groups. Levels were compared using the Mann 
Whitney U test. 
NO levels in the three groups were not significantly different from each other at 1 hour and 
12 hours post-intoxication (p>0.05). The NO levels at 24 hours post-intoxication in the 
melatonin+PAM+atropine group were not significantly different from that of the 
PAM+atropine group (p>0.05, Table 2). 
 
Treatment group 1 hour 12 hours 24 hours 
Sham 5.36±1.89 5.92±3.65  
Pralidoxime + atropine 5.10±1.81 6.21±1.68 7.73±2.67 
Melatonin+pralidoxime+atropine 5.41±2.10 5.81±1.89 7.05±2.71 
p value p>0.05 p>0.05 p>0.05 
Table 2. Mean erythrocyte nitric oxide levels (mmol/gr Hb) at various times after 
intoxication with dichlorvos in the three groups. Levels were compared using the Mann 
Whitney U test. 
At one hour post-intoxication, mean erythrocyte MDA levels were similar in all groups.  
At 12 hours, the mean erythrocyte MDA levels in the melatonin+PAM+atropine group  
were lower than those of both the sham group and the PAM+atropine group (p=0.001, 
p=0.012). At 24 hours, the mean erythrocyte MDA levels in the melatonin+PAM+atropine 
group were significantly lower than those of the PAM+atropine group (p=0.002,  
Table 3). 
Mean brain tissue ACE levels in the melatonin+PAM+atropine group were significantly 
higher than those of the sham group and PAM+atropine group (p=0.001, p=0.041,  
Figure 1).  
Mean brain tissue NO levels in the melatonin+PAM+atropine group were not significantly 
different from those of the sham group and PAM+atropine group (p=0.28, p=0.65, Figure 2).  
The mean brain tissue MDA levels in the melatonin+PAM+atropine group were 
significantly lower than those of both the sham group and PAM+atropine group (p=0.001, 
p=0.002, Figure 3). 
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Treatment group 1 hour 12 hours 24 hours 
Sham 5.40±0.45 9.05±0.66  
Pralidoxime + atropine 5.37±0.67 8.80±0.30 9.48±0.76 
Melatonin+pralidoxime 
+ atropine 5.12±0.53 5.93±0.37 6.14±0.42 
p value p>0.05 p<0.05 p<0.05 
Table 3. Mean erythrocyte malondialdehyde levels (nmol/mL) at various times after 
intoxication with dichlorvos in the three groups. Levels were compared using the Mann 
Whitney U test. 
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Fig. 3.  
4. Discussion  
Reactive oxygen species play a key role in initiating secondary brain damage (Özdemir et al, 
2005; Tyurin et al, 2000). The brain is prone to oxidative damage which results from high 
oxygen administration. High concentrations of metals like iron can catalyze reactive 
radicals, which leads to intense reactive radical production. Neural membranes are also rich 
in polyunsaturated fatty acids which also contribute to lipid peroxidation reactions (Reiter 
et al, 2000). Lipid peroxidation changes cell membrane permeability, increases the rate of 
protein degradation, and ultimately results in the destruction of cell membranes (Tyurin et 
al, 2000). Non-radical substances containing alkaline and carbonyl moieties produced 
during the last phases of lipid peroxidation can be measured by their reaction with 
thiobarbituric acid. Thiobarbituric acid reactive substances (TBARS), of which MDA is the 
most significant, reflect lipid peroxide production. Increased erythrocyte TBARS 
concentrations are correlated with severity of cerebral damage (Kasprzak et al, 2001).  
Toxicity after an acute intentional or accidental exposure to OP insecticides is largely a 
reflection of inhibition of ACE in the peripheral and central nervous systems. However, the 
toxic effects of OPs are not limited to ACE inhibition. In both acute and chronic OP toxictity, 
changes in antioxidant enzymes occur, and lipid peroxidation increases in many organs, 
especially the brain. In acute OP poisonings, a decrease in antioxidants occur, which upsets 
the critical balance between oxidants and antioxidants – thus accumulation of reactive 
oxygen species and cell destruction begins. In OP toxicity, oxidative stress is an important 
patho-physiological mechanism, especially for neurotoxicity and cerebral damage 
(Lukaszewicz-Hussain, 2008).  
Atropine and oximes are the fundamental medicines used in the treatment of OP 
intoxications. Atropine blocks muscarinic receptors in the peripheral and central nervous 
systems, crosses the blood-brain barrier, and is widely used in OP poisonings. Pralidoxime 
is the most commonly used oxime in the management of OP poisonings. It reactivates ACE 
which has been inhibited by OPs (Eddleston et al, 2008). In OP acute poisoning, PAM’s 
penetration into brain tissue may be enhanced by local inflammation. In sublethal OP 
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poisoning in rats, the group given oxime and atropine preserved cognitive functions 
compared to the atropine only group. The helpful effects of PAM on brain damage in OP 
intoxication may be partially explained by its peripheral effects which resolve any 
respiratory problems. Hypoxic brain damage is slight due to the peripheral effects of PAM 
(Shrot et al, 2009).      
We found that in rabbit model of OP poisoning, melatonin added to PAM and atropine had 
more positive effects on erythrocytes and brain tissue than PAM and atropine alone. For 
example, erythrocyte ACE activity of the melatonin+PAM+atropine group was higher than 
the PAM+atropine group, a finding which can be attributed to lower lipid peroxidation in 
the group receiving melatonin. The activity of ACE localized in erythrocyte membranes is a 
significant indicator of OP poisoning severity (13). In previous studies (chronic and sub-
chronic exposure) in rats and humans, acute OP poisoning erythrocyte ACE activity was not 
significantly different than levels in healthy controls (Tinoco & Halperine, 1998; Öğüt et al, 
2011). On the contrary, in a rat study of subchronic OP exposure, erythrocyte ACE activity 
and TBARS levels were found to be significantly lower in the toxicity group compared to 
healthy controls (Lukaszewicz-Hussain & Moniuszko-Jakoniuk, 2005). In our acute toxicity 
study, we found that melatonin added to PAM-atropine was beneficial to erythrocyte and 
brain tissue, findings similar to those of Lukaszewicz-Hussein.  
In an in vitro study by Durak D et al, the effect of C and E vitamins in human erythrocytes 
exposed to OPs on some anti-oxidant enzymes and MDA levels was measured (Durak et al, 
2009). In their study, antioxidant enzyme levels in erythrocytes pre-treated with vitamin C 
and E were higher, and lipid peroxidation was slighter lower.   
In our study, the addition of melatonin to ‘routine’ treatments for OP poisoning did not 
make a significant effect on erythrocyte NO levels compared to PAM+atropine. Casares et 
al. stated that OPs may spoil cell calcium homeostasis and change NO and NOS production, 
and thus decrease the effect of additional environmental negative factors. In our study, we 
did not find any result that supported Casares’s hypothesis (Casares & Mantione, 2007).  
In an in vitro OP toxicity study, levels of antioxidant enzymes like erythrocyte superoxide 
dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) decreased and 
erythrocyte MDA level increased (Karademir Çatalgöl et al, 2007). Öğüt et al. (Öğüt et al, 
2011) reported that MDA levels in erythrocyte samples taken from agriculture workers who 
were chronically exposed to OP insecticides were significantly higher compared to levels in 
healthy controls. On the contrary, erythrocyte SOD, CAT and GSH-Px levels were 
significantly lower than healthy controls. In another in vitro study, in the group in which C 
and E vitamins were added before OP toxicity occurred, erythrocyte MDA levels were 
significantly lower compared to the group which was not treated with vitamins C and E. 
In our study, erythrocyte MDA levels of the sham group were higher than those of other 
groups. Erythrocyte MDA levels of the melatonin+PAM+atropine group were lower than 
those of PAM+atropine group. This result is compatible with the results of the previous 
studies (Puntel et al, 2009). The intense oxidative tissue damage caused by OPs can be 
decreased with PAM+atropine. Puntel et al., who studied the antioxidant effects of oximes, 
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oximes. In our study, melatonin added to routine treatment decreased lipid peroxidation 
compared to routine PAM+atropine treatment. Thus, erythrocytes are better protected from 
oxidative stress when melatonin is added to the treatment regimen. 
In OP poisonings, the brain is one of the most damaged organs. Sub-acute poisonings are 
characterized by significant brain edema and corresponding clinic symptoms. Even with a 
 
Brain Injury – Pathogenesis, Monitoring, Recovery and Management 92
 
Fig. 3.  
4. Discussion  
Reactive oxygen species play a key role in initiating secondary brain damage (Özdemir et al, 
2005; Tyurin et al, 2000). The brain is prone to oxidative damage which results from high 
oxygen administration. High concentrations of metals like iron can catalyze reactive 
radicals, which leads to intense reactive radical production. Neural membranes are also rich 
in polyunsaturated fatty acids which also contribute to lipid peroxidation reactions (Reiter 
et al, 2000). Lipid peroxidation changes cell membrane permeability, increases the rate of 
protein degradation, and ultimately results in the destruction of cell membranes (Tyurin et 
al, 2000). Non-radical substances containing alkaline and carbonyl moieties produced 
during the last phases of lipid peroxidation can be measured by their reaction with 
thiobarbituric acid. Thiobarbituric acid reactive substances (TBARS), of which MDA is the 
most significant, reflect lipid peroxide production. Increased erythrocyte TBARS 
concentrations are correlated with severity of cerebral damage (Kasprzak et al, 2001).  
Toxicity after an acute intentional or accidental exposure to OP insecticides is largely a 
reflection of inhibition of ACE in the peripheral and central nervous systems. However, the 
toxic effects of OPs are not limited to ACE inhibition. In both acute and chronic OP toxictity, 
changes in antioxidant enzymes occur, and lipid peroxidation increases in many organs, 
especially the brain. In acute OP poisonings, a decrease in antioxidants occur, which upsets 
the critical balance between oxidants and antioxidants – thus accumulation of reactive 
oxygen species and cell destruction begins. In OP toxicity, oxidative stress is an important 
patho-physiological mechanism, especially for neurotoxicity and cerebral damage 
(Lukaszewicz-Hussain, 2008).  
Atropine and oximes are the fundamental medicines used in the treatment of OP 
intoxications. Atropine blocks muscarinic receptors in the peripheral and central nervous 
systems, crosses the blood-brain barrier, and is widely used in OP poisonings. Pralidoxime 
is the most commonly used oxime in the management of OP poisonings. It reactivates ACE 
which has been inhibited by OPs (Eddleston et al, 2008). In OP acute poisoning, PAM’s 
penetration into brain tissue may be enhanced by local inflammation. In sublethal OP 
 
The Effects of Melatonin on Brain Injury in Acute Organophosphate Toxicity 93 
poisoning in rats, the group given oxime and atropine preserved cognitive functions 
compared to the atropine only group. The helpful effects of PAM on brain damage in OP 
intoxication may be partially explained by its peripheral effects which resolve any 
respiratory problems. Hypoxic brain damage is slight due to the peripheral effects of PAM 
(Shrot et al, 2009).      
We found that in rabbit model of OP poisoning, melatonin added to PAM and atropine had 
more positive effects on erythrocytes and brain tissue than PAM and atropine alone. For 
example, erythrocyte ACE activity of the melatonin+PAM+atropine group was higher than 
the PAM+atropine group, a finding which can be attributed to lower lipid peroxidation in 
the group receiving melatonin. The activity of ACE localized in erythrocyte membranes is a 
significant indicator of OP poisoning severity (13). In previous studies (chronic and sub-
chronic exposure) in rats and humans, acute OP poisoning erythrocyte ACE activity was not 
significantly different than levels in healthy controls (Tinoco & Halperine, 1998; Öğüt et al, 
2011). On the contrary, in a rat study of subchronic OP exposure, erythrocyte ACE activity 
and TBARS levels were found to be significantly lower in the toxicity group compared to 
healthy controls (Lukaszewicz-Hussain & Moniuszko-Jakoniuk, 2005). In our acute toxicity 
study, we found that melatonin added to PAM-atropine was beneficial to erythrocyte and 
brain tissue, findings similar to those of Lukaszewicz-Hussein.  
In an in vitro study by Durak D et al, the effect of C and E vitamins in human erythrocytes 
exposed to OPs on some anti-oxidant enzymes and MDA levels was measured (Durak et al, 
2009). In their study, antioxidant enzyme levels in erythrocytes pre-treated with vitamin C 
and E were higher, and lipid peroxidation was slighter lower.   
In our study, the addition of melatonin to ‘routine’ treatments for OP poisoning did not 
make a significant effect on erythrocyte NO levels compared to PAM+atropine. Casares et 
al. stated that OPs may spoil cell calcium homeostasis and change NO and NOS production, 
and thus decrease the effect of additional environmental negative factors. In our study, we 
did not find any result that supported Casares’s hypothesis (Casares & Mantione, 2007).  
In an in vitro OP toxicity study, levels of antioxidant enzymes like erythrocyte superoxide 
dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) decreased and 
erythrocyte MDA level increased (Karademir Çatalgöl et al, 2007). Öğüt et al. (Öğüt et al, 
2011) reported that MDA levels in erythrocyte samples taken from agriculture workers who 
were chronically exposed to OP insecticides were significantly higher compared to levels in 
healthy controls. On the contrary, erythrocyte SOD, CAT and GSH-Px levels were 
significantly lower than healthy controls. In another in vitro study, in the group in which C 
and E vitamins were added before OP toxicity occurred, erythrocyte MDA levels were 
significantly lower compared to the group which was not treated with vitamins C and E. 
In our study, erythrocyte MDA levels of the sham group were higher than those of other 
groups. Erythrocyte MDA levels of the melatonin+PAM+atropine group were lower than 
those of PAM+atropine group. This result is compatible with the results of the previous 
studies (Puntel et al, 2009). The intense oxidative tissue damage caused by OPs can be 
decreased with PAM+atropine. Puntel et al., who studied the antioxidant effects of oximes, 
reported that lipid peroxidation caused by various oxidizing substances was decreased with 
oximes. In our study, melatonin added to routine treatment decreased lipid peroxidation 
compared to routine PAM+atropine treatment. Thus, erythrocytes are better protected from 
oxidative stress when melatonin is added to the treatment regimen. 
In OP poisonings, the brain is one of the most damaged organs. Sub-acute poisonings are 
characterized by significant brain edema and corresponding clinic symptoms. Even with a 
 
Brain Injury – Pathogenesis, Monitoring, Recovery and Management 94
single high dose, heavy axonal degeneration can be seen (Read et al, 2010). Major side effects 
of OP poisoning are rapid loss of conscious resulting from hyperstimulation in central 
cholinergic synapses, and inhibition of the respiratory center in the medulla oblongata. In 
animal models, status epilepticus with profound brain damage occurs after significant OP 
intoxications. Oximes pass through the blood-brain barrier insubstantially and reactivate 
ACE enzymes which were previously inactivated by OPs. Although the concentrations of 
oximes in the brain are low, they are adequate to reactivate ACE enzymes and produce 
positive clinical responses. However, oximes’ positive effects on brain tissue are not only 
dependent on reactivation of ACE enzymes, because studies to date have not found a 
significant correlation between ACE enzyme levels reactivated in the brain (Eddleston et al, 
2008). On the other hand, studies have found that even a small amount of ACE reactivation 
can increase the rate of survival (Shrot et al, 2009). 
In our study, brain tissue ACE activity of the melatonin+PAM+atropine group was higher 
than that of PAM+atropine group, which were only slightly higher than that of the sham 
group. This result suggests that the beneficial effects of melatonin are not only related to 
PAM’s reactivation of inactivated ACE enzyme. Hsu et al. studied the effects of melatonin 
on antioxidant enzymes and MDA levels in the brain tissue of rats that they exposed to OPs 
in vivo and in vitro (Hsu et al, 2002). OPs lead to lipid peroxidation and DNA oxidation 
both in vivo and in vitro mediums. However, in the melatonin-treated groups, GSH-Px 
activity in the brain was significantly higher than non-treated groups; MDA levels were 
much lover afer melatonin treatment. Our study results are compatible with theirs. Brain 
tissue MDA levels of the PAM+atropine group were close to those of the sham group. The 
MDA levels in the animals receiving melatonin were lower than the other two groups. This 
result indicates that a significant amount of peroxidation lipid develops in the brain after 
exposure to OPs. This lipid peroxidation and ensuing damage in brain tissue can be 
significantly decreased with melatonin.  
Rats with untreated subchronic OP toxicity develop very high MDA levels in the 
hippocampus and low SOD levels (Chen et al, 2010). In another study, ACE activity in the 
hippocampus decreased after subchronic dermal exposure (Mitra et al, 2008). In chronic and 
subchronic exposures to OPs, the memory and learning functions of the brain are seriously 
affected due to damage in this area. Giving melatonin before and after acute OP poisoning 
in rats prevented an increase in brain tissue MDA levels. Brain tissue NO levels in groups 
treated with melatonin before and after toxicity were significantly higher than those of 
controls not given OP. In our study, lipid peroxidation in a particular region of the brain, 
localized ACE activity, NO levels, and oxidative damage were not researched. However, in 
our acute OP poisoning model, lipid peroxidation in brain tissue and oxidative damage 
decreased in general, and ACE activity decreased. In our study, melatonin did not show any 
beneficial effect on brain tissue NO levels. However, lipid peroxidation in brain tissue of the 
group in which melatonin was added to treatment and ACE levels were positively 
influenced. Our results suggest that brain damage may be decreased and memory and 
learning functions can be preserved with the addition of melatonin to routine OP poisoning 
treatment. Further studies should be performed to determine melatonin’s effect in a variety 
of clinical processes. 
Limitations of this study include its low number of subjects; but the ethics board did not 
allow us to use more subjects. In addition, histopathological examination of brain tissue 
samples was not performed.    
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5. Conclusion 
Melatonin added to PAM and atropine in the treatment of acute OP poisoning increases 
ACE activity in brain tissue, and shows a beneficial effect on brain injury by decreasing lipid 
peroxidation and oxidative stress in brain tissue.  
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1. Introduction 
Aging nations are growing worldwide and now one in four of us may expect to experience 
an ischemic brain injury by the age 85. Stroke is the third most common cause of death and 
the second most common cause of dementia in industrialized societies with a mortality rate 
of circa 30% and an incidence of about 250–400 in 100,000. Stroke affects circa 700,000 people 
each year in the US alone, and about 50% of these individuals will experience lasting 
functional dysfunctions including sensory problems and cognitive deficits (Hillis 2006). It is 
estimated that ischemic stroke is responsible for approximately half of all patients 
hospitalized for acute neurological disorders. As outlined earlier, it can cause neurological 
dysfunctions in a number of neurological functions most commonly in the motor activity, 
cognitive decline, and dementia. Postischemic dementia is characterized by progressive 
cognitive deterioration including language, reasoning and memory. Of those individuals 
suffering from ischemic brain injury less than 50% will return to independent living during 
the following year. Even among those who regain functional independence, many stroke 
patients continue to manifest significant deficits, limitations and changes in their cognitive 
functioning and behavior. As such, stroke is one of the leading causes of disability and 
experiencing a stroke results in two-fold increase in risk for dementia. Other data showed 
that 1-in-10 developing dementia soon after first stroke, and over 1-in-3 being demented 
after recurrent stroke. The brain has limited responses to different kind of neuropathogens. 
Similar neuropathological features are observed in different cerebrovascular diseases and 
Alzheimer’s disease (Kalaria 2000; Pluta 2004a; Pluta 2004b; De la Torre 2005; Pluta 2006a; 
Benarroch 2007; Niedermeyer 2007; Pluta 2007c; Bell, Zlokovic 2009). Brain stroke is the 
leading cause of cognitive impairment worldwide. These data are supported by 
observations in clinical as well as in experimental studies, which suggest that ischemic brain 
injury is a major risk factor of dementia ranking only second to age (Gorelick 1997; Pluta 
2006a; Pluta 2007c). Dementia, which is observed following different brain ischemic injuries, 
is associated with intellectual impairment and finally brain atrophy (Hossmann et al., 1987; 
Loeb et al., 1988; Tatemichi et al., 1990; Pluta 2002b; Kiryk et al., 2011). Amyloid plaques, 
which are the main pathological hallmarks of Alzheimer’s disease, account for about 90% of 
dementias including ischemic-type dementia (Jendroska et al., 1995; Wisniewski, Maslinska 
1996; Shi et al., 1998; Pluta, 2007a; Qi et al., 2007). The relationship between brain ischemic 
injury dementia and Alzheimer’s disease type dementia is recently much debated. The 
mechanisms of the progressive cognitive decline after ischemic brain injury are not yet clear 
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but animal  investigations have demonstrated an increase in expression and processing of 
amyloid precursor protein to β-amyloid peptide (Pluta et al., 1994b; Pluta et al., 1997b; Pluta 
et al., 1997c; Pluta et al., 1998b; Lin et al., 1999; Shi et al., 2000; Lin et al., 2001; Badan et al., 
2004; Pluta et al., 2009) and an increase in the phosphorylation of tau protein (Dewar,  
Dawson 1995; Wen et al., 2004b; Wen et al., 2004c, Wen et al., 2007). Moreover, the common 
mechanism that links progressive cognitive decline after ischemic brain injury and during 
Alzheimer’s disease is neuroinflammation (Koistinaho et al., 2002), which can cause gradual 
neurodegeneration during prolonged face of injury. However, the link between ischemic 
brain injury and delayed progressive cognitive decline opens a new area for potential 
treatment in that the onset of the progressive cognitive decline after ischemia is delayed. The 
above data raise the question whether Alzheimer’s related proteins affect ischemic brain 
tissue. The details of Alzheimer’s protein-related mechanisms, which probably mediate 
ischemic brain cell damage and neurotoxicity (Mattson et al., 2000; Malm, Koistinaho 2007) 
and involvement of these proteins in brain accumulation will be reviewed. This chapter 
summarizes some of the findings, which suggest that ischemic overexpression of amyloid 
precursor protein renders the brain more vulnerable to ischemic episodes (Koistinaho et al., 
2002) and describes the factors that are involved in increased neuronal susceptibility to 
ischemic injury (Mattson et al., 2000; Malm, Koistinaho 2007). 
1.1 Consequences of ischemic brain injury 
Brain ischemic injury is the most common chronic cause of disability around world and has 
generally a negative influence on the individuals it affects, caregivers and society as a whole 
(Flynn et al., 2008). Ischemic stroke survivors suffer from chronic progressing neurological 
disabilities that significantly influence their ability to return to society. A more insidious 
consequence of brain ischemia is a post-stroke dementia (Jellinger 2007) that is also associated 
with severe disability. Worldwide brain vascular disorders like ischemia are responsible for 5.4 
million deaths every year (Flynn et al., 2008). Circa 3% of total healthcare finances are 
attributable to brain ischemia. Cost of ischemic stroke to the EU economy is estimated at 21 
billion euro and to USA economy at 2.2 trillion dollars (Fillit, Hill 2002, Flynn et al., 2008). The 
global scale of the problem and the enormous associated costs it is clear that there is an urgent 
need for advances in the prevention of ischemic brain injury and its consequences like 
postischemic dementia. Dementia is the worst consequence for survivors following brain 
ischemia and being responsible for approximately 20% of all confirmed dementias (Fillit, Hill 
2002). Globally cerebrovascular diseases dementia varies from 10 to 50% depending on the 
diagnostic criteria, geographic location and population demographic (Leys et al., 2002). 
Recently it is becoming clear, that cerebrovascular diseases dementia in fact shares many risk 
factors in common with Alzheimer’s disease. Indeed ischemic brain injuries may precede the 
onset of this form of dementia strongly suggesting that brain ischemic episodes may trigger 
neurodegenerative dementias. Postischemic dementia connected with chronic delayed 
secondary injury occurs in individuals suffering from focal or global brain ischemia in a 
progressive manner (Jellinger 2007). The chronic postischemic injury including dementia has 
received far less attention in clinical and experimental stroke investigations. Vascular 
dementia incorporates cognitive dysfunction with cerebrovascular diseases.  
1.2 Epidemiology of postischemic dementia 
Epidemiological studies have shown that the prevalence of dementia in ischemic brain 
injury patients is nine-fold higher than controls at 3 months (Madureira et al., 2001; 
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Pohjasvaara et al., 1998; Tatemichi et al., 1992)  and 4-12 times higher than in controls 4 years 
after a lacunar infarct (Loeb et al., 1992). Different patterns of cognitive decline as effect of 
ischemia brain injury have been shown by longitudinal epidemiological, studies which have 
suggested a progressive course of dementia following ischemic stroke. Tatemichi et al., 
(1990) presented that the incidence of dementia was 6.7% among patients directly after 1 
year of survival in a group of 610 subjects who were initially free of dementia following 
stroke. Bornstein et al., (1996) reported that 32% individuals who were initially free of 
dementia directly after stroke developed incidental dementia during 5 years of survival 
following first ischemic episode. Henon et al., (2001) observed a sample of 169 patients who 
had been free of dementia before stroke and reported that the cumulative proportion of 
individuals with incidental dementia was 21.3% after 3 years of survival. Altieri et al., (2004) 
examined 191 free of dementia stroke patients for a 4 years, and noted that the incidence of 
dementia increasing gradually with 21.5% subjects had developed dementia by the end of 
the follow-up time. In population-based investigations of stroke and dementia subjects, 
Kokmen et al., (1996) checked the medical records of 971 patients who were nondemented 
before first stroke. The incidence of dementia was 7% at 1 y, 10% at 3 y, 15% at 5 y and 23% 
at 10 y. Desmond et al., (2002) performed functional assessments annually on 334 ischemic 
brain injury patients and 241 ischemia free control individuals, all of whom were free of 
dementia in baseline examinations, and noted a progressive course of dementia with the 
incidence rate of 8.94/100 person/year in the ischemic group and 1.37/100 person/year in 
the control group. In two studies based on subjects presenting with a lacunar infarction as 
their first ischemic stroke, Samuelsson et al., (1996) found that 4.9% and 9.9% of 81 patients 
had dementia after 1 and 3 years of observation, respectively, and Loeb et al., (1992) 
reported that 23.2% individuals had dementia during an average of 4 years of survival. 
Removal of the above deficits/abnormalities is a topic to which a neurologist and scientists 
devotes little time. In different patients, some spontaneous functional restoration is noted 
during weeks/months after ischemic brain injury. However, in general, this spontaneous 
recovery is incomplete. Moreover, ischemic brain injury often leaves its victims functionally 
devastated and as such is the leading cause of permanent disability requiring long-term 
institutional care in our nations. The loss of life quality years and health care resources are 
staggering. The situation is even aggravated by the fact that unlike many other neurological 
diseases, no safe, effective therapy is available for the majority of patients with acute ischemic 
brain injury. The burden after ischemic brain injury on our societies is dramatically increasing. 
Thus, an understanding of the underlying progressing pathological processes/cascades is 
urgently needed. This chapter tends to summarize the neuropathological changes of chronic 
postischemic brain injury and reveal the convinced mechanisms. 
2. Amyloid precursor protein and β-amyloid peptide after ischemia 
After brain ischemia, amyloid precursor protein mRNA had enhanced till 200% in the brain 
during the seventh day of reperfusion. The above data suggest that local ischemic brain 
injury increases amyloid precursor protein mRNA level, which may contribute to the 
progression of cognitive impairment in ischemic brain injury (Abe et al., 1991; Koistinaho et 
al., 1996; Shi et al., 1998; Shi et al., 2000). Above studies also show that focal ischemic brain 
injury alters Kunitz protease inhibitor amyloid precursor protein/amyloid precursor protein 
695 ratios in brain and this shift in precursor isoforms could be related to degeneration and 
activation of astrocyte following the ischemic injury (Kim et al., 1998). In permanent local 
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onset of this form of dementia strongly suggesting that brain ischemic episodes may trigger 
neurodegenerative dementias. Postischemic dementia connected with chronic delayed 
secondary injury occurs in individuals suffering from focal or global brain ischemia in a 
progressive manner (Jellinger 2007). The chronic postischemic injury including dementia has 
received far less attention in clinical and experimental stroke investigations. Vascular 
dementia incorporates cognitive dysfunction with cerebrovascular diseases.  
1.2 Epidemiology of postischemic dementia 
Epidemiological studies have shown that the prevalence of dementia in ischemic brain 
injury patients is nine-fold higher than controls at 3 months (Madureira et al., 2001; 
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Pohjasvaara et al., 1998; Tatemichi et al., 1992)  and 4-12 times higher than in controls 4 years 
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suggested a progressive course of dementia following ischemic stroke. Tatemichi et al., 
(1990) presented that the incidence of dementia was 6.7% among patients directly after 1 
year of survival in a group of 610 subjects who were initially free of dementia following 
stroke. Bornstein et al., (1996) reported that 32% individuals who were initially free of 
dementia directly after stroke developed incidental dementia during 5 years of survival 
following first ischemic episode. Henon et al., (2001) observed a sample of 169 patients who 
had been free of dementia before stroke and reported that the cumulative proportion of 
individuals with incidental dementia was 21.3% after 3 years of survival. Altieri et al., (2004) 
examined 191 free of dementia stroke patients for a 4 years, and noted that the incidence of 
dementia increasing gradually with 21.5% subjects had developed dementia by the end of 
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before first stroke. The incidence of dementia was 7% at 1 y, 10% at 3 y, 15% at 5 y and 23% 
at 10 y. Desmond et al., (2002) performed functional assessments annually on 334 ischemic 
brain injury patients and 241 ischemia free control individuals, all of whom were free of 
dementia in baseline examinations, and noted a progressive course of dementia with the 
incidence rate of 8.94/100 person/year in the ischemic group and 1.37/100 person/year in 
the control group. In two studies based on subjects presenting with a lacunar infarction as 
their first ischemic stroke, Samuelsson et al., (1996) found that 4.9% and 9.9% of 81 patients 
had dementia after 1 and 3 years of observation, respectively, and Loeb et al., (1992) 
reported that 23.2% individuals had dementia during an average of 4 years of survival. 
Removal of the above deficits/abnormalities is a topic to which a neurologist and scientists 
devotes little time. In different patients, some spontaneous functional restoration is noted 
during weeks/months after ischemic brain injury. However, in general, this spontaneous 
recovery is incomplete. Moreover, ischemic brain injury often leaves its victims functionally 
devastated and as such is the leading cause of permanent disability requiring long-term 
institutional care in our nations. The loss of life quality years and health care resources are 
staggering. The situation is even aggravated by the fact that unlike many other neurological 
diseases, no safe, effective therapy is available for the majority of patients with acute ischemic 
brain injury. The burden after ischemic brain injury on our societies is dramatically increasing. 
Thus, an understanding of the underlying progressing pathological processes/cascades is 
urgently needed. This chapter tends to summarize the neuropathological changes of chronic 
postischemic brain injury and reveal the convinced mechanisms. 
2. Amyloid precursor protein and β-amyloid peptide after ischemia 
After brain ischemia, amyloid precursor protein mRNA had enhanced till 200% in the brain 
during the seventh day of reperfusion. The above data suggest that local ischemic brain 
injury increases amyloid precursor protein mRNA level, which may contribute to the 
progression of cognitive impairment in ischemic brain injury (Abe et al., 1991; Koistinaho et 
al., 1996; Shi et al., 1998; Shi et al., 2000). Above studies also show that focal ischemic brain 
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695 ratios in brain and this shift in precursor isoforms could be related to degeneration and 
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brain ischemia injury, amyloid precursor protein mRNA species, which contain a Kunitz-
type protease inhibitor domain, were expressed in the cortex by day 21 of survival but the 
net amount of precursor mRNA did not change. This investigation suggests a selective role 
of amyloid precursor protein species that contain the Kunitz protease inhibitor domain in 
cascade of focal brain ischemia (Abe et al., 1991). After local ischemia amyloid precursor 
protein 770 and amyloid precursor protein 751 mRNAs were increased during 7 days in the 
brain (Koistinaho et al., 1996). 
Animals after focal and global ischemic brain injury with a survival time up to 1 year 
presented increased brain immunoreactivity to the β-amyloid peptide and as well as to  
the N- and C-terminal of amyloid precursor protein. The staining was observed 
extracellularly and intracellularly (Pluta et al., 1994b; Hall et al., 1995; Tomimoto et al., 1995; 
Horsburgh, Nicoll, 1996a; Ishimaru et al., 1996a; Yokota et al., 1996; Pluta et al., 1997b; Pluta 
et al., 1998b; Lin et al., 1999; Pluta 2000; Lin et al., 2001; Sinigaglia-Coimbra et al., 2002; 
Fujioka et al., 2003; Yang, Simpkins 2007). Different fragments of amyloid precursor protein 
were noted in astrocytes, neurons, oligodendrocytes, and microglia (Banati et al., 1995; 
Palacios et al., 1995; Pluta et al., 1997b; Nihashi et al., 2001; Pluta, 2002a; Pluta2002b; Badan 
et al., 2003; Badan et al., 2004). Animals with long survival after ischemic brain injury from 
0.5 to 1 year showed pathological brain staining only to the β-amyloid peptide and to the  
C-terminal of amyloid precursor protein (Pluta et al., 1998b; Pluta 2000). The reactive 
astrocytes with deposition of different fragments of amyloid precursor protein might be 
involved in the development of glial scar (Nihashi et al., 2001; Pluta 2002a; Pluta 2002b; 
Badan et al., 2003; Badan et al., 2004). Reactive astrocytic cells with pathological level of  
β-amyloid peptide deposition might be involved in pathological repair of host tissue after 
ischemic brain injury including astrocytes death (Pluta et al., 1994b; Pluta 2002b; Wyss-
Coray et al., 2003; Takuma et al., 2004). 
Pathological amyloid precursor protein staining especially for β-amyloid peptide and  
C-terminal has been observed in periventricular and subcortical white matter after ischemic 
brain injury (Pluta et al., 2006, Pluta et al., 2008). The more intense postischemic brain injury 
of white matter is, the more extensive is the staining of different parts of amyloid precursor 
protein in this region (Yam et al., 1997). In contrast, in our unpublished studies, the data are 
opposite. We noted ischemic time-independent intensity of immunostaining, shorter 
ischemic brain injury stronger reactivity. Probably, this kind of abnormalities is responsible 
for leukoaraiosis formation after ischemic brain injury (Pluta et al., 2008). Extracellular 
accumulation of different fragments of amyloid precursor protein ranged from multifocal 
widespread very small dots to regular amyloid plaques (Pluta et al., 1994b; Pluta et al., 
1998b; Pluta 2000; Pluta 2002b; Pluta 2003). Multifocal and widespread different kinds of 
amyloid plaques were observed mainly in the ischemic hippocampus, brain and entorhinal 
cortex, and corpus callosum, and subventriculary (Pluta et al., 1994b; Pluta et al., 1997b; 
Pluta et al., 1998b; Pluta 2000; Pluta 2003; Pluta 2005; Pluta et al., 2006; Pluta et al., 2008; 
Pluta et al., 2009; Pluta et al., 2010).  
The accumulation of the β-amyloid peptide in astrocytes and the C-terminal of amyloid 
precursor protein in ischemic neurons underline the likely importance of these two proteins 
in ischemic brain injury cascade of degeneration (Pluta et al., 1994b; Yokota et al., 1996; Pluta 
2002b; Badan et al., 2003; Badan et al., 2004). Moreover, the above parts of precursor deposits 
suggest that these fragments of precursor may initiate synaptic pathology and finally 
promote retrograde neuronal death after ischemic injury (Oster-Granite et al., 1996). The 
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aforementioned observations indicate that the late neurotoxic β-amyloid peptide and  
C-terminal of amyloid precursor protein deposition after ischemic brain injury may 
represent a secondary injury process that could deteriorate the ischemic brain outcome by 
unexpected additional neurons death (Pluta et al., 1997c, Pluta et al., 1998b). Following 
ischemia β-amyloid peptide is produced as a result of neurons injury (Ishimaru et al., 1996a) 
and probably appears its effects, influencing ischemic neurons and glia as dementia. It is 
generally received that β-amyloid peptide takes part in neurons death (Cotter et al., 1999). 
The β-amyloid peptide is a toxic protein and entangles within an ischemic process in 
astrocytes, oligodendrocytes, and microglia that lead neurons and glia finally to death 
(Giulian et al., 1995). 
3. Amyloid precursor protein secretases after ischemia 
The amyloid precursor protein is cleaved by α-secretase and it is not pathological pathway 
in brain. Ischemic brain injury results in the downregulation of α-secretase mRNA and 
decreases its net activity (Nalivaeva et al., 2004; Yan et al., 2007). In the pathological 
pathway called amyloidogenic precursor is cleaved by β-secretase and γ-secretase to form  
β-amyloid peptide. The formation of β-amyloid peptide in the brain after ischemic injury 
increases and impairs the memory (Yan et al., 2007). Current investigations have shown that 
brain ischemia stimulates the formation and activity of β-secretase in brain tissue (Wen et 
al., 2004a; Chuang et al., 2008). Presenilin, which is overexpressed after ischemic brain injury 
(Tanimukai et al., 1998; Pennypacker et al., 1999), is involved in ischemic β-amyloid peptide 
synthesis by γ-secretase (Polavarapu et al., 2008). 
4. Amyloid precursor protein intracellular domain after ischemia 
Important brain trigger, which initiates amyloid precursor protein cleavage, is ischemic 
episode. The main proteolysis is performed by α- or β-secretase that produce large soluble 
N-terminal parts called respectively soluble N-terminal domain of amyloid precursor 
protein α (sAPPα) or soluble N-terminal domain of amyloid precursor protein β (sAPPβ). 
These fragments are release into the extracellular space. Remaining C-terminal domains are 
bind with membrane and called respectively C-terminal fragment 83 or 99 (CTF83/CTFα or 
CTF99/CTFβ). The second cleavage occurs in the intramembrane area by γ-secretase, which 
depending on where the first proteolysis was made and finally releases either the β-amyloid 
peptide or p3 fragment. This phenomenon seems to be largely nonselective occurring in at 
least 3 different sites of the amyloid precursor protein like V636, A638 and L645 (ε-cleavage 
site) (Sastre et al., 2001; Yu et al., 2001). The final products are β-amyloid peptide 40/42 and 
an intracellular 50 aa C-terminal of amyloid precursor protein domain (5kDa) (Pinnix et al., 
2001). Amyloid intracellular domain is very labile and can be further disintegrated by the 
insulin degrading enzyme or proteasome. Amyloid intracellular domain with specific 
binding proteins initiating a signal cascade, which subsequently migrates to the cell nucleus 
to become a component of a transcriptional process but the adaptor protein FE65 rescues the 
amyloid intracellular domain from rapid proteolysis. 
5. Tau protein after ischemia 
Tau protein overexpression in neurons was observed in the hippocampus (Geddes et al., 
1994) and the brain cortex (Dewar et al., 1993; Dewar et al., 1994) after ischemic brain injury 
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brain ischemia injury, amyloid precursor protein mRNA species, which contain a Kunitz-
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aforementioned observations indicate that the late neurotoxic β-amyloid peptide and  
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unexpected additional neurons death (Pluta et al., 1997c, Pluta et al., 1998b). Following 
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and probably appears its effects, influencing ischemic neurons and glia as dementia. It is 
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The β-amyloid peptide is a toxic protein and entangles within an ischemic process in 
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The amyloid precursor protein is cleaved by α-secretase and it is not pathological pathway 
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decreases its net activity (Nalivaeva et al., 2004; Yan et al., 2007). In the pathological 
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to become a component of a transcriptional process but the adaptor protein FE65 rescues the 
amyloid intracellular domain from rapid proteolysis. 
5. Tau protein after ischemia 
Tau protein overexpression in neurons was observed in the hippocampus (Geddes et al., 
1994) and the brain cortex (Dewar et al., 1993; Dewar et al., 1994) after ischemic brain injury 
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(Sinigaglia-Coimbra et al., 2002). Moreover, an increase of tau immunostaining was noted in 
glia and oligodendrocytes following local brain ischemia (Dewar, Dawson 1995; Irving et al., 
1997). Additionally pathological tau protein was found in microglia around the ischemic 
core (Uchihara et al., 2004). The above data indicate that only some neurons display 
pathologically changed tau protein following ischemic brain injury (Dewar, Dawson 1995), 
which may reflect an early alterations state of the degenerative processes in these cells 
(Irving et al., 1997). Another study noted a complete dephosphorylation of tau protein after 
ischemic brain injury (Mailliot et al., 2000). The dephosphorylation of tau protein may 
influence its transportation between axon and cell body and affects its susceptibility to 
proteolysis (Shackelford, Yeh 1998). Some other study noted that tau protein itself blocks 
transport of amyloid precursor protein from the neuron body into axon and dendrites 
causing amyloid precursor accumulation in the neuron body (Stamer et al., 2002). The recent 
studies show that after ischemic brain injury, hyperphosphorylated tau protein accumulates 
in cortical neurons and colocalizes with signs of apoptosis. This process may be important 
element in the etiology in ischemic brain degeneration. The above observations indicate that 
neuron ischemic apoptosis is connected with tau protein hyperphosphorylation (Wen et al., 
2004b; Wen et al., 2007). Wen et al. (2004c, 2007) noted that reversible brain ischemia is 
associated with neurofibrillary tangle-like tauopathy formation in the brain. These data 
provide groundwork for the cause of dementia after ischemic brain injury (Wen et al., 
2004c).  
6. Presenilins after ischemia 
Ischemic brain injury overexpression of presenilin 1 gene in neurons of the CA3 sector and 
dentate gyrus was noted (Tanimukai et al., 1998). In above study, increased expression of 
presenilin 1 mRNA was the highest at day 3 of reperfusion in affected regions. The above 
data suggest that the overexpression of presenilin 1 mRNA may be associated with some 
responses of neurons injured by ischemic pathology. In another study, the increased 
expression of presenilin mRNA was found in the hippocampus, striatum, cortex, and 
cerebellum following local ischemic brain injury (Pennypacker et al., 1999). Generally 
presenilin mRNA exhibited the highest expression in the hippocampus and brain cortex. 
The expressions were higher on the contralateral side to the local ischemic brain injury. This 
difference may reflect a loss in brain cells e.g. neurons expressing presenilin genes on the 
ipsilateral side. Staining of presenilin was more expressed in glia than in neurons and in a 
trace of the pyramidal neurons of hippocampus after ischemic brain injury (Pluta 2001). 
Presenilin 1 increases neuron vulnerability to ischemia by increasing intracellular calcium 
(Mattson et al., 2000; Pluta et al., 2009). A current investigation presented that presenilin 1 
and intracellular calcium regulates neuron glutamate uptake (Yang et al., 2004). Taken 
together, above data indicate that presenilins and intracellular calcium may play an 
important role in regulating glutamate uptake, and therefore they may influence glutamate 
toxicity in the ischemic brain injury.  
7. Apolipoproteins after ischemia 
Astrocytic apolipoprotein E mRNA overexpression with the highest level at day 7 after 
ischemic brain injury was found, which suggests that ischemic neuron injury results in the 
induction of certain genes in the brain within reactive astrocytes and this induction may 
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contribute to amyloidogenesis following brain ischemia (Ali et al., 1996). Apolipoprotein E 
mRNA overexpression in glia but not in neurons was noted in ischemic penumbra with a peak 
on 21st day. In ischemic core apolipoprotein E mRNA overexpression was observed in 
macrophages (Kamada et al., 2003). Overexpression of clusterin mRNA was shown in the 
penumbra in permanent focal brain ischemia. In these studies, reactive astrocytes in the cortex 
were stained abnormally for apolipoprotein J. It was suggested that local expression of 
clusterin mRNA might contribute to the neuroinflammation, which representing a main factor 
in secondary injury processes after focal ischemic brain episodes (Van Beek et al., 2000). After 
moderate ischemic brain injury a time-dependent deposition of clusterin was noted in 
pyramidal neurons of the CA1 and the CA2 sector in the hippocampus undergoing delayed 
neuronal death. Overexpression of apolipoprotein J mRNA in contrast to neuronal protein 
staining appeared to be glial in origin with increases in mRNA the hippocampus fissure and 
only a very weak signal over the CA1 and the CA2 pyramidal neuron layer. The above results 
support the idea that clusterin is synthesized in the astrocytes, secreted outside and next taken 
up by dying neurons (Nishio et al., 2003). Clusterin deposition was observed in neurons 
destined to die by apoptosis. Moreover, pathological overexpression of clusterin suggests that 
the synthesis of this protein was a result of selective delayed neuronal death rather than 
involvement in the pathological cascade of events that cause it (Walton et al., 1996). 
The pathological immunostaining for apolipoproteins A1, E, and J was shown extracellularly 
and intracellularly (Hall et al., 1995; Kida et al., 1995; Pluta et al., 1995a; Horsburgh, Nicoll 
1996a, Horsburgh, Nicoll 1996b; Ishimaru et al., 1996b; Pluta 2000; Kamada et al., 2003). 
Intracellular staining was noted in damaged neurons exhibiting features of ischemic injury 
(Pluta 2000). Less often immunostaining for above proteins was observed in glia (Kamada et 
al., 2003). Extracellular accumulations of apolipoproteins were irregular and well delineated 
and mainly diffuse. Strong staining was noted also in acellular, necrotic, irregular and spider-
like foci (Kida et al., 1995; Pluta et al., 1995a; Ishimaru et al., 1996a). It is important to notice 
that accumulations of apolipoproteins colocalize with aggregates of different parts of amyloid 
precursor protein (Kida et al., 1995; Pluta et al., 1995b). Apolipoprotein E promotes the 
deposition of β-amyloid peptide into the oligomeric and the fibrillar form. Clusterin is 
engaged in transport of β-amyloid peptide through the blood-brain barrier. The main activity 
of apolipoproteins A1, E and J is controlling the level of soluble β-amyloid peptide in the 
intracellular and the extracellular space of brain tissue as well as their influence on fibrillar  
β-amyloid peptide conversion. Apolipoprotein E induces β-amyloid peptide increased 
lysosomal leakage and finally apoptosis in neuronal cells (Ji et al., 2002). Apolipoproteins A1, 
E, and J influence the deposition, structure and neurotoxicity of the β-amyloid peptide in brain 
ischemia. Additionally, in β-amyloid peptide production apolipoproteins E and J are involved 
prior to its accumulation. The above studies show principal roles of apolipoproteins E and J in 
β-amyloid peptide accumulation and that they play an important role in it extracellular  
β-amyloid peptide metabolism independent of β-amyloid peptide synthesis. These 
observations indicate that apolipoproteins A1, E and J deposition following ischemic brain 
injury may be a secondary damaging phenomenon, which could deteriorate healing of 
ischemic neurons indirectly influences development of ischemic-type dementia.  
8. -synuclein after ischemia 
Brain ischemia provoked changes in a presynaptic protein α-synuclein in the ischemic 
hippocampus (Ishimaru et al., 1998; Kitamura et al., 2001). Intense α-synuclein 
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(Sinigaglia-Coimbra et al., 2002). Moreover, an increase of tau immunostaining was noted in 
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presenilin mRNA exhibited the highest expression in the hippocampus and brain cortex. 
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contribute to amyloidogenesis following brain ischemia (Ali et al., 1996). Apolipoprotein E 
mRNA overexpression in glia but not in neurons was noted in ischemic penumbra with a peak 
on 21st day. In ischemic core apolipoprotein E mRNA overexpression was observed in 
macrophages (Kamada et al., 2003). Overexpression of clusterin mRNA was shown in the 
penumbra in permanent focal brain ischemia. In these studies, reactive astrocytes in the cortex 
were stained abnormally for apolipoprotein J. It was suggested that local expression of 
clusterin mRNA might contribute to the neuroinflammation, which representing a main factor 
in secondary injury processes after focal ischemic brain episodes (Van Beek et al., 2000). After 
moderate ischemic brain injury a time-dependent deposition of clusterin was noted in 
pyramidal neurons of the CA1 and the CA2 sector in the hippocampus undergoing delayed 
neuronal death. Overexpression of apolipoprotein J mRNA in contrast to neuronal protein 
staining appeared to be glial in origin with increases in mRNA the hippocampus fissure and 
only a very weak signal over the CA1 and the CA2 pyramidal neuron layer. The above results 
support the idea that clusterin is synthesized in the astrocytes, secreted outside and next taken 
up by dying neurons (Nishio et al., 2003). Clusterin deposition was observed in neurons 
destined to die by apoptosis. Moreover, pathological overexpression of clusterin suggests that 
the synthesis of this protein was a result of selective delayed neuronal death rather than 
involvement in the pathological cascade of events that cause it (Walton et al., 1996). 
The pathological immunostaining for apolipoproteins A1, E, and J was shown extracellularly 
and intracellularly (Hall et al., 1995; Kida et al., 1995; Pluta et al., 1995a; Horsburgh, Nicoll 
1996a, Horsburgh, Nicoll 1996b; Ishimaru et al., 1996b; Pluta 2000; Kamada et al., 2003). 
Intracellular staining was noted in damaged neurons exhibiting features of ischemic injury 
(Pluta 2000). Less often immunostaining for above proteins was observed in glia (Kamada et 
al., 2003). Extracellular accumulations of apolipoproteins were irregular and well delineated 
and mainly diffuse. Strong staining was noted also in acellular, necrotic, irregular and spider-
like foci (Kida et al., 1995; Pluta et al., 1995a; Ishimaru et al., 1996a). It is important to notice 
that accumulations of apolipoproteins colocalize with aggregates of different parts of amyloid 
precursor protein (Kida et al., 1995; Pluta et al., 1995b). Apolipoprotein E promotes the 
deposition of β-amyloid peptide into the oligomeric and the fibrillar form. Clusterin is 
engaged in transport of β-amyloid peptide through the blood-brain barrier. The main activity 
of apolipoproteins A1, E and J is controlling the level of soluble β-amyloid peptide in the 
intracellular and the extracellular space of brain tissue as well as their influence on fibrillar  
β-amyloid peptide conversion. Apolipoprotein E induces β-amyloid peptide increased 
lysosomal leakage and finally apoptosis in neuronal cells (Ji et al., 2002). Apolipoproteins A1, 
E, and J influence the deposition, structure and neurotoxicity of the β-amyloid peptide in brain 
ischemia. Additionally, in β-amyloid peptide production apolipoproteins E and J are involved 
prior to its accumulation. The above studies show principal roles of apolipoproteins E and J in 
β-amyloid peptide accumulation and that they play an important role in it extracellular  
β-amyloid peptide metabolism independent of β-amyloid peptide synthesis. These 
observations indicate that apolipoproteins A1, E and J deposition following ischemic brain 
injury may be a secondary damaging phenomenon, which could deteriorate healing of 
ischemic neurons indirectly influences development of ischemic-type dementia.  
8. -synuclein after ischemia 
Brain ischemia provoked changes in a presynaptic protein α-synuclein in the ischemic 
hippocampus (Ishimaru et al., 1998; Kitamura et al., 2001). Intense α-synuclein 
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immunostaining was found in the perivascular neighborhood of the CA1 sector in 
experiments with long-term survival following ischemic brain injury (Kitamura et al., 2001). 
In degenerating regions after brain ischemia glia presented intense reactivity for α-synuclein 
(Ishimaru et al., 1998). The above results suggest that α-synuclein may be essential protein in 
the neuropathological ischemic cascade (Goedert 2001). Abnormal α-synuclein 
accumulation might disrupt synaptic function, resulting in cognitive deficits (Hashimoto, 
Masliah 1999). The pathology of α-synuclein disturbs the synaptic activity that finally causes 
retrograde neurons loss in the ischemic brain injury (Goedert 2001).  
9. Platelets after ischemia 
Pluta et al., (1994c) for the first time directly presented the involvement of platelets in 
pathological processes after ischemic brain injury. They documented a key role of platelets 
during repeated vessels occlusion following ischemic brain injury (Pluta et al., 2009). These 
authors observed augmented thrombocytes aggregations and adhesiveness to vessel 
endothelium, which very well correlated with ischemic brain disease progression. Other 
study presented increased platelet microparticles and membrane remnants during 
reperfusion after ischemic brain damage (Mossakowski et al., 1993; Horstman et al., 2009). 
Next some study reported circulating platelets complexes and platelets-leukocytes 
aggregates in systemic circulation following brain ischemia injury (Ritter et al., 2005). Thus 
chronic abnormal platelets activity following brain ischemia injury now is established as an 
important pathological phenomenon. It may be suggested that platelets activity after 
ischemic insult is directly connected with development of general inflammation reply. 
However, the founding of platelets outside brain vessels after ischemic brain injury (Pluta et 
al., 1994c; Pluta 2003; Pluta 2006b; Pluta 2007a; Pluta 2007b) comes to evidence of platelets 
involvement in complex processes of neuroinflammtion and neurodegeneration. Different 
elements of coagulation system have been noted in brain ischemia episodes including 
collagen in perivascular space (Pluta et al., 1994c). Above findings, together with other 
direct evidences suggest that platelets interaction with white blood cells and next with the 
blood-brain barrier vessels is responsible for leukocyte passage through ischemic blood-
brain barrier. Platelets are capable of directly activating lymphocytes and are responsible for 
synthesis of immunoglobulins (Cognasse et al., 2007). In addition it is suggested 
involvement of platelet-activating factor in disruption endothelial tight junctions what 
means opening of the blood-brain barrier (Callea et al., 1999; Brkovic, Sirois 2007; Adamson 
et al., 2008; Knezevic et al., 2009). We feel that above observations are important in 
understanding the etiology of ischemic brain neurodegeneration with dementia and 
Alzheimer’s disease etiology. 
10. Neuropathology after ischemia 
Most of the experiments with reference to ischemic brain injury were conducted on small 
rodents. The reproduction of overlapping pathological mechanisms in small rodent models 
is a suitable approach to unravel of causal relationships. Studies were conducted to support 
the hypothesis that the anatomy of the brain vasculature in small rodents is not different 
from that of humans. The preference to perform brain ischemia studies on rodents are also 
supported by pragmatic reasons including a high homogeneity due to inbreeding, 
accessibility and lower costs. For several reasons, the favored brain region for the study of 
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ischemic injury is the hippocampus. First, the hippocampus is the part of brain, which 
displays the same pathology as human ischemic brain. Second, the hippocampus is 
implicated in spatial learning and memory. Third, the hippocampus, especially its area CA1 
is one of the brain sectors very sensitive to ischemic injury like in humans. Finally, the 
distinct laminar organization of the hippocampus and its final mapped synaptic connections 
allow exact layer-type or cell-type investigations. With respect to the above observations 
and metabolism, cerebral blood flow and pathology few models of brain ischemia, which 
mimicked human condition have been presented (Kirino 1982; Pulsinelli et al., 1982; Smith 
et al., 1984; Pluta et al., 1991). In these models selective ischemic pyramidal neurons death 
was noted in the CA1 sector of the hippocampus (Kirino 1982; Pulsinelli et al., 1982; Pluta 
2000; Pluta 2002b). Loss of neurons develops during 7 days after ischemia and is called 
delayed neuronal death (Kirino 1982). Three min of ischemic brain injury in gerbils and 10 
min in rats are sufficient to start this characteristic hippocampal pathology (Kirino 1982; 
Pulsinelli et al., 1982; Pluta 2000; Pluta 2002b). Prolongation of ischemic brain injury in rats 
to 10-20 min results in complete neurons death in the CA1 sector of the hippocampus and 
neuronal injury in the brain cortex and striatum (Pulsinelli et al., 1982; Kiryk et al., 2011). 
Prolongation of recirculation time ends in neuronal alterations in hippocampal regions of 
nonselective vulnerability (Pluta et al., 2009). Striatal pathology is mainly noted in the 
dorsolateral area and influence medium-sized neurons (Pluta 2002b). In the brain cortex, the 
layers 3, 5 and 6 presented neuronal changes (Pulsinelli et al., 1982; Pluta 2000; Pluta 2002b). 
Within these regions of selective neurons pathology strong activation of astrocytes and 
microglia were showed (Petito et al., 1990; Schmidt-Kastner et al., 1990; Gehrmann et al., 
1992; Morioka et al., 1992; Orzyłowska et al., 1999; Pluta 2000; Pluta 2002b). In brain areas 
with neuronal disappearance and neuronal cobweb interruption brain ischemic atrophy 
finally develops (Hossmann et al., 1987; Pluta 2002b; Pluta 2004b; Pluta, Ulamek 2006) with 
all neurodegenerative consequences. 
11. Neuroinflammation after ischemia 
Ischemic brain injury is associated with both acute and chronic neuroinflammatory reactions, 
involving activation, hypertrophy and proliferation of astrocytes and microglia. Ischemically 
activated astrocytes in the CA1 area of the hippocampus overexpress cytokines (Orzylowska et 
al., 1999). These data show that upregulation of neuroinflammatory mediators by astrocytes 
are directly connected with selective vulnerability of neuronal cells in ischemic brain injury 
(Orzylowska et al., 1999; Touzani et al., 2002). The above data suggest that neurons in 
vulnerable sectors in ischemic brain are targets of astrocytes interleukin-1β. This idea is 
supported by overexpression of neuronal interleukin-1 receptor (Touzani et al., 2002). In 
addition, it was confirmed that interleukin-1β is the important factor in brain ischemia cells 
damage and edema formation (Yamasaki et al., 1995). Chronic synthesis by ischemic brain 
neuroinflammatory factors may start a self-sufficient cycle that shifts ischemic pathology into 
hallmarks typical for Alzheimer’s disease. In ischemic brain interleukin-1 is a key factor, which 
motivates neurons to pathological cleavage of amyloid precursor (Griffin et al., 1998) and 
emits inflammatory mediators. All these events result in neuronal abnormal function and 
finally their death. Neuronal loss arises from neuroinflammatory factors, which induce 
neuronal damages that trigger microglia activity with further self-propagation of the 
neuroinflammatory events. Additionally, evidence has been showed that β-amyloid promotes 
the release of neuroinflammatory pathogens by microglia (Giulian et al., 1995). In the 
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immunostaining was found in the perivascular neighborhood of the CA1 sector in 
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blood-brain barrier vessels is responsible for leukocyte passage through ischemic blood-
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ischemic injury is the hippocampus. First, the hippocampus is the part of brain, which 
displays the same pathology as human ischemic brain. Second, the hippocampus is 
implicated in spatial learning and memory. Third, the hippocampus, especially its area CA1 
is one of the brain sectors very sensitive to ischemic injury like in humans. Finally, the 
distinct laminar organization of the hippocampus and its final mapped synaptic connections 
allow exact layer-type or cell-type investigations. With respect to the above observations 
and metabolism, cerebral blood flow and pathology few models of brain ischemia, which 
mimicked human condition have been presented (Kirino 1982; Pulsinelli et al., 1982; Smith 
et al., 1984; Pluta et al., 1991). In these models selective ischemic pyramidal neurons death 
was noted in the CA1 sector of the hippocampus (Kirino 1982; Pulsinelli et al., 1982; Pluta 
2000; Pluta 2002b). Loss of neurons develops during 7 days after ischemia and is called 
delayed neuronal death (Kirino 1982). Three min of ischemic brain injury in gerbils and 10 
min in rats are sufficient to start this characteristic hippocampal pathology (Kirino 1982; 
Pulsinelli et al., 1982; Pluta 2000; Pluta 2002b). Prolongation of ischemic brain injury in rats 
to 10-20 min results in complete neurons death in the CA1 sector of the hippocampus and 
neuronal injury in the brain cortex and striatum (Pulsinelli et al., 1982; Kiryk et al., 2011). 
Prolongation of recirculation time ends in neuronal alterations in hippocampal regions of 
nonselective vulnerability (Pluta et al., 2009). Striatal pathology is mainly noted in the 
dorsolateral area and influence medium-sized neurons (Pluta 2002b). In the brain cortex, the 
layers 3, 5 and 6 presented neuronal changes (Pulsinelli et al., 1982; Pluta 2000; Pluta 2002b). 
Within these regions of selective neurons pathology strong activation of astrocytes and 
microglia were showed (Petito et al., 1990; Schmidt-Kastner et al., 1990; Gehrmann et al., 
1992; Morioka et al., 1992; Orzyłowska et al., 1999; Pluta 2000; Pluta 2002b). In brain areas 
with neuronal disappearance and neuronal cobweb interruption brain ischemic atrophy 
finally develops (Hossmann et al., 1987; Pluta 2002b; Pluta 2004b; Pluta, Ulamek 2006) with 
all neurodegenerative consequences. 
11. Neuroinflammation after ischemia 
Ischemic brain injury is associated with both acute and chronic neuroinflammatory reactions, 
involving activation, hypertrophy and proliferation of astrocytes and microglia. Ischemically 
activated astrocytes in the CA1 area of the hippocampus overexpress cytokines (Orzylowska et 
al., 1999). These data show that upregulation of neuroinflammatory mediators by astrocytes 
are directly connected with selective vulnerability of neuronal cells in ischemic brain injury 
(Orzylowska et al., 1999; Touzani et al., 2002). The above data suggest that neurons in 
vulnerable sectors in ischemic brain are targets of astrocytes interleukin-1β. This idea is 
supported by overexpression of neuronal interleukin-1 receptor (Touzani et al., 2002). In 
addition, it was confirmed that interleukin-1β is the important factor in brain ischemia cells 
damage and edema formation (Yamasaki et al., 1995). Chronic synthesis by ischemic brain 
neuroinflammatory factors may start a self-sufficient cycle that shifts ischemic pathology into 
hallmarks typical for Alzheimer’s disease. In ischemic brain interleukin-1 is a key factor, which 
motivates neurons to pathological cleavage of amyloid precursor (Griffin et al., 1998) and 
emits inflammatory mediators. All these events result in neuronal abnormal function and 
finally their death. Neuronal loss arises from neuroinflammatory factors, which induce 
neuronal damages that trigger microglia activity with further self-propagation of the 
neuroinflammatory events. Additionally, evidence has been showed that β-amyloid promotes 
the release of neuroinflammatory pathogens by microglia (Giulian et al., 1995). In the 
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hippocampus glia activity precedes neurons alternations and persists for long time after 
ischemic brain injury. Initially, this activity was combined with repair responses at the site of 
the brain injury, but currently it has been shown that neuroinflammatory reaction is a key play 
in the evolution processes of ischemic brain pathology (Stoll et al., 1998). 
 Considerable evidence indicates that neuroinflammatory cascade modulates both the 
synthesis factors and proliferation reactions of activated astrocytes (Smith, Hale 1997), which 
exert both beneficial and harmful effects during repair mechanisms in the injured brain (Stoll 
et al., 1998). The reactive glia produce cytokines, which next stimulate glia, cytokine 
production and gliosis in a self-propagating, cycle (Barone, Feuerstein 1999). 
Neuroinflammatory genes overexpression peaks 24 h in the damage area, then decrease 
(Schroeter et al., 2003). Additionally, ischemic brain injury not only causes tissue cell injury, 
but also engages neuroinflammatory reactions that include the movement and depositions of 
leukocytes, macrophages, monocytes and different serum proteins due to open of the blood 
brain barrier (Danton, Dietrich 2003). In addition to the core ischemic injury 
neuroinflammatory reactions in the remote region to the primary ischemic injury have also 
been observed. Using the focal model of brain ischemia degeneration was noted in thalamus 
and substantia nigra in areas which are supplied by opened cerebral arteries and these areas 
showed no sign of ischemia (Danton, Dietrich 2003). Neurodegeneration in thalamus and 
substantia nigra were preceded by TNF overexpression, supporting the role of 
neuroinflammation in the remote region to the ischemic brain lesion (Danton, Dietrich 2003). 
Other authors additionally reported a transient overexpression of IL-6 in the substantia nigra 
following focal brain ischemia (Dihne, Block 2001). Increased number of neuronal progenitor 
cells has been noted in the hippocampus following focal (Takasawa et al., 2002) and global (Jin 
et al., 2001) brain ischemia and in subventricular zone after cardiac arrest in rats (Andjus et al., 
2010), with a considerable number of cells differentiating into astrocytes that support the 
neuroinflammatory reaction in the remote area distal to the primary deadly injury. Finally 
focal or global brain ischemic can induce a general inflammatory reaction both in the brain and 
peripheral body system. Inflammatory markers such as interleukin-6 and matrix 
metalloproteinases-9 are significantly elevated in blood plasma following brain ischemia 
(Castillo, Rodriguez 2004). 
Neuroinflammation has also been implicated in the neuropathogenesis of dementia. In 
dementia patients neuroinflammation is often combined with -amyloid peptide accumulation 
and neurofibrillary tangles development (Moore, O'Banion 2002). Neuronal cells in the 
hippocampus are peculiarly vulnerable to the influence of chronic inflammation (Hauss-
Wengrzyniak et al., 2000; Wenk, Barnes 2000). In addition, hippocampus, the center involved 
in learning and memory, which demonstrates the greatest early activation of microglia in the 
different diseases, finally shows the highest degree of neuropathology and atrophy 
(Hossmann et al., 1987; Cagnin et al., 2001; Pluta 2002b; Pluta 2004b; Pluta, Ulamek 2006). A 
large number of different experimental and clinical treatment studies presented that reactive 
microglia and proinflammatory factors are present at areas of -amyloid plaques accumulation 
and anti-inflammatory therapy decreases the progression of the diseases connected with 
amyloid pathology in own etiology (McGeer et al., 1996; Kalaria 1999; Akiyama et al., 2000).  
12. Ischemic brain cells and β-amyloid peptide 
In the ischemic brain, the main pathological focus is concentrated on pyramidal neurons in 
hippocampus because this region of the brain is selectively vulnerable to ischemia. In 
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generally, complete loss of vulnerable neurons in the CA1 sector was noted during 7 days 
following brain ischemia (Butler et al., 2002). Moreover, one third of subjects with ischemic 
brain injury did not present full loss of neurons in CA1 sector following ischemia with long-
term survival (Sadowski et al., 1999; Pluta 2000). In some cases, complete disappearance of 
all neurons of CA1 area was observed in very late stages after ischemia (Pluta 2000; Pluta 
2002a; Pluta 2002b; Pluta et al., 2009). Some investigations presented marked 
neuropathological alterations in pyramidal neurons considered to be completely resistant to 
ischemic injury such as: in areas CA2, CA3, and CA4 of hippocampus and dentate gyrus 
(Pluta 2000; Pluta et al., 2009). These regions presented unexpectedly acute ischemic changes 
in neuronal cells from 1 to 24 months after ischemic brain injury (Pluta 2000; Pluta et al., 
2009). Currently was noted that neuropathological processes in ischemic neurons continue 
well beyond the acute stage of insult (Pluta 2000; Pluta 2002a; Pluta et al., 2009; Kiryk et al., 
2011). In these situations, enduring ischemic blood–brain barrier opening (Pluta 2003; Pluta 
2005; Pluta 2006b; Pluta 2007b, Pluta et al., 2010) probably leads to enhanced ischemic 
neurons vulnerability to β-amyloid peptide (Koistinaho et al., 2002). 
Some investigations reported that astrocytic apoptosis may contribute to the 
neuropathogenesis of different diseases such as ischemic brain injury (Koistinaho et al., 
2004; Takuma et al., 2004; Pluta 2006a). Astrocytic abnormal activities observed in the 
ischemic brain injuries: swelling, astrogliosis, and astrocytosis (Bernaudin et al., 1998; 
Stoltzner et al., 2000). In ischemic brain some animal studies showed the early import of 
different parts of amyloid precursor protein from brain tissue and systemic circulatory to 
the astrocytes and in the late stages the export of the toxic β-amyloid peptide and C-terminal 
of amyloid precursor protein from dead astrocytes to the brain parenchyma (Pluta et al 
1994b; Pluta 2002b; Koistinaho et al., 2004; Pluta 2004a; Pluta 2004b). 
At early stages of ischemia-reperfusion brain injury, the N-terminal of amyloid precursor 
protein (Pluta et al., 1994b) may be produced by vascular endothelium that became 
damaged following injury (Badan et al., 2004). This hypothesis is supported by the 
overexpression and synthesis of β-secretase after brain ischemia (Wen et al., 2004a; Sun et 
al., 2006; Zhang et al., 2007). Furthermore presenilin overexpressed in postischemic brain 
(Tanimukai et al., 1998; Pennypacker et al., 1999; Pluta 2001) is involved in the cleavage of 
amyloid precursor protein to synthesize β-amyloid peptide through the γ-secretase complex 
(Wolfe et al., 1999). This secretase is involved in amyloidogenic cleavage of amyloid 
precursor protein. At the first step, amyloid precursor protein is cut at the N-terminal of the 
β-amyloid peptide fragment by protease called β-secretase. In the second step, the 
metabolite of β-secretase is cut by γ-secretase to form soluble β-amyloid peptide. 
Endothelial cells change structural features like: shape and size during time to become 
incorporated into the amyloid plaques in a close spatial relationship with damaged and 
dead astrocytes. The same investigations show that C-terminal of amyloid precursor protein 
aggregates in neurons following local brain ischemia and as the infarct increases, the C-
terminal of amyloid precursor protein staining become increasingly larger in the core even 
though the neurons are dying and the core becomes largely acellular (Badan et al., 2004). 
The same and other studies reported that β-amyloid peptide and C-terminal of amyloid 
precursor protein noted in microglia could be due to the phagocytosis of dead neurons 
remnants containing β-amyloid peptide and C-terminal of amyloid precursor protein by 
microglia (Badan et al., 2004; D’Andrea et al., 2004). Moreover, there are data demonstrating 
that astrocytes but not microglia can swallow up β-amyloid peptide (Matsunaga et al., 2003; 
Wyss-Coray et al., 2003; Pluta 2006a). Other studies show that C-terminal of amyloid 
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hippocampus glia activity precedes neurons alternations and persists for long time after 
ischemic brain injury. Initially, this activity was combined with repair responses at the site of 
the brain injury, but currently it has been shown that neuroinflammatory reaction is a key play 
in the evolution processes of ischemic brain pathology (Stoll et al., 1998). 
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synthesis factors and proliferation reactions of activated astrocytes (Smith, Hale 1997), which 
exert both beneficial and harmful effects during repair mechanisms in the injured brain (Stoll 
et al., 1998). The reactive glia produce cytokines, which next stimulate glia, cytokine 
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(Hossmann et al., 1987; Cagnin et al., 2001; Pluta 2002b; Pluta 2004b; Pluta, Ulamek 2006). A 
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2002a; Pluta 2002b; Pluta et al., 2009). Some investigations presented marked 
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in neuronal cells from 1 to 24 months after ischemic brain injury (Pluta 2000; Pluta et al., 
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incorporated into the amyloid plaques in a close spatial relationship with damaged and 
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aggregates in neurons following local brain ischemia and as the infarct increases, the C-
terminal of amyloid precursor protein staining become increasingly larger in the core even 
though the neurons are dying and the core becomes largely acellular (Badan et al., 2004). 
The same and other studies reported that β-amyloid peptide and C-terminal of amyloid 
precursor protein noted in microglia could be due to the phagocytosis of dead neurons 
remnants containing β-amyloid peptide and C-terminal of amyloid precursor protein by 
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precursor protein triggers the loss of astrocytes whereas the death of neurons is a secondary 
and result of the neuronal dependency on astrocytes for antineurotoxic amyloid guard 
(Abramov et al., 2003; Pluta 2006a). The accumulation of some parts of amyloid precursor 
protein in astrocytes may be important in promotion of amyloidosis in ischemic brain tissue 
in which chronic astrocytosis is probably play a key role in the occurrence of different kinds 
of amyloid plaques.  
13. Blood–brain barrier after ischemia 
Ischemic brain injury provoked a number of vessel abnormalities, which are open tight 
junctions and blood–brain barrier, diffuse leakage through necrotic vessels and vasospasm 
(Petito et al., 1982; Mossakowski et al., 1993; Mossakowski et al., 1994; Pluta et al 1994a; 
Wisniewski et al., 1995; Gartshore et al., 1997; Shinnou et al., 1998; Lippoldt et al., 2000; Ueno 
et al., 2002; Pluta 2003; Pluta 2005; Pluta et al., 2006b). Till one year after ischemic brain 
injury brain white and gray regions contained many diffuse and focal sites of horseradish 
peroxidase and gadolinium extravasations (Mossakowski et al., 1994; Pluta et al., 1994a; 
Pluta 2003; Pluta 2005; Pluta et al., 2006; Andjus 2010). Horseradish peroxidase leakage 
involved capillaries, venules, veins and arterioles. The above leakage was observed in 
hippocampus, cortex, thalamus and basal ganglia, and cerebellum. In summary in ischemic 
brains were chronic blood–brain barrier abnormalities.  
Short-term survival after ischemic brain injury, animals presented within gray and white 
matter around blood-brain barrier vessels staining for all parts of amyloid precursor protein 
(Pluta et al., 1994b). On the contrary, after long-term survival immunostaining only for the 
neurotoxic β-amyloid peptide and to the C-terminal of amyloid precursor protein was noted 
(Pluta et al., 1997b; Pluta 2000; Pluta 2003; Pluta 2005; Pluta et al., 2010). Multiple and 
abundant β-amyloid peptide and C-terminal of amyloid precursor protein staining 
embraced or adjoined the blood-brain barrier vessels. Diffuse deposits of β-amyloid peptide 
and C-terminal of amyloid precursor protein like “puff of smoke” were also noted. 
Immunostaining inside capillaries with a halo of β-amyloid peptide and C-terminal of 
amyloid precursor protein staining around vessels (Pluta 2005; Pluta et al., 2009) indicated 
diffusion of this part of amyloid precursor and β-amyloid peptide across the blood-brain 
barrier vessels. Above deposits were observed mainly in the hippocampus, entorhinal and 
brain cortex. 
The above observations were supported by i.v. injection of human β-amyloid peptide 42 into 
animals with cardiac arrest, which accumulated amyloid in the ischemic brain white and gray 
matter in perivascular space (Pluta et al., 1996; Pluta et al., 1997a; Pluta et al.,  1999). β-
amyloid peptide 42 can be moved by the blood–brain barrier receptor mediated system 
(Deane et al., 2003; Deane et al., 2004a; Deane et al., 2004b) and by blood–brain barrier 
leakage caused by ischemic brain injury (Pluta et al., 1996; Pluta et al., 1997a; Pluta et al., 
1999; Pluta et al., 2000) or β-amyloid peptide toxicity on blood–brain barrier after ischemia 
(Thomas et al., 1996; Fiala et al., 1998; Farkas et al., 2003; Paris et al., 2004a; Paris et al., 
2004b). 
The pathological immunostaining for apolipoproteins A1, E and J was observed mainly 
around vessels (Kida et al., 1995; Pluta 2000). Perivascular deposits of above proteins were 
well delineated and irregular. Diffuse, broad, but faint areas were also seen. Extracellular 
apolipoproteins E and J staining were strongly labeled by antibody to apolipoprotein A1, 
stronger than by apolipoprotein E antibody (Kida et al., 1995; Pluta et al., 1995a). They were 
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immunostained stronger by antibody to apolipoprotein E than apolipoprotein J (Kida et al., 
1995; Pluta et al., 1995a). It is important to notice that deposits around vessels of 
apolipoproteins colocalize with deposits of different parts of amyloid precursor protein 
(Kida et al., 1995; Pluta et al., 1995a). Apolipoprotein E can promote the aggregation of β-
amyloid peptide into the fibrillar formation. Clusterin is involved in transport of β-amyloid 
peptide through the blood–brain barrier. The general role of apolipoproteins is controlling 
the content of β-amyloid peptide in the extracellular space of brain tissue as well as their 
control on amyloid plaques development. These data demonstrate significant additive 
effects of apolipoproteins on controlling β-amyloid peptide accumulation around blood-
brain barrier vessels and that they play a main role in influencing extracellular brain β-
amyloid peptide metabolism/clearance independent of β-amyloid peptide formation. 
Another activity, for apolipoprotein E in ischemic brain tissue is the proposed extracellular 
clearance of ischemic brain parenchyma by reverse movement of amyloid into blood (Pluta 
et al., 2000). Delayed clearance may exacerbate healing of the ischemic blood–brain barrier. 
Above data point out that around vessels apolipoproteins deposition following ischemic 
brain injury represents a secondary injury processes that could hamper healing and outcome 
of ischemic brain. 
After brain ischemia injury thrombocytes are forming aggregates, which adhere to the 
endothelium lining of blood–brain barrier vessels (Pluta et al., 1994c; Pluta 2003; Pluta 2005). 
As an effect of this pathology the “no-reflow phenomenon” is developing (Mossakowski et 
al., 1993; Pluta et al., 1994c; Pluta 2003). Moreover, trombocytes were noted on the abluminal 
side of vessels following ischemic brain injury (Pluta et al., 1994c; Pluta 2003; Pluta 2005). 
This kind of pathology was observed in capillaries, venules, veins and arterioles 
independently of time after ischemic brain injury. Some study suggests that brain ischemia 
results in development platelet-leukocytes aggregates (Ishikawa et al., 2004) in the 
peripheral circulatory system (Ritter et al., 2005). Another study showed strong platelet-
leukocyte-endothelium reactions following focal ischemic brain injury (Ishikawa et al., 
2004). An increasing body of evidence has supported the idea that white cells can play an 
additional pathological function in brain ischemia injury (Caceres et al., 1995; Gidday et al., 
2005). White blood cells matrix metalloproteinase-9 recruited to the brain ischemic tissue 
next white blood cells to the same brain regions in a positive feedback manner and influence 
chronic opening of blood–brain barrier following a primary ischemic injury (Gidday et al., 
2005). Investigation by electron microscopy of ischemic blood–brain barrier presented 
leukocytes adhering to the endothelial cells of capillaries and venules (Caceres et al., 1995). 
This observation is suggested probable movement of leukocytes across blood-brain barrier 
vessels. Endothelial cells alterations and white blood cells aggregation and finally their 
adherence to vessel wall also reflect a “no-reflow phenomenon”. 
14. Ischemic blood–brain barrier and β-amyloid peptide  
In ischemic blood-brain barrier vessels damaged endothelium presented ruptures of 
endothelial membranes (Caceres et al., 1995). Other studies of ischemic endothelium 
presented an increased number of endothelium microvilli and deep crater-like pits, and 
enlarged junctional ridging with undulations of basement membrane (Pluta et al., 1991). As 
an effect of presented alterations, platelets developed microthrombi, which attached to the 
vessel wall and caused a permanent supply of neurotoxic constrictors such as β-amyloid 
peptide (Chen et al., 1995; Thomas et al., 1996). Final effect of above phenomenon is 
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precursor protein triggers the loss of astrocytes whereas the death of neurons is a secondary 
and result of the neuronal dependency on astrocytes for antineurotoxic amyloid guard 
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protein in astrocytes may be important in promotion of amyloidosis in ischemic brain tissue 
in which chronic astrocytosis is probably play a key role in the occurrence of different kinds 
of amyloid plaques.  
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pathological vasoconstriction during reperfusion (Wisniewski et al., 1995; Ohtake et al., 
2004). Recent data suggest that thrombocytes are the main ischemic factor in recirculation 
injury, not only through thrombus formation but also as cause of inflammation in 
cooperation with leukocytes (Nishijima et al., 2004). Due to the fact that β-amyloid peptide 
causes vasoconstriction (Thomas et al., 1996; Niwa et al., 2000) and endothelium damage 
(Thomas et al., 1996), a role for β-amyloid peptide in vasoconstriction and blood–brain 
barrier pathology has been proved. During reperfusion after brain ischemia, islets of 
necrotic endothelial cells in blood-brain barrier were noted (Petito et al., 1982; Mossakowski 
et al., 1994; Pluta et al., 1994a). Necrotic blood–brain barrier characterizes diffuse leakage of 
blood elements (Petito et al., 1982; Mossakowski et al., 1994; Pluta et al., 1994a; Pluta et al., 
1994c) and different parts of amyloid precursor protein from blood serum (Pluta et al., 
1994b; Pluta et al., 1996). This process is probably due to senescent endothelium and this 
phenomenon is increased during recirculation and is augmented by β-amyloid peptide 
toxicity (Mossakowski et al., 1994). Senescent endothelium is a common feature of vessel 
aging (Erusalimsky, Kurz 2005) and is also influenced by ischemic episodes (Mossakowski 
et al., 1994). Another problem during reperfusion with senescent endothelium is covering it 
with β-amyloid peptide where β-amyloid peptide acts as antiangiogenic factor (Paris et al., 
2004a; Paris et al., 2004b). Ischemic brain insults together with β-amyloid peptide have 
harmful effects on astrocytes and pericytes (Lupo et al., 2001; Anfuso et al., 2004) and can 
influence blood–brain barrier vessel angiogenesis and finally can regulate the blood–brain 
barrier activity (Ramsauer et al., 2002). 
15. Disabilities after ischemia 
In addition to pathological and pathophysiological effects, cognitive abnormalities have 
been showed after ischemic brain injury (Block 1999; Kiryk et al., 2011). The cognitive 
abnormalities were found in regions of selective vulnerability to ischemic injury and they 
come before neuronal death. In addition, other brain areas, which are devoid of ischemic 
primary neurons lesions, display some functional changes. These abnormalities mainly seem 
to be due synaptic damage. Ischemic brain injury does not result in long-lasting neurological 
deficits in ischemic animals (Block 1999; Kiryk et al., 2011). Some spontaneous recovery of 
sensorimotor function has been demonstrated after brain ischemia (Yang, Simpkins 2007). 
Following ischemic brain injury a locomotor hyperactivity has been noted for 7 days 
(Kuroiwa et al., 1991; Karasawa et al., 1994). Hyperactivity was directly connected with 
neuronal alterations in the ischemic hippocampus (Kuroiwa et al., 1991; Kiryk et al., 2011). 
Longer ischemia and longer locomotor hyperactivity is significantly associated with 
increased hippocampal neurons changes (Block 1999). After ischemic brain injury, 
impairment in habituation up to 6 months as revealed by longer exploration time was noted 
(Mileson, Schwartz 1991; Colbourne, Corbett, 1995). Brain ischemia results in reference and 
working memory deficits (Davis et al., 1986; Kiyota et al., 1991; Kiryk et al., 2011). In 
addition, brain ischemia in animals leads to deterioration of spatial memory for up to 1.5 
year (Block, Schwarz 1998; Karhunen et al., 2003; Kiryk et al., 2011). Deterioration of 
cognitive impairment has been observed consistently during reperfusion (Roof et al., 2001; 
Karhunen et al., 2003; Kiryk et al., 2011). Besides, data on repetitive ischemic brain injury 
have shown persistent locomotor hyperactivity, reduced anxiety, and severe cognitive 
deficits (Ishibashi et al., 2006). Above pathology was associated with brain atrophy, which 
connected with diffuse neurons loss in the CA1 sector of the hippocampus and in the brain 
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cortex (Ishibashi et al., 2006). Alertness and sensorimotor capacities are affected for 2 days, 
whereas deficits in learning and memory seem to be rather long lasting (Kiryk et al., 2011). 
Taken together strong evidence from both basic research and epidemiological studies 
indicated that the deterioration of cognitive activities could not be explained only by direct 
primary ischemic brain injury, but rather by a progressive consequence of the additive 
effects of the ischemic episodes, aging and Alzheimer’s factors (Pasquier, Leys 1997; Popa-
Wagner 2007).  
16. New guarding of ischemic brain injury 
16.1 Anti-amyloid therapy  
1998 is a turning point in the new history of novel strategies in ischemic brain injury and 
Alzheimer’s disease treatment (Pluta et al., 1998a). At first the full success against human β-
amyloid peptide 42 i.v. immunization in rats with brain ischemic injury (Pluta et al., 1998a; 
Pluta et al., 1999) and second moderate effect by intraperitoneal immunization in transgenic 
mouse overexpressing amyloid precursor (Schenk et al., 1999) and third peripheral 
administration antibodies against β-amyloid peptide (Bard et al., 2000) led to the fast 
development of new therapies against amyloid pathology.  
Human β-amyloid peptide removal/treatment has remarkable effects in ischemic brain 
injury (Pluta et al., 1998a; Pluta et al., 1999; Pluta, Ulamek 2008) and less effect in mice with 
overexpressed amyloid pathology (Schenk et al., 1999). Experience in patient’s vaccination 
was less convincing (Nicoll et al., 2003; Lemere et al., 2006; Hawkes, McLaurin 2007). Trials 
in cases with amyloid pathology were stopped when 6% of immunized patients developed 
meningoencephalitis (Nicoll et al., 2003; Orgogozo et al., 2003; Gilman et al., 2005). 
Moreover, only 20% of patients synthesized antibody against amyloid (Gilman et al., 2005). 
Patients treated with autovaccine in post mortem examination had less amyloid plaques in 
brain, as well as occurrence of T-cell lymphocytes. Recently, it has been proved that 
antibodies against β-amyloid are in normal human immunoglobulin that in particular 
recognize and inhibit the toxic hallmarks of β-amyloid peptide (Dodel et al., 2004). Within 
the past decade treatments have been concerned on inhibitors of γ- and β-secretases 
responsible for cleavage β-amyloid peptide from amyloid precursor protein (Dovey et al., 
2001; Selkoe 2001; Roberts 2002). Reduction of β-amyloid peptide in the brain parenchyma 
of aged rats after oral administration of the γ-secretase inhibitors has been noted result in 
decrease levels of β-amyloid in both cerebrospinal fluid and brain tissue (Best et al., 2006; El 
Mouedden et al., 2006). Another recent study was used antibody anti-β-secretase in which 
decrease of amyloid was shown in transgenic model of amyloid pathology (Rakover et al., 
2007). This decrease correlated very well with improvement of cognitive function. Two 
single-chain antibodies have been shown to possess α-secretase activity supplying a novel 
use of vaccine (Rangan et al., 2003; McCarty 2006). Another group of scientists have used 
small particle libraries to screen for substances that either interfere with assembly of β-
amyloid particles into fibrils (Lashuel et al., 2002; De Felice et al., 2004) or disaggregate them 
(Soto 2001; Gong et al., 2003; Blanchard et al., 2004). 
Neprilysin is β-amyloid peptide degrading enzyme in the brain (Kanemitsu et al., 2003). 
Human neprilysin gene transfer into brain leads to a remarkable decrease of β-amyloid 
deposits in transgenic mice with amyloid pathology (Marr et al., 2003). These observations 
proved that the deficient metabolism of β-amyloid caused by decrease level of neprilysin 
might contribute to pathological amyloidogenic cascades including ischemic brain injury. 
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pathological vasoconstriction during reperfusion (Wisniewski et al., 1995; Ohtake et al., 
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Ischemic brain injury results in the downregulation of α-secretase mRNA and decreases its 
net activity (Nalivaeva et al., 2004; Yan et al., 2007). Insulin degrading enzyme is another 
enzyme for β-amyloid clearance in the brain (McCarty 2006). Overexpression of above 
enzyme reduces β-amyloid levels and retards or completely prevents amyloid plaques 
development in the brain (Leissring et al., 2003). Some other enzymes like endothelin 
converting enzyme and angiotensin converting enzyme degraded/metabolized β-amyloid 
peptide, too (Eckman et al., 2003, Hemming, Selkoe 2005).  
Treatment by gelsolin a molecule that has high affinity for β-amyloid reduced the level of  
β-amyloid in the brain intra- and extracellular space by peripheral action (Matsuoka et al., 
2003). Other β-amyloid drug curcumin can moved across blood-brain barrier and reduce 
amyloid level and amyloid plaque burden in transgenic mice with amyloid pathology (Yang 
et al., 2005). The enoxaparin β-amyloid drug significantly reduced β-amyloid aggregates in 
cortex and the total amyloid cortical concentration by combining the blood serum β-amyloid 
peptide in systemic circulatory (Bergamaschini et al., 2004). In compliance with the sink 
hypothesis molecules, which are combining β-amyloid peptide in inactive complexes in the 
blood serum decreases the level of blood β-amyloid peptide, which then increase a net efflux 
of β-amyloid peptide from the brain into blood plasma (DeMattos et al., 2001; DeMattos et 
al., 2002). 
Recently endogenous receptor for advanced glycation-end-products peptides and β-amyloid 
peptide antibodies has been found in sick and healthy subjects (Mruthinti et al., 2004). These 
observations suggest that naturally occurring antibodies for β-amyloid peptide and receptor 
for advanced glycation-end-products control β-amyloid peptide level in brain and 
peripheral blood. 
16.2 Anti-tauopathy therapy 
A novel therapy has been directed against hyperphosphorylated tau protein either by 
inhibiting various protein kinases or promoting phosphatase activities (Lau et al., 2002; 
Iqbal, Grudke-Iqbal 2004; Klafki et al., 2006). Recent in vitro studies shown particles, which 
inhibited tau protein fibrillization making these molecules a promising candidate to test 
them in experimental conditions (Chirita et al., 2004). A new interesting data concerning 
therapy against amyloid have been presented lastly in animals in which triple transgenic 
mice were injected with β-amyloid peptide antibodies (Oddo et al., 2004). β-amyloid peptide 
antibodies inducted i.v. lead to clearance of early hyperphosphorylated tau protein deposits 
(Oddo et al., 2004). 
Some study showed that memantine reversed hyperphosphorylation of tau protein in 
hippocampal slices (Li et al., 2004) and this effect of memantine occurred by disinhibition of 
the activity of protein phosphatase 2A (Chohan et al., 2006) that earlier was noted to  
be downregulated in brains with amyloid pathology (Gong et al., 1993). Based on above 
data it was shown in humans that treatment amyloid pathology by memantine during one 
year significantly decreases hyperphosphorylated tau in cerebrospinal fluid (Gunnarsson et 
al., 2006).   
16.3 Suppressing neuroinflammation 
In ischemic brains the microglia are presented as neuroinflammatory invaders, which 
adding additional events via synthesis of cytokines designed to answer to primary 
neuropathology. This activity may lead to significant progression of brain ischemia cases 
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through neurons loss. Epidemiological studies suggest that long use of anti-inflammatory 
treatment in amyloid and neuroinflammatory disease like Alzheimer’s disease can prevent 
its development (Moore, O’Banion 2002; Szekely et al., 2004). From these observations 
considerable studies were undertaken to investigate the influence of anti-inflammation 
treatment in ischemic and amyloid brain diseases. These studies include nonsteroidal anti-
inflammatory therapy (Morihara et al., 2005), cannabinoids (Ramirez et al., 2005) and 
peroxisome proliferator-activated receptor-γ agonists (Sastre et al., 2003; Echeverria et al., 
2005; Heneka et al., 2005; Sastre et al., 2006). Current results from transgenic model of 
amyloid pathology was presented data that therapy against β-secretase decreases reaction of 
neuroinflammation in brain (Rakover et al., 2007). 
Delivery umbilical cord blood cells 48 h after ischemic brain injury are developing 
neuroprotection by blocking the neuroinflammatory reactions (Willing et al., 2007).  Above 
cells show protective activities via: modulating the neuroinflammatory response, stopping 
the apoptotic events and enhancing neurogenesis and angiogenesis. Activation of sigma-1 
and -2 receptors via 1,3-di-0-tolylguanidin injection 24 h after ischemic brain injury is 
impressive in reducing ischemic damage (Willing et al., 2007). Above substance is protective 
by reducing inflammatory reaction and decreasing intracellular calcium in neurons and by 
stopping the synthesis of cytokines. In ischemic brain informations from the damaging 
neuronal cells trigger immune cells for an inflammatory activity, with overproduction of 
cytokines.  Whether the cause is known or not, neurological disorders present similar 
cellular neuronal abnormalities and inflammation. These treatments approaches may not 
only be beneficial for therapy of ischemic brain injury (Willing et al., 2007) but also other 
neurological disorders. Above presented treatments act in a similar manner by increasing 
neurons survival and inhibiting the activity of general immune system (Willing et al., 2007).  
16.4 Protecting blood-brain barrier  
The natural activity of the brain is associated with the coupling between cerebral blood flow 
and transport via the blood-brain barrier and neurons activity. Cerebral blood flow controls 
the neuronal physiological environment not only by regulation of local blood flow but also 
by regulating focal transport through blood-brain barrier. The blood-brain barrier is an 
energetic system with two sites of transport by its blood- and brain-facing sites. Structure 
and function of the blood facing side allows entry of nutrients products but opposite brain 
facing eliminate metabolites such as β-amyloid peptide from brain (Pluta et al., 2000; Deane 
et al., 2004a; Deane et al., 2004b; Zlokovic 2005). A main role of the blood-brain barrier is 
control of the brain pool of pathological β-amyloid peptide. The aim of this part of chapter is 
to analyze knowledge of the association of the ischemic blood-brain barrier with final 
ischemic brain injury, especially with regards to the formation different amyloid plaques 
(Pluta 2006a; Pluta 2006b; Pluta 2007a; Pluta 2007b) and to develop a consensus on whether 
blood-brain barrier changes are a valid target for brain ischemia treatment (Pluta 2006a; 
Pluta 2006b; Pluta 2007a; Pluta 2007b; Pluta, Ulamek 2008). 
According to the new ischemic blood-brain barrier maturation idea of ischemic brain injury 
(Pluta 2006a) all parts of blood-brain barrier such as endothelium, basal lamina, pericyte and 
astrocyte cells are main targets for treatment of above disorder (Sohrabji 2007). The current 
idea states that pathological blood-brain barrier activity caused by ischemic injury at its 
abluminal and luminal sides for -amyloid with damaged neurons by ischemic insult are 
responsible for full-blown late onset ischemic-type dementia (Pluta 2004b; Pluta 2006a; Pluta 
2006b; Pluta 2007a; Pluta 2007b). In this way a novel and more effective therapy approaches 
 
Brain Injury – Pathogenesis, Monitoring, Recovery and Management 
 
112 
Ischemic brain injury results in the downregulation of α-secretase mRNA and decreases its 
net activity (Nalivaeva et al., 2004; Yan et al., 2007). Insulin degrading enzyme is another 
enzyme for β-amyloid clearance in the brain (McCarty 2006). Overexpression of above 
enzyme reduces β-amyloid levels and retards or completely prevents amyloid plaques 
development in the brain (Leissring et al., 2003). Some other enzymes like endothelin 
converting enzyme and angiotensin converting enzyme degraded/metabolized β-amyloid 
peptide, too (Eckman et al., 2003, Hemming, Selkoe 2005).  
Treatment by gelsolin a molecule that has high affinity for β-amyloid reduced the level of  
β-amyloid in the brain intra- and extracellular space by peripheral action (Matsuoka et al., 
2003). Other β-amyloid drug curcumin can moved across blood-brain barrier and reduce 
amyloid level and amyloid plaque burden in transgenic mice with amyloid pathology (Yang 
et al., 2005). The enoxaparin β-amyloid drug significantly reduced β-amyloid aggregates in 
cortex and the total amyloid cortical concentration by combining the blood serum β-amyloid 
peptide in systemic circulatory (Bergamaschini et al., 2004). In compliance with the sink 
hypothesis molecules, which are combining β-amyloid peptide in inactive complexes in the 
blood serum decreases the level of blood β-amyloid peptide, which then increase a net efflux 
of β-amyloid peptide from the brain into blood plasma (DeMattos et al., 2001; DeMattos et 
al., 2002). 
Recently endogenous receptor for advanced glycation-end-products peptides and β-amyloid 
peptide antibodies has been found in sick and healthy subjects (Mruthinti et al., 2004). These 
observations suggest that naturally occurring antibodies for β-amyloid peptide and receptor 
for advanced glycation-end-products control β-amyloid peptide level in brain and 
peripheral blood. 
16.2 Anti-tauopathy therapy 
A novel therapy has been directed against hyperphosphorylated tau protein either by 
inhibiting various protein kinases or promoting phosphatase activities (Lau et al., 2002; 
Iqbal, Grudke-Iqbal 2004; Klafki et al., 2006). Recent in vitro studies shown particles, which 
inhibited tau protein fibrillization making these molecules a promising candidate to test 
them in experimental conditions (Chirita et al., 2004). A new interesting data concerning 
therapy against amyloid have been presented lastly in animals in which triple transgenic 
mice were injected with β-amyloid peptide antibodies (Oddo et al., 2004). β-amyloid peptide 
antibodies inducted i.v. lead to clearance of early hyperphosphorylated tau protein deposits 
(Oddo et al., 2004). 
Some study showed that memantine reversed hyperphosphorylation of tau protein in 
hippocampal slices (Li et al., 2004) and this effect of memantine occurred by disinhibition of 
the activity of protein phosphatase 2A (Chohan et al., 2006) that earlier was noted to  
be downregulated in brains with amyloid pathology (Gong et al., 1993). Based on above 
data it was shown in humans that treatment amyloid pathology by memantine during one 
year significantly decreases hyperphosphorylated tau in cerebrospinal fluid (Gunnarsson et 
al., 2006).   
16.3 Suppressing neuroinflammation 
In ischemic brains the microglia are presented as neuroinflammatory invaders, which 
adding additional events via synthesis of cytokines designed to answer to primary 
neuropathology. This activity may lead to significant progression of brain ischemia cases 
 
Alzheimer’s Factors in Ischemic Brain Injury 
 
113 
through neurons loss. Epidemiological studies suggest that long use of anti-inflammatory 
treatment in amyloid and neuroinflammatory disease like Alzheimer’s disease can prevent 
its development (Moore, O’Banion 2002; Szekely et al., 2004). From these observations 
considerable studies were undertaken to investigate the influence of anti-inflammation 
treatment in ischemic and amyloid brain diseases. These studies include nonsteroidal anti-
inflammatory therapy (Morihara et al., 2005), cannabinoids (Ramirez et al., 2005) and 
peroxisome proliferator-activated receptor-γ agonists (Sastre et al., 2003; Echeverria et al., 
2005; Heneka et al., 2005; Sastre et al., 2006). Current results from transgenic model of 
amyloid pathology was presented data that therapy against β-secretase decreases reaction of 
neuroinflammation in brain (Rakover et al., 2007). 
Delivery umbilical cord blood cells 48 h after ischemic brain injury are developing 
neuroprotection by blocking the neuroinflammatory reactions (Willing et al., 2007).  Above 
cells show protective activities via: modulating the neuroinflammatory response, stopping 
the apoptotic events and enhancing neurogenesis and angiogenesis. Activation of sigma-1 
and -2 receptors via 1,3-di-0-tolylguanidin injection 24 h after ischemic brain injury is 
impressive in reducing ischemic damage (Willing et al., 2007). Above substance is protective 
by reducing inflammatory reaction and decreasing intracellular calcium in neurons and by 
stopping the synthesis of cytokines. In ischemic brain informations from the damaging 
neuronal cells trigger immune cells for an inflammatory activity, with overproduction of 
cytokines.  Whether the cause is known or not, neurological disorders present similar 
cellular neuronal abnormalities and inflammation. These treatments approaches may not 
only be beneficial for therapy of ischemic brain injury (Willing et al., 2007) but also other 
neurological disorders. Above presented treatments act in a similar manner by increasing 
neurons survival and inhibiting the activity of general immune system (Willing et al., 2007).  
16.4 Protecting blood-brain barrier  
The natural activity of the brain is associated with the coupling between cerebral blood flow 
and transport via the blood-brain barrier and neurons activity. Cerebral blood flow controls 
the neuronal physiological environment not only by regulation of local blood flow but also 
by regulating focal transport through blood-brain barrier. The blood-brain barrier is an 
energetic system with two sites of transport by its blood- and brain-facing sites. Structure 
and function of the blood facing side allows entry of nutrients products but opposite brain 
facing eliminate metabolites such as β-amyloid peptide from brain (Pluta et al., 2000; Deane 
et al., 2004a; Deane et al., 2004b; Zlokovic 2005). A main role of the blood-brain barrier is 
control of the brain pool of pathological β-amyloid peptide. The aim of this part of chapter is 
to analyze knowledge of the association of the ischemic blood-brain barrier with final 
ischemic brain injury, especially with regards to the formation different amyloid plaques 
(Pluta 2006a; Pluta 2006b; Pluta 2007a; Pluta 2007b) and to develop a consensus on whether 
blood-brain barrier changes are a valid target for brain ischemia treatment (Pluta 2006a; 
Pluta 2006b; Pluta 2007a; Pluta 2007b; Pluta, Ulamek 2008). 
According to the new ischemic blood-brain barrier maturation idea of ischemic brain injury 
(Pluta 2006a) all parts of blood-brain barrier such as endothelium, basal lamina, pericyte and 
astrocyte cells are main targets for treatment of above disorder (Sohrabji 2007). The current 
idea states that pathological blood-brain barrier activity caused by ischemic injury at its 
abluminal and luminal sides for -amyloid with damaged neurons by ischemic insult are 
responsible for full-blown late onset ischemic-type dementia (Pluta 2004b; Pluta 2006a; Pluta 
2006b; Pluta 2007a; Pluta 2007b). In this way a novel and more effective therapy approaches 
 
Brain Injury – Pathogenesis, Monitoring, Recovery and Management 
 
114 
can be formulated and more data on different kind amyloidosis can be gathered. 
Aforementioned data suggest that reducing movement of -amyloid peptide from blood to 
brain tissue (Dickstein et al., 2006) and significantly improving reverse transport from brain 
into blood plasma (Pluta et al., 2000; Bell et al., 2009) and preventing ischemic events in 
neurons (Pluta 2007c see for references) are principal main future points in treatment of 
ischemic brain injury (Iwata et al., 2001; Moore, O’Banion 2002; Cheng et al., 2003; Deane et 
al., 2003; Borlongan et al., 2004; Deane et al., 2004a; Deane et al., 2004b; Guo et al., 2004; 
Kalback et al., 2004; Koistinaho et al., 2004; Tanzi et al., 2004; Pluta, Ulamek 2008]. Current 
data provide new information that injection with -amyloid peptide reduces blood-brain 
barrier leakage, amyloid burden and microgliosis in transgenic model of amyloid pathology 
(Dickstein et al., 2006). It was presented that the blood-brain barrier is damaged in amyloid 
diseases and after -amyloid peptide delivery the immune system clears amyloid from the 
brain as it would in peripheral organs lacking barriers. Once -amyloid is cleared the 
activity of the blood-brain barrier is restored (Dickstein et al., 2006). This study directly 
proves that the blood-brain barrier is disrupted in amyloid brain diseases (Bowman et al., 
2007; Sohrabji 2007; Zipser et al., 2007; Pluta et al., 2009) and that vaccination with -amyloid 
peptide heals the sides of damage blood-brain barrier in transgenic mice with amyloid 
pathology (Dickstein et al., 2006) and ischemic brain injury (Pluta et al., 2000). Earlier my 
laboratory has proved that i.v. immunization with human -amyloid peptide 42 in brain 
ischemia heals blood-brain barrier leakage for -amyloid peptide 42 (Pluta et al., 2000) and 
prevent disease neuroprogression (Pluta et al., 1998a; Pluta et al., 1999). Possible explanation 
of the reparation of the blood-brain barrier is that the vaccination leads to the decrease in the 
level of circulating -amyloid peptide (Dickstein et al., 2006), which could directly and/or 
indirectly damage the blood-brain barrier (Farkas et al., 2003; Marco, Skaper 2006; Bell et al., 
2009). For example inflammatory factors (Boutin et al., 2001) that stimulate angiogenesis 
(Grammas, Ovase 2001) and -amyloid peptide have been shown to influence an increase of 
some angiogenic factors like VEGF and TGF- (Tarkowski et al., 2002; Pogue, Lukiw 2004). 
It can be proposed that with the removal of information provided by -amyloid peptide the 
endothelial cells behave normally and tight junctions are closed, thereby restoring a natural 
blood-brain barrier function. Increased concentration in plasma -amyloid peptide has been 
observed in a transgenic mice with amyloid pathology after active amyloid vaccination and 
i.v. delivery of molecules with an affinity to -amyloid peptide (DeMattos et al., 2002; 
Matsuoka et al., 2003) and after active immunization (Pluta et al., 1998a; Pluta et al., 1999) of 
non-human primates (Lemere et al., 2004). It is proposed that molecules that sequester blood 
serum β-amyloid peptide may decrease or prevent brain amyloidosis (Matsuoka et al., 
2003). In addition studies with antibodies anti-intercellular adhesion molecule-1 (Zhang et 
al., 1994) or platelet-endothelial cell adhesion molecule-1 (Rosenblum et al., 1994) have 
presented that blockage of adhesion molecules and leukocyte adhesion or platelets (>90% of 
β-amyloid peptide is stored in blood platelets) attachment respectively reduces ischemic 
brain damage after effects.  
Several different ways have been suggested to remove β-amyloid peptide by blood-brain 
barrier including: receptor-mediated β-amyloid peptide transport by blood-brain barrier, 
enzyme mediated β-amyloid peptide metabolism and β-amyloid peptide bindable 
molecules that mediated β-amyloid peptide clearance. Receptor mediated transport of  
β-amyloid peptide by blood-brain barrier is responsible for both influx and efflux of  
β-amyloid peptide. Lipoprotein receptor-related protein mediates efflux of β-amyloid 
peptide from brain tissue into blood (Deane et al., 2004a; Deane et al. 2004b; Bell et al., 2009). 
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The interaction between lipoprotein receptor-related protein and β-amyloid peptide 
mediates amyloid blood-brain barrier vessels binding, endocytosis and transcytosis through 
blood-brain barrier into circulatory system (Herz 2003). Moreover, p-glycoprotein has been 
proposed to be engaged in amyloid movement by blood-brain barrier (Lam et al., 2001). 
Currently some data noted that the neonatal Fc receptor at the blood-brain barrier has an 
important role in IgG-assisted β-amyloid peptide removal from the brain (Deane et al., 
2005). Receptor for advanced glycation-end-products mediates influx of β-amyloid peptide 
from blood into brain tissue (Deane et al., 2003; Deane et al., 2004b). Decrease of receptor for 
advanced glycation-end-products can reduce influx of β-amyloid peptide into brain (Deane 
et al., 2003). Glycoprotein 330/megalin probably is involved in receptor-mediated transport 
of apolipoprotein J alone and in a complex with amyloid at the blood-brain barrier (Zlokovic 
et al., 1996). Lipoprotein receptor-related protein and receptor for advanced glycation-end-
products play opposing roles in amyloid transport through blood-brain barrier (Deane et al., 
2004b). For now the most important way would be to look for new drugs, which influence 
the function or overexpression of β-amyloid peptide transport receptors by blood- 
brain barrier. The reduced function of receptor for advanced glycation-end-products and 
increased activity of lipoprotein receptor-related protein in ischemic blood-brain barrier 
might readjust the movement equilibrium for β-amyloid peptide by increasing its net efflux 
from brain into blood plasma. Statins, which increased lipoprotein receptor-related protein 
in blood-brain barrier, might facilitate the movement of β-amyloid peptide from brain tissue 
(Deane et al., 2004a). It is worth noting that receptor for advanced glycation-end-products 
blockades using receptor for advanced glycation-end-products specific IgG (Mruthinti  
et al., 2004) can also increase the expression of lipoprotein receptor-related protein (Deane  
et al., 2004b).  
16.5 Therapy by estrogens 
The incidence of ischemic brain injury is gender related (Pluta 2006a) and the risk of 
ischemic brain injury in aged women is greater than in men. The cumulative risk for 
ischemic brain insults in women is higher because of a lack of estrogen after menopause 
(Pluta 2006a). Estrogen treatment has been noted as blood–brain barrier function control 
through intercellular junction proteins (Kang et al., 2006) and/or intracellular transport 
elements and through protective effects on the cell elements of barrier such as endothelium, 
pericyte and astrocyte cells (Yang et al., 2005), cells which are vulnerable to influence of 
ischemia and aging together in the context of natural blood–brain barrier action (Sohrabji 
2007; Zipser et al., 2007). Pathological opening of the blood–brain barrier can expose 
ischemic brain tissue to different cellular and plasma elements from blood that indirectly or 
directly impair neurons and press other pathological cascades. Age-related events in 
different sectors of the brain can have far reaching consequences for cognitive deficits e.g. 
after ischemic brain injury (Kiryk et al., 2011). Most scientists have taken the approach of 
studying estrogen effects on pathology related to ageing disorders (Simpkins et al., 1997; 
Dubal et al., 1998; Shi et al., 1998; Chi et al., 2002; Chi et al., 2005). Estrogens exert protective 
activity in animals ischemic brain injury (Simpkins et al., 1997; Dubal et al., 1998; Shi et al., 
1998; Chen et al., 2001; Chi et al., 2002; Yang et al., 2005), but the mechanisms of their 
protection are not understood. These hormones may guard neuronal integrity (Chen et al., 
2001) by readjusting the physiological activity of the blood–brain barrier (Chi et al., 2002; 
Chi et al., 2005). Another probable mechanism is that estrogens decreases overexpression of 
amyloid precursor protein messenger RNA in ischemic brain injury (Shi et al., 1998). The 
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can be formulated and more data on different kind amyloidosis can be gathered. 
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protective effects of estrogens are observed in all of the neurovascular elements like: 
endothelial, pericyte, astrocyte and neuron cells and microglia (Chen et al., 2001; Yang et al., 
2005). In addition after ischemic brain injury estrogens increase cerebral blood flow and 
decrease secondary ischemic episodes (McCullough et al., 2001). Prevention of ischemic 
brain injury and treatment of repeated ischemic episodes after primary ischemic insult may 
have important implications for delayed postischemic pathology like dementia. In view of 
the earlier data that cognitive deficits are progressing after ischemic brain injury (Kiryk et 
al., 2011), there is the distinct possibility that we can stop this decline by targeting the 
gradually progressing degenerative events, which follows ischemic brain injury by aiming 
at molecular processes now shown to change after brain ischemia. 
17. Conclusion 
The complex of overlapping events, which potentially lead to neurons death and finally 
dementia in ischemic brain injury, start with neuronal energy shortages due to the stopped 
delivery of nutrients products during ischemic episodes. The energy failure during ischemic 
brain injury is reflected by a fast and rapid depletion of ATP. Ischemic loss of ATP is 
followed by the dysfunction of ion pumps and depolarization of the neural cells, and the 
production of high level of reactive oxygen species, which are dangerous for neurons. 
Reactive oxygen species initiate lipid peroxidation and generation of lipid peroxides, which 
are metabolized to pathological products (Muralikrishna Adibhatla, Hatcher 2006). Parallel 
to these events, the activities of antioxidants decrease following ischemic brain injury (Nita 
et al., 2001). During recirculation a marked increase in the neurotoxic β-amyloid peptide,  
C-terminal of amyloid precursor protein and neuroinflammatory factors were noted. The  
β-amyloid peptide and C-terminal of amyloid precursor protein can act as glia stimulants. 
The presence of large numbers of astrocytes associated with the β-amyloid peptide and  
C-terminal of amyloid precursor protein deposits, in particular around vessels of the 
hippocampus, suggest that these amyloid deposits generate chemotactic mediators, which 
stimulate recruitment of next astrocytes. This suggests that astrocytes gradually accumulate 
β-amyloid peptide and the amount of accumulation correlates very well with the extent of 
pathology in the hippocampus and the survival time after ischemic brain injury. β-amyloid 
peptide within astrocytes appears to be of blood origin, possibly deposited by phagocytosis 
of locally opened blood-brain barrier (Pluta et al., 1996). In contrast, current results suggest 
that astrocytes could also act as a source for β-amyloid peptide, because they overexpress  
β-secretase in response to long-term pathology (Rossner et al., 2005). Although it remains 
unclear to which degree astrocytes contribute to β-amyloid peptide synthesis or its clearance, 
it seems apparent that astrocytes contribute to neuroinflammation cascades. In addition, 
microglia has been associated with amyloid plaques, which indicates that plaques 
development and the degree of microglia activation are interrelated. β-amyloid peptide 
stimulates a nuclear factor kappa B dependent pathway that is important for cytokine gene 
transcription, reactive astrocytes and activated microglia. Moreover, other Alzheimer 
proteins involved in the ischemic metabolism of amyloid precursor protein have also been 
implicated in neuroinflammatory reactions. Evidence suggests that neurons themselves are 
capable of synthesizing neuroinflammatory factors. Thus, neurons can serve as a source of 
cytokines including tumor necrosis factor-α and interleukin-1β (Orzyłowska et al., 1999; 
Heneka, O’Banion 2007). It is possible that the neurons proper may exacerbate local 
neuroinflammatory activities and thus contribute to own progressive distraction in ischemic  
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brain injury. A study with a transgenic model of amyloid pathology supports the notion that 
cytokines influence brain deposition of serum amyloid (Guo et al., 2002). It has been 
suggested that neuroinflammatory factors either raise the susceptibility for β-amyloid 
peptide deposition or directly influence amyloid precursor protein cleavage. Additionally, 
cytokines are able to transcriptionally upregulate β-secretase mRNA and its enzymatic 
activity (Sastre et al., 2003). β-secretase and γ-secretase are key enzymes for β-amyloid 
peptide synthesis. The above data can be linked to the increased overexpression and activity 
of β-secretase and γ-secretase noted in animal ischemic brain (Wen et al., 2004a; Polavarapu 
et al., 2008). Finally, interleukin-1β has been shown to significantly increase amyloid 
precursor protein production in astrocytes (Rogers et al., 1999). Moreover, cytokines may be 
involved in neurofibrillary tangle formation. The idea that interleukin-1 is the common link 
between β-amyloid peptide production, microglia activation and tau phosphorylation has 
recently been supported by a study in a triple transgenic animal model of amyloid 
pathology (Oddo et al., 2006). In this study, tau phosphorylation precedes β-amyloid 
peptide accumulation. Because the β-amyloid peptide and C-terminals of amyloid precursor 
protein and cytokines, such as interleukin-1β and tumor necrosis factor-α, directly impair 
neuronal activity, focal neuroinflammatory events may contribute to neurons dysfunction 
before neurons death. Neuroinflammatory mediators may directly contribute to ischemic 
brain degeneration like in Alzheimer’s disease. β-amyloid peptide is formed by β- and γ-
secretases from the amyloid precursor protein. Above reaction is called amyloidogenic 
cascade. In nonamyloidogenic process mediated by α- and γ-secretases amyloid precursor 
protein is cleaved within the β-amyloid peptide fragment. In both pathways is the synthesis 
of a 5 kDa fragment called the amyloid precursor protein intercellular domain that is 
proposed to contribute the progressing neuropathology in degenerative diseases including 
ischemic brain episodes (Muller et al., 2008). Scientists during the last 15 y have suggested 
the important role of amyloid precursor protein and its enzymatic processing in the 
neuropathology of ischemic brain injury. Above is also highlighted by the fact of noted 
overexpression of mRNA amyloid precursor protein (Shi et al., 1998; Shi et al., 2000), mRNA 
presenilins (Tanimukai et al., 1998; Pennypacker et al., 1999) and mRNA β-secretase 
following brain ischemia (Wen et al., 2004a; Chuang et al., 2007). The amyloid precursor 
protein intercellular domain is synthesized intracellular following enzymatic processing 
from the plasma membrane-derived amyloid precursor protein and probably might have a 
more direct influence on ischemic pathology than extracellular β-amyloid peptide. Over the 
past decade the participation of amyloid precursor protein intercellular domain in cell 
events have been presented including modulation in gene expression, apoptosis, 
cytoskeletal dynamics and suppression of neurogenesis (Muller at al., 2008). All these 
processes initiate and contribute to a vicious cycle of the disease process, resulting in 
progressive synaptic and neuronal dysfunction and loss in ischemia with dementia (Pluta et 
al., 2009; Kiryk et al., 2011). 
Primary brain ischemia creates secondary repeated, transient and silent focal ischemic 
episodes, which are sufficient to sustain chronic/gradual oxidative stress and other events 
that could be the reason for the creepy and progressive neurons damage and death (Pluta et 
al., 2009; Pluta et al., 2010). Evidence derived from mice overexpressing the C-terminal of 
amyloid precursor protein, indicates that this part of the amyloid precursor protein may 
promote synaptic degeneration and retrograde neurons death (Oster-Granite et al., 1996), 
and finally dementia (Nalbantoglu et al., 1997). Moreover, ischemic brain injury is age-
dependent (Oster-Granite et al., 1996; Popa-Wagner 2007).  
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precursor protein production in astrocytes (Rogers et al., 1999). Moreover, cytokines may be 
involved in neurofibrillary tangle formation. The idea that interleukin-1 is the common link 
between β-amyloid peptide production, microglia activation and tau phosphorylation has 
recently been supported by a study in a triple transgenic animal model of amyloid 
pathology (Oddo et al., 2006). In this study, tau phosphorylation precedes β-amyloid 
peptide accumulation. Because the β-amyloid peptide and C-terminals of amyloid precursor 
protein and cytokines, such as interleukin-1β and tumor necrosis factor-α, directly impair 
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1. Introduction  
Proliferation and differentiation of hematopoietic stem cells into mature white blood cells 
(WBC) in the bone marrow, followed by release into the circulation of mature WBC, is an 
extremely regulated process (Metcalf, 2008). Differentiation and maturation of the 
hematopoietic cells into granulocytes, monocytes, lymphocytes, megakaryocytes and 
erythroid cells is influenced by soluble factors including growth factors and cytokines with 
the bone marrow stroma, and are mediated to a certain extent through an interaction of 
adhesion molecules. The synchronized production of leukocytes in bone marrow is crucial 
for innate and adaptive immunity. Leukocytes encompass several subtypes including 
neutrophils, lymphocytes, monocytes, eosinophils, and basophils, and play a vital role in 
innate and adaptive immunity against invading microorganisms. They are also involved in 
the pathogenesis of various acute and chronic diseases. The circulating numbers of 
leukocytes can be influenced by stress, infection, or inflammation.  
Mature neutrophils are ephemeral and localize rapidly to inflammatory sites where they 
deliver microbicidal activity. It takes about 14 days until it reaches the blood, of which the 
last 6-7 days are spent in maturation and storage pool. In less than a day after it arrives in 
the blood vessel, the neutrophil emigrates from the circulation in a random manner and 
enters the tissue. If not utilized in an inflammatory response, the neutrophils leave the body 
within a few days via secretions in bronchi, saliva, gastrointestinal tract and urine, or are 
destroyed by the reticuloendothelial system. The kinetics of eosinophils are similar to the 
neutrophils, they are stored in the bone marrow for several days after going through the 
different maturational stages. The half-life in the blood is approximately 18 hours before 
entering the tissues. Basophils have a life span similar to eosinophil; the maturation time in 
the marrow is about 7 days. Basophils circulate in the blood and are not normally found in 
the tissue. Monocytes share the same committed progenitor cell as neutrophils; they 
undergo maturation for a period of about 50-60 hours before being released in to the blood. 
Once monocytes enter the blood they leave randomly with a half-time of 8.4 hours. After 
monocytes leave the blood, they spend several months, or longer as tissue macrophages. 
(McPherson & Pincus, 2006). 
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2. Leukocyte count and immature granulocyte count as prognostic marker 
for traumatic brain injury   
Traumatic Brain Injury persists to be a major health problem, and a recurrent cause of death 
and severe disability among a primarily young population. Worldwide, traumatic brain 
injury (TBI) is the single largest cause of death and disability following injury. Most TBI’s 
are due to roadside accidents. According to WHO, by the year 2020, head trauma will be 
third largest killer in the developing world. The statistics from India are even more 
alarming. Studies show, on an average one person dies every six minutes, 70% of these 
being directly attributable to head and spinal trauma. The annual social costs of road 
accidents are estimated 3% of India’s Gross Domestic Product (GDP). The accident rate of 35 
per 1000 vehicles in India is also amongst the highest in the world (Ahmed et al., 2009). 
Traumatic brain injury (TBI) is also a major cause of disability, with survivors acquiring 
long-term cognitive, motor, behavioral or speech-language disabilities (Rutland-Brown, 
2003, as cited in Namas et al., 2009). The various forms of traumatic injury therefore 
represent a pandemic disease that affects every nation in the world without regard for 
economic development, racial or religious predominance, or political ideology; this disease 
is acute in onset and often results in chronic, debilitating health problems affecting far 
beyond the individual victims (Kauvar & Wade, 2005, as cited in Namas et al., 2009). 
Trauma acts as a trigger of a complex cascade of posttraumatic events that can be divided 
into a hemodynamic, metabolic, neuro-endocrine and immune responses leading to a 
multifocal pathophysiologic process (DeLong & Born, 2004, as cited in Namas et al., 2009). 
Inflammation is a  a well-coordinated communication network operating at an intermediate 
time scale between neural and longer term endocrine processes which is necessary for the 
removal or reduction of challenges to the organism and  subsequent restoration of 
homeostasis. (Vodovotz et al., 2008, as cited in Namas et al., 2009). Inflammation is 
necessary for the removal or reduction of challenges to the organism and subsequent 
restoration of homeostasis. (Nathan, 2002, as cited in Namas et al., 2009). 
Although the inflammatory response is crucial in clearing invading organisms and offending 
agents and promoting tissue repair, these same responses carried out under a set of extreme 
conditions can also compromise healthy tissue and further exacerbate inflammation (Nathan, 
2002, Jarrar, 1999, as cited in Namas et al., 2009). Thus, early identification of reliable 
prognostic factors for severely head-injured patients is of significance to both the practicing 
neurosurgeon and the clinical investigator. The ability to predict likely outcome in acutely 
admitted hospital patients can be beneficial in several ways. Risk assessment on the basis of 
laboratory investigations is also commonly used, but is usually applied in specific disease 
situations, and generally gives subjective assessments of risk. Several prognostic factors, such 
as age group, gender, pupillary reactivity, Glasgow Coma Scale (GCS) on admission, serum 
glucose level, total white blood cell counts, platelet counts, coagulation profile, computerised 
tomography (CT) scan, have been authenticated in various studies to predict outcome in adult 
traumatic brain injury patients. 
A number of other variables have also been suggested to be important for determining the 
prognosis of patients with severe head injury. These include multimodality evoked 
potentials, electroencephalography, cerebral perfusion pressure, blood flow velocity on 
transcranial doppler, jugular venous oxygen saturation, brain tissue oxygenation, and 
specific serum biochemical markers such as creatine-kinase isoenzyme BB, neuronspecific 
enolase, and S-100B protein (Dings et al., 1996; Moulton et al., 1994; Nordby and Urdal, 1985; 
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Raabe et al., 1999; Raabe and Seifert, 2000; Sheinberg et al., 1992 as cited in Rovlias & 
Kotsou, 2004). Also several studies have shown that hyperglycemia and leukocytosis are 
associated with a worse outcome, particularly during focal ischemia or hypoxia, which are 
frequently found in patients with severe head injury (De Salles et al., 1987; Graham et 
al.,1989; Zhuang et al., 1993 as cited in Rovlias & Kotsou, 2004). Although nonreactive 
pupils, Sub Arachnoid Hemorrhage, acute subdural and intracerebral haematoma hold 
clinical significance there are routine laboratory investigations which emerge to be 
associated with mortality risk in hospital patients.   
The complete blood count and leukocyte differential count are among the most frequently 
requested clinical laboratory tests. Leukocytosis, an increase in the number of circulating white 
blood cells, was first described by Virchow and Andral in the mid 19th century (Lawerence et 
al., 2007) is a common phenomenon in head injuries. High leukocyte count though nonspecific 
has been used more specifically as a prognostic indicator in myocardial infarction and as a 
predictor of plasma urinary oestrogen levels in women undergoing gonadotrophic treatment 
for infertility (Hughes, 1963, Cruichshank, 1970, 1972). Early trends in WBC alert the physician 
about the possibility of sepsis and allow prompt therapeutic response. Leukocytosis above a 
certain level could serve as a marker for bacterial infection despite the known physiologic 
leukocytosis following splenectomy (Toutouzas et al., 2002). Leukocytosis is also associated 
with a worse outcome, particularly during focal ischemia or hypoxia, which are frequently 
found in patients with severe head injury (Rovlias & Kotsou, 2004).  
Leukocyte (WBC) count is considered a biomarker of inflammatory processes that actively 
contribute to vascular injury and atherosclerosis (Mehta et al., 1998, Alexander, 1994, as 
cited in Ruggiero et al., 2007). Whether elevated WBC count directly contributes to 
cardiovascular disease and mortality (Coller, 2005, as cited in Ruggiero et al., 2007) or is 
merely a marker of negative cardiovascular risk profile remains controversial (Loimaala et 
al., 2006, Smith et al., 2003 as cited in Ruggiero et al., 2007). 
Injury educe a response from all cells of the immune system in which cytokines and other 
metabolic products of activated leukocytes can act either beneficially to provide for  
enhanced host resistance or deleteriously to depress the function of remote organs and 
causes systemic inflammation.  
A nonspecific systemic inflammatory response occurs after both ischemic and hemorrhagic 
stroke, either as part of the process of brain damage or in response to complications such as 
deep venous thrombosis. 
Inflammation alters normal leukocyte production by promoting granulopoiesis over 
lymphopoiesis, a response that supports the reactive neutrophilia following infection. 
Leukocytosis in trauma is due to neutrophilia, caused by neutrophil margination, and not due 
to increased marrow production or release of immature cells or bands. The phenomenon is 
short-lived, lasting only minutes to hours (Abramson & Beckz, 2000 as cited in Santucci et al., 
2008).  It is hypothesized that, patients with significant injury should have a higher degree of 
leukocytosis compared to patients with minor injuries (Santucci et al., 2008). 
Traumatic brain injury is associated with elevated serum levels of catecholamines (Clifton et 
al., 1981, Hortangl et al., 1980, Rosner et al., 1984 as cited in Gürkanlar et al., 2009). 
Catecholamines are responsible for the release of neutrophil stores while corticosteroids 
cause a decrease in the egress of neutrophils from the circulation. Catecholamines increase 
the leukocyte count by release of the marginated cells into the circulating pool. 
Corticosteroids increase the neutrophil count by releasing the cells from the storage pool in 
the bone marrow into the blood and by preventing egress from the circulation into these 
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tissues (Boggs, 1967 as cited in Gürkanlar et al., 2009). Brain swelling occurring after head 
trauma is probably an inflammatory response due to tracerebral cytokine production and  
increased leukocyte adhesion as a result of a direct effect on vascular permeability and 
leucocyte activation (Dietrich et al., 2004, Fee et al., 2003, Gourin & Shackford, 1997, 
Juurlink, 2000, Lenzlinger, 2001 as cited in Gurkanlar et al., 2009). Another theory of 
leukocytosis after trauma can be explained as follows:  In post traumatic injury, the cell 
body of the microglia becomes hypertrophic with long, branched and crennellated processes 
during the first 60 minutes post injury, as the blood brain barrier (BBB) opens at the time of 
the trauma and approaches closure at about 60 minutes post injury (Bednar et al., 1997 as 
cited in Gürkanlar et al., 2009). Microglia cells express class I and class II MHC antigens and 
these antigens could be presented to lymphocytes in the regional lymph nodes and trigger the 
activation of circulating lymphocytes in the central nervous system (Capps, 1896, Kakarieka, 
1997, Neil-Dwyer & Cruickshank 1974, Rovlias & Kotsou, 2001 as cited in Gürkanlar et al., 
2009). Microglia cells play a predominant role in the induction and maintenance of the 
immune response following head trauma (Czigner et al., 2007 as cited in Gürkanlar et al., 
2009). An alternative mechanism by which leucocytes can be associated with cerebral damage 
is the traumatic rupture of microvessels followed by physical occlusion. The leucocytes are less 
deformable than the erythrocytes, and a greater pressure gradient is therefore required to force 
them through the capillaries with small diameter. Under conditions of reduced perfusion 
pressure, the capillaries may behave like a sieve and trap the leucocytes to increase the WBC 
count. After the entrapment, the leucocytes form a common area of contact with the 
endothelium and may not be dislodged even after the perfusion pressure returns to normal 
(Hallenbeck, 1986, Janoff, 1965, Suval, 1987, Yamakawa, 1987 as cited in Gürkanlar et al., 2009). 
The mechanical occlusion of the capillaries may become more evident as a result of the release 
of a number of cytotoxic chemicals that leads to increased leucocyte endothelial interactions 
(Harlan & Winn, 2007 as cited in Gürkanlar et al., 2009). 
The presence of immature granulocytes (IG) in the peripheral blood may indicate bacterial 
sepsis, inflammation, trauma, cancer, steroid therapy or myeloproliferative diseases (Ansari-
Lari et al., 2003, Briggs, 2003, 2009, Iddles, 2007.) They are also present in the later stages of 
pregnancy. In these cases, there is often an increased neutrophil count. Nevertheless 
neutrophils morphological abnormalities and automated left shift flags are notoriously 
unreliable as specific diagnostic features. 
The measurement of the immature cells of the myeloid series, specifically “band” cells, is 
considered clinically useful for the diagnosis of infections, especially neonatal sepsis. 
Rodwell et al., 1988, Seebach et al., 1997 as cited in Buttarello & Plebani, 2008) Even though a 
morphologic definition of these cells exists, it is not universally accepted. (Cornbleet & 
Novak, 1995, as cited in Buttarello & Plebani, 2008). Immature granulocytes, normally 
absent from peripheral blood, are increased also in other conditions such as tissue necrosis, 
acute transplant rejection, surgical and orthopedic trauma. In these cases, the increase in 
immature granulocytes is accompanied by an increase in neutrophils, which are freed from 
the marginal pool and bone marrow. In some subjects, especially elderly people, neonates, 
and myelosuppressed patients, the increase in neutrophils may be absent, and in other 
conditions, such as sepsis, there can even be neutropenia. In these situations, the increase in 
IGs (>2%), even if isolated, can be useful for identifying an acute infection, even when not 
suspected (Briggs et al., 2003 as cited in Buttarello & Plebani, 2008).    
Microscopic immature granulocytes counts has limits of imprecision and lack clinical 
sensitivity because these components are usually found in low concentrations (<10%). 
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Published studies agree that IG counts have a high specificity for infectious conditions (from 
83% to 97%) but are accompanied by low sensitivity (between 35% and 40%) (Briggs et al., 
2003, Ansari-Lari et al., 2003,  as cited in Buttarello & Plebani, 2008). This low sensitivity 
means that this count is not indicated as a screening test for infection, even though a 
significant association exists between elevated IG counts and positive blood cultures 
(Buttarello & Plebani, 2008). The presence of low numbers of immature granulocytes is more 
reliably detected on automated hematology analyzers than using manual microscopy. 
Automated blood cell counters have undergone a formidable technological evolution owing 
to the introduction of new physical principles for cellular analysis and the progressive 
evolution of software, resulting in high number of cells being counted (Briggs et al., 2003, as 
cited in Briggs, 2009). This is because of the high number of cells counted and an increase of 
IG (>2%) can be useful in identifying infection even when not suspected (Briggs et al., 2003, 
as cited in Briggs, 2009).  
2.1 Aim 
Our aim for this study was to correlate on admission leukocyte and immature granulocyte 
count (IG) with the severity of head injury (according to the Glasgow coma score), 
computed tomography findings and pupillary reaction in trauma patients with isolated 
head injuries.  We also intended to determine the factors influencing the immediate 
clinical outcome (dead or alive) in isolated head injury patients. The acute-phase 
response due to trauma is characterized by a leukocytosis upon admission. Therefore, an 
increase in the white blood cell (WBC) count might serve as an additional diagnostic and 
prognostic indicator in head injury. Our goal was to demonstrate that a reliable prediction 
of outcome based on the admission day leukocyte and immature granulocyte count is of 
great clinical relevance. We aimed to develop a prognostic model with readily available 
traditional laboratory parameters for the selection of those trauma patients who are likely 
to progress towards an adverse outcome, in turn ensuring their optimum management. 
2.2 Materials and method 
For the purpose of this study retrospective analysis of case files of patients admitted with, 
non  penetrating head injury (mild, moderate and severe) at a level I trauma centre for 
duration of two months (June - July 2008) was performed. Patients with brain death, 
penetrating injury, infection and possible diseases that may alter the white blood cell 
count (myocardial infarction, cerebral vascular accident, surgical procedures etc) were 
excluded from the study.   
Two ml of venous blood was collected in a disposable EDTA tubes, on the same day as 
clinical assessment or, for patients admitted to the hospital, as soon after assessment as 
possible, for the estimation of basic hemogram parameters and immature granulocyte count. 
The WBC and IG count was measured using a fully automated hematology analyzer, 
Sysmex XE 2100 (Sysmex, Kobe, Japan).  
The results of all the routinely done, laboratory investigations were documented in the 
institution computerised patient record system (CPRS). The patients clinical and laboratory 
details were extracted from the CPRS and patient files, for the purpose of this study. 
The XE-2100TM is a haematology analyser that, utilises the technology of fluorescence 
flow cytometry to quantitate the standard five part , immature granulocytes 
(metamyelocytes, myelocytes and promyelocytes), nucleated red blood cells (NRBC), 
reticulocyte count, immature reticulocyte fraction and  “optical” fluorescent platelet 
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count. A hemolytic reagent causes disruption of mature WBC membranes, leaving bare 
nuclei, while immature myeloid cells with low cell membrane lipid content remain intact. 
A surfactant increases membrane permeability allowing a poly-methylene dye with high 
affinity for nucleic acid to enter the cells. When excited by a 633-nm laser beam, the 
stained cells emit fluorescence proportional to their content of nucleic acid. The 
combination of side scatter (inner complexity of the cell), forward scatter (volume) and 
fluorescence intensity of nucleated cells gives a concise but precise image of each cell 
detected in the peripheral blood. A well-defined physical description of the different 
leucocyte populations (clusters) is obtained. Immature granulocytes are recognized by 
their increased fluorescence emission compared with segmented neutrophils because they 
contain more RNA and DNA. The immature information (IMI) channel of the XE-2100 
counts human progenitor cells (HPC). The reagents specifically affect the lipid 
components of the cell membranes; the membranes of mature cells, with a higher content 
of lipid are lysed while immature cells retain their membranes. In normal samples no 
intact cells are seen in the IMI area. The HPC has been shown to be an important 
parameter in the prediction of the apheresis yields of CD34+ cells in peripheral blood in 
patients undergoing progenitor cell mobilisation. It has been demonstrated that the use of 
peripheral blood HPC counts gives a more precise measurement of early cells than visual 
blast cell counts and allows a more quantitative assessment of the release of progenitor 
cells into the blood (Briggs et al., 1999).  
The Sysmex XE 2100 automated analyzer can count immature granulocyte while performing 
the differential leukocyte (WBC) count, with notably lower imprecision [Coefficient 
Variance (CV) near 7%]. On comparison with microscopic examination or flow cytometry 
using Monoclonal antibody (MoAb) methods high accuracy was observed  for the Sysmex 
XE 2100 automated analyzer (r between 0.78 and 0.96). (Briggs et al., 2003, Field et al., 2006 
as cited in Buttarello & Plebani, 2008). 
The corresponding computed tomography (CT) scan findings and pupillary reaction were 
extracted from the case files and analyzed. For purposes of analysis, pupillary reaction was 
noted as unilaterally present, bilaterally present or bilaterally absent reaction. The CT scan 
findings were recorded as subdural hemorrhage (SDH), extradural hemorrhage (EDH), 
intracerebral hemorrhage (ICH) and contusion and subarachnoid hemorrhage (SAH). The 
severity of head injury was graded according to the GCS as mild (GCS 14-15), moderate 
(GCS 8-13) and severe (GCS 3-7).   
The WBC and IG counts were correlated with severity of head injury, pupillary reaction and 
CT scan findings (SDH, EDH, ICH and SAH). Death during the hospital stay was 
considered as the study immediate outcome and WBC count, IG count, pupillary reaction 
and severity of head injury were considered as its potential determinants. 
Data was recorded on a predesigned proforma and managed on an excel spread  
sheet. Categorical variables such as pupillary reaction, severity of head injury (mild, 
moderate, severe), CT findings (SDH, SAH, EDH, ICH and contusion) and immediate 
outcome (dead/ alive) were summarized as frequency (%). Quantitative variables (WBC 
and IG counts) were summarized as mean±S.D (standard deviation) for normally 
distributed and median (Inter quartile range) for non-normally distributed variables 
Students’s t-Test was used to compare mean values between two groups, while Wilcoxon 
rank sum test was used to compare median values between two  groups. For the overall 
comparison of mean values between more than two groups, One Way Analysis  
Of Variance (ANOVA) followed by Bonferroni’s correction in post-hoc analysis was 
applied. 
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To find out the statistical correlation of various clinical factors with the immediate 
outcome (dead/ alive), firstly, chi square test was used to measure the statistical 
association of these factors in the binary form with the outcome, followed by a  bivariate 
logistic regression  to compute unadjusted odds ratio (95% confidence interval) of each of 
the separate factors with the outcome. Lastly all the factors were considered 
simultaneously in the stepwise multivariate logistic regression analysis with probability 
to enter as 0.05 and the probability to remove as 0.1. STATA 10.0 statistical software 
(STATA corporation, Texas, US) was used for data analysis. In this study p value < 0.05 is 
considered as statistically significant.  
2.3 Results 
A total of eighty patients were included in the study. The mean age was 33.5±13.9 years; 
there were 70 (87.5%) males. The head injury was mild (GCS 14-15) in 17(21.3%) patients, 
moderate (GCS 8-13) in 21(26.2%) patients and severe (GCS 3-7) in 42 patients (52.5%). The 
overall admission day mean± S.D. leukocyte count and median (IQR) immature granulocyte 
counts were 14,062 ± 5383 cells/cumm and 0.07 (0-1.54) cells/cumm respectively. Mortality 
rate of 28.8% (23) was observed in the study group during the course of their hospital stay. 
The mean WBC count was associated with the severity of head injury according to the GCS 
scores, pupillary reaction and CT scan findings and the results were tabulated (table 1). The 
head injury patients with low GCS scores (3-7) had higher mean WBC counts compared to 
moderate and mild head injury groups (p<0.001). Head injured patients with bilaterally 
absent pupillary reaction had higher mean WBC counts compared to unilaterally present 
and bilaterally present pupillary reaction groups (p<0.001). However, the mean WBC count 
between the unilaterally present and bilaterally present pupillary reaction groups was not 
significant (p<1.00). Statistically significant association was not observed between the mean 
WBC count and CT scan findings. The results of the comparison between the median IG 
count and the other variables are shown in table 2. The median IG count in the, CT scan 
findings, SAH group was significantly lower than groups with other CT scan findings the 
non SAH group (p=0.04).  
To dichotomize the variables, cut-offs were derived for the WBC and the IG counts. The 
mean WBC count among the survivors and non survivors was 12,096 ± 3842 cells/cumm 
and 18,934±1172 cells/cumm respectively. Similarly, the median range IG count among the 
survivors and non survivors was 0.07 (0-0.26) cells/cumm and 0.13 (0-1.54) cells/cumm 
respectively. The mean value of WBC and IG count among survivors was taken as the cut 
off and variables were entered in to bivariate analysis to derive the significant factors.The 
mean value of WBC and IG count among survivors was taken as the cut off and variables 
were entered in to bivariate analysis to determine the significant independent role of these 
investigations in head injury patients. The results of bivariate and multivariate logistic 
regression are shown in table 3. The non survivors had high WBC counts (>12,096 
cells/cumm, p<0.0001), severe head injury (GCS 3-7, p<0.001) and higher abnormal 
pupillary reaction (unilaterally present and bilaterally absent pupillary reaction, p<0.01) 
compared to the survivors. Multivariate logistic regression analysis to determine the 
correlation of each individual factor with mortality revealed only high WBC count [OR (95% 
CI): 4.9 (0.8-29.5)] and severe head injury (GCS 3-7) [OR (95% CI): 4.4 (0.9-21.2)] to be 
independent significant predictors of mortality. Bilaterally absent pupillary responses was 
not found to be statistically significant in predicting mortality, thus it should not always be 
associated with a hopeless outcome. 
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Table 2. Median (Inter quartile range) Immature Granulocytes (IG) counts in head injury 
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Few authors have studied the association between WBC count, outcome and head injury. 
Keskil et al illustrated in a study of 153 head trauma patients that WBC count exceeding 
20 x 106/l was associated with poor clinical grade on admission and high mortality 
compared to those patients with normal or slightly above normal WBC counts (Keskil et 
al.,1994). Rovlias & Kotsou did a prospective analysis of 125 patients of severe head injury 
to study the prognostic significance of WBC counts in these patients. Patients with severe 
head injury had significantly higher white blood cell counts than did those with moderate 
or minor injury (p < 0.001). Among the patients with severe head injury, a significant 
relationship was found between WBC counts and Glasgow Coma Scale score, pupillary 
reaction, and presence of subarachnoid haemorrhage (p < 0.001). WBC counts were also 
found to be an independent significant predictor of outcome on multivariate 
analysis (Rovlias & Kotsou, 2001). Our results were concordant to that demonstrated by 
Rovlias & Kotsou. (Rovlias & Kotsou, 2001). Our results were concordant to that 
demonstrated by Rovlias & Kotsou.  
Akin results were also seen in the study by Kan et al, wherein 146 children with Severe 
TBI were evaluated in attempt to establish the prognostic factors of severe TBI. They 
observed that a low coma score upon admission was independently associated with poor 
outcome, also the presence of diabetes insipidus within 3 days post-TBI (OR: 1.9), 
hyperglycemia (OR: 1.2), prolonged PT ratio (OR: 2.3) and leukocytosis (OR: 1.1) were 
associated with poorer outcome (Khan et al., 2009). In a study by Gurkanlar et al on 59 
patients of head trauma, it was shown that WBC count exceeding 17.5x106/l had a 
predictive value for poor GCS score and long hospital stay. Similarly, CT progression was 
significantly seen in patients with moderate and severe head injury. Other studies in the 
literature were done on either trauma patients overall or on specific type of trauma 
patients such as blunt trauma victims.  
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Results of bivariate and multivariate logistic regression analysis 
 









Post Hoc Analysis 
p value 







17495.2  ±  4687.4
11114.2  ±  3557.7
9223.5  ±  1933.7 
F = 34.1; 
p = 0.0001 
 
Severe vs. Moderate 
: 0.001 














19533.3  ±  5884.8
 
13227.2  ±  6103.9
 
13071.9  ±  4458.2 
F = 8.72; 
p = 0.0004 
 
B/L absent vs. U/L 
absent  : 0.009 
U/L absent vs. B/L 
present : 1.000 
B/L absent vs. B/L 
present : 0.000 
























11985.7  ±  4250.2
 
 
15878.9  ±  6878.1
 
 
14727.2  ±  5828.0
 
 
14063.6  ±  4582.7 
F = 1.46; 
p = 0.23 
 
___ 
Table 1. Comparison of mean WBC counts in various Clinical parameters in Head Injury 























χ 2  = 3.48; 




Bilaterally (B/L) absent  
Unilaterally (U/L) absent  










χ 2  = 0.4; 
p = 0.78 
 
- 
CT scan finding 
Extra Dural Hemorrhage (EDH) 
Sub Dural Hemorrhage (SDH) 
Sub Arachnoid Hemorrhage 
(SAH) 
Intra Cerebral Hemorrhage  








0.08  (0-0.1) 
0.08  (0-1.5) 
0.04  (0-0.2) 
 
0.08  (0-1.3) 
 
χ 2  = 9.68; 
p = 0.04 
 
SAH vs. EDH- p<0.05 
SAH vs. SDH - p=0.05 
SAH vs. ICH  - p<0.05 
Table 2. Median (Inter quartile range) Immature Granulocytes (IG) counts in head injury 
patients: Results of Kruskal-Wallis Test and overall comparison using one way ANOVA & 
Bonferroni correction 
The Leukocyte Count, Immature Granulocyte  




Few authors have studied the association between WBC count, outcome and head injury. 
Keskil et al illustrated in a study of 153 head trauma patients that WBC count exceeding 
20 x 106/l was associated with poor clinical grade on admission and high mortality 
compared to those patients with normal or slightly above normal WBC counts (Keskil et 
al.,1994). Rovlias & Kotsou did a prospective analysis of 125 patients of severe head injury 
to study the prognostic significance of WBC counts in these patients. Patients with severe 
head injury had significantly higher white blood cell counts than did those with moderate 
or minor injury (p < 0.001). Among the patients with severe head injury, a significant 
relationship was found between WBC counts and Glasgow Coma Scale score, pupillary 
reaction, and presence of subarachnoid haemorrhage (p < 0.001). WBC counts were also 
found to be an independent significant predictor of outcome on multivariate 
analysis (Rovlias & Kotsou, 2001). Our results were concordant to that demonstrated by 
Rovlias & Kotsou. (Rovlias & Kotsou, 2001). Our results were concordant to that 
demonstrated by Rovlias & Kotsou.  
Akin results were also seen in the study by Kan et al, wherein 146 children with Severe 
TBI were evaluated in attempt to establish the prognostic factors of severe TBI. They 
observed that a low coma score upon admission was independently associated with poor 
outcome, also the presence of diabetes insipidus within 3 days post-TBI (OR: 1.9), 
hyperglycemia (OR: 1.2), prolonged PT ratio (OR: 2.3) and leukocytosis (OR: 1.1) were 
associated with poorer outcome (Khan et al., 2009). In a study by Gurkanlar et al on 59 
patients of head trauma, it was shown that WBC count exceeding 17.5x106/l had a 
predictive value for poor GCS score and long hospital stay. Similarly, CT progression was 
significantly seen in patients with moderate and severe head injury. Other studies in the 
literature were done on either trauma patients overall or on specific type of trauma 
patients such as blunt trauma victims.  
 
 













WBC count  >12,096 
cells/cumm 26 (45.6) 21(91.3) 0.001 0.0001 12.5(2.6  - 58.4) 4.9 (0.8-29.5) 



























3.43  (1.2- 9.6) __ 
 
WBC count Cut off = 12,096 cells/cumm; IG count Cut off = 0.07 cells/cumm 
Table 3. Association of various factors with the death as outcome in head injured patients: 
Results of bivariate and multivariate logistic regression analysis 
 
Brain Injury – Pathogenesis, Monitoring, Recovery and Management 
 
148 
Chang et al did a prospective analysis of 786 trauma victims and found ISS >15, GCS≤8 and 
white race to be associated with increase in white cell count. Their study included all trauma 
patients irrespective of the site of injury (Chang et al., 2003). WBC count as a laboratory 
marker has also been studied in blunt trauma patients to predict the severity of injury 
(Santucci et al., 2008). 
Schnüriger et al conducted a study to ascertain the significance of serial white blood cell 
(WBC) counts in trauma patients with a suspected hollow viscus injury (HVI), on an overall 
study population of 5,950. A significant relationship between increasing Injury Severity 
Score and increasing WBC count on admission was found by linear regression and they 
concluded that WBC count elevation on admission is nonspecific and does not predict the 
presence of Hollow Viscus Injury (HVI)  (Schnüriger et al., 2010). 
Similarly, in the study done on 805 trauma patient, to test the diagnostic use of white blood 
cell (WBC) count in differentiating major from minor injuries. Paladino et al. concluded that 
WBC count was not a useful addition as a diagnostic indicator of major trauma in their 
study population (Paladino et al., 2010). 
While the WBC had moderate discriminatory capability for serious injury, was not 
considered to be a reliable independent marker to rule in or out serious injury. Nevertheless, 
the use of WBC on presentation to the emergency department as an adjunct for making 
disposition decisions is recommended. 
Rovlias & Kotsou observed that, WBC counts were significantly higher in those with an 
unfavorable outcome (p < 0.001) i.e. a high mean± S.D.WBC count of 18144.93±467/cumm was 
seen in patients  with unfavourable outcome (severe disability, persistent vegetative state, 
dead) in contrast to a mean± S.D. WBC count of 13711.85±415.61/cumm in patients with a 
favourable outcome, i.e. good recovery, moderate disability (Rovlias & Kotsou, 2001). In 
another study, the mean WBC count was higher i.e. 21.1x106/l in patients with Glasgow 
outcome score (GOS) of one (death) and comparatively low i.e. 12.3x106/l when the GOS was 
five (good recovery) (Gürkanlar et al., 2009). Keskil et al showed in a prospective analysis, a 
low mortality rate (23%) in patients with WBC counts less than 20x106/l Compared to those 
with counts more than 20x106/l (mortality rate 96%) (Keskil et al., 1994). The present study 
showed that a high WBC count (>12,096 cells/cumm) [OR (95% CI): 4.9 (0.8-29.5)] and severe 
head injury (GCS 3-7) [OR (95% CI): 4.4 (0.9-21.2)] to be independent significant predictors of 
mortality. 
Rangarajan et al. in their study designed to find out the factors influencing mortality in 
acutely injured trauma patients receiving massive blood transfusion (MBT). They observed a 
total leukocyte count (TLC) ≥ 10,000 cells/cubic mm, GCS ≤ 8, the presence of coagulopathy 
and major vascular surgery as four independent determinants of mortality in multivariate 
logistic regression analysis (Rangarajan et al., 2011). 
Immature granulocyte count is a recently introduced parameter in the automated hematology 
analyzers that provides the number of promyelocytes, myelocytes and metamyelocytes in the 
peripheral blood. The presence of low numbers of immature granulocytes is more reliably 
detected on automated hematology analyzers than using manual microscopy (Ali Ansari-Lari 
et al., 2003; Briggs, 2003, 2009; Iddles et al., 2007). The performance analysis of the automated 
hematology analyzer for this parameter has been performed earlier (Walters & Garrity, 2000). 
The immature granulocyte parameter measured using Sysmex-2100 is presently used only for 
research purposes and in the context of clinical decision making requires more prospective 
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trials. There are no accredited external quality assessment schemes (EQAS) available for this 
parameter. Nevertheless, this instrument has internal quality control material available for this 
parameter and has been proven to be accurate, precise and highly suitable as a screening 
analyzer reducing the need for manual differentials. 
Bruegel et al. analyzed immature granulocytes in 156 healthy donors by using IG count and 
IMI channel. Men and women showed comparable values for IGs with the highest value of 
0.03 x109/l for men and 0.06 x109/l for women. No age dependency for the IG counts was 
reported (Bruegel et al., 2004). 
In the study to determine the usefulness of immature granulocyte measurement as a 
predictor of infection or positive blood culture.  Blood samples from 102 infected and 69 non 
infected patients were analyzed using the Sysmex XE-2100 automated blood cell counter 
(Sysmex, Kobe, Japan). The percentage of immature granulocytes was found to be 
significantly higher (P < .001) in infected than in non infected patients and in patients with 
positive than patients with negative blood cultures (P = .005). Also, a percentage of 
immature granulocytes of > 3 was observed to be a very specific predictor of sepsis. On 
comparing  the results of immature granulocyte measurement with total WBC count and 
absolute neutrophil count (ANC), receiver operating characteristic curves (ROC)  showed 
that the percentage of immature granulocytes was a better predictor of infection than the 
WBC count and comparable to the ANC. They concluded that immature granulocyte 
measurements reflect a biologically and clinically relevant phenomenon but are not sensitive 
enough to be used as screening assays for prediction of infection or bacteremia. However, 
although infrequently encountered, a percentage of immature granulocytes of more than 3 
might help expedite microbiologic laboratory evaluation of a subset of patients. (Ali Ansari-
Lari et al., 2003) 
In the present study, the role of admission WBC and IG count as prognostic determinants  
of mortality in isolated head injury patients was investigated. The study revealed  
that the mean WBC count was high in patients with severe (GCS 3-7) head injury and 
bilaterally absent pupillary reaction groups. The independent significant determinants of 
mortality due to head injury were high WBC count (>12,096 cells/cumm) and severe head 
injury (GCS 3-7). IG count was not found to be a potential determinant of mortality in this 
study.  
We observed high WBC counts in the non survivors compared to the survivors and  
the difference was statistically significant (p<0.001). Similar results were observed by 
Rovlias et al. 
We found that the IG count in patients with subdural haemorrhage, extradural hemorrhage, 
intracerebral hemorrhage and contusion was significantly higher than those patients who 
had subarachnoid haemorrhage. 
3. Conclusion  
Leukocytosis at initial examination is associated with adverse prognosis in trauma patients. 
High admission WBC count (>12,096 cells/cumm) and low GCS scores (3-7) portends a 
worse prognosis in isolated head trauma patients. Percentage of immature granulocytes 
correlates with CT findings (p=0.04) of Head injury patients, but its association with  
severity of injury and mortality is clinically insignificant. More prospective studies would be 
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required to evaluate the role of IG count as a marker of head injury in a larger  
study population, also to assess whether immature granulocyte measurements could be 
combined with other markers to create an algorithm with better diagnostic sensitivity or 
specificity. 
4. Acknowledgment  
We would like to thank Dr Kanchana Rangarajan, Senior Resident at the department of 
laboratory medicine, Trauma Center, AIIMS, for dedicated work and support. Mr 
Bhupender for helping in the statistical analysis of the study.  
Prof. Dr. Mahesh Chandra Misra , Chief of Trauma Center for providing the ammenities and 
facilities, that made this study possible.  
5. References  
Ali Ansari-Lari M, Kickler TS, Borowitz MJ. (2003). Immature granulocyte measurement 
using the sysmex XE-2100. Relationship to infection and sepsis. Am J Clin Pathol, 
Vol. 120, pp (795-99) 
Ahmed S, Khan S, Agrawal D, Sharma B S. (2009). Out come in Head Injured patients 
:Experience at a level 1 Trauma Centre. Indian Journal of Neurotrauma, Vol. 6, No. 2, 
n.d., pp. (119-122) 
Briggs C, Harrison P, Grant D, Staves J, Chavada N, Machin S J. (1999). Performance 
Evaluation of the Sysmex XE-2100™ Automated Haematology Analyser. Sysmex 
Journal International, Vol.9, No.2, n.d., pp.( 113 – 119) 
Briggs C, Kunka S, Fuijimoto H, Hamaguchi Y, Davies B, Machin SJ.(2003).Evaluation of the 
immature granulocyte counts by the XE-IG Master: upgraded software for the XE-
2100 automated hematology analyser. Laboratory Hematology, Vol. 9, No. , n.d., pp: 
117-24. 
Bruegel M, Fiedler GM, Matthes G, Thierry J. (2004). Reference values for immature 
granulocytes in healthy blood donors generated on the Sysmex XE2100 automated 
hematology analyzer. Sysmex Journal International, Vol 14, pp (5-7) 
Buttarello M, Plebani M.(2008). Automated blood cell counts: state of the art. Am J Clin 
Pathol, Vol. 130, No. 1, n.d, pp (104-16) 
Briggs C.(2009). Quality counts: new parameters in blood cell counting. Int J Lab Hematol. 
Vol. 31. , n.d., pp.(277-97) 
Cruichshank JM, Morris R, Butt WR, Crooke AC.(1970). The relationship of total and 
differential leukocyte counts with urinary oestrogen and plasma cortisol levels. J 
Obstet Gynaec Br Commonw, Vol 77, No. ,n.d, pp.(634-9) 
Cruichshank JM, Morris R, Butt WR, Corker CS. Interrelationships between levels of plasma 
oestradiol, urinary total oestrogens and blood haemoglobin and neutrophil 
counts.(1972). J Obstet Gynaec Br, Vol. 79, No. , n.d, pp.(450-4) 
Chang DC, Cornwell EE 3rd, Phillips J, Paradise J, Campbell K.(2003).Early leukocytosis in 
trauma patients: what difference does it make?. Curr Surg, Vol.  60, No. , n.d., 
pp.(632-5) 
The Leukocyte Count, Immature Granulocyte  
Count and Immediate Outcome in Head Injury Patients 
 
151 
Gürkanlar D, Lakadamyali H, Ergun T, Yilmaz C, Yücel E, Altinörs N.(2009). Predictive 
value of leucocytosis in head trauma. Turkish Neurosurgery, Vol: 19, No: 3, pp. (211-
215) 
Hughes WL, Kalbfleisch JM, Brandt EN, Costiloe JP.(1963).Myocardial infarction prognoses 
by discriminant analysis. Arch Intern Med, Vol. 111, No. , n.d, pp. (338-45) 
Iddles C, Taylor J, Cole R, Hill FGH. (2007).Evaluation of the immature granulocyte count in 
the diagnosis of sepsis using the sysmex XE-2100 analyser. Sysmex J Int , Vol. 17, 
No. , n.d., pp. (20-29)  
Keskil S, Baykaner MK, Ceviker N, Aykol Ş.(1994).Head Trauma and Leucocytosis. Acta 
Neurochir (Wien), Vol. 131, No. , n.d., pp.(211-14) 
Kan C H, Saffari1 M, Khoo T H.(2009).Prognostic Factors of Severe Traumatic Brain Injury 
Outcome in Children Aged 2-16 Years at A Major Neurosurgical Referral Centre. 
Malaysian Journal of Medical Sciences, Vol. 16,No. 4, pp (25-33) 
Lawrence Y R, Raveh D, Rudensky B, Munter G. (2007). Extreme leukocytosis in the 
emergency department. QJM. Vol. 100, No. 4, n.d., pp. (217-223) 
McPherson, R A. Pincus, M R.( August 18, 2006). Henry's Clinical Diagnosis and 
Management by Laboratory Method (21st Edittion),  W. B. Saunders Company, 
ISBN-13: 978-1-4160-0287-1, ISBN-13: 978-1416002871, USA. 
Metcalf D (2008) Hematopoietic cytokines. Blood, Vol.111. pp (485–491) 
Namas R, Ghuma A, Hermus L, Zamora R, Okonkwo DO, Billiar TR, Vodovotz Y. (2009). 
The Acute Inflammatory Response in Trauma / Hemorrhage and Traumatic Brain 
Injury: Current State and Emerging Prospects. Libyan J Med. Vol. 4, No. 3,.n.d., pp. 
(97-103) 
Paladino L, Subramanian A R, Bonilla E, Sinert R H.(2010). Leukocytosis as Prognostic 
Indicator of Major Injury. Western Journal of Emergency Medicine. Vol. 11, No. 5. Pp. 
(450-455) 
Rangarajan K, Subramanian A, Pandey R M. (2011). Determinants of mortalityin trauma 
patients following massive blood transfusion. Journal of emergency trauma and shock, 
Vol. 4, No. 1, n.d., pp.(58-63) 
Rovlias A, Kotsou S.(2001) The Blood Leucocyte count and its prognostic significance in 
severe head injury. Surg Neurol , Vol. 55, No. , n.d., pp.(190-96) 
Rovlias A, Kotsou S. (2004). Classification and Regression Tree for Prediction of Outcome 
after Severe Head Injury Using Simple Clinical and Laboratory Variables. Journal of 
Neurotrauma. Vol. 21, No. 7, n.d., Pp. (886–893), ISSN 0897-7151   
Ruggiero C, Metter EJ, Cherubini A, Maggio M, Sen R, Najjar SS, Windham GB, Ble A, Senin 
U, Ferrucci L.(2008). White Blood Cell Count and Mortality in the Baltimore 
Longitudinal Study of Aging. J Am Coll Cardiol. Vol. 49, No. 18,n.d., pp. (1841- 
50) 
Santucci CA, Purcell TB, Mejia C.(2008). Leukocytosis as a predictor of severe injury in blunt 
trauma Western Journal of Emergency Medicine. Vol. 9, No.2, pp. ( 81-85) 
Schnüriger B, Inaba K, Barmparas G, Barbara M. Eberle B. M., Lustenberger T., Lam L., 
Talving P.,Demetriades D.(2010). Serial White Blood Cell Counts in Trauma: Do 
They Predict a Hollow Viscus Injury?.J Truma of Injury, infection and critical care, Vol. 
69, No. 2, n.d., pp. (302-307) 
 
Brain Injury – Pathogenesis, Monitoring, Recovery and Management 
 
150 
required to evaluate the role of IG count as a marker of head injury in a larger  
study population, also to assess whether immature granulocyte measurements could be 
combined with other markers to create an algorithm with better diagnostic sensitivity or 
specificity. 
4. Acknowledgment  
We would like to thank Dr Kanchana Rangarajan, Senior Resident at the department of 
laboratory medicine, Trauma Center, AIIMS, for dedicated work and support. Mr 
Bhupender for helping in the statistical analysis of the study.  
Prof. Dr. Mahesh Chandra Misra , Chief of Trauma Center for providing the ammenities and 
facilities, that made this study possible.  
5. References  
Ali Ansari-Lari M, Kickler TS, Borowitz MJ. (2003). Immature granulocyte measurement 
using the sysmex XE-2100. Relationship to infection and sepsis. Am J Clin Pathol, 
Vol. 120, pp (795-99) 
Ahmed S, Khan S, Agrawal D, Sharma B S. (2009). Out come in Head Injured patients 
:Experience at a level 1 Trauma Centre. Indian Journal of Neurotrauma, Vol. 6, No. 2, 
n.d., pp. (119-122) 
Briggs C, Harrison P, Grant D, Staves J, Chavada N, Machin S J. (1999). Performance 
Evaluation of the Sysmex XE-2100™ Automated Haematology Analyser. Sysmex 
Journal International, Vol.9, No.2, n.d., pp.( 113 – 119) 
Briggs C, Kunka S, Fuijimoto H, Hamaguchi Y, Davies B, Machin SJ.(2003).Evaluation of the 
immature granulocyte counts by the XE-IG Master: upgraded software for the XE-
2100 automated hematology analyser. Laboratory Hematology, Vol. 9, No. , n.d., pp: 
117-24. 
Bruegel M, Fiedler GM, Matthes G, Thierry J. (2004). Reference values for immature 
granulocytes in healthy blood donors generated on the Sysmex XE2100 automated 
hematology analyzer. Sysmex Journal International, Vol 14, pp (5-7) 
Buttarello M, Plebani M.(2008). Automated blood cell counts: state of the art. Am J Clin 
Pathol, Vol. 130, No. 1, n.d, pp (104-16) 
Briggs C.(2009). Quality counts: new parameters in blood cell counting. Int J Lab Hematol. 
Vol. 31. , n.d., pp.(277-97) 
Cruichshank JM, Morris R, Butt WR, Crooke AC.(1970). The relationship of total and 
differential leukocyte counts with urinary oestrogen and plasma cortisol levels. J 
Obstet Gynaec Br Commonw, Vol 77, No. ,n.d, pp.(634-9) 
Cruichshank JM, Morris R, Butt WR, Corker CS. Interrelationships between levels of plasma 
oestradiol, urinary total oestrogens and blood haemoglobin and neutrophil 
counts.(1972). J Obstet Gynaec Br, Vol. 79, No. , n.d, pp.(450-4) 
Chang DC, Cornwell EE 3rd, Phillips J, Paradise J, Campbell K.(2003).Early leukocytosis in 
trauma patients: what difference does it make?. Curr Surg, Vol.  60, No. , n.d., 
pp.(632-5) 
The Leukocyte Count, Immature Granulocyte  
Count and Immediate Outcome in Head Injury Patients 
 
151 
Gürkanlar D, Lakadamyali H, Ergun T, Yilmaz C, Yücel E, Altinörs N.(2009). Predictive 
value of leucocytosis in head trauma. Turkish Neurosurgery, Vol: 19, No: 3, pp. (211-
215) 
Hughes WL, Kalbfleisch JM, Brandt EN, Costiloe JP.(1963).Myocardial infarction prognoses 
by discriminant analysis. Arch Intern Med, Vol. 111, No. , n.d, pp. (338-45) 
Iddles C, Taylor J, Cole R, Hill FGH. (2007).Evaluation of the immature granulocyte count in 
the diagnosis of sepsis using the sysmex XE-2100 analyser. Sysmex J Int , Vol. 17, 
No. , n.d., pp. (20-29)  
Keskil S, Baykaner MK, Ceviker N, Aykol Ş.(1994).Head Trauma and Leucocytosis. Acta 
Neurochir (Wien), Vol. 131, No. , n.d., pp.(211-14) 
Kan C H, Saffari1 M, Khoo T H.(2009).Prognostic Factors of Severe Traumatic Brain Injury 
Outcome in Children Aged 2-16 Years at A Major Neurosurgical Referral Centre. 
Malaysian Journal of Medical Sciences, Vol. 16,No. 4, pp (25-33) 
Lawrence Y R, Raveh D, Rudensky B, Munter G. (2007). Extreme leukocytosis in the 
emergency department. QJM. Vol. 100, No. 4, n.d., pp. (217-223) 
McPherson, R A. Pincus, M R.( August 18, 2006). Henry's Clinical Diagnosis and 
Management by Laboratory Method (21st Edittion),  W. B. Saunders Company, 
ISBN-13: 978-1-4160-0287-1, ISBN-13: 978-1416002871, USA. 
Metcalf D (2008) Hematopoietic cytokines. Blood, Vol.111. pp (485–491) 
Namas R, Ghuma A, Hermus L, Zamora R, Okonkwo DO, Billiar TR, Vodovotz Y. (2009). 
The Acute Inflammatory Response in Trauma / Hemorrhage and Traumatic Brain 
Injury: Current State and Emerging Prospects. Libyan J Med. Vol. 4, No. 3,.n.d., pp. 
(97-103) 
Paladino L, Subramanian A R, Bonilla E, Sinert R H.(2010). Leukocytosis as Prognostic 
Indicator of Major Injury. Western Journal of Emergency Medicine. Vol. 11, No. 5. Pp. 
(450-455) 
Rangarajan K, Subramanian A, Pandey R M. (2011). Determinants of mortalityin trauma 
patients following massive blood transfusion. Journal of emergency trauma and shock, 
Vol. 4, No. 1, n.d., pp.(58-63) 
Rovlias A, Kotsou S.(2001) The Blood Leucocyte count and its prognostic significance in 
severe head injury. Surg Neurol , Vol. 55, No. , n.d., pp.(190-96) 
Rovlias A, Kotsou S. (2004). Classification and Regression Tree for Prediction of Outcome 
after Severe Head Injury Using Simple Clinical and Laboratory Variables. Journal of 
Neurotrauma. Vol. 21, No. 7, n.d., Pp. (886–893), ISSN 0897-7151   
Ruggiero C, Metter EJ, Cherubini A, Maggio M, Sen R, Najjar SS, Windham GB, Ble A, Senin 
U, Ferrucci L.(2008). White Blood Cell Count and Mortality in the Baltimore 
Longitudinal Study of Aging. J Am Coll Cardiol. Vol. 49, No. 18,n.d., pp. (1841- 
50) 
Santucci CA, Purcell TB, Mejia C.(2008). Leukocytosis as a predictor of severe injury in blunt 
trauma Western Journal of Emergency Medicine. Vol. 9, No.2, pp. ( 81-85) 
Schnüriger B, Inaba K, Barmparas G, Barbara M. Eberle B. M., Lustenberger T., Lam L., 
Talving P.,Demetriades D.(2010). Serial White Blood Cell Counts in Trauma: Do 
They Predict a Hollow Viscus Injury?.J Truma of Injury, infection and critical care, Vol. 
69, No. 2, n.d., pp. (302-307) 
 
Brain Injury – Pathogenesis, Monitoring, Recovery and Management 
 
152 
Toutouzas K G, Velmahos G C, Kaminski A, Chan L, Demetriades D. (2002). Leukocytosis 
After Posttraumatic Splenectomy A Physiologic Event or Sign of Sepsis?. Arch 
Surg.Vol. 137, No. 8, n.d.,pp. (924-928)  
Walters J, Garrity P.(2000). Performance evaluation of the Sysmex XE-2100 hematology 
analyzer. Lab Hematol , Vol. 6, No. , n.d., pp.(83-92)  
8 
Animal Models of Retinal Ischemia 
Gillipsie Minhas and Akshay Anand* 
Neuroscience Research Lab, Department of Neurology 
Postgraduate Institute of Medical Education and Research, Chandigarh 
India 
1. Introduction  
Retinal ischemia is a frequent source of irreparable visual impairment and even loss of sight, 
affecting over a hundred million individuals in the world. It is associated with a wide range 
of clinical retinal disorders, like ischemic optic neuropathies, obstructive retinopathies, 
carotid occlusive disorders, diabetic retinopathy and glaucoma. Retinal ischemia occurs 
when the blood supply to retina is inadequate to meet the metabolic requirements of the 
retina. If treatment is not given to fix this imbalance, the outcome is irreversible, ischemic 
and apoptotic cascades resulting in cell death. Appropriate study models, particularly 
animal models, are necessary for further understanding the etiology, pathology, and 
evolution of retinal ischemia and also in order to help in the evaluation, development, and 
improvement of therapeutic strategies. Accordingly, quite a few in-vivo and ex-vivo 
mammalian models have been developed to study this syndrome. The rat models of retinal 
ischemia are frequently used, because the distribution of retinal and choroidal blood supply 
is quite similar to that in humans. 
The retina has been extensively used for the study of pathophysiology of ischemia and 
mechanism of damage triggered by ischemia and excitotoxicity. Compared to all the other 
tissues, retina has a higher metabolic rate; any disturbance in blood supply can have an 
effect on the supply of oxygen and the substrates leading to retinal ischemia.  The retina has 
a dual blood supply. The photoreceptors and most of the outer plexiform layer (OPL) are 
nourished by choriocapillaries, while the inner retinal layers are nourished by the central 
retinal artery. The actual effects of retinal ischemia vary, depending on the position of the 
occlusion. It is clear that occlusion of the retinal artery leads to inner retinal ischemia only, 
but occlusion of ophthalmic artery leads to global retinal ischemia, as it supplies blood to 
the central retinal artery as well as choriocapillaries.   
2. Retinal architecture  
The retina of mammals is a functionally specialised tissue. It is capable of light detection and 
perception as well as processing and transmission of the information received to the central 
nervous system. It has two major elements – the neurosensory retina and the pigment 
epithelium (RPE). During the embryonic development, the RPE and neural development are 
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nourished by choriocapillaries, while the inner retinal layers are nourished by the central 
retinal artery. The actual effects of retinal ischemia vary, depending on the position of the 
occlusion. It is clear that occlusion of the retinal artery leads to inner retinal ischemia only, 
but occlusion of ophthalmic artery leads to global retinal ischemia, as it supplies blood to 
the central retinal artery as well as choriocapillaries.   
2. Retinal architecture  
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nervous system. It has two major elements – the neurosensory retina and the pigment 
epithelium (RPE). During the embryonic development, the RPE and neural development are 
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derived from the same layer, i.e. the neuroectoderm, although they are morphologically not 
similar. Hence, they are considered collectively as “retina”.  
The retina is made up of three principal layers of nuclei, which are, from internal to 
external, the thin ganglion cell layer, the inner nuclear layer and the outer nuclear layer 
(Figure 1). The ganglion cell layer consists of cell bodies of various classes of ganglion 
cells and amacrine cells. The inner nuclear layer is the layer with nuclei of bipolar cells, 
amacrine cells, horizontal cells and Muller cells. And the outer layer is the one which 
contains the nuclei of rod and cone photoreceptors. There are also two plexiform or 
synaptic layers that are not filled with any cell nuclei. The inner plexiform layer (IPL) lies 
between the ganglion cells and inner nuclear layer and the outer plexiform layer (OPL) is 
sandwiched between the outer and inner nuclear layer. These synaptic layers contain 
axons and dendrites, which aid in early visual processing and also help in adjusting to 
different light intensities.  
The retina contains a rich assortment of cell types including light-sensing photoreceptors. 
The outermost layer of the cells in the retina is the RPE. It is a simple cuboidal epithelium, 
containing melanosomes that help in quenching photons that are not absorbed and 
therefore, minimise light scattering. RPE also has other biological functions like 
maintenance of choroidal vasculature and blood-retinal barrier. The retinal photoreceptor 
cells are specialised neurons found in the outer retina. The diversity of inner retinal 
neurons is really complex. Bipolar cells span from the OPL to the IPL, in which they form 
synapses with photoreceptor cells and ganglion cells respectively. The nuclei of bipolar 
cells are found in the inner nuclear layer. Amacrine cells in themselves as a group are 
considerable in number as well as diversity. These are present in both inner nuclear layer 
plus the ganglion cell layer where they are involved in relaying impulses (Masland, 1988). 
Another type of cells that also occur in the retina are the ganglion cells. Ganglion cells 
have long axons that are pass through the optic nerve (Berson, 2007). Glial cells are also 
found in the retina. These cells support the retinal microenvironment. These include 
Muller cells, astrocytes and microglia. Another type of cell found in the ganglion cell layer 
and optic nerve head are the astrocytes. These cells contribute to the blood retinal barrier 
(Kaur et al., 2008).  
3. Retinal blood supply  
As mentioned earlier, the cause of retinal ischemia is insufficient supply of blood, which is 
unable to meet the metabolic demands of the retina. When occlusion occurs in any tissue, 
anatomy of blood supply plays a significant role. The retina has a higher metabolic rate, 
even than that of the brain. The retina is a specialised extension of central nervous system 
and has a complex and dual blood supply, i.e the choroidal and the retinal. The choroid gets 
the maximum blood supply (around 65-85% of total supply to the eye), whereas the retina 
gets just 20-30%blood (Henkind, et al., 1979). The photoreceptors in the outer nuclear layer 
and the outer plexiform layer are nourished indirectly from the choriocapillaries; whereas, 
the inner retinal layers are nourished by branches of central retinal artery, which arises from 
the ophthalmic artery as the central retinal artery enters the retina, it divides into four main 
branches. The retinal blood vessels also help in maintaining the blood-retinal barrier. Outer 
retinal layer ischemia is caused by occlusion in choriocapillaries. On the other hand, 
complete retinal ischemia and infarction require ophthalmic artery occlusion (Saint-Geniez 
and D’Amore, 2004). 
 




Fig. 1. Different cell layers in retina (where RPE – Retina Pigmented Epithelium, OLM – 
Outer Limiting Membrane, ONL – Outer Nuclear Layer, OPL – Outer Plexiform Layer,    
INL – Inner Nuclear Layer, IPL – Inner Plexiform Layer, GCL – Ganglion Cell Layer) 
(reproduced and readapted with permission – Poche & Reese, 2009) 
4. Correlation between the brain and the retina 
The retina shares many functional, embryological and anatomic characteristics with the 
brain. In humans, the eye starts developing at about 3 weeks of pregnancy. The eye is 
mainly derived from three types of embryonic tissue – neuroectoderm forms retina, pigment 
cell layers and optic nerves, mesoderm leads to cornea, sclera and blood vessels and the 
ectoderm forms the lens. At 22 days of embryonic stage, a pair of optic vesicles is formed on 
each side of the forebrain. These vesicles form connections with the developing central 
nervous system through stalk-like structures. As the development progresses, these stalks 
become thinner and form optic nerves. Thus, it is a representative of the CNS. The 
mesoderm in the embryo forms the blood vessels – the hyaloid artery and vein, that 
nourishes the developing lens, which later on in development transform to the central artery 
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and the vein. The retina can be visualised directly, thus, it can be used to study stroke. Many 
retinal conditions are associated with stroke, such as occlusion of middle cerebral artery also 
leads to retinal ischemia, as can be seen in figure 2, where it shows that the ophthalmic 
artery originates nearby to the MCA. Thus, the mechanisms that affect the eye and the brain 
are linked to some extent. But, the examination of retina to predict future stroke incidence is 
still doubtful.  
Retinal neurons and glia show same response to ischemia as the neurons in the other part of 
the CNS. Retina also has a blood-retinal barrier similar to the blood-brain barrier (Tso & 
Jampol, 1982). These two also differ in the resistance to the ischemic injury. The retina can 
survive much longer than the brain. Also, the retina shows geographical difference in 




Fig. 2. The figure depicting Circle of Willis showing blood supply to brain and retina 
(Reproduced with permission from M. F. Block, 1997) 
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5. Susceptibility to retinal ischemia 
Various changeable and non-changeable factors are involved in ischemia, such as age, 
family history, ethnic group, and previous medical history. Kawai et al studied the different 
risk factors related to neuronal injury using an intraocular pressure rat model. The number 
of retinal ganglion cells (RGCs) keeps on decreasing with age and the residual RGCs become 
more susceptible to damage. Calorie intake has also been proven to be a factor involved in 
ischemia. The diet restriction has a neuroprotective effect and thus, leads to lesser damage to 
RGCs. As seen in the case of glaucoma, pre-existing diabetes is a reason for greater harm to 
RGCs (Kawai et al, 2001).  
Genetic background is one of the principal determinants of susceptibility to retinal 
neovascularisation and breakdown of blood retinal barrier. Vulnerability to ischemia-induced 
retinal neovascularisation depends on the strain of animal model used. Strain difference in rat 
model leads to variation in expression of VEGF and thus, causes an increase in permeability 
and leakage of fluid and plasma proteins, resulting in edema. It has been demonstrated that 
Brown-Norway rats are more susceptible to Sprague-Dawley rats (Gao et al., 2002). 
It is seen that a certain percentage of cell death that occurs in transient cerebral and  
retinal ischemia occurs by means of apoptosis. An apoptosis cascade involves both pro-
apoptotic and anti-apoptotic genes. One of these is p53, which is a DNA-binding 
transcription factor involved in DNA damage and repair. Ischemia leads to increase in 
expression of p53. The p53 causes selective vulnerability of inner retina to transient 
ischemia. Also, it is observed that transgenic mice lacking in p53 are resistant to 
excitotoxicity. Mice heterozygous for null mutation in p53 gene are resistant to retinal 
ischemia. From the above discussion, it is safe to say that p53 can be one more target for 
therapeutic strategy for retinal ischemia (Zhang et al., 2005). 
6. Pathophysiology of retinal ischemia 
Retina has a really high metabolic rate. Glucose and oxygen deprivation can harm the whole 
retina, but all cells are not equally vulnerable. The loss of cells due to ischemia is irregular. 
The retinal cells that lie near the blood vessels are exposed to an environment rich in oxygen 
and thus, are more prone to the ischemic damage. But, another thing to consider is that 
these cells are the first one to be cured on reperfusion. Temporary interruption of blood 
circulation prevents the exchange of metabolic substrates and products, affecting cells in 
retina. However, in addition, there are many indirect effects which are sustained even after 
restoration of blood supply. These effects may be systemic, such as respiratory or vasomotor 
centre failure or the outcome can also be localised, i.e. impaired reperfusion, edema or 
breakdown of blood-brain barrier. Thus, evidently, these effects are so complicated that it is 
hard to identify the order of events leading to damage. 
Retinal ischemia causes a number of morphological and functional changes. These changes 
are a product of combined and inter-related pathophysiological pathways – leading to 
imbalance in ion transport, changes in neurotransmitter levels, neuronal depolarisation, 
oxidative stress, and energy failure. The occurrence of ischemia leads to a complex cascade 
of response to energy failure and ATP depletion which eventually causes cell death. Studies 
have shown that substrate deprivation is the less damaging as compared to oxygen 
deprivation, which reduces protein synthesis. The irreversible damage increases with an 
increase in the duration of oxygen deprivation. The cells which are the most affected are the 
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photoreceptor cells as these have the maximum oxidative metabolic rates. But when both 
substrate and oxygen deprivation are combined, a reduction in the ATP synthesis is 
observed.  This leads to energy metabolism failure. The process can be explained as follows - 
decrease in ATP levels disrupt the Na+/K+ ATPase transporter, leading to disruption of 
membrane potential and ion gradients, preventing the repolarisation of axons and synaptic 
membranes. There are many studies which testify to the discharge of various 
neurotransmitters, e.g. GABA, glycine, dopamine, acetylcholine, after the occurrence of 
ischemia. During the ischemia the receptors for different neurotransmitters, present on the 
retina, are opened in response to the elevated levels of their ligands, e.g. GABA, glycine, 
extracellularly. Under normal circumstances, neurotransmitter levels are low extracellularly. 
Glutamate is recognized as the major excitatory retinal neurotransmitter. It is released by 
photoreceptor bipolar cells and the ganglion cells. During retinal ischemia glutamate gets 
accumulated in the extracellular space (Louzada-Junior et al., 1992). Lucas and Newhouse 
showed the occurrence of glutamate excitotoxicity in ischemia.  Neurons in inner retina and 
ganglion cells are more susceptible to ischemia due to the incidence of high levels of 
glutamate receptors. Glutamate causes neurotoxicity by several different mechanisms, i.e., 
increase in Ca2+ ion levels, Na+ influx, which depolarises the plasma membranes. There are a 
number of receptors which can activate glutamate neurotoxicity. These can be NMDA as 
well as non-NMDA based receptors (Lucas & Newhouse, 1957). In 1992, Osborne stated the 
role of NMDA – based excitotoxicity in retinal ischemia. NMDA receptors are Ca2+ 
permeable, and thus, increase in glutamate levels raises the Ca2+ ion levels intracellularly. 
Excess glutamate causes Na+ influx, which is followed by Cl- influx, which cannot be 
countered by outward efflux as the membranes are impermeable to most intracellular 
anions. Therefore, transport of cations and Cl- ions increases the intracellular osmolarity, 
causing osmotic shock, edema and cell lysis and death (Osborne et al., 1992). The voltage 
gated Ca2+ channels are also opened, leading to rise in intracellular levels of Ca2+ ions, which 
inhibit the mitochondrial metabolism. Another group also validated the involvement of 
NMDA as well as non-NMDA based receptors in retinal degeneration. Romano et al., in an 
in-vitro model of ischemia in the retina from a chick embryo reported by using the blockers 
of both NMDA and non-NMDA receptors that the damage to the retina is due to 
overexcitation of the receptors (Romano et al., 1998). Ueda et al also showed that the NMDA 
caused damage to blood vessels in the retina. They created a rat model by injecting NMDA 
into the eye, which led to loss of retinal ganglion cells and thinning of the inner plexiform 
layer, thus damaging the inner retinal layers and also led to loss of endothelial cells in the 
blood vessels in the retina (Ueda et al., 2010). 
Reperfusion, i.e. restoration of blood supply after the ischemic injury, can also lead to cell 
damage. Oxygen restoration to the deprived tissue can add up to the injury caused by 
ischemia (Jennings et al., 1960). Also, it has been shown that LDH, marker of cell death 
increases after oxygen restoration (Sims et al., 1992).  
7. In-vitro models of retinal ischemia 
Most of the cell culture models for ischemia utilise primary nerve cell cultures, that are 
exposed to insults associated with ischemia in-vivo, e.g., glutamate neurotoxicity, glucose 
and oxygen deprivation. One of the approach involved chemical ischemia in immortalised 
rat retinal ganglion cell line (RGC-5). They used iodoacetic acid (IAA), a known inhibitor of 
enzyme glyceraldehyde 3-phosphate dehydrogenase. This IAA treatment induces changes 
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seen in retinal ischemia, such as disturbance in membrane potential, ATP loss and reactive 
oxygen species generation (Malur et al., 2008). Another way of inducing ischemic-like 
changes in-vitro is to incubate retinal pigmented epithelium (RPE) cells with oligomycin (an 
ATP synthase inhibitor) and sodium cyanide (inhibits cytochrome-c oxidase), along with 
IAA (Palmero et al., 2000). In-vitro model can also be induced by glucose/oxygen 
deprivation. 
These in-vitro models can be used for testing and identifying novel neuroprotective 
compounds. Many herbal products are nowadays being used, the Chinese herbal medicines, 
in a large number of disorders, e.g. coronary heart disease, cardiovascular disease and 
traumatic wounds. Romano et al examined the neuroprotective activity of an extract from 
Chinese safflower (Cartnamus tinchoris, Honghua). An in-vitro model of retinal ischemia was 
made from chick embryo retina. The ischemia was generated by removing glucose from the 
media and growing the culture in nitrogen atmosphere. It was seen that Honghua protected 
the retina from the effects of toxins like NMDA and also from the ischemic conditions 
(Romano, et al., 1993).  
Another herbal extract that has been used in Korea and China are derived from the shrub, 
Thuja orientalis. It has been shown to be effective in disorders such as, gout, diarrhoea and 
rheumatism. It was demonstrated by Jung et al in the transformed retinal ganglion cell line 
(RGC-5) in vitro that the extract of Thuja orientalis has anti-oxidant properties. In this study, 
RGC-5 cells were exposed to H2O2 to create oxidative stress. The major component found in 
this extract with anti-oxidant properties is the isoquercitrin, which can be in future used for 
treating glaucoma, but requires further investigation (Jung, et al., 2010). The roots of another 
plant, Scutellaria baicalensis, are also used in China. It contains three flavnoids – wogonin, 
baicalin, baicalein. These flavenoids are natural free-radical scavengers. Out of the three 
flavenoids found, baicalin has been shown to have neuroprotective action, but the mode of 
its action is unknown. The role of baicalin was observed in in vitro model in RGC-5 cell line, 
where it reduces the damage caused by reactive species and apoptosis (Jung et al., 2008). 
Matteucci et al have also tested the curcumin, the phenolic extract obtained from Curcuma 
longa in primary retinal cell cultures. It showed protective effect for both the retinal as well 
as hippocampal neurons from NMDA excitotoxicity. The mode of action of curcumin may 
be through the increase in production of NMDA receptor subunits (Matteucci, et al., 2011). 
But these in-vitro models have some limitations of their own, such as getting sufficient 
quantities of cells and obtaining reproducible and comparable data. Also, the in vitro models 
do not correlate much to the in vivo conditions as these do not provide apt physiological 
environment and are based on chemical interactions. 
8. Need for animal models  
Animal models have been a mainstay of basic and applied research. Animal testing has been 
used since second century where early writings by Greeks discuss its use. Dissection and 
experimentation has been used to get knowledge about anatomy and physiology in humans. 
The use of animal models has allowed the fast progression of scientific discovery. Animal 
models have had a central place in medical research, in developing new therapeutic 
strategies for treating human diseases as well as in preclinical trials. The aim of using animal 
models is to achieve better understanding of pathways involved in the disease without 
causing any harm to the human being. A number of animal models are available for 
studying the mechanisms of retinal ischemia. The vascular supply and pathways involved 
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seen in retinal ischemia, such as disturbance in membrane potential, ATP loss and reactive 
oxygen species generation (Malur et al., 2008). Another way of inducing ischemic-like 
changes in-vitro is to incubate retinal pigmented epithelium (RPE) cells with oligomycin (an 
ATP synthase inhibitor) and sodium cyanide (inhibits cytochrome-c oxidase), along with 
IAA (Palmero et al., 2000). In-vitro model can also be induced by glucose/oxygen 
deprivation. 
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in a large number of disorders, e.g. coronary heart disease, cardiovascular disease and 
traumatic wounds. Romano et al examined the neuroprotective activity of an extract from 
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made from chick embryo retina. The ischemia was generated by removing glucose from the 
media and growing the culture in nitrogen atmosphere. It was seen that Honghua protected 
the retina from the effects of toxins like NMDA and also from the ischemic conditions 
(Romano, et al., 1993).  
Another herbal extract that has been used in Korea and China are derived from the shrub, 
Thuja orientalis. It has been shown to be effective in disorders such as, gout, diarrhoea and 
rheumatism. It was demonstrated by Jung et al in the transformed retinal ganglion cell line 
(RGC-5) in vitro that the extract of Thuja orientalis has anti-oxidant properties. In this study, 
RGC-5 cells were exposed to H2O2 to create oxidative stress. The major component found in 
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baicalin, baicalein. These flavenoids are natural free-radical scavengers. Out of the three 
flavenoids found, baicalin has been shown to have neuroprotective action, but the mode of 
its action is unknown. The role of baicalin was observed in in vitro model in RGC-5 cell line, 
where it reduces the damage caused by reactive species and apoptosis (Jung et al., 2008). 
Matteucci et al have also tested the curcumin, the phenolic extract obtained from Curcuma 
longa in primary retinal cell cultures. It showed protective effect for both the retinal as well 
as hippocampal neurons from NMDA excitotoxicity. The mode of action of curcumin may 
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8. Need for animal models  
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used since second century where early writings by Greeks discuss its use. Dissection and 
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The use of animal models has allowed the fast progression of scientific discovery. Animal 
models have had a central place in medical research, in developing new therapeutic 
strategies for treating human diseases as well as in preclinical trials. The aim of using animal 
models is to achieve better understanding of pathways involved in the disease without 
causing any harm to the human being. A number of animal models are available for 
studying the mechanisms of retinal ischemia. The vascular supply and pathways involved 
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in retinal ischemia in animal models must be better understood for developing new 
therapies for human disorders. 
In-vitro models have always been used to get insight of biochemical and molecular events 
caused by ischemia; but animal models are essential in understanding pathophysiology of 
retinal ischemia. In all animal models of retinal ischemia, the retinal circulation is 
obstructed to study the balance between energy supply and demands, vascular and 
neuronal changes. Different species such as monkeys, rabbits, rodents, cats, dogs have 
been used as animal models. In choosing an animal model, several factors are considered 
like anatomy of vascular circulation and retina, relevance to humans and also the 
availability of the animals. 
9. Desirable characteristics in animal models  
Animal models are used to understand the mechanism behind a particular disease and also 
to discover new as well as validate the already therapeutics for it. Animal models can either 
be spontaneous or induced and can be developed in any species which fits best for the 
disease to be studied and the purpose of our study. 
The model should show up same characteristics and symptoms as seen in human disorders. 
The model should have common features with the humans, such as anatomy, vascular 
system and retina in case of animal models for retinal ischemia. But at the same time these 
animals should be easy to manipulate, i.e. they should have small size, high reproducibility 
and easy for genetic manipulation. For testing the therapeutics, the animal models being 
used should mimic the humans and give same response as desired in the humans, so that 
the humans will show similar response. Other desirable characteristics include low cost, 
easy availability, easy to handle and breed and less prone to infections or diseases other 
than the desired one. 
10. Animal models of retina ischemia 
10.1 Raising the intraocular pressure 
It is the most widely used method to study the mechanisms involved in retinal ischemia. 
Peachey et al. demonstrated that the high intraocular pressure (IOP) induced retinal 
ischemia model has been established as an important model system. IOP model creates 
ischemia by elevating and maintaining the intraocular pressure above the systemic arterial 
pressure (Peachey et al., 1993). Flower et al described the retinal ischemia model in cats. The 
IOP was raised to 110mm Hg by cannulation of anterior chamber with a 26-gauge needle, 
which is connected through nylon tubing to an elevated container with normal saline. This 
increase in intraocular pressure blocks the retinal blood circulation and thus, leads to 
ischemia (Flower et al., 1971). Following a similar procedure, a model of pressure-induced 
retinal ischemia/reperfusion injury was established in rats (Buchi et al., 1991). 
It has been used to study changes in protein expression, excitotoxicity and alteration in 
membrane properties in various different models. IOP animal models have also been used 
to study changes in serum antibody reactivities after ischemia. Joachim et al. created IOP 
model by raising the pressure to 130mm Hg for an hour to check the antibody response to 
ischemia/reperfusion injury (Joachim, et al., 2011). On the other hand, Hirelinger et al. 
investigated the involvement of ion imbalance and role of Muller cells in degeneration of 
retina in a mouse IOP model (Hirelinger, et al., 2010).  
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Baicalin, a flavenoid found in roots of Scutellaria biacalensis, when was administered in rats 
intraperitoneally showed protection from the retinal ischemia’reperfusion injury, as was 
seen in vitro. The baicalin was given before subjecting the animals to raised intraocular 
pressure of 120mm Hg for 50 minutes (Jung, et al., 2008). 
The principle limitation of this model include that the raised intraocular pressure itself can 
contribute to the resulting retinal damage. Thus, this model is complicated by a combination 
of ischemic as well as pressure-induced injury.  
10.2 Cerebral artery occlusion 
Acute thrombotic/embolic stroke in humans are often associated with temporary 
diminishment (amaurois fugax) or even permanent loss of vision. Middle cerebral artery 
occlusion (MCAO) is a purely vascular model of retinal ischemia that reproduces transient 
human vision loss. MCAO in rodents is one of the most widely used experimental 
paradigms to induce focal cerebral ischemia. This model occludes arterial blood flow 
intraluminally and allows reperfusion by removing the inserted filament. The ophthalmic 
artery that mainly supplies the inner retina originates from the internal carotid artery 
proximal to the origin of the middle cerebral artery. Therefore, it is expected that MCAO 
simultaneously obstructs blood flow in the ipsilateral retina. Block et al demonstrated the 
first evidence of retinal ischemia by MCAO in rats (Block et al., 1992). Steele et al have shown 
for the first time that MCAO simultaneously obstructs blood flow in ipsilateral retina in 
mice (Steele et al., 2008).  
Kaja et al indicates that the MCAO/ reperfusion model is more appropriate than other 
retinal ischemia models such as high intraocular pressure or optic nerve ligation models to 
study the cellular and molecular changes in retina after stroke (Kaja et al., 2003). This model 
is non-invasive with respect to the eye and does not induce blood-retina barrier disruption 
or mechanical damage to retina. The model is reproducible and easily reversible and 
involves vascular structure of the entire eye. Therefore, MCAO is a more relevant model for 
studying changes and testing the efficacy of therapeutic strategies for retinal ischemia. 
This model has been used to validate the effect of a various herbs of Chinese origin. The 
extracts from wolfberries (Lycium barbarum, Gougizi) mostly consist of polysaccharides and 
are believed to be good for the eye. It has also been shown previously in many studies that 
these extracts have protective effect against liver damage, ageing and oxidation (Ha, et al., 
2005, Li, et al., 2007, Yu, et al., 2007).The group created a model by occluding the internal 
carotid artery in rats. The extracts were given orally for 1 week before the occlusion. This 
study showed that this pre-treatment with the extracts protected the retina from various 
conditions linked with retinal ischemia, such as, neuronal death, apoptosis, glial cell 
activation and blood-retinal barrier disruption (Li, et al., 2011). 
10.3 Chronic carotid ligation 
In two-vessel occlusion model, the occlusion is permanent and long-lasting and reperfusion 
does not occur. This model reduces the cortical/hippocampal blood flow to 25-50% of the 
normal levels in 2.5 hours post occlusion (Yamamoto et al., 2006). The blood flow in the 
retina may be more severely reduced than in the brain. Davidson et al have also shown that 
the two-vessel occlusion, i.e. the bilateral carotid artery occlusion causes an early loss of the 
pupillary reflex in 50% of the animals (Davidson et al., 2000). The 2-VO model mimics the 
ocular pathology of human carotid artery disease. The internal carotid artery (ICA) which 
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in retinal ischemia in animal models must be better understood for developing new 
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and easy for genetic manipulation. For testing the therapeutics, the animal models being 
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ischemia model has been established as an important model system. IOP model creates 
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which is connected through nylon tubing to an elevated container with normal saline. This 
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ischemia (Flower et al., 1971). Following a similar procedure, a model of pressure-induced 
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membrane properties in various different models. IOP animal models have also been used 
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Baicalin, a flavenoid found in roots of Scutellaria biacalensis, when was administered in rats 
intraperitoneally showed protection from the retinal ischemia’reperfusion injury, as was 
seen in vitro. The baicalin was given before subjecting the animals to raised intraocular 
pressure of 120mm Hg for 50 minutes (Jung, et al., 2008). 
The principle limitation of this model include that the raised intraocular pressure itself can 
contribute to the resulting retinal damage. Thus, this model is complicated by a combination 
of ischemic as well as pressure-induced injury.  
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Acute thrombotic/embolic stroke in humans are often associated with temporary 
diminishment (amaurois fugax) or even permanent loss of vision. Middle cerebral artery 
occlusion (MCAO) is a purely vascular model of retinal ischemia that reproduces transient 
human vision loss. MCAO in rodents is one of the most widely used experimental 
paradigms to induce focal cerebral ischemia. This model occludes arterial blood flow 
intraluminally and allows reperfusion by removing the inserted filament. The ophthalmic 
artery that mainly supplies the inner retina originates from the internal carotid artery 
proximal to the origin of the middle cerebral artery. Therefore, it is expected that MCAO 
simultaneously obstructs blood flow in the ipsilateral retina. Block et al demonstrated the 
first evidence of retinal ischemia by MCAO in rats (Block et al., 1992). Steele et al have shown 
for the first time that MCAO simultaneously obstructs blood flow in ipsilateral retina in 
mice (Steele et al., 2008).  
Kaja et al indicates that the MCAO/ reperfusion model is more appropriate than other 
retinal ischemia models such as high intraocular pressure or optic nerve ligation models to 
study the cellular and molecular changes in retina after stroke (Kaja et al., 2003). This model 
is non-invasive with respect to the eye and does not induce blood-retina barrier disruption 
or mechanical damage to retina. The model is reproducible and easily reversible and 
involves vascular structure of the entire eye. Therefore, MCAO is a more relevant model for 
studying changes and testing the efficacy of therapeutic strategies for retinal ischemia. 
This model has been used to validate the effect of a various herbs of Chinese origin. The 
extracts from wolfberries (Lycium barbarum, Gougizi) mostly consist of polysaccharides and 
are believed to be good for the eye. It has also been shown previously in many studies that 
these extracts have protective effect against liver damage, ageing and oxidation (Ha, et al., 
2005, Li, et al., 2007, Yu, et al., 2007).The group created a model by occluding the internal 
carotid artery in rats. The extracts were given orally for 1 week before the occlusion. This 
study showed that this pre-treatment with the extracts protected the retina from various 
conditions linked with retinal ischemia, such as, neuronal death, apoptosis, glial cell 
activation and blood-retinal barrier disruption (Li, et al., 2011). 
10.3 Chronic carotid ligation 
In two-vessel occlusion model, the occlusion is permanent and long-lasting and reperfusion 
does not occur. This model reduces the cortical/hippocampal blood flow to 25-50% of the 
normal levels in 2.5 hours post occlusion (Yamamoto et al., 2006). The blood flow in the 
retina may be more severely reduced than in the brain. Davidson et al have also shown that 
the two-vessel occlusion, i.e. the bilateral carotid artery occlusion causes an early loss of the 
pupillary reflex in 50% of the animals (Davidson et al., 2000). The 2-VO model mimics the 
ocular pathology of human carotid artery disease. The internal carotid artery (ICA) which 
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begins at the bifurcation of the common carotid artery (CCA) provides the major blood 
supply to brain. It also provides the blood supply to the eye through the ophthalmic artery.  
Many studies have shown that bilateral common carotid artery occlusion in rat causes 
functional impairment of retina (Block et al., 1992). The electroretinogram have also 
demonstrated that b-wave amplitude representing bipolar and Muller cell activity in 
response to light exposure is decreased 7 days after the onset of 2VO (Barnett and Osborne, 
1995). These functional changes are accompanied by structural damage. In animals that lost 
their pupillary reflex, the total retinal thickness decreased from approximately 120 μm to 
around 87 μm. The most affected layers being the synaptic zones in inner plexiform as well 
as the outer plexiform layer (Lavinsky et al., 2006).  
In this model, occlusion of both CCAs cuts off blood supply to the retina, however, some 
retinal perfusion is maintained by retrograde blood flow to ophthalmic artery through the 
Circle of Willis. The degree of retinal damage also varies greatly within the same 
experiment, due to heterogeneity in tolerance towards ischemia in individual animal. 
10.4 Photocoagulation of retinal vessels 
There are only a few studies at present that report the ischemia of less than 5 minutes, which 
is often observed during the ocular surgeries. The faults that are present in other methods, 
such as invasiveness and inflammation in raising the intraocular pressure or ligation of optic 
vessels that causes changes in retina unrelated to ischemia, can be reduced by direct laser 
exposure of the main retinal vessels.  
Kalamkarov et al. induced the characteristics of retinal ischemia in rats by direct laser 
coagulation of blood vessels using argon laser (Kalamkarov et al., 2000). Selective occlusion 
of vessels using laser permits creation of local and extensive retinal ischemia by choosing 
various retinal vessels and by modifying the exposure dose. In this technique, Rose Bengal, 
an iodinated photosensitive dye is injected intravenously through tail vein. The eyes are 
then exposed to 7 minutes of intense light (550nm, which is the absorption peak for this 
dye). Retinal vein occlusion was simulated in non-human primate model, i.e. cynomolgus 
monkey (Maccaca fascicularis). Dye yellow (577nm) laser light was used to occlude all branch 
retinal veins in the eye (Miller et al., 1994). Photodynamic thrombosis with green argon laser 
light and Rose Bengal dye was also used to create retinal ischemia model in pigs by 
occluding the retinal veins. 
Laser coagulated Sprague Dawley rats were used to validate the effect of Hongua in vivo. In 
this model, Honghua extract was injected intravitreally, before they were subjected to Rose 
Bengal dye and laser (550nm). It is hypothesised that as the major component in the 
Honghua extract is glucose, the neuroprotective effect of the same could be due to 
availability of energy source after ischemia (Romano, et al., 1993). Another Chinese herbal 
medicine – Fufang Xuehuantong capsule was also studied by Yuan et al. They created a rat 
model for retinal vein occlusion by using laser photocoagulation and then validated the 
therapeutic benefits Chinese herbal medicine by quantitating the expression of various 
growth factors in the animal model (Yuan et al., 2011). 
10.5 Central retinal artery occlusion  
In humans, CRAO results in severe retinal ischemia, resulting in irreversible damage within 
hours. A minimal invasive model of transient retinal ischemia was introduced by 
Dangeliene et al., which involves photothrombotic central retinal artery occlusion (CRAO) 
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using intravenous injection of Rose Bengal and green laser irradiation of CRA in rats 
(Dangeliene et al., 2000). Rose Bengal is a photosensitive dye that releases oxygen free 
radicals when irradiated by the laser. This active oxygen results in intraluminal thrombus 
formation and thus, occlusion of CRA.  Another retinal ischemia-reperfusion model through 
the occlusion of central retinal artery involves placing a suture behind the eye globe, 
including the CRA and ciliary artery. Both ends of the suture were then passed through a 
small plastic tube and ischemia is caused by pressing the tube against the artery. Prasad et al 
used the central retinal artery ligation model in rats to compare between different occlusion 
times as well as different time-period of reperfusion. They studied gene expression of 
various transcription-related genes after 30 and 90 minutes of occlusion and at 3 hours and 
12 hours of reperfusion (Prasad et al., 2010).  
10.6 Endothelin administration 
Transient obstruction of central retinal artery can also be obtained by injecting 
vasoconstrictive drug. This method is less invasive, simple and does not require any special 
equipment. Endothelin-1 (ET-1) is a potent vasoconstrictive peptide produced by the 
vascular endothelial cells. Endothelin is found naturally in various tissues and is involved in 
a variety of biological activities. It has been linked with pathophysiology of various human 
disorders, e.g. cardiovascular, renal and ocular. Endothelin-1 can cause apoptosis of neurons 
in the CNS (Syed, et al., 2006). Endothelin-1 causes cell death through mechanism involving 
free-radicals (Oku, et al., 2008). Sugiyama et al have shown the association of endothelin with 
glaucoma. The authors investigated the effect of ET-1 on rabbit eye and observed that the 
intravenous as well as intravitreal administration of ET-1 reduces both the intraocular 
pressure and the blood flow in the optic nerve (Sugiyama, et al., 1995). Granstam et al 
demonstrated similar effects of endothelin in a cat model (Granstam, et al., 1992). Masuzawa 
et al have shown that a high dose of ET-1 when injected under the conjunctiva obstructs the 
central retinal artery without any damage to other tissues. Endothelin-1 causes retinal 
ganglion cell loss and activates glial cells (Masuzawa et al., 2006). It has also been seen that 
the intravitreal administration of ET-1 affects the retinal arteries directly. A dose of 10-7 M 
ET-1 led to decrease in the diameter by 17% (Bursell, et al., 1995). 
Endothelin-1 also causes constriction of arteries in-vitro. Yu et al showed that ET-1 dose 
causes constriction even in cryopreserved human retinal arterioles. But the relation between 
the dose and the related activity is still not known (Yu, et al., 1998).  
Thus, in this method there is no problem regarding inflammation or infection. But, like any 
other method being used, this method too is not completely free from drawbacks. The dose 
of endothelin-1 used is quite high, which may pass into the systemic circulation and exert 
some undesired effects in other tissues. 
11. Current and potential therapeutic strategies for retinal ischemia 
Many strategies have been used but have not been successful or have shown various 
limitations and are at experimental stage. Current treatments available for retinal ischemia 
include intravitreal or retinal vein administration of tissue-plasminogen activator (t-PA), 
hemodilution, pan-retinal laser photocoagulation or anti-VEGF antibodies or medication 
(Lucentis or Avastin). Occlusion of retinal vessels or retinal ischemia leads to retinal 
neovascularisation. Laser photocoagulation is used to decrease the neovascularisation in 
retina and thus, the oxygen demand. The decrease in overall oxygen requirement will stop 
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using intravenous injection of Rose Bengal and green laser irradiation of CRA in rats 
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ischemia and hence, further damage to the eye. Ischemic conditions also cause up-regulation 
of expression of angiogenic factors, such as vascular endothelial growth factor or VEGF. 
VEGF is involved in angiogenesis and causes abnormal vessels growth or 
neovascularisation. To reduce the damage of ischemia, oxygen supply to retina has to be 
improved. Therefore, anti-VEGF drugs can be directly injected in the eye, e.g. the drugs that 
have been most tested in animal models include, bevacizumab, ranibizumab, pegaptanib 
sodium. Corticosteroids, such as, dexamethasone, are also under experimentation, as these 
inhibit VEGF and inflammatory factors (Lattanzio, et al., 2011). Another technique that holds 
promise is the use of anti-VEGF antibodies. Neutralising anti-VEGF monoclonal antibodies 
have been demonstrated to block neovascularisation when administered in a primate model 
of laser-induced retinal ischemia. Aiello et al showed the in-vivo inhibition of VEGF with the 
help of VEGF- neutralising proteins-containing extracellular domain of human (Flt) or 
mouse (Flk) VEGF receptors attached to IgG. These chimeric proteins showed 100% 
reduction in neovascularisation with human Flt and 95% with murine Flk domains. The 
suppression of VEGF was dose-dependent (Aeillo et al., 1995). 
There are many other drugs and chemical compounds which have been tested in animal 
models of retinal ischemia with positive results and hope for future therapeutics. Cao et al in 
1994 provided the evidence for the neuroprotective effect of NMDA antagonists in retinal 
ischemia. They showed that the NMDA receptor antagonist, dextromethorphan has a 
protective effect after retinal ischemia. However, it is not still clear whether 
dextromethorphan works via NMDA receptors.  Other NMDA antagonists, such as MK-801 
or memantine also protect from retinal ischemia (Lam et al., 1997 and Osborne, 1999). 
Blockers of voltage-gated Ca2+ channels, e.g. nifediprine and betaxolol also decrease 
neurotoxicity by reducing Ca2+ ions influx (Melena et al., 1999).  
Another approach can be the use of the free- radical scavengers. Free-radicals play an 
important role in the damage caused by retina ischemia. Free-radicals are formed when 
reduced compounds, which accumulate during ischemia, are reoxidised during reperfusion. 
This free radical burst causes oxidative stress (Gilgun Sherki, 2002). Intravenous injection of 
SOD reduces the development of edema in rat model. SOD or superoxide dismutase is a 
well-known scavenger of superoxide radicals. Another compound that can be used is 
dimethylthiourea or DMTU, which is a synthetic compound that traps OH., H2O2 and other 
free radicals. Intravitreal injections of both SOD and DMTU have been shown to lead to 
recovery in IOP-induced ischemia rat model. DMTU (75μg/eye) resulted in 40% functional 
recovery when assessed through electroretinogram. SOD, on the other hand, leads to 99% 
functional recovery on post-treatment and 81% on pre-treatment. Thus, all these chemical 
compounds and drugs that decrease or reverse the cause of ischemia can be helpful in 
reducing the damage to some extent. 
RNA interference (RNAi) is a natural phenomenon in mammals, which is involved in 
silencing of gene expression. It involves a double-stranded RNA which cleaves any RNA 
complimentary to it. RNAi has been proposed to be used in therapeutics by downregulating 
the expression of specific genes. Reich et al used the technique of RNA interference in retinal 
cells in vitro, as well as in vivo in the mouse retina. They used this technique to downregulate 
the VEGF expression, which is known to be upregulated in retinal ischemia (Reich et al., 
2003). RNAi can be further investigated and tested for other genes, e.g. cytokines that are 
upregulated in the pathophysiology of retinal ischemia. 
Stem cell therapy is a promising technique for tissue repair and regeneration. Advances in 
the field of stem cells have lead to their use in treatment of various disorders (Lenka & 
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Anand, 2010, Rajarathna, 2009). Stem cells basically are unspecialised cells which are 
capable of self – renewal and under specific defined environment these cells can form 
functionally specialised cells. The stem cells can either be obtained from early embryos or 
certain tissues in adults, such as umbilical cord and peripheral blood, bone marrow. They 
work through either replacing damaged cells or through the factors released by them. Stem 
cells have been used in various vascular neurodegenerative diseases and most of the ocular 
disorders involve problem in either of the two. Eye is an accessible organ and with large 
number of animal models available, the use of stem cells poses a promise for preserving 
functionality (Cogliati & Swaroop, 2009).  
Adult bone marrow contains hematopoietic stem cells (HSCs) and hematopoietic progenitor 
cells (HPCs), which can differentiate into various cell types of myeloid and endothelial 
lineages. Bone-marrow contains stem cells which can either differentiate into Lin+ 
(hematopoietic lineage) or Lin- (non-hematopoietic lineage). Lin- population contains 
progenitor cells that differentiate into vascular endothelial cells, i.e. the endothelial 
progenitor cells (EPCs). Many preclinical and clinical studies have shown bone-marrow 
derived cells contribute to neoangiogenesis during wound healing, retinal ischemia, 
myocardial infarction, neonatal growth and tumor growth.  Lin- population have been 
shown to express neuronal markers after transplantation in brain or retina in various mouse 
models. Bone-marrow cells differentiate into neuronal cells, astrocytes in-vitro and also in-
vivo when injected intravenously into brain of mouse model (Mezey, et al., 2000). Also, it has 
been shown that BMCs can differentiate into retinal neural cells in-vivo (Woodbury, et al., 
2000). Lin- bone-marrow stem cells when injected intravitreally into photocoagulated retina 
of a mouse model, migrated to astrocytes and formed retinal vessels.  Ischemic conditions 
release cytokines that recruit EPCs to the site. Ischemia results in up-regulation of 
angiogenic factor, vascular endothelial growth factor or VEGF-A, which has its receptors 
Flk-1 and Flt-1 on EPCs, HSCs and HPCs, thus leading to their migration to the site (Kalka, 
et al., 2000). But their importance in clinics is still unknown as the success depends on their 
functional incorporation.  
Mesenchymal stem cells (MSCs) also found in bone marrow and other tissues such as cord 
blood, peripheral blood, fallopian tube, and fetal liver and lung have been used in over a 
range of different clinical trials (US NIH clinical trial database – www.clinicaltrials.gov), 
including those in fractures, diabetes, heart and liver disease and neurological disorders. 
MSCs have the potential to differentiate into neurons, especially retinal neurons. These cells 
also secrete molecules that modify the environment for the surrounding cells. MSCs for 
instance, express a number of neuroprotective factors, such as BDNF, CNTF, IGF, bFGF and 
NGF, which protect the injured retina. MSCs have another remarkable property, i.e. the 
homing potential; they can migrate to pathological areas (Prabhakar, et al., 2010). They can 
migrate from blood circulation to brain, spinal cord, and eye (Kan, et al., 2005). Thus, MSCs 
have shown neuroprotection in various neurodegenerative models, but clinical translation is 
still questionable.  
Another source of stem cell therapy is the embryonic stem cells (ESCs), obtained from the 
inner cell mass of blastocyst. ESCs can differentiate into various cell types, such as 
hematopoietic cells, astrocytes, hepatocytes, glial cells, neurons. Wei et al., 2005, showed that 
the transplantation of human embryonic cells in MCAO stroke model led to structural as 
well as functional recovery. Transplanted ESCs differentiated into neurons, astrocytes, 
oligodendrocytes and endothelial cells. These ESC – derived endothelial cells can form 
vascular-like structures in-vivo as well as in-vitro, thus induce angiogenesis (Levenberg, et 
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al., 2002). Embryonic stem cells have issue of ethical restrictions as well as immune rejection. 
Thus, alternate source of stem cells was identified from non-pluripotent cells. Every 
nucleated cell in an individual has identical genome, except the gametes. Different cell types 
are identified on the basis of the genes that are expressed. In 2006, four transcription factors 
– Oct 3/4, Sox-2, Klf-4 and c-myc, that are capable of reprogramming DNA were identified 
(Takahashi & Yamanaka, 2006). Forced expression of these specific genes in a non-
pluripotent cell lead to a pluripotent stem cell, known as induced pluripotent stem cell 
(iPC). Human iPCs have been derived successfully from patients with neurological 
disorders – Parkinson’s disease, muscular dystrophy, Huntington’s (Park et al., 2008). iPC 
from the skin cells of an amylotrophic lateral sclerosis (ALS) patient have been differentiated 
into motor neurons (Dimos et al., 2008). Takahashi group for the first time generated 
photoreceptor cells from the embryonic stem cells (Takahashi & Yamanaka, 2006). The same 
method has been used to create human photoreceptor and retinal pigmented epithelium 
phenotype (Hirami et al., 2009). Human neuronal cells can also be generated from iPC 
(Karumbayaram et al., 2009). Human umbilical cord blood is a well known source of 
hematopoietic stem cells and has been used in various disorders. Umbilical cord blood 
contains higher percentage of hematopoietic stem cells than the bone marrow and also poses 







Fig. 3. Formation of iPC from adult somatic cell  
 




Fig. 4. Different sources of neural stem cells (NSCs) in human and rat brain (Reproduced with 
permission http://pubs.niaaa.nih.gov/publications/arh27-2/197-204.htm) 
The mammalian central nervous system was considered is a non-renewable tissue. But 
studies have demonstrated that neural stem cells (NSCs) do exist not only in developing 
CNS, but also in adult nervous system of all mammals and are capable of differentiating 
into neurons, astrocytes and oligodendrocytes. Neural stem or progenitor cells can be 
isolated from various parts of CNS, such as hippocampus, subventricular zone, spinal cord 
and ependyma. Palmer et al for the first time isolated NSCs from the hippocampus of an 
adult rat. These hippocampus-derived NSCs have an ability to migrate and differentiate into 
neuronal lineage in injured retina, but are unable to form retina-specific cells (Nishida et al., 
2000). Embryonic retina derived neural progenitors can differentiate into photoreceptors in-
vitro (Ahmad et al., 2004). NSCs have an advantage over the embryonic stem cells with 
respect to their clinical translation, i.e. NSC can be expanded through numerous passages 
in-vitro and can be easily manipulated (English & Anand, 2010) . But, further studies are 
required to derive retinal neurons from the NSCs.  
But there are some limitations and barriers for stem cell transplantation in retina, as retina 
shows poor cell integration. Like any other part in the central nervous system, the retina too 
is rigid to cell migration. Thus, most of the cells that are transplanted do not reach the retina. 
It has been shown that only 1% of intraocularly transplanted cells reach the retina (Johnson, 
et al., 2010).The stem cell therapy holds a promising future in retinal disorders, but the 
problems need to be dealt with before clinical translation. 
Another therapeutic approach that shows a promising future is the concept of personalised 
therapy, where the candidate genes linked with various eye disorders can be identified and 
the genetic make-up of an individual can be used for disease prediction and treatment. 
12. Conclusion 
Retinal ischemia is a common cause for visual impairment and vision loss. It is a condition 
related with many different human disorders, such as diabetic retinopathy, glaucoma, and it 
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occurs when the blood supply is not sufficient to meet the demand. The retina and brain 
share common development pathway. Retina, like CNS, originates from ectoderm, however, 
it can be non-invasively studied. Also, as the retinal blood vessels share many features with 
the cerebral blood vessels, the investigations can be extrapolated to brain pathology. Thus, 
studying the retina, through the retinal ischemia models can help in understanding the 
mechanism and pathophysiology of stroke as well as in validating potential therapeutics. 
But all the methods discussed here have their own strengths and limitations. Out of all the 
above mentioned animal models, pressure elevation model is commonly used as it is easily 
reproducible and it mimics many human disorders – central retinal artery occlusion 
(CRAO), glaucoma, occlusion of ophthalmic artery. For example, some methods require 
penetration of a needle through the cornea, and must be fixed in the anterior chamber for 
one hour. The invasiveness can lead to inflammation and other damages. Similarly, 
unilateral and bilateral occlusion of carotid artery requires specialised skills in vascular 
surgery. It may cause incomplete ischemia and all of these procedures alter blood flow to 
the brain. Likewise, photocoagulation is simple but has many disadvantages including 
variable degrees of exposure and hence, variable damage. Besides, the ischemic damage 
caused is permanent because of which reperfusion cannot be studied. The choice of animal 
models for pre-clinical testing, therefore, depends on the research questions which have 
been raised. 
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models for pre-clinical testing, therefore, depends on the research questions which have 
been raised. 
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1. Introduction  
In a modern world the traumatic brain injury (TBI) becomes one of major health problems, 
with annually 500.000 cases in the US alone (Narayan et al., 2002), it poses the largest threat 
and considerably the most common cause of both the morbidity and mortality of the human 
young and pediatric population, and it is one of the major cases of disability and long 
capability in all ages (Langfitt et al., 1977; Levin et al., 1982; Fife & Jagger, 1984; Luerssen et 
al., 1988; Kraus et al., 1990). Moreover, TBI to children younger than 4 years of age has been 
shown to cause significantly more severe neurological, cognitive and motor deficits than in 
older children (Khoshyomn & Tranmer 2004). Thus TBI is a serious social, medical and 
scientific problem as well. New data, available to improve both efficacy of treatment and life 
quality after TBI would benefit each patient with TBI. 
Despite many successful clinical and laboratory investigations on TBI, many questions of 
pathophysiology of development and an effective treatment remain open and demand 
further investigation and understanding (Potts et al., 2006). There is experimental 
evidence that the inflammatory response may differ in the developing brain as compared 
to the adult (Fan et al., 2003; Claus et al., 2010; Yoneyama-Sarnecky et al., 2010), another 
possible factor could be age-dependent differences in posttraumatic cerebral blood 
circulation (Bayir et al., 2003).  
2. Cerebral blood flow in TBI 
The comprehensive understanding of pathophysiological processes developing in an injured 
brain always demands proper understanding of the cerebral blood flow (CBF) alterations as 
one of the most important factors, which plays an influental role both in disease 
development and prognosis prediction. In many cases of clinical and animal research, it has 
proved the importance of monitoring blood flow violations and interesting data were found 
involving CBF disturbances following the injury. Vascular events after TBI involve 
hemorrhage, breakdown or increased permeability of the blood brain barrier and edema, 
and certain changes in cerebral blood flow and local perfusion to the injured area. The exact 
role of each of these events after trauma is complex and has yet to be fully elucidated. 
Post mortem studies of patients who died of severe TBI (90% of these patients had 
histologic evidence of ischemia) a few decades years ago (Graham & Adams, 1971; 
Graham et al., 1978; Graham et al., 1989), partly stimulated the interest of CBF; whether 
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the ischemia was a factor of mortality or a reflection of the severity of injuries is still 
unknown. Ever since that time, despite many investigations, there is no universally 
accepted model of CBF changes in TBI. Therefore, the role of cerebral perfusion, both local 
and general, as well vasoreactivity in development of a cascade of biochemical reactions 
after the injury, could be paramount.  
Significant changes, perturbations and impairment in CBF and brain metabolism are very 
common following severe TBI, and the severity of impaired CBF correlate with the severity 
of TBI and poor outcome (Adelson et al., 1997; Muizelaar et al., 1989). The main peculiarities 
of cerebral circulation are the ability to autoregulation and high vulnerability to ischemia. 
Due to unique biological organization, as an extremely high metabolic activity and absence 
of metabolic stores, the brain requires a constant its supply of blood. Ischemia is poorly 
tolerated by a non injured brain, and TBI can lead to devastating impairment of 
autoregulation and profound ischemia (Bayir et al, 2003).  
Historically, investigations of CBF were done mostly in adults and mainly without 
including of the important factor of the timeline. Clinical studies have reported inconsistent 
and sometimes confusing, findings as decreased blood flow-hypoperfusion, increased flow–
hyperemia, and even cerebral vasospasm (Meixensberger, 1993). It was considered that in 
children with TBI hyperemia is the cause of increased intracranial pressure and cerebral 
swelling (Bruce et al., 1981), those studies were completed using the intravenous Xenon 133 
technique and external probes, in only six people. Animal studies in immature rats as the 
model of child TBI supported that point of view (Biagas et al., 1996). The authors 
demonstrated prominent increase of pericontusional CBF 24 hrs after injury, however, the 
increase was not observed immediately after.  
Muizelaar et al. performed 72 measurements of CBF in 32 children with TBI (Muizelaar et 
al., 1989). CBF is lowest after injury and correlates with the Glasgow Coma score, but 
founded increase of CBF at some point in their course leads authors to statement the 
prevalence of hyperemia. Obrist et al. performed serial CBF studies of 75 head-injured 
adults using Xe133 technique (Obrist et al., 1984). They found that 55% of patients had 
hyperemia at some point after their injury, and 45% had consistently low CBF, accordingly, 
hyperemia was associated with elevated intracranial pressure. Kelly et al (Kelly et al., 1996; 
Kelly et al., 1997), evaluated the role of hyperemia and CBF in outcome and intracranial 
hypertension, and observed the highest CBF on post injury days 1 to 5, when the lowest 
blood flows were documented on the day of injury. Significant decrease of posttraumatic 
CBF has been demonstrated both in human and laboratory investigations (Adelson et al., 
1997; McQuire et al., 1998; Chan et al., 1992; Marion et al., 1991; Yamakami & McIntosh, 
1991; Bryan et al., 1995; Cherian et al., 1999; Armstead, 1996). In the G. Bouma study of 186 
adults after severe TBI, using Xe133 radioactive labeling was shown relatively low CBF in 
the first 6 hours after injury (Bouma et al., 1991). The average CBF in this study at 4 to 6 
hours after injury was 22 mL/100 g/min, and about one third of patients had CBF low 
enough to be considered ischemic (<18 mL/100 g/min) (Diringer et al., 2002; Astrup et al., 
1981), when normal CBF in adults ranges from 33 to 55 mL/100 g/min (Obrist et al., 1984; 
Chiron et al., 1992). There was a strong correlation between low CBF and poor outcome, 
with a higher mortality rate for those with ischemia than those without. Thus, ischemia after 
TBI seems to occur early after injury. These findings were confirmed in a subsequent study 
using the inhaled stable Xe133 enhanced CT scan CBF technique (Bouma et al., 1995). 
Another study of 32 adults shows the significant changes of CBF from 27 cc/100 g/min at 
admission to 44 cc/100 g/min by 24 hrs (Marion et al., 1991).  
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Infants during the first 6 months of life also have a CBF of about 40 mL/100 g/min, which 
steadily increases during childhood to reach a peak of about 108 mL/100 g/min between 
the ages of 3 and 4 years, then goes down to 71 mL/100 g/min after the age of 9 years 
(Suzuki, 1990), and decreases to adult levels in the late teen age (Chiron et al., 1992). 
Therefore, it seems that CBF rises through early childhood, then decreases to reach adult 
levels by late adolescence (Chiron et al., 1992; Mansfield, 1997). Considering that large range 
of age depending variations, comparisons of CBF data in children could be valid only in 
small, well-defined age selected ranges, and some investigators of CBF revisited their 
opinion on prevalence of hyperemia in pediatric TBI (Zwienenberg & Muizelaar, 1999). In 
the largest report of CBF in 30 children with TBI (Adelson et al., 1997) it isobserved, that 
hypoperfusion was common in admission (about 25 mL/100 g/min) and increased by 24 
hrs up to 55 mL/100 g/min. Young age (<24 months) and low CBF in the early period after 
TBI were associated with poor outcomes. In the most recent publication of the same group 
of authors it was proven that a younger age, early or later low CBF are correlated with 
poorer outcomes in children, a relationship of low CBF and an unfavorable outcome 
(Adelson et al., 2011). 
3. CBF Doppler studies in humans 
The application of investigative methods based on Doppler Effect allows the performance of 
continuous monitoring of cerebral blood flow. Due to non-invasiveness and simplicity of 
application they become one of the first choice investigative methods in clinical and animal 
research, as Transcranial Doppler, Laser Doppler, etc.  
Investigations of CBF with Transcranial Doppler (TCD) techniques allowed the performance 
of noninvasive and more frequent studies, and as it was shown in study of 57 patients with 
severe TBI (GCS =<8), that decreased flow was most pronounced during first eight hrs after 
injury, and significantly increased after that time period (van Santbrink et al., 2002). 
Correlation between impaired flow and GCS and outcome on admission, was founded in 
another study in 121 patients with TBI (Chan et al., 1992). Experimental TBI investigations 
show reduced response of CBF to endogenous vasodilators as nitric oxide (NO) (Cherian et 
al., 2004; Hlatky et al., 2003).  
There are several investigations on Cerebral Blood Flow (CBF) in TBI. It is well established 
that CBF decreases significantly following TBI in clinical patients (Golding et al., 1999; 
Robertson et al., 1992) and in experimental animal models (Cherian et al., 1999). Moderate to 
severe TBI leads to severe reduction of CBF, causing secondary ischemia to already injured 
brain tissue with increased metabolic demands (Bayir et al., 2003; Potts et al, 2006; 
Manvelyan, 2006). Clinical research proves the dependence of TBI mortality to primary or 
secondary ischemia during autopsy (Adams et al., 1983).  
It is suggested that trauma roughly disturbs the brain autoregulation, the fine relations 
between vasoconstrictor and vasodilator production, and accordingly with increased 
cerebral metabolic demands, makes the brain more vulnerable to ischemia. But, it is very 
speculative to suggest that the hypoperfusion is connected with vasodilator activity, 
following hyperemia with vasoconstrictors. Blood flow in the brain is influenced by a wide 
variety of vasodilators as arachidonic acid metabolites, prostacyclin (Bayir et al., 2003), 
acetylcholine, calcitonin gene-related peptide, adenosine, and many others (Golding et al., 
1999; Bayir et al., 2003), and vasoconstrictors as serotonin, thromboxane, endothelin, and 
others (Golding, 2002).  
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The reductions in CBF and further hyperemia after TBI may have been due to the 
production or reduction of one or more of these cerebral vasoconstrictors or vasodilators. 
TBI increases the synthesis of cerebral vasoconstrictors including thromboxane (DeWitt et 
al., 1988) and endothelin (Armstead, 1996) and decreases the release or impairs the 
vasodilator action of prostacyclin (Al-Turki & Armstead, 1998). Greater TBI-induced release 
of endothelin-1 in newborn pigs vs. juvenile as age dependent differences in cerebral 
autoregulation response was shown in Armstead study (Armstead, 1999). 
So, insufficient and sometimes controversial data on CBF, demands further investigation, 
and proper understanding of the role of regional vascular changes beyond vasoactive 
mediators, as a result of local inflammatory and angiogenesis. This will be appreciated in 
understanding mechanisms of cerebral autoregulation impairment and CBF disturbances in 
TBI and then CBF effective regulation will become a therapeutic real target.  
We started our own investigations of CBF changes in 69 patients with severe TBI using 
Ultrasound Transcranial Doppler measurements by strictly considering the timeline. The 
measurements were started immediately after patient admission to the hospital, in initial 
hours of TBI onset, and then monitored during the subsequent two week period. Thus, 
letting us perform the monitoring of the CBF changes in the injured brain. We recorded the 
mean blood flow velocity in Median Cerebral Artery (MCA), as the biggest artery of the 
Willis Circle, providing the main blood volume of anterior circulation. The selection of 
patients was done according to their severity of injury; patients with intracranial hematoms 
due to possible vascular external compressions were excluded from the study.  
The most interesting finding was the total drop in the blood flow during initial hours after 
injury onset. If it is considered that the mean velocity in MCA, measured in healthy 
volunteers, is equal to 6212 cm/s, in patients with acute TBI it was notably reduced down 
to 3614 cm/s, which is on the border for development of cerebral primary ischemia. This 
condition is described as hypovolemia, which means reduced blood flow to the brain. 
The following next two days (post-injury 2-3) were marked with notable increase of the CBF 
velocity in MCA, reaching and overcoming the mean numbers, up to 8714 cm/s, and 
continuously growing during a week after injury, up to 120 cm/s, which is Doppler sign of 
hypervolemia. Some exceptional cases recorded blood flow velocity of 174 cm/s, which 
exceeds the mean flow velocity three times (!), and develops exclusively as the vasospasm, 
on postinjury days 6-8. Later on, by the end of two week monitoring period, the CBF 
velocity drops to mean levels, 668 cm/s.  
Two patients did not survive the injury; one with the lowest flows recorded, passed on Day 
1, and another with the severe cerebral vasospasm, passed on Day 8 post-injury. 
Clinical data suggests that during severe neurotrauma cerebral blood flow goes through 
succeeding processes of hypovolemia, hypervolemia and in most uncontrolled and/or 
severe cases, vasospasm. Hypovolemia develops immediately after injury and lasts one-two 
days, and could lead to primary brain ischemia, then cerebral perfusion trends to recover 
and increasing intensity, reaching hypervolemia also. Development of the arterial spasm  
(on days 7-8) leads to secondary ischemia.  
4. Laser Doppler animal experimental studies 
Clinical investigations proved the key role of CBF in primary (due to hypoperfusion) and 
secondary (mostly due to vasospasm) ischemia in TBI. The animal studies show the 
correlation between trauma severity and reduction of CBF. The pathological pathways of 
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CBF reductions are impairments of cerebral autoregulation and cerebral perfusion pressure, 
and release endogenous vasoconstrictors, responsible also for inflammatory response, 
serotonin, endothelin, alteration in brain tissue metabolism and ions transport, etc. These 
experiments demonstrate that TBI leads to significant reduction in cortical CBF of mature 
and immature experimental animals.  
Reduced CBF has been shown in many models of TBI. Moderate fluid percussion injury 
caused up to 50% reduction in CBF within 15-30 min after injury (Yamakami & McIntosh, 
1989). Controlled cortical impact reduced cortical CBF by about 35% (Cherian et al., 1994) to 
50% (Bryan et al., 1995).  
The recent data of different investigators shows the one-time only continuous monitoring of 
CBF in animals with TBI model during a few minutes and up to hours. Due to technical 
difficulties there was no data on the subsequent days and weeks, whenever clinical data 
shows significant importance of CBF monitoring and repeated investigation during at least a 
two week period after TBI onset.  
For our investigation of cerebral circulation in TBI a rodent model of cortical impact injury 
was used including adult mice and 21 day immature mice as a model of adult and baby 
brain injury (a total of 50 animals). For the CBF investigations we used the laser Doppler 
device LASERFLO BPM2 (Vasamedics, US). Laser Doppler flowmeter (LDF) measures 
relative perfusion continuously, using a transmitter/receiver probe that emits 
monochromatic laser light which is reflected by moving RBC according Doppler effect 
(Stern et al., 1977; Wardel et al., 1993). The power and frequency of the reflected are 
proportional to the blood volume and blood velocity. Perfusion is calculated as a product of 
blood volume and velocity in 1mm3 tissue volume under the probe (Haberl et al., 1989). The 
blood flow in the scanned area is presented in absolute or relative numbers. The power and 
CBF was monitored using a LDF with the fiber optic needle probe mounted on a stereotactic 
manipulator and placed approximately 0.5 mm above the dura mater or the pial surface, 
carefully positioned away from the visible large vessels. Once a suitable placement was 
obtained, the probe was left at that point for the duration of the experiment, and removed 
and replaced on the same position after cortical injury. 
Measurements were recorded and compared between mice based on a percentage change 
from baseline values (intact cortex) after experimental procedures. LDF monitored the 
cortical blood flow in different time points: from the intact skull, intact cortex right after 
craniotomy, from injured cortex after TBI, and prior to scarification of the animal on 5 
different groups (five animals in each) on Day 1, Day 3, Day 7, Day 14 and Day 28. Prior to 
euthanasia all animals under surgical dosage of anesthesia were placed on a warming pad 
(to keep the animal under the same condition as during initial investigation) and after a skin 
incision right above the craniotomy site, the Doppler probe was maintained above the 
cortex. The measurements show the sufficient drop of flow right after the injury in both 
groups of animals, CBF falls down about 31% in adults and 33% in babies (t-test: P<0.05, the 
difference between two groups is not significant). The next investigation was performed on 
the next day, and it is more likely the tendency to restoration of the CBF, when the Flow in 
adults were reduced about 15% of the Pre-Injury level, and increased about 15 % in babies 
(t-test: P<0.05, the difference is not significant). On the Day 3 blood flow continues the 
tendency to restoration and the differences were less prominent in adults (decreased about 
5% of the Pre Injury level) and babies (increased about 8%), there was no statistically 
significant difference between that values again (t-test: P<0.05, the difference is not 
significant).  
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The most significant changes of CBF were recorded on Day 7, when in both groups the Flow 
reached the highest values during all investigation time points, 43% in adults and 56% in 
babies comparing the Pre-Injury level of the flow. On days 14 and 28 we saw the restoration 
of the Flow in both groups. The mean values of the flow presented by those numbers: the 
flow in the intact cortex is about 25 mlLD/min/100gTissue +/- 8 (in adults) and +/- 5 (in 
immature) (t-test: P<0.05, the difference is not significant). When tissue perfusion was less 
then 10-12 mlLD/min/100gTissue right after injury, it is an indication of severe cortical 
ischemia, leading to death of the animal.   
Performing 35-day long monitoring of cortical local perfusion gives the following data. 
Cortical perfusion in an intact brain is similar in both mature and immature CNS. The mean 
absolute values of the perfusion in the intact cortex are 25 +/- 8 mlLD/min/100gTissue (in 
adults) and 25 +/- 5 mlLD/min/100gTissue (in immature) (t-test: P<0.05, the difference is not 
significant). The consequent measurements show the sufficient drop of perfusion 
immediately after the injury in both groups of animals, falls down about 31% in adults and 
33% in immature (t-test: P<0.05, the difference between two groups is not significant). 
During the following posttraumatic days one and three local cortical perfusion in both 
groups had tendency toward the restoration of flow in pre-injury level, as it was measured 
from the intact brain, then significant change in perfusion was recorded in both groups on 
day seven, when perfusion reached its highest values during all investigative time points. 
On following days 14 and 28 the restoration of the perfusion in the both groups were 
recorded.  
Next we examined brain slices stained for vascular proliferation with Esculentum Lectin. 
Enormously large dilated blood vessels appeared at the 7 days post injury in both groups, 
coinciding with the maximal perfusion, registered by Doppler monitoring. Moreover, on the 
same day activated microglia/macrophages were prominent within the ipsi-lateral cortex 
and hippocampus of both age groups (figure 1).  
The fact of decreasing blood flow immediately after injury still demands further 
understanding. Recent papers show the connection between the CBF decreases and NO 
level reduction after moderate TBI, increase of the cytokines expression (Ahn et al., 2004). 
One of the probable ways of understanding it is cerebral circulation. Cerebral 
microcirculation depends on very delicate interaction of vasoconstrictors and 
vasodilators. TBI is roughly interacting with that system, which leads to the release of 
cerebral vasoconstrictors (DeWitt et al., 2000) and decreases the production or affect of the 
activity of vasodilators (Al-Turki & Armstead, 1998). The other findings associated  
with CBF reduction on early time points after TBI, is the increased cytokine expression 
and production. However, the role of their changes in activity is not clear yet (Ahn et  
al., 2004).  
So, the reduction of CBF immediately after severe TBI onset could be explained by the 
changing histochemistry of the brain and vessels, but the symmetric changes in CBF in 
immature and mature brain on day 7 demands further investigation and understanding. 
One of the most probable reasons of it could be prevalence of vasodilatation effect due to 
impairment of cerebral autoregulation. Clinical studies shows the presence of vasospasm on 
days 7-9, and it shows increased blood flow in main arteries of the brain, Willis circle, 
whenever the microcirculation in cerebral cortex could be altered due to local conditions. It 
remains speculative since simultaneous measurement of cerebral hemodinamics and 
vasoactive agents in vivo studies is limited.  
 




Fig. 1. Enormously enlarged vessel with activated microglial cells. 
5. Conclusion 
Cerebral Blood Flow is an important chain in the development of cascade of multiple 
biochemical and vascular events in TBI, contributing to both severity and prognosis. Despite 
the lack of complete data and existing controversies, and the level of brain maturity, CBF 
changes in brain injury in both human and experimental research are similar: immediate 
drop after injury onset (hypovolemia), recovery up to initial levels on following days, and 
further developement of hyperperfusion and vasospasm.  
In normal condition the cerebral circulation has the ability to maintain a stable CBF over a 
wide range of cerebral perfusion pressures (CPP); this phenomenon is designated as 
cerebral autoregulation and mainly represents the capacity of the brain’s resistance vessels 
to dilate in response to a decrease in CPP or to constrict in response to an increase in CPP. 
The caliber changes of the autoregulatory vessels are mediated by myogenic, metabolic, or 
neurogenic mechanisms (Brownlee & Langille, 1991; Bryan et al., 1995; Busto et al., 1997). 
The smaller arterioles dilate proportionately more than larger arterioles at a mean arterial 
blood pressure below physiological levels (Ellis et al., 1979; Engelborghs et al., 2000). 
However, larger arterioles tend to be more responsive than smaller arterioles at normal and 
increased levels of arterial pressure (Engelborghs et al., 2000). The other findings associated 
with CBF reduction at early time points after TBI is the increased cytokine expression and 
production, however the role of their activity changes is not clear yet (Ahn et al., 2004). 
Destruction of cortical regions could effectively produce deafferentation in subcortical and 
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cortical target regions resulting in reduced energy requirement and metabolic rates. The 
blood vessel can participate in the regulation of blood flow by changing its own structure, a 
process known as vascular remodeling (Langfitt et al., 1977; Langille et al., 1989; Brownlee & 
Langille, 1991). It is characterized by changes in vessel wall thickness and organization, 
which allows the vasculature to cope with physiological or pathological conditions. The 
processes involved in vascular remodeling include cellular hypertrophy and hyperplasia, as 
well as enhanced protein synthesis (Golding et al., 1999; Golding, 2002). So, the reduction of 
regional CBF immediately after severe TBI onset could be explained by the changing 
histochemistry of the brain and caliber of the vessels, but the symmetric changes in CBF in 
immature and mature brain on day 7 demand further investigations and understanding. 
The most probable reason for it could be the reverse effect of changed levels of vasoactive 
agents due to impairment of cerebral autoregulation, or expressed production of 
vasoconstrictors. Clinical studies show the presence of vasospasm on days 7-9 (Hlatky et al., 
Robertson, 2003; Voulgaris et al., 2005) and it shows increased blood flow in the main 
arteries of the brain, Willis circle, whenever the microcirculation in cerebral cortex could be 
different and altered due to local conditions.  
Being an influent factor in outcomes of TBI, cortical perfusion is not the determinant of 
increased vulnerability of immature to neurotrauma.  
CBF must be monitored in TBI, as an important participating factor in pathophysiology, 
strong predictor of prognosis and a tool to prevention of primary and secondary ischemia.  
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cortical target regions resulting in reduced energy requirement and metabolic rates. The 
blood vessel can participate in the regulation of blood flow by changing its own structure, a 
process known as vascular remodeling (Langfitt et al., 1977; Langille et al., 1989; Brownlee & 
Langille, 1991). It is characterized by changes in vessel wall thickness and organization, 
which allows the vasculature to cope with physiological or pathological conditions. The 
processes involved in vascular remodeling include cellular hypertrophy and hyperplasia, as 
well as enhanced protein synthesis (Golding et al., 1999; Golding, 2002). So, the reduction of 
regional CBF immediately after severe TBI onset could be explained by the changing 
histochemistry of the brain and caliber of the vessels, but the symmetric changes in CBF in 
immature and mature brain on day 7 demand further investigations and understanding. 
The most probable reason for it could be the reverse effect of changed levels of vasoactive 
agents due to impairment of cerebral autoregulation, or expressed production of 
vasoconstrictors. Clinical studies show the presence of vasospasm on days 7-9 (Hlatky et al., 
Robertson, 2003; Voulgaris et al., 2005) and it shows increased blood flow in the main 
arteries of the brain, Willis circle, whenever the microcirculation in cerebral cortex could be 
different and altered due to local conditions.  
Being an influent factor in outcomes of TBI, cortical perfusion is not the determinant of 
increased vulnerability of immature to neurotrauma.  
CBF must be monitored in TBI, as an important participating factor in pathophysiology, 
strong predictor of prognosis and a tool to prevention of primary and secondary ischemia.  
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Brain Injury: Region Specific Tissue Damage, 
Hemodynamic Changes and Axonal Injury  
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1. Introduction 
In this chapter we describe magnetic resonance imaging (MRI) findings in a rat model of 
traumatic brain injury (TBI). Although studied in a rodent model, these findings correspond 
closely to those seen in patients. The experimental study setup allows mapping of the 
spatio-temporal interrelations of different pathological features in the injured brain as well 
as correlation of non-invasive MRI results with tissue histochemistry data. We combine the 
information provided by some selected MRI techniques to characterize the interplay 
between structural and hemodynamic changes.  
1.1 Non-invasive imaging and animal models are needed for understanding the 
complex and progressive brain alterations that occur after traumatic brain injury (TBI)   
TBI is a devastating disease with a variety of cognitive and motor function deficits that 
manifest from immediately after the impact and even up to several years later. The 
mechanisms of TBI are complex and there is a great unmet medical need to find 
neuroprotective treatments. Primary TBI damage is caused by the shear forces of the impact 
itself, which initiates ionic, molecular, and cellular alterations within seconds (McIntosh et 
al., 1994; Rink et al., 1995) followed by immediate cytotoxic edema and later vasogenic 
edema (Faden et al., 1989). Thereafter, the secondary injury begins to develop and continues 
to worsen for days, months, or even years. The neurodegenerative cascades of secondary 
injury are composed of complex combinations of cellular and metabolic alterations 
(Pitkänen et al., 2009). The cortical contusion site suffers most, but other cortical areas and 
sub-cortical gray matter regions are exposed to the destructive cascades as well. The impact 
forces stretch the white matter tract network and adjacent vasculature, which causes 
microbleeds within the white matter bundles. These microbleeds are one early indicator of 
diffuse axonal injury (DAI), which involves progressive demyelination and axonal damage 
throughout the brain. DAI is recognized as a key factor in the consequential progressive 
cognitive impairment. Histological studies of TBI report the co-occurrence of chronic 
inflammation, glial hypertrophy, and axonal injury (Lenzlinger et al., 2001; Morganti-
Kossmann et al., 2002; Soares et al., 1995). We know that eventually the combination of these 
gray matter and white matter associated cascades leads to functional disabilities including 
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motor impairment, cognitive decline, emotional disturbance, or epilepsy (Kharatishvili et al., 
2006; Thompson et al., 2005), but the exact mechanisms remain unrevealed. 
Animal studies permit control of the inter subject variability, elimination of environmental 
un-known factors, long-term follow-up of the same subject, multimodal testing, and 
accurate correlation of radiological, behavioural, histological and molecular findings. The 
following chapter focuses on describing the multimodal MRI findings in a rat model of lateral 
fluid percussion injury (LFPI) induced TBI, which is the most widely used and best 
characterized experimental model of human closed head injury (Kharatishvili et al., 2006; 
Thompson et al., 2005).  
Magnetic resonance imaging (MRI) methods offer a variety of approaches to study the 
different features of brain pathologies non-invasively. Particularly, in complex nervous 
system diseases that progress slowly and carry unknown mechanisms, the application of 
multimodal MRI techniques that target different underlying phenomena can provide crucial 
information about the spatio-temporal developments of the tissue damage and thereby 
provide added insights into the disease mechanisms. 
2. Multimodal MRI of the injured brain: Access to morphology and tissue 
atrophy, transient edema, neurodegeneration, white matter damage, 
intracerebral hemorrhages and hemodynamics 
2.1 Characterization of damage extent and region specific pathological features                
MRI has an important role after head injury in detecting the primary lesion, tissue atrophy 
and lysis, microbleeds and hematomas, transient oedema coverage and other morphological 
features. In particular, ultra high magnetic fields (such as 7 T – 16 T) can access the fine 
details in cortical and sub-cortical structures and map the entire brain of a mouse in, for 
example, a resolution of tens of micrometers. Clinical scanners (1.5 T - 3 T) are able to pick 
up the same features in patients at the sub-millimeter scale. Figures 1 and 2 demonstrate the 
extent and sparse distribution of pathological morphological MRI findings post 
experimental TBI and therefore stress the importance of both the whole-brain coverage and 
high resolution agenda in imaging. 
In the lateral fluid percussion injury rat model, the direct damage caused by the impact 
forces (pressure and shear stress) depends upon the impact pressure and exact direction. 
Figures 1 and 2 show example cases of severe injury caused by higher than 3 atm fluid 
mediated pressure. Figure 1 shows how the atrophy gradually worsens at 3 hours, 3 days, 9 
days, 23 days, 2 months, 3 months and 6 months after injury in one representative animal. 
Figure 2 shows a higher resolution image set of another example animal at 2 months post 
injury and how the hematomas, atrophy and calcifications extend through the brain rostro-
caudally. Immediately after impact the integrity of the blood brain barrier (BBB) is 
compromised both in gray matter at the contusion site and inside/next to major white 
matter tracts that are exposed to and transduce the mechanical shear forces. This creates 
hematomas in cortical gray matter at the contusion site and microbleeds along more distal 
white matter bundles. Thereafter, the contusion site and ipsilateral surrounding regions 
suffer from transient edema (hyperintense, swollen cortical area in Figure 1, visible already 
at 3 hours, maximal at 3 days and partially resolving after 9 days). The impact launches 
destructive cellular cascades, and the area of neurodegeneration and subsequent atrophy 
can be first identified at the core of the contusion site as very high intensity (i.e. high free 
water content) T2 weighted signal. The tissue degradation area expands from 23 days post 
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injury onwards and is called here ‘the focal lesion’. At later time points a glia scar is found to 
be outlining this cerebrospinal fluid filled cavity. Macroscopically, it is evident that the 
hippocampus ipsilaterally to the impact is deformed as atrophy progresses. Microscopically, 
very pronounced and well described loss of hilar interneurons has been reported in this 
model (Lowenstein et al., 1992; Hunt et al., 2011). In long follow-up studies of rats, repeated 
MRI scans have shown that the atrophy volume continues to increase up to 6 months post 
injury, which correspond to decades in humans (when comparing the relative age). 
 
 
Fig. 1. Progressive atrophy mapped by non-invasive MRI. T2 weighted MRI made at a 4.7 T 
scanner. Long-term follow-up studies of the LFPI rat model for TBI demonstrate how tissue 
atrophy continues until 6 months. This is one time series from the same animal imaged from 
3 hours to 6 months post-injury. Sub-acute progression continues for over 2 months and a 
‘plateau’ state is reached 6 months post-injury. The corresponding time scale for humans 
could be from years to decades. (Immonen et al., 2009b) 
 
 
Fig. 2. T2/T2* weighted images of a rat brain after TBI. The high resolution achievable in an 
ultra high 9.4 T magnetic field with small animal models characterizes the morphological 
brain pathology in detail. Left: In vivo MRI of a living mouse at 5 weeks after fluid 
percussion injury: a series of transverse images showing every fifth slice of 200 µm-thick 
slices that cover the entire brain (in-plane resolution 70*70 µm). Right: Ex vivo MRI of an 
intact, fixed rat brain 12 weeks post injury acquired at 50*50*60 µm resolution, coronal view. 
Anatomical high resolution MRI demonstrates the extent of atrophy (tissue lysis at the 
primary lesion site and enlargement of ventricles, cerebrospinal fluid appears bright), 
hematomas and microbleeds (white arrows) and thalamic calcifications (black arrows) 
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The literature concerning clinical and experimental MRI findings as well as histological 
correlates after TBI shows good compatibility with our data. In patients, intracerebral 
hemorrhage, lesion and edema formation at the acute phase are common clinical MRI 
findings (Caroli et al., 2001; Kurth et al., 1994; Morais et al., 2008; Scheid et al., 2007). Axonal 
damage following TBI has been frequently detected using diffusion tensor imaging (DTI) 
and the changes in diffusion anisotropy have been reported in both acute and chronic TBI 
patients (Sidaros et al., 2008).   
In experimental studies, MRI findings resemble the clinical findings with accelerated 
temporal progression. MRI alterations associated with edema and hemorrhage have been 
reported (Graham et al., 2000b; Iwamoto et al., 1997) and axonal damage has been linked to 
changes in diffusion MRI (Mac Donald et al., 2007). Studies in rats have described prolonged 
relaxation times due to increased water content and decreased cell density. For example, the 
hyperintensity in T2 weighted images has been used to show edema, neuronal loss or, the 
consequence of tissue atrophy and partial volume effect. The hippocampal T2 relaxation 
time has been reported to increase during the first 7 days after TBI induced by controlled 
cortical impact (Obenaus et al., 2007). A 3 month follow-up showed enlarged ventricles, 
cisterns, and that the necrotic tissue in the primary contusion site was absorbed and 
replaced by cerebrospinal fluid (Iwamoto et al., 1997). Diffusion weighted imaging has 
shown decreased apparent water diffusion (ADC) acutely (<24 hours) after TBI followed by 
increased diffusion days or weeks after TBI (Albensi et al., 2000; Obenaus et al., 2007; 
Onyszchuk et al., 2007; Van Putten et al., 2005; Vink et al., 2001).  
Histological studies in rat models have verified these aforementioned MRI findings and the 
robust cellular loss and cavity formation in the primary cortical contusion site during the 
early weeks post-injury, the degeneration has been found to be selective for certain cell 
types and brain regions (Conti et al., 1998; Cortez, McIntosh, Noble 1989a; Hallam et al., 
2004; Raghupathi et al., 2002; Rink et al., 1995; Sato et al., 2001) and it has been demonstrated 
to go on up to 1 year (Bramlett et al., 1997; Pierce et al., 1998; Smith et al., 1997).  
2.2 Progressive brain alterations: Quantitative mapping of relaxation properties  
Slow degradation and plastic neuronal processes after trauma may not show in anatomical 
images in their early phase but they cause alterations in magnetic relaxation properties of 
tissue locally and can thereby be detected and followed by quantitative MRI. Particularly 
the gray matter areas surrounding the primary contusion site appear visually completely 
normal in conventional anatomical images (both in T2 or T1 weighted MRI) but the 
quantitative mapping is sensitive enough to pick out the regions that are undergoing 
microstructural changes. Figure 3 shows how the perifocal area and ipsilateral hippocampus 
can appear healthy initially and then later display increased relaxation and diffusion values 
at 23 days post-injury.  Only a 5-10% change in absolute relaxation and diffusion values in 
perilesional cortical regions at the sub-acute phase (secondary increase after resolution of 
edema) post injury reveals regions that later progress to atrophy. Maps of T1, T2, T1ρ and 
diffusion (ADC/Dav) parameters discern regions of irreversible and reversible tissue 
damage, and are sensitive enough to monitor the progression and potential treatment 
responses in different brain regions. Both the magnitude and the temporal pattern of the 
observed MRI changes differ between the primary lesion site (irreversible damage) and in 
the perilesional regions (tissue at risk but potentially salvageable), including the 
hippocampus. Figures 3 and 4 describe the alteration pattern of quantitative MRI data in the 
acute phase 3 hours post-trauma associated with the immediate mechanical consequences of  
MRI Characterization of Progressive Brain Alterations After Experimental Traumatic  
Brain Injury: Region Specific Tissue Damage, Hemodynamic Changes and Axonal Injury 195 
 
Fig. 3. Early progression of Dav, T2 and T1ρ in the lesion (left column), in the perifocal area 
(middle column) and in the ipsilateral hippocampus (right column). Graphs compare the 
quantitative relaxation and average diffusion values from TBI and sham groups at 3 hours, 3 
days, 9 days and 23 days after TBI induction. Data points are group averages from region of 
interest (ROI) analysis of quantitative maps. Each ROI shows a characteristic pattern. The 
lesion: Dav increased rapidly in the lesion area starting from day 3. Both T2 and T1ρ also 
increased steadily, and T1ρ was significantly elevated already at 3 hours after TBI induction. 
The perifocal area (i.e. ipsilateral cortex excluding the lesion): Dav dropped acutely (3 hours) 
after TBI. T2 and T1ρ show a transient peak at day 3 post-TBI, but unlike T2, T1ρ remained 
elevated still at day 9. The ipsilateral hippocampus: Dav dropped acutely (3 hours) after TBI 
and increased 23 days later. Both T2 and T1ρ peaked at day 3 post TBI and were elevated at 
day 23, but T2 recovered at day 9 while T1ρ remained elevated. Differences between groups 
are indicated as **, p<0.01 and *, p<0.05 (Mann Whitney post hoc test), and the differences 
between time points as #, p<0.05 and ##, p<0.01 (Wilcoxon post hoc test). Note that the scale 
on lesion graphs differs from that on the perifocal and hippocampus graphs. (Immonen et 
al., 2009ab) 
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impact injury and cytotoxic edema (1), in the sub-acute phase 1-5 days after trauma 
associated with some recovery processes and vasogenic edema (2), during secondary injury 
cascades associated with neurodegeneration, gliosis and inflammation (and more) that 
become detectable around 2 weeks after trauma by quantitative MRI and show persistent 
progression up to 6 months (3), and in the chronic, apparently stable stage 7-12 months after 
trauma (4). Note again, that this time scale in rats can correspond to a period of tens of years 
in patients.  
 
 
Fig. 4. Schematic graph of the temporal development of average diffusion (Dav), T2 and T1ρ 
relaxation times over a 1 year period. A) Note the differences in both the magnitude and the 
temporal pattern at the lesion core (irreversible fast damage, values increase by 100-400%) 
compared to the perilesional region (initial fluctuating values due to transient edema, 
secondary increase with slow progression, potentially reversible, values increase 5-10%). B) 
When comparing the two main regions at risk: perifocal cortex and ipsilateral hippocampus, 
the patterns are very similar. The observation that the hippocampus displays somewhat 
higher secondary alterations (values increase 10-20%) than the perifocal cortical region may 
partly be a consequence of the perifocal ROI selection (the ROI may include some well 
preserved cortical tissue). In both cases, the Dav and T1ρ seem to be more sensitive than T2, 
and when focusing on the time point around day 9 (edema is resolving), the only parameter 
that does not appear normal is T1ρ. 
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Thus, quantitative MRI has the capability to probe two important characteristics of TBI. 
First, it is sensitive enough to detect that gray matter alterations continued for several 
months. While the volume of the primary focal lesion continued to expand for 3 months, the 
quantitative MRI observations showed progressive changes at the primary cortical lesion 
site for 6 months. In the perifocal region and in the hippocampus the slow secondary 
increase in quantitative Dav, T2 and T1ρ continued steadily for the first 2-3 months 
(significant further increase in the hippocampus until 3 months and in the perifocal area 
until 2 months). 
Secondly, the quantitative MRI is specific enough to discern the irreversible damage and 
tissue at risk. In the lesion site the drastic increase of all T2, T1ρ and Dav, detectable already 3 
hours or 3 days post-injury and rapidly increasing henceforth, was several fold in 
magnitude as compared to the more subtle alterations detected in the perilesional regions. 
For example, when considering the situation 9 days after injury, the observed changes at 
that time in the perilesional regions were maximally +8% (for T1ρ) or even undetectable (for 
T2 and Dav) while in the primary lesion the irreversible damage was revealed by a 70% 
increase in diffusion, 54% increase in T2, and 80% increase in T1ρ. Thereafter, the lesion 
values rose up to the values equal to those in CSF, that is, the tissue was absorbed and the 
cavity filled with CSF was generated (Fig. 4). In addition to the magnitude differences the 
temporal pattern of MRI changes differed between lesion and surroundings. In the primary 
lesion the T2, T1ρ and Dav values simply shot up, continuing the rapid irreversible increase, 
while in the perilesional regions (the perifocal cortical area and the hippocampus) the values 
first displayed acute edema related increase, recovery, and then a delayed, slow, persistent 
secondary increase. The magnitude of quantitative MRI contrast parameter deviations 
during the delayed secondary increase remained around 10-13% for the relaxation times in 
the ipsilateral hippocampus (4-7% in the contralateral hippocampus and 3-9% in the 
perifocal area) and around 7-15% for the diffusion in the ipsilateral hippocampus (6-8% in 
the contralateral hippocampus and 4-6% in the perifocal area). (Immonen et al., 2009ab)  
2.3 Diffuse axonal injury  
After studying the visually detectable morphological and more subtle gray matter 
alterations post-TBI, the next major subject of interest is the white matter integrity. White 
matter shear injury and myelin damage can be selectively probed by MRI. One MRI 
technique that provides information about diffuse axonal injury (in addition to diffusion 
tensor imaging and magnetization transfer imaging that are not discussed here) is 
susceptibility weighted imaging (SWI) that has been reported to detect diffuse axonal injury 
associated microbleeds after TBI, detailed vascular properties, fine structure of lesions and 
myelin content related features (particularly in high > 3Tesla field strengths) (Haacke, 2004; 
Akiyama, 2009). It also distinguishes calcifications due to their diamagnetic properties. SWI 
utilizes the phase information of MR images in combination with magnitude information, 
but this phase content can be presented separately to provide phase contrast images or 
phase maps. This phase contrast is one hot topic in current experimental MRI method 
development, and even though it is easily transferable to clinical scanners, it is not yet in 
general use for patient care. Figure 5 shows some recent unpublished preliminary data (by 
Immonen) with a very robust phase mapping approach in the fluid percussion injury rat 
model for TBI, and Figure 6 compares the MRI magnitude and phase information to tissue 
myelin histochemistry of brain sections. 
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compared to the perilesional region (initial fluctuating values due to transient edema, 
secondary increase with slow progression, potentially reversible, values increase 5-10%). B) 
When comparing the two main regions at risk: perifocal cortex and ipsilateral hippocampus, 
the patterns are very similar. The observation that the hippocampus displays somewhat 
higher secondary alterations (values increase 10-20%) than the perifocal cortical region may 
partly be a consequence of the perifocal ROI selection (the ROI may include some well 
preserved cortical tissue). In both cases, the Dav and T1ρ seem to be more sensitive than T2, 
and when focusing on the time point around day 9 (edema is resolving), the only parameter 
that does not appear normal is T1ρ. 
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Thus, quantitative MRI has the capability to probe two important characteristics of TBI. 
First, it is sensitive enough to detect that gray matter alterations continued for several 
months. While the volume of the primary focal lesion continued to expand for 3 months, the 
quantitative MRI observations showed progressive changes at the primary cortical lesion 
site for 6 months. In the perifocal region and in the hippocampus the slow secondary 
increase in quantitative Dav, T2 and T1ρ continued steadily for the first 2-3 months 
(significant further increase in the hippocampus until 3 months and in the perifocal area 
until 2 months). 
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tissue at risk. In the lesion site the drastic increase of all T2, T1ρ and Dav, detectable already 3 
hours or 3 days post-injury and rapidly increasing henceforth, was several fold in 
magnitude as compared to the more subtle alterations detected in the perilesional regions. 
For example, when considering the situation 9 days after injury, the observed changes at 
that time in the perilesional regions were maximally +8% (for T1ρ) or even undetectable (for 
T2 and Dav) while in the primary lesion the irreversible damage was revealed by a 70% 
increase in diffusion, 54% increase in T2, and 80% increase in T1ρ. Thereafter, the lesion 
values rose up to the values equal to those in CSF, that is, the tissue was absorbed and the 
cavity filled with CSF was generated (Fig. 4). In addition to the magnitude differences the 
temporal pattern of MRI changes differed between lesion and surroundings. In the primary 
lesion the T2, T1ρ and Dav values simply shot up, continuing the rapid irreversible increase, 
while in the perilesional regions (the perifocal cortical area and the hippocampus) the values 
first displayed acute edema related increase, recovery, and then a delayed, slow, persistent 
secondary increase. The magnitude of quantitative MRI contrast parameter deviations 
during the delayed secondary increase remained around 10-13% for the relaxation times in 
the ipsilateral hippocampus (4-7% in the contralateral hippocampus and 3-9% in the 
perifocal area) and around 7-15% for the diffusion in the ipsilateral hippocampus (6-8% in 
the contralateral hippocampus and 4-6% in the perifocal area). (Immonen et al., 2009ab)  
2.3 Diffuse axonal injury  
After studying the visually detectable morphological and more subtle gray matter 
alterations post-TBI, the next major subject of interest is the white matter integrity. White 
matter shear injury and myelin damage can be selectively probed by MRI. One MRI 
technique that provides information about diffuse axonal injury (in addition to diffusion 
tensor imaging and magnetization transfer imaging that are not discussed here) is 
susceptibility weighted imaging (SWI) that has been reported to detect diffuse axonal injury 
associated microbleeds after TBI, detailed vascular properties, fine structure of lesions and 
myelin content related features (particularly in high > 3Tesla field strengths) (Haacke, 2004; 
Akiyama, 2009). It also distinguishes calcifications due to their diamagnetic properties. SWI 
utilizes the phase information of MR images in combination with magnitude information, 
but this phase content can be presented separately to provide phase contrast images or 
phase maps. This phase contrast is one hot topic in current experimental MRI method 
development, and even though it is easily transferable to clinical scanners, it is not yet in 
general use for patient care. Figure 5 shows some recent unpublished preliminary data (by 
Immonen) with a very robust phase mapping approach in the fluid percussion injury rat 
model for TBI, and Figure 6 compares the MRI magnitude and phase information to tissue 
myelin histochemistry of brain sections. 
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Fig. 5. A) T2/T2* weighted magnitude images of a representative rat made one month after 
lateral fluid percussion injury, and B) corresponding phase maps. The contrast in the phase 
maps highlights the major white matter tracts (positive frequency shift, white arrowheads) 
and picks out dark hematomas and microbleeds (negative frequency shift, black 
arrowheads), while the contrast in surrounding tissue and accross ventricles appears very 
flat. The main magnetic field B0 orientation is through the plane and the shown axial slices 
are 0.2 mm thick. 
2.4 From morphology to function - Hemodynamic alterations after TBI            
Autoregulation of brain perfusion is impaired after traumatic brain injury. The immediate 
and focal effects of the impact pressure and stretching of the vessels cause tears and BBB 
leakage. Blood clots can form and they may cause occlusions that seize the delivery of blood 
to some regions, which causes ischemia. Both the acute and sub-acute tissue edema and the 
later developing hydrocephalus can apply extra compression locally or through elevated 
intracranial pressure. The later changes in regional circulation can be beneficial if they are a 
controlled physiological response to the increased metabolic demands of the recovery 
processes. However, if the vascular system is unable to respond to these needs then the 
situation further deteriorates and can launch adverse cascades. The causal relations and 
exact mechanisms of autoregulation failure, structural tissue degradation, and functional 
brain injury development over the course of TBI are still largely unknown. 
A valuable MRI method that probes cerebral hemodynamics non-invasively is arterial spin 
labeling (ASL) technique. This technique yields cerebral blood flow (CBF) maps. In ASL, no 
exogenous contrast agent is used because the protons in the blood-stream are labeled by an 
180° inversion RF-pulse applied at a location covering the incoming vasculature upstream 
from the level of interest. This technique determines the perfusion rate by quantifying the 
labeled portion of blood that moves into/through the region of interest (Williams et al., 1992). 
In severely brain injured patients three distinct cerebral hemodynamic phases have been 
recognized based on cerebral blood flow (CBF) changes (Martin et al., 1997): hypoperfusion 
(decreased CBF during the day of the injury), hyperemia (i.e. increased perfusion in the 
tissue capillary bed and vasculature during the next 3 days), and vasospasm that invokes a 
fall in the CBF that lasts for the next two weeks. Particularly, decreased CBF acutely after 
impact has been documented (Kelly et al., 1996; Kelly et al., 1997; Martin et al., 1997). Long 
term deviations from the normal CBF level have been depicted, and even patients with 
symptomatic mild traumatic brain injury but without any other abnormal MRI findings 
have shown persistent regional hypoperfusion (Bonne et al., 2003).  
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Fig. 6. Histology of the myelinated structures and how they appear in MRI: findings in a TBI 
rat model. T2/T2* weighted contrast of fixed trauma brain and myelin stained brain sections 
of the same animal are shown on the left. The two regions selected (dashed squares on top 
of T2/T2* weighted MRI) are highlighting A: microbleeds within white matter and associated 
myelin damage in corpus callosum and external capsule ipsilaterally (A.i) as compared to 
the contralateral corresponding region (A.c). B: Loss of thalamic white matter and myelin 
structures and formation of calcifications ipsilaterally (B.i) while no myelin pathology 
occurs contralaterally (B.c). The right side column of the figure shows an in vivo phase map 
(PHASE) of the same situation and demonstrates the differences in frequency shift between 
closely located white matter bundles (dashed square in phase map and corresponding 
region in myelin stained section (C), note the higher frequency shift in cingulum (Cg), dorsal 
hippocampal commissure (dhc), and external capsule (ec) as compared to the corpus 
callosum (cc) in between them). The phase contrast reflects the myelin content but depends 
also on the structure orientation in respect to the main magnetic field B0 (here, B0 orientation 
is through the plane). Abbreviations of indicated white matter bundles: Cg, cingulum; cc, 
corpus callosum; ec, external capsule; dhc, dorsal hippocampal commissure. Scale bar 
equals 1 mm. 
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Hemodynamic disturbances found in experimental models of TBI include local CBF 
decrease from 15 minutes to 4 hours post-injury close to the LFP site (Ginsberg et al., 1997; 
Muir et al. 1992; Ozawa et al., 1991) and transient hypoperfusion also in the contralateral 
hemisphere (Pasco et al., 2007). Perfusion deficits after traumatic impact can lead to a local 
ischemic state of the tissue where the oxygen and glucose delivery is so severely impaired 
that it causes disturbances in energy metabolism and mitochondrial function. Dietrich and 
collaborators report severe ischemia (i.e., mean local CBF < 25 ml/100g/min) after severe 
TBI (fluid percussion rat model) within lateral parietal cortex, moderate reductions in CBF 
throughout the traumatized hemisphere, including the frontal and occipital cortices, 
hippocampus, thalamus, and striatum, along with milder decreases in CBF also throughout 
the contralateral cerebral cortex. Their parallel histological studies report subarachnoid 
hemorrhage, blood-brain barrier (BBB) breakdown overlying the pial surface and superficial 
cortical layers of the injured hemisphere, focal leakage at the gray-white matter interface of 
the lateral cortex, petechial hemorrhages associated with small venules and focal platelet 
accumulation. (Dietrich et al., 1994a, 1994b, 1996, 1998). 
Although the initiation mechanisms of TBI are more complex than those of ischemia the 
thresholds for tissue perfusion reductions and adjacent cellular consequences are common 
for both. The tissue in the ischemic core region suffers irreversible damage when the blood 
supply drops below a threshold level of around 10-15 ml/100g/min, corresponding to the 
anoxic cell depolarization (Hossmann and Schuier 1980), and is not restored immediately. 
The surrounding region, the ischemic penumbra, is hemodynamically compromised and 
suffers from protein synthesis inhibition [CBF between 35-55 ml/100g/min] and impaired 
glucose metabolism [CBF 22-35 ml/100g/min] which promotes anaerobic glycolysis, and 
lactic acidosis (Allen et al., 1993; Obrenovitch et al., 1988). Once the CBF declines below 20 
ml/100g/min the adenosine triphosphate (ATP) levels reduce markedly and functional 
impairment (cessation of evoked potentials and electroencephalographic (EEG) activity) 
follows. The ischemic penumbra is hemodynamically defined as the region between this 
functional impairment and anoxic depolarisation, thus it is salvageable if the blood supply is 
restored acutely. The aforementioned perfusion thresholds are estimates and the factors 
such as the variability between measurement techniques, tissue types and animal species 
must be kept in mind (Baron 2001; Takasawa et al., 2008). Regarding the ischemic state  
of the tissue, perfusion findings are complemented by data from diffusion studies. Diffusion 
values reduce about 40-50% within hours after severe focal ischemia in experimental 
models, while thereafter some normalization of values precedes a gradual secondary 
increase in diffusion (Hoehn-Berlage et al., 1995). The diffusion-perfusion mismatch is  
a recognized marker for the ischemic penumbra. The mismatch means that the acute 
diffusion decrease indicates the ischemic core and the region of reduced perfusion extends 
further to include the penumbra (Baird et al., 1997; Finelli et al., 1992; Pierce et al., 1997; 
Roberts et al., 1993; Sorensen et al., 1996). Local ischemia can be one consequence of 
traumatic impact, due to the vascular damage at the primary contusion site or due to blood 
clots, but otherwise the role of perfusion and blood supply changes in traumatic head injury 
mechanisms are largely unknown. 
Our recent studies in the rat LFPI rat model have highlighted region specific CBF alterations 
at acute, sub-acute and chronic time points post-injury. Blood flow alterations vary 
remarkably between perilesional, hippocampal, thalamic, and contralateral areas. 
Importantly, the animal data shows temporal developments of the autoregulation status 
that are much like those seen in TBI patients. The three observed phases of the 
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hemodynamic profile around the lesion are acute hypoperfusion, normalization, and 
secondary hypoperfusion. The CBF map series in Figures 7 and 8 display the regional 
perfusion patterns (Hayward et al., 2010). 
 
 
Fig. 7. T2 weighted images (top row) and cerebral blood flow (CBF) maps measured by 
arterial spin labeling (bottom row) from a healthy (left) and chronic trauma animal  
(right, 8 months post LFPI). Note hypoperfusion in the ipsilateral cortex surrounding the 
cerebrospinal fluid filled cavity (lesion & hydrocephalus) and hyperperfusion in the 
ipsilateral thalamus in the chronic TBI rat. Scale bar equals 2 mm. (data by Hayward, see 
further details in Hayward et al., 2010) 
It has been shown that immediately after TBI the cytotoxicity leads to increased cerebral 
glucose utilization while CBF remains low (Ginsberg et al, 1997; Richards et al, 2001). After 
TBI the decreased CBF results from vasoconstriction induced by endothelium-derived 
signaling (reviewed in Golding, 2002). This may explain the initial cerebral hypoperfusion 
we observed after experimental TBI induction. Later, cellular efforts to reestablish ionic 
gradients (Hovda et al, 1995) lead to hyperglycolysis (Martin et al, 1997) and this may lead 
to hyperemia. Furthermore, gliosis begins ~24 hours after TBI (Gehrmann et al, 1995; 
Graham et al, 2000), and demands energy, which may in part be the reason for the recovery 
of CBF observed at this time point in many regions. Thereafter, vasospasm (Martin et al, 
1997) or vasoconstriction caused by delayed vasogenic edema (Rangel-Castilla et al, 2008) 
may lead to the second hypoperfusion phase we observed.  
We compared CBF findings with the immunohistochemistry of the vascular reorganization 
and density alterations that may be due to post-traumatic  angiogenesis (RECA-1 staining). 
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Each of the investigated brain areas had a unique pattern of vascular abnormalities, but they 
did not explain the observed MRI CBF results (Figures 7 and 8). At 8 months after TBI in the 
perilesional cortex, chronic hypoperfusion co-occurred with increased vascular density, while 
in the ipsilateral hippocampus we observed mild hypoperfusion despite no blood vessel 
changes. Differently again, hyperperfusion the ipsilateral thalamus was associated with a 
considerably increased vascular density. Although regional CBF has long been suggested to 
correlate positively with regional blood vessel density in healthy tissues (Gross et al., 1986), 
these results indicated very few links between CBF and chronic vascular reorganization after 
trauma. The fact that we found that the lower the CBF in the perilesional cortex, the higher the 
vascular density implies that cortical angiogenesis after TBI may not provide new vessels with 
sufficient vascular integrity to recover the chronic perfusion deficit. Due to the mixed 
cerebrovascular results from the thalamus and hippocampus, chronic alterations in CBF 8 
months post-injury could not be attributed to changes in vascular density.  
We have found even fewer links between vascular reorganization and CBF in acute and sub-
acute phases after TBI. We reported an acute loss of blood vessel density and subsequent 
increase between 6 hours and 2 weeks after TBI in the stratum oriens and perilesional cortex. 
In the perilesional cortex, CBF measures did not correlate with vessel density and it is possible 
that newly formed vessels may not be fully functional at 2 weeks after TBI. A recent 
immunohistochemistry study by Park and colleagues (Park et al., 2009) demonstrated cortical 
blood vessel loss 24 hours after LFPI, which recovered by 2 weeks in moderately injured rats 
but not in severely injured rats (the TBI rats in Hayward’s study all have severe injury). We 
also observed hypoperfusion in regions without significant vessel loss, such as the thalamus. 
 
 
Fig. 8. CBF maps of a control rat (top left) and time series of a representative TBI rat during 2 
weeks follow-up after LFPI induction. In the perilesional cortex around the lesion, the flow 
alterations over time have three phases: acute decrease to 54% of the CBF in controls, 
recovery, and secondary decrease to 75% of control measures (solid arrows). The ipsilateral 
hippocampal (open arrows) CBF changes show a similar pattern, but secondary 
hypoperfusion appears sooner at 48 h. The ipsilateral thalamus suffers from acute 
hypoperfusion at 6 hours after injury (dashed oval) and displays hyperperfusion 2 weeks 
later in its subregions. (data by Hayward, see further details in Hayward et al., 2011) 
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3. Correlation of MRI findings with cognitive deficits and hyperexcitability: 
can early MRI predict behavioral outcome? 
It is of course essential to understand the cellular changes and histologically determined 
correlates that underlie the observed MRI abnormalities. But equally or even more 
important is the ability to use MRI as a direct predictor or marker for brain functionality. 
The morphological MRI findings, alterations in quantitative MR relaxation and diffusion 
properties and cerebral blood flow changes could all potentially have a role in predicting 
long-term TBI outcomes such as cognitive impairment, motor deficits or the development of 
epilepsy. The chance of head injury patients presenting with epilepsy later in life is 16% 
after moderate brain injury and may be as high as 53% after ballistics or blast injuries 
(Lowenstein 2009).  
In clinical head trauma studies, intracranial and intracerebral hemorrhages have been found 
to be associated with poor long-term outcome, as assessed with the Glasgow Outcome Scale 
(Chieregato et al., 2005). Increased diffusivity of white matter structures has been reported 
to correlate with later impairment of learning and memory functions (Salmond et al., 2006; 
Sidaros et al., 2008). Magnetization transfer ratio decrease in the corpus callosum and 
abnormal fractional anisotropy values in several major white matter tracts (obtained by 
techniques called magnetization transfer imaging and diffusion tensor imaging, 
respectively) are used to estimate the myelin loss and axonal injury. The severity of these 
DAI related changes have been found to correlate with cognitive recovery in mild TBI 
(Belanger et al., 2007). Herniation, due to a swollen ipsilateral hemisphere can be seen as 
midline shift in MRI and it has been listed as a risk factor for human post traumatic epilepsy 
(Pitkänen et al., 2011). Metting and colleagues reviewed the early MRI findings with 
predictive values for chronic outcome in mild-to-moderate head injury (defined by having 
Glasgow Coma Score > 8) (Metting et al., 2007). The list included the number of lesions 
(detected by a T2* weighted gradient echo technique), lesion size, perfusion abnormalities 
and reduced cerebral blood volume observed days to weeks (< 3 weeks) post-injury. These 
early findings could be linked to outcome at 3 to 12 months later.  
In experimental research, many of the factors contributing to long term outcome after brain 
injury can be controlled for and monitored. Our follow-up studies in the LFPI rat model 
have yielded many potential MRI surrogate markers for neurodegeneration, memory 
deficits and epileptogenesis. As outcome measures, the final atrophy extent 6 months post-
injury, spatial memory and learning ability tested in Morris Water maze 7 months post-
injury, and histopathological neuronal loss 12 months post-injury were assessed. At the 
chronic phase after TBI the animals displayed largely expanded lesion cavities, the 
ipsilateral hippocampal volume was decreased by 21%, the number of hilar neurons was 
decreased by 63% and the hippocampus related learning and memory performance was 
impaired in trauma animals. Non-invasive MRI was performed frequently over the course 
of disease progression. The lesion volume measured and the amount of intracerebral 
hemorrhage in the acute (3 hours) and sub-acute (3-23 days) phases after injury correlated 
with the final lesion extent 6 months later. The T1ρ increase in the perifocal area surrounding 
the lesion at 9 days post-injury correlated with the final cortical lesion volume. The edema 
related transient increase in T1ρ and T2 in the ipsilateral hippocampus 3 days post-injury 
correlated with the chronic volume reduction of the ipsilateral hippocampus and with the 
hilar neuron loss (in the dentate gyrus of the hippocampus) - and so did the T1ρ increase 9 
days post-injury. The delayed secondary increase 23 days post-injury in T1ρ, T2 and Dav in 
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In the perilesional cortex, CBF measures did not correlate with vessel density and it is possible 
that newly formed vessels may not be fully functional at 2 weeks after TBI. A recent 
immunohistochemistry study by Park and colleagues (Park et al., 2009) demonstrated cortical 
blood vessel loss 24 hours after LFPI, which recovered by 2 weeks in moderately injured rats 
but not in severely injured rats (the TBI rats in Hayward’s study all have severe injury). We 
also observed hypoperfusion in regions without significant vessel loss, such as the thalamus. 
 
 
Fig. 8. CBF maps of a control rat (top left) and time series of a representative TBI rat during 2 
weeks follow-up after LFPI induction. In the perilesional cortex around the lesion, the flow 
alterations over time have three phases: acute decrease to 54% of the CBF in controls, 
recovery, and secondary decrease to 75% of control measures (solid arrows). The ipsilateral 
hippocampal (open arrows) CBF changes show a similar pattern, but secondary 
hypoperfusion appears sooner at 48 h. The ipsilateral thalamus suffers from acute 
hypoperfusion at 6 hours after injury (dashed oval) and displays hyperperfusion 2 weeks 
later in its subregions. (data by Hayward, see further details in Hayward et al., 2011) 
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3. Correlation of MRI findings with cognitive deficits and hyperexcitability: 
can early MRI predict behavioral outcome? 
It is of course essential to understand the cellular changes and histologically determined 
correlates that underlie the observed MRI abnormalities. But equally or even more 
important is the ability to use MRI as a direct predictor or marker for brain functionality. 
The morphological MRI findings, alterations in quantitative MR relaxation and diffusion 
properties and cerebral blood flow changes could all potentially have a role in predicting 
long-term TBI outcomes such as cognitive impairment, motor deficits or the development of 
epilepsy. The chance of head injury patients presenting with epilepsy later in life is 16% 
after moderate brain injury and may be as high as 53% after ballistics or blast injuries 
(Lowenstein 2009).  
In clinical head trauma studies, intracranial and intracerebral hemorrhages have been found 
to be associated with poor long-term outcome, as assessed with the Glasgow Outcome Scale 
(Chieregato et al., 2005). Increased diffusivity of white matter structures has been reported 
to correlate with later impairment of learning and memory functions (Salmond et al., 2006; 
Sidaros et al., 2008). Magnetization transfer ratio decrease in the corpus callosum and 
abnormal fractional anisotropy values in several major white matter tracts (obtained by 
techniques called magnetization transfer imaging and diffusion tensor imaging, 
respectively) are used to estimate the myelin loss and axonal injury. The severity of these 
DAI related changes have been found to correlate with cognitive recovery in mild TBI 
(Belanger et al., 2007). Herniation, due to a swollen ipsilateral hemisphere can be seen as 
midline shift in MRI and it has been listed as a risk factor for human post traumatic epilepsy 
(Pitkänen et al., 2011). Metting and colleagues reviewed the early MRI findings with 
predictive values for chronic outcome in mild-to-moderate head injury (defined by having 
Glasgow Coma Score > 8) (Metting et al., 2007). The list included the number of lesions 
(detected by a T2* weighted gradient echo technique), lesion size, perfusion abnormalities 
and reduced cerebral blood volume observed days to weeks (< 3 weeks) post-injury. These 
early findings could be linked to outcome at 3 to 12 months later.  
In experimental research, many of the factors contributing to long term outcome after brain 
injury can be controlled for and monitored. Our follow-up studies in the LFPI rat model 
have yielded many potential MRI surrogate markers for neurodegeneration, memory 
deficits and epileptogenesis. As outcome measures, the final atrophy extent 6 months post-
injury, spatial memory and learning ability tested in Morris Water maze 7 months post-
injury, and histopathological neuronal loss 12 months post-injury were assessed. At the 
chronic phase after TBI the animals displayed largely expanded lesion cavities, the 
ipsilateral hippocampal volume was decreased by 21%, the number of hilar neurons was 
decreased by 63% and the hippocampus related learning and memory performance was 
impaired in trauma animals. Non-invasive MRI was performed frequently over the course 
of disease progression. The lesion volume measured and the amount of intracerebral 
hemorrhage in the acute (3 hours) and sub-acute (3-23 days) phases after injury correlated 
with the final lesion extent 6 months later. The T1ρ increase in the perifocal area surrounding 
the lesion at 9 days post-injury correlated with the final cortical lesion volume. The edema 
related transient increase in T1ρ and T2 in the ipsilateral hippocampus 3 days post-injury 
correlated with the chronic volume reduction of the ipsilateral hippocampus and with the 
hilar neuron loss (in the dentate gyrus of the hippocampus) - and so did the T1ρ increase 9 
days post-injury. The delayed secondary increase 23 days post-injury in T1ρ, T2 and Dav in 
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the ipsilateral hippocampus, which was already an indicator of the severity of the secondary 
injury cascades, correlated with the later hippocampal volume decrease at 6 months and 
with the final hilar neuron loss. This same delayed diffusion increase (in the ipsilateral 
hippocampus 23 days post-injury) correlated also with the long-term learning impairment 7 
months post-injury. Also, the severity of hemorrhage at the sub acute phase was indicative 
of long-term learning impairment. See the behavioural test and correlation details in 
Immonen et al., 2009a. Upon assessing the risk for posttraumatic epilepsy, we have shown 
that acute diffusion drop 3 hours post lateral fluid percussion injury has predictive value for 
seizure susceptibility one year later (Kharatishvili et al., 2007).  
The causal relationship between hemodynamic alterations and behavioral symptoms is still 
under investigation and the studies presented here, using arterial spin labeling technique for 
CBF mapping (Hayward et al., 2010), touched the surface by showing that enhanced seizure 
susceptibility post TBI was associated with reduced CBF in the ipsilateral hippocampus 
(r = 0.78, p < 0.05) and increased vascular density in the thalamus (r = 0.69, p < 0.05). Although 
the perilesional cortex may generate ictal activity after LFPI (D'Ambrosio et al., 2004, 2005, 
Kharatishvili et al. 2006), we did not find any association between the hypoperfusion or 
increased vascular density in the perilesional cortex and seizure susceptibility. This might be 
because injury to more caudal cortical areas associates with hyperexcitability, while the cortical 
regions close to the lesion may not be involved (Kharatishvili and Pitkänen 2010a). More 
importantly, we found that a reduction in the ipsilateral hippocampal CBF at 8 months after 
TBI was associated with increased seizure susceptibility at 9 months such that the lower the 
CBF, the higher the seizure susceptibility. Circuitry alterations and cerebrovascular responses 
in the hippocampus are common in experimental epilepsy and in epilepsy patients (Pitkänen 
and Lukasiuk 2009, Ndode-Ekane et al. 2010) and the ipsilateral hippocampus is involved in 
electrographic activity during spontaneous seizures after TBI  (Kharatishvili et al. 2006). 
Indeed, previous reports have used ASL together with other neuroimaging techniques to 
delineate the ictogenic zone (Rougier et al. 1999, Lim et al. 2008). Further studies are needed, 
however, to discern whether chronic hippocampal hypoperfusion after TBI can be used as a 
surrogate marker for epileptogenesis. 
Our study did not yield any correlations between CBF changes and memory and learning 
impairment, but poor performance in the Morris water maze was found to correlate with 
enhanced thalamic vessel density (r = -0.81, p < 0.01). The thalamus is often found to be 
damaged in moderate and severely injured TBI patients as well as in animal models (Pierce 
et al. 1998, Maxwell et al. 2004, 2006, Tollard et al. 2009, Little et al. 2010), but the role of the 
thalamic pathology in epileptogenesis after acquired etiologies like TBI is poorly understood 
(Bonilha et al. 2004, Blumenfeld et al. 2009). We also found that a high vessel density in the 
ipsilateral thalamus was associated with increased CBF and enhanced seizure susceptibility 
in injured rats. A recent clinical report measured increased thalamic CBF during secondary 
generalization of focal onset seizures (Blumenfeld et al. 2009). Still, one must be cautious 
with the interpretation of such clinical and preclinical correlations and keep in mind that in 
most of the cases it is still unclear whether the cerebrovascular sequelae is the cause or the 
consequence of abnormal neural activity. 
4. Conclusions 
This chapter introduced several different MRI techniques and how each of them aid in 
probing TBI pathology. Techniques target features at the micro- and macro size scales, gray 
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matter pathology, white matter injury, and hemodynamic disturbances. Non-invasive MRI 
has been demonstrated to be a highly sensitive and valuable tool in progressive brain 
disease research and care. The temporal pattern and magnitude of measured T2, T1ρ, Dav, 
and CBF changes varied substantially between brain regions highlighting how quantitative 
MRI can be used to differentiate the regions with risk of delayed secondary damage from 
those of continuously progressing irreversible damage or from the normal areas. 
Importantly, quantitative MRI can also identify how advanced the pathological processes in 
each region are, which is a major advantage in targeting treatments and following the 
treatment response. 
Considering the prognostic value of early MRI findings in evaluating long term outcomes, 
many of the promising singular MRI findings and their correlations with outcome are 
lacking in specificity, and thus we must continue to search for more robust MRI markers. In 
particular, the multimodal approach and utilization of a combination of different MRI 
parameters for more sensitive and specific prediction paradigm is on the rise. A series of 
reviews emphasized the need for predictive markers (Belanger et al., 2007; Catroppa et al., 
2008; Gallagher, Hutchinson, Pickard 2007; Kharatishvili and Pitkänen 2010b, Lewine et al., 
2007; Metting et al., 2007, Pitkänen et al., 2009a, 2009b, 2011). 
The MRI techniques discussed in this chapter are only a fraction of all available non-
invasive MRI ‘probes’. Furthermore, there is a wealth of information about the metabolic 
alterations in TBI accessible by variety of MR spectroscopy techniques. 
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The causal relationship between hemodynamic alterations and behavioral symptoms is still 
under investigation and the studies presented here, using arterial spin labeling technique for 
CBF mapping (Hayward et al., 2010), touched the surface by showing that enhanced seizure 
susceptibility post TBI was associated with reduced CBF in the ipsilateral hippocampus 
(r = 0.78, p < 0.05) and increased vascular density in the thalamus (r = 0.69, p < 0.05). Although 
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because injury to more caudal cortical areas associates with hyperexcitability, while the cortical 
regions close to the lesion may not be involved (Kharatishvili and Pitkänen 2010a). More 
importantly, we found that a reduction in the ipsilateral hippocampal CBF at 8 months after 
TBI was associated with increased seizure susceptibility at 9 months such that the lower the 
CBF, the higher the seizure susceptibility. Circuitry alterations and cerebrovascular responses 
in the hippocampus are common in experimental epilepsy and in epilepsy patients (Pitkänen 
and Lukasiuk 2009, Ndode-Ekane et al. 2010) and the ipsilateral hippocampus is involved in 
electrographic activity during spontaneous seizures after TBI  (Kharatishvili et al. 2006). 
Indeed, previous reports have used ASL together with other neuroimaging techniques to 
delineate the ictogenic zone (Rougier et al. 1999, Lim et al. 2008). Further studies are needed, 
however, to discern whether chronic hippocampal hypoperfusion after TBI can be used as a 
surrogate marker for epileptogenesis. 
Our study did not yield any correlations between CBF changes and memory and learning 
impairment, but poor performance in the Morris water maze was found to correlate with 
enhanced thalamic vessel density (r = -0.81, p < 0.01). The thalamus is often found to be 
damaged in moderate and severely injured TBI patients as well as in animal models (Pierce 
et al. 1998, Maxwell et al. 2004, 2006, Tollard et al. 2009, Little et al. 2010), but the role of the 
thalamic pathology in epileptogenesis after acquired etiologies like TBI is poorly understood 
(Bonilha et al. 2004, Blumenfeld et al. 2009). We also found that a high vessel density in the 
ipsilateral thalamus was associated with increased CBF and enhanced seizure susceptibility 
in injured rats. A recent clinical report measured increased thalamic CBF during secondary 
generalization of focal onset seizures (Blumenfeld et al. 2009). Still, one must be cautious 
with the interpretation of such clinical and preclinical correlations and keep in mind that in 
most of the cases it is still unclear whether the cerebrovascular sequelae is the cause or the 
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each region are, which is a major advantage in targeting treatments and following the 
treatment response. 
Considering the prognostic value of early MRI findings in evaluating long term outcomes, 
many of the promising singular MRI findings and their correlations with outcome are 
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1. Introduction   
Worldwide, traumatic brain injury is one of the leading cause of permanent disability and 
death. Contextually, close monitoring and immediate therapy for any accompanying 
abnormalities are crucial in order to reduce the rate of mortality or morbidity associated 
with this acquired brain injury. For this purpose, an isolated neurointensive care (NIC) 
specialised for brain injury is highly warranted, manned by appropriately trained staff who 
understand the current pathophysiology of brain injury and equipped with various modes 
of therapy to tackle any diagnosed abnormalities. To date, we are witnessing progress in 
managing severely injured brain from no specific monitoring to specific ones, and from a 
single intracranial pressure monitoring to future trend of multiple cranial monitoring 
alongside availability of various mode of therapies. The multimodal brain monitoring as it is 
commonly known is a concept whereby, intracranial pressure as well as various other 
important cerebral parameters can readily be monitored.  
Monitoring alone will not alter the outcomes of severely injured brain patients. Prompt 
recognition of any abnormality from the monitoring and availability of therapy to correct 
the diagnosed abnormality are some of the factors that are recognised to influence better 
outcome score. However, at present, two obvious limitations in the multimodality brain 
monitoring are our incomplete understanding of the underlying pathophysiology of the 
severely injured brain and the limited availability of mode of therapy to the neurosurgeon 
or neurointensivist to treat abnormalities detected from the state-of-the-art monitoring. 
Research are ongoing in these areas and in this chapter, we discuss in details the current 
pathophysiology of traumatic brain injury, roles of multimodality brain monitoring in NIC 
and the prospects of brain hypothermia to correct commonly associated abnormal 
monitored-parameters. 
2. Pathophysiology underlying severely injured brain   
Closed brain injury processes can be divided into two phases, primary and secondary brain 
injury. The primary brain injury occurs during the initial insult. The severity and type of 
impact incurred during the initial insult will substantially influence the structural lesions 
that ensue. This severely injured brain is vulnerable to further insult which is known as the 
secondary brain injury (figure 1). In this phase, the commonly associated forms of insult can 
be broadly categorised into three: 1) intracranial hypertension; 2) cerebral hypoxia and 
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2. Pathophysiology underlying severely injured brain   
Closed brain injury processes can be divided into two phases, primary and secondary brain 
injury. The primary brain injury occurs during the initial insult. The severity and type of 
impact incurred during the initial insult will substantially influence the structural lesions 
that ensue. This severely injured brain is vulnerable to further insult which is known as the 
secondary brain injury (figure 1). In this phase, the commonly associated forms of insult can 
be broadly categorised into three: 1) intracranial hypertension; 2) cerebral hypoxia and 
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hypoperfusion which can lead to hypoxic-ischaemic damage and 3) electrographic seizures. 
These secondary insults can progress to three major forms of end-stage events: 1) cerebral 
infarct; 2) cerebral or brain swelling and 3) herniation syndromes, all of which impose a 
negative impact on outcome. Alternatively, pathophysiology of brain injury can be viewed 
consisting of three components: 1) macroscopic pathophysiological events or primary brain 
injury; 2) microscopic pathophysiological events which are part of secondary brain injury 
consisting of intracranial hypertension, cerebral ischaemia and hypoxia, and electrographic 
seizures and finally 3) ultramicroscopic events which are also part of secondary brain injury 
processes including cascades of glial cells and molecular events, microvascular dysfunction, 
blood brain barrier (BBB) disruption, inflammatory cells recruitment and reactivation, and 
immunological response. All of these, macroscopic, microscopic and ultramicroscopic 
processes or events are related to patient‘s outcome. The ‘micro‘ and ‘ultramicro’ 
pathophysiological events are potentially avoidable and amenable to treatment. Currently, 
the primary focus in the acute management of traumatic brain injury is to prevent and 
ameliorate these micro and ultramicroscopic events that accentuate secondary brain injury. 
In practice, the multimodality brain monitoring to certain extent, bears much reflection of 
these complex inter-related events, and hence explains the rationale of such monitoring 
approach in severely injured brain as we attempt to expand our scientific understanding on 
this complex issue.   
 
 
Fig. 1. Schematic flow of events in the pathophysiology of traumatic non penetrating 
(closed) brain injury 
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2.1 Primary and secondary brain injury 
Primary brain injury occurs at the time of impact with an instantaneous clinical effect. 
Pathological classification for this form of injury is largely evident either clinically or by 
imaging (macroscopic events) which include focal-epidural, subdural, intracerebral 
haematomas, focal contusion and laceration, focal or diffused subarachnoid haemorrhage 
and focal or diffused axonal and vascular injuries. Surgery plays a major role to treat some 
of these pathologies. On the other hand, secondary brain injury or damage occurs at some 
stage after the initial impact and therefore can aggravate the primary brain injury. From 
figure 1, it is apparent that the microscopic and ultramicroscopic events contribute to the 
secondary brain injury pathogenesis. However, currently there are limited treatment options 
available in treating the secondary brain injury processes or damages. In 2002, Narayan 
reviewed clinical trials in head injury and concluded that most trials assessing 
pharmacological neuroprotective agents failed to show clinically robust efficacy (Narayan et 
al., 2002). Surgically, the typical available options are burr hole and cerebrospinal fluid 
(CSF) drainage and a wide decompressive craniectomy. The latter has regained therapeutic 
interest in the past years with beneficial effects shown for massive brain infarcts, brain 
swelling and brain herniation that constitute the end results of secondary brain injury 
processes as discussed above (Carandang & Krieger, 2008; Cooper et al., 2008; Eberle et al., 
2010; Figaji et al., 2007). Other possible alternatives to treat secondary brain damage include 
therapeutic cerebral hypothermia (Dietrich & Bramlett, 2010; Gluckman et al., 2005), 
barbiturates therapy (Marshall et al., 2010), raising cerebral blood flow and perfusion by 
using pressors (Lewis et al., 1998) and rheological agents such as mannitol and hypertonic 
saline therapy (Berger et al., 1995; Oddo et al., 2009). 
2.1.1 Ultramicroscopic events 
Trauma will induce a significant and protracted inflammatory, molecular, microvascular 
and immunological responses. These response cascades following direct damage to the 
neurovascular unit which incite ischaemic-hypoxic events. Systematically, four major 
mechanisms may contribute to cerebral ischaemia or hypoxia: a) direct or indirect structural 
damage to intracerebral arteries, neurons and glial cells (neurovascular unit); b) 
cerebrovascular-metabolic uncoupling; c) intracranial hypertension and, d) vasospasms of 
cerebral artery. These mechanisms are the interrelated cascades which underlie the 
pathophysiological processes that propagate the brain injury (figure 2). Damage to the 
neurovascular unit which comprises cerebral endothelial cells, astrocytes and neurons as 
well as extracellular matrix plays significant role in these cascades (Dirnagl et al., 1999). The 
cascades involved opening of voltage dependent and agonist-gated ion and calcium 
channels causing intracellular calcium and sodium overload and efflux of potassium. 
Intracellular sodium overload causes cytotoxic oedema while efflux of potassium leads to 
peri-infarcted brain tissue depolarisation and seizures. Influx of calcium is further promoted 
by the release of large amount of excitatory amino acids particularly glutamate. Intracellular 
calcium and glutamate act in a vicious circle which augments the amount of intracellular 
calcium. Excess intracellular calcium can induce damage to the organelles such as 
mitochondria, intracellular second messengers, cellular membrane and activation of 
numerous intracellular enzymes system which finally lead to apoptosis. Apoptosis is a form 
of cell death in which a programmed sequence of events leads to the elimination of cells 
without releasing much harmful substances. When brain cells experienced an injury or 
episode of ischaemia, they either become dead and the area involved is better known as 
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infarcted area, or the cells may survive the injuries and in time recover completely or 
partially, or alternatively the cells enter the apoptotic pathway. Interestingly, during the 
early stages of injury, the process of apoptosis can still be reversed. This reversal is made 
possible by correcting the cellular energy metabolism or cerebrovascular metabolic coupling 
or by lowering the brain temperatures (Liou et al., 2003). In addition to the events described 
above, damage to the neurovascular unit can also cause production of free radicals. Free 
radicals are atomic or molecular species with unpaired electrons. They are highly reactive 
and unstable, therefore capable of oxidizing and damaging all cellular components when 
their amounts exceed the anti-oxidant defence mechanisms as seen in episode of 
ischaemia/reperfusion brain injury (Lewen et al., 2000). Other harmful events that occur at 
ultramicroscopic levels when the brain is injured are inflammatory and immunological 
responses. Increased levels of pro-inflammatory cytokines such as interleukin-6 (IL-6), 
interleukin-8 (IL-8), interleukin-10 (IL-10) and tumour necrosis factor alpha (TNF-α) have 
been demonstrated in cerebrospinal fluid, serum and brain tissue following head injury 
(Csuka et al., 1999; Is et al., 2007; Kossmann et al., 1997). The underlying dynamics of 
inflammation in traumatic brain injury are complex, encompassing cytokines, chemokines, 
adhesion molecules, complement factors and even the free radicals. The lead triggers for 
inflammatory activation are multi-factorial and thought to involve factors such as 
extravasated blood products, intracellular components, reactive free oxygen and nitrogen 
radicals by brain resident microglia and astrocytes sensing perturbation of tissue 
homeostasis (Juliet et al., 2008; Mathew et al., 1994). These initial events fuel further release 
of inflammatory mediators which facilitate influx of extracerebral inflammatory cells by 
vascular endothelial changes and chemotaxis. Studies have also shown the role of adhesion 
molecules such as vascular cell adhesion molecule, P-selectin, intracellular adhesion 
molecule-1 and gradient of chemotactic chemokines in upregulating these events 
(Hausmann et al., 1998). The ensuing extracellular oedema is triggered by vascular 
dilatation and leakage as a result of vasoactive inflammatory molecules such as nitric oxide 
(NO) and vascular endothelial growth factor, as well as activations of complement system 
by dying cells to aggravate the initial inflammation and secondary tissue damage (Grzybicki 
et al., 1998; Stahel et al., 1998). Currently, monitoring of neuroinflammation is only made 
possible with techniques such as brain microdialysis, whilst others such as free radical 
imaging and monitoring remains under intensive research (Vergely et al., 2003).  
2.1.2 Microscopic events 
Typically in normal subjects, the cerebral blood flow (CBF) and metabolism are a coupled 
phenomenon. Cerebrovascular metabolic uncoupling is reported to occur in over half of 
brain injured patients (Obrist et al., 1984). Uncoupling, which impairs the CBF and 
metabolism following traumatic severe brain injury is related to unfavourable functional 
outcome because of the correlation with ischaemic-hypoxic events. Reduction in CBF is 
obviously affecting the status of cellular metabolism and hence promoting cellular death. 
Interestingly, uncoupling is also expected with an excessive increased in CBF (luxury 
perfusion or hyperaemia) which is harmful to the injured brain by causing brain swelling 
(congested brain) or oedema. In 2007, Menashe Zaaroor noted significant reduction in CBF 
within 24 hours of brain injury and then increased at the second day after the injury. Further 
analysis revealed patients with good outcome after head injury had stable and normal CBF 
after initial period of significant reduction, whereas in patients with poor outcome, the 
course of CBF is triphasic with a secondary decrease on the third day post trauma (Menashe 
 
Neurointensive Care Monitoring for Severe Traumatic Brain Injury 
 
217 
Zaaroor et al., 2007). They postulated the subsequent decrease in CBF may be due to brain 
swelling or persistent impairment in cerebral autoregulation with disruption in blood brain 
barrier (BBB). In addition, persistent ischaemic insults would subsequently progress 
towards destructive processes involving disintegration of cell membranes and intracellular 
organelles, failure of various ion pumps, development of mitochondrial dysfunction, 
inappropriate activation of numerous enzyme systems with cellular hyperactivity and 
increment in lactate levels. All these contribute to the development of intracellular acidosis 
and retention of carbon dioxide which can further aggravate the preceding insults which 
could finally lead to cerebral oedema, swelling and peri-infarct cerebral depolarisation. The 
ultramicroscopic and microscopic cascades as illustrated in figure 2, depict the 
pathophysiological mechanisms acting in vicious circle, with the consequential brain 
swelling and oedema that inflict intracranial hypertension and reduction in cerebral 
perfusion pressure (CPP). The reduction in CPP further aggravates the ischaemia and 
encourages local release of vasoactive mediators such as endothelin, thomboxane A2 and 
prostaglandin I2. Endothelin and thromboxane A2 are powerful vasoconstrictor, whereas 
prostaglandin I2 is a potent vasodilator. Thromboxane can also induce platelet aggregation. 
Thromboxane and prostaglandin I2 play an important role in regulating local cerebral blood 
flow. This local homeostasis may be disrupted following an ischaemic event or direct 
neurovascular injury, with a relative increase in the production of thromboxane (Chen et al., 
1986). The predominant increase in thromboxane can lead to vasoconstriction and hence 
further reduces cerebral perfusion and also promotes local thrombus formation. Aside from 
the mechanisms involved in cerebral hypoperfusion state in brain injury as highlighted 
above, cerebral vasospasm could also play a pivotal role. An obvious culprit to this is the 
presence of blood products such as haemoglobin that act through multiple mechanisms. 
Such mechanisms include decreased production of a vasodilator such as NO, increased 
vasoconstrictors, free radical production and lipid peroxidation of cell membranes, 
modification of potassium and calcium channels, direct oxidative stress on smooth muscle 
cells, differential up-regulation of genes and cortical spreading depolarisation. The state of 
cortical spreading depolarisation or depression inverses the coupling between spreading 
depolarisation of the cortex and CBF by increasing the extracellular potassium and endothelin 
concentration and decreasing NO concentration. This finally leads to microarterial spasm and 
spreading cerebral ischaemia which act in a vicious circle (Pluta et al., 2009). In addition, 
cortical spreading depolarisation arising from peri-infarcted brain tissues (peri-infarcted 
depolarisation) underlying an ischaemic brain can also induce subclinical or non-convulsive 
seizures which can worsen the brain ischaemia (Fabricius et al., 2008).   
3. Neurointensive care monitoring 
The neurointensive care (NIC) warded critical patients who are mostly intubated. To the 
clinician, the clinical status assessment or monitoring for intubated patients are difficult. 
Hence, various important patients’ parameters must be monitored. Monitoring should 
therefore be focused on two categories; a) standard monitoring and b) specific monitoring. 
The standard NIC monitoring covers multiple vitals including the brain and other organ 
systems. The specific monitoring is focused mainly on the brain. Monitoring the pressure 
inside the cranium is regarded by most as the gold standard for severely injured brain 
patients in NIC (Ross & Eynon, 2005). Our latest understanding of the macroscopic, 
microscopic and ultramicroscopic pathophysiological events that underlie brain injury has  
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Fig. 2. A hypothetical scheme to depict post-traumatic and post-ischaemic events. ** 
treatment available; *monitoring only; orange boxed - no treatment yet, but under intensive 
research (BBB – Blood brain barrier; NO – Nitric oxide) 
widened our scopes of monitoring. Although intracranial hypertension is one of the main 
pathophysiological processes involved in secondary brain injury, it is not the sole predictor 
of the patient’s outcome. Notably, the observed intracranial hypertension in severely injured 
brain is a common end-point of the various pathophysiological cascades involved. Hence, 
other cerebral-specific monitoring parameters are required to assist neurointensivists detect 
‘earlier’ secondary insults and prevent the harmful progression to three end-stage processes 
as mentioned earlier, i.e. a) cerebral infarct b) brain swelling and oedema and c) herniation 
syndromes. The ‘extra’ monitoring parameters include cerebral blood flow, oxygenation, 
metabolites, brain temperature and perfusion, or otherwise known as the multimodality 
monitoring.   
3.1 Standard monitoring 
The severely injured brain is vulnerable to further insults after sustaining the traumatic 
primary brain injury. The secondary insults are commonly identified as systemic hypoxia 
and hypotension, intracranial hypertension and cerebral hypoperfusion which can progress 
to cerebral ischaemia, brain swelling and herniation syndrome. These secondary insults are 
regarded as the survival determinants for patients receiving care in the NIC. Therefore the 
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aim of standard monitoring is to prevent or to recognize these potential threats which could 
originate from other body systems besides the brain. Head injured patients in NIC should be 
monitored for nine key body systems: a) central nervous system (discussed specifically 
under brain monitoring); b) cardiovascular system which includes parameters such as heart 
rate and rhythm, blood and venous pressure, stroke volume, cardiac output and total 
peripheral resistance; c) pulmonary system with regular monitoring of arterial blood gases, 
chest radiographs, and breathing and ventilator parameters; d) renal and metabolic system 
with regular blood, urine and metabolic profiles monitoring; e) gastrointestinal and 
nutritional status pertaining to body calories; f) hematological profiles; g) microbiologic and 
sepsis profiles; h) peripheries and skin condition and lastly i) endocrine and hormonal 
profiles which are frequently overlooked, except for features of diabetes insipidus or 
syndrome of inappropriate antidiuretic hormone hypersecretion. Recent studies have 
demonstrated 75% incidence of endocrine dysfunction at 6 months post trauma in children 
and 21% incidence of hypothalamic-pituitary dysfunction in adults (Kaulfers et al., 2010; 
Krahulik et al., 2010). These findings prompted debates as to whether hormonal profile 
evaluation should be routinely checked in all head injured patients and treated accordingly. 
3.2 Specific monitoring 
Since limitations exist in bedside neurological findings as a monitoring tool for various 
pathophysiological processes described in previous sections, specific central nervous system 
monitoring is needed for severe brain injured patients in the NIC. The use of serial 
computed tomography (CT) brain scanning protocol to predict the presence or absence of 
abnormality or raised ICP has not been well received in practice, partly due to poor 
correlations between CT findings and raised ICP, and because of undesirable effects from 
repeated radiation exposure and frequent mobilization to the patients (Kouvarellis et al., 
2011; Miller et al., 2004). Therefore, specific brain monitoring seems necessary. Currently, 
the assessment of intracranial status for severely injured brain is commonly done with gold 
standard ICP monitoring alone. Lately, as our understanding on the complex 
pathophysiology underlying severely injured brain expands, new modalities of brain 
monitoring emerge, incorporating various brain parameters known as the multimodality 
monitoring (Idris et al., 2007; Isa et al., 2003; Stuart et al., 2010). 
4. Multimodality monitoring 
The development of new neuromonitoring techniques has been particularly important 
because typically standard cranial monitoring techniques such as ICP and CPP 
measurements seem insufficient in detecting subtle manifestations of brain injury or poor 
surrogates for physiologic parameters of interest. For these reasons, multimodality 
monitoring which monitors more brain parameters is required. Multimodality monitoring 
includes monitoring of the following parameters: 
i. Intracranial pressure (ICP)  
ii. Cerebral perfusion pressure (CPP) 
iii. Cerebral blood flow (CBF parameters) 
iv. Focal and global cerebral tissue oxygenation (PtiO2 and SjVO2) 
v. Cerebral tissue carbon dioxide tension (PtiCO2) 
vi. Cerebral pH  
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aim of standard monitoring is to prevent or to recognize these potential threats which could 
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with regular blood, urine and metabolic profiles monitoring; e) gastrointestinal and 
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vii. Cerebral temperature 
viii. Cerebral metabolic parameters (brain microdialysis) 
ix. Cerebral EEG (EEG and BIS) 
x. Cerebral evoked potentials (somatosensory, brainstem and visual evoked potentials: 
SSEP/BAEP/VEP) 
Figure 3 shows the role of multimodality monitoring for the injured brain. Intracranial 
pressure is used to monitor the cranial pressure, Licox or Neurotrends system is used to 
monitor status of regional brain oxygenation, carbon dioxide tension, pH and brain 
temperature, while jugular bulb oximetry is used to monitor global brain oxygenation. Saber 
cerebral blood flow, transcranial doppler, cerebral EEG and evoked potentials can be used 
to monitor cerebral blood flow and therefore identifying ischaemic insults, and cerebral 
microdialysis can monitor the cellular events. Furthermore, continuous EEG monitoring in 
NIC can also diagnose the subclinical seizures which play significant role in secondary brain 
injury and one of the parameters that determine the prognosis (Kazibutowska et al., 1992). 
 
 
Fig. 3. Multimodality monitoring and secondary brain injury. 
5. Two major parameters to consider during multimodality monitoring: ICP 
and CBF 
Intracranial hypertension causes a reduction in cerebral perfusion pressure which can lead 
to ischaemia, brain swelling and ultimately infarction. In addition, persistent increased in 
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ICP could cause a shift in intracranial structures (midline shift or mass effect) and finally 
herniation syndromes. Therefore, monitoring ICP is considered a standard part of head 
injury management. Nonetheless, monitoring the ICP alone seems inadequate, because 
raised in ICP in head injured patients can be associated with both an increment and a 
reduction in CBF (Menashe Zaaroor, 2007). In 1992, Bouma noted about one-third of head 
injured patients had low CBF and therefore showed an early cerebral blood flow-
metabolism mismatch (Bouma et al., 1992). Figure 2 highlights the importance of CBF 
monitoring to prevent or reduce the degree of cerebral ischaemic-hypoxic insults. Whilst the 
optimal method for measuring CBF remains to be established, there are numerous 
alternatives when used together can estimate the CBF. Those alternatives include: a) CPP; b) 
blood flow velocity by transcranial doppler; c) focal and global cerebral oxygenation with 
Licox or Neurotrends systems or jugular bulb oximetry; d) regional CBF with Saber 2000; e) 
cerebral metabolic parameters with brain microdialysis; f) cerebral perfusion imaging 
techniques and g) cerebral evoked potentials and EEG. These are in fact features of 
multimodality neuromonitoring.  
The CBF and CPP are two variables that are inter-related. The CBF is proportional to CPP 
and inversely related to the cerebral vascular resistance (CVR). The CPP represents the 
pressure gradient driving CBF and hence oxygen and metabolite delivery, i.e. in other 
words, the CPP is the perfusion pressure gradient across cerebral vascular bed whereby the 
incoming systemic arterial pressure minus the opposing force from venous outflow 
pressure. In traumatic brain injury cases, the elevated ICP is the opposing force to the 
incoming mean systemic arterial pressure (MAP). Therefore, CPP in equation form can be 
stated as CPP = MAP – ICP. In theory, CPP is equivalent to the transmural pressure across 
the cerebral vessel walls. In other words, at the arteriolar level, CPP is the stimulus for 
autoregulatory response and at the capillary, it is the driving force for fluid exchange. The 
normal brain autoregulates its blood flow to provide a constant flow regardless of blood 
pressure by altering the CVR to obtain a maintained flow within an autoregulatory range of 
60 - 160 mmHg of MAP or CPP of 50 – 150 mmHg. These homeostatic mechanisms are often 
lost in severely injured brain due to impairment in cerebral autoregulation, implying that 
cerebral autoregulation is a homeostatic mechanism that minimizes deviations in CBF when 
CPP or MAP changes. It acts through vasomotor effectors that control CVR. Vasomotor 
effectors are controlled by a) CPP; b) metabolites; c) oxygen pressure; d) carbon dioxide 
pressure and e) temperature. In NIC setting, the level of changes in cerebral autoregulation 
among patients is individualised and therefore the optimum CPP may vary considerably. 
Clinically, continuous methods of autoregulation tests or monitoring rely on the observation 
of spontaneous responses of CBF to spontaneous fluctuations in MAP or CPP (Zweifel et al., 
2008), arterial partial pressure of CO2 (Puppo et al., 2008)  or metabolites (Lee et al., 2001). 
Study by Lee in 2001 showed that during the first 2 weeks after head injury, CO2 reactivity 
remains relatively intact, pressure autoregulation is variably impaired and metabolic 
suppression reactivity remains severely impaired and they further noted that unlike 
hypotension, hypoxia or haemorrhagic brain lesions, elevated ICP appears to affect  
all components of vasoreactivity that were tested (Lee et al., 2001). In similar year, Czosnyka 
also noted that autoregulation is not only impaired when associated with a high ICP or low 
arterial blood pressure, but it can also be disturbed by an excessive CPP (Czosnyka et  
al., 2001). Studies have shown that impairment or failure of autoregulation can contribute  
to unfavorable outcome (Czosnyka et al., 2001; Lam et al., 1997; Smielewski et al., 1997).  
This could possibly be explained by a disturbance in the pressure-volume (elastance) curve 
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that is steeper suggesting poor compliance of the brain (figure. 4). Since elevated ICP  
and changes in CBF are two key factors to consider in all severely injured brain patients 
(figure. 2), besides cerebral autoregulation, the concept of cerebral pulsation is also thought 
to play a significant role in head injury pathogenesis. 
 
 
Fig. 4. Pressure-volume curves of craniospinal contents. (A) is normal pressure-volume 
curve of compliant system and (B) is the pressure-volume curve when brain compliance is 
reduced. 
5.1 Monro-Kellie doctrine, cerebral autoregulation, cerebral pulsation, pulsatility and 
resistive index and brain compliance 
According to Monro-Kellie doctrine, the sum of the intracranial volumes of blood, brain and 
CSF is constant and that an increase in any one component must be offset by an equal 
decrease in another or else ICP rises. For traumatic brain injury, a pathological increase in 
brain volume due to cerebral oedema or an increase in blood volume would induce an 
initial reduction in CSF volume response. This has been traditionally viewed as CSF being 
forced out into the spinal dural sac to maintain ICP. This anatomical compensatory response 
can quickly become exhausted and further rise in ICP is expected. Since raised ICP can lead 
to reduction in CPP and therefore compromising CBF, the body finally has to utilise the 
second defence mechanism, functional compensatory response (augment the CBF). This type of 
compensatory response is to ensure the brain receives an adequate blood flow and hence 
counteracts the effect of raised ICP. Once the body compensatory responses (anatomical and 
functional) become overstretched, that is the only time we note a fast increase in ICP and 
striking reduction in brain compliance (the steep part of the elastance curve). This 
decompensatory phase is related to poor brain compliance, raised ICP and reduction in CBF 
(figure. 5, labelled as A,B and C). Besides cerebral autoregulation, increased in intracranial 
vessels pulsation is one of the mechanisms that could augment the CBF during ischaemic-
hypoxic events (Chan et al., 1992; Egnor et al., 2002; Muttaqin et al., 1993). Since both seem 
to be important, monitoring level of autoregulation and assessing the intracranial vessels 
pulsation are two parameters that should be done in NIC for multimodality monitoring. 
Cerebral autoregulation is normally tested or monitored with transcranial doppler by using 
static (vasopressor) or dynamic (Aaslid leg-cuff, carotid artery compression or tilt table 
declination) provoking test or with cerebrovascular reactivity index (PRx) whereby digitised 
ICPs is divided with digitised MAPs and focusing on their trends or values; positive values 
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imply that increases in MAP are positively associated with increases in ICP, suggesting 
autoregulatory impairment, whereas negative or flattened values indicate intact 
autoregulatory mechanism, with vasoconstriction and decreased or maintained ICPs in 
relation to surges in MAPs (figure 6) (Aaslid et al., 1989; Mitsis et al., 2006; Smielewski et al., 
1997; Timofeev et al., 2011; Zweifel et al., 2008). Similarly, assessing the intracranial vessels 
pulsation is made possible using transcranial doppler (TCD) and measuring the velocity of 
middle cerebral artery (MCA) and quoted as pulsatility (PI) or resistive index (RI). 
Researchers have found strong correlation between the RI or PI with raised ICP (Bellner et 
al., 2004; Gura et al., 2011; Voulgaris et al., 2005).   
 
 
Fig. 5. The correlation between ICP and CBF. The compensatory phase exists at the 
beginning of raised ICP and followed by the decompensatory phase in some cases with 
persistently raised ICP. There exist individual variations labeled as A, B or C with different 
degrees of ICP increment or CBF reduction. Similarly, there is also harmful compensatory 
phase, labeled as D,E and F, in which increased in CBF would cause increment in ICP 
(commonly induced by clinicians). The role of multimodality monitoring is to identify ICPY 
and CBFX and to identify the time-shift from compensatory to decompensatory or harmful 
compensatory phase. 
The correlation between intracranial brain pulsations and brain compliance can also be 
noted on ICP waveforms. A good ICP waveform looks similar to an arterial pressure wave 
(Ross & Eynon, 2005). There are three peaks (figure. 7, labelled A): a) P1 is known as 
percussion wave and produced by systolic arterial pressure transmitted from the choroid  
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Fig. 6. Positive and negative trends for the cerebrovascular pressure reactivity index (PRx). 
Positive trends signify impaired cerebral autoregulation whereas, negative and flattened 
trends denote intact autoregulation. 
plexus to the ventricle; b) P2 is the tidal wave, its shape is more variable and originated from 
central venous wave from the right atrium and correlated with venous volume or venous 
congestion, sinus pressure and brain pulsations in injured brain. P2 may also stand for 
overall brain compliance; c) P3 is the dicrotic wave and is due to closure of the aortic valves. 
In between P2 and P3, there is dicrotic notch which is also thought arising from the effect of 
aortic valves closure. In 1965, Lundberg described three time-dependent patterns of 
pressure waves in patients with raised ICP (Lundberg et al., 1965). Lundberg A or plateau 
waves are 50 – 100 mmHg high and last for 5 to 20 minutes. This type of pressure waves 
demonstrate an early functional compensatory response between raised ICP and CBF. 
Cerebral vasculatures start to dilate in response to intracranial hypertension and critically 
low CBF, however, this autoregulatory vasodilatory response can dangerously lead to 
further increment in ICP via increased in intracranial blood volume in some brain injured 
patients with impaired autoregulation (figure. 5, labelled as D,E and F). Lundberg B waves 
occur at frequency of 0.5 – 2/min and are up to 50 mmHg in amplitude. It is detectable in 
normal and some individuals with impaired cerebral autoregulation (Balestreri et al., 2004). 
Lundberg C waves last 4 to 5 minutes and are up to 20 mmHg in amplitude and are of little 
clinical significance. Studies on ICP waveforms and Lundberg patterns of pressure waves 
have demonstrated that in the presence of raised ICP and intact cerebral autoregulation, the 
brain is able to regulate or optimise its CBF through compensatory mechanisms. 
Maintainance of CBF can be made via autoregulatory cerebral vasculature dilatations and 
increased in cerebral vasculature pulsations. Since P2 indicates overall compliance of the 
brain, at an early stage of compensation the peak-interval between P1 and P2 is increased 
which signifies increased cerebral vasculature pulsations and increased brain compliance 
(figure.7, labelled B). In the presence of persistently raised ICP, this initial response is 
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followed by a gradual reduction in the peak-interval between P1 and P2 (P2 is nearly at 
the same level or is higher than P1) signifying decreased brain compliance as well as 
marked reduction in brain pulsations suggesting decreased distensibility or increased 
stiffness of the brain (figure.7, labelled C). This decompensatory phase starts when the 
body is unable to maintain an adequate CBF with simultaneous rapid increment in ICP 
and invariably manifests in various ways: a) reduced in any parameters that measured 
CBF; b) increased in RI measured with TCD; c) elevation in anaerobic metabolism 
parameters which commonly measured with microdialysis; d) retention of carbon dioxide, 
presence of hypoxia or acidosis and increased in brain temperature as measured by 
Neurotrends or Licox system  and e) change in EEG waveforms or alterations in evoked 
potentials. The time-shift from compensatory to decompensatory or harmful 
compensatory phase is not known unless ICP and various other monitorings are 
implemented on patients monitored in NIC. Therefore, the roles of multimodality 
monitoring are as follows: 
1. To identify early the potential dangerous effect of known vicious circle of ICP and CBF, 
therefore guiding the clinician to institute the appropriate mode of therapy (ICP or CPP 
targeted therapy) with closed neuromonitoring 
2. To identify the time-shift from compensatory to decompensatory or harmful 
compensatory phase, therefore helping the clinician to proceed with end-tier therapy 
(decompressive craniectomy or barbiturate coma therapy) when absolutely indicated 
3. To help clinician understand the complex pathophysiology of severely injured brain, 
therefore creating a future possibility to develop new and innovative therapy 
 
 
Fig. 7. Intracranial pressure waveforms. In a non-compliant system, P2 wave is exceeding P1. 
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5.1.1 Vicious circle of ICP and CBF: ICP and CPP targeted therapy versus 
multimodality monitoring 
In previous sections, we recognised that an increase in ICP sets in an autoregulatory 
response to compensate for a reduction in CBF. Since CPP is proportional to CBF, increment 
in ICP would cause decrement in CPP. This is easily understood from the equation: CPP = 
MAP – ICP, whereby raised ICP causes reduction in CPP when MAPs are kept constant. 
Reduced CPP can be corrected by raising the MAP or by reducing the ICP. Reduction in ICP 
is normally called ICP targeted therapy, whilst CPP targeted therapy corrects the reduced 
CPP by raising the MAP. In 2003, Young recommended an aggressive CPP management for 
patients with elevated ICP (Young et al., 2003). Four patients in their study had 
comparatively good neurological outcome after receiving such management for extremely 
high ICP. Nonetheless, in some severely injured brain patients who have high CPP values or 
those received an aggressive CPP management appeared to develop cerebral oedema or 
brain swelling and had poor outcomes. This phenomenon is thought to arise from 
impairment in cerebral autoregulatory mechanisms (Dickman et al., 1991; Nujaimin et al., 
2009; Zweifel et al., 2008). In patients with an impaired cerebral autoregulation, ICP targeted 
therapy seems more appropriate than CPP targeted therapy. This is mainly because of the 
vicious circle that can occur in patients with impaired cerebral autoregulation whereby ICP 
is further elevated by elevating the CPP (figure 5, labelled D,E and F). Many studies have 
shown a strong association between an elevated ICP and poor patient outcome in head 
injury (Cooper et al., 2008; Eberle et al., 2010; Idris et al., 2007). In most cases with poor 
outcome, both, elevated ICP and low CPP values appeared common features. Therefore it 
seems prudent to conclude that in such patients, the emphasis should not only on raising 
CPP but also on lowering the ICP to gain better outcome. In fact, the combination of ICP and 
CPP therapy forms the basis of the guidelines or protocols proposed by the US Brain 
Trauma Foundation (Bullock et al., 1996), European Brain Injury Consortium (EBIC) (Maas 
et al., 1997), Addenbrooke protocol from the Cambridge (Patel et al., 2002) and Lund 
protocol (that is still considering the importance of reducing ICP and improving the CPP) 
(Asgeirsson et al., 1994). In relation to figure 5, it is a daunting task to speculate which 
patient will benefit from CPP or ICP targeted therapy. Additional tests or monitoring are 
obviously needed to facilitate this difficult task in deciding which patients are likely to 
tolerate CPP targeted therapy. Since multimodality monitoring does monitor various 
cerebral parameters (ICP, CPP and CBF) and at the same time allowing cerebral 
autoregulation test or monitoring to be done, therefore it serves as an appropriate 
monitoring approach. Multimodality monitoring can detect not only further increment in 
ICP values but also the presence of any compromise in CBF in patients who already have 
elevated, extremely elevated or lethal levels of ICP and still undergoing CPP targeted 
therapy. 
5.1.2 Shift from compensatory to decompensatory or harmful compensatory  
phase – Role of multimodality monitoring 
Intracranial hypertension (high ICP/low CPP) and reduction in CBF are two important 
parameters that determine the outcome of severely injured brain patients. Figure 2 
illustrates cerebral ischaemic-hypoxic insults are the core events that trigger various vicious 
circles, including intracranial hypertension. Therefore, CBF monitoring should be 
incorporated into the standard care for severely injured brain patients in the NIC. The 
multimodality monitoring for the ICP and CBF offers crucial information on the status of 
 
Neurointensive Care Monitoring for Severe Traumatic Brain Injury 
 
227 
cerebral oxygenation, nutrition and function. The combination of various monitored 
parameters can cross-validate one another and can give indications as to the phase the brain 
is in for the managing clinicians (figure 5). Patients who are in the compensatory phase with 
raised ICP and undergoing CPP targeted therapy may not yet be a candidate for 
decompressive craniectomy or barbiturate therapy as long as the ICP is kept stable and CBF 
parameters are within an acceptable range. However, those with deteriorating CBF 
parameters (figure 5, labelled A,B and C) and/or persistently raised ICP (figure 5, labelled 
A,B,C,D,E and F) may be considered for above mentioned end-tier therapy. In summary, 
besides its potential to safe guard the CPP targeted therapy, multimodality monitoring of 
the severely injured brain patients aids clinicians to decide on the appropriate timing for 
end-tier therapy, decomperessive craniectomy or barbiturate therapy. 
6. Measuring the two major parameters: ICP and CBF 
The multimodality monitoring can be viewed as way of monitoring two important 
parameters that play significant roles in the pathogenesis of ischaemic-hypoxic events, 
namely, the ICP and CBF. 
6.1 Intracranial pressure 
The ICP is normally monitored until an acceptable upper limit of 20 mmHg (Balestreri et al., 
2006). This is attained by using either ventricular catheter if the ventricles are opened or a 
compliance monitor (Spiegelberg GmbH & Co., Hamburg, Germany) or an 
intraparenchymal ICP, using Codman (Codman, Randolph, MA, USA) or Camino 
transducers (Camino Laboratories, San Diego, CA)(Idris et al., 2007; Isa et al., 2003). If the 
ICP values persistently read more than 20 mmHg and/or direct calculation of cerebral 
perfusion pressure (CPP) appears less than 50 mmHg, draining of CSF is warranted. If the 
ICP remains high, other modes of therapy such as adding muscle relaxants, giving mannitol 
or hypertonic saline, temporary hyperventilation, hypothermia with cooling blanket and 
fans are usually considered. At this stage, further investigation with CT brain is justifiable 
provided that these additonal steps fail to reduce the ICP values. The subsequent treatment 
should be based on the new imaging and monitored parameters. Generally, if the CT brain 
revealed no new surgical lesion but the brain appeared swollen, the ICP values remained 
high (or CPP values remained low) and/or presence of abnormal cerebral blood flow 
parameters, the patient should then be treated with either one of the following: 
1. Bifrontal decompressive craniectomy and dura augmentation for diffuse brain swelling 
without midline shift, or 
2. Unilateral  wide decompressive craniectomy and dura augmentation for diffuse brain 
swelling and presence of midline shift, or  
3. Barbiturate therapy until burst suppression attained on continuous EEG monitoring. 
Nonetheless, if the ICP values remain persistently high, decompressive craniectomy can 
still be considered.  
For patients with persistently low CPP values without a corresponding raised ICP, 
decompressive craniectomy surgery or barbiturate therapy is not yet indicated. Instead, 
these patients should be treated with inotropes and/or hypervolumic therapy to increase 
CPP values. If by implementing CPP targeted therapy and the ICP started to increase, then 
the end-tier therapy should now be considered.  
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6.2 Cerebral blood flow 
CBF can be measured in various ways. Measuring CBF can be classified into 4 ways: 
a. Direct measurement of CBF 
b. Indirect measurement of CBF 
c. Quantitative measurement of CBF 
d. Qualitative measurement of CBF 
Quantitative and qualitative measurements are employed mainly for research purposes and 
hardly used during monitoring of severely brain injured patients in NIC. Examples include 
using radioisotope or tracer to measure CBF with imaging modality such as PET or SPECT 
scan. 
A) Direct measurement of CBF 
The direct measurement of CBF can be made by means of thermal diffusion techniques 
(Saber 2000) and LASER Doppler Flowmetry (LDF) which measure the local or regional 
CBF.  
1. Thermal diffusion technique (Saber 2000) 
The thermal diffusion measurement of cortical CBF is based on the thermal conductivity of 
cortical tissue (Carter et al., 1982; Dickman et al., 1991). The Saber 2000 regional cerebral 
blood flow (rCBF) sensor (flowtronics, Phoenix, AZ) consists of two small flat gold plates, 
one of which is neutral and the other heated, is placed through a burr hole or craniotomy on 
a cortical region of interest. The rCBF is estimated from the temperature difference between 
these two plates. Then, a microprocessor continuously converts the temperature difference 
to CBF in ml/100g/min. In practice, the sensor measures cortical area of approximately 1 cm 
deep in the cerebral hemisphere and 3 cm by implication. Its sensor plates are 24-k gold, 
whereas its wires are solid silver and teflon-coated. Although rCBF is not representative of 
blood flow in the whole hemisphere or in deeper regions of the brain, continuous 
measurement of relative changes in days after severe head injury may be of great value in 
guiding clinical management as an indirect measurement of perfusion status of the brain. 
Normal rCBF measured by Saber 2000 should be ≥ 30 ml/100g/min. 
 
 
Fig. 8. Saber 2000 measures regional cerebral blood flow 
2. LASER Doppler Flowmetry (LDF) 
LDF measures continuously the local microcirculatory blood flow. The method is based on the 
principle of doppler shift. Monochromatic LASER light reflected from stationary tissue 
remains unchanged in frequency, but when it is reflected from moving blood cells, it 
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undergoes a frequency shift and therefore light reflected from the microcirculation measures 
the movements of red blood cells (Meyerson et al., 1991). The light is carried by a fibreoptic 
probe and the reflected light is converted into an electrical signal from which several values 
are derived. The flux (flow unit) represents the movement and concentrations of blood cells 
through the microvasculature. It is derived from the concentration of moving blood cells 
(CMBC) in the measured volume multiplied by the mean velocity. All three values, flux, 
CMBC and velocity are continuously recorded and displayed by the computer (Bolognese et 
al., 1993). LDF measures the local flow within a very small sample volume of approximately 1 
mm3. LDF can also be used to measure the state of cerebral autoregulation via CO2 reactivity. 
B) Indirect measurement of CBF 
The indirect measurement of CBF consists of near infrared spectroscopy (NIRS), jugular 
bulb venous oximetry (SjVO2), transcranial doppler sonography (TCD), cerebral interstitial 
tissue oxygen (PtiO2) and carbon dioxide tension (PtiCO2), brain pH and temperature, 
intracerebral microdialysis and electrical function monitoring. 
1. Near infrared spectroscopy (NIRS) 
It is a non invasive monitoring that detects changes in brain oxygenation, CBF and cerebral 
blood volume. NIRS depends upon the relative transparency of biological tissue to light in 
the near-infrared spectrum. The absorption of oxyhemoglobin, deoxyhemoglobin and 
oxidized cytochrome can be detected transcranially. In adults, only certain brain areas can 
be monitored because of bone thickness produces a scattering of the light spectrum (Elwell 
et al., 1993).  This made NIRS less accurate and only focal measurement is feasible. 
2. Jugular bulb venous oximetry (SjVO2) 
A 5G fibreoptic oxygen saturation catheter is inserted percutaneously in a retrograde 
direction into the internal jugular vein. The tip of the catheter must be placed within the 
dominant jugular bulb which is determined by separate test compression on each internal 
jugular vein and note an increment in ICP values. Prior to monitoring, its position must be 
verified by the mastoid x-ray. SjVO2 can be used to calculate arteriovenous difference or 
cerebral oxygen extraction (AVDO2) and to monitor cerebral oxygenation. Both determine 
the status of cerebral metabolic rate for oxygen (CMRO2) and CBF which are coupled when 
under physiological conditions. The relationships between CBF, CMRO2 and AVDO2 can be 
summarised by the formula CMRO2 = CBF × AVDO2. The normal values for AVDO2 is 
approximately 6.5 ml O2/100 ml blood, for CMRO2 is 3.2 ml O2/100g/min and for cerebral 
oxygenation ranges between 50% - 75% (Idris et al., 2007; Muizelaar & Schroder, 1994). 
Ischaemic brain with low CBF exhibits low SjVO2 reading of less than 50%, whereas for the 
hyperaemic brain, the reading is more than 75%. Similarly, in brain dead patient where no 
uptake of oxygen occurred, the SjVO2 would also be higher than 75%.  
 
 
Fig. 9. Jugular bulb venous oximetry monitor 
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3. Transcranial doppler sonography (TCD) 
Transcranial doppler provides a mean of measuring relative changes in CBF by observing 
blood flow velocity (FV) in basal cerebral arteries, mostly on middle cerebral artery (MCA) 
or anterior cerebral artery (ACA) (Muttaqin et al., 1993). It uses doppler shift as a basic 
principle. This shift is monitored intermittently by using a 2 MHz pulsed TCD 
ultrasonography probe (model MultiDop 2; DWL Electronishe System GmbH, Sipplingen, 
Germany) inserted at depths of between 4 to 6 cm. TCD measures the velocity of red blood 
cell moving within a vessel, quoted in cm/sec. In contrast, CBF is a three dimensional 
measure of volume of blood delivered per unit of cerebral tissue per unit of time, quoted as 
ml/100g/min. As the two parameters are quantitatively different, the correlation between 
absolute values of FV and CBF is poor. However, in normal individuals, the cross-sectional 
area of the insonated blood vessels remains constant, hence, the CBF and FV should vary 
directly with one another. In traumatic brain injury, the blood vessel diameter may be 
altered by changes in ICP (altered autoregulation and vascular pulsation) and/or the 
possible effect of vasospasm, reducing the reliability of the relationship between relative 
CBF and FV. This variable relationship between the absolute FV and CBF is a clear 
disadvantage, as reflected by the normal variation in MCA FV of between 35 – 90 cm/sec in 
the awake resting state. Thus caution is needed in interpreting TCD data in its estimate of 
CBF. Abnormally low (ischaemic brain) or high (vasospasm or hyperaemic brain) FV must 
be interpreted carefully and preferably in conjunction with other CBF monitoring 
parameters (Idris et al., 2007; Isa et al., 2003).  
 
 
Fig. 10. Continuous transcranial doppler sonography monitoring in neurointensive care 
4. Cerebral interstitial tissue oxygen tension (PtiO2), carbon dioxide (PtiCO2), pH and temperature 
measured by Licox or Neurotrend/Paratrend system. 
Neurotrend (old system called Paratrend 7TM) system (Codman, Johnson & Johnson, 
Raynham, MA, USA) is an effective method of measuring tissue cerebral oxygen tension 
(PtiO2), along with carbon dioxide tissue levels (PtiCO2), brain pH and brain temperature 
(Charbel et al., 1997). On the other hand, Licox system (GMS, Kiel-Mielkendorf, Germany) is 
capable in measuring only PtiO2 and brain temperature. The importance of CBF to maintain 
neuronal viability is well known. In brain tissue, this can be defined as maintaining tissue 
oxygenation and a metabolic environment for oxidative energy production and therefore for 
optimal neuronal function. Patients with brain ischaemia secondary to head injury are 
thought to have changes in brain tissue partial pressure for oxygen (Po2) and carbon dioxide 
(Pco2), pH and temperature. During ischaemia, the Po2 decreases due to increased 
consumption, Pco2 increases due to decreased clearance and the interstitial tissue 
environment is acidic with falling pH and accumulation of toxic metabolites. The system can 
provide continuous quantitative measurements of regional brain. Normally, the sensor is 
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inserted into peri-contusional, peri-infarted, peri-haemorrhagic or peri-lacerated brain areas. 
The purpose of measuring these parameters is to safeguard the ischaemic or penumbra 
areas of brain which are compromised and the measured abnormal parameters could reflect 
the globally threatened CBF. Normal values for these parameters have been acquired 
experimentally, whereby in normal individuals PtiO2 ranges between 37 to 48 mmHg. 
However, hypoxia of brain tissue has been reported to occur when PtiO2 is < 15 mmHg 
(Hoffman et al., 1996; van Santbrink et al., 1996). PtiCO2 normal values is within the range of 
49 to 59 mmHg, normal brain pH is 7 to 7.16 and normal brain temperature is 0.3 to 0.5 
higher than the normal range of core body temperature which is within 36 to 39°C (the ideal 
core body temperature is the midpoint of this range, that is 37.7°C) (Hoffman et al., 1996; 
Sakai et al., 2011; Zauner et al., 1995). Brain temperature of healthy person denotes the 
balance between two processes: cerebral metabolism and CBF. Under normal conditions, the 
brain metabolises glucose via the Krebs cycle to carbon dioxide, water and adenosine 
triphosphate (ATP). Cells in the brain use ATP as energy resource and consequently 
generate heat. CMRO2 and cerebral metabolic rate for glucose (CMRglu) are the factors that 
directly related to heat production in the brain. Conversely, the heat is removed by CBF. 
Therefore, in presence of ischaemia (reduction in CBF), the brain temperature is higher than 
normal (Sakai et al., 2011).  
 
 
Fig. 11. A: Neurotrend and B: Licox system. Neurotrend is capable of measuring brain 
temperature, brain pH, PtiO2, PtiCO2 and HCO3 whereas Licox only measures PtiO2 and 
brain temperature. 
5. Intracerebral microdialysis 
Intracerebral microdialysis (CMA70 and CMA 71 catheters and CMA600 and ISCUS 
analyser; CMA Microdialysis AB, Solna, Sweden) enables endogenous substances in the 
extracellular fluid of the brain to be retrieved. Excitatory amino acids, neurotransmitter, 
electrolytes and energy-related metabolites are released in abnormal quantities after severe 
head injury. There would be an increase in glutamate, glycerol, aspartate, K+ and 
lactate/pyruvate ratio and a decrease in glucose level in head injured patient with cerebral 
ischaemia (Timofeev et al., 2011). Their continuous measurements via dialysis principle can 
help the neurointensivist to correlate their findings with imaging of the brain, other 
monitored parameters and patient conditions to decide on the appropriate management. 
6) Electrical function monitoring and bispectral index (BIS) 
Electrophysiological monitoring is a measurement of brain electrical function which is 
regarded as vital in nervous communication. The electroencephalogram (EEG) and evoked 
potentials such as visual evoked potential (VEP), brainstem auditory evoked potential 
(BAEP) and somatosensory evoked potential (SSEP) can give valuable information 
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regarding the status of CBF and metabolism. The normal CBF is 45 to 55 ml/100g/min, and 
the electrical function is impaired (isoelectric silence) if CBF is < 23 ml/100g/min with 
irreversible damage occurs if CBF is < 8 ml/100g/min. Deterioration in their values 
correspond to reduced levels of transcranial oxygen extraction and hence CBF (Jordan, 1993; 
Procaccio et al., 2001). Besides, continuous bedside EEG monitoring is the best method for 
detecting non-convulsive seizures and presence of significant amount of background 
slowing frequencies informs the neurointensivist regarding the depth of coma and 
prognosis of the severely injured brain patients.  
 
 
Fig. 12. Intracerebral microdialysis. 
The bispectral index (BIS) of the electroencephalogram is a weighted sum of 
electroencephalographic subparameters containing time domain, frequency domain and 
higher-order spectral information, which are optimized to correlate maximally with clinical 
signs of hypnosis (Fabregas et al., 2004) and CBF (Myles, 2009). BIS system is patched onto 
the forehead of patients. The aim is to keep the general anaesthesia effect or adequate 
hypnotic effect at 40 – 60% (Gan et al., 1997). The targeted values indicate adequacy of 
muscle relaxants and sedation to reduce the cerebral metabolic rate and ICP. Inadequacy 
(higher values) indicates higher titrating dose of sedative medications is required and 
equally important is to realise that an abnormally low or presence of sudden deterioration in 
BIS values should alert the neurointensivist for possible CBF compromise. However, this 
should be interpreted carefully with other cerebral monitoring to realise its importance. 
 
 
Fig. 13. A: Electrical function monitoring and B: The BIS system was patched onto the 
patient’s forehead. 
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7. Interpretation of data and management steps 
In general, two parameters are monitored during multimodality monitoring for severe head 
injury: ICP and CBF (Idris et al., 2007). Combination of these two important parameters help 
neurointensivist to know the status of brain autoregulation, either impaired or intact 
(cerebrovascular reactivity index or PRx)(Smielewski et al., 1997). Therefore, based upon this 
observation, the clinician can opt for ICP or CPP targeted therapy. ICP targeted therapy 
aims to reach ICP < 20 mmHg and CPP targeted therapy aims CPP > 50 mmHg. The 
commonly targeted CPP is 60 - 70 mmHg, but when managing patients with impaired 
cerebral autoregulation, the targeted CPP should be kept < 50 – 60 mmHg. Recently, 
Johnson studied status of cerebral autoregulation, targeted CPP and clinical outcome for 
trauma patients and found that in patients with impaired cerebrovascular autoregulation, 
the favorable outcome was noted when CPP kept less than 50 - 60 mmHg (Johnson et al., 
2011). Besides ICP (ICP is a factor in pathophysiology of midline shift, mass effect, 
herniation syndromes), monitoring CBF (CBF is a factor in pathophysiology of ischaemic-
hypoxic damage or cerebral infarction) is also important and plays significant role in 
determining patient’s outcome as depicted in figure 2 and discussed in details above. Since 
currently there is still no optimal and practical method to be used in NIC for measuring 
CBF, other methods of monitoring (besides ICP) in ‘multimodality monitoring’ are trying to 
estimate the CBF values for either the whole brain (CPP, SjVO2, TCD, electrical function, 
EEG and BIS) or for only at certain region of the brain (Saber 2000, LDF, NIRS, Neurotrends 
and cerebral microdialysis). The main goal of these modalities can be viewed as to identify 
early and at a reversible stage either intracranial hypertension or ischaemic-hypoxic insults 
(other goal is to identify subclinical seizures as discussed above).  
In term of CBF (management for ICP or CPP has been discussed previously), the clinician 
effort consists of several aims: to optimize CBF to all regions of the brain whilst to prevent 
expansion of intracranial haematoma or contusion and to restore perfusion of the penumbra 
area. Regional CBF (rCBF) can be measured with many methods as mentioned earlier. The 
Saber 2000 which can be laid onto the area of interest seems more appropriate when the 
clinician wants to safeguard the peri-contusional, peri-haematoma or peri-ischaemic areas. 
The combination of Saber 2000 rCBF monitoring with microdialysis, Licox or Neurotrends 
system would certainly be a helpful approach. Reduction or abnormality in almost all 
parameters would validate one another and hint corrective measures for the clinician to 
take. Similarly, the availability of information on the more globalised CBF (gCBF) 
monitorings such as SjVO2, would indicate any compromise to CBF on a more global basis 
to instigate appropriate corrective actions to prevent ischaemia from inflicting more areas of 
the brain. During ischaemic insults, if both rCBF (Saber 2000 CBF < 30 ml/100g/min; PtiO2 < 
15 mmHg; PtiCO2 > 59 mmHg, hyperthermia, acidotic profiles on pH or microdialysis) and 
gCBF (SjVO2 of decreasing trends or persistent values of less than 50%, abnormal EEGs, low 
value of TCDs) are abnormal, cerebral hypoperfusion is the likeliest suspicion. Further 
actions are needed to try and correct these abnormalities, especially for correctable causes. 
For instance, CBF may be low because of low in mean arterial pressure (MAP) due to the 
new onset cardiac abnormalities such as abnormal rhythms or abnormal stroke volume. 
Other related possibilities include overdosage or side effects of drugs such as anti-epileptics 
or overzealous use of inotropic drugs, new onset pneumothorax, cerebral or cardiac 
embolisation or cerebral vessels vasospasm. TCD monitoring of MCAs, ACAs and other 
major intracranial or neck vessels can readily diagnose vasospasm. Contradictory values 
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7. Interpretation of data and management steps 
In general, two parameters are monitored during multimodality monitoring for severe head 
injury: ICP and CBF (Idris et al., 2007). Combination of these two important parameters help 
neurointensivist to know the status of brain autoregulation, either impaired or intact 
(cerebrovascular reactivity index or PRx)(Smielewski et al., 1997). Therefore, based upon this 
observation, the clinician can opt for ICP or CPP targeted therapy. ICP targeted therapy 
aims to reach ICP < 20 mmHg and CPP targeted therapy aims CPP > 50 mmHg. The 
commonly targeted CPP is 60 - 70 mmHg, but when managing patients with impaired 
cerebral autoregulation, the targeted CPP should be kept < 50 – 60 mmHg. Recently, 
Johnson studied status of cerebral autoregulation, targeted CPP and clinical outcome for 
trauma patients and found that in patients with impaired cerebrovascular autoregulation, 
the favorable outcome was noted when CPP kept less than 50 - 60 mmHg (Johnson et al., 
2011). Besides ICP (ICP is a factor in pathophysiology of midline shift, mass effect, 
herniation syndromes), monitoring CBF (CBF is a factor in pathophysiology of ischaemic-
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CBF, other methods of monitoring (besides ICP) in ‘multimodality monitoring’ are trying to 
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EEG and BIS) or for only at certain region of the brain (Saber 2000, LDF, NIRS, Neurotrends 
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early and at a reversible stage either intracranial hypertension or ischaemic-hypoxic insults 
(other goal is to identify subclinical seizures as discussed above).  
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Saber 2000 which can be laid onto the area of interest seems more appropriate when the 
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new onset cardiac abnormalities such as abnormal rhythms or abnormal stroke volume. 
Other related possibilities include overdosage or side effects of drugs such as anti-epileptics 
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major intracranial or neck vessels can readily diagnose vasospasm. Contradictory values 
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between TCDs and the stated parameters discussed in earlier sections would alert the 
clinician towards cerebral vasospasm as the aetiology for cerebral hypoperfusion (high TCD 
but reduce CBF parameters). Triple-H therapy (includes expanding the plasma volume or 
hypervolemia, hemodilution and importantly hypertension), nimodipine or urgent 
interventional angiography for vasospasm should then be attempted to treat the identified 
problem. If only rCBF is impaired, steps should be taken to augment blood flow to those 
compromised areas only. However, currently, there is limited choice available for clinician 
to optimize rCBF.  Most of the corrective measures for rCBF are in fact lending to optimize 
the gCBF. By augmenting the gCBF, the clinician may face notorious effect of ‘hyperaemic 
insult’ which in cases with markedly impaired cerebral autoregulation can be associated 
with brain swelling or odema and further elevation in ICPs that can aggravate the 
ischaemic-hypoxic circle. Therefore, multimodality monitoring offers more parameters to be 
closely considered when practicing ‘CPP targeted therapy’. By pushing the CPP, the 
clinician should look at SjVO2 which can become more than 75% suggesting cerebral 
hyperaemia and patterns of TCDs values which can become abnormally high. The 
aggressive CPP targeted therapy should not stop unless there is simultaneous elevation in 
ICPs, especially with parallel gradual emergence of deterioration in other monitored 
parameters (especially from Licox or Neurotrends and cerebral microdialysis), suggesting 
presence of markedly impaired cerebral autoregulation and evolving brain swelling which 
finally ends up with reduction in CBF in ‘that particular patient’. If ICPs become elevated 
(with other abnormal parameters suggesting/confirming reliable ICPs), the CPP targeted 
therapy should be stopped and measures such as lowering the MAP, reduction in plasma 
volume or inducing diuresis (with mannitol or diuretics), ICP lowering measures (such as 
mannitol or hypertonic saline, draining of CSF, adding or increasing sedative agent or 
muscle relaxant) should be taken. Decompressive craniectomy or barbiturate therapy should 
be reserved for patients who failed to respond to the initial measures and displayed 
concurrent features of time shift from compensatory to harmful compensatory or 
decompensatory phase. 
8. Malaysia experience in multimodality monitoring   
Our initial study published in 2003 on outcome of severe traumatic brain injury comparing 
the 3 monitoring approaches (multimodality, ICP alone and no cranial monitoring) revealed 
a statistically significant difference in the proportions of good outcomes between the 
multimodality group compared with the group of patients that underwent a single 
intracranial-based monitoring method and the group that received no monitoring (p = 0.003) 
based on a disability rating scale after a follow up of 12 months. Death was the focus of 
outcome in this study in which the multimodality approach to monitoring had superior 
results (Isa et al., 2003). The subsequent studies done in our centre were prognostic and cost 
effectiveness analysis studies of using different monitoring modalities in treating severe 
traumatic brain injury which were completed in 2004 and published in 2007 (Ibrahim et al., 
2007; Idris et al., 2007). 
8.1 Prognostic and cost effectiveness analysis studies of using different monitoring 
modalities in treating severe traumatic brain injury 
Between June 2002 and March 2004, 52 adult patients with severe traumatic non penetrating 
head injury were recruited into our prospective randomised study at our University 
 
Neurointensive Care Monitoring for Severe Traumatic Brain Injury 
 
235 
Hospital, Universiti Sains Malaysia. The aim of the study was to investigate whether 
multimodality monitoring in severe traumatic brain injury would alter the outcome score. 
All adult patients, age of more than 14 years old with traumatic non penetrating head injury 
who had GCS of less than 9 and CT brain without infratentorial pathology were included. 
We excluded those who had a unilateral or bilateral fixed and dilated pupils resulted from 
an on-going herniation, brain dead patient and patient known to have any condition that 
lowering his or her functional status score. The randomisation process was made to allocate 
to either multimodality monitoring or to standard ICP monitoring. In the multimodality 
group, we monitored basic intensive care parameters and multiple cerebral parameters. In 
the standard ICP monitoring group, only ICP was monitored together with basic intensive 
care parameters. Monitoring proceeded for at least 3 days if uneventful. We recorded the 
outcome at 6 months post treatment using the Barthel index score. 
The sixth month’s outcome between those groups (26 patients in each group) was not 
statistically significant (p < 0.48). However, the percentage of cases independent at 6 months 
was higher in the multimodality group compared with single modality group, 21.2% and 
17.3% respectively. The multimodality monitoring group had also lower percentage of 
dependent cases at 6 months in comparison to the single ICP modality group, 28.8% and 
32.7% respectively. The univariate analysis revealed, age (p < 0.03), GCS on arrival (p < 
0.01), 24 hours fluid balance at day 2 of monitoring (p < 0.01), serum sodium (p < 0.03) 
and intracranial pressure at day 3 of monitoring (p < 0.01) were correlated with the 
outcomes. The trends of the parameters disclosed younger, higher GCS, lower injury 
severity score and Marshall grade would have a higher chance to be independent at 6 
months post trauma. Tachycardic, hyperthermic, hypo- and hyper-volumic patients 
during the first 3 days of monitoring tend to be dependent at 6 months post injury. The 
dependent patients also tend to be acidotic or alkalotic for their arterial blood gases, have 
Paco2 of < 20 mmHg or Paco2 > 45 mmHg, blood haemoglobin level of < 8 g/dl, high blood 
urea and sodium, have persistently high ICP of more than 20 mmHg, CPP of < 55 mmHg, 
SjVO2 of < 50% or > 75%, rCBF < 35 ml/100g/min, TCD MCA flow velocity of < 35 
cm/sec and PtiO2 of < 15 mmHg. Despite no significant statistical difference between  
the multimodality and single modality group, a possiblity of better outcome obtained 
with multimodality monitoring technique remains because of higher cases with 
independent status observed in that group. Obviously, this requires larger sample size for 
future study (Idris et al., 2007). We also did a study on cost effectiveness analysis of using 
multiple neuromodalities in treating severe traumatic brain injury. Despite a higher cost 
in multimodality monitoring, the application of multimodality monitoring for severe 
traumatic brain injury was more cost-effective (considering the cost of the equipment  
and the clinical outcome of the studied patients) than baseline neuromonitoring  
(p < 0.001)(Ibrahim et al., 2007).  
8.2 Limitation of multimodality monitoring 
Despite various available cerebral monitoring, the current limitation in managing severely 
injured brain is the therapy to optimize all monitored parameters. Except for high ICP, we 
are yet to have any accepted standard for treating abnormalities detected by CBF/CPP 
monitoring. Future works should focus on improving these diagnostic monitoring tools as 
well as ways to treat or correct those detected abnormalities. Research on therapy is 
continuing and one of the potential therapies is cerebral hypothermia. 
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Fig. 14. Multimodality monitoring for a patient with severe traumatic brain injury. 
9. The future of monitoring and managing the severely injured brain – 
multimodality monitoring and cerebral hypothermia    
Figure 2 illustrates various pathways that promote cerebral ischaemic-hypoxic events which 
can lead to cell death or apoptosis. Interestingly, one can take note that these pathways are 
mostly temperature dependent and therefore can be mitigated with cerebral hypothermia. 
In 2006, Vincent and Polderman reviewed the neuroprotective mechanisms underlying 
hypothermia and listed out various benefits of hypothermic therapy (Vincent & Polderman, 
2006). Hypothermia can inhibit the activation of caspase enzymes, prevents or mitigates 
mitochondrial dysfunction, decrease the metabolism as well as decrease the overload of 
excitatory neurotransmitters such as glutamate and free oxygen radicals, modify the cellular 
disorders of intracellular ion concentrations, suppress the inflammatory and immunological 
responses and epileptic activity, reduce the disruption in blood brain barrier, vascular 
permeability and oedema, improve the microcirculatory circuits and intra- and extra-
cellular acidosis, correct the hyperthemia after brain injury, influence the local secretion of 
various vasoactive mediators secreted by the endothelium and enhance expression of 
immediate early genes and cold shock proteins. Building on the vast benefits of cerebral 
hypothermia, currently underway is a locally adapted approach to induce hypothermia in 
severely injured brain patients using a direct method and study their outcomes. 
9.1 Our current study - Direct brain hypothermia for trauma patient with Glasgow 
coma score of 6 and 7  
The objective 
To determine the effect of direct focal brain cooling on outcomes of severely injured brain 
patients. 
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Materials and Methods 
This is a randomized controlled study following an approval by the research and ethics 
committee of Universiti Sains Malaysia (USM). All adult patients with severe traumatic 
brain injury with GCS score of 6 - 7 and require decompressive craniectomy (DC) will be 
screened for eligibility to be recruited into this study. Once included, the patient will be 
randomized to either group A or B. Group A (treatment group) patients will receive therapy 
with direct focal brain cooling and group B is a control group, consists of patients who do 
not have direct focal brain cooling therapy. All patients will have ICP, Licox, BIS, EEGs and 
cardiac parameters monitoring during cooling period, and bloods will be drawn for 
immunological parameters prior to surgery and after local cooling therapy to the brain. This 
mode of multimodality monitoring and therapy will last for 24 - 48 hours, or longer if 
intracranial pressure parameters stays abnormal. The neurosurgical DC is a standard 
operation. A unilateral DC is planned for patients with the presence of ipsilateral pathology 
with midline shift and a bifrontal DC for brain swelling in patients with or without frontal 
pathology but in the absence of midline shift. The monitoring and therapy given after the 
surgery are the standard therapy for severely injured brain.  
Direct focal brain cooling method is achieved through continual irrigation of the brain with 
cold Hartmann’s solution in which the temperature of the infused fluid is divided into 2 
groups as follows: 1. deep cooling (Hartmann’s temperature of 20 - 29 degree celcius) and 2. 
mild cooling (Hartmann’s temperature of 30 - 36 degree celcius). The cold Hartmann’s 
solution is infused via neurojaf external ventricular drainage (EVD) with multiple modified-
extra holes catheter which is placed superior to the dura flap and in contact with the surface 
of the brain. It acts like rain flushing through the surface of the swollen brain, and with 
pulsation of the brain, the cold fluid is expected to be distributed to other areas of the brain. 
The infusion rate is targeted at 500 mls of Hartmann’s solution within 7 hours (70 mls/hr). 
Because of the position of the head in NIC, the second draining tube will be inserted at the 
lower part of the craniectomy flap outside the dura which at some areas, the closure is 
purposely made loose to drain the excess fluid with low suction pressure. The temperature 
of the infused Hartmann’s solution is always checked via the three way connector, draining 
the fluid out to the collection port for temperature assessment. If temperature reading is 
under or above the intended value, new solution with correct intended temperature will 
replace the previous one. All patients will have CT scan done if the ICP shows persistently 
raised values despite standard therapies being given. This is important to exclude any new 
surgical lesions and to exclude the retention of infused solution as a cause of raised ICP. If 
the ICPs show normal values, the CT scan of the brain will be done after 48 hours of therapy 
prior to removal of the EVD tube to document the location of the EVD tip. The outcome 
assessment for this study is the Glasgow Outcome Score at discharge and at 6 months after 
trauma and requirement for tracheostomy together with number of days ventilated in NIC.   
Preliminary Results   
Based on the preliminary recruitment of 7 patients in each group, there was significant 
difference in outcome upon discharge with better outcome score for the cooling group (p < 
0.02). In the cooling group, five patients had good GOS of 4 [independent status] and one 
patient attained dependent status with GOS of 3 [dependent]. The remaining one patient in 
this group who has an initial GOS of 3 had sudden onset aspiration pneumonia and died 
(GOS upon discharge scored as 1). On the contrary, five patients had GOS of 3 and two 
patients with GOS of 2 [all were dependent status] in the non cooling-control group. 
Furthermore, there were marked reductions in the ICP and brain temperature, and 
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improvement in PtiO2 and CPP of patients who had received cooling treatment. There was 
also faster ventilator weaning in the cooling group with median duration of 7 days 
compared to the control group of 9 days duration. Detailed analysis is yet performed 
because this study is still ongoing. 
 
 
Fig. 15. The typical multimodality monitoring set up for the randomized controlled trial 
involving the management of the severely injured brain with hypothermia at our NIC, 
University Hospital, Universiti Sains Malaysia 
10. Conclusion   
The pathophysiology of the severe non-penetrating traumatic brain injury involves complex 
chain of events at molecular, cellular or vascular levels. These pathophysiological processes 
extend beyond the confine of the brain as they also involve other body systems such as the 
cardiopulmonary system. Understanding these complex mechanisms is vital in our efforts to 
expand the usefulness of multimodality monitoring for the severely injured brain patients. 
However monitoring alone will not greatly alter the outcome, therefore future research 
should also focus on the therapeutic aspects of ICP and CBF monitored parameters. 
Currently, multimodality monitoring of the brain together with therapeutic cerebral 
hypothermia hold leading promises in the monitoring and treatment of the severely injured 
brain patients. 
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improvement in PtiO2 and CPP of patients who had received cooling treatment. There was 
also faster ventilator weaning in the cooling group with median duration of 7 days 
compared to the control group of 9 days duration. Detailed analysis is yet performed 
because this study is still ongoing. 
 
 
Fig. 15. The typical multimodality monitoring set up for the randomized controlled trial 
involving the management of the severely injured brain with hypothermia at our NIC, 
University Hospital, Universiti Sains Malaysia 
10. Conclusion   
The pathophysiology of the severe non-penetrating traumatic brain injury involves complex 
chain of events at molecular, cellular or vascular levels. These pathophysiological processes 
extend beyond the confine of the brain as they also involve other body systems such as the 
cardiopulmonary system. Understanding these complex mechanisms is vital in our efforts to 
expand the usefulness of multimodality monitoring for the severely injured brain patients. 
However monitoring alone will not greatly alter the outcome, therefore future research 
should also focus on the therapeutic aspects of ICP and CBF monitored parameters. 
Currently, multimodality monitoring of the brain together with therapeutic cerebral 
hypothermia hold leading promises in the monitoring and treatment of the severely injured 
brain patients. 
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1. Introduction 
Road traffic injuriy (RTI) is a serious threat to human life and health. Currently, there are about 
130 million people died and about 200 to 500 million people injured in road traffic accidents 
worldwide each year [1]. In the developing country, for example, in China, there are 10 million 
people died and 50 million people injured in road traffic accidents each year [2]. With social 
progress and development of medicine, many diseases (such as some infectious diseases) have 
been effectively controlled, but the road traffic injury is increasing [3].  
The biomechanics of head impact injury has become a research focus in the impact injury 
biomechanics. The study aims to understand the mechanical response of brain tissue to the 
impact, and to determine the dose-effect relationship between the brain injury and the 
mechanical load. It can clarify the mechanism of brain injury and provide a theoretical basis 
for the development of head injury protection and injury indicators. 
Besides brain tissue outside the body wrapped in the scalp, there is other non-transparent 
tissue covering the skull. And brain tissue itself is non-transparent organization. Therefore, 
it is extremely difficult to research the stress-strain for brain tissue under deceleration 
impact. In this regard, scholars of various countries have done a lot of meaningful 
exploration and research. 
In order to observe the impact stress wave propagation of the skull and brain tissue, 
Yanping Jiang [4], has developed a brain static and dynamic photoelastic model (Fig.1). As 
the model deformed by the collision, with the light reflectivity and angle changing 
accordingly, and the formation of photoelastic fringes, the changes can be calculated by the 
stripes of the force of brain tissue, for photoelastic fringe dense area with larger force. 
However, for the mechanical properties of the model and the response calibration and other 
reasons, it is difficult to conduct quantitative research on stress and strain. 
In order to produce the same size with the real head of the head model, in 2005, Johnson and 
Young [5] applied rapid prototyping technology to produce a true copy of the skull (Fig.2). It 
has been used in the research of the brain impact response, confirming that the effective 
impact time decreases with the decrease of hammer quality. The model is made with 
opaque material. However, because of it, it can be only used for the skull study, and not 
suitable for the force characteristics of brain tissue. 
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In 2007, there was a very classic corpse occipital head impact experiment finished by Wayne 
State University and other research organizations (Fig.3) [6,7]. Before the experiment, markers 
had been made by metal balls and thin-walled tubes whose density was close to the brain 
tissue. During the impact, markers had been placed in the brain model as well as mini 
markers planted into the skull, then the high-speed X-ray machine (250 frames/sec) was 
used to record the impact process. After analyzing for the captured images, it concluded the 
"8" shaped trajectory (Fig.4) of markers relative to the skull and its laws. It is a new means of 
measurement and it has provided valuable raw data for the study of injury mechanism of 
injury provide valuable raw data. 
 
 





Fig. 2. The rapid prototyping skull model 
 




Fig. 3. Shooting of the impact process for the corpse head by the high-speed X-ray device [6] 
 
 
Fig. 4. The relative "8" shaped trajectory of the markers in the skull model [7] 
The high-speed X-ray machine can obtain the displacement and even the strain information 
of markers in brain tissue, but it cannot detect intracranial stress. 
To this end, a visual model of the physical brain containing bubbles has been developed 
(Shengxiong Liu, 2010)[8] for brain injury mechanism research. This visual model can 
effectively reflect the brain impact stress response. The study provides an intuitive non-
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invasive intracranial stress wave detection and analysis method. It is a non-destructive and 
non-contact testing method, as an innovation test concept. The following will introduce the 
visualize brain model, the experimental device and the stress wave detection experiments. 
In addition, it provides conditions for the body digital model and the study of brain injury 
by the development of electronics technology, computer science, and computational 
mathematics. Finite element (FE) method is a numerical analysis method developed from 
the analysis of engineering structures for solving problems of continuum mechanics. In 
1969, Fridenbery applied finite element theory to the medical field for the first time, which 
has provided new methods and theories for human biomechanics research. FE model of 
human first started from the local model, and the earliest FE model is the human head 
model. By the head finite element model, it has greatly promoted the study of head injury 
biomechanics. With the increasing development of science and technology, computer 
simulation is more and more likely to replace the traditional biomechanical studies on the 
biological impact test. Finite element model of the skull has been built [9] to study the 
intracranial stress and strain distribution of the brain during the deceleration impact, as well 
as the reproduction of traumatic brain injury. 
2. The dynamic visualization technology of head injury based on the 
transparent physical model 
2.1 Physical model 
2.1.1 Screening of brain tissue substitute materials  
It can generate pure bubbles anywhere within the model with a syringe by plant hydro gel 
to simulate brain tissue before gel solution. During the collision process, the bubble 
locations are fixed without interfere movement. Bubble deformations are uniform that it is 
helpful for calculating the bubble volume changes. 
2.1.2 Screening of skull alternative materials 
The glass and PC resins are all optional alternative materials to the skull. The glass is of 
good transparency and drawing easy, which is easy to observe the morphological changes 
of markers in the brain impact. PC resin is of good impact resistance, good transparency and 
low water absorption, that its mechanical properties are relatively close to the skull. 
2.1.3 Model development 
In this study, the transparent skull physical model (Fig.5) has been produced with the real 
skull and the PC resin by the molds technology. Molds technology ensures the high degree 
of geometric similarity to the real skull. PC resin ensures the transparency of the model that 
it has good impact resistance and mechanical properties. It reaches the same level of 
magnitude to the real skull with low water absorption as the research foundation. 
The brain model is of well transparency for the markers observation that it can get a clear 
bubble deformation by high-speed camera during the impact course. Since the model has 
similar geometry to the real skull, it is a very effective way for quantitative analysis of the 
deceleration injury mechanism. 
2.2 Deceleration impact device 
It needs firstly to solve about the initial velocity of the skull model for the deceleration 
injury impact experiments, then the model fixation during the experiments. If the subjects  
 




Fig. 5. The visualization skull model by the PC resin on the molds technology [8] 
were fixed on the pulley, then let the pulley "free" fall along the track, its final fall speed (test 
speed) can be controlled by the fall height (h). The experimental principle is shown in Figure 
6, and the specific principles can be derived based on Newton's laws of motion. 
According to Newton's laws of motion it has the following formula: 
 20 2tv v as       (1) 
Where: 
vt as the speed for experimental subjects falling from the height h; 
v0 as the initial velocity for subjects before falling; 
s as the acceleration distance, where calculated by the fall height h; 
a as the acceleration, here as the acceleration of gravity g; 
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s as the acceleration distance, where calculated by the fall height h; 
a as the acceleration, here as the acceleration of gravity g; 
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Since the subject falling from height h with initial velocity (0m/s), its immediate speed is: 
 2tv gh         (2) 
 
 
Fig. 6. The schematic diagram of deceleration injury simulation device 
It can be seen from Figure 6 that the pulley is located between the upper platform and the 
lower platform where is the falling space for the pulley. The pulley rolling along the guiders 
which are two vertical stainless guide rails parallelled to each other are set up in the space. 
Their upper ends are fixed to the upper platform while their lower ends to the lower 
platform. Tightness of guiders can be adjusted as needed to prevent the obstruction 
disturbances during the experiment. In addition, the four poles are connected with the 
movable platform by the groove mode. The spacing among the poles can be adjusted to 
adapt to different sizes and shapes for the skull model. 
2.3 Intracranial stress wave detection experiments 
2.3.1 Experimental platform 
Experimental platform as shown below (Fig.7), the device made by a transparent head 
model of the PC resin material geometrically consisted with the real brain and a deceleration 
impact test device. 
2.3.2 Experiment preparation 
First, the warm plant hydrogel was put into the model waiting for cool. During the cool 
process, three bubbles were injected into the semi-liquid and -solid gel by the special syringe 
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at positions of the impact, the neutral and the hedge points. After standing, due to thermal 
expansion and contraction, there should be small gaps at the junction of the gel and the 
container. Gaps were filled with some water, which could simulate the structural 
components of cerebrospinal fluid to some extent. The model was sealed by the rubber plug 
with a small needle connecting the gel and the external environment, which could simulate 
the connectivity of the foramen magnum. Then the brain model was fixed with sensors 
accessing to the data acquisition system. 
 
 
Fig. 7. The deceleration impacting system for the PC transparent resin skull model [8] 
2.3.3 Test steps 
At the beginning, the model together with the pulley are upgraded to the position about 
0.60±0.01m away from the lower platform to simulate the moderate impact of the brain 
injury. Then the tackle was released and free fell along the guiders, hitting the lower 
platform, which triggered the sensor and the high speed camera system to record the whole 
impact process. 
2.3.4 Stress wave analysis 
By high-speed video analysis, the axial length of the bubbles were extracted from the photo. 
Volume changes of the bubble were analysed to obtain the changing curves of the average 
pressure for each bubble. Then the stress and the changing information of the brain tissue at 
the  corresponding location were analysed. 
The bubble volume during the impact can be calculated by the ellipsoid formula. According 
to formula (3), it is based on the short axis (a) and long axis (b) ( the other axis is equivalent 
to the short axis (b)) as: 
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V a b   (3) 
Here, Vn is the volume of the bubble at the frame of n; an is the short axis of the bubble at the 
frame of n; and bn is the long axis of the bubble at the frame of n. 
Therefore, the mean stress for the brain tissue, that is the average bubble pressure, can be 





   (4) 
Here, P0 is the initial pressure of the bubble before the collision, which is approximately 
equal to a standard atmosphere pressure, in order to make Pn easy to calculate and compare 
with each other. V0 is the initial volume of the bubble before the collision; Vn is the volume 
of the bubble at the frame of n during the collision; and Pn is the average pressure of the 
bubble at the frame of n. 
2.3.5 Results 
There were 28 photographs extracted from the video from the crash on the first frame to 
bubbles returning to its initial size. Then the average pressures of each bubble were 
calculated and compared with the average stresses of the two bubbles at the impact point 
and the hedging point. 
2.3.5.1 Overview of photograph series 
Figure 8 shows the sequence of 28 photographs about bubbles from the crash on the first 
frame (0 ms) to bubbles back to its original volume (5.4 ms). 
 
 
Fig. 8. Twenty eight serial frames from the onset frame of the impact to the frame in which 
the air bubbles came near to their original volumes [8] 
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As can be seen from Figure 8, in the upper pictures, the volume of small bubbles at the 
hedge points is increasing; while in the lower pictures, it is decreasing. In contrast, in the 
upper pictures, the volume of small bubbles at the impact points is decreasing; while in the 
lower pictures, it is increasing. It illustrates the different changing trends of the average 
stress for the hedging point and bubbles during the impact. 
2.3.5.2 The average pressure and transmission characteristics for the hedging point and 
bubbles 
Figure 9 shows the details of the average pressure, the changing process and the 
transmission characteristics for the hedging point and the bubble pressure: 
 
 
Fig. 9. The mean pressure changes and the transmission characteristics of the bubbles in 
coup and contrecoup points from frame 1 to frame 28 [8] 
In Figure 9, the average pressure of bubbles from the first frame to the 14th frame is 
increasing; while from the 15th to the 28th, it is decreasing, in which the largest average 
pressure is 3.06×100K Pa. It demonstrates that the brain tissue at the impact locations must 
suffer in a larger positive pressure which produces compressive stress and results into 
compression injury. Similarly, it can be seen from Figure 9 that the average pressure is 
decreasing based on the bubbles at the hedge points from the first frame to the 13th frame; 
while from the 14th frame to the 28th frame, the average pressure is increasing, in which the 
smallest average pressure is 0.54×100K Pa. It indicates that the brain tissue in the hedge 
location must suffer in a continuous negative pressure in the impact process. Although the 
intensity of the negative pressure to the hedging point is lower than the intensity of the 
positive pressure to the impact point, the hedge position of the brain tissue will be injured 
by the tension stress and its stretch for the tensile resistant strength is lower than the 
pressure resistant strength. 
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3. The dynamic visualization technology based on the skull FE model 
3.1 Establishment of FE model 
3.1.1 Data sources and working platform 
The data is from the second case in the CVH data. It has taken the from the 1049th to the 
1791st level of the continuous thin layer of cross-sectional images from the registration 
data set. The layer spacing is 0.25mm and the resolution is 3072 × 2048 pixels. The image 
format is the uncompressed ". tiff" format. Choose the singular images as the objects in 
total of 372 layers to do image process in the HP xw9300 graphics workstation of high 
performance. 
The following FE skull model was built on the platforms of the 64-bit WindowsXP operating 
system, three-dimensional image reconstruction software Amira 4.1 (TGS French company), 
Photoshop (Adobe, USA) and Hypermesh8.0 (U.S. Altair's). 
3.1.2 The finite element modeling of the skull  
It was identified and done segmentation on thesuccessive layers of the cross-section images 
on the brain, ventricular system, brain stem, cerebellum, falx, tentorium, sinus, calvarial, 
facial bone and mandible and other parts of the relevant structures through Photoshop (CS4, 
USA) software. layers of the same structure was filled with the same RGB color values (red, 
green and blue). Any two structures should not be in the same RGB color value and the 
image background was removed. 
Different gray values were given to each structuire of the segmentations which was then 
changed into the grayscale. These images were input into the HP image workstations. The 
software of Amira 4.1 was applied to do the 3D reconstruction of the skull. 
The trias unit was used to fit the anatomy of the 3D skull reconstruction. The model was 
simplified and smoothed according to the complexity of the anatomical structure of the 
model. The various parts of the shell head unit were stored as the hmascii format. The face 
was reconstructed by the semi-automatic way and it was by the closed surface for the brain, 
the cerebellum, the brain stem and other brain structures. 
The surface triangulation of the skull structure was splited according to the radius of 
curvature of the anatomy. Then the 2D grids were splited on these surfaces. At last, the 3D 
meshes were splited from the 2D surfaces. They were checked on the skewness (Skew), 
Warp (Warpage), Jacoby number (Jacobian), aspect ratio (Aspect), the grid unit length 
(length) and other grid qualities. 
The penetration inspection was done on the grid belonging to different structures. The self-
contact inspection was done on the single structures. Ignore penetrations were set to 0. The 
penetrating grids were zoomed or adjusted in the penetrating direction until all the self-
exposure structures were eliminated. 
3.1.3 Skull FE model 
The partition structure can be automatically extracted by the specified gray value through 
the thresholding function without segmentation leakage and fault. In the software of Amira, 
the 3D images of each partition structure can be clearly distinguished after the 3D 
reconstruction of the extracted segmentation information. These images are smooth and 
lifelike in which the small structure can be observed completely like the maxillofacial and 
skull base (Fig. 11). Can be constructed based on the observed need to rotate images at any 
angle. Image angels can be rotated arbitrarily by the observing need. 
 




        
                                    (a)                          (b) 
Fig. 10. Slice Image of Head 
(a) Raw CVH slice image; (b) Segmented CVH slice image 
 
   
                          (a)                                                 (b)                                                  (c) 
Fig. 11. 3D Reconstruction of Head 
(a) skull; (b) fundus cranii; (c) brain 
The solid skull model reconstructed from 3D images is of good correspondence with the 
anatomy especially in facial and skull base parts. From three-dimensional image 
reconstruction of the skull and three-dimensional image corresponding to the solid model is 
good, no distortion. Solid models and surface subdivisions of skull and brain are shown in 
Figure 12. 
The quality tests results of Skewness (Skew), Warp (Warpage) and Jacoby number (Jacobian) 
for the finite element grid meet the engineering requirements (Table 1) with uniform grid 
cell size mainly in the 1.5 to 4.5. The nodes and elements numbers of the FE model are 31,223 
and 119,911. All elements are solid elements. Head finite element model of the number of 
nodes and elements are 31,223 and 119,911. There is no contact between the skull and the 
brain. There is grid contact between the brain and the brain stem without Penetration. 
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                        (a)                                                    (b)                                                    (c) 
Fig. 12. Reconstruction of Solid Model and Partition 
(a) skull; (b) inferior maxilla; (c) cerebrum 
 
Checking items Engineering requirements Actual values 
Nodes —— 31223 
Elements —— 119911 
Length Distribution 1.5~4.5 
Skew <600 <500 
Warpage <500 <500 
Jacobian >0.7 >0.95 
Aspect <5.0 <2.8 
Table 1. Mesh Quality Check for Finite Element Model of Head 
The finite element mesh of the skull includes two parts as skull and brain. The skull includes 
three parts as the cranium, the facial bones and the mandible bones. The FE grid of the 
cranium contains the frontal skull, the temporal bone, the occipital bone, the sphenoid, the 
ethmoid, the parietal bone and the maxillofacial bone and other anatomical structures in detail. 
Fine structure of the skull FE model has been carved out in detail as shown in Figure 13. 
3.2 The brain deceleration injury research based on the finite element  
(FE) model 
3.2.1 A case for the brain deceleration injury 
A male of 19 years old, height 1.70 m and weight 55 kg fell accidentally in the work from 4.0 
m to the cement floor grounded with right occipital and immediately coma for 3.5 hours 
with cerebrospinal fluid rhinorrhea not accompanied by incontinence and no vomiting. He 
had been head injured and in disturbance of consciousness for 1 day and waked severe 
headache with vomiting 2 times. Specialist examination: inspection cooperation, a right 
occipital palpable size of about 1 × 2 cm scalp hematoma, lethargy, poor time orientation, 
memory loss, calculated power loss and hallucinations. GCS score: Opening eyes responses 
4, language 5, movement 6, total scores 15. 
Brain CT images after injury: the right occipital scalp hematoma, linear fracture of the right 
occipital whose fracture line extended to the right parietal bone and the left occipital, right 
anterior and middle cranial fossa fracture, bilateral frontal lobe contusion with a small  
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            (a)          (b) 
 
    
          (c)              (d) 
Fig. 13. Finite Element Model of Chinese Head 
(a) skull; (b) brain; (c) transverse plane of fundus cranii; (d) sagittal plane of skull 
hematoma (dual frontal pole and the inner side and the right amount of bottom), bilateral 
temporal lobe (temporal pole) contusion with a small hematoma, left temporal and occipital 
subdural hematoma, subarachnoid hemorrhage (around tentorial) (Fig.14-15). 
3.2.2 Computer simulation of damage process 
The 3D FE model was input into the software of LS-DYNA to do simulation and analysis for 
reconstruction of the occipital brain deceleration injury. The skull is defined as a general 
elastic material, and the brain as a viscoelastic material. The material mechanical parameters 
of the skull FE model are directly referred to the literature data [10,11]. The skull and the brain 
contact with each by the coupling gap as friction coefficient Fs (mean value as 0.08). It was 
established a finite element model of the flat impactor to simulate the stationary blunt hard 
objects of great quality. The flat impactor limited at the base part was defined by the 
Solid164 elements with E as 15000GPa and μ as 0.3. It simulated the brain deceleration 
injury through the hitting of the flat impactor and the right occipital (Fig.16) based on the 
formula v02 = 2gh where the initial velocity of the skull was 9m/s. The software of 
Hyperview was applied to do analysis of the simulation and the load step brain Von Mises 
stress was output by the graphics form. 
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Fig. 14. A linear fracture of the right occipital, which extends to the right parietal bone and 




     
 
Fig. 15. Bilateral frontal and temporal lobe contusion with a small hematoma 
 




Fig. 16. A simulation model of brain deceleration injury in the flat hard board on the right 
occipital. 
3.2.3 The intracranial stress and strain distribution of brain deceleration injury 
Stress of brain tissue changes firstly in the bottom of the right occipital (the focus), then 
extending along the adjacent skull and the skull front and base. Von-Mises stress peaks at 
the right occipital. The stress wave gradually spreads from the collision site to the adjacent 
skull in radiating form. Stress changes include the left occipital bone, bilateral parietal and 
right temporal bone with high stress concentration (yellow). Stress wave moves forward 
involving the bilateral temporal bone, zygomatic arch and the left frontal bone, but the Von-
Mises stress distribution valuesare low (light blue). Stress wave in the skull base moves 
from back to front and gradually expands to the bilateral posterior fossa of the foramen 
magnum rear, bilateral anterior and middle cranial fossa with a stress concentration 
(yellow) , and the right part is of more obvious changes (Fig.17-18). 
 
 
Fig. 17. The stress distribution on the back of the skull 
Stress of brain tissue changes firstly in the bottom of the right occipital lobe (the focus), 
then diffusing along the bottom of the brain and brain surface. Von-Mises stress peaks at 
the right occipital lobe. In the brain surface, the stress wave spreads gradually around to 
the right occipital lobe in radiating form. Ranges of stress changes include the right 
parietal lobe, the temporal lobe, the cerebellum and the left occipital lobe, but the 
distribution of Von-Mises stress values are low (light blue). Stress wave gradually 
extended from back to front along the bottom of a gradient of brain. The changing scopes 
include the corpus callosum, bilateral cerebral peduncle back, bilateral temporal lobe 
 







Fig. 14. A linear fracture of the right occipital, which extends to the right parietal bone and 




     
 
Fig. 15. Bilateral frontal and temporal lobe contusion with a small hematoma 
 




Fig. 16. A simulation model of brain deceleration injury in the flat hard board on the right 
occipital. 
3.2.3 The intracranial stress and strain distribution of brain deceleration injury 
Stress of brain tissue changes firstly in the bottom of the right occipital (the focus), then 
extending along the adjacent skull and the skull front and base. Von-Mises stress peaks at 
the right occipital. The stress wave gradually spreads from the collision site to the adjacent 
skull in radiating form. Stress changes include the left occipital bone, bilateral parietal and 
right temporal bone with high stress concentration (yellow). Stress wave moves forward 
involving the bilateral temporal bone, zygomatic arch and the left frontal bone, but the Von-
Mises stress distribution valuesare low (light blue). Stress wave in the skull base moves 
from back to front and gradually expands to the bilateral posterior fossa of the foramen 
magnum rear, bilateral anterior and middle cranial fossa with a stress concentration 
(yellow) , and the right part is of more obvious changes (Fig.17-18). 
 
 
Fig. 17. The stress distribution on the back of the skull 
Stress of brain tissue changes firstly in the bottom of the right occipital lobe (the focus), 
then diffusing along the bottom of the brain and brain surface. Von-Mises stress peaks at 
the right occipital lobe. In the brain surface, the stress wave spreads gradually around to 
the right occipital lobe in radiating form. Ranges of stress changes include the right 
parietal lobe, the temporal lobe, the cerebellum and the left occipital lobe, but the 
distribution of Von-Mises stress values are low (light blue). Stress wave gradually 
extended from back to front along the bottom of a gradient of brain. The changing scopes 
include the corpus callosum, bilateral cerebral peduncle back, bilateral temporal lobe 
 
Brain Injury – Pathogenesis, Monitoring, Recovery and Management 
 
260 
(temporal pole, bottom and outer side) and bilateral frontal lobe (frontal pole, bottom and 
inner side). In , there is a stress concentration (yellow) at the back of the corpus callosum 
and the bilateral cerebral peduncle. Then, there is stress concentrations (yellow) (Figure 
19-20) in the bilateral temporal pole, bilateral medial frontal pole and the right and frontal 
underside of the lobe. 
 
 
Fig. 18. The stress distribution inside the skull bottom. 
 
 
Fig. 19. The stress distribution behind the brain 
 
 
Fig. 20. The stress distribution at the bottom of the brain 
3.2.4 The comparison of brain stress response results and clinical CT images 
The comparison of the brain stress concentration showed by the FE model and clinical  
CT images is shown in Table 2. From the Table, locations of clinical skull fracture,  
brain contusion, subarachnoid hemorrhage are consistent with the stress concentration 
locations of DE simulation, but the changing locations in the FE calculation is not necessarily 
for the brain injury (such as the right occipital lobe). 
 




FE anlaysis Stress concentration  
Right occipital, right parietal bone, left occipital, bilateral 
posterior fossa of the foramen magnum rear, bilateral 
anterior and middle cranial fossa 
CT 
performance 
Skull fracture Right occipital, right parietal bone, left occipital, right anterior and middle cranial fossa 
Subarachnoid 
hemorrhage Around the posterior fossa transtentorial 
Brain 
tissue 
FE anlaysis Stress concentration 
Right occipital lobe, corpus callosum, bilateral cerebral 
peduncle back, bilateral temporal pole, bilateral medial 
frontal pole and the right frontal lobe underside 
CT 
performance Brain contusion 
Bilateral temporal pole, bilateral medial frontal pole and 
the right frontal lobe underside 
Table 2. The comparison of the stress concentration calculated by the FE simulation and the 
clinical head CT images  
4. Discussion 
4.1 The dynamic visualization technology of head injury based on the transparent 
physical model 
In the classic experiment (Nahum, 1977 ) [12], a columnar load unit with a circular contact 
surface has been used to hit the forehead of the body head. Although the experiment is 
limited to the acceleration impact, it is more similar to the bubble experiments than other 
known experiments. From both the experimental data, their results are consistent. The 
absolute value of head acceleration and the HIC value in the bubble experiment are slightly 
larger than in the Nahum experiment (experiment 43). These differences lead to the more 
severity of the pressure values for the impact point and the hedging point in the bubble 
experiments than in the Nahum experiment (experiment 43). Through these two 
experiments and their results, it has compared and further demonstrated the feasibility of 
the bubble model. 
4.2 Dynamic visualization technology of brain injury based on FE model 
4.2.1 Skull FE model based on the Chinese visual figure set 
Since the early 1990s, a new research has begin by Ruan, et al [13], to establish the FE model 
of head injury. The model simulates a 50-year-old male head totally weighted 5.059 kg. 
Structural organization of the head included: the scalp, the skull (including the plate, in 
plate and intermediate layers), the meninges (including the dural membrane and sickle), the 
cerebrospinal fluid, the left and right cerebral hemispheres, the cerebellum, the midbrain 
and the brain stem. Other series of head models established based on Ruan's have achieved 
a lot of progress in the application, such as Zhou [14], Zhang [15], Prasad [16] and so on. FE 
researches on the brain injury have also made some progress in China, such as Lai Man[17], 
Yang Ji-hong [18] and Nguyen [19,20] and so on. 
The accuracy and the reasoning of the structure directly affects the accuracy of FE analysis. 
So it is one of the conditions that it has the similar geometry of the FE skull model with the 
object. The constructed FE skull models are taken the CT or MRI slice images as the primary 
data sources to build the FE model that they are not of good accuracy in details because of 
the blurred scanning boundary limitations of CT/MRI.  
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In recent years, the human visualization technology has become a high tech integrated of 
anatomy, computers and virtual reality. Digitized visible human (DVH) relyies on the 
computer 3D technology showing the structure of real human organs. Professor Zhang 
Shaoxiang (Third Military Medical University, China) has completed the CVH image data 
acquisition after other researchers in the United States and South Korea [21,22]. The FE skull 
modelin this study has selected data from the second case of CVH. The data set selected was 
of no organic disease and defects in the human body; the entire specimen cross-section was 
of no segmental defects; the layer spacing was 0.25mm; the resolution were 3072 × 2048 
pixels; the uncompressed digital image resolution were cross-section 6.3 million pixels; and 
each section of the image file size was 36MB. The detail results were more accurate and 
reliable. Therefore, it has more advantages in data integrity, and accuracy of representation 
than the currently reported FE skull model. 
4.2.2 Brain deceleration injury research based on the head finite element model 
It has successfully simulated and reproduced the distribution and characteristics of skull 
and brain tissue in the occipital deceleration shock by the brain 3D FE model materialized 
with CVH to hit the plate impactor by the right occipital in falls-style head deceleration 
injury. From the finite element simulation, it can be found that the stress wave pass in all 
directions along the skull and brain tissue at the focal point. In the path of the stress wave, 
the brain tissue may be damaged. The stress wave passes along two ways in the brain at the 
same time: one way is from the impact side to the contra-side along the skull; the other way 
is from the impact side to the contra-side along the brain tissue. In the occipital deceleration 
shock, in addition to impact parts of the skull and brain tissue under stress concentration, 
the hedge position is also apparent stress concentration area. For the distribution of stress 
concentration, it is not only of good correlation of clinical CT images, but also significant for 
the common clinical brain injuries. 
5. Conclusion 
With the achievements of materials science and computer science, researches on the head 
deceleration injury has achieved the dynamic visualization in the biomechanics research. 
Through dynamic visualization techniques, it can be visually observed and analysed for the 
intracranial pressure distribution in the brain and the transmission process of the stress 
wave. It is also an important supplement for the modern testing technology. It is a non-
destructive and non-contact testing method which can reveal the mechanism of the brain 
deceleration injury from a different angle, and to provide biomechanical basis for its 
prevention and treatment. 
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1. Introduction 
The traffic injury research originated during World War I. An American pilot named H. De 
Haven found the seat belt buckle and other cockpit parts of the fighter usually caused 
damage in crash accidents.Fifteen years later, he had confirmed the rubber windshield 
wipers could effectively prevent the metal penetrating injury caused by the forehead and 
facial scratches. Shortly after World War II, a mechanist J. P. Stapp led a preliminary study 
on the damage tolerance through accelerating pulley crash tests. Moseley (1970) tied a 5.1cm 
thick foam rubber pad to the right chest armpit of a dog, and fixed a steel of 7.6cm diameter, 
with a pistol firmly against the steel plate firing through the device to trigger shooting at the 
end of the spontaneous breathing. The model could cause the extensive parenchymal 
contusion, with the classical X-ray photographs performance and cardiopulmonary function 
changes. Anatomy of a few hours after the animal could be extensive lung hemorrhage, and 
there was often blood in the right bronchus. 
2. Series devices for biological impact 
In late 1960s, a simple gravity or gas-driven hammer impact animal unit has been appeared; 
as well as a model of liquid impact in nerve trauma study used, namely the liquid through 
the closed pipeline to transmit the hammer force to the brain tissue to cause damage. With 
the deepening of the study, it had been noted that the force changing on organisms and the 
precise control were critical for the study of dynamic effects. It needed to establish an ideal 
experimental device or model on the impact injury studies, that a series of bio-shock devices 
had been developed.  
1) Vertical biological impact machine  
1. Controllable biological impact systems 
In 1974 the Swedish scholar successfully developed a controllable biological impact system 
to do impact injury experiments. It composed of the tower and the hit platform. The tower 
was equipped with a vertical pipe and cable guide. The hammer could vertically drop along 
the guide under the action of gravity acceleration. The impact platform included the steel 
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had been developed.  
1) Vertical biological impact machine  
1. Controllable biological impact systems 
In 1974 the Swedish scholar successfully developed a controllable biological impact system 
to do impact injury experiments. It composed of the tower and the hit platform. The tower 
was equipped with a vertical pipe and cable guide. The hammer could vertically drop along 
the guide under the action of gravity acceleration. The impact platform included the steel 
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frame, the second hammer, the second hammer stopper and animal movement supporting 
frames. The impact machine works by: The hammer from different heights along the guide 
rail whereabouts -- drove down the second hammer impact sports -- animals -- injury. It was 
by adjusting the height (0.1 ~ 25m) and the quality (2 ~ 10kg) of the hammer to get different 
impact velocities (1 ~ 20m / s) and impact energy; by adjusting the height of animal 
backstop and the relative position of the second hammer to change the compression degree; 
by replacing the second hammer head to get different impact shapes and areas. In addition, 
there were mechanical power sliding displacement sensors and accelerometers which could 
respectively recorded in three parameters of time curves for the second hammer as the 
motion displacement, the displacement of the body wall deformation and the impact 
acceleration. The force sensor on the animal backstop could record the pressure pulses 
delivered to the body. The hammer was of a great range of quality that it was suitable for 
large animal impact injury experiments, but of a lower impact velocity for the drive limit. 
2. Vertical air/hydraulic biological impact machine 
For different driver ways, it has derived a variety of types of vertical biological impact 
machines. In addition to the type of free-fall impact machine, the vertical impact machine 
driven by pressure has been widely used. Because of power-driven, the hammer can 
provide higher impact velocity without falling from high altitude, which reduced the 
machine size greatly. Ways includes the gas and the liquid drive that two machines are 
basically of the same structure and working principle. These machines are mainly formed by 
the gas/liquid access, the sealed high-pressure piston, the impact hammer (piston), the test 
equipment and animal injuries units. The piston piston cylinder is divided into upper and 
lower chambers. The high-pressure gas or liquid goes into the chamber, pushing the piston 
downward to impact to the animal. The gas or the liquid in the lower champer discharges 
through the pipeline. In structure, the impact hammer and the piston has been integrated. 
The head of the piston becomes the hitting side, and can be made shapes of the steering 
wheel or others as needed, in order to directly simulate the whole process of traffic injuries 
caused by different parts of motor vehicle. There are energy-absorbing cushions under the 
piston cylinder head side to prevent downward movement of the piston to adjust the shock 
compression rate. The device is set on the rear chamber to monitor the moving process of 
the piston. Sensors are put under the animal injury platform to record the pressure pulses of 
the loading process of the body and the body's output during the impact. 
Because gas has compressibility, the high pressure gas makes piston move forward  
quickly at the early stage of piston movement, and then it turns into a uniform motion. 
While driving the piston with liquid, the piston impacts animals with constant speed. The 
range of impact velocity of perpendicular type gas, liquid biology is commonly between 
5m/s and 20 m/s. 
3. Biological hit machine of horizontal type 
Biological hit machine of horizontal type always moves as the high pressure air drives 
impact hammer. In 1978, the Viano etc. in motor vehicles research lab of the United States 
Michigan state biological medical department used hit machine of gas driving type. The 
main part of machine is the bubble similar to the above-mentioned high pressure cylinder, 
when launching trigger device, high pressure gas in the high-pressure chamber drives 
piston to do high speed forward movement and hit secondary hammer which hits animals 
or other simulative contents. The forward movement distance of piston is 10 cm, the weight 
of secondary hammer is 23.4 kg hung by guide ropes, the forward movement distance is  
20 cm. Compared to vertical hit machine, animal injury frame has made a big improvement; 
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first, it can slide forward with fixed animal car when hitting animal; second, the pulley 
placed animal is hung on the framework which can slide on the rail, when hitting 
framework, animal and sliding framework do the reverse movement because of inertance, 
and it leads to damage when hitting simulative steering wheel fixed on framework. 
4. Several domestic biological hit machines 
The third military medical university institute of surgical field first successfully developed 
biological hit machine series of type BIM-I, II and III in 1990 in China, it provided a good 
experimental method for research of injury by collision. 
1) Vertical biological hit machine of type BIM-I  
This machine is composed of the impacting tower, cushion and animal injury frame with 
about six tons of total weight. The impacting tower is welded from angel steel, it forms 
closed structure with outsourcing wind sheet. The weight of impact hammer gradually 
increases 0.5 kg every time and its heaviest weight is 50 kg, the drop height can be 
controlled in 0.5 ~ 36.5 m. Impact hammer can trigger buffering devices automatically when 
rising to a predetermined height, and it can drop along with vertical orientation steel wire to 
hit secondary hammer. 
Cushion consists of about a ton of table-board, pillar, buffer block and secondary hammer, 
its main function is to control impact range and absorb great energy produced by impact. 
The fastest impact speed of this machine is 26 m/s, and the instant impact speed simulated 
is 90 km/h. 
Animal hurt frame can fix animals flexibly, according to the adjustment of horizontal and 
vertical position; it can precisely control impact site and the impact amplitude of the 
compression.  
2) Horizontal biological hit machine of type BIM- II   
This machine mainly consists of high-speed air cannon, secondary hammer, animal hurt 
frame, sliding rail system and velocity measurement system with the total weight of about 
two tons. The pressure of gas storage tank in high-speed gas cannon is 25 MPa, but the 
practical working pressure is no more than 10 MPa, the opening time of pneumatic valve is 
about 2ms, diameter and length of bore is 50 mm and 1300mm, the fastest initial speed of 
bore can reach to 90 m/s, it can simulate crash condition that the bus speed is no more than 
320 km/h. It can accurately control impact amplitude of the compression through the 
secondary hammer, different impact area and geometric shape can be chosen when hitting 
head. Using secondary hammer seat as limiting stopper to avoid bullet breaking away from 
bore, and avoid the damage happened when bullet impacts with other objects, bullet can be 
used again. In order to adapt to research needs of different kinds of animal injury by 
collision, both bullet and secondary hammer have various standards of length and quality. 
Velocity measurement system consists of speed measurement table, laser generator, shock 
tube beam splitter, guiding light implement, photosensitive components and signal 
amplification receiving circuit, the error of measuring secondary hammer speed is no more 
than 0.01 mm/s, it fully meet the requirement of speed measuring precision in the biological 
experiment. 
Impact can be divided into standard static state and dynamic according to the difference of 
animal hurt frame and ways of fixation. Impact way of standard static state adopts fixed 
animal hurt frame, then animals cannot move forward when hitting. In the biomechanical 
testing experiments, it is need to put some sensors on the animal body, therefore, impact 
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frame, the second hammer, the second hammer stopper and animal movement supporting 
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Because gas has compressibility, the high pressure gas makes piston move forward  
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of secondary hammer is 23.4 kg hung by guide ropes, the forward movement distance is  
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first, it can slide forward with fixed animal car when hitting animal; second, the pulley 
placed animal is hung on the framework which can slide on the rail, when hitting 
framework, animal and sliding framework do the reverse movement because of inertance, 
and it leads to damage when hitting simulative steering wheel fixed on framework. 
4. Several domestic biological hit machines 
The third military medical university institute of surgical field first successfully developed 
biological hit machine series of type BIM-I, II and III in 1990 in China, it provided a good 
experimental method for research of injury by collision. 
1) Vertical biological hit machine of type BIM-I  
This machine is composed of the impacting tower, cushion and animal injury frame with 
about six tons of total weight. The impacting tower is welded from angel steel, it forms 
closed structure with outsourcing wind sheet. The weight of impact hammer gradually 
increases 0.5 kg every time and its heaviest weight is 50 kg, the drop height can be 
controlled in 0.5 ~ 36.5 m. Impact hammer can trigger buffering devices automatically when 
rising to a predetermined height, and it can drop along with vertical orientation steel wire to 
hit secondary hammer. 
Cushion consists of about a ton of table-board, pillar, buffer block and secondary hammer, 
its main function is to control impact range and absorb great energy produced by impact. 
The fastest impact speed of this machine is 26 m/s, and the instant impact speed simulated 
is 90 km/h. 
Animal hurt frame can fix animals flexibly, according to the adjustment of horizontal and 
vertical position; it can precisely control impact site and the impact amplitude of the 
compression.  
2) Horizontal biological hit machine of type BIM- II   
This machine mainly consists of high-speed air cannon, secondary hammer, animal hurt 
frame, sliding rail system and velocity measurement system with the total weight of about 
two tons. The pressure of gas storage tank in high-speed gas cannon is 25 MPa, but the 
practical working pressure is no more than 10 MPa, the opening time of pneumatic valve is 
about 2ms, diameter and length of bore is 50 mm and 1300mm, the fastest initial speed of 
bore can reach to 90 m/s, it can simulate crash condition that the bus speed is no more than 
320 km/h. It can accurately control impact amplitude of the compression through the 
secondary hammer, different impact area and geometric shape can be chosen when hitting 
head. Using secondary hammer seat as limiting stopper to avoid bullet breaking away from 
bore, and avoid the damage happened when bullet impacts with other objects, bullet can be 
used again. In order to adapt to research needs of different kinds of animal injury by 
collision, both bullet and secondary hammer have various standards of length and quality. 
Velocity measurement system consists of speed measurement table, laser generator, shock 
tube beam splitter, guiding light implement, photosensitive components and signal 
amplification receiving circuit, the error of measuring secondary hammer speed is no more 
than 0.01 mm/s, it fully meet the requirement of speed measuring precision in the biological 
experiment. 
Impact can be divided into standard static state and dynamic according to the difference of 
animal hurt frame and ways of fixation. Impact way of standard static state adopts fixed 
animal hurt frame, then animals cannot move forward when hitting. In the biomechanical 
testing experiments, it is need to put some sensors on the animal body, therefore, impact 
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way of standard static state is mostly adopted. The major structure of dynamic hitting way 
is sliding rail system, which is composed of horizontal sliding rail, holder and pulley etc., 
the effective length is 3.5m and height is 1.9m. Fixing the animal on the pulley, then using 
secondary hammer to impact, it can move ahead with pulley after getting impact. If 
installing baffle in front of sliding rail, animal can strike baffle after moving, it can lead to 
the animal model of acceleration injury accompanying with deceleration injury. This kind of 
hurting way can simulate the impacting conditions that pedestrian collides with road or 
other objects after hitting and throwing. 
3) Portable biological hit machine of type BIM-III   
The structure of this machine is simple, it is easy to install and remove with the total weight 
of about 11 kg, and the volume is about 70 x 20 x 10 cm3 after remove. Its working principle 
is to hit animals relying on impact hammer dropping from different heights; it can carry out 
fixed or unfixed impacts using turning institution of animal frame. It is suitable for the 
impact injury research on mice, rats, and guinea pig head, chest and abdomen. 
3. Injury device of deceleration injury 
The kinetic object impacts the still experimental object to make it accelerate along with 
external force, and the injury happens when impacting the experimental one. Deceleration 
damage means the damage happened with the sudden deceleration of kinetic experimental 
object when it impacts the still one. Because of buffer distance, the accelerated damage is  
relatively light, which is often limited to stress side; while the decelerated damage is 
relatively heavy,  the damage can happen both on stress side and offside, and the offside 
damage is heavier. The first purpose of developing injury model of deceleration device is to 
make the experiment object accept certain initial velocity, and then solve the fixed problems 
of experimental object. Tan Yuanfu has designed a device for craniocerebral deceleration 
injury research with the power provision of rubber band, and with this device, he has 
developed rabbit craniocerebral deceleration injury model. This device consists of turn 
board(A), axis of rotation(O), elastic belt(F) and holder(B), The two-thirds of the turn board 
is fixed to the table through the axis of rotation, turn board can rotate 360 °, the groove(40 
mm x 200 mm) in the front of turn board can be put animal head.  There are many 600mm 
long elastic belts at the end of turn board. the elastic belt is flabby under horizontal position, 
the center of turn board front end is put on the cushion (E) to make it on the horizontal 
position, the 35 mm in diameter bump anvil(C) on the holder protrudes into groove 5mm. 
When turn board is on a vertical position, the elongate elastic belt is at a high tension state, 
and position of turn board is fixed through a pull hook (G). Turn board return to horizontal 
position with the help of elasticity after loosening pull hook, at this time the rabbit head in 
the groove of turn board gets craniocerebral deceleration injury because of collision with 
bump anvil, and the degree of damage can be adjusted through the number of elastic belts. 
Moments after impact, turn board rebounds because of the function of cushion, at this time, 
the hands need to hold turn board quickly to avoid the second damage. 
Author has developed an injury device of slow injury according to the transforming 
principle between potential energy and kinetic energy, initial velocity of experimental 
subject is controlled by height of fall. This device is composed of turn board (A), animal 
fixed trolley (E), foundation bed (G), chopping block(C) and holder(B)(Figure 2). Sliding 
guide rail is installed in fixed bases, which consists of four steel wires, the degree of 
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tightness is regulated by the prestressing steel wire below foundation bed. The distance that 
animal fixed trolley slides along with guide rail is 7.0m, the height is marked with scale 
plate(D). The rolling bearing installed around that car can make it slide freely along with the 
sliding guide. The animal is fixed on trolley and its head is held by holder to make its 
position oppose to collision anvil. Bumper block is placed between animal fixed trolley and 
foundation bed, and the adjustment of deceleration coming from collision between trolley 
and foundation bed is based on bumper block features such as elasticity coefficient and 
thickness, it also can protect the trolley. Relying on the device, besides a series of rabbit 
cerebral injuries of deceleration injury tests, we still do the injuries of deceleration injury 















Fig. 1. Injury device of deceleration injury: A . turn board, B. holder, C. bump anvil, D. 
elastic belt fixed place, E. cushion, F. elastic belt, G. fixed pull hook, O. axis of rotation 
4. Collision experiment of real car 
In the experimental research of large traffic accident/injury, the foreign country regard real 
cars as injury tools, animals or dummy devices as received subjects, and it realistically 
imitates mechanical force that people get when cars collide with pedestrians, cars and other 
fixations, then multidimensional high-speed camera and all kinds of sensors will do detailed 
records and analysis. Many domestic organizations also have the condition of real car 
collision experiment, and have already conducted a large number of real car crash tests. The 
data and authenticity of real car crash tests is reliable, it is reliable mean to check and accept 
protective equipment and evaluate the safety standards. But the deficiency is that it needs 
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Fig. 2. Injury device of slow injury: A. guide rail, B. holder, C. chopping block, D. scale plate, 
E. animal fixed trolley, F. bumper block, G. foundation bed 
5. Biological impact test platform of rail type 
In fact, the occurrence of traffic injury is a dynamic process, which involves the hurting of the 
whole experimental objects, while the previous road traffic injury researches are mainly on the 
local impact tests, which cannot completely simulate the whole and dynamic engineering of 
traffic injury occurrence and development. Some foreign research institutes have established 
collision equipment for traffic medical research. And in recent years, China has also 
established collision laboratories in Beijing, Tianjin, Hubei and Shanghai, and they are mainly 
used for the real car crash tests and the test of safety performance of automobile parts; its 
purpose is to test the security of the car. But these researches are mainly based on engineering, 
and its purpose is to provide the basis and theoretical guidance for car improvement and 
protection of people, which combine less with medicine, especially with clinical medicine. 
In view of the above reasons, the administrative office where the author is decides to 
establish a biological collision laboratory of track type, which gives priority to biological 
trolley and gives consideration to the car crash tests, its purpose is to realistically simulate 
occurrence process of various traffic injuries, then doo further research on trauma occurred 
mechanism, protection and treatment, the research laboratory began to construct in 2003, 
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This lab can carry out car crash test and collision experiment (including front collision, angle 
collision etc.); Crash conditions correspond to the basic requirements of related laws and 
regulations of the American FMVSS, European EEC and Chinese CMVDR294 etc, when 
collision speed is ≤64km/h, the speed control precision is ≤±2%, the maximum traction 
acceleration is not more than 0.5g, the average traction acceleration is not more than 0.3g; 
the fastest collision speed can reach to 120km/h。The biological impact test platform of rail 
type is composed of ground equipment, rail system, motor traction and control system, test 
system, lighting system and biological car etc. 
1) Facility 
The length of lab and acceleration road is about 88 meters and 75 meters, the width and 
length of collision hall is about 20 meters and 30 meters, and the total construction area is 
1400 square meters. The main equipments of facility include the fixed counterguard and 
track beam to support collision of experimental vehicles. The counterguard is composed of 
reinforced concrete construction, and the impact surface is edged with a T shape channel 
steel plate, which can prevent it from movement and damage when the 2500 kg trolley 
impacts with the speed of 80 km/h. There are good vibration isolation measures between 
counterguard and surrounding, which can ensure that the collision experiment will not 
cause the vibration of the workshop and damage of surrounding ground. Rail beam is made 
of reinforced concrete (78m 2.4m 1.0m), which is used to support trolley rail, traction 
guides and parking buffer, etc. The shape of track girder is regular to make sure that the 
rupture, deformation or displacement will not appear in using process. According to the test 
requirements, corresponding facilities can be set up in the area to complete particular test 
content. 
2) Rail system 
Rail system includes trolley rail, traction guide rail, rail cover plate, track girders, etc. Two 
trolley rails are installed in both sides of traction rail symmetrically; the experimental 
vehicles can accelerate through trolley rail or rail cover plate, and reach the setting speed in 
the prescribed distance, then complete collision experiment in collision hall.   
1. Trolley track  The trolley track has two rails of 82m total length with center distance of 
1.80m in east-west direction. The two rails are fastened symmetrically to the track beam 
by the fastener with an interval of 1.25m. 
The fine finishing heavy rail of 50kgf/m has been welded into the seamless track. The 
distance between the weld and the anchor fasteners is 0.30m. Each rail has seven welds. The 
south rail is selected as the main rail while the north rail as the vice rail. The length of the 
main rail should be no more than ±0.5mm. The error of the vice rail relative to the main rail 
in the vertical and horizontal position should be no more than ±0.5mm. The deviation of the 
two tracks distance should be no more than ±1mm. The elevation of the upper plane of the 
rail is -0.010m with deviation of less than ±1mm. 
2. Traction rail  The traction rails are the running tracks of the traction car which is used to 
connect the traction rope and the experimental trolley for acceleration. The traction rails 
is a double structure with a small span. The track center distance is 0.235m. The rail is of 
the 25b channel. The vertical and horizontal of the upper plane of the traction rails 
should be in level and the elevation should be no more than ±2mm. The spacing of the 
edge above the guide rails is 150 10

 mm and the total length of the vertical and 
horizontal straight line should be no more than ±2mm. 
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
 mm and the total length of the vertical and 
horizontal straight line should be no more than ±2mm. 
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3. Rail cover  The rail cover is a key component both for trolley and real vehicle 
experiments. It Requires that when carrying out real car crash tests, it should ensure 
smooth movement of vehicles and the "pavement" friction coefficient should be not less 
than 0.75. 
3) The traction motor and control system 
The traction power is from the two 225kw DC. The accurate closed-loop feedback control is 
from the DC speed controller to achieve precise control of pre-collision speed. The test data 
show that the motor is running smooth, with qwll synchronization of two-motor and load 
capability. 
4) The hydraulic tensioning and control system 
A mechanical tensioning device is placed in the test preparation room mainly for adjusting 
elastic rope seasonally. The hydraulic tensioning device is placed in the collision hall.  
For each test, it needs to do tension work. The hydraulic tensioning device is arranged 
behind the rear-wheel drive drum. After tensioning action, the wire rope is firmly pressed 
in the trough of the drum rope in order to pass the torque of the motor to the wire  
rope. 
There are two frameworks with rectangular slide on the side of the rack panel. The T-slot on 
the base plate and the iron plate is linked by special screws which can resist to four tons of 
tension. The two rope tensioners moves straightly by two hydraulic cylinders, making the 
rope in tension or relaxation. The tension wheel assembly runs independentlyin the 
rectangular slide. The tensioning assembly includes a curved file block to prevent the rope 
relaxed state of the slide-out round of the slot. The tensioning wheel has a diameter of 400. 
The cylinder of the stainless steel tube of SMC (Japan) has magnetic limit switches in the 
front and rear of the two extreme positions. It transmits the signal to ban the motor running 
in the front and rear of the two extreme positions. The hydraulic system provides a stable 
and adjustable pressure for the cylinder and braking system of the hydraulic tensioning 
device. Pumping station has a perfect control system to contact with the upper total control 
system. 
5) lighting control system with hydraulic tensioner 
For shooting the dynamic changing process of test objects in real trolley/vehicle 
experiments, it needs to ensure adequate lighting illumination that it can guarantee 5000lux 
illumination in front of 5m×2m range of the barrier and that it must meet the spot 
uniformity, light color stable, high energy efficiency, color reproduction and good 
requirements. The lighting system installs on the movable three-dimensional light shelves 
which can meet the lighting needs of any location in the collision hall with mobile stands for 
light adding. 
6) The biological trolley 
The previous bilogical impact experiments are usually on real cars with animals. But all 
know that the real vehicle collision tests are of high costs with poor reproducibility between 
different vehicles, the long preparing time as well as the space limitations for animal 
numbers. This shows that it is not suitable for biological impact tests by real vehicles with 
animals. The large number of biological traffic crash tests is conducted to the study for 
traffic medicine. It is necessary to develop the biological trolley on the orbital biological 
impact platform for replicating the traffic injury animal models. 
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To do biological trolley experiments, it needs to solve the problems like the power, the 
animal fixing and the energy-absorbing. The traffic injury trolley for small animals has been 
developed based on the orbital biological impact laboratory. The biological trolley of small 
animal injury is an important part of the platform including the powered trolley and the 
animal fixable trolley. The trolley system is directly tracked by the guide rails and the wire 
ropes from the motor traction system in the lab. The car is free to slide on the traction rail 
through the pulley (Figure 3). The powered of the car is from the mechanical hook of the 
fastening wire ropes. When it gets the expected speed, they leave from each other to keep 
the constant speed. Different types of small animals can be fixed on the animal trolley for 
traffic injury collision experiments. Two types of trolleys can be applied as needed to 




Fig. 3. The animals fixed trolley. 
The energy-absorbing device is on the biological trolley or in front of the barrier. In 
addition to absorbing the energy of the impact moment from the barrier and the trolley, it 
can generate different damping forces to replicate different deceleration curves to carry 
out different types of traffic injury experiments for the biological trolley system. There are 
lots of energy absorbing forms, and usually it takes the hydraulic or combined thin-
walled beams. 
The structure of the hydraulic buffer is a high-pressure damping chamber. There is an oil 
pool above the high-pressure chamber. There are several orifices on the chamber wall as the 
connection of the high-pressure chamber and the oil pool. When the piston rod impacted, its 
front pushes the oil in to the pool. There is heat from the friction of the oil and the throttle. 
The majority of car's kinetic energy changses into hydraulic oil heat, and parts of the energy 
store in the oil pool. By adjusting the orifice area, it can get a specific deceleration waveform 
to meet the experimental needs. 
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Fig. 4. The schematic diagram of the hydraulic shock absorbers: 1. trolley; 2. buffer block; 3. 
rod; 4. orifice; 5. Inner liner; 6. high-pressure chamber; 7. oil pool; 8. discharge hole; 9. 
cylinder; 10. cutting bolts. 
The combined thin-walled beams are energy absorption devices taken a standard thin-walled 
square steel tube with adjusting the length and thickness of thin-walled square steel pipe 
combinations, to solve problems such as high costs, the single waveform and the poor 
reproducibility of the existing car-absorbing devices. By controlling the thin-walled square 
tube length of each group, this combination can control the time to make up peaks and troughs 
for each other in order to get a smoother deceleration waveform. The combination forms of the 
thin-walled square tubes are determined by the according to the mass and the deceleration 
curve of the trolley. The average length of thin-walled square tube is determined by the 
collision speed. The mounting block has been put on the trolley, so the thin-walled square tube 
and the trolley can be tight closely. It is applied the pre-strain in front of the thin-walled square 
tube with the direct rigid collision between the fixed barrier without the buffer block to let the 
deceleration waveform meet the test requirements. It provides a practical solution for many 
collision experiments on the safety of the auto parts and for biological experiments. 
 
 
Fig. 5. The combined thin-walled beam of absorption method in trolley crash tests: 1. 
Trolley; 2. Mounting Block; 3. Thin-walled square steel pipe; 4. Pre-strain; 5. Fixed barrier. 
Around the car crash tests, the biological assessment of traffic safety, the vehicle crash and 
safety protection equipment and the security measures, it can carry out certification tests for 
vehicle regulations, biological collision experiments, pedestrian crash tests, rollover tests 
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and motorcycle crash tests, etc. The platform can realistically simulate the impact of various 
vehicles and traffic injuries. It is an ideal platform for basic research of traffic injury and 
impact injury. It is also an important technical platform for the development of new vehicles 
and car parts. 
6. Computer simulation tests 
Today, computational science has been the third branch of sciences as well as the other two 
traditional sciences that are the theoretical science and the practical science. When the 
theoretical model is very complex or has not been established, or the experiment is so 
expensive that it cannot be done, the computer simulation experiment becomes the the main 
or only means. In recent years, with the development of the electronic technology, computer 
science and computational mathematics, it has become a trend to to study the road traffic 
injury through computer simulation experiments. 
The traffic injury study is a wide range including the digital reconstruction of human injury 
in the accident scene, the biological injury testing in the laboratory and trauma 
biomechanics research on some individual organ damages. Since there are different 
purposes and objects for the traffic injury research, there are a variety of computer 
simulation methods and software systems which can be used to transport medical research. 
1) Impulse / momentum method 
Large number of real traffic accidents cases is fresh sata for traffic injury research. The traffic 
accident reconstruction is essential means for real case studies, and the impulse/momentum 
method is one of the most common means for real digital reconstructions. According to 
rigid body plane collision theory, the car is simplified as the plane crash model of three 
freedom degrees with single mass. Assuming a car driving on a flat and regular road before 
and after the collision, base on linear momentum and angular momentum conservation 
principle, it considers the energy loss by rebound factor from deformations. 
PC-Crash is a typical software based on the impulse/momentum principles. In addition to the 
digital reconstruction for collisions like motor vehicles - motor vehicles and motor vehicles, it 
can also do numerical simulation for accidents like the motor vehicle - pedestrian, motor 
vehicle - cylinder and roll. This software can simulate up to 32 cars multi-hit at the same time 
and show the three-dimensional animation. A common method in the PC-Crash for accident 
reconstruction is taking the vehicle brake or the stop location as the optimizing target, and 
taking the car speed, the initial contact position, the rebound coefficient, the friction coefficient 
and other parameters as the optimizing variables. When the calculated results of braking 
traces or the stopping position consists with the real circumstances, parameters corresponding 
to this state are considered as closest to the real situation that it can analyse the accident cause 
and the human injury based on the computer simulation. 
2) Energy / deformation methods 
In car crashes, the deformation of the vehicle depends on the collision energy, while the 
collision energy depends on the relative speed between two vehicles. It shows that it is an 
important means of digital reconstruction by the deformation of the vehicle to infer the 
vehicle collision speed and to estimate the collision point. Its goal is to optimize the vehicle 
deformation. And the collision speed, the initial contact position, trajectory, friction 
coefficient and other parameters are optimization variables to do iterative calculation. When 
the calculation of the vehicle deformation consists with the real circumstances of the 
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accident, it is considered as the closest to the real situation under the state corresponding to 
the parameters. 
A typical software based on the energy/deformation theory is SMAC (Simulation Model of 
Automobile Collisions). The software is an open process. In use, the user need to develop in 
form of card on vehicle size, inertia, deformation and tire characteristics, as well as initial 
velocity, angle and motion control input, etc. These values can be modified at any time. The 
program calculated the detailed information such as speed, acceleration, position, angle, 
deformation and the force of each tire and other values by the collision process. Users 
modify the initial value by constantly adjusting the input of the initial velocity, impact angle 
and other variables according to the differences between simulation results and actual 
results, until the simulation results matched up with physical evidence. In recent years, M-
SMAC has been continuously developed. Users need only simply enter the trajectory of the 
collision, the vehicle deformation and the stop position that the program can optimize 
computing and eventually get a real situation with the closest results. 
3) Multi-body dynamics Method 
Currently, human biomechanics research based on numerical simulation techniques receives 
more and more attention in the analysis of traffic accidents. By the numerical simulation 
technology, it can reasonablely interpret in mechanics for the collision part of the bodies, the 
injury degree and causes. The body damage analysis can directly reflect the contact position 
and force size between people and cars, and people and ground. The accident reconstruction 
method based on the impulse/momentum principles or energy/deformation theory only 
depends on the brake marks or deformation of the body contours of the vehicle velocity and 
other parameters to solve problems. It cannot analyse or describe the human body injuries 
in the accidents. 
Multi-body dynamics analysis is a powerful tool for human injury analysis. It is a 
mechanical branch combining the rigid body mechanics, analytical mechanics and the 
computer technology. Multi-body dynamics has versatility in calculating the movement of 
large displacement etc. with high speed in traffic injury research. 
The software of MADYMO (Mathematical Dynamic Model) is based on multi-body 
dynamics methods. It is now one of simulation softwares for the collision damage 
simulation with extensive applications. In MADYMO software, it predict the injury of the 
occupant/pedestrian collision and the dynamic and kinetic characteristics of vehicle 
structures through the establishment of the appropriate model. MADYMO models are 
multiple rigid bodies connected by a group of different types of hinges. They usually form 
an open loop tree by defining the freedom degree of the hinge, binding constraint stiffness 
and inertia of the rigid body to get the rigid multi-body system dynamics model. The shape 
of the model is composed of rigid bodies such as the plane, the cylinder, the ellipsoid or 
other super-ellipsoid shapes, which constitute the contact surface of the multi-body model. 
MADYMO software is based on theories of multi-body dynamics to generate motion 
equations of multi-body system. In addition to describing movement and interaction, the 
multi-body motion of the system has been affected by the forces from springs, dampers and 
the restraint system. MADYMO software can not only be used to calculate the acceleration, 
displacement and contact force, but also provide some body damage index calculation, such 
as head injury index (HIC), Severity Index, chest resultant acceleration values, chest injury 
index, viscosity index and femur axial load and so on. Although the original mind of 
MADYMO design was for the study of vehicle collision mechanics, it has been applied to 
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analyze other modes of transport such as trains crash, aircraft, motorcycles and bicycles, 
while the software has also been used to evaluate the applicability of different restraint 
systems, such as seat belts and airbags. 
4) FEM (Finite Element Method) 
The finite element method (FEM) is a more innovative and effective numerical method 
developed for computer use. This method originated from aeronautical engineering in 
aircraft structure matrix analysis in the middle of 20th century. 
For the structure matrix analysis, the overall structure can be seen as a collection 
interconnected by limited numbers of mechanics units, and each unit can be seen as the 
building brick that their assemblies can provide the overall mechanical structure properties. 
In 1960, an aircraft structural engineer named Clough firstly used the term of Finite Element 
Method in his paper to solve the plane elasticity problem. Since then, not only engineers but 
also mathematicians and mechanics began to realize the efficacy and the great prospect of 
the finite element method that they have been in-depth discussed to give it a more solid 
theoretical foundation. In the joint efforts of engineers and scholars, the finite element 
method has gone into the real continuum mechanics, becoming one of the most effective 
ways for solving mechanical problems. In 1969, Fridenbery finited the element theory for the 
first time, then it has been applied as a new methods and theories to the medical field on 
human biomechanics research. Currently, FEM has been widely used in the human body 
biomechanics and collision damage mechanics. 
Typical FEM-related softwares include: 
1. LS-DYNA 
LS-DYNA program is mainly based on Lagrange algorithm, with ALE and Euler algorithms; 
oriented in the explicit solution, with the implicit solution function; on non-linear dynamic 
analysis with the static analysis. LS-DYNA program currently has 140 kinds of metal and 
non-metallic materials, with consideration of material failure, damage, viscosity, creep and 
strain rate associated with such properties. 
2. ABAQUS 
ABAQUS provides a wide range of functions, and very easy to use. Input ABAQUS data first, 
then enter the options block. The beginning of each option is labeled a descriptive name, so it 
is very convenient for the achieve of ABAQUS data. A lot of complex problems can be 
simulated easily by different combinations of option blocks. For example, for complex multi-
component combination of simulation problems, it is by combination of defining each option 
bocks of component set sizes with the corresponding material properties. For lots of 
simulations, even for some higher non-linear problems, users only need to provide some 
project data, set sizes of the structure, material properties, boundary conditions and load 
conditions. In some non-linear analysis, ABAQUS can automatically select the appropriate 
load increments and convergence accuracy. It can not only choose the right parameters, but 
also to adjust the parameters in the analysis process to ensure effective exact solutions. By 
accurate definition of parameters, users can control the numerical results effectively. 
7. References 
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analyze other modes of transport such as trains crash, aircraft, motorcycles and bicycles, 
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1. Introduction 
Monitoring the injured brain to detect and treat harmful events that can cause secondary 
injury during the acute recovery period is a central part of neurointensive care. The most 
basic monitoring tool is the neurological examination, such as the Glasgow Coma Score; 
however, a large component of this scale involves verbal communication and brain-
injured patents are often comatose, mechanically ventilated or sedated. As well, 
symptoms of neurological deterioration detected by examination often occur at late stages 
of brain injury. Since the brain is extremely vulnerable to ischemia, a more direct indicator 
of potential brain injury is detecting impaired cerebral blood flow (CBF). Multiple factors 
following brain injury can cause ischemia, including systemic hypotension, cerebral 
hemorrhage, and edema – all of which independently worsen survival (Helmy et al., 
2007). This focus has lead to the recognition that continuous monitoring of CBF in patients 
with, or at risk of, brain injury could improve outcome by providing the ability to detect 
and prevent cerebral ischemia. 
Imaging techniques, such as magnetic resonance imaging (MRI) and computed tomography 
(CT), are critical to the management of brain-injured patients as they provide detailed 
structural and functional information of the brain when patients are admitted to an 
emergency department (Gallagher et al., 2007). CT is the modality of choice because it is 
widely available and examination times are relatively short. Furthermore, techniques for 
measuring CBF have been developed on these imaging modalities (Wintermark et al., 2005) 
and subsequently used to identify CBF abnormalities following brain injury (DeWitt & 
Prough, 2003; Gowda et al., 2006; Soustiel et al., 2008). Despite these promising advances, 
conventional imaging modalities suffer from serious disadvantages regarding cerebral 
monitoring. First, they require transferring patients to imaging facilities which represents a 
significant risk factor when dealing with critically ill patients. Second, they only provide a 
single time-point measurement and, therefore, suffer from the possibility of missing flow 
abnormalities that occur at different times during intensive care. Clearly, effective cerebral 
monitoring requires bedside techniques. 
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Since CBF is driven in part by the cerebral perfusion pressure (CPP) which depends on 
intracranial pressure (ICP), using these pressures as surrogate markers of CBF is becoming 
an integral part of critical care practice. Intracranial pressure is typically measured using 
either a ventricular catheter or an intraparenchymal probe, and CPP is determined by the 
difference between mean arterial pressure (MAP) and ICP. Although there have been no 
large randomized trials comparing target thresholds, it is generally recommended that the 
ICP threshold above which treatment should be initiated is between 20-25 mm Hg (Bratton 
et al., 2007b). Similarly, CPP should be maintained above 60 mm Hg to ensure adequate CBF 
(Bratton et al., 2007a). However, the thresholds for ICP and CPP remain a source of 
contention. Increasing CPP (70-90 mm Hg) was found to reduce ischemia (Coles et al., 2004), 
but comes at the cost of increased incidence of extracranial complications and possibly 
contributes to vasogenic edema (Robertson et al., 1999). The Lund protocol advises a lower 
limit of 50 mm Hg to prevent complications while avoiding extremely low CBF (Asgeirsson 
et al., 1994). It has even been suggested that CPP/ICP therapy only increases therapy 
intensity without improving outcome (Cremer, 2008). Strictly adhering to targets can 
therefore give clinicians a false sense of security. A method of measuring CBF at the bedside 
would remove this ambiguity since the occurrence of ischemia due to inadequate CPP or 
hyperemia due to excessive CPP therapy would be readily apparent. 
The most widely used beside technique for monitoring CBF is transcranial Doppler (TCD). 
This non-invasive technique derives blood flow velocity from the Doppler shift caused by 
moving red blood cells in a cerebral artery. Provided the angle of insonation and the 
diameter of the interrogated vessel remain constant, changes in TCD measurements reflect 
CBF changes (Valdueza et al., 1997). However, the accuracy of TCD is operator dependent 
due to problems of probe fixation, the TCD signal is not found in 10-30% of patients, and the 
technique cannot monitor blood flow in the microvasculature, which can be quite different 
from flow in the major arteries (Wright, 2007). Invasive techniques for monitoring CBF that 
require inserting probes directly into brain tissue include laser Doppler (LDF) and thermal 
diffusion flowmetry (TDF) (Bolognese et al., 1993; Sioutos et al., 1995). These techniques 
have been used to detect ischemia in brain-injured patients and TDF was shown to be more 
sensitive than TCD to assessing vasospasm, demonstrating the value of assessing CBF 
directly (Kirkpatrick et al., 1994; Vajkoczy et al., 2001). Besides being invasive, the major 
limitation with LDF and TDF is that they can only monitor the vascular territory where the 
probes are placed. Wider applicability of CBF monitoring requires non-invasive techniques 
that can assess CBF in multiple brain regions. 
A promising alterative to current invasive monitoring techniques is near-infrared spectroscopy 
(NIRS). Due to the relative transparency of biological tissue to near-infrared (NIR) light, the 
brain can be interrogated non-invasively by probes placed on the scalp (Jobsis, 1977). Not only 
is NIRS non-invasive and safe, due to the use of non-ionizing radiation, the major tissue 
endogenous chromophores – water, oxy- and deoxy-hemoglobin (HbO2 and Hb), cytochrome 
c oxidase, and lipids – have unique absorption properties in this wavelength range. The 
challenge to quantifying tissue chromophores concentrations with NIRS is the need to account 
for the strong light scattering, which dominates over light absorption. To meet this challenge, 
techniques that can take into account the effects of scattering have been developed and NIRS is 
now widely used to continuously monitor HbO2 and Hb, and derive cerebral blood 
oxygenation. The most reported NIRS parameter is the ratio of HbO2 to total haemoglobin (i.e., 
HbO2 + Hb), which reflects cerebral blood oxygen saturation and is commonly referred to as 
the tissue oxygenation index (TOI). The TOI has been proposed for detecting ischemia and 
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assessing autoregulation by comparison to MAP (Al-Rawi & Kirkpatrick, 2006; Brady et al., 
2008). The difficulties with using TOI as a surrogate of CBF are that blood oxygenation is 
influenced by multiple factors (CBF, cerebral metabolism, arterial saturation and hematocrit) 
and the “normal range” has yet to be defined. Reported TOI values have ranged from 60 to 
85%, and this variation is as great as the change attributed to ischemia (Al-Rawi & Kirkpatrick, 
2006; Thavasothy et al., 2002; Yoshitani et al., 2002). 
NIRS techniques that can directly measure CBF have been developed. The first method proposed 
was based on the Fick principle and used a rapid change in arterial oxygen concentration as a 
blood flow tracer (Edwards et al., 1988). Improved sensitivity was achieved using indocyanine 
green (ICG) due to its strong light-absorbing properties (Patel et al., 1998). This FDA-approved 
dye has been in clinical use for over 30 years and has a high safety record; a study involving 
more than 3000 human subjects, showed that intravenous injection of ICG resulted in 
significant allergic reaction in only one subject (Hope-Ross et al., 1994). Absolute CBF, rather 
than a relative measure, was obtained with the ICG approach using a dye densitometer, to 
measure the arterial blood ICG concentration, a NIRS method capable of quantifying the tissue 
ICG concentration and a deconvolution method (Brown et al., 2002; Springett et al., 2001). 
Because of the inherent sensitivity of NIRS to blood oxygenation, CMRO2 can also be 
measured by combining NIRS measurements of CBF and oxygenation. In addition, CMRO2 
has been shown to be a better marker of injury severity in hypoxia-ischemia than CBF alone 
(Tichauer et al., 2006a). In this chapter we will show that NIRS can be used to measure cerebral 
blood flow and oxygen metabolism, and to detect general and focal brain injuries. 
2. Theory 
2.1 Cerebral blood flow model 
The hemodynamics of an organ can be quantified by tracking the passage of a contrast agent 
through the vascular bed, an approach that has been adapted to imaging modalities including 
MRI and CT, and to NIRS. With this method, the amount of contrast agent in the organ at a 
given time t (Q(t)) is related to the difference between its arterial (Ca(t)) and venous 
concentrations (Cv(t)), and to blood flow (F) via the Fick Principle (Meier & Zierler, 1954): 
 ( ) ( ) ( ).a v
dQ t FC t FC t
dt
    (1) 
If Q(t), Ca(t) and Cv(t) could be measured non-invasively, then the calculation of flood flow 
would be a simple mathematical operation but that is not the case since Cv(t) cannot be 
measured noninvasively. However, the venous concentration of contrast agent can be 
expressed in term of Ca(t) as (Lee, 2002): 
 ( ) ( ) ( ),v aC t C t h t    (2) 
where * is the convolution operator and h(t) is the impulse response function of the organ 
(i.e., the distribution of transit times) and represents the venous concentration of contrast 
agent if the arterial input was a Dirac-delta function. From Eq. (1) and (2) it can be shown 
that Q(t) can be expressed as (Lee, 2002): 
 ( ) ( ) ( )aQ t C t F R t   .                  (3) 
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Equation (3) shows that CBF can be determined by measuring Q(t) and Ca(t), and applying a 
deconvolution technique to extract F·R(t). The initial height of the function FR(t) is CBF, as 
by definition R(0) = 1, and the area under the curve is the cerebral blood volume (CBV) 
(Brown et al., 2002). It is clear from Eq. (3) that determining CBF requires the quantification 
of the tracer concentration in the brain. Fig. 1 shows an example of Q(t) and Ca(t) measured 
on a piglet and the retrieved FR(t). 
 
 
Fig. 1. (A) An example of tissue and arterial ICG concentration curves measured with a 
NIRS apparatus and a dye densitometer respectively.  The curves were measured 
simultaneously over a period of 50 seconds after injection of an ICG bolus. The peak arterial 
concentration is approximately 20 times greater than that of tissue. This is because blood 
volume in tissue is approximately 5 % of the total tissue volume. (B) Cerebral blood flow 
scaled impulse residue function, F.R(t), retrieved from the deconvolution of the curves in 
(A). Height of initial plateau yields CBF (50 ml/min/100g) and area under the curve is CBV. 
2.2 Measuring the cerebral metabolic rate of oxygen 
The NIRS CBF measurements can be used to determine CMRO2 by applying the Fick 
Principle (Tichauer et al., 2006b): 
 2 2( )CMRO F AVDO  ,  (4) 
where AVDO2 is the arterial-venous difference of oxygen, or the difference between the 
oxygen concentration of the arterial system feeding the tissue of interest and the oxygen 
concentration of the venous system draining the tissue. Assuming that the oxygen content of 
arterial blood is the same throughout the body (Brown et al., 2003), the arterial O2 
concentration can be obtained from hemoximeter analysis of arterial blood samples from a 
periphery artery or non-invasively from a pulse oximeter. The venous O2 concentration is 
more difficult to determine non-invasively. However, considering that the Hb measured in 
the brain is due solely to O2 dissociation from HbO2, the NIRS measurements of tissue Hb 
concentration can be used as an indirect measure of the venous O2 concentration. With this 
approach, it is necessary to account for the fact that the tissue Hb concentration is a 
weighted average of the three blood compartments: arterial, capillary and venous. The 
relative distribution of arterial, capillary, and venous compartments in the total CBV is 
generally accepted to be approximately 20%, 10%, and 70% respectively (Phelps et al., 1979). 
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Assuming that the capillary concentration of Hb is the average of arterial and venous 
concentrations, the venous concentration of Hb can be expressed as: 







   

, (5) 
where  VHb ,  THb , and   aHb  are the venous, tissue, and arterial concentrations of Hb, 
respectively. The tissue Hb concentration,  THb , is measured by NIRS and   aHb  can be 
measured by either hemoximeter analysis of an arterial blood sample or pulse oximetry. The 
NIRS measurement of  THb  is normalized by the dilution factor, CBV  , to determine the 
concentration of Hb in just the blood compartment of the tissue region of interest. The 
density of brain tissue,  , is 1.05 g/ml and is used to convert the CBV from volume of 
blood per mass of tissue to volume of blood per volume of tissue. Finally, with knowledge 
of the total hemoglobin (tHb = Hb + HbO2) measured from a blood sample, the venous O2 
concentration can be determined as follows (Brown et al., 2003): 
 2 2VenousO Concentration ([ ] [ ] ) 1.39ml O /gHbvtHb Hb   .                        (6) 
3. Measurement of Q(t) and Ca(t) 
3.1 Measurement of tissue chromophores concentration  
Fig. 2 shows a picture of the cart housing the broadband continuous-wave NIRS instrument. 
The main components of the apparatus are the light source, the fiber optic cables (optodes), 
and the spectrometer. The light source is a power-stabilized halogen light bulb and the 
spectrometer consists of a holographic grating and a cooled CCD camera. During 
measurements, the two optodes are placed 3.0 cm apart on the skull of the subject. One 
optode is used to guide the light from the source to the head and the other collects light re-
emitted from the head and transmits it to the holographic grating of the spectrometer, where 
it is dispersed across the cooled CCD chip (cooled to 70°C to reduce electronic dark noise) to 
generate an attenuation spectrum every 200 ms. 
Measured spectra were analyzed on the basis of the principle that when NIR light enters 
tissue, it is multiply scattered and partially absorbed by endogenous tissue chromophores, 
such as water, HbO2, Hb, cytochrome c oxidase, and lipids. Since scattering causes the total 
pathlength traveled by the NIR light from the emission optode to detection probe to be 
larger than the physical distance between the two optodes, a simple approach is to take into 
account the increase in pathlength using the differential pathlength factor (DPF), as first 
described by Delpy et al. (Delpy et al., 1988). With accurate knowledge of the DPF, a 
modified version of the Beer-Lambert law can be used to determine absolute changes in the 
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where ( )A   is the change in the attenuation spectra, ic  is the absolute change in 
concentration of the ith NIR absorber, L is the physical distance between the emission and 
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of wavelength. In particular, Eq. (7) can be used to quantify tissue ICG concentration, 
following a bolus injection of the dye, since there is no ICG in the brain prior to the injection. 
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Equation (3) shows that CBF can be determined by measuring Q(t) and Ca(t), and applying a 
deconvolution technique to extract F·R(t). The initial height of the function FR(t) is CBF, as 
by definition R(0) = 1, and the area under the curve is the cerebral blood volume (CBV) 
(Brown et al., 2002). It is clear from Eq. (3) that determining CBF requires the quantification 
of the tracer concentration in the brain. Fig. 1 shows an example of Q(t) and Ca(t) measured 
on a piglet and the retrieved FR(t). 
 
 
Fig. 1. (A) An example of tissue and arterial ICG concentration curves measured with a 
NIRS apparatus and a dye densitometer respectively.  The curves were measured 
simultaneously over a period of 50 seconds after injection of an ICG bolus. The peak arterial 
concentration is approximately 20 times greater than that of tissue. This is because blood 
volume in tissue is approximately 5 % of the total tissue volume. (B) Cerebral blood flow 
scaled impulse residue function, F.R(t), retrieved from the deconvolution of the curves in 
(A). Height of initial plateau yields CBF (50 ml/min/100g) and area under the curve is CBV. 
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where AVDO2 is the arterial-venous difference of oxygen, or the difference between the 
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Assuming that the capillary concentration of Hb is the average of arterial and venous 
concentrations, the venous concentration of Hb can be expressed as: 
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
, (5) 
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Furthermore, the second derivative technique described by Matcher et al. (Matcher et al., 
1994) can be applied to the broadband data, in conjunction with the assumption of 85% 
water concentration in the brain in infants and 80% in adults (Matcher & Cooper, 1994), to 
obtain the DPF and absolute concentrations of endogenous absorbers – as opposed to 
absolute changes of concentrations – in real time. 
 
 
Fig. 2. Picture of the potable NIRS apparatus. 
3.2 Arterial ICG concentration measurement 
Arterial ICG concentration can be measured noninvasively on a peripheral artery (e.g., a 
foot in the case of a piglet) using a dye densitometer unit (model DDG-2001 A/K, Nihon 
Kohden, Tokyo, Japan). The probe of the dye densitometer can be held on the skin using a 
spring-loaded clip, much the same as used for a regular pulse oximeter probe.  
4. Validation experiments 
4.1 CBF validation 
Cerebral blood flow and blood volume were altered in a newborn piglet model, by changing 
the partial arterial carbon dioxide tension (PaCO2), and concomitantly measured with 
NIRS and CT perfusion (Brown et al., 2002). Because of the portable nature of the NIRS 
apparatus, both NIRS and CT measurements were acquired with the piglet in the CT 
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scanner. Newborn piglets (less than a week old) were chosen to avoid complications due to 
extracerebral contamination of the NIRS signal that occurs in older subjects, which is 
discussed section 6. As shown in Fig. 3, there is a strong linear correlation between CT and 
NIRS hemodynamic measurements over a wide range. In addition, there is no significant 
statistical difference between CT and NIRS measurements of CBF and CBV, and the 
estimated bias are small relative to the respective mean values in each case. The precision of 
NIRS CBF and CBV measurements - determined using analysis of variance of repeated 
measurements - were 9.71% and 13.05% respectively. These results show that this NIRS 
technique is capable of accurate and reliable bedside measurement of cerebral 





Fig. 3. Comparison of CT and NIRS measurements of cerebral blood flow and blood  
volume. 
There are, however, some challenges facing the clinical application of the technique. 
Although the piglet head mimics that of a neonate in terms of skull composition and 
thickness, the two are significantly different in size and dimension. In this validation study 
an inter-optode distance of 3.0 cm was used and this yields a maximum depth of light 
 
Brain Injury – Pathogenesis, Monitoring, Recovery and Management 
 
284 
Furthermore, the second derivative technique described by Matcher et al. (Matcher et al., 
1994) can be applied to the broadband data, in conjunction with the assumption of 85% 
water concentration in the brain in infants and 80% in adults (Matcher & Cooper, 1994), to 
obtain the DPF and absolute concentrations of endogenous absorbers – as opposed to 
absolute changes of concentrations – in real time. 
 
 
Fig. 2. Picture of the potable NIRS apparatus. 
3.2 Arterial ICG concentration measurement 
Arterial ICG concentration can be measured noninvasively on a peripheral artery (e.g., a 
foot in the case of a piglet) using a dye densitometer unit (model DDG-2001 A/K, Nihon 
Kohden, Tokyo, Japan). The probe of the dye densitometer can be held on the skin using a 
spring-loaded clip, much the same as used for a regular pulse oximeter probe.  
4. Validation experiments 
4.1 CBF validation 
Cerebral blood flow and blood volume were altered in a newborn piglet model, by changing 
the partial arterial carbon dioxide tension (PaCO2), and concomitantly measured with 
NIRS and CT perfusion (Brown et al., 2002). Because of the portable nature of the NIRS 
apparatus, both NIRS and CT measurements were acquired with the piglet in the CT 
Towards Non-Invasive Bedside Monitoring of Cerebral Blood Flow  
and Oxygen Metabolism in Brain-Injured Patients with Near-Infrared Spectroscopy 
 
285 
scanner. Newborn piglets (less than a week old) were chosen to avoid complications due to 
extracerebral contamination of the NIRS signal that occurs in older subjects, which is 
discussed section 6. As shown in Fig. 3, there is a strong linear correlation between CT and 
NIRS hemodynamic measurements over a wide range. In addition, there is no significant 
statistical difference between CT and NIRS measurements of CBF and CBV, and the 
estimated bias are small relative to the respective mean values in each case. The precision of 
NIRS CBF and CBV measurements - determined using analysis of variance of repeated 
measurements - were 9.71% and 13.05% respectively. These results show that this NIRS 
technique is capable of accurate and reliable bedside measurement of cerebral 





Fig. 3. Comparison of CT and NIRS measurements of cerebral blood flow and blood  
volume. 
There are, however, some challenges facing the clinical application of the technique. 
Although the piglet head mimics that of a neonate in terms of skull composition and 
thickness, the two are significantly different in size and dimension. In this validation study 
an inter-optode distance of 3.0 cm was used and this yields a maximum depth of light 
 
Brain Injury – Pathogenesis, Monitoring, Recovery and Management 
 
286 
penetration of ~1.73 cm (Brown et al., 2002). This inter-optode separation should be 
appropriate for neonatal application since it has been shown that in this population, the 
thickness of the tissue overlying the brain are typically less than 5 mm and do not 
significantly interfere with NIR monitoring of the brain for inter-optode distance of at least 3 
cm (Benaron et al., 1995). A potential inconvenience with this technique is that it requires an 
ICG injection. Although the use of an exogenous blood flow tracer is somewhat less 
appealing than using one of the endogenous NIR absorbers (for example HbO2 or Hb), ICG 
results in a much higher signal-to-noise ratio. 
This study demonstrated the ability of NIRS to accurately measure cerebral hemodynamics 
at the bedside and showed that this technique can monitor and diagnose ischemic injury in 
neonates. In ischemic brain injury, CBF is often low for an extended period of time before 
symptoms of injury are apparent. The ability to detect diminished CBF at an earlier stage 
would significantly aid earlier intervention and greatly reduce mortality and morbidity. It 
has also been suggested that loss of PaCO2 reactivity is associated with poor 
neurodevelopmental outcome and/or hypoxic-ischemic encephalopothy and that the loss of 
PaCO2 reactivity is a candidate for predicting early severe brain damage in preterm infants 
(Blankenberg et al., 1997; Muller et al., 1997). Because the NIRS-CBF technique is capable of 
providing reliable, non-invasive, repeatable measurements it can be used to detect loss of 
PaCO2 reactivity, thereby greatly improving diagnosis. 
4.2 CMRO2 validation 
The cerebral metabolic rate of oxygen measured by the NIRS technique were compared to 
CMRO2 determined from the product of CBF and the cerebral arterial-venous difference in 
oxygen (AVDO2) measured from blood samples (Tichauer et al., 2006b). The experiments 
were conducted in newborn piglets subjected to five cerebral metabolic states created by 
varying the plane of anesthesia. The blood samples were collected from a peripheral artery 
and the superior sagittal sinus. As such, the two CMRO2 measurements were not collected 
from exactly the same brain volumes. However, there should be significant overlap between 
the two sampled volumes since both techniques primarily measure cortical tissue (Scremin 
et al., 1982). In addition, partial volume errors were avoided by using anesthetics to alter 
CMRO2 globally (Schultz, 1978). No statistically significant difference was found, within a 
range of ~ 1.5 to 4.0 mlO2/min/100g, between CMRO2 measurements obtained with the two 
techniques at any anesthetic level. There was also a strong correlation between concomitant 
CMRO2 values obtained from the two techniques (Fig. 3 in Tichauer et al., 2006b). 
Furthermore, repeated measurements obtained while maintaining constant CMRO2 showed 
that the NIRS technique can measure CMRO2 with a precision of 10.7%. All of this shows 
that CMRO2 can be determined accurately by combining NIRS measurements of CBF and 
deoxy-hemoglobin. 
It is evident from Eq. 4 that there are two key parameters that must be determined 
accurately to calculate CMRO2: CBF and AVDO2. Due to the difficulty of measuring these 
parameters, introduced by the high scattering properties of biological tissue, few studies 
have attempted to measure absolute CMRO2 with NIRS. In this validation, the second 
derivative technique was applied to broadband data to account for scattering (Matcher et 
al., 1994) and real-time measurements of the differential pathlength were acquired using 
the known water concentration in brain (Matcher & Cooper, 1994). A consequence of the 
second derivative approach is that the AVDO2 must be calculated solely from the Hb 
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signal as the second derivative of the HbO2 absorption spectrum is relatively featureless 
(Cope, 1991). With this approach, an independent measure of the arterial oxygenation 
must be obtained, which can be determined directly from an arterial blood sample or 
indirectly from the arterial oxygen saturation. It is also necessary to normalize the tissue 
by CBV, which was obtained from the ICG measurements, and to assume a relative 
distribution of in the vasculature. 
Quantitative measures of AVDO2 were calculated under the assumption that the relative 
contribution of venous and arterial blood to the total blood volume in the brain is 3:1 
(Phelps et al., 1979). Because of its importance, there have been a number of studies  
that have attempted to measure the relative vascular distribution (Hueber et al., 2001; 
Kusaka et al., 2002; Watzman et al., 2000; Wiedeman, 1963). These studies compared NIRS 
tissue oxygenation measurements to oxygenation measurements from arterial and venous 
blood samples, and found results similar to the 3:1 ratio which was originally derived 
from cerebrovascular resistance measurements. In addition, it has been shown that the 
AVDO2 is relatively insensitive to errors in the assumed relative vascular contribution 
(Tichauer et al., 2010). 
5. Applications 
5.1 Detection of hypoxia-ischemia 
Recent clinical trials have demonstrated that the incidence of death and disability from 
hypoxic-ischemic brain injury in newborns can be significantly reduced by initiating 
treatment strategies – hypothermia for example – after birth and within a 6 h therapeutic 
window (Chaudhari & McGuire, 2008; Eicher et al., 2005a; Eicher et al., 2005b; Gluckman et 
al., 2005; Shankaran et al., 2005). Due to the brevity of the therapeutic window, early 
detection of injury and an early determination of those infants who are likely candidates for 
treatment are crucial (Gunn & Bennet, 2008). In this regard, traditional early indicators of 
brain injury – including Apgar scores, umbilical artery acidosis and fetal heart rate 
monitoring – suffer from poor specificity (Carter et al., 1998; Shankaran, 1998) and  
more specific indicators of injury, such as magnetic resonance imaging and spectroscopy, 
are insensitive or difficult to implement within the therapeutic window (Cady, 2001;  
Martin & Barkovich, 1995). To this point, the most promising and clinically-feasible 
monitoring technique for early indicator of hypoxia-ischemia (HI) after birth has been 
amplitude-integrated electroencephalography (aEEG) due to its ease of use, non-
invasiveness and high prognostic value as early as 3 h after birth (al Naqeeb et al., 1999; Toet 
et al., 1999). However, recent studies have questioned the sensitivity of aEEG to detect 
infants with milder injuries that could still benefit from treatment (Sarkar et al., 2008). 
Another potentially promising early indicator is reduction in CMRO2 since HI is believed to 
impair oxidative metabolism. 
To test the idea that NIRS-CMRO2 measurements can improve early detection of perinatal 
HI, measurements were acquired in newborn piglets (Tichauer et al., 2009) before and after 1 
h of reperfusion from HI – the duration of which was varied from piglet to piglet with a 
range of 3-24 min – under fentanyl/nitrous oxide anesthesia to mimic awake-like levels of 
cerebral metabolism. CMRO2 was found to be significantly depressed following the insult; 
mean CMRO2 was 2.61 ± 0.11 mlO2·min-1·100g-1 prior to the insult and 1.58 ± 0.09 mlO2·min-
1·100g-1 after 1 h of reperfusion, respectively. The NIRS-CMRO2 measurements were 
combined with aEEG and both measurements displayed statistically significant correlations 
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with duration of ischemia (p < 0.05; r = 0.71 and r = 0.89, respectively); however, only 
CMRO2 was sensitive to milder injuries (< 5 min). These evidences suggest that the NIRS-
CMRO2 technique has the potential to delineate different insult severities within 1 h of 
reperfusion from hypoxia-ischemia in a piglet model of perinatal HI. Since the technique can 
be applied at the bedside of the sick newborn, these results highlight its potential to improve 
diagnosis and to monitor treatment of hypoxic-ischemic encephalopathy within the 
therapeutic window. 
5.2 Focal brain injury 
Although the previous sections highlight the potential of using NIRS for early detection of 
brain injury in newborns, CBF and CMRO2 were only measured in a single brain volume as 
the NIRS instrument had only one detection channel. This limits the clinical applicability of 
the technique due to selective patterns of damage associated with major causes of neonatal 
brain injury, such as hypoxia-ischemia and intraventricular hemorrhage, and due to focal 
injury caused by ischemic stroke. To expand the detection capabilities of the NIRS apparatus 
to enable the measurements of regional CBF and CMRO2, a relatively simple multiplexing 
approach based on electronically controlled mechanical shutters has been proposed (Diop et 
al., 2009). The entire apparatus was housed in a cart (see Fig. 2) and could be moved to the 
bedside. The ability of this multi-detector NIRS instrument to detect regional CBF and 
CMRO2 abnormalities was tested in newborn piglets in which the vasoconstrictor 
Endothelin-1 (ET-1) was injected into the brain to cause a focal ischemic injury. Endothelin-1 
is an amino acid peptide that possesses prolonged and profound vasoconstrictive effects on 
cerebral blood vessels (Diop et al., 2009). For comparison, regional CBF was concurrently 
measured by CT perfusion. Due to limited space on the piglet head, only four detection 
channels were used in that study. A general reduction in CBF was observed across all 
detection channels with the magnitude decreasing farther from the site of ET-1 injection; a 
trend that was also observed in the CT perfusion images. An excellent agreement was also 
observed between CBF in the lesion site, as determined from the CT perfusion images, and 
CBF measured by the NIRS optode nearest to the lesion site (optode 1 in Fig. 4). The NIRS-
CMRO2 measurements showed that ET-1 injection did not cause a significant change in 
cerebral energy metabolism. This was expected as CMRO2 would be maintained, despite the 
reduction in CBF, by an increase in cerebral oxygen extraction. Although both NIRS and CT 
measured ~ 50% CBF reduction in the lesion region, this decrease was likely not sufficient to 
exhaust the compensatory effects of increased oxygen extraction. Typically, reductions in 
CMRO2 are not observed until CBF falls below 25 ml/100g/min. 
A limitation with this multi-channel NIRS apparatus is that it is not immune to partial-
volume errors which could result in an overestimation of CBF in focal lesions significantly 
smaller than the sensitivity volume of a source-detector unit. One approach to improving 
the spatial resolution would be to combine the multi-channel NIRS instrument with a 
discrete-wavelength continuous-wave system with multiple emission and detection 
optodes. Broadband NIRS could be used to determine the DPF and the steady-state Hb 
concentration needed to determine CMRO2. A discrete-wavelength imaging system could 
then be used to rapidly acquire dynamic ICG concentration data. The relative ICG data 
would be converted into absolute units using the DPF measurements. With such an 
approach, it may be possible to apply diffuse optical tomographic methods to further 
improve spatial resolution. 
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Fig. 4. Brain tissue ICG concentration curves obtained from detection optodes 1-4 before (a) 
and after (b) ET-1 injection. The reduction in the peak height of the ICG curve for optode 1 
after ET-1 injection reflects the reduction in CBF caused by the drug. Shown in the top right 
hand side of (a) is a cartoon of a piglet head showing the location of the 4 detection optodes 
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with duration of ischemia (p < 0.05; r = 0.71 and r = 0.89, respectively); however, only 
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exhaust the compensatory effects of increased oxygen extraction. Typically, reductions in 
CMRO2 are not observed until CBF falls below 25 ml/100g/min. 
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concentration needed to determine CMRO2. A discrete-wavelength imaging system could 
then be used to rapidly acquire dynamic ICG concentration data. The relative ICG data 
would be converted into absolute units using the DPF measurements. With such an 
approach, it may be possible to apply diffuse optical tomographic methods to further 
improve spatial resolution. 
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measurements, the measured ICG tissue concentration curve is comprised of both cerebral 
and non-cerebral components that are highly correlated. Using tracer kinetic models to 
recover CBF from a contaminated curve would result in an underestimation of CBF (Elliott 
et al., 2010; Gora et al., 2002; Owen-Reece et al., 1996). Solutions to overcoming this 
challenge have been proposed, including more advanced instrumentation as well as 
analytical approaches, with the main goal of increasing sensitivity to cerebral components. 
The presence of the extra-cerebral component in the measured signal makes the analytical 
problem underdetermined when using a single-channel continuous-wave configuration. To 
differentiate between signal arising from cerebral tissue and extracerebral contamination, 
more information about the light-tissue interaction is necessary. Several instrumentation 
approaches have emerged which provide additional information and include multi-distance 
(also known as spatially resolved), time-resolved and frequency-domain approaches. The 
additional data provided by these techniques facilitate the removal of extracerebral 
contamination by further constraining the system of equations which describe the change in 
light propagation due to the inflow of tracer. 
In depth-resolved NIRS, multiple detectors are used to simultaneously measure the optical 
signal at difference source-detector distances (Hongo et al., 1995; Pucci et al., 2010). This 
approach is based on the principle that the penetration depth of light increases with source-
detector distance. Therefore, the distance that light travels in each tissue type depends on both 
the geometry of the tissue layers as well as the source-detector distance. Measuring the NIR 
signal at a variety of source-detector distances for the same tissue structure provides a means 
of algebraically isolating information from the cerebral tissue. The main limitation of this 
approach is that the mean partial pathlength of light for a given source-detector distance is 
unknown and must therefore be determined using mathematical modeling, spectral 
information, anatomical priors, or a combination of these. Recently, a depth-resolved NIRS 
method that incorporated CT imaging data into a light propagation model  has been validated 
(Elliott et al., 2010). The determination of mean partial pathlengths using this approach 
allowed the removal of extracerebral contamination, and the recovered CBF values were in 
good agreement with independent measurements obtained with CT perfusion. Several other 
multi-distance techniques have been proposed, using time-resolved or frequency-domain 
methods to provide additional information (Liebert et al., 2004; Steinbrink et al., 2006). 
An effective way to isolate the deeper cerebral component of the signal is to collect 
information about individual photons, mainly the time required to travel from the source 
fibre, through the tissue, to the detector. This “time-of-flight” is a function of the optical 
properties of the tissue and the distribution of times-of-flight for a sample of photons can be 
considered as a unique signature of the tissue geometry and type. Similar to the depth-
resolved approach, photons with late arrival times are more likely to have propagated into 
cerebral tissue, but unlike in the case of depth-resolved NIRS, the relationship is not 
straight-forward. Instead, it is necessary to mathematically model the time-of-flight 
distribution (Kienle et al., 1998; Wang et al., 1995) to determine the optical properties of each 
medium. Changes in light attenuation recovered from this modeling can be converted to 
ICG concentration and deconvolved to yield CBF (Diop et al., 2010). 
In a similar way, when a frequency-modulated light signal is introduced into a tissue, the 
amplitude and phase components of the detected light depend on the tissue geometry and 
optical properties (Choi et al., 2004). In theory, the same time-of-flight information collected 
using time-resolved NIRS is contained in frequency-domain measurements. Since most 
analytical models employed in time-resolved analysis have solutions for the frequency 
domain as well, the two techniques are theoretically equivalent. 
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When using the methods discussed above, a certain amount of prior information is 
necessary to properly analyze the measured data. These priors include information 
regarding the geometry and type of tissue being interrogated, the optical properties of the 
tissues, and the placement and efficiency of the optical probes. Because the determination of 
these priors can often be challenging in a clinical environment, it is common to make a 
limited number of assumptions and simplifications. However, the number and quality of 
priors will usually affect the accuracy of the CBF measurement, making it necessary to 
carefully consider this trade-off. 
Perhaps the most important prior from a clinical perspective is anatomical information 
pertaining to the thickness and shape of the extracerebral layers, and must be incorporated 
into light propagation models. In the absence of this information, the head is treated either as a 
homogenous medium or as a simple two-layered structure with a top layer thickness based on 
the population average. Measurements of CBF determined using either of these two 
assumptions have been shown to be inaccurate under most clinical situations (Gora et al., 2002; 
Schytz et al., 2009). The accuracy of CBF measurements can be improved when the total 
thickness of the extra-cerebral layer, or preferably, the individual thicknesses of the scalp, skull 
and CSF layers are known (Elliott et al., 2010). Recent studies have also suggested that 
incorporating an imaging dataset from CT or MRI may further increase the accuracy of the 
measurements (Dehaes et al., 2011), but this has not yet been demonstrated experimentally. 
An alternative approach to the quantitative methods discussed above is to use semi-
quantitative comparisons to assess the relative change in blood flow as a function of time, or 
the relative difference in blood flow between different areas on the head (Liebert et al., 2005). 
While these techniques cannot quantify CBF, they may be effective in specific clinical 
applications even if no priors are available. Recently, Steinkeller et al. demonstrated the use of 
a semi-quantitative time-resolved NIRS technique to monitor cerebral perfusion in acute 
ischemic stroke patients (Steinkellner et al., 2010).  In this study, NIRS measurements were 
acquired over both hemispheres following the injection of tracer, and the time-to-peak, or time 
between first appearance of tracer and the peak concentration of tracer, was determined. In all 
patients, a larger time-to-peak was observed in the affected hemisphere, when compared to 
the normal hemisphere. 
7. Conclusion 
Near-infrared spectroscopy is already an accepted and widely used monitoring tool for the 
clinical management of patients since the ubiquitous pulse oximeter is in fact a NIRS 
instrument. Although NIRS instruments are in general relatively simple, analyzing the 
measured signal is not always straightforward. For this reason, interpreting NIRS data 
remains one of the major obstacles preventing its wide spread and routine clinical use. To 
overcome this challenge, better analytical tools need to be developed as well as stronger 
collaboration between researchers and clinicians. Another major problem with NIRS is the 
lack of widely accepted standards. Efforts are being made to solve this issue with multiple 
research groups working together to develop calibrated tissue mimicking phantoms. 
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1. Introduction 
Cerebrovascular accidents carry significant morbidity and mortality and are vastly present 
in current society. One of the most prevalent causes of death and long-term disability within 
the United States, stroke was found to directly cause 6 million deaths in 2006 and was found 
to be indirectly attributed to $73.7 billion in health care costs in 2010 (Lloyd-Jones et al., 
2010). Current standard of care requires that patients present to a health care facility very 
early in disease onset so thrombolytic therapy can be initiated; however, this therapy, 
focusing on the establishment of reperfusion is not ideal as reperfusion often worsens 
ischemic injury (Yang and Betz, 1994). Clearly, new therapeutic and pharmacologic 
interventions are needed. 
Exercise has long been known to provide protection for ischemic stroke through the 
amelioration of stroke risk factors. Through its beneficial effects on hypertension, lipid 
profiles, obesity, and diabetes, exercise training has been associated with decreased stroke 
incidence and better outcomes after stroke (Evenson et al., 1999; Gillum et al., 1996; Hu et 
al., 2004). Despite risk factor management, exercise has also been shown to provide 
endogenous neuroprotection, preserving neuronal viability in the setting of ischemia/ 
reperfusion injury, resulting in decreased infarct volume and improved neurologic 
recovery (Chaudhry et al., 2010; Curry et al., 2009; Davis et al., 2007; Ding et al., 2004a, 
2004b, 2005, 2006a, 2006b; Guo et al., 2008a; Liebelt et al., 2010; Zwagerman et al.,  
2010a, 2010b). These beneficial endogenous effects of exercise preconditioning have  
been seen even after multivariate analysis has controlled for risk factor alterations (Hu et 
al., 2005).  
Multiple studies have shown the endogenous protection of rat myocardium following 
exercise preconditioning (Powers et al., 2002; Siu et al., 2004) through attenuation of 
apoptosis and better outcomes following reperfusion. Similarly, endogenous 
neuroprotection has been shown to take place through multiple mechanisms, including 
upregulation of neurotrophin expression, strengthening of the blood brain barrier (BBB), 
enhancing the cerebral capillary and arterial networks, decreasing inflammation and 
apoptosis, and improving cerebral metabolism. Through these mechanisms, exercise 
preconditioning provides valuable insight into the science of endogenous neuroprotection 
and its potential therapeutic and clinical implications. 
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Fig. 1. Exercise generates endogenous neuroprotection through the development of 
neurogenesis, improved integrity of the neurovascular unit, enhanced metabolism, 
decreased apoptosis, and amelioration of inflammation. 
2. Methods of preconditioning 
To date, no specific guidelines have been established through human studies to convey 
adequate or optimal neuroprotection.  Although exercise has been shown to convey 
endogenous neuroprotection and innate cardioprotection (Hu et al., 2004; Kloner, 2001), the 
extent, duration, and type of exercise has not been conclusively studied.  Despite this, a 
previous study revealed that moderate intensity and duration of exercise, as opposed to 
mild or strenuous, correlates with better outcomes and life improvements (Larson et al., 
2006). There are specific exercise modalities which convey more potent neuroprotection, and 
exercise of any duration appears to be neuroprotective.  Certainly more studies, especially 
with human subjects, need to be performed in order to determine exercise regimens 
resulting in maximal neuroprotection. 
2.1 Duration of preconditioning  
Despite its known neuroprotective effects, no specific duration of exercise has been shown 
to provide maximal neuronal survival or lead to better neurologic outcomes.  Through 
multiple studies in rats, it can be seen that exercise preconditioning prior to 
ischemia/reperfusion injury for a duration of as little as 2 weeks and up to 12 weeks 
provides similar levels of neuroprotection (Ang et al., 2003; Curry et al., 2009; Davis et al., 
2007; Ding et al., 2004a; Stummer et al., 1994; Wang et al., 2001). In addition to the 
duration of exercise needed, another important factor revolves around the extent of 
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neuroprotection after exercise has stopped.  Another study revealed that the 
neuroprotective effects of exercise preconditioning appear to be long-lasting, showing 
that 3 weeks after cessation of exercise, rats still maintained lower levels of neurologic 
deficit and decreased stroke volume when compared to non-exercise rats (Ding et al., 
2004b).  Future human studies ought to determine the exact duration needed for maximal 
endogenous neuroprotection. 
2.2 Preconditioning modalities 
While various modalities, such as treadmill running, voluntary running, simple and 
complex exercise, have been shown to provide variable amounts of neuroprotection.  When 
comparing forced exercise on a treadmill to voluntary running on a running wheel, rats 
forced to exercise on a treadmill tend to have better neurologic outcomes after stroke (Hayes 
et al., 2008). Previous studies have shown that forced exercise on a treadmill is slower but 
more constant than voluntary exercise occurs in shorter spurts with faster speed, although 
the total distance is equal in the two groups (Noble et al., 1999). This neuroprotection in 
forced exercise subjects led to decreased stroke volume, lessened neurologic deficit, 
upregulation of heat shock proteins, increased neurogenesis and cerebral metabolism 
(Hayes et al., 2008; Kinni et al., 2011; Leasure and Jones, 2008). These findings show that 
moderate exercise over a longer time period conveys more efficient and greater 
neuroprotection than more vigorous exercise over shorter time periods. 
In addition to the studies assessing forced and voluntary exercise, differences have also been 
established when comparing simple and complex exercise. This study analyzed simple 
exercise as the repetitive movements of treadmill running, whereas complex exercise 
constituted enriched activities which required both balance and coordination (Ding et al., 
2003). Following ischemia/reperfusion injury, rats preconditioned with complex exercise 
demonstrated increased synaptogenesis and improved neurologic outcomes when 
compared to simple treadmill exercise (Ding et al., 2003; Jones et al., 1999).  Simple exercise 
training also alleviates much of the injury following ischemia/reperfusion, but its benefit is 
less pronounced than what is observed with complex exercise training.  Although no human 
studies have definitively shown the most effective means of exercise for enhanced 
neuroprotection, these animal studies provide a solid framework for the development of 
appropriate exercise regimens. Moderate exercise intensity, including components of 
balance, coordination and stress, taking place over a sustained duration seem to be the most 
neuroprotective when compared to other exercise modalities and intensities. 
3. Mechanisms of neuroprotection 
Exercise clearly provides substantial endogenous neuroprotection in addition to its role in 
risk factor reduction for ischemia/reperfusion injury.  These effects have been shown 
through a wide variety of neuroprotective mechanisms all which increase neuronal survival 
in the setting of ischemic stroke.  These protective effects revolve around the neurovascular 
unit, composed of neuronal, glial, and vascular cells. This unit is significantly enhanced 
through exercise training and is injured through ischemia/reperfusion. As such, its integrity 
is paramount for proper cerebral functioning and is the focal point of the neuroprotective 
effects of exercise in ameliorating ischemic injury.  This neuroprotection is, in part, conveyed 
through the upregulation of neurotrophin expression, including brain derived neurotrophic 
factor (BDNF) and nerve growth factor (NGF).  These important regulatory proteins increase 
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neurogenesis, providing a richer neuronal network prior to injury and a more potent 
neuronal regenerative ability.  
In addition to enhanced neurogenesis, exercise neuroprotection also serves to enhance 
neurovascular unit integrity through strengthening of the blood brain barrier (BBB).  
Exercise has been shown to enhance the expression of basal lamina proteins and to increase 
astrocytosis, effectively providing greater stability to the BBB and the neurovascular unit.  
Matrix metalloproteinases have also been shown to be downregulated following exercise, 
enzymes which normally degrade the BBB. Furthermore, angiogenic factors, such as 
vascular endothelial growth factor (VEGF) and angiopoietins (Ang1 and Ang 2), are 
upregulated following exercise and correlated with increased blood vessel density and 
increased cerebral blood flow (CBF). These changes provide further stability to the 
neurovascular unit and have been shown to provide better outcomes following 
ischemia/reperfusion injury.  
Exercise also regulates apoptotic pathways in such a way as to tip the balance in favor of 
anti-apoptotic to pro-apoptotic gene expression.  Carried out through mediators, such as 
tumor necrosis factor (TNF)-α, extracellular regulated kinase (ERK)-1/2, and heat shock 
protein (HSP)-70, increasing the anti:pro-apoptotic ratio effectively decrease apoptosis and 
prolongs neuronal survival, providing obvious benefit following ischemia/reperfusion 
injury. Furthermore, exercise preconditioning decreases the expression of vascular adhesion 
molecules (ICAM-1), which decreases leukocyte infiltration and secondary damage 
following ischemic stroke. These changes ameliorate much of the neuronal damage and 
death after hypoxic conditions.  Finally, neuronal metabolism is upregulated following 
chronic exercise, correlating with increased ATP production in the acute phase following 
ischemia/reperfusion injury.  This is done through upregulation of glucose transport 
enzymes, glycolytic enzymes, and the upstream regulator protein hypoxia-inducible factor 
(HIF)-1α. The pathways underlying these mechanistic changes in response to exercise 
preconditioning will be defined in detail as each provides valuable clues to understanding 
the protective ability of exercise following ischemia/reperfusion injury. 
3.1 Neurotrophin expression 
Neurotrophins are well known to enhance neurogenesis and synaptogenesis while working to 
promote cerebral integrity at its most basic unit.  Multiple human and animal studies have 
revealed that brain derived neurotrophic factor (BDNF) and nerve growth factor (NGF) 
facilitate this process (Cohen-Cory et al., 2010; Kim et al., 2004; Kuipers and Bramham, 2006). 
These trophic factors generate more abundant neuronal and synaptic networks, and they have 
also been shown to be protective of the neural and cerebrovascular systems. BDNF and NGF 
mRNA levels have been shown to be upregulated following several weeks of continuous 
exercise (Ding et al., 2004b), which has been specifically seen in astrocytes and neuronal cells. 
In addition, providing exercise in an enriched environment, including running wheels, toy 
balls, ladders, and wooden planks, increased synaptogenesis and neurologic functioning  even 
more than previously seen with basic exercise preconditioning, which was also associated with 
an increase in BDNF and NGF mRNA levels (Neeper et al., 1996; Ickes et al., 2000). This further 
implies that complex exercise, requiring balance and coordination, transmits greater 
neuroprotection that basic repetitive exercise. 
Upregulation of these proteins following chronic exercise generates increased neurogenesis, 
which is protective in advance of ischemia/reperfusion injury. Several studies have shown 
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that exercise preconditioned rats have elevated levels of BDNF and NGF following 
ischemia/reperfusion injury, which correlates with decreased neurologic deficit and 
decreased stroke volume when compared to non-exercised rats (Ang et al., 2003; Ding et al., 
2004a).  Another study has shown these factors to be upregulated within the reperfusion 
stage as well (Schabitz et al., 2007), suggesting a possible reparative role post-ischemic 
insult.  The ability to upregulate these neurogenic factors in the reperfusion stage provides 
the potential for cell survival and regeneration, especially within the ischemic penumbra 
zone.  These results suggest a temporally duel role of BDNF and NGF in exercise 
preconditioning in which their upregulation via chronic exercise training strengthens the 
neurovascular unit before and after injury. Altogether, the upregulation of BDNF and NGF 
seen following exercise preconditioning promotes neuronal survival following 
ischemia/reperfusion injury. 
3.2 Integrity of the neurovascular unit 
In addition to neuronal health and viability, integrity of the neurovascular unit as a whole 
requires maintenance of the blood brain barrier (BBB), structural support provided by 
astrocytic glial cells, and an intact cerebrovascular network.  Composed of capillary 
endothelial cells, the basal lamina, and astrocytic end-feet, the BBB provides a robust 
filtration mechanism which serves as the functional barrier for neurovascular unit integrity 
in the setting of ischemic stroke. Also the first structure injured after ischemia/reperfusion 
injury, the strength of the BBB is of utmost importance and is a key component to the 
neuroprotection afforded by exercise training. 
While viewing the neurovascular unit as the most basic structure for neuroprotection and 
stability, astrocytes also play a key role in maintaining the cerebral architecture. Seen 
following chronic exercise, astrocytosis strengthens the BBB and neurovascular unit, 
providing a rigid framework to withstand ischemia/reperfusion insults against the 
neurovascular unit.   
Not only does exercise promote neuronal health, BBB integrity, and astrocytic structure, but 
it also generates an increased blood vessel density.  Increased collateral circulation coupled 
with richer capillary beds allows a more efficient and effective response to ischemia.  The 
angiogenesis and arteriogenesis seen after exercise allow the brain to be rapidly reperfused. 
In exercised subjects with enhanced BBB integrity, this elevated reperfusion potential occurs 
much more proficiently and with less damage than is seen in non-exercised subjects.  These 
neuroprotective changes in exercised animals in the setting of ischemia/reperfusion injury 
underlie the importance of pre-ischemic exercise conditioning and provide potential novel 
therapeutic interventions. 
3.2.1 Blood Brain Barrier integrity 
The integrity of the blood brain barrier (BBB) is paramount to maintaining proper filtration 
of nutrients from the vascular system and in providing the necessary structure to the 
neurovascular unit.  Composed of endothelial cell walls, the basal lamina, and astrocytic 
end-feet, this filtration barrier is the first structure injured during ischemia/reperfusion 
injury (del Zoppo and Hallenbeck, 2000; del Zoppo and Mabuchi, 2003), making its integrity 
a key focal point in the neuroprotective nature of exercise. While an intact endothelial cell 
wall and astrocytic end-feet are necessary for proper BBB functionality, the basal lamina 
provides the central structural support and selective permeability necessary to maintain a 
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neurogenesis, providing a richer neuronal network prior to injury and a more potent 
neuronal regenerative ability.  
In addition to enhanced neurogenesis, exercise neuroprotection also serves to enhance 
neurovascular unit integrity through strengthening of the blood brain barrier (BBB).  
Exercise has been shown to enhance the expression of basal lamina proteins and to increase 
astrocytosis, effectively providing greater stability to the BBB and the neurovascular unit.  
Matrix metalloproteinases have also been shown to be downregulated following exercise, 
enzymes which normally degrade the BBB. Furthermore, angiogenic factors, such as 
vascular endothelial growth factor (VEGF) and angiopoietins (Ang1 and Ang 2), are 
upregulated following exercise and correlated with increased blood vessel density and 
increased cerebral blood flow (CBF). These changes provide further stability to the 
neurovascular unit and have been shown to provide better outcomes following 
ischemia/reperfusion injury.  
Exercise also regulates apoptotic pathways in such a way as to tip the balance in favor of 
anti-apoptotic to pro-apoptotic gene expression.  Carried out through mediators, such as 
tumor necrosis factor (TNF)-α, extracellular regulated kinase (ERK)-1/2, and heat shock 
protein (HSP)-70, increasing the anti:pro-apoptotic ratio effectively decrease apoptosis and 
prolongs neuronal survival, providing obvious benefit following ischemia/reperfusion 
injury. Furthermore, exercise preconditioning decreases the expression of vascular adhesion 
molecules (ICAM-1), which decreases leukocyte infiltration and secondary damage 
following ischemic stroke. These changes ameliorate much of the neuronal damage and 
death after hypoxic conditions.  Finally, neuronal metabolism is upregulated following 
chronic exercise, correlating with increased ATP production in the acute phase following 
ischemia/reperfusion injury.  This is done through upregulation of glucose transport 
enzymes, glycolytic enzymes, and the upstream regulator protein hypoxia-inducible factor 
(HIF)-1α. The pathways underlying these mechanistic changes in response to exercise 
preconditioning will be defined in detail as each provides valuable clues to understanding 
the protective ability of exercise following ischemia/reperfusion injury. 
3.1 Neurotrophin expression 
Neurotrophins are well known to enhance neurogenesis and synaptogenesis while working to 
promote cerebral integrity at its most basic unit.  Multiple human and animal studies have 
revealed that brain derived neurotrophic factor (BDNF) and nerve growth factor (NGF) 
facilitate this process (Cohen-Cory et al., 2010; Kim et al., 2004; Kuipers and Bramham, 2006). 
These trophic factors generate more abundant neuronal and synaptic networks, and they have 
also been shown to be protective of the neural and cerebrovascular systems. BDNF and NGF 
mRNA levels have been shown to be upregulated following several weeks of continuous 
exercise (Ding et al., 2004b), which has been specifically seen in astrocytes and neuronal cells. 
In addition, providing exercise in an enriched environment, including running wheels, toy 
balls, ladders, and wooden planks, increased synaptogenesis and neurologic functioning  even 
more than previously seen with basic exercise preconditioning, which was also associated with 
an increase in BDNF and NGF mRNA levels (Neeper et al., 1996; Ickes et al., 2000). This further 
implies that complex exercise, requiring balance and coordination, transmits greater 
neuroprotection that basic repetitive exercise. 
Upregulation of these proteins following chronic exercise generates increased neurogenesis, 
which is protective in advance of ischemia/reperfusion injury. Several studies have shown 
 
Mechanisms of Neuroprotection Underlying Physical Exercise in Ischemia – Reperfusion Injury 
 
303 
that exercise preconditioned rats have elevated levels of BDNF and NGF following 
ischemia/reperfusion injury, which correlates with decreased neurologic deficit and 
decreased stroke volume when compared to non-exercised rats (Ang et al., 2003; Ding et al., 
2004a).  Another study has shown these factors to be upregulated within the reperfusion 
stage as well (Schabitz et al., 2007), suggesting a possible reparative role post-ischemic 
insult.  The ability to upregulate these neurogenic factors in the reperfusion stage provides 
the potential for cell survival and regeneration, especially within the ischemic penumbra 
zone.  These results suggest a temporally duel role of BDNF and NGF in exercise 
preconditioning in which their upregulation via chronic exercise training strengthens the 
neurovascular unit before and after injury. Altogether, the upregulation of BDNF and NGF 
seen following exercise preconditioning promotes neuronal survival following 
ischemia/reperfusion injury. 
3.2 Integrity of the neurovascular unit 
In addition to neuronal health and viability, integrity of the neurovascular unit as a whole 
requires maintenance of the blood brain barrier (BBB), structural support provided by 
astrocytic glial cells, and an intact cerebrovascular network.  Composed of capillary 
endothelial cells, the basal lamina, and astrocytic end-feet, the BBB provides a robust 
filtration mechanism which serves as the functional barrier for neurovascular unit integrity 
in the setting of ischemic stroke. Also the first structure injured after ischemia/reperfusion 
injury, the strength of the BBB is of utmost importance and is a key component to the 
neuroprotection afforded by exercise training. 
While viewing the neurovascular unit as the most basic structure for neuroprotection and 
stability, astrocytes also play a key role in maintaining the cerebral architecture. Seen 
following chronic exercise, astrocytosis strengthens the BBB and neurovascular unit, 
providing a rigid framework to withstand ischemia/reperfusion insults against the 
neurovascular unit.   
Not only does exercise promote neuronal health, BBB integrity, and astrocytic structure, but 
it also generates an increased blood vessel density.  Increased collateral circulation coupled 
with richer capillary beds allows a more efficient and effective response to ischemia.  The 
angiogenesis and arteriogenesis seen after exercise allow the brain to be rapidly reperfused. 
In exercised subjects with enhanced BBB integrity, this elevated reperfusion potential occurs 
much more proficiently and with less damage than is seen in non-exercised subjects.  These 
neuroprotective changes in exercised animals in the setting of ischemia/reperfusion injury 
underlie the importance of pre-ischemic exercise conditioning and provide potential novel 
therapeutic interventions. 
3.2.1 Blood Brain Barrier integrity 
The integrity of the blood brain barrier (BBB) is paramount to maintaining proper filtration 
of nutrients from the vascular system and in providing the necessary structure to the 
neurovascular unit.  Composed of endothelial cell walls, the basal lamina, and astrocytic 
end-feet, this filtration barrier is the first structure injured during ischemia/reperfusion 
injury (del Zoppo and Hallenbeck, 2000; del Zoppo and Mabuchi, 2003), making its integrity 
a key focal point in the neuroprotective nature of exercise. While an intact endothelial cell 
wall and astrocytic end-feet are necessary for proper BBB functionality, the basal lamina 
provides the central structural support and selective permeability necessary to maintain a 
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healthy cerebral environment.  The basal lamina is composed of various proteins of the 
extracellular matrix, including collagen type IV, laminin, heparan sulphate, proteoglycan, 
and fibronectin, which are produced by surrounding endothelial cells and astrocytes.  The 
importance for proper integrity and functionality of this structure has been repeatedly 
established (Lo et al., 2003, Lo et al., 2005). When this barrier is damaged, as is the case 
following ischemia/reperfusion injury, its ability to selectively discriminate products of the 
cerebrovascular system is compromised, which is clinically evident as vasogenic edema.   
In a hypoxic setting, this loss of BBB integrity and introduction of cerebral edema further 
disturbs cerebral homeostasis in a step-wise manner.  Soon after arterial occlusion, the 
endothelial permeability barrier is lost and matrix proteins, primarily fibronectin, collagen, 
and laminin, also begin to lose their integrity (del Zoppo and Mabuchi, 2003). As ischemia 
continues, a lack of selective permeability and continued vasogenic edema lead to cellular 
swelling. Swelling of astrocytes and endothelial cells separates them further from the basal 
lamina, further promoting leakage of vascular contents into the cerebral interstitial spaces 
(del Zoppo and Mabuchi, 2003). Reperfusion tends to worsen this damage, despite its role as 
the current mainstay of therapy for ischemic stroke. These alterations in the ischemic phase 
severely damage the integrity of the BBB, and the sudden increase in cerebrovascular flow 
in the reperfusion stage leads to excessive leakage of water and generation of oxygen free 
radicals, further promoting cerebral damage (Ayata and Ropper, 2002; Yang and Betz, 1994). 
Studies have shown that exercise training increases basal lamina thickness, adding both 
strength and stability to the BBB (Davis et al., 2007). These changes were associated with 
decreases cerebral edema, decreased stroke volume, and improved neuronal recovery 
following ischemia/reperfusion injury.  Collage type IV, a major component of the basal 
lamina, was found to be upregulated in exercise preconditioned rats, and these subjects 
maintained a decreased net loss of collagen type IV levels after stroke as well (Davis et al., 
2007). Also confirmed by immunocytochemistry, elevated levels of collagen type IV-positive 
cells were observed in previously exercise rats, and these rats had significantly lower levels 
of neurologic deficit following stroke (Davis et al., 2007). 
In a similar manner to collagen expression, integrin proteins also provide stability to the 
basal lamina and BBB, providing additional support to the neurovascular unit. Composed of 
α and β heterodimers, these proteins serve as cell adhesion molecules within the basal 
lamina and extracellular matrix, anchoring astrocytes and endothelial cells together, 
ultimately maintaining the integrity of these structures and the neurovascular unit as a 
whole (Dans and Giancotti, 1999; Hynes, 1992). Integrins, which are anchored to astrocytic 
and endothelial cytoskeletons, serve as receptors for numerous ligands and proteins within 
the basal lamina matrix, primarily collagen and laminin (del Zoppo and Mabuchi, 2003; 
Tawil et al., 1994). These structural proteins also serve as signalling receptors for astrocytes 
and endothelial cells, allowing for dynamic alterations of the BBB in response to exercise, 
ischemia, and other noxious stimuli (Hynes, 1992). Following ischemic/reperfusion injury, 
these proteins rapidly lose affinity for their associated ligands within the basal lamina, 
decreasing the connective integrity between endothelial and astrocytic cells and the 
extracellular matrix (Tagaya et al., 2001; Wagner et al., 1997). However, in exercised-trained 
rats, integrin expression was found to be significantly higher in astroglia and endothelium 
following ischemic stroke (Ding et al., 2005; Tawil et al., 1994), which correlated with a 
decrease in neurologic deficit (Ding et al., 2006b). These changes suggest that integrin 
expression is uniquely important to BBB integrity as it serves to bind all three components 
 
Mechanisms of Neuroprotection Underlying Physical Exercise in Ischemia – Reperfusion Injury 
 
305 
together, and this increased expression following exercise serves as another mechanism of 
its neuroprotective nature.  Through both increased collagen and integrin expression 
following exercise preconditioning, the enhanced integrity of the BBB decreases vasogenic 
edema, secondary damage, and neuronal death following ischemia/reperfusion. 
While it can clearly be seen that exercise increases the thickness and integrity of the basal 
lamina and BBB as a whole, pre-ischemic exercise also improves integrity of the 
neurovascular unit by decreasing BBB breakdown. Matrix metalloproteinase (MMP) is an 
enzyme produced by endothelial cells, microglia, and astrocytes with a primary function to 
degrade extracellular matrix and basal lamina proteins (Lo et al., 2003). Expression of MMPs 
increases exponentially following cerebral damage and, as a result, has been heavily 
implicated following ischemia/reperfusion injury (Lo et al., 2003). Upregulation of MMP 
following stroke has been implicated in multiple animal and human studies (Clark et al., 
1997; Gasche et al., 1999), leading to increased BBB permeability and vasogenic edema. In 
addition to these damaging changes, MMP expression has also been correlated with 
increased inflammation and leukocyte infiltration (Romanic et al., 1998). Pharmacologic 
inhibition (Romanic et al., 1998) and genetic knockout (Asahi et al., 2001) of MMPs leads to a 
dramatic decrease in associated edema and neurologic damage. MMP-induced damage 
following ischemia/reperfusion is mechanistically linked to extracellular matrix breakdown, 
including degradation of collagen, leading to loss of integrity of the BBB and the 
neurovascular unit.   
Following exercise preconditioning, rats were found to have reduced MMP-9 expression, 
which correlated with elevated collagen IV levels (Davis et al., 2007), and similar results 
were seen following pharmacologic inhibition.  This neuroprotective effect of exercise is 
mediated by improved microvascular integrity and basal lamina reinforcement, ultimately 
decreasing neurologic deficit, infarct volume, and leukocyte infiltration following 
ischemia/reperfusiom injury (Curry et al., 2009). Interestingly, when these same rats were 
treated with tumor necrosis factor (TNF)-α antibody or inhibition of extracellular regulated 
kinase (ERK), MMP-9 levels were not decreased, and the positive effects on neurologic 
outcome and infarct volume were no longer seen (Curry et al., 2009; Hosomi et al., 2005), 
suggesting that TNF-α and ERK serve as regulators of MMP expression.  Further studies 
have shown that ERK1/2 mediates a TNF-α induced an increase in MMP-9 expression in the 
acute setting (Arai et al., 2003), while the gradual increases in TNF-α and ERK1/2 have been 
shown to decrease MMP-9 expression and lead to decreased neuronal cell death (Chaudhry 
et al., 2010). These gradual changes are seen following exercise training, in which gradual 
upregulation of TNF-α and ERK1/2 lead to decreased levels of MMP-9 expression, which 
also correlates with better outcomes following ischemia/reperfusion injury (Chaudhry et al., 
2010). In this study, following ischemic injury, neuronal apoptosis was seen to be reduced in 
association with decreased levels of MMP-9 expression in exercise preconditioned rats 
(Chaudhry et al., 2010). Following pharmacologic inhibition of both ERK1/2 and MMP-9, 
similar effects were also seen, resulting in less neuronal apoptosis and better neurologic 
outcomes; however, when only ERK1/2 was inhibited, MMP expression returned to the 
level of non-exercised control rats, suggesting a pathway involving regulation by ERK1/2 
and TNF-α of MMP-9 expression (Chaudhry et al., 2010).  ERK1/2 has previously been 
shown to also work through upregulation of tissue inhibitors of metalloproteinases (TIMPs) 
(Tong et al., 2004), and TIMPs have been previously shown to be upregulated following 
chronic exercise in association with decreased MMP-9 levels (Guo et al., 2008a). The 
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healthy cerebral environment.  The basal lamina is composed of various proteins of the 
extracellular matrix, including collagen type IV, laminin, heparan sulphate, proteoglycan, 
and fibronectin, which are produced by surrounding endothelial cells and astrocytes.  The 
importance for proper integrity and functionality of this structure has been repeatedly 
established (Lo et al., 2003, Lo et al., 2005). When this barrier is damaged, as is the case 
following ischemia/reperfusion injury, its ability to selectively discriminate products of the 
cerebrovascular system is compromised, which is clinically evident as vasogenic edema.   
In a hypoxic setting, this loss of BBB integrity and introduction of cerebral edema further 
disturbs cerebral homeostasis in a step-wise manner.  Soon after arterial occlusion, the 
endothelial permeability barrier is lost and matrix proteins, primarily fibronectin, collagen, 
and laminin, also begin to lose their integrity (del Zoppo and Mabuchi, 2003). As ischemia 
continues, a lack of selective permeability and continued vasogenic edema lead to cellular 
swelling. Swelling of astrocytes and endothelial cells separates them further from the basal 
lamina, further promoting leakage of vascular contents into the cerebral interstitial spaces 
(del Zoppo and Mabuchi, 2003). Reperfusion tends to worsen this damage, despite its role as 
the current mainstay of therapy for ischemic stroke. These alterations in the ischemic phase 
severely damage the integrity of the BBB, and the sudden increase in cerebrovascular flow 
in the reperfusion stage leads to excessive leakage of water and generation of oxygen free 
radicals, further promoting cerebral damage (Ayata and Ropper, 2002; Yang and Betz, 1994). 
Studies have shown that exercise training increases basal lamina thickness, adding both 
strength and stability to the BBB (Davis et al., 2007). These changes were associated with 
decreases cerebral edema, decreased stroke volume, and improved neuronal recovery 
following ischemia/reperfusion injury.  Collage type IV, a major component of the basal 
lamina, was found to be upregulated in exercise preconditioned rats, and these subjects 
maintained a decreased net loss of collagen type IV levels after stroke as well (Davis et al., 
2007). Also confirmed by immunocytochemistry, elevated levels of collagen type IV-positive 
cells were observed in previously exercise rats, and these rats had significantly lower levels 
of neurologic deficit following stroke (Davis et al., 2007). 
In a similar manner to collagen expression, integrin proteins also provide stability to the 
basal lamina and BBB, providing additional support to the neurovascular unit. Composed of 
α and β heterodimers, these proteins serve as cell adhesion molecules within the basal 
lamina and extracellular matrix, anchoring astrocytes and endothelial cells together, 
ultimately maintaining the integrity of these structures and the neurovascular unit as a 
whole (Dans and Giancotti, 1999; Hynes, 1992). Integrins, which are anchored to astrocytic 
and endothelial cytoskeletons, serve as receptors for numerous ligands and proteins within 
the basal lamina matrix, primarily collagen and laminin (del Zoppo and Mabuchi, 2003; 
Tawil et al., 1994). These structural proteins also serve as signalling receptors for astrocytes 
and endothelial cells, allowing for dynamic alterations of the BBB in response to exercise, 
ischemia, and other noxious stimuli (Hynes, 1992). Following ischemic/reperfusion injury, 
these proteins rapidly lose affinity for their associated ligands within the basal lamina, 
decreasing the connective integrity between endothelial and astrocytic cells and the 
extracellular matrix (Tagaya et al., 2001; Wagner et al., 1997). However, in exercised-trained 
rats, integrin expression was found to be significantly higher in astroglia and endothelium 
following ischemic stroke (Ding et al., 2005; Tawil et al., 1994), which correlated with a 
decrease in neurologic deficit (Ding et al., 2006b). These changes suggest that integrin 
expression is uniquely important to BBB integrity as it serves to bind all three components 
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together, and this increased expression following exercise serves as another mechanism of 
its neuroprotective nature.  Through both increased collagen and integrin expression 
following exercise preconditioning, the enhanced integrity of the BBB decreases vasogenic 
edema, secondary damage, and neuronal death following ischemia/reperfusion. 
While it can clearly be seen that exercise increases the thickness and integrity of the basal 
lamina and BBB as a whole, pre-ischemic exercise also improves integrity of the 
neurovascular unit by decreasing BBB breakdown. Matrix metalloproteinase (MMP) is an 
enzyme produced by endothelial cells, microglia, and astrocytes with a primary function to 
degrade extracellular matrix and basal lamina proteins (Lo et al., 2003). Expression of MMPs 
increases exponentially following cerebral damage and, as a result, has been heavily 
implicated following ischemia/reperfusion injury (Lo et al., 2003). Upregulation of MMP 
following stroke has been implicated in multiple animal and human studies (Clark et al., 
1997; Gasche et al., 1999), leading to increased BBB permeability and vasogenic edema. In 
addition to these damaging changes, MMP expression has also been correlated with 
increased inflammation and leukocyte infiltration (Romanic et al., 1998). Pharmacologic 
inhibition (Romanic et al., 1998) and genetic knockout (Asahi et al., 2001) of MMPs leads to a 
dramatic decrease in associated edema and neurologic damage. MMP-induced damage 
following ischemia/reperfusion is mechanistically linked to extracellular matrix breakdown, 
including degradation of collagen, leading to loss of integrity of the BBB and the 
neurovascular unit.   
Following exercise preconditioning, rats were found to have reduced MMP-9 expression, 
which correlated with elevated collagen IV levels (Davis et al., 2007), and similar results 
were seen following pharmacologic inhibition.  This neuroprotective effect of exercise is 
mediated by improved microvascular integrity and basal lamina reinforcement, ultimately 
decreasing neurologic deficit, infarct volume, and leukocyte infiltration following 
ischemia/reperfusiom injury (Curry et al., 2009). Interestingly, when these same rats were 
treated with tumor necrosis factor (TNF)-α antibody or inhibition of extracellular regulated 
kinase (ERK), MMP-9 levels were not decreased, and the positive effects on neurologic 
outcome and infarct volume were no longer seen (Curry et al., 2009; Hosomi et al., 2005), 
suggesting that TNF-α and ERK serve as regulators of MMP expression.  Further studies 
have shown that ERK1/2 mediates a TNF-α induced an increase in MMP-9 expression in the 
acute setting (Arai et al., 2003), while the gradual increases in TNF-α and ERK1/2 have been 
shown to decrease MMP-9 expression and lead to decreased neuronal cell death (Chaudhry 
et al., 2010). These gradual changes are seen following exercise training, in which gradual 
upregulation of TNF-α and ERK1/2 lead to decreased levels of MMP-9 expression, which 
also correlates with better outcomes following ischemia/reperfusion injury (Chaudhry et al., 
2010). In this study, following ischemic injury, neuronal apoptosis was seen to be reduced in 
association with decreased levels of MMP-9 expression in exercise preconditioned rats 
(Chaudhry et al., 2010). Following pharmacologic inhibition of both ERK1/2 and MMP-9, 
similar effects were also seen, resulting in less neuronal apoptosis and better neurologic 
outcomes; however, when only ERK1/2 was inhibited, MMP expression returned to the 
level of non-exercised control rats, suggesting a pathway involving regulation by ERK1/2 
and TNF-α of MMP-9 expression (Chaudhry et al., 2010).  ERK1/2 has previously been 
shown to also work through upregulation of tissue inhibitors of metalloproteinases (TIMPs) 
(Tong et al., 2004), and TIMPs have been previously shown to be upregulated following 
chronic exercise in association with decreased MMP-9 levels (Guo et al., 2008a). The 
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upregulation of ERK1/2 and TNF-α following exercise preconditioning, leads to decreased 
MMP-9 expression, decreased BBB dysfunction, improved neurovascular unit integrity, and 
better neurologic outcomes.  In addition to these important findings regarding the role of 
ERK1/2 and TNF-α, heat shock proteins (HSP-70) are also thought to play a synergistic role 
in the downregulation of MMP-9 expression (Liebelt et al., 2010). HSP-70 works in concert 
with TNF-α to decreased MMP-9 expression and has been shown to be increased following 
chronic exercise training.  Taken together, these various pathways reveal multiple 
synergistic pathways which function to reduce the breakdown of the BBB, reinforcing the 
integrity of the neurovascular unit and the cerebral environment. 
3.2.2 Astrocytosis 
Another vital player in the neurovascular unit is the astrocyte, which also forms the cerebral 
side of the blood brain barrier (BBB). Astrocytic glial cells are well known to induce 
strengthening of the BBB (Park et al., 2003; Petty and Lo, 2002).  Specifically, these cells have 
been shown to cover 90% of the cerebrovascular surface and primary function to restrict the 
permeability across the BBB, providing crucial integrity to the neurovascular unit (Igarashi 
et al., 1999; Janzer and Raff, 1987; Kondo et al., 1996; Willis et al., 2004). The density and 
integrity of astrocytes within the brain have also been shown to maintain neurovascular 
integrity in the setting of acute ischemic stroke (del Zoppo and Mabuchi, 2003; Lo et al., 
2005).  The damaging effects of ischemia/reperfusion are primarily seen at the BBB, 
classically affecting endothelial cells and astrocytes and their corresponding adherence to 
the extracellular matrix.  This interaction between endothelial cells, the extracellular matrix, 
and astrocytes provides the central trigger for neuronal injury and death in the setting acute 
stroke (Petty and Wettstein, 2001).  In addition to its other effects, pre-ischemic exercise 
conditioning has been shown to upregulate the degree of astrocytosis, and this upregulation 
has been shown to be correlated with better outcomes following ischemic/reperfusion 
injury (Li et al., 2005). An increased number of astrocytes within the neurovascular unit, 
provided by exercise training, cover a greater percentage of the BBB. This increased 
coverage allows the neurovasculature to be more restricted in the blood products that are 
allowed to permeate the BBB, providing important integrity in the setting of 
ischemia/reperfusion injury. 
3.2.3 Angiogenesis and arteriogenesis 
Exercise training transforms the neurovascular system of the neurovascular unit, developing 
a vital metabolic response network in response to ischemia/reperfusion injury. Under 
normal conditions, angiogenesis and endothelial cell proliferation is scant in the adult brain 
(Ogunshola et al., 2000). Nonetheless, as a major element of the neurovascular unit, it plays 
a crucial role in maintaining an appropriate and healthy cerebral environment. Previous 
studies have shown that physical activity on a treadmill increases blood vessel density in the 
brain (Black et al., 1990; Isaacs et al., 1992; Kleim et al., 2002; Swain et al., 2003), and forced 
exercise on a treadmill induces cortical and striatal angiogenesis (Ding et al., 2004a, 2004b).  
In addition to these increases in angiogenesis, exercise preconditioning also increases 
arteriogenesis, which promotes cerebral blood flow (CBF), increases collateral circulation, 
and ameliorates neuronal injury and death following ischemia/reperfusion injury (Lloyd et 
al., 2003, 2005). Closely linked to the metabolic requirements needed by the brain during 
levels of high activity, the amount of blood supply provides the necessary avenue to 
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produce the needed glucose and oxygen. Through increasing this metabolic demand, 
exercise leads to permanent structural alterations, such as angiogenesis and arteriogenesis, 
and these changes allow the increased delivery of vital nutrients to active neurons (Isaacs et 
al., 1992; Vissing et al., 1996). These structural changes not only facilitate increased glucose 
and oxygen delivery, but they have also been shown to reduce brain damage as well (Ding 
et al., 2004a). 
The structural alterations seen with angiogenesis are driven by several regulator proteins, 
namely vascular endothelial growth factor (VEGF) and angiopoietins (Ang) 1 and 2.  VEGF 
and Ang1/2 are known to be expressed in greater abundance following exercise training, 
and these changes lead to increased blood vessel density (Ding et al., 2004b).  Expression of 
Ang 1 and 2 mRNA has been shown to be increased as early as 1 week after the onset of 
exercise training (Ding et al., 2006b), and VEGF mRNA expression has been shown to be 
mildly increased at 1 week but exponentially higher after 3 weeks of exercise training 
(Matsumori et al., 2005; Nawashiro et al., 1997; Sawatzky et al., 2006; Yong et al., 2001).  
Exercise-induced angiogenesis was also seen in aging rats with associated increases in VEGF 
and Ang1/2 mRNA levels (Ding et al., 2006b), suggesting that angiogenesis can be expected 
in the adult brain.  Although most proliferation of the neurovascular system occurs during 
cerebral development, these findings reveal that VEGF and Ang1/2 drive this process in 
aging brains as well, further promoting the endogenous neuroprotection afforded by 
exercise preconditioning. 
These changes occurring after chronic exercise also lead to better outcomes following 
ischemia/reperfusion injury.  In addition to correlating with increased cerebral blood flow 
and glucose utilization, the angiogenesis and arteriogenesis observed following exercise 
preconditioning is associated with decreased neuronal cell death following 
ischemia/reperfusion injury (Li et al., 2005).  The process of angiogenesis provides 
considerably denser cerebrovascular networks, which bathes the brain in a network of 
vessels more apt to deliver the vital nutrients necessary for proper brain health and 
functioning.  The additional benefit seen from arteriogenesis, following exercise 
preconditioning underscores the importance of increased collateral circulation, particularly 
vital in saving vital brain volume in the ischemic penumbra. Especially when coupled with 
astrocytosis, the angiogenesis seen following exercise preconditioning substantially 
contributes to the development and integrity of the BBB, further promoting the 
neurovascular unit and protecting against ischemic/reperfusion injury.   
3.2.4 Cerebral blood flow and glucose uptake 
As previously discussed, exercise training increases angiogenesis and arteriogenesis, 
providing more avenues for potential blood delivery to the cerebral system.  Previous 
studies with Laser Doppler flowmtery (LDF) and 15O-H2O positron emission tomography 
(PET) have shown that preischemic exercise preserves the cerebral blood flow (CBF) 
during the reperfusion stage in ischemia/reperfusion injury (Zwagerman et al., 2010b).  
Although CBF was similar in exercised and non-exercised groups during ischemia, CBF 
was significantly higher in the exercise preconditioned animals during reperfusion and 
was associated with a decreased volume of the infarct.  This increase in perfusion during 
the reperfusion stage in preconditioned animals suggests that this training may partial 
ameliorate the “no reflow” phenomenon often seen following ischemia/reperfusion 
injury. 
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upregulation of ERK1/2 and TNF-α following exercise preconditioning, leads to decreased 
MMP-9 expression, decreased BBB dysfunction, improved neurovascular unit integrity, and 
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integrity of the neurovascular unit and the cerebral environment. 
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2005).  The damaging effects of ischemia/reperfusion are primarily seen at the BBB, 
classically affecting endothelial cells and astrocytes and their corresponding adherence to 
the extracellular matrix.  This interaction between endothelial cells, the extracellular matrix, 
and astrocytes provides the central trigger for neuronal injury and death in the setting acute 
stroke (Petty and Wettstein, 2001).  In addition to its other effects, pre-ischemic exercise 
conditioning has been shown to upregulate the degree of astrocytosis, and this upregulation 
has been shown to be correlated with better outcomes following ischemic/reperfusion 
injury (Li et al., 2005). An increased number of astrocytes within the neurovascular unit, 
provided by exercise training, cover a greater percentage of the BBB. This increased 
coverage allows the neurovasculature to be more restricted in the blood products that are 
allowed to permeate the BBB, providing important integrity in the setting of 
ischemia/reperfusion injury. 
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Exercise training transforms the neurovascular system of the neurovascular unit, developing 
a vital metabolic response network in response to ischemia/reperfusion injury. Under 
normal conditions, angiogenesis and endothelial cell proliferation is scant in the adult brain 
(Ogunshola et al., 2000). Nonetheless, as a major element of the neurovascular unit, it plays 
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arteriogenesis, which promotes cerebral blood flow (CBF), increases collateral circulation, 
and ameliorates neuronal injury and death following ischemia/reperfusion injury (Lloyd et 
al., 2003, 2005). Closely linked to the metabolic requirements needed by the brain during 
levels of high activity, the amount of blood supply provides the necessary avenue to 
 
Mechanisms of Neuroprotection Underlying Physical Exercise in Ischemia – Reperfusion Injury 
 
307 
produce the needed glucose and oxygen. Through increasing this metabolic demand, 
exercise leads to permanent structural alterations, such as angiogenesis and arteriogenesis, 
and these changes allow the increased delivery of vital nutrients to active neurons (Isaacs et 
al., 1992; Vissing et al., 1996). These structural changes not only facilitate increased glucose 
and oxygen delivery, but they have also been shown to reduce brain damage as well (Ding 
et al., 2004a). 
The structural alterations seen with angiogenesis are driven by several regulator proteins, 
namely vascular endothelial growth factor (VEGF) and angiopoietins (Ang) 1 and 2.  VEGF 
and Ang1/2 are known to be expressed in greater abundance following exercise training, 
and these changes lead to increased blood vessel density (Ding et al., 2004b).  Expression of 
Ang 1 and 2 mRNA has been shown to be increased as early as 1 week after the onset of 
exercise training (Ding et al., 2006b), and VEGF mRNA expression has been shown to be 
mildly increased at 1 week but exponentially higher after 3 weeks of exercise training 
(Matsumori et al., 2005; Nawashiro et al., 1997; Sawatzky et al., 2006; Yong et al., 2001).  
Exercise-induced angiogenesis was also seen in aging rats with associated increases in VEGF 
and Ang1/2 mRNA levels (Ding et al., 2006b), suggesting that angiogenesis can be expected 
in the adult brain.  Although most proliferation of the neurovascular system occurs during 
cerebral development, these findings reveal that VEGF and Ang1/2 drive this process in 
aging brains as well, further promoting the endogenous neuroprotection afforded by 
exercise preconditioning. 
These changes occurring after chronic exercise also lead to better outcomes following 
ischemia/reperfusion injury.  In addition to correlating with increased cerebral blood flow 
and glucose utilization, the angiogenesis and arteriogenesis observed following exercise 
preconditioning is associated with decreased neuronal cell death following 
ischemia/reperfusion injury (Li et al., 2005).  The process of angiogenesis provides 
considerably denser cerebrovascular networks, which bathes the brain in a network of 
vessels more apt to deliver the vital nutrients necessary for proper brain health and 
functioning.  The additional benefit seen from arteriogenesis, following exercise 
preconditioning underscores the importance of increased collateral circulation, particularly 
vital in saving vital brain volume in the ischemic penumbra. Especially when coupled with 
astrocytosis, the angiogenesis seen following exercise preconditioning substantially 
contributes to the development and integrity of the BBB, further promoting the 
neurovascular unit and protecting against ischemic/reperfusion injury.   
3.2.4 Cerebral blood flow and glucose uptake 
As previously discussed, exercise training increases angiogenesis and arteriogenesis, 
providing more avenues for potential blood delivery to the cerebral system.  Previous 
studies with Laser Doppler flowmtery (LDF) and 15O-H2O positron emission tomography 
(PET) have shown that preischemic exercise preserves the cerebral blood flow (CBF) 
during the reperfusion stage in ischemia/reperfusion injury (Zwagerman et al., 2010b).  
Although CBF was similar in exercised and non-exercised groups during ischemia, CBF 
was significantly higher in the exercise preconditioned animals during reperfusion and 
was associated with a decreased volume of the infarct.  This increase in perfusion during 
the reperfusion stage in preconditioned animals suggests that this training may partial 
ameliorate the “no reflow” phenomenon often seen following ischemia/reperfusion 
injury. 
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In the same study, intracerebral glucose uptake was also assessed using an 18F-fluorodeoxy-
D-glucose (FDG) radiotracer (Zwagerman et al., 2010b). Following ischemia/reperfusion 
injury, cerebral metabolism was significantly reduced as evidenced by a decrease in glucose 
uptake.  However, in rats preconditioned with physical exercise, brain glucose uptake and 
metabolism was substantially preserved following reperfusion and was associated with a 
decrease in infarct volume and functional neurologic deficit. CBF and metabolism also 
increase during the act of physical exercise, signifying the increased metabolic demand on 
neuronal cells during training (Hellstrom et al., 1996; Ide and Secher, 2000; Vissing et al., 
1996; Williamson et al., 1997) and the likely underlying mechanism through which 
neuroprotection is obtained. The angiogenic changes that occur following exercise 
preconditioning provide the brain with an enriched vascular bed with an enhanced ability 
for proper cerebral blood flow and glucose delivery to neurons, yielding more tolerance to 
reperfusion injury in the setting of ischemia/reperfusion. 
3.3 Inflammatory response 
The “no reflow” phenomenon refers to the tendency towards hypoperfusion during the 
reperfusion stage following ischemia. This hypoperfusion following transient ischemia is 
thought to stem from multiple mechanisms, including microvascular damage and 
cerebrovascular occlusion from cellular elements (Aspey et al., 1989; Dietrich et al., 1987; 
Mori et al., 1992; Nishigaya et al., 1991). In addition to these observed changes, 
hemoconcentration, red blood cell sludging, hyperviscosity, and platelet plugging tend to 
occur as well in the reperfusion phase, further exacerbating the damage seen in 
ischemia/reperfusion injury (Choudhri et al., 1998). While these effects of reperfusion injury 
causes significant damage, the accumulation of polymorphonuclear leukocytes are the 
primary contributors to the perfusion abnormalities observed following transient ischemia. 
The secondary inflammation after ischemia/reperfusion injury plays a major role in 
secondary brain damage through increased leukocyte infiltration, microvascular damage, 
and free radical accumulation during reperfusion. 
3.3.1 Adhesion molecules and toll-like receptors 
In the setting of ischemia/reperfusion injury, cytokines tend to stimulate the expression of 
cellular adhesion molecules, attracting leukocytes to the cerebrovascular system and 
promoting their diapedesis into the interstitial space.  Two central cytokines in this process, 
interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), are known to be upregulated 
following periods of hypoxia and promote the expression of intercellular adhesion molecule 
1 (ICAM-1), P-selectin, and E-selectin on leukocytes and endothelial cells. These changes 
lead to the leukocyte accumulation classically seen in ischemia/reperfusion, leading to 
adhesion of leukocytes to the damaged vascular endothelium, clogging of the neurovascular 
vessels, and infiltration into the brain parenchyma. Previous studies have shown that pre-
ischemic exercise training reduces the expression of ICAM-1, leading to decreased leukocyte 
infiltration and accumulation, in the reperfusion stage (Ding et al., 2005).  This 
downregulation leads to decreased inflammation following ischemia/reperfusion injury 
and serves as another neuroprotective mechanism of exercise preconditioning. 
Another mechanism underlying the inflammatory damage in the reperfusion stage pertains 
to the expression of toll-like receptors.  These cell surface receptors are found within the 
brain and throughout the body and are actively involved in the immune response by 
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binding endogenous and foreign materials and triggering a cytokine cascade (Gleeson et al., 
2006). Previous research studies have also revealed that exercise preconditioning reduces 
the expression of Toll-like receptor-4 (McFarlin et al., 2006), and reduction of these receptors 
in Toll-like receptor-4 deficient mice has been shown to decrease tissue damage and 
neurologic deficits following ischemia/reperfusion injury (Cao et al., 2007). Another study 
looking at both of these factors has indicated that exercise preconditioning simultaneously 
reduces expression of Toll-like receptor-4, which leads to a reduction in brain injury 
following ischemic stroke (Zwagerman et al., 2010a).   
3.3.2 Leukocyte invasion 
Through the downregulation of adhesion molecules and toll-like receptors, exercise 
preconditioning is able to significantly reduce the amount of damage seen following 
ischemia/reperfusion injury.  The underlying mechanism through which this process works 
focuses on the decreased leukocyte migration and diapedesis often seen in the reperfusion 
stage following stroke.  Decreased leukocyte infiltration decreases many of the secondary 
changes such as free radical formation and subsequent edema formation.  Ultimately, the 
decreased leukocyte invasion seen in exercise preconditioned subjects leads to better 
neurologic outcome following ischemia/reperfusion injury. 
3.4 Neuronal death and survival signalling pathways 
Neuronal survival depends on both external and internal stimuli and environments. Many 
of the changes following exercise preconditioning, involving inflammation, strengthening of 
the blood brain barrier, and increased integrity of the neurovascular unit, improve the 
cerebral environment in the setting of acute ischemia/reperfusion injury.  In addition, 
internal cellular stimuli and pathways have a profound effect on neuronal survival.  
Following exercise preconditioning, apoptosis is attenuated and heat shock proteins are 
upregulated through a variety of biomolecular mechanisms following ischemia/reperfusion 
injury. Likewise, external stimuli through tumor necrosis factor (TNF)-α protect the brain 
during hypoxia. These changes seen in rats preconditioned with physical exercise are 
neuroprotective in the setting of ischemia/reperfusion injury, decreasing neuronal death 
and improving neurologic outcomes. 
3.4.1 Anti:Pro apoptotic ratio 
Neuronal apoptosis following ischemia/reperfusion injury is regulated by cascades of pro- 
and anti-apoptotic proteins.  Notable among these include pro-apoptotic Bax, Bad, and Bak 
and anti-apoptotic Bcl-2 and Bcl-xL (Lazou et al., 2006; Mayer and Oberbauer, 2003). 
Upregulation of anti-apoptotic proteins (Bcl-2, Bcl-xL) and corresponding downregulation 
of pro-apoptotic proteins (Bax, Bad, and Bak) are seen following exercise preconditioning 
and are protective in the event of cerebral ischemia (Rybnikova et al., 2006; Wu et al., 2003). 
In addition to these key regulatory proteins, both caspase-dependent and caspase 
independent pathways appear to be involved in cerebral ischemia and neuronal death (Cao 
et al., 2003; Joza et al., 2001; Zhu et al., 2003), and apoptosis induced factor (AIF) also plays a 
key role in pro-apoptosis (Daugas et al., 2000; Susin et al., 1999). 
Exercise preconditioning has been shown to not only enhance the expression of anti-apoptotic 
Bcl-xL, but to also decrease the expression of pro-apoptotic AIF and Bax, ultimately leading to 
decreased apoptosis and prolonged neuronal survival (Chaudhry et al., 2010). Following 
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In the same study, intracerebral glucose uptake was also assessed using an 18F-fluorodeoxy-
D-glucose (FDG) radiotracer (Zwagerman et al., 2010b). Following ischemia/reperfusion 
injury, cerebral metabolism was significantly reduced as evidenced by a decrease in glucose 
uptake.  However, in rats preconditioned with physical exercise, brain glucose uptake and 
metabolism was substantially preserved following reperfusion and was associated with a 
decrease in infarct volume and functional neurologic deficit. CBF and metabolism also 
increase during the act of physical exercise, signifying the increased metabolic demand on 
neuronal cells during training (Hellstrom et al., 1996; Ide and Secher, 2000; Vissing et al., 
1996; Williamson et al., 1997) and the likely underlying mechanism through which 
neuroprotection is obtained. The angiogenic changes that occur following exercise 
preconditioning provide the brain with an enriched vascular bed with an enhanced ability 
for proper cerebral blood flow and glucose delivery to neurons, yielding more tolerance to 
reperfusion injury in the setting of ischemia/reperfusion. 
3.3 Inflammatory response 
The “no reflow” phenomenon refers to the tendency towards hypoperfusion during the 
reperfusion stage following ischemia. This hypoperfusion following transient ischemia is 
thought to stem from multiple mechanisms, including microvascular damage and 
cerebrovascular occlusion from cellular elements (Aspey et al., 1989; Dietrich et al., 1987; 
Mori et al., 1992; Nishigaya et al., 1991). In addition to these observed changes, 
hemoconcentration, red blood cell sludging, hyperviscosity, and platelet plugging tend to 
occur as well in the reperfusion phase, further exacerbating the damage seen in 
ischemia/reperfusion injury (Choudhri et al., 1998). While these effects of reperfusion injury 
causes significant damage, the accumulation of polymorphonuclear leukocytes are the 
primary contributors to the perfusion abnormalities observed following transient ischemia. 
The secondary inflammation after ischemia/reperfusion injury plays a major role in 
secondary brain damage through increased leukocyte infiltration, microvascular damage, 
and free radical accumulation during reperfusion. 
3.3.1 Adhesion molecules and toll-like receptors 
In the setting of ischemia/reperfusion injury, cytokines tend to stimulate the expression of 
cellular adhesion molecules, attracting leukocytes to the cerebrovascular system and 
promoting their diapedesis into the interstitial space.  Two central cytokines in this process, 
interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), are known to be upregulated 
following periods of hypoxia and promote the expression of intercellular adhesion molecule 
1 (ICAM-1), P-selectin, and E-selectin on leukocytes and endothelial cells. These changes 
lead to the leukocyte accumulation classically seen in ischemia/reperfusion, leading to 
adhesion of leukocytes to the damaged vascular endothelium, clogging of the neurovascular 
vessels, and infiltration into the brain parenchyma. Previous studies have shown that pre-
ischemic exercise training reduces the expression of ICAM-1, leading to decreased leukocyte 
infiltration and accumulation, in the reperfusion stage (Ding et al., 2005).  This 
downregulation leads to decreased inflammation following ischemia/reperfusion injury 
and serves as another neuroprotective mechanism of exercise preconditioning. 
Another mechanism underlying the inflammatory damage in the reperfusion stage pertains 
to the expression of toll-like receptors.  These cell surface receptors are found within the 
brain and throughout the body and are actively involved in the immune response by 
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binding endogenous and foreign materials and triggering a cytokine cascade (Gleeson et al., 
2006). Previous research studies have also revealed that exercise preconditioning reduces 
the expression of Toll-like receptor-4 (McFarlin et al., 2006), and reduction of these receptors 
in Toll-like receptor-4 deficient mice has been shown to decrease tissue damage and 
neurologic deficits following ischemia/reperfusion injury (Cao et al., 2007). Another study 
looking at both of these factors has indicated that exercise preconditioning simultaneously 
reduces expression of Toll-like receptor-4, which leads to a reduction in brain injury 
following ischemic stroke (Zwagerman et al., 2010a).   
3.3.2 Leukocyte invasion 
Through the downregulation of adhesion molecules and toll-like receptors, exercise 
preconditioning is able to significantly reduce the amount of damage seen following 
ischemia/reperfusion injury.  The underlying mechanism through which this process works 
focuses on the decreased leukocyte migration and diapedesis often seen in the reperfusion 
stage following stroke.  Decreased leukocyte infiltration decreases many of the secondary 
changes such as free radical formation and subsequent edema formation.  Ultimately, the 
decreased leukocyte invasion seen in exercise preconditioned subjects leads to better 
neurologic outcome following ischemia/reperfusion injury. 
3.4 Neuronal death and survival signalling pathways 
Neuronal survival depends on both external and internal stimuli and environments. Many 
of the changes following exercise preconditioning, involving inflammation, strengthening of 
the blood brain barrier, and increased integrity of the neurovascular unit, improve the 
cerebral environment in the setting of acute ischemia/reperfusion injury.  In addition, 
internal cellular stimuli and pathways have a profound effect on neuronal survival.  
Following exercise preconditioning, apoptosis is attenuated and heat shock proteins are 
upregulated through a variety of biomolecular mechanisms following ischemia/reperfusion 
injury. Likewise, external stimuli through tumor necrosis factor (TNF)-α protect the brain 
during hypoxia. These changes seen in rats preconditioned with physical exercise are 
neuroprotective in the setting of ischemia/reperfusion injury, decreasing neuronal death 
and improving neurologic outcomes. 
3.4.1 Anti:Pro apoptotic ratio 
Neuronal apoptosis following ischemia/reperfusion injury is regulated by cascades of pro- 
and anti-apoptotic proteins.  Notable among these include pro-apoptotic Bax, Bad, and Bak 
and anti-apoptotic Bcl-2 and Bcl-xL (Lazou et al., 2006; Mayer and Oberbauer, 2003). 
Upregulation of anti-apoptotic proteins (Bcl-2, Bcl-xL) and corresponding downregulation 
of pro-apoptotic proteins (Bax, Bad, and Bak) are seen following exercise preconditioning 
and are protective in the event of cerebral ischemia (Rybnikova et al., 2006; Wu et al., 2003). 
In addition to these key regulatory proteins, both caspase-dependent and caspase 
independent pathways appear to be involved in cerebral ischemia and neuronal death (Cao 
et al., 2003; Joza et al., 2001; Zhu et al., 2003), and apoptosis induced factor (AIF) also plays a 
key role in pro-apoptosis (Daugas et al., 2000; Susin et al., 1999). 
Exercise preconditioning has been shown to not only enhance the expression of anti-apoptotic 
Bcl-xL, but to also decrease the expression of pro-apoptotic AIF and Bax, ultimately leading to 
decreased apoptosis and prolonged neuronal survival (Chaudhry et al., 2010). Following 
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ischemia/reperfusion injury, this increased anti:pro apoptotic ratio generates decreased 
neuronal death and smaller infarct size. While these neuroprotective mechanisms of exercise 
are newly evolving, they provide a possible point of therapeutic intervention. While 
neuroprotective agents that target cell death pathways have been tried in the past, the 
potential for increasing cell survival reveals a potential novel strategy for improving outcomes 
following ischemia/reperfusion (Chan, 2004). This could provide a neuroprotective therapy 
that would simultaneously promote cell survival and decrease neuronal death, thus 
ameliorating much of the functional loss following acute ischemic stroke. 
3.4.2 TNF-α and TNF-α receptor 
Tumor necrosis factor (TNF)-α is a major deleterious pro-inflammatory cytokine found 
throughout the systemic circulation and upregulated following stroke and traumatic brain 
injury (Botchkina et al., 1997; Sairanen et al., 2001).  Despite its inflammatory and injurious 
effects, evidence also points to TNF-α as a beneficial factor in tissue repair and 
neuroprotection (Bruce et al., 1996; Feuerstein and Wang, 2001; Wang et al., 2000). 
Furthermore, this cytokine may serve to induce endogenous neuroprotection following 
chronic exercise preconditioning. It is believed that exercise training produces a chronic low 
grade increase in TNF-α concentration, ultimately generating neuronal tolerance and 
protection in the setting of ischemia/reperfusion injury (Ginis et al., 1999; Liu et al., 2000; 
Wang et al., 2000). In a similar manner, TNF-α concentration was chronically elevated 
following exercise, which resulted in reduced myocardial infarction (Yamashita et al., 1999); 
however, acutely elevated levels of TNF-α following ischemia results in harmful myocardial 
remodelling (Jobe et al., 2009).   
In the brain, exercise preconditioning also chronically increases the level of TNF-α that is 
exposed to neuronal cells, an effect which prevents the downstream inflammatory reaction 
which is induced by acutely elevated levels of TNF-α following cerebral 
ischemia/reperfusion injury (Ding et al., 2005).  Furthermore, TNF-α has also been shown to 
reduce blood brain barrier injury and neuronal damage following ischemic stroke (Guo et 
al., 2008b). This scenario reveals two sides to the effect of TNF-α on neuronal survival and 
cerebral integrity. With chronic low levels of the cytokine, it is profoundly beneficial and 
neuroprotective; however, following ischemia/reperfusion, the acute increase of TNF-α into 
the cerebrovascular circulation destroys the integrity of the neurovascular unit, increases 
cell death, and enlarges the infarct volume. Exercise preconditioning enhances the former 
effect, increasing chronic low grade levels of the cytokine, which ameliorates the latter effect 
and dampens the injury following acute increases of TNF-α. 
Mechanisms underlying this complex picture of TNF-α have not been completely 
uncovered, but are thought to involve the expression of TNF-α receptors.  Previous studies 
have shown that the chronic exercise-induced levels of TNF-α serve to reduce the expression 
of TNF-α receptor after ischemia/reperfusion (Reyes, Jr. et al., 2006). Following ischemic 
injury in a rat model, pre-ischemic exercise was indeed found to decrease the expression of 
TNF-α receptors I and II, leading to reduced brain damage and enhance neurologic recovery 
(Reyes, Jr. et al., 2006). These results indicate a classic desensitization of the TNF-α receptor 
following exercise preconditioning, promoting neuronal tolerance to acutely elevated levels 
of TNF-α following ischemia/reperfusion injury. 
3.4.3 Heat shock proteins 
Neuronal survival and neuroprotection appears to be further driven by heat shock protein 
(HSP)-70, a highly inducible protein of 70 kDa. HSP-70 is well known to respond to various 
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types of stress, including heat shock, hypoxia, oxidative stress, and exposure to metals and 
toxins (Kiang and Tsokos, 1998). Constitutively expressed, this molecular chaperone protein 
assists in the folding both nascent and denatured proteins during times of neuronal stress 
(Schlesinger, 1990). Overexpression of HSP-70 has previously been shown to be 
neuroprotective in the setting of ischemia/reperfusion (Giffard and Yenari, 2004). This 
neuroprotective protein interferes with apoptosis inducing factor (AIF), a pro-apoptotic 
protein. HSP-70 also increases the levels of anti-apoptotic proteins, Bcl-2 and Bcl-xL, thus 
serving as another mechanism to increase the anti:pro apoptotic ratio and push neurons 
toward cellular survival, especially in the setting of ischemia/reperfusion (Liebelt et al., 
2010; Ohtsuka and Suzuki, 2000).  
Multiple studies have shown that ischemic preconditioning induces HSP-70 expression and 
promotes neuroprotection (Chen and Simon, 1997; Kirino et al., 1991; Masada et al., 2001). 
Despite these benefits, the effects of HSP-70 are limited. If the insult is very severe or if 
expression of HSP-70 is too low, the beneficial effects may not be seen (Giffard and 
Yenari, 2004; Lee et al., 2001; Matsumori et al., 2005).  Nonetheless, HSP-70 mice convey 
more potent neuroprotection than wild type mice, underlying its importance as a key 
factor in exercise-induced neuroprotection for ischemia/reperfusion injury (Matsumori et 
al., 2005). In addition to its neuroprotective effects, HSP-70 has also been seen to be 
cardioprotective following upregulation after exercise preconditioning (Hamilton et al., 
2003; Lennon et al., 2004).   
Also, HSP-70 alone does not appear to be neuroprotective, but it requires other proteins for 
optimal neuroprotection (Lee et al., 2001).  Upregulation of TNF-α appears to be critical for 
HSP-70 to effectively reduce apoptosis and prolong neuronal survival (Liebelt et al., 2010). 
Furthermore, TNF-α and HSP-70 appear to work in concert through an ERK1/2 signal 
transduction pathway to increase the expression of anti-apoptotic genes and decrease the 
expression of pro-apoptotic genes (Goel et al., 2010). These results reveal the 
neuroprotective nature of HSP-70, but they also reveal its limitations.  For HSP-70 to truly be 
effective in the setting of ischemia/reperfusion injury, it requires a large insult, significant 
HSP-70 expression, and the upregulation of other proteins as well, including TNF-α. Despite 
these constraints, HSP-70 does appear to induce neuroprotection in ischemia/reperfusion 
injury following exercise preconditioning. 
3.5 Extracellular signal-regulated kinase 
Extracellular signal-regulated kinases (ERK1/2) are involved in mitogen-activated protein 
kinase pathways and are constitutively expressed in the adult brain (Fiore et al., 1993; 
Sharony et al., 2005).  These ERK1/2-regulated pathways are pivotal in signal transduction 
and neuroprotection in the setting of ischemia/reperfusion injury. Numerous studies have 
shown a pro-apoptotic role for ERK1/2 in neurons and other cells as well (Chu et al., 2004; 
Shackelford and Yeh, 2006; Zhuang and Schnellmann, 2006). Although ERK1/2 has been 
shown to push cells towards death, a protective and beneficial role has also been established 
(Rybnikova et al., 2006). Activation of this regulatory kinase has been shown to enable tissue 
repair in the setting of ischemia/reperfusion injury, thus decreasing cell death (Cavanaugh, 
2004; Hetman and Gozdz, 2004; Ostrakhovitch and Cherian, 2005; Sawatzky et al., 2006). 
Furthermore, exercise preconditioning appears to upregulate ERK1/2, leading to an 
ischemic neuronal tolerance under hypoxic condition (Gu et al., 2001; Jones and Bergeron, 
2004; Shamloo and Wieloch, 1999). While ERK1/2 is upregulated following ischemic 
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ischemia/reperfusion injury, this increased anti:pro apoptotic ratio generates decreased 
neuronal death and smaller infarct size. While these neuroprotective mechanisms of exercise 
are newly evolving, they provide a possible point of therapeutic intervention. While 
neuroprotective agents that target cell death pathways have been tried in the past, the 
potential for increasing cell survival reveals a potential novel strategy for improving outcomes 
following ischemia/reperfusion (Chan, 2004). This could provide a neuroprotective therapy 
that would simultaneously promote cell survival and decrease neuronal death, thus 
ameliorating much of the functional loss following acute ischemic stroke. 
3.4.2 TNF-α and TNF-α receptor 
Tumor necrosis factor (TNF)-α is a major deleterious pro-inflammatory cytokine found 
throughout the systemic circulation and upregulated following stroke and traumatic brain 
injury (Botchkina et al., 1997; Sairanen et al., 2001).  Despite its inflammatory and injurious 
effects, evidence also points to TNF-α as a beneficial factor in tissue repair and 
neuroprotection (Bruce et al., 1996; Feuerstein and Wang, 2001; Wang et al., 2000). 
Furthermore, this cytokine may serve to induce endogenous neuroprotection following 
chronic exercise preconditioning. It is believed that exercise training produces a chronic low 
grade increase in TNF-α concentration, ultimately generating neuronal tolerance and 
protection in the setting of ischemia/reperfusion injury (Ginis et al., 1999; Liu et al., 2000; 
Wang et al., 2000). In a similar manner, TNF-α concentration was chronically elevated 
following exercise, which resulted in reduced myocardial infarction (Yamashita et al., 1999); 
however, acutely elevated levels of TNF-α following ischemia results in harmful myocardial 
remodelling (Jobe et al., 2009).   
In the brain, exercise preconditioning also chronically increases the level of TNF-α that is 
exposed to neuronal cells, an effect which prevents the downstream inflammatory reaction 
which is induced by acutely elevated levels of TNF-α following cerebral 
ischemia/reperfusion injury (Ding et al., 2005).  Furthermore, TNF-α has also been shown to 
reduce blood brain barrier injury and neuronal damage following ischemic stroke (Guo et 
al., 2008b). This scenario reveals two sides to the effect of TNF-α on neuronal survival and 
cerebral integrity. With chronic low levels of the cytokine, it is profoundly beneficial and 
neuroprotective; however, following ischemia/reperfusion, the acute increase of TNF-α into 
the cerebrovascular circulation destroys the integrity of the neurovascular unit, increases 
cell death, and enlarges the infarct volume. Exercise preconditioning enhances the former 
effect, increasing chronic low grade levels of the cytokine, which ameliorates the latter effect 
and dampens the injury following acute increases of TNF-α. 
Mechanisms underlying this complex picture of TNF-α have not been completely 
uncovered, but are thought to involve the expression of TNF-α receptors.  Previous studies 
have shown that the chronic exercise-induced levels of TNF-α serve to reduce the expression 
of TNF-α receptor after ischemia/reperfusion (Reyes, Jr. et al., 2006). Following ischemic 
injury in a rat model, pre-ischemic exercise was indeed found to decrease the expression of 
TNF-α receptors I and II, leading to reduced brain damage and enhance neurologic recovery 
(Reyes, Jr. et al., 2006). These results indicate a classic desensitization of the TNF-α receptor 
following exercise preconditioning, promoting neuronal tolerance to acutely elevated levels 
of TNF-α following ischemia/reperfusion injury. 
3.4.3 Heat shock proteins 
Neuronal survival and neuroprotection appears to be further driven by heat shock protein 
(HSP)-70, a highly inducible protein of 70 kDa. HSP-70 is well known to respond to various 
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types of stress, including heat shock, hypoxia, oxidative stress, and exposure to metals and 
toxins (Kiang and Tsokos, 1998). Constitutively expressed, this molecular chaperone protein 
assists in the folding both nascent and denatured proteins during times of neuronal stress 
(Schlesinger, 1990). Overexpression of HSP-70 has previously been shown to be 
neuroprotective in the setting of ischemia/reperfusion (Giffard and Yenari, 2004). This 
neuroprotective protein interferes with apoptosis inducing factor (AIF), a pro-apoptotic 
protein. HSP-70 also increases the levels of anti-apoptotic proteins, Bcl-2 and Bcl-xL, thus 
serving as another mechanism to increase the anti:pro apoptotic ratio and push neurons 
toward cellular survival, especially in the setting of ischemia/reperfusion (Liebelt et al., 
2010; Ohtsuka and Suzuki, 2000).  
Multiple studies have shown that ischemic preconditioning induces HSP-70 expression and 
promotes neuroprotection (Chen and Simon, 1997; Kirino et al., 1991; Masada et al., 2001). 
Despite these benefits, the effects of HSP-70 are limited. If the insult is very severe or if 
expression of HSP-70 is too low, the beneficial effects may not be seen (Giffard and 
Yenari, 2004; Lee et al., 2001; Matsumori et al., 2005).  Nonetheless, HSP-70 mice convey 
more potent neuroprotection than wild type mice, underlying its importance as a key 
factor in exercise-induced neuroprotection for ischemia/reperfusion injury (Matsumori et 
al., 2005). In addition to its neuroprotective effects, HSP-70 has also been seen to be 
cardioprotective following upregulation after exercise preconditioning (Hamilton et al., 
2003; Lennon et al., 2004).   
Also, HSP-70 alone does not appear to be neuroprotective, but it requires other proteins for 
optimal neuroprotection (Lee et al., 2001).  Upregulation of TNF-α appears to be critical for 
HSP-70 to effectively reduce apoptosis and prolong neuronal survival (Liebelt et al., 2010). 
Furthermore, TNF-α and HSP-70 appear to work in concert through an ERK1/2 signal 
transduction pathway to increase the expression of anti-apoptotic genes and decrease the 
expression of pro-apoptotic genes (Goel et al., 2010). These results reveal the 
neuroprotective nature of HSP-70, but they also reveal its limitations.  For HSP-70 to truly be 
effective in the setting of ischemia/reperfusion injury, it requires a large insult, significant 
HSP-70 expression, and the upregulation of other proteins as well, including TNF-α. Despite 
these constraints, HSP-70 does appear to induce neuroprotection in ischemia/reperfusion 
injury following exercise preconditioning. 
3.5 Extracellular signal-regulated kinase 
Extracellular signal-regulated kinases (ERK1/2) are involved in mitogen-activated protein 
kinase pathways and are constitutively expressed in the adult brain (Fiore et al., 1993; 
Sharony et al., 2005).  These ERK1/2-regulated pathways are pivotal in signal transduction 
and neuroprotection in the setting of ischemia/reperfusion injury. Numerous studies have 
shown a pro-apoptotic role for ERK1/2 in neurons and other cells as well (Chu et al., 2004; 
Shackelford and Yeh, 2006; Zhuang and Schnellmann, 2006). Although ERK1/2 has been 
shown to push cells towards death, a protective and beneficial role has also been established 
(Rybnikova et al., 2006). Activation of this regulatory kinase has been shown to enable tissue 
repair in the setting of ischemia/reperfusion injury, thus decreasing cell death (Cavanaugh, 
2004; Hetman and Gozdz, 2004; Ostrakhovitch and Cherian, 2005; Sawatzky et al., 2006). 
Furthermore, exercise preconditioning appears to upregulate ERK1/2, leading to an 
ischemic neuronal tolerance under hypoxic condition (Gu et al., 2001; Jones and Bergeron, 
2004; Shamloo and Wieloch, 1999). While ERK1/2 is upregulated following ischemic 
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preconditioning (Lecour et al., 2005), ERK1/2 activation also is detrimental following stroke, 
trauma and degenerative disease (Chu et al., 2004). This dual role of ERK1/2, being both 
beneficial and detrimental, may be similar in mechanism to the effects of TNF-α in which 
chronic upregulation following exercise preconditioning generates neuronal tolerance and 
improved outcome following ischemia/reperfusion injury. 
Following inhibition of ERK1/2 in exercise preconditioned animals, neuroprotection was 
substantially reduced in ischemia/reperfusion, suggesting the pertinent role of ERK1/2 in 
exercise-induced neuroprotection (Guo et al., 2008b). However, exercise preconditioned 
animals did have elevated levels of ERK1/2 and TNF-α following exercise training, which 
correlated with decreased neurologic deficit, smaller brain infarcts, and less inflammation 
(Curry et al., 2009). A recent study has shown that ERK1/2 activation also helps to regulate 
apoptosis (Liebelt et al., 2010). Again, pre-ischemic exercise led to minor increases in 
ERK1/2, which was neuroprotective against the large acute elevations seen following 
ischemia/reperfusion injury. In the setting of hypoxic injury, ERK1/2 regulates the anti- and 
pro-apoptotic pathways involving such regulators as Bcl-xL, Bax, and AIF. Following 
exercise preconditioning, the upregulation of ERK1/2 served to promote anti-apoptosis, 
leading to decreased neuronal apoptosis and infarct volume.   
ERK1/2, while shown to ameliorate ischemia/reperfusion through its apoptotic 
regulatory effects and inflammatory changes, has also been linked with HSP-70 and TNF-
α. Several studies have shown these three important proteins to be fundamentally linked 
in a relationship where TNF-α and HSP-70 activate the MEK/ERK signalling pathway, 
leading to neuroprotection (Gortz et al., 2005; Lee et al., 2001,2005).  While ischemic 
preconditioning has been shown to induce ERK1/2-mediated neuroprotection, 
pharmacologic pre-treatment with TNF-α has not shown similar results (Lecour et al., 
2005), suggesting that multiple interacting pathways and proteins are likely necessary to 
observe the full neuroprotective effect.  It seems likely that a cross talk between TNF-α, 
HSP-70, and ERK1/2 occurs in exercise training, allowing for a greater neuroprotective 
response following ischemia/reperfusion injury. Nonetheless, these studies have clarified 
a dual role of ERK1/2 in neuroprotection, in which chronic low levels protect against 
acute elevations of the protein and ameliorate the damage and neuronal loss following 
ischemia/reperfusion injury. 
3.6 Metabolic enhancement 
The association between exercise preconditioning and neuroprotection in 
ischemia/reperfusion has been well established.  In addition to the aforementioned 
mechanisms, chronic exercise training also affects cerebral metabolism and energy 
production, allowing neurons to re-establish homeostasis more rapidly following acute 
ischemic stroke.  A recent study revealed that forced exercise resulted in enhanced cerebral 
glycolysis and cerebral metabolism (Kinni et al., 2011).  In addition to increasing glycolysis, 
exercise preconditioning is also well known to increase cerebral blood flow (CBF) and 
adenosine triphosphate (ATP) production (Ide and Secher, 2000; McCloskey et al., 2001; 
Ogoh and Ainslie, 2009). Exercise can be best viewed as a chronic state of metabolic stress, 
which requires increased glucose delivery, glycolysis, and ATP production in order to 
match the energy demand.  Chronic exercise preconditioning enables the neuronal cells to 
accumulate the necessary machinery for mass ATP production, which elevates the metabolic 
and ATP production potential in these cells.  In the setting of ischemia/reperfusion injury, 
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these preconditioned neurons have an increased metabolic capacity and are better able to 
avoid hypoxic damage. 
3.6.1 ATP production 
The process of ATP production requires several key steps, involving detection of low ATP 
stores, glucose transport and glycolysis.  5’-AMP-activated protein kinase (AMPK) serves 
as an energy sensor and is capable of detecting low ATP stores in cells (Minchenko et al., 
2003).  The protein is a heterotrimeric serine/threonine kinase, which becomes activated 
in times of metabolic stress and decreased ATP stores (Emerling et al., 2007; Hardie et al., 
2003; Zorzano et al., 2005).  When ATP concentrations drop, AMPK activates glycolysis in 
order to restore the cell’s energy balance, allowing it to serve as an excellent marker of 
metabolic demand (Kahn et al., 2005).  Following exercise training, levels of the active 
phosphorylated form of AMPK are increased in response to the elevated metabolic 
demand (Aschenbach et al., 2004; Kinni et al., 2011).  Following ischemia/reperfusion 
injury, the active phosphorylated form of AMPK has been shown to be upregulated in 
preconditioned rats, suggesting an increased metabolic response to hypoxia in these 
exercised animals (unpublished data).  This increased capacity for metabolism 
upregulation is mirrored in elevated levels of glucose transporters and glycolytic 
enzymes, which are also seen following exercise training and correlate with better 
outcomes following ischemia/reperfusion injury. 
While increases in cerebral blood flow associated with exercise facilitate greater transport 
of glucose to the neurovascular system, transport across the BBB and neuronal membrane 
are controlled by glucose transporters (GLUT).  GLUT1 is primarily found in the 
endothelial cells of the BBB and generates a basal glucose level, while GLUT3 is found 
exclusively in neurons, and both of these glucose transporters have previously been 
shown to increase in response to hypoxia and elevated metabolic demand (Maurer et al., 
2006).  The increased need for energy production following hypoxia requires more 
glucose to be available within neurons, and these two glucose transporters work together 
to shuttle glucose from the circulation into neurons.  GLUT1 and GLUT3 are known to 
have increased expression following exercise preconditioning (Kinni et al., 2011).  
Following ischemia/reperfusion injury, GLUT1 and GLUT3 levels are elevated in the first 
4 hours after reperfusion is established in exercise preconditioned rats, but expression is 
equal to control at 24 hours after injury (unpublished data).  This elevation in GLUT 
expression in the acute phase of reperfusion indicates that these preconditioned animals 
have the cellular machinery in place immediately when it is needed.  Non-exercised rats 
take longer to transcribe and translate the needed metabolic proteins, leading to increased 
metabolic dysfunction.  Thus, exercise preconditioning provides neuroprotection by 
increasing the levels of available glucose within neurons, providing the necessary 
substrate for ATP production. 
Once inside neurons, glucose must be metabolized to produce ATP for the cell.  The initial 
steps of glycolysis are primarily regulated by the key rate limiting step of 
phosphofructokinase (PFK), which catalyzes the phosphorylation of fructose-6-phosphate to 
fructose-1,6-bisphosphonate. PFK expression is known to be upregulated following 
increased metabolism and glycolysis and is has been shown to be neuroprotective in 
hypoglycemic conditions (Minchenko et al., 2003).  Another study has revealed PFK is 
increased following exercise preconditioning (Kinni et al., 2011), and this enzyme is 
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preconditioning (Lecour et al., 2005), ERK1/2 activation also is detrimental following stroke, 
trauma and degenerative disease (Chu et al., 2004). This dual role of ERK1/2, being both 
beneficial and detrimental, may be similar in mechanism to the effects of TNF-α in which 
chronic upregulation following exercise preconditioning generates neuronal tolerance and 
improved outcome following ischemia/reperfusion injury. 
Following inhibition of ERK1/2 in exercise preconditioned animals, neuroprotection was 
substantially reduced in ischemia/reperfusion, suggesting the pertinent role of ERK1/2 in 
exercise-induced neuroprotection (Guo et al., 2008b). However, exercise preconditioned 
animals did have elevated levels of ERK1/2 and TNF-α following exercise training, which 
correlated with decreased neurologic deficit, smaller brain infarcts, and less inflammation 
(Curry et al., 2009). A recent study has shown that ERK1/2 activation also helps to regulate 
apoptosis (Liebelt et al., 2010). Again, pre-ischemic exercise led to minor increases in 
ERK1/2, which was neuroprotective against the large acute elevations seen following 
ischemia/reperfusion injury. In the setting of hypoxic injury, ERK1/2 regulates the anti- and 
pro-apoptotic pathways involving such regulators as Bcl-xL, Bax, and AIF. Following 
exercise preconditioning, the upregulation of ERK1/2 served to promote anti-apoptosis, 
leading to decreased neuronal apoptosis and infarct volume.   
ERK1/2, while shown to ameliorate ischemia/reperfusion through its apoptotic 
regulatory effects and inflammatory changes, has also been linked with HSP-70 and TNF-
α. Several studies have shown these three important proteins to be fundamentally linked 
in a relationship where TNF-α and HSP-70 activate the MEK/ERK signalling pathway, 
leading to neuroprotection (Gortz et al., 2005; Lee et al., 2001,2005).  While ischemic 
preconditioning has been shown to induce ERK1/2-mediated neuroprotection, 
pharmacologic pre-treatment with TNF-α has not shown similar results (Lecour et al., 
2005), suggesting that multiple interacting pathways and proteins are likely necessary to 
observe the full neuroprotective effect.  It seems likely that a cross talk between TNF-α, 
HSP-70, and ERK1/2 occurs in exercise training, allowing for a greater neuroprotective 
response following ischemia/reperfusion injury. Nonetheless, these studies have clarified 
a dual role of ERK1/2 in neuroprotection, in which chronic low levels protect against 
acute elevations of the protein and ameliorate the damage and neuronal loss following 
ischemia/reperfusion injury. 
3.6 Metabolic enhancement 
The association between exercise preconditioning and neuroprotection in 
ischemia/reperfusion has been well established.  In addition to the aforementioned 
mechanisms, chronic exercise training also affects cerebral metabolism and energy 
production, allowing neurons to re-establish homeostasis more rapidly following acute 
ischemic stroke.  A recent study revealed that forced exercise resulted in enhanced cerebral 
glycolysis and cerebral metabolism (Kinni et al., 2011).  In addition to increasing glycolysis, 
exercise preconditioning is also well known to increase cerebral blood flow (CBF) and 
adenosine triphosphate (ATP) production (Ide and Secher, 2000; McCloskey et al., 2001; 
Ogoh and Ainslie, 2009). Exercise can be best viewed as a chronic state of metabolic stress, 
which requires increased glucose delivery, glycolysis, and ATP production in order to 
match the energy demand.  Chronic exercise preconditioning enables the neuronal cells to 
accumulate the necessary machinery for mass ATP production, which elevates the metabolic 
and ATP production potential in these cells.  In the setting of ischemia/reperfusion injury, 
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these preconditioned neurons have an increased metabolic capacity and are better able to 
avoid hypoxic damage. 
3.6.1 ATP production 
The process of ATP production requires several key steps, involving detection of low ATP 
stores, glucose transport and glycolysis.  5’-AMP-activated protein kinase (AMPK) serves 
as an energy sensor and is capable of detecting low ATP stores in cells (Minchenko et al., 
2003).  The protein is a heterotrimeric serine/threonine kinase, which becomes activated 
in times of metabolic stress and decreased ATP stores (Emerling et al., 2007; Hardie et al., 
2003; Zorzano et al., 2005).  When ATP concentrations drop, AMPK activates glycolysis in 
order to restore the cell’s energy balance, allowing it to serve as an excellent marker of 
metabolic demand (Kahn et al., 2005).  Following exercise training, levels of the active 
phosphorylated form of AMPK are increased in response to the elevated metabolic 
demand (Aschenbach et al., 2004; Kinni et al., 2011).  Following ischemia/reperfusion 
injury, the active phosphorylated form of AMPK has been shown to be upregulated in 
preconditioned rats, suggesting an increased metabolic response to hypoxia in these 
exercised animals (unpublished data).  This increased capacity for metabolism 
upregulation is mirrored in elevated levels of glucose transporters and glycolytic 
enzymes, which are also seen following exercise training and correlate with better 
outcomes following ischemia/reperfusion injury. 
While increases in cerebral blood flow associated with exercise facilitate greater transport 
of glucose to the neurovascular system, transport across the BBB and neuronal membrane 
are controlled by glucose transporters (GLUT).  GLUT1 is primarily found in the 
endothelial cells of the BBB and generates a basal glucose level, while GLUT3 is found 
exclusively in neurons, and both of these glucose transporters have previously been 
shown to increase in response to hypoxia and elevated metabolic demand (Maurer et al., 
2006).  The increased need for energy production following hypoxia requires more 
glucose to be available within neurons, and these two glucose transporters work together 
to shuttle glucose from the circulation into neurons.  GLUT1 and GLUT3 are known to 
have increased expression following exercise preconditioning (Kinni et al., 2011).  
Following ischemia/reperfusion injury, GLUT1 and GLUT3 levels are elevated in the first 
4 hours after reperfusion is established in exercise preconditioned rats, but expression is 
equal to control at 24 hours after injury (unpublished data).  This elevation in GLUT 
expression in the acute phase of reperfusion indicates that these preconditioned animals 
have the cellular machinery in place immediately when it is needed.  Non-exercised rats 
take longer to transcribe and translate the needed metabolic proteins, leading to increased 
metabolic dysfunction.  Thus, exercise preconditioning provides neuroprotection by 
increasing the levels of available glucose within neurons, providing the necessary 
substrate for ATP production. 
Once inside neurons, glucose must be metabolized to produce ATP for the cell.  The initial 
steps of glycolysis are primarily regulated by the key rate limiting step of 
phosphofructokinase (PFK), which catalyzes the phosphorylation of fructose-6-phosphate to 
fructose-1,6-bisphosphonate. PFK expression is known to be upregulated following 
increased metabolism and glycolysis and is has been shown to be neuroprotective in 
hypoglycemic conditions (Minchenko et al., 2003).  Another study has revealed PFK is 
increased following exercise preconditioning (Kinni et al., 2011), and this enzyme is 
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increased following ischemia/reperfusion injury, leading to increased neuronal metabolism 
and decreased neurologic deficits (unpublished data).  The elevated ability of neurons to 
process glucose through glycolysis in exercise preconditioned animals underlies another key 
component of exercise-induced neuroprotection.  Not only does exercise training increase 
glucose delivery to cells through angiogenesis and glucose transport, it also upregulates the 
machinery needed for glucose breakdown and ATP production. 
Ultimately, these processes work to increase ATP production to meet the energy demand 
of neurons.  One test used to assess the ATP production capacity of a neuron is an 
ADP:ATP ratio, which has been found to be decreased following ischemia/reperfusion 
injury in exercise preconditioned rats (unpublished data).  A lower ADP:ATP ratio 
indicates a lower level of metabolic dysfunction and increased capacity for ATP 
production in exercise trained rats.  Through the increased expression of various 
metabolic proteins, including AMPK, GLUT1, GLUT3, and PFK, exercise preconditioning 
upregulates multiple stages of ATP production, providing cells with the important energy 
substrate.  The increased capacity for ATP production allows neurons in exercise trained 
rats to decrease their energy deficit following ischemia/reperfusion injury. In turn, this 
promotes neuronal survival and decreases infarct size, leading to better outcomes 
following ischemia/reperfusion. 
3.6.2 HIF-1α and metabolism 
Hypoxic-induced factor-1α (HIF-1α) is a transcription factor, which is normally inhibited by 
oxygen-dependent hydroxylase enzymes, but in hypoxic conditions, these hydroxylase 
enzymes lose their ability to function and allow HIF-1α to initiate gene transcription 
(Bracken et al., 2006).  HIF-1α is known to be neuroprotective in rats following 
ischemia/reperfusion injury (Bernaudin et al., 2002; Schubert, 2005).  Not only is HIF-1α 
increased following hypoxia, but it also is increased in rats that are chronically exposed to 
hypoxic events (Bernaudin et al., 2002; Bracken et al., 2006).  The expression of HIF-1α is also 
known to be increased following exercise preconditioning (Kinni et al., 2011).  In addition to 
these findings, the transcription factor has also been shown to increase the expression of 
genes and proteins involved in angiogenesis and glycolysis, revealing its metabolism 
promoting activity (Bergeron et al., 1999; Bernaudin et al., 2002; Iyer et al., 1998; Jones and 
Bergeron, 2001; Schubert, 2005; Semenza, 2009).  HIF-1α is known to increase the expression 
of VEGF, glucose transporters and enzymes involved in glycolysis, such as PFK (Bergeron et 
al., 1999; Jones and Bergeron, 2001; Kim et al., 2006).  HIF-1α is not only involved in 
enhanced expression of metabolic enzymes and pathways, but the expression of HIF-1α is 
also increased by AMPK, a master regulator of neuronal metabolism (Emerling et al., 2007; 
Lee et al., 2003; Neurath et al., 2006). In fact, studies in chronically exercised rats have 
demonstrated that increased levels of AMPK induce HIF-1α to increase the expression of 
glucose transporters and PFK (Emerling et al., 2007; Hardie et al., 2003; Kahn et al., 2005; 
McGee and Hargreaves, 2006). 
HIF-1α, through its multiple mechanistic pathways, can increase metabolism and 
angiogenesis in an oxygen-deficient state, allowing it to simultaneously increase the mode of 
glucose delivery and the mechanism of ATP production.  In addition to being increased 
following exercise preconditioning (Kinni et al., 2011), HIF-1α is also increased in exercise 
trained animals following ischemia/reperfusion injury, which correlated with better 
neurologic outcomes and decreased infarct size (unpublished data).  These results indicate 
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that exercise equips neurons with a greater ability to upregulated glucose transport and 
metabolism, resulting in greater ATP production and decreased metabolic dysfunction, 
following acute ischemic stroke. This rapid response to an elevated energy demand 
promotes neuronal recovery and survival and serves as another mechanism of exercise-
induced neuroprotection in the setting of ischemia/reperfusion injury. 
4. Clinical implications 
Exercise-induced preconditioning is useful in prevention and amelioration of neuronal 
loss and neurologic dysfunction following ischemia/reperfusion injury, but it also has 
many therapeutic implications as well.  The potential for future drug targets at various 
levels of the neuroprotective mechanisms are abundant as the effects of neurotrophic 
factors, neurovascular unit integrity, inflammatory markers, and metabolic changes 
provide potential avenues for future pharmacologic intervention.  Particularly evident in 
patients with a history of ischemic stroke, traumatic brain injury, or transient ischemic 
attacks, pharmacologic interventions that could increase metabolism, strengthen the 
neurovascular unit, or decrease inflammation could have profound effects on morbidity 
and mortality associated with cerebrovascular accidents. Finally, the implications for 
exercise preconditioning prior to neurosurgical intervention can clearly be seen.  Through 
its ability to strengthen the neurovascular unit and decrease brain inflammation, exercise 
training should be strongly encouraged in any individuals prior to neurosurgical 
intervention. 
5. Conclusion 
Exercise preconditioning clearly is neuroprotective in the setting of ischemia/reperfusion 
injury, and these protective effects are conveyed through multiple mechanisms.  The 
neuroprotection derived as a result of exercise training is an endogenous effect that occurs 
independently of the risk factor modification that is also seen following exercise.  Innate 
neuroprotection from exercise is derived from elevated levels of neurotrophin proteins, 
which increase neuronal abundance and strength.  Furthermore, enhanced integrity of the 
neurovascular unit occurs through strengthening of the blood brain barrier, astrocytosis, 
angiogenesis, and arteriogenesis.  Exercise preconditioning also decreases the inflammatory 
response and leukocyte invasion following ischemia/reperfusion injury, thus decreasing 
much of the secondary damage seen following the reperfusion stage.  Neuronal apoptosis is 
reduced as exercise training increases anti-apoptotic factors and simultaneously decreases 
pro-apoptotic factors, pushing neurons towards a state of survival rather than programmed 
cell death.  Finally, exercise increases the metabolic capacity of neurons through 
upregulation of cerebral blood flow, glucose transport, glycolysis, and ATP production.  
Altogether, these changes seen following exercise preconditioning decreased neuronal loss, 
reduce infarct volume, and improve neurologic outcomes after ischemia/reperfusion injury. 
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increased following ischemia/reperfusion injury, leading to increased neuronal metabolism 
and decreased neurologic deficits (unpublished data).  The elevated ability of neurons to 
process glucose through glycolysis in exercise preconditioned animals underlies another key 
component of exercise-induced neuroprotection.  Not only does exercise training increase 
glucose delivery to cells through angiogenesis and glucose transport, it also upregulates the 
machinery needed for glucose breakdown and ATP production. 
Ultimately, these processes work to increase ATP production to meet the energy demand 
of neurons.  One test used to assess the ATP production capacity of a neuron is an 
ADP:ATP ratio, which has been found to be decreased following ischemia/reperfusion 
injury in exercise preconditioned rats (unpublished data).  A lower ADP:ATP ratio 
indicates a lower level of metabolic dysfunction and increased capacity for ATP 
production in exercise trained rats.  Through the increased expression of various 
metabolic proteins, including AMPK, GLUT1, GLUT3, and PFK, exercise preconditioning 
upregulates multiple stages of ATP production, providing cells with the important energy 
substrate.  The increased capacity for ATP production allows neurons in exercise trained 
rats to decrease their energy deficit following ischemia/reperfusion injury. In turn, this 
promotes neuronal survival and decreases infarct size, leading to better outcomes 
following ischemia/reperfusion. 
3.6.2 HIF-1α and metabolism 
Hypoxic-induced factor-1α (HIF-1α) is a transcription factor, which is normally inhibited by 
oxygen-dependent hydroxylase enzymes, but in hypoxic conditions, these hydroxylase 
enzymes lose their ability to function and allow HIF-1α to initiate gene transcription 
(Bracken et al., 2006).  HIF-1α is known to be neuroprotective in rats following 
ischemia/reperfusion injury (Bernaudin et al., 2002; Schubert, 2005).  Not only is HIF-1α 
increased following hypoxia, but it also is increased in rats that are chronically exposed to 
hypoxic events (Bernaudin et al., 2002; Bracken et al., 2006).  The expression of HIF-1α is also 
known to be increased following exercise preconditioning (Kinni et al., 2011).  In addition to 
these findings, the transcription factor has also been shown to increase the expression of 
genes and proteins involved in angiogenesis and glycolysis, revealing its metabolism 
promoting activity (Bergeron et al., 1999; Bernaudin et al., 2002; Iyer et al., 1998; Jones and 
Bergeron, 2001; Schubert, 2005; Semenza, 2009).  HIF-1α is known to increase the expression 
of VEGF, glucose transporters and enzymes involved in glycolysis, such as PFK (Bergeron et 
al., 1999; Jones and Bergeron, 2001; Kim et al., 2006).  HIF-1α is not only involved in 
enhanced expression of metabolic enzymes and pathways, but the expression of HIF-1α is 
also increased by AMPK, a master regulator of neuronal metabolism (Emerling et al., 2007; 
Lee et al., 2003; Neurath et al., 2006). In fact, studies in chronically exercised rats have 
demonstrated that increased levels of AMPK induce HIF-1α to increase the expression of 
glucose transporters and PFK (Emerling et al., 2007; Hardie et al., 2003; Kahn et al., 2005; 
McGee and Hargreaves, 2006). 
HIF-1α, through its multiple mechanistic pathways, can increase metabolism and 
angiogenesis in an oxygen-deficient state, allowing it to simultaneously increase the mode of 
glucose delivery and the mechanism of ATP production.  In addition to being increased 
following exercise preconditioning (Kinni et al., 2011), HIF-1α is also increased in exercise 
trained animals following ischemia/reperfusion injury, which correlated with better 
neurologic outcomes and decreased infarct size (unpublished data).  These results indicate 
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that exercise equips neurons with a greater ability to upregulated glucose transport and 
metabolism, resulting in greater ATP production and decreased metabolic dysfunction, 
following acute ischemic stroke. This rapid response to an elevated energy demand 
promotes neuronal recovery and survival and serves as another mechanism of exercise-
induced neuroprotection in the setting of ischemia/reperfusion injury. 
4. Clinical implications 
Exercise-induced preconditioning is useful in prevention and amelioration of neuronal 
loss and neurologic dysfunction following ischemia/reperfusion injury, but it also has 
many therapeutic implications as well.  The potential for future drug targets at various 
levels of the neuroprotective mechanisms are abundant as the effects of neurotrophic 
factors, neurovascular unit integrity, inflammatory markers, and metabolic changes 
provide potential avenues for future pharmacologic intervention.  Particularly evident in 
patients with a history of ischemic stroke, traumatic brain injury, or transient ischemic 
attacks, pharmacologic interventions that could increase metabolism, strengthen the 
neurovascular unit, or decrease inflammation could have profound effects on morbidity 
and mortality associated with cerebrovascular accidents. Finally, the implications for 
exercise preconditioning prior to neurosurgical intervention can clearly be seen.  Through 
its ability to strengthen the neurovascular unit and decrease brain inflammation, exercise 
training should be strongly encouraged in any individuals prior to neurosurgical 
intervention. 
5. Conclusion 
Exercise preconditioning clearly is neuroprotective in the setting of ischemia/reperfusion 
injury, and these protective effects are conveyed through multiple mechanisms.  The 
neuroprotection derived as a result of exercise training is an endogenous effect that occurs 
independently of the risk factor modification that is also seen following exercise.  Innate 
neuroprotection from exercise is derived from elevated levels of neurotrophin proteins, 
which increase neuronal abundance and strength.  Furthermore, enhanced integrity of the 
neurovascular unit occurs through strengthening of the blood brain barrier, astrocytosis, 
angiogenesis, and arteriogenesis.  Exercise preconditioning also decreases the inflammatory 
response and leukocyte invasion following ischemia/reperfusion injury, thus decreasing 
much of the secondary damage seen following the reperfusion stage.  Neuronal apoptosis is 
reduced as exercise training increases anti-apoptotic factors and simultaneously decreases 
pro-apoptotic factors, pushing neurons towards a state of survival rather than programmed 
cell death.  Finally, exercise increases the metabolic capacity of neurons through 
upregulation of cerebral blood flow, glucose transport, glycolysis, and ATP production.  
Altogether, these changes seen following exercise preconditioning decreased neuronal loss, 
reduce infarct volume, and improve neurologic outcomes after ischemia/reperfusion injury. 
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1. Introduction 
Adaptations, conservation or evolution of physiological systems in human indicates that the  
physiological system for hypoxia tolerance represents an adaptive character that is present 
in humans, just like in poikilotherms or endotherms(Hochachka 1993; Hochachka et al. 
1996). Precisely, brain metabolic organization capability is thought to represent an adaptive 
physiological system that is present in humans, but composed of so many neurochemical 
products and physiological mechanisms  that make it difficult to account for its plasticity  
for manipulation to induce  protection(Hochachka 1993; Frappell et al. 2002). Evidence that 
hypoxia tolerating mammals  suppressed metabolic demand in response to hypoxia 
contributed substantially to the understanding  of metabolic regulation as a neuroprotective 
strategy that can be adapted for the protection of tissue hypoxia in humans. In that case,  
understanding the physiological mechanisms that are involved in such ability in hypoxia 
tolerating species may provide a clue for specific mechanisms that could be manipulated in 
the brain of stroke patients to prevent the death of metabolically vulnerable neurons. In this 
context, knowledge of  the specific role of the central neurotransmitter systems and 
pathways that control metabolic suppression  during  hypoxia tolerance is important. This is  
because the neurochemical-mediators that may defend against hypoxic insults during  brain 
injury act through  interconnections within the neural systems that are highly protected in 
hypoxia tolerating species(Mravec et al. 2006). Exposure of non hypoxia tolerating species to  
severe hypoxia results in the alteration of the connections within the neural systems because 
of loss control of  local  microcirculation of oxygen. This leads to ineffectiveness  of  
membrane potentials  to modulate neuronal function (Ackland et al. 2007). If this occurs,  
there is some hope for effective neuropharmacological intervention through 
neurotransmitter-mediators. The fact that chemical neurotransmitters are part of normal 
physiology, whether during development or adulthood, means that specific agonists and 
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antagonists that restore physiological  homeostasis can lead to pharmacological repair of 
hypoxia-induced neuronal damage in humans.  
2. Physiological strategies that protect the brain during ischemic stroke 
Hypothermia is one strategy that can  decrease hypoxic/ischemic injury under regulated 
conditions (Rincon 2008; Statler 2008). This is possible because a  decline in brain 
temperature can prevent the dead of  neurons that are deprived of nutrients. Such a 
protective strategy has been attributed to the  reversible protein phosphorylation that   
regulates suppression of the rates of multiple ATP-production, ATP-utilization and related 
cellular processes that allow animals to go through a stable hypometabolic state (Storey and 
Storey 2007; Storey and Storey 2005). A stable hypometabolic state mechanism is known to 
protect against pathological effects of cortical neuronal pathology or oxidative stress in 
stroke patients (Ma et al. 2005). Cumulative evidence from  studies of  hypometabolism 
during hibernation in small mammals suggests that hypometabolism is  a stable metabolic 
state that allows  timely limited  energy regulation during hypoxia (Heldmaier et al. 2004). 
This is because a stable metabolic state  activates  defense mechanisms, such as antioxidants, 
proteins, protease inhibitors that stabilize macromolecules and promote long-term neuronal 
viability in the stable metabolic state (Zhou et al. 2001; Zhao and Zuo 2005). These 
adaptations   can be manipulated in humans to  prevent the death of metabolically 
vulnerable neurons in stroke patients. Although these adaptations do not fully account for  
the mechanisms that facilitate  the suppression of metabolism during exposure to hypoxia 
(Nathaniel et al. 2009) or during mammalian hibernation (Drew et al. 2007), it has been 
proposed that hypoxia itself could facilitate a systematic regulation of  metabolism through 
cooling of core body temperature and stabilization of temperature in the new metabolic rate 
(Barros et al. 2001). Future studies that explore the mechanisms that switch-off energy 
demand, when supplies become limited during metabolic suppression could provide clues 
of how to develop metabolic suppression as novel therapy in the clinical management of 
stroke.  
3. Cellular implications of disruption of brain energy balance when oxygen 
delivery fails to meet demand  
The mammalian brain is a highly oxidative organ that accounts for an inexplicably large 
percentage of the whole body oxygen consumption that provides the major source of energy 
during aerobic metabolism (Wang et al. 2002). This implies that structural and functional 
integrity of brain functions strongly depend on a regular oxygen and glucose supply. 
Therefore, any disruption of the homeostasis of brain energy demand and supply becomes 
life threatening. This is because a reduction in oxygen availability due to the abnormality in 
systemic or local blood circulation cannot be endured for a prolonged period by a non 
hypoxia tolerant species (Zhou et al. 2001a; Barger et al. 2003). The immediate effect is 
variation in oxygen partial pressure (PO2), within the brain that is detected by cellular 
oxygen sensors. The cellular oxygen sensors, such as hypoxia inducible transcription factors 
(HIFs), are thought to be available to regulate oxygen homeostasis in the brain. In order for 
the brain to cope with variations in oxygen partial pressure, these sensors induce adaptive 
mechanisms to avoid, or at least minimize, brain damage (Nawashiro et al. 1996). Any 
abnormality in cellular oxygen-sensor response is a reflection of the low partial pressure and 
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concentrations of oxygen in the brain. The abnormality is primarily because of the inability 
of a specific oxygen-sensor or target system  to tailor adaptive responses according to 
differences in the cellular oxygen availability in a short or long term. In this context, the 
arising question is how does low cellular oxygen availability affect neuronal and 
physiological activities? Major cellular operations in the brain are dependent on the oxygen 
level in the physiological range (Erecinska et al. 2005). Limitation of oxygen supply to the 
brain below a critical physiological level blocks oxidative phosphorylation, which 
drastically decreased cellular ATP leading to a collapse in ion gradients. Consequently, 
neuronal activity stops. If the process of re-oxygenation is not re-introduced quickly, 
neurons will die(Nawashiro et al. 1996). In  the brain of a stroke patient, early interruption 
of energy homeostasis when oxygen delivery fails to meet oxygen demand is the first step in 
a surge of events that leads to cell death of metabolically susceptible neurons. If hypoxia 
does not set in, availability of glucose will help maintain ATP levels through glycolysis. 
However, if glucose supply is limited, reduction of high-energy phosphates (e.g. ATP) 
results in loss of cellular ionic homeostasis (Erecińska and Silver 2001). This is because the 
disruption of ion homeostasis causes an influx of Na+ and Cl– ions, the release of 
neurotransmitters, opening of voltage-gated Ca2+ channels, and anoxic depolarization 
(Erecinska et al. 2005). This finding suggests that anoxic depolarization is directly associated 
with hypoxia-induced neuronal loss that leads to irreversible brain damage. An interesting 
question relevant to this idea is how does anoxic depolarization trigger neuronal death 
during hypoxia? This question has been investigated in the context of the mechanism of 
anoxic depolarization. For instance, concurrent changes in (K+)0t that lead to  failure of (Na+ 
,K+) ATPase occur during hypoxia due to ATP depletion(Balestrino et al. 1989). In support of 
this idea, electrophysiological evidence reveals that failure of ATPase causes anoxic 
depolarization through some intermediate event, such as Na+-induced cell swelling(Rufini 
et al. 2009). To clarify the direct relationship between anoxic depolarization and ATP levels, 
synaptic transmission analysis  in rat hippocampus revealed that first, Na+ influx plays a 
relatively larger role in ATP consumption during hypoxia than Ca2+ influx; second, anoxic 
depolarization imposes a large and rapid drop in ATP levels(Fowler et al. 1999). Taken 
together, it then implies that depolarization and increased sodium concentration during 
hypoxia seem to account for a significant portion of the neuronal damage induced by 
hypoxia that eventually leads to both necrotic and apoptotic processes (Reshef et al. 2000; 
Gonchar and Mankovskaya 2009). 
4. Stimulation of glutamate, activation of NMDA and AMPA receptors regulate 
calcium influx and promote neuronal damage 
Although  increased sodium concentration during hypoxia seems to account for a major part 
of  neuronal damage during hypoxia,  additional structural damages develop hours or days 
later because Ca2+ influx into neurons is  stimulated by glutamate (He et al. 2009), and 
amplified by activation of NMDA and AMPA receptors (Zamalloa et al. 2009). Glutamate is 
one of the most widespread excitatory neurotransmitters in the brain. In small amounts, it is 
indispensable for neuronal function, while in excessive amounts it is a neuronal poison 
(excitotoxin) that stimulates Ca2+ influx into neurons (Liljequist et al. 1995; Bonde et al. 
2005). If the excessive extracellular release of glutamate is not regulated, it could lead to 
brain damage(Robinson 2006). This idea is strengthened by the observation  that 
overstimulation of glutamate receptors promotes neuronal death(Sheldon and Robinson 
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protect against pathological effects of cortical neuronal pathology or oxidative stress in 
stroke patients (Ma et al. 2005). Cumulative evidence from  studies of  hypometabolism 
during hibernation in small mammals suggests that hypometabolism is  a stable metabolic 
state that allows  timely limited  energy regulation during hypoxia (Heldmaier et al. 2004). 
This is because a stable metabolic state  activates  defense mechanisms, such as antioxidants, 
proteins, protease inhibitors that stabilize macromolecules and promote long-term neuronal 
viability in the stable metabolic state (Zhou et al. 2001; Zhao and Zuo 2005). These 
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vulnerable neurons in stroke patients. Although these adaptations do not fully account for  
the mechanisms that facilitate  the suppression of metabolism during exposure to hypoxia 
(Nathaniel et al. 2009) or during mammalian hibernation (Drew et al. 2007), it has been 
proposed that hypoxia itself could facilitate a systematic regulation of  metabolism through 
cooling of core body temperature and stabilization of temperature in the new metabolic rate 
(Barros et al. 2001). Future studies that explore the mechanisms that switch-off energy 
demand, when supplies become limited during metabolic suppression could provide clues 
of how to develop metabolic suppression as novel therapy in the clinical management of 
stroke.  
3. Cellular implications of disruption of brain energy balance when oxygen 
delivery fails to meet demand  
The mammalian brain is a highly oxidative organ that accounts for an inexplicably large 
percentage of the whole body oxygen consumption that provides the major source of energy 
during aerobic metabolism (Wang et al. 2002). This implies that structural and functional 
integrity of brain functions strongly depend on a regular oxygen and glucose supply. 
Therefore, any disruption of the homeostasis of brain energy demand and supply becomes 
life threatening. This is because a reduction in oxygen availability due to the abnormality in 
systemic or local blood circulation cannot be endured for a prolonged period by a non 
hypoxia tolerant species (Zhou et al. 2001a; Barger et al. 2003). The immediate effect is 
variation in oxygen partial pressure (PO2), within the brain that is detected by cellular 
oxygen sensors. The cellular oxygen sensors, such as hypoxia inducible transcription factors 
(HIFs), are thought to be available to regulate oxygen homeostasis in the brain. In order for 
the brain to cope with variations in oxygen partial pressure, these sensors induce adaptive 
mechanisms to avoid, or at least minimize, brain damage (Nawashiro et al. 1996). Any 
abnormality in cellular oxygen-sensor response is a reflection of the low partial pressure and 
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concentrations of oxygen in the brain. The abnormality is primarily because of the inability 
of a specific oxygen-sensor or target system  to tailor adaptive responses according to 
differences in the cellular oxygen availability in a short or long term. In this context, the 
arising question is how does low cellular oxygen availability affect neuronal and 
physiological activities? Major cellular operations in the brain are dependent on the oxygen 
level in the physiological range (Erecinska et al. 2005). Limitation of oxygen supply to the 
brain below a critical physiological level blocks oxidative phosphorylation, which 
drastically decreased cellular ATP leading to a collapse in ion gradients. Consequently, 
neuronal activity stops. If the process of re-oxygenation is not re-introduced quickly, 
neurons will die(Nawashiro et al. 1996). In  the brain of a stroke patient, early interruption 
of energy homeostasis when oxygen delivery fails to meet oxygen demand is the first step in 
a surge of events that leads to cell death of metabolically susceptible neurons. If hypoxia 
does not set in, availability of glucose will help maintain ATP levels through glycolysis. 
However, if glucose supply is limited, reduction of high-energy phosphates (e.g. ATP) 
results in loss of cellular ionic homeostasis (Erecińska and Silver 2001). This is because the 
disruption of ion homeostasis causes an influx of Na+ and Cl– ions, the release of 
neurotransmitters, opening of voltage-gated Ca2+ channels, and anoxic depolarization 
(Erecinska et al. 2005). This finding suggests that anoxic depolarization is directly associated 
with hypoxia-induced neuronal loss that leads to irreversible brain damage. An interesting 
question relevant to this idea is how does anoxic depolarization trigger neuronal death 
during hypoxia? This question has been investigated in the context of the mechanism of 
anoxic depolarization. For instance, concurrent changes in (K+)0t that lead to  failure of (Na+ 
,K+) ATPase occur during hypoxia due to ATP depletion(Balestrino et al. 1989). In support of 
this idea, electrophysiological evidence reveals that failure of ATPase causes anoxic 
depolarization through some intermediate event, such as Na+-induced cell swelling(Rufini 
et al. 2009). To clarify the direct relationship between anoxic depolarization and ATP levels, 
synaptic transmission analysis  in rat hippocampus revealed that first, Na+ influx plays a 
relatively larger role in ATP consumption during hypoxia than Ca2+ influx; second, anoxic 
depolarization imposes a large and rapid drop in ATP levels(Fowler et al. 1999). Taken 
together, it then implies that depolarization and increased sodium concentration during 
hypoxia seem to account for a significant portion of the neuronal damage induced by 
hypoxia that eventually leads to both necrotic and apoptotic processes (Reshef et al. 2000; 
Gonchar and Mankovskaya 2009). 
4. Stimulation of glutamate, activation of NMDA and AMPA receptors regulate 
calcium influx and promote neuronal damage 
Although  increased sodium concentration during hypoxia seems to account for a major part 
of  neuronal damage during hypoxia,  additional structural damages develop hours or days 
later because Ca2+ influx into neurons is  stimulated by glutamate (He et al. 2009), and 
amplified by activation of NMDA and AMPA receptors (Zamalloa et al. 2009). Glutamate is 
one of the most widespread excitatory neurotransmitters in the brain. In small amounts, it is 
indispensable for neuronal function, while in excessive amounts it is a neuronal poison 
(excitotoxin) that stimulates Ca2+ influx into neurons (Liljequist et al. 1995; Bonde et al. 
2005). If the excessive extracellular release of glutamate is not regulated, it could lead to 
brain damage(Robinson 2006). This idea is strengthened by the observation  that 
overstimulation of glutamate receptors promotes neuronal death(Sheldon and Robinson 
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2007a). Since excessive glutamate is harmful to the brain, how exactly can excess amounts of 
glutamate be regulated in the brain cells? It is possible that such regulation could be 
achieved by controlling a specific effector system that modulates the activities of glutamate. 
In support of this idea, studies by Pellegrini-Giampietro et al.(1999), Sheldon and Robinson 
(2007a) suggest that the mechanism that regulates glutamate transporter activity within 
minutes is a major redistributor of  proteins in the plasma. This idea is further strengthened 
by the finding that glutamate transporters are regulated by the mechanism that redistributes 
proteins to or from the plasma membrane(Savolainen et al. 1995; Noda et al. 2000; Sheldon 
and Robinson 2007b). Findings from these studies  indicate that longer-term activation of 
protein kinase C (PKC) decreased the activity and cell surface expression of the 
predominant forebrain glutamate Glu-1 transporter that is being redistributed from the 
plasma membrane to an intracellular compartment. Taken together, the existing studies 
reveal that the cellular machinery required for redistribution is via lysosomal degradation 
and not proteosomal degradation. Since longer-term activation of PKC results in 
degradation of GLT-1 that can be  blocked by inhibitors of lysosomal but not proteosomal 
degradation, we speculate that regulation of total GLT-1 levels during hypoxia could play a 
significant role in hypoxia neuroprotection. Since the stimulative effect of glutamate (Noda 
et al. 2000) and activation of NMDA and AMPA receptors (Sobczyk et al. 2005) led to 
calcium overload (Mulvey and Renshaw 2009), our interest in this review to determine 
whether the different roles of glutamate, NMDA and AMPA receptors are the sole means of 
extracellular accumulation of calcium following hypoxic insults. By analyzing the influence 
of a specific ion channel inhibitor on the rise of cytosolic free calcium (Ca2+) during hypoxia 
in a  rat’s cerebrocortical brain slices, Bickler (1998) found that the cytosolic calcium changes 
during hypoxia  are due to multiple mechanisms. The changes are incompletely inhibited by 
a combined ion channel blockade. They are associated with the disruption of the cell 
membrane integrity. There is evidence that other factors may be at work as well. One factor 
is oxidative stress that is associated with the activation of microglia. Activation of microglia 
in turn, releases inflammatory cytokines, nitric oxide and extracellular accumulation of 
calcium, resulting in stress and neuronal death. Another factor is an increase in reactive 
oxygen species production. This alters cellular components including calcium levels and 
contributes to cytotoxic events that lead to cell death.  
5. Cellular responses in brain neural systems can help in understanding 
hypoxia-induced hypometabolism and neuroprotection 
In the previous section, we described how the stimulation of glutamate, activation of 
NMDA and AMPA receptors can regulate calcium influx and promote neuronal damage. It 
is now important to discuss how cellular responses in brain neural systems can help in 
understanding hypoxia-induced hypometabolism to initiate neuroprotection. Obviously, 
this proposal needs an explanation on how the cellular responses in any brain neural 
network would be a major factor for understanding hypoxia-induced hypometabolism and 
functional integrity. Indeed, a correlative neurophysiological observation tells us that 
understanding hypometabolism during  neuroprotection should be in the context of 
functional integrity, because hypoxic response of each neuron can be unexpectedly 
heterogeneous, even within the same brain region(Boutilier 2001). The heterogeneity might 
be due to the fact that hypoxia itself leads to considerable downregulation of ion channels 
inside the brain neuronal systems, such that hypoxic reaction of individual neurons vary 
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(Pena and Ramirez 2005). The variation, in turn, may help in maintaining functional 
integrity. The idea is supported by the observation that ion channel arrest does not lead to 
the shutdown of entire networks, nor can networks operate by all cellular components 
entering a general hypometabolic-neuroprotective state(Ramirez et al. 2007). For instance, a 
general shutdown of NMDA or Ca2+ dependent processes would not be beneficiary to a 
hypoxia tolerating animal in a hypometabolic state. This is because such a shutdown would 
severely compromise higher-brain functions. Therefore, hypoxia research should focus on 
understanding mechanisms of  hypometabolism during  neuroprotection in the context of 
functional integrity, and as expressed by hypoxia tolerating species. This disconnect may 
explain why the protection against tissue hypoxia during stroke is still a main medical 
problem. There is no doubt that activation of NMDA receptors or intracellular Ca2+ may 
lead to necrosis and apoptosis. However, restraining these mechanisms is not very helpful 
because they also affect neuroprotection. Taken together, understanding  how hypoxia-
tolerant neurons sense changes in oxygen dynamics and create signals that have instant and 
long-term effects on neuronal survival will be significant in developing new strategies for 
neuroprotection. Studies of how metabolism is regulated at cellular levels during which 
energy-producing and energy-consuming processes are balanced, facilitated by 
neurotransmitters-mediated mechanism would be of considerable interest. Since many of 
the existing studies support the idea that adenosine  induces neuroprotection during  
hypoxia, we will now focus on the different physiological and molecular mechanisms used 
by adenosine  in inducing protection in natural systems of hypoxia tolerance.  
6. Adenosine induces neuroprotection by mediating ion signaling during 
response to chronic hypoxia 
Several lines of evidence indicate that reduced ion leakage is an important mechanism for 
energy conservation during extreme hypoxia, and adenosine has been implicated in ion 
channel activity. Precisely, it has been shown that A1 receptor stimulation inhibits the 
brain’s electrical activity through K+ channel activation (direct coupling via G-proteins to ion 
channels) and/or by inhibiting the high-voltage-activated Ca2+ channels (Fowler et al. 1999; 
Reshef et al. 2000). Extracellular adenosine plays a role in the reduction of K+ influx (channel 
arrest) that occurs in a brain that was subjected to chronic hypoxia(Reshef et al. 2000). 
Monitoring of the changes in extracellular K+ concentration (K+)o in the in-situ brain of the 
turtle (Trachemys scripta), following inhibition of Na+/K(+)-ATPase with ouabain revealed 
that  the time to reach full depolarization (K+)o plateau) was 3 times more in the chronic 
hypoxic brain than in normoxic controls (Pék  and Lutz 1997). The initial rate of K+ leakage 
was reduced by approximately 70%. Following  superfusing the brain, before the onset of 
chronic hypoxia with the non selective  adenosine receptor blocker, theophylline, or the 
specific adenosine A1 receptor blocker, 8-cyclopentyltheophylline, there was a significant 
reduction in the time to full depolarization in the ouabain-challenged  hypoxic-brain and an 
increase in  the rate of K+  efflux(Pék  and Lutz 1997). The results indicate that A1 receptors 
are involved in the expression of chronic hypoxia-induced ion channel arrest in the brain. 
This finding is supported by other studies that indicated that in a chronic hypoxic tolerant 
specie, the basic strategy for hypoxia survival is  the  maintenance of ion gradients to avoid 
anoxic depolarization (Lutz et al. 1996; Perez-Pinzon and Born 1999). To this extent, an 
important question that re-occurred in many of the most recent theoretical papers is how 
does hypoxia tolerant species respond to anoxia? In our physiological perspective of 
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2007a). Since excessive glutamate is harmful to the brain, how exactly can excess amounts of 
glutamate be regulated in the brain cells? It is possible that such regulation could be 
achieved by controlling a specific effector system that modulates the activities of glutamate. 
In support of this idea, studies by Pellegrini-Giampietro et al.(1999), Sheldon and Robinson 
(2007a) suggest that the mechanism that regulates glutamate transporter activity within 
minutes is a major redistributor of  proteins in the plasma. This idea is further strengthened 
by the finding that glutamate transporters are regulated by the mechanism that redistributes 
proteins to or from the plasma membrane(Savolainen et al. 1995; Noda et al. 2000; Sheldon 
and Robinson 2007b). Findings from these studies  indicate that longer-term activation of 
protein kinase C (PKC) decreased the activity and cell surface expression of the 
predominant forebrain glutamate Glu-1 transporter that is being redistributed from the 
plasma membrane to an intracellular compartment. Taken together, the existing studies 
reveal that the cellular machinery required for redistribution is via lysosomal degradation 
and not proteosomal degradation. Since longer-term activation of PKC results in 
degradation of GLT-1 that can be  blocked by inhibitors of lysosomal but not proteosomal 
degradation, we speculate that regulation of total GLT-1 levels during hypoxia could play a 
significant role in hypoxia neuroprotection. Since the stimulative effect of glutamate (Noda 
et al. 2000) and activation of NMDA and AMPA receptors (Sobczyk et al. 2005) led to 
calcium overload (Mulvey and Renshaw 2009), our interest in this review to determine 
whether the different roles of glutamate, NMDA and AMPA receptors are the sole means of 
extracellular accumulation of calcium following hypoxic insults. By analyzing the influence 
of a specific ion channel inhibitor on the rise of cytosolic free calcium (Ca2+) during hypoxia 
in a  rat’s cerebrocortical brain slices, Bickler (1998) found that the cytosolic calcium changes 
during hypoxia  are due to multiple mechanisms. The changes are incompletely inhibited by 
a combined ion channel blockade. They are associated with the disruption of the cell 
membrane integrity. There is evidence that other factors may be at work as well. One factor 
is oxidative stress that is associated with the activation of microglia. Activation of microglia 
in turn, releases inflammatory cytokines, nitric oxide and extracellular accumulation of 
calcium, resulting in stress and neuronal death. Another factor is an increase in reactive 
oxygen species production. This alters cellular components including calcium levels and 
contributes to cytotoxic events that lead to cell death.  
5. Cellular responses in brain neural systems can help in understanding 
hypoxia-induced hypometabolism and neuroprotection 
In the previous section, we described how the stimulation of glutamate, activation of 
NMDA and AMPA receptors can regulate calcium influx and promote neuronal damage. It 
is now important to discuss how cellular responses in brain neural systems can help in 
understanding hypoxia-induced hypometabolism to initiate neuroprotection. Obviously, 
this proposal needs an explanation on how the cellular responses in any brain neural 
network would be a major factor for understanding hypoxia-induced hypometabolism and 
functional integrity. Indeed, a correlative neurophysiological observation tells us that 
understanding hypometabolism during  neuroprotection should be in the context of 
functional integrity, because hypoxic response of each neuron can be unexpectedly 
heterogeneous, even within the same brain region(Boutilier 2001). The heterogeneity might 
be due to the fact that hypoxia itself leads to considerable downregulation of ion channels 
inside the brain neuronal systems, such that hypoxic reaction of individual neurons vary 
Physiological Neuroprotective Mechanisms in Natural Genetic  
Systems: Therapeutic Clues for Hypoxia-Induced Brain Injuries 331 
(Pena and Ramirez 2005). The variation, in turn, may help in maintaining functional 
integrity. The idea is supported by the observation that ion channel arrest does not lead to 
the shutdown of entire networks, nor can networks operate by all cellular components 
entering a general hypometabolic-neuroprotective state(Ramirez et al. 2007). For instance, a 
general shutdown of NMDA or Ca2+ dependent processes would not be beneficiary to a 
hypoxia tolerating animal in a hypometabolic state. This is because such a shutdown would 
severely compromise higher-brain functions. Therefore, hypoxia research should focus on 
understanding mechanisms of  hypometabolism during  neuroprotection in the context of 
functional integrity, and as expressed by hypoxia tolerating species. This disconnect may 
explain why the protection against tissue hypoxia during stroke is still a main medical 
problem. There is no doubt that activation of NMDA receptors or intracellular Ca2+ may 
lead to necrosis and apoptosis. However, restraining these mechanisms is not very helpful 
because they also affect neuroprotection. Taken together, understanding  how hypoxia-
tolerant neurons sense changes in oxygen dynamics and create signals that have instant and 
long-term effects on neuronal survival will be significant in developing new strategies for 
neuroprotection. Studies of how metabolism is regulated at cellular levels during which 
energy-producing and energy-consuming processes are balanced, facilitated by 
neurotransmitters-mediated mechanism would be of considerable interest. Since many of 
the existing studies support the idea that adenosine  induces neuroprotection during  
hypoxia, we will now focus on the different physiological and molecular mechanisms used 
by adenosine  in inducing protection in natural systems of hypoxia tolerance.  
6. Adenosine induces neuroprotection by mediating ion signaling during 
response to chronic hypoxia 
Several lines of evidence indicate that reduced ion leakage is an important mechanism for 
energy conservation during extreme hypoxia, and adenosine has been implicated in ion 
channel activity. Precisely, it has been shown that A1 receptor stimulation inhibits the 
brain’s electrical activity through K+ channel activation (direct coupling via G-proteins to ion 
channels) and/or by inhibiting the high-voltage-activated Ca2+ channels (Fowler et al. 1999; 
Reshef et al. 2000). Extracellular adenosine plays a role in the reduction of K+ influx (channel 
arrest) that occurs in a brain that was subjected to chronic hypoxia(Reshef et al. 2000). 
Monitoring of the changes in extracellular K+ concentration (K+)o in the in-situ brain of the 
turtle (Trachemys scripta), following inhibition of Na+/K(+)-ATPase with ouabain revealed 
that  the time to reach full depolarization (K+)o plateau) was 3 times more in the chronic 
hypoxic brain than in normoxic controls (Pék  and Lutz 1997). The initial rate of K+ leakage 
was reduced by approximately 70%. Following  superfusing the brain, before the onset of 
chronic hypoxia with the non selective  adenosine receptor blocker, theophylline, or the 
specific adenosine A1 receptor blocker, 8-cyclopentyltheophylline, there was a significant 
reduction in the time to full depolarization in the ouabain-challenged  hypoxic-brain and an 
increase in  the rate of K+  efflux(Pék  and Lutz 1997). The results indicate that A1 receptors 
are involved in the expression of chronic hypoxia-induced ion channel arrest in the brain. 
This finding is supported by other studies that indicated that in a chronic hypoxic tolerant 
specie, the basic strategy for hypoxia survival is  the  maintenance of ion gradients to avoid 
anoxic depolarization (Lutz et al. 1996; Perez-Pinzon and Born 1999). To this extent, an 
important question that re-occurred in many of the most recent theoretical papers is how 
does hypoxia tolerant species respond to anoxia? In our physiological perspective of 
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hypoxia neuroprotection, adaption to anoxia (an extreme form of hypoxia) is mainly 
controlled by hypoxia/ischemic conditioning mechanism(Liu et al. 1991). In addition, the 
different physiological adaptations for extreme hypoxia have been well described in turtles, 
one of the species with a unique ability to tolerate extreme hypoxia. In humans, an extreme 
hypoxia condition causes major histopathological events to the brain. However, in turtles 
that have the ability to resist extreme form of hypoxia, tolerance is seen when a sublethal 
ischemic/anoxia insult is induced sometime before a lethal ischemic/anoxia insult is 
induced(Liu et al. 1991). The mechanisms involved are not well understood. Therefore, a 
better understanding of the mechanisms that induce extreme tolerance to hypoxia in turtles 
may provide novel therapeutic interventions that may aide human brain to resist the 
ravages of extreme hypoxia.  
6.1 Adenosine facilitates hypoxia neuroprotection by mediating intracellular signaling 
pathways 
Several lines of evidence indicate that severe hypoxia can cause an imbalance between 
oxygen supply and consumption. This is  usually accompanied by transportation of  
adenosine down its concentration gradient from the cell via nucleoside transporters, such as 
ENT1 and the ENT2. These transporters are equilibrative nucleoside transporters that are 
expressed in  the CNS (Chaudary et al. 2004b; Chaudary et al. 2004a), to promote the 
extracellular accumulation of adenosine. In this context, adenosine seems to act as an 
autocrine signal that indicates the disproportion between cellular oxygen availability and 
oxygen usage. Since adenosine is also an essential component of ATP synthesis, adenosine 
pools need to be vigilantly sustained in metabolically active cells in the brain. This could be 
done by minimizing extracellular release of adenosine, first by down-regulation of ENT 
activity. This would  aid the restoration of  ATP pools once the hypoxic stress has been 
removed. It is also important to point out that an ENT activity could lead to reuptake of 
extracellular adenosine to terminate receptor activation, as uniquely done by the 
neurotransmitter transporters to help restore intracellular pools of adenosine. The precise 
nature of the relationship between adenosine transporters, adenosine receptors and 
intracellular signaling pathways is not well known. Hypoxia is known to regulate the 
adenosine transporter mENT1 (inhibitor-sensitive), and protein kinase c q (PKCq) is 
involved in regulation of mENT1(Chaudary et al. 2004a), suggesting that chronic hypoxia 
regulates ENT1, both in terms of protein and overall reactivity through PKC-mediated 
hypoxia preconditioning. 
The PKC-mediated hypoxia protection occurs when extracellular adenosine interacts with 
adenosine receptors (A1, A2A, A2B, and/or A3), and activation of adenosine receptors 
stimulate signaling pathways that "resist" the stress caused by hypoxia (David et al. 2002). It 
then implies that the onset of hypoxia leads to a decrease in cellular ATP stores and 
subsequent generation of adenosine, which is then released extracellularly. An increase in 
adenosine levels, in addition to bradykinin and opioids, initiate a series of intracellular 
signaling events via G-protein-coupled receptor signaling leading to activation of PKC 
activation (Di-Capua et al. 2003). Several studies have shown that injections of adenosine 
could protect neuronal cells against hypoxic-type injury via a PKC-mediated mechanism 
(Dave et al. 2009). A series of intracellular signaling that leads to the adenosine-mediated 
PKC-induced mechanism of hypoxia protection include; i) adenosine stimulates G-protein–
coupled receptors, such as the A1/A3 adenosine receptors which activate phospholipases 
(phospholipase C; PLC) via G-proteins (Gi/o). ii) Other preconditioning stimulus, such as 
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extracellular glutamate stimulates NMDARs, leading to increased cytosolic calcium and 
PLC activation. iii) PKC is activated by PLC, and it increases di-acylglycerol (DAG) 
production, which in turn activates PKC isozymes including PKC. Finally, the PKC 
activation of extracellular signal-regulated kinase (ERK) promotes survival. Neuronal 
survival occurs because PKC may induce the opening of K (ATP) channels in the 
mitochondria (KATP) to regulate ATP production, and reduce generation of ROS. 
Interestingly, mitochondria are ideally located to serve as the cellular oxygen signal and 
mediator of protective mechanisms, such as ion channel arrest. Thus, regulation of 
mitochondria based mechanism of ion channel arrest involving ATP-sensitive mitochondrial 
K(+) channels, cytosolic calcium and ROS concentrations could contribute to neuronal 
survival. 
It is also very important to point out that adenosine-mediated PKC  signaling is mediated 
in part through ERK, a mitogen-activated protein kinase (MAPK) family member that has 
been implicated in antiapoptotic signaling(Lange-Asschenfeldt et al. 2004). ERK maintains 
mitochondrial function by inhibiting deleterious Bcl-2 associated death domain protein BAD 
activity(Qiu et al. 2001).Taken together, adenosine-mediated PKC signaling seems to 
activate ERK. This activation is involved in antiapoptotic signaling and cell survival during 
the induction of hypoxia preconditioning state, in order  to salvage ‘at-risk-tissue’ with 
residual energy levels. The role of adenosine-mediated PKC signaling in altering the 
expression or activity of calcium/calmodulin-dependent protein kinase II, MAPK family 
members, c-Jun N-terminal kinase, ERK, protein kinase B and PKC indicates that multiple 
kinases participate in the response of the tissue to counteract the effect of hypoxia (Obexer et 
al. 2006). This is important because PKC activity has been implicated in cell injury in the 
cerebral brain  (Bright et al. 2008)indicating that it could be involved in a conserved hypoxia 
response pathway. εPKC activation delays the collapse of ion homeostasis during ischemia 
in arctic ground squirrels(Dave et al. 2009). This finding suggests that εPKC mediates 26 
collapse of ion homeostasis in Arctic Ground Squirrels. This is possible  because εPKC 
inhibits both 27 Na(+)/K(+)-ATPase and voltage-gated sodium channels, which are primary 
mediators of 28 the collapse of ion homeostasis during ischemia in Arctic Ground Squirrel 
(Perez-Pinzon et 29 al. 2005). For this reason, the specific role of PKC in mediating 
hypoxia/ischemia-induced brain injury following the onset of stroke will be an interesting 
area of attention. Even more interesting is that the controversy  over whether  PKC mediates 
or is simply activated during hypoxia/ischemia-induced cell injury has been resolved to an 
extent by studies in ischemic models  that  suggest that PKC activity occurs via  PKC  that 
mediates adenosine-induced preconditioning via K+ATP function (Chaudary et al. 2004b; 
Bright et al. 2008). 
Several lines of evidence suggest that PKC can confer cerebral protection partly by 
maintaining mitochondrial function via ERK activity and by modulating adenosine-induced 
mK+ATP channel function. It is also possible that PKC activity inside the mitochondria may 
facilitate the regulation of mK+ATP channels, which is important for defending mitochondrial 
membrane potential and robust maintenance of ionic homeostasis. Recently, the role of 
PKC as a key mediator of neuroprotection was investigated (Teshima et al. 2003). Finding 
from this study  indicates that epsilonPKC inhibits both Na(+)/K(+)-ATPase and voltage-
gated sodium channels, which are primary mediators of the collapse of ion homeostasis 
during ischemia in Arctic Ground Squirrel. Their results support the hypothesis that PKC 
activation is neuroprotective by delaying the collapse of ion homeostasis during ischemia or 
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hypoxia neuroprotection, adaption to anoxia (an extreme form of hypoxia) is mainly 
controlled by hypoxia/ischemic conditioning mechanism(Liu et al. 1991). In addition, the 
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ischemic/anoxia insult is induced sometime before a lethal ischemic/anoxia insult is 
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better understanding of the mechanisms that induce extreme tolerance to hypoxia in turtles 
may provide novel therapeutic interventions that may aide human brain to resist the 
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oxygen supply and consumption. This is  usually accompanied by transportation of  
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autocrine signal that indicates the disproportion between cellular oxygen availability and 
oxygen usage. Since adenosine is also an essential component of ATP synthesis, adenosine 
pools need to be vigilantly sustained in metabolically active cells in the brain. This could be 
done by minimizing extracellular release of adenosine, first by down-regulation of ENT 
activity. This would  aid the restoration of  ATP pools once the hypoxic stress has been 
removed. It is also important to point out that an ENT activity could lead to reuptake of 
extracellular adenosine to terminate receptor activation, as uniquely done by the 
neurotransmitter transporters to help restore intracellular pools of adenosine. The precise 
nature of the relationship between adenosine transporters, adenosine receptors and 
intracellular signaling pathways is not well known. Hypoxia is known to regulate the 
adenosine transporter mENT1 (inhibitor-sensitive), and protein kinase c q (PKCq) is 
involved in regulation of mENT1(Chaudary et al. 2004a), suggesting that chronic hypoxia 
regulates ENT1, both in terms of protein and overall reactivity through PKC-mediated 
hypoxia preconditioning. 
The PKC-mediated hypoxia protection occurs when extracellular adenosine interacts with 
adenosine receptors (A1, A2A, A2B, and/or A3), and activation of adenosine receptors 
stimulate signaling pathways that "resist" the stress caused by hypoxia (David et al. 2002). It 
then implies that the onset of hypoxia leads to a decrease in cellular ATP stores and 
subsequent generation of adenosine, which is then released extracellularly. An increase in 
adenosine levels, in addition to bradykinin and opioids, initiate a series of intracellular 
signaling events via G-protein-coupled receptor signaling leading to activation of PKC 
activation (Di-Capua et al. 2003). Several studies have shown that injections of adenosine 
could protect neuronal cells against hypoxic-type injury via a PKC-mediated mechanism 
(Dave et al. 2009). A series of intracellular signaling that leads to the adenosine-mediated 
PKC-induced mechanism of hypoxia protection include; i) adenosine stimulates G-protein–
coupled receptors, such as the A1/A3 adenosine receptors which activate phospholipases 
(phospholipase C; PLC) via G-proteins (Gi/o). ii) Other preconditioning stimulus, such as 
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extracellular glutamate stimulates NMDARs, leading to increased cytosolic calcium and 
PLC activation. iii) PKC is activated by PLC, and it increases di-acylglycerol (DAG) 
production, which in turn activates PKC isozymes including PKC. Finally, the PKC 
activation of extracellular signal-regulated kinase (ERK) promotes survival. Neuronal 
survival occurs because PKC may induce the opening of K (ATP) channels in the 
mitochondria (KATP) to regulate ATP production, and reduce generation of ROS. 
Interestingly, mitochondria are ideally located to serve as the cellular oxygen signal and 
mediator of protective mechanisms, such as ion channel arrest. Thus, regulation of 
mitochondria based mechanism of ion channel arrest involving ATP-sensitive mitochondrial 
K(+) channels, cytosolic calcium and ROS concentrations could contribute to neuronal 
survival. 
It is also very important to point out that adenosine-mediated PKC  signaling is mediated 
in part through ERK, a mitogen-activated protein kinase (MAPK) family member that has 
been implicated in antiapoptotic signaling(Lange-Asschenfeldt et al. 2004). ERK maintains 
mitochondrial function by inhibiting deleterious Bcl-2 associated death domain protein BAD 
activity(Qiu et al. 2001).Taken together, adenosine-mediated PKC signaling seems to 
activate ERK. This activation is involved in antiapoptotic signaling and cell survival during 
the induction of hypoxia preconditioning state, in order  to salvage ‘at-risk-tissue’ with 
residual energy levels. The role of adenosine-mediated PKC signaling in altering the 
expression or activity of calcium/calmodulin-dependent protein kinase II, MAPK family 
members, c-Jun N-terminal kinase, ERK, protein kinase B and PKC indicates that multiple 
kinases participate in the response of the tissue to counteract the effect of hypoxia (Obexer et 
al. 2006). This is important because PKC activity has been implicated in cell injury in the 
cerebral brain  (Bright et al. 2008)indicating that it could be involved in a conserved hypoxia 
response pathway. εPKC activation delays the collapse of ion homeostasis during ischemia 
in arctic ground squirrels(Dave et al. 2009). This finding suggests that εPKC mediates 26 
collapse of ion homeostasis in Arctic Ground Squirrels. This is possible  because εPKC 
inhibits both 27 Na(+)/K(+)-ATPase and voltage-gated sodium channels, which are primary 
mediators of 28 the collapse of ion homeostasis during ischemia in Arctic Ground Squirrel 
(Perez-Pinzon et 29 al. 2005). For this reason, the specific role of PKC in mediating 
hypoxia/ischemia-induced brain injury following the onset of stroke will be an interesting 
area of attention. Even more interesting is that the controversy  over whether  PKC mediates 
or is simply activated during hypoxia/ischemia-induced cell injury has been resolved to an 
extent by studies in ischemic models  that  suggest that PKC activity occurs via  PKC  that 
mediates adenosine-induced preconditioning via K+ATP function (Chaudary et al. 2004b; 
Bright et al. 2008). 
Several lines of evidence suggest that PKC can confer cerebral protection partly by 
maintaining mitochondrial function via ERK activity and by modulating adenosine-induced 
mK+ATP channel function. It is also possible that PKC activity inside the mitochondria may 
facilitate the regulation of mK+ATP channels, which is important for defending mitochondrial 
membrane potential and robust maintenance of ionic homeostasis. Recently, the role of 
PKC as a key mediator of neuroprotection was investigated (Teshima et al. 2003). Finding 
from this study  indicates that epsilonPKC inhibits both Na(+)/K(+)-ATPase and voltage-
gated sodium channels, which are primary mediators of the collapse of ion homeostasis 
during ischemia in Arctic Ground Squirrel. Their results support the hypothesis that PKC 
activation is neuroprotective by delaying the collapse of ion homeostasis during ischemia or 
 
Brain Injury – Pathogenesis, Monitoring, Recovery and Management 334 
hypoxia. This probably involves robust maintenance of ion homeostasis, which leads to the 
conservation of energy by  plummeting calcium influx during metabolic challenges. In 
summary, studies exploring the specific signaling pathways in which PKC participates, 
including different downstream effectors in different phases of stroke injury will be 
significant to develop an adenosine-mediated PKC signaling therapeutic strategy for the 
clinical management of stroke patients. It is also important to emphasize that continuous 
cerebral blood flow, maintenance of cerebral oxygen tension and normal mitochondrial 
function are vital for the maintenance of brain function and tissue viability in the face of 
chronic hypoxia. The maintenance of normal brain functions require many parameters to 
work together and contribute to the homeostasis of brain energy demand and supply. Such 
a combination of parameters that could, in turn, lead to hypoxia protection include 
regulation of levels of inducible nitric oxide synthase (Thompson and Dong 2005; Thompson 
et al. 2009)and expression of HIF-1a(Trollmann and Gassmann 2009). Other parameters 
include the  activation of extracellular-signal-regulated kinase(Osorio-Fuentealba et al. 2009; 
Wilkerson and Mitchell 2009)and c-Jun N-terminal kinase/stress-activated protein kinases 
(Comerford et al. 2004). Understanding the central mechanism that regulates the 
combination of the parameters is necessary when developing new approaches to remedying 
hypoxia-induced brain injuries. This is because there is the possibility that a single central 
cellular mechanism could invoke a combination of parameters that could lead to the 
remarkable tolerance to hypoxia as seen in natural genetic models of hypoxia-tolerance. 
7. Conclusion 
Physiological mechanisms of hypoxia neuroprotection in natural systems of hypoxia 
tolerance represent the core of our understanding of how the brain of a stroke patient can be 
made to resist hypoxic insults. Our understanding of physiological adaptations associated 
with hypoxia tolerance in natural systems, and the diverse cellular implications of 
disrupting brain energy balance when oxygen delivery fails to meet demand provide the 
insights of how the human brain can be made tolerant to hypoxia. In this review, we suggest 
that the physiological mechanisms used by hypoxia-tolerant species offer clues on strategies 
to adapt for the clinical management of brain injuries where oxygen demand fails to match 
the supply.  
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cellular mechanism could invoke a combination of parameters that could lead to the 
remarkable tolerance to hypoxia as seen in natural genetic models of hypoxia-tolerance. 
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1. Introduction 
Management of the multiply injured trauma patient can be defined by its complex nature 
and the necessity to reconcile multiple competing clinical priorities. Approach to single 
anatomic region/organ system traumatic injury tends to be relatively straight forward, 
although increasing severity of any isolated injury can by itself pose a formidable 
therapeutic challenge. In fact, any such “isolated” injury can be life threatening if severe 
enough and/or not managed optimally.  
When the effects of simultaneous injuries to different anatomic regions and organ systems 
are combined, the cumulative complexity of trauma management can increase 
dramatically.1 This chapter discusses clinical approaches to patients with traumatic brain 
injury in the context of multiple simultaneous associated injuries, focusing on addressing 
competing priorities and triage strategies needed to successfully manage these patients. 
2. Team management and leadership 
Effective diagnostic and therapeutic approaches to the multiply injured patient require the 
presence of well-functioning trauma systems and integrated specialty teams.2 The optimal 
approach to the multiply injured patient involves the involvement of trauma-trained 
surgeons, intensivists, orthopedic specialists, urologists, neurosurgeons, and interventional 
radiologists.3, 4 Highly skilled team management, leadership, and communication skills are 
of critical importance.4 Excellent communication between physicians and teams, including 
awareness of important clinical pitfalls and constant vigilance on the part of all participating 
teams (i.e., presence of multiple cross-checks), as well as the need for centralized care 
planning (including multi-disciplinary patient care conferences) are crucial.5 
3. Physiologic and outcome considerations 
Restoration and maintenance of homeostasis is critical in management of the multiply 
injured patient. This often formidable task requires the achievement of a delicate balance 
between satisfying individual organ-system physiologic needs while reconciling the 
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frequent necessity for micro-management of often competing specific organ- or body 
system-oriented considerations (i.e., maintenance of relatively lower blood pressure levels in 
a patient with concomitant aortic and brain injury versus maintenance of higher blood 
pressures to ensure adequate brain perfusion). The critical nature of clinical decision making 
is exemplified by the finding that morbidity and mortality in head injured patients can as 
much as triple in the presence of hypotension.6 Additionally, when matched for injury 
severity and age, multiply injured patients with brain trauma have a significantly worse 
long term outcomes compared to multiply injured patients without brain trauma.1,2  
Early predictors of outcome from traumatic brain injury (TBI) include age, Glasgow Coma 
Scale, pupillary exam, computed tomographic (CT) characteristics, and the presence of 
hypotension (systolic blood pressure <90 mmHg).7 The key consideration is to maintain 
homeostasis and to triage clinical management in a manner that optimizes recovery of all 
affected organ systems. This involves the need for intimate knowledge of individual organ 
system tolerance limits, the knowledge of common clinical management pitfalls, as well as 
familiarity with temporal evolution of injuries and injury patterns in the context of 
overlapping priorities and biomedical parameter ranges.  
The overarching goal is to prevent the so-called “secondary hits” that have been shown to 
adversely affect outcomes.2 These secondary insults, in contrast to the primary trauma, are 
amenable to prevention and may be reversible if detected and managed promptly.8 As many 
as 40% of patients with TBI exhibit some form of significant neurologic deterioration during 
their hospital stay, most often from secondary insults.3  Significant proportion of patients 
with traumatic brain injury are initially lucid after injury but deteriorate quickly. Therefore, 
practitioners should always have a high index of suspicion and should avoid potentially 
dangerous clinical assumptions (i.e., assuming acute intoxication) when approaching 
patients with possible TBI. One must remember that nearly one-third of all head injured 
patients who die may belong in this category9, and up to 75% of these have an identifiable 
and avoidable secondary insult.10  Hypotension accompanies severe head trauma in 
approximately 35% of cases and entails a near doubling of mortality (from 27% to 50%).10 
Hypotension in the setting of hemorrhagic shock is also associated with increased mortality. 
A hematocrit of less than 30% may be associated with a reduction in blood oxygen carrying 
capacity and potential worsening of cerebral ischemia. Acute anemia associated with head 
injuries has been cited to carry an associated mortality of 52%.10 Despite that, universal 
blood transfusion triggers continue to be controversial, and there is evidence to suggest that 
“dosing” blood by unit(s) as opposed to absolute hematocrit targets may be more prudent in 
the context of brain tissue oxygenation.11-13 The age of the transfused blood may also be an 
important consideration, with more favorable cerebral oxygenation responses seen 
following transfusions of blood stored for fewer than 19 days.11      
Therapy directed at correcting hypovolemic shock includes prompt volume expansion with 
crystalloid solutions, followed by administration of blood products as per established 
trauma guidelines. It is hypothesized that, following traumatic brain injury, cerebrovascular 
dysfunction results in loss of brain compliance, resulting in increased sensitivity to elevated 
venous pressures. Increased central venous pressure (CVP) occurring with vigorous 
crystalloid resuscitation may therefore contribute to the loss of brain compliance and the 
development of intracranial hypertension.14  Cerebral perfusion pressure (CPP), defined as 
the difference between mean arterial pressure (MAP) and intracranial pressure (ICP) is an 
important factor in determining the adequacy of cerebral blood flow. Cerebrovascular 
autoregulation, present in the uninjured brain, is lost when the CPP falls below 50 mmHg.15  
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Xenon 133 scanning to measure cerebral blood flow in brain injured patients found that 
cerebrovascular dysfunction and global cerebral ischemia was seen in 13% of patients with a 
GCS of 8 or less, and of these patients 63% were in a persistent vegetative state or died.16 In 
some cases, patients with spinal cord injury may exhibit hypotension secondary to 
dysfunction of the sympathetic nervous system and loss of peripheral vascular tone, an 
important consideration due to the association between the relatively frequent co-
occurrence of TBI and spinal injury.17, 18   
4. Overview of injury mechanisms and related considerations 
Blunt trauma is associated with some form of brain injury in as many as 40-50% of 
patients.19, 20 Among those with TBI, the incidence of associated injuries can exceed 60%.19  
Moreover, the very presence of TBI and an associated injury approximately doubles the 
mortality (from ~10% to ~20%) when compared to TBI alone.19 In patients with a GCS of less 
than 8, mortality is as high as 45%.  In terms of the components of the GCS scale, a motor 
score of 2 or less was associated with the lowest survival.5  Certain associated injuries, when 
combined with TBI carry an especially high mortality, including great vessel (50% 
mortality), liver (39%), bowel (37%), spleen (34%), lung (34%), spine (26-32%), and various 
skeletal injuries (18-29%).21 Of note, many of these “high mortality” concurrent injuries tend 
to be associated with either blood loss and hemorrhage (i.e., femur fracture, splenic/hepatic 
laceration) or hypoxia (i.e., pulmonary injury). 
5. Concurrent spinal injury 
Spinal injuries and TBI frequently occur together. Combination of TBI and spinal injury 
without neurologic deficit carries an approximate mortality of 25%, which increases to 
about 33% when neurologic deficit is present.21 In addition to a defined set of priorities 
associated with the management of TBI, the trauma practitioner must be aware of 
important considerations unique to the setting of spinal injury. The overarching 
consideration is the avoidance of secondary injury by preventing both hypotension and 
hypoxia.8 This spans an entire spectrum of preventive measures, including adequate 
spinal immobilization with spinal precautions, avoidance of excessive manipulation 
during patient transfers and procedures (i.e., endotracheal intubation), and provision of 
adequate cardio-respiratory support. Patients with spinal cord injuries (SCI) may be at 
increased risk of respiratory failure due to diaphragmatic and/or intercostal muscle 
dysfunction, depending on the level of SCI.22 The most common causes of spinal cord 
injuries are motor vehicle crashes (48%), falls (21%), assaults (15%) and sports-related 
accidents (14%).4 It is imperative that the practitioner be aware of the possibility of spinal 
cord injury in the multiply injured patient. Of all trauma patients that die within the first 
30 minutes after injury, 20-25% have a cervical SCI.6 
A distinct set of complicating factors can be brought about by hemodynamic derangements 
associated with spinal cord injury. Included are factors such as hypotension requiring 
vasopressor administration, bradycardia requiring pharmacologic and/or procedural 
intervention, patient positioning restrictions, as well as inability to perform a reliable injury 
assessment below the level of neurologic injury associated with spinal cord disruption. 
Cervical SCI may cause profound changes in heart rate and rhythm, blood pressure, and 
cardiac output. Patients may exhibit hypotension secondary to dysfunction of the 
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sympathetic nervous system and loss of peripheral vascular tone.17 Patients with high 
cervical SCI (levels C1-C5) have significantly higher requirements for cardiovascular 
intervention (i.e., need for of vasoactive agents or assistive device use) than patients with 
lower injuries (levels C6-C7).17 Shortly after spinal cord injury (seconds to minutes) there 
may be a systemic pressor response characterized by widened pulse pressure that results 
from short-term outflow of sympathetic activity and adrenal hormones.23 This pressor 
response is then quickly replaced by neurogenic shock characterized by bradycardia and 
hypotension.24  In order to maintain proper systemic tissue perfusion, affected patients 
commonly require fluid resuscitation, supplemented by administration of vasoactive agents 
(if patient remains hypotensive despite adequate fluid resuscitation). Because patients with 
high spinal cord injuries are more susceptible to developing pulmonary edema, it is 
important to limit the amount of fluid resuscitation while maintaining a systolic blood 
pressure of 100-110 mmHg.8  
Ventilatory management strategies for patients with diaphragm dysfunction differ from 
those used in cases without muscular functional deficits. With injuries involving spinal 
segments of T1 or higher, the intercostal muscles, important in expanding the anterior-
posterior dimension of the thoracic cavity, are flaccid. With higher injuries of the cervical 
spine, the diaphragm itself may become paralyzed.  This results in a paradoxic inward 
movement of the abdominal wall during inspiration.25 Pulmonary capacity is further 
reduced while the patient is supine. Because of the weakened diaphragm, the abdominal 
contents push cephalad.26 Initial respiratory management is aimed at providing adequate 
ventilatory support while reducing ventilator associated complications.   
6. Concurrent chest injury 
The simultaneous presence of TBI and chest injury involves a distinct set of clinical 
circumstances and considerations. Life-threatening pulmonary injuries may require 
aggressive ventilatory approaches, and when considered in the context of TBI, may 
predispose the patient to both systemic and brain hypoxia. Pericardial tamponade and 
tension pneumo- and/or hemothorax also represent a life threat by causing hypotension 
and brain hypoperfusion. In addition, traumatic aortic injury may impose a unique set of 
hemodynamic restrictions with regards to maintenance of narrow blood pressure and heart 
rate ranges.27  For a given mean arterial pressure, any rise in ICP results in a decrease in 
CPP. In order to maintain adequate cerebral perfusion, CPP should be maintained around 
60-70 mmHg.   
One special consideration specific to the patient with TBI is the entity of acute lung injury 
(ALI) associated with isolated brain trauma.28 This clinico-pathologic entity may not be 
associated with traumatic pulmonary injury per se. Instead, it may be more closely reflective 
of the global increase in TBI severity (i.e., the presence of a large mass lesion or midline shift 
on imaging is associated with 5-10 fold increase in risk of ALI).28 
In addition to ALI, patients with severe brain injury can develop neurogenic pulmonary 
edema (NPE), which is defined as increased interstitial or alveolar lung water occurring in 
the absence of cardiac or pulmonary disorders or hypervolemia.29 The disease process is 
characterized by alveolar hemorrhage, pulmonary vascular congestion, and the presence of 
protein rich exudate.30 Comparatively, the incidence of NPE following severe head injury 
(20%) is similar to the incidence of NPE in subarachonoid hemorrhage (23%).9  NPE can 
present within minutes to hours of the insult and usually resolves by 72 hours.  Significant 
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pulmonary edema past this time point suggests another diagnosis. During the injury there is 
a sympathetic discharge that causes increases in arterial and venous pressures and 
subsequent vascular damage. This damage is thought to result in vascular extravasation and 
the development of NPE. In animal models NPE is most reproducible with insults to the 
nucleus tractus solitarius or the noradrenergic A1 cell group.31 Interestingly, the exudate 
seen in NPE has a much higher protein content than that seen in cardiogenic pulmonary 
edema, supporting a distinct physiologic process.32   
7. Concurrent abdominal injury 
Traumatic abdominal injuries are among the most lethal overall, with intra-abdominal 
and pelvic hemorrhage continuing to be associated with significant morbidity and 
mortality. This section will discuss diagnostic and therapeutic approaches needed to 
effectively manage concurrent abdominal and traumatic brain injuries. Included in the 
discussion is the management of the abdominal compartment syndrome and the damage 
control approach to severe abdominal trauma. At times, increasing ICP may be noted in 
patients with TBI and significant abdominal injury. In highly select cases, the correct 
diagnosis and surgical decompression of the abdominal compartment syndrome (ACS) 
may improve intracranial hypertension that is otherwise unresponsive to traditional 
medical therapy.33   
It is not uncommon for the brain injured patient to have simultaneous abdominal injury, 
especially in the setting of blunt polytrauma. In this case, the presence of intra-abdominal 
hypertension (IAH) can exacerbate elevations in ICP. Thus, the presence of IAH is an 
independent risk factor for secondary brain injury.34  The increase in intraabdominal 
pressure is directly reflected in intrathoracic pressure and central venous pressure.  
Elevations in central venous and jugular venous pressures result in increased resistance to 
cerebral outflow, which causes an increase in ICP and decrease in CPP.35 Animal 
experiments have demonstrated that IAH of >20 mmHg causes significant increases in ICP 
and decreases in CPP. Additionally, elevations in CSF lactate and interleukin-6 were also 
seen, suggesting the associated presence of cerebral ischemia.36 
Treatment for refractory ICP elevations in the setting of IAH involves several modalities 
including neuromuscular blockade, vasopressor use to preserve CPP, and abdominal 
compartment release.37 In the setting of new onset end-organ dysfunction (i.e., renal failure, 
worsening pulmonary dysfunction) many physicians would advocate abdominal fascial 
release (a.k.a., abdominal damage control).38 Several authors advocate more liberal use of 
decompressive laparotomy, extending this paradigm to patients with refractory elevations 
in ICP without intra-abdominal hypertension.  In a group of 17 poly-trauma patients with 
refractory increases in ICP, decompressive laparotomy resulted in significant ICP reductions 
from 30.0±4.0 to 17.5±3.2 mmHg.39 
Occasionally, emergent laparotomy and abdominal damage control may be coupled with 
damage control neurosurgery (DCNS) in the acute setting. Initial neurosurgical 
interventions include arrest of intracranial bleeding followed by evacuation of 
hematoma/mass lesion. Therapeutic craniectomy appears beneficial in children with diffuse 
brain edema.40 However, DCNS can not be fully recommended in adults until the ICP 
becomes uncontrolled despite optimal medical therapy.41, 42  
Stopping non-cranial hemorrhage is critical in the overall management of the multiply 
injured patient with brain trauma. Continued emphasis on team work and close 
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aggressive ventilatory approaches, and when considered in the context of TBI, may 
predispose the patient to both systemic and brain hypoxia. Pericardial tamponade and 
tension pneumo- and/or hemothorax also represent a life threat by causing hypotension 
and brain hypoperfusion. In addition, traumatic aortic injury may impose a unique set of 
hemodynamic restrictions with regards to maintenance of narrow blood pressure and heart 
rate ranges.27  For a given mean arterial pressure, any rise in ICP results in a decrease in 
CPP. In order to maintain adequate cerebral perfusion, CPP should be maintained around 
60-70 mmHg.   
One special consideration specific to the patient with TBI is the entity of acute lung injury 
(ALI) associated with isolated brain trauma.28 This clinico-pathologic entity may not be 
associated with traumatic pulmonary injury per se. Instead, it may be more closely reflective 
of the global increase in TBI severity (i.e., the presence of a large mass lesion or midline shift 
on imaging is associated with 5-10 fold increase in risk of ALI).28 
In addition to ALI, patients with severe brain injury can develop neurogenic pulmonary 
edema (NPE), which is defined as increased interstitial or alveolar lung water occurring in 
the absence of cardiac or pulmonary disorders or hypervolemia.29 The disease process is 
characterized by alveolar hemorrhage, pulmonary vascular congestion, and the presence of 
protein rich exudate.30 Comparatively, the incidence of NPE following severe head injury 
(20%) is similar to the incidence of NPE in subarachonoid hemorrhage (23%).9  NPE can 
present within minutes to hours of the insult and usually resolves by 72 hours.  Significant 
 
Competing Priorities in the Brain Injured Patient: Dealing with the Unexpected 
 
345 
pulmonary edema past this time point suggests another diagnosis. During the injury there is 
a sympathetic discharge that causes increases in arterial and venous pressures and 
subsequent vascular damage. This damage is thought to result in vascular extravasation and 
the development of NPE. In animal models NPE is most reproducible with insults to the 
nucleus tractus solitarius or the noradrenergic A1 cell group.31 Interestingly, the exudate 
seen in NPE has a much higher protein content than that seen in cardiogenic pulmonary 
edema, supporting a distinct physiologic process.32   
7. Concurrent abdominal injury 
Traumatic abdominal injuries are among the most lethal overall, with intra-abdominal 
and pelvic hemorrhage continuing to be associated with significant morbidity and 
mortality. This section will discuss diagnostic and therapeutic approaches needed to 
effectively manage concurrent abdominal and traumatic brain injuries. Included in the 
discussion is the management of the abdominal compartment syndrome and the damage 
control approach to severe abdominal trauma. At times, increasing ICP may be noted in 
patients with TBI and significant abdominal injury. In highly select cases, the correct 
diagnosis and surgical decompression of the abdominal compartment syndrome (ACS) 
may improve intracranial hypertension that is otherwise unresponsive to traditional 
medical therapy.33   
It is not uncommon for the brain injured patient to have simultaneous abdominal injury, 
especially in the setting of blunt polytrauma. In this case, the presence of intra-abdominal 
hypertension (IAH) can exacerbate elevations in ICP. Thus, the presence of IAH is an 
independent risk factor for secondary brain injury.34  The increase in intraabdominal 
pressure is directly reflected in intrathoracic pressure and central venous pressure.  
Elevations in central venous and jugular venous pressures result in increased resistance to 
cerebral outflow, which causes an increase in ICP and decrease in CPP.35 Animal 
experiments have demonstrated that IAH of >20 mmHg causes significant increases in ICP 
and decreases in CPP. Additionally, elevations in CSF lactate and interleukin-6 were also 
seen, suggesting the associated presence of cerebral ischemia.36 
Treatment for refractory ICP elevations in the setting of IAH involves several modalities 
including neuromuscular blockade, vasopressor use to preserve CPP, and abdominal 
compartment release.37 In the setting of new onset end-organ dysfunction (i.e., renal failure, 
worsening pulmonary dysfunction) many physicians would advocate abdominal fascial 
release (a.k.a., abdominal damage control).38 Several authors advocate more liberal use of 
decompressive laparotomy, extending this paradigm to patients with refractory elevations 
in ICP without intra-abdominal hypertension.  In a group of 17 poly-trauma patients with 
refractory increases in ICP, decompressive laparotomy resulted in significant ICP reductions 
from 30.0±4.0 to 17.5±3.2 mmHg.39 
Occasionally, emergent laparotomy and abdominal damage control may be coupled with 
damage control neurosurgery (DCNS) in the acute setting. Initial neurosurgical 
interventions include arrest of intracranial bleeding followed by evacuation of 
hematoma/mass lesion. Therapeutic craniectomy appears beneficial in children with diffuse 
brain edema.40 However, DCNS can not be fully recommended in adults until the ICP 
becomes uncontrolled despite optimal medical therapy.41, 42  
Stopping non-cranial hemorrhage is critical in the overall management of the multiply 
injured patient with brain trauma. Continued emphasis on team work and close 
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collaboration between clinical teams is crucial.43 In the multiply injured patient, an  
ICP monitor (mostly under local anesthesia or during cranitomy) can be inserted in the 
emergency room or in the intensive care unit while the patient is being stabilized.  
At times, ICP monitoring is initiated in tandem with emergency laparotomy, thoracotomy 
or any other life-saving procedures.43 Occasionally, a craniotomy concurrent to  
other operative procedures may be required if the patient has a significant intracranial 
mass lesion and evidence of critical ICP increases on clinical exam. General surgeons  
may have to occasionally perform neurosurgery in remote locations for patients with  
TBI as statistics have shown that early simple interventions have resulted in increased 
rates of survival between 10-50%.44, 45 Simpson et al have recommended evacuation  
of an extradural hematoma by the general surgeon in a remote location if the trauma 
center is >1-2 hours away.44 Rinker et al advise emergency craniotomy if the GCS is  
<8, there are lateralizing signs such as a dilated pupil, hemiparesis or development  
of sustained bradycardia and hypertension.45 Immediate availability of neurosurgeons 
may not be essential if a properly trained and credentialed trauma surgeon  
can appropriately monitor patients for neurologic deterioration and facilitate early 
transfer to a center capable of full-time operative and postoperative neurosurgical  
care.46 In certain extreme situations, the performance of an emergency burr hole may be  
life saving.47       
8. Concurrent skeletal injuries 
Skeletal injuries are associated with a number of unique therapeutic challenges, especially 
when associated with significant blood loss and need for emergent skeletal fixation. This 
section discusses best approaches to deal with brain injured patients who also present with 
fractures, dislocations, and other musculo-skeletal emergencies. Included in the discussion 
is the topic of extremity compartment syndrome.  
The management of skeletal fractures in brain injured patients continues to be a 
controversial topic. A comparison of early (<24 hours) versus late fracture fixation 
demonstrated that early fracture stabilization does not result in increased central nervous 
system complications.48 Same study showed that patients undergoing delayed fixation 
experienced significantly higher pulmonary morbidity.48 Another study showed that lower 
extremity fracture fixation within 24 hours did not entail greater risk for adverse outcomes 
in patients with TBI.49, 50 The authors did emphasize, however, that avoidance of any undue 
hypoxia and hypotension is critical.49, 50 Orthopedic “damage control” strategies have 
evolved in order to assist in early management of skeletal trauma in multiply injured 
patients with TBI who may be unable to tolerate traditional operative approaches or may 
not even be stable enough to leave their intensive care bed.34, 51 
The clinical syndrome of fat embolism can influence the clinical course in the multiply 
injured patient, especially following long bone extremity fracture fixation.52 Although 
early fracture fixation is thought to minimize the risk of this occurrence, some 
experimental studies show that intramedullary nailing of femoral fractures and 
subsequent liberation of bone marrow contents may have a negative influence on the 
central nervous system function.52 
An important aspect of orthopedic care in the multiply injured patient with brain trauma is 
the lack of reliable physical examination. Due to this limitation, extremity compartment 
syndrome may evade timely diagnosis. The reliance on the traditional early clinical signs 
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and symptoms of compartment syndrome – pain on passive motion that is out of proportion 
to clinical findings and the presence of paresthesias – has to be substituted with hightened 
index of clinical suspicion and extremity compartment pressure measurements.53 
Fasciotomies should be performed in a timely fashion when evidence of elevated 
compartment pressures is present.54, 55 
9. Concurrent vascular injury 
Vascular injuries present a special challenge in the context of simultaneous brain trauma. 
Specifically, direct managment priority conflicts can be seen with regards to the need for 
therapeutic anticoagulation and the risk of secondary intracranial hemorrhage. Likewise, the 
maintenance of cerebral perfusion pressure can pose an increased risk in patients with 
concurrent traumatic pseudoaneurysms and other injuries that may necessitate strict blood 
pressure and heart rate control. In addition, high dose vasopressor use to maintain adequate 
cerebral perfusion may lead to distal extremity ischemic complications up to and including 
the need for amputation. 
With ever improving quality of modern imaging modalities, cerebrovascular injuries are 
being detected more frequently. Neurologic assessment following blunt cerebrovascular 
injury can be difficult and distinguishing cerebral ischemia from cerebral infarction is 
often complex, especially in the setting of altered mental status.56 The main challenge 
associated with the diagnosis of blunt carotid or vertebral injury (BCVI) is the relative 
rarity of BCVI and the need for constant vigilance and high index of suspicion. One of the 
most important clinical findings associated with BCVI is the presence of an unexplained 
or new neurologic deficit in the setting of otherwise normal (or unchanged) brain 
imaging. Trauma practitioners should be familiar with major risk factors for BCVI, both 
from the injury mechanism standpoint (i.e., cervical seat belt sign, blunt assault to 
craniofacial area with LeFort III fracture pattern, cervical spine fracture) and from the 
clinical presentation standpoint (i.e., high-speed motor vehicle crash, flexion-extension 
neck injury).57 
10. Missed injuries and diagnostic delays 
Important in the context of multiple trauma patient with concomitant brain injury are the 
concepts of missed injury and delayed diagnosis. Delay in diagnosis occurs when an 
injury is identified after the usually accepted initial phases of trauma evaluation (i.e., 
primary, secondary, or tertiary surveys) but before the injury manifests as an overt clinical 
problem.58 Missed injury can be defined as a delay in diagnosis that is associated  
with clinical symptoms and/or is not identified until after discharge from hospital.58 
Although the incidence goal for missed injuries and diagnostic delays should be “zero”, 
this target remains elusive. Major series cite missed injury rates between 0.5% and  
65%, with anywhere between 1 and 2.3 missed injuries per patient, depending  
on population under study, type of study (prospective versus retrospective), and 
diagnostic definitions (missed injury versus delayed diagnosis).58 Among missed injuries, 
over 10% are clinically significant and, of those, 14% to 50% can be associated directly 
with patient mortality.1, 58, 59  
The importance of this topic to the brain injured trauma population becomes obvious when 
one considers the most common contributing factors to missed injury: (a) altered mental 
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collaboration between clinical teams is crucial.43 In the multiply injured patient, an  
ICP monitor (mostly under local anesthesia or during cranitomy) can be inserted in the 
emergency room or in the intensive care unit while the patient is being stabilized.  
At times, ICP monitoring is initiated in tandem with emergency laparotomy, thoracotomy 
or any other life-saving procedures.43 Occasionally, a craniotomy concurrent to  
other operative procedures may be required if the patient has a significant intracranial 
mass lesion and evidence of critical ICP increases on clinical exam. General surgeons  
may have to occasionally perform neurosurgery in remote locations for patients with  
TBI as statistics have shown that early simple interventions have resulted in increased 
rates of survival between 10-50%.44, 45 Simpson et al have recommended evacuation  
of an extradural hematoma by the general surgeon in a remote location if the trauma 
center is >1-2 hours away.44 Rinker et al advise emergency craniotomy if the GCS is  
<8, there are lateralizing signs such as a dilated pupil, hemiparesis or development  
of sustained bradycardia and hypertension.45 Immediate availability of neurosurgeons 
may not be essential if a properly trained and credentialed trauma surgeon  
can appropriately monitor patients for neurologic deterioration and facilitate early 
transfer to a center capable of full-time operative and postoperative neurosurgical  
care.46 In certain extreme situations, the performance of an emergency burr hole may be  
life saving.47       
8. Concurrent skeletal injuries 
Skeletal injuries are associated with a number of unique therapeutic challenges, especially 
when associated with significant blood loss and need for emergent skeletal fixation. This 
section discusses best approaches to deal with brain injured patients who also present with 
fractures, dislocations, and other musculo-skeletal emergencies. Included in the discussion 
is the topic of extremity compartment syndrome.  
The management of skeletal fractures in brain injured patients continues to be a 
controversial topic. A comparison of early (<24 hours) versus late fracture fixation 
demonstrated that early fracture stabilization does not result in increased central nervous 
system complications.48 Same study showed that patients undergoing delayed fixation 
experienced significantly higher pulmonary morbidity.48 Another study showed that lower 
extremity fracture fixation within 24 hours did not entail greater risk for adverse outcomes 
in patients with TBI.49, 50 The authors did emphasize, however, that avoidance of any undue 
hypoxia and hypotension is critical.49, 50 Orthopedic “damage control” strategies have 
evolved in order to assist in early management of skeletal trauma in multiply injured 
patients with TBI who may be unable to tolerate traditional operative approaches or may 
not even be stable enough to leave their intensive care bed.34, 51 
The clinical syndrome of fat embolism can influence the clinical course in the multiply 
injured patient, especially following long bone extremity fracture fixation.52 Although 
early fracture fixation is thought to minimize the risk of this occurrence, some 
experimental studies show that intramedullary nailing of femoral fractures and 
subsequent liberation of bone marrow contents may have a negative influence on the 
central nervous system function.52 
An important aspect of orthopedic care in the multiply injured patient with brain trauma is 
the lack of reliable physical examination. Due to this limitation, extremity compartment 
syndrome may evade timely diagnosis. The reliance on the traditional early clinical signs 
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and symptoms of compartment syndrome – pain on passive motion that is out of proportion 
to clinical findings and the presence of paresthesias – has to be substituted with hightened 
index of clinical suspicion and extremity compartment pressure measurements.53 
Fasciotomies should be performed in a timely fashion when evidence of elevated 
compartment pressures is present.54, 55 
9. Concurrent vascular injury 
Vascular injuries present a special challenge in the context of simultaneous brain trauma. 
Specifically, direct managment priority conflicts can be seen with regards to the need for 
therapeutic anticoagulation and the risk of secondary intracranial hemorrhage. Likewise, the 
maintenance of cerebral perfusion pressure can pose an increased risk in patients with 
concurrent traumatic pseudoaneurysms and other injuries that may necessitate strict blood 
pressure and heart rate control. In addition, high dose vasopressor use to maintain adequate 
cerebral perfusion may lead to distal extremity ischemic complications up to and including 
the need for amputation. 
With ever improving quality of modern imaging modalities, cerebrovascular injuries are 
being detected more frequently. Neurologic assessment following blunt cerebrovascular 
injury can be difficult and distinguishing cerebral ischemia from cerebral infarction is 
often complex, especially in the setting of altered mental status.56 The main challenge 
associated with the diagnosis of blunt carotid or vertebral injury (BCVI) is the relative 
rarity of BCVI and the need for constant vigilance and high index of suspicion. One of the 
most important clinical findings associated with BCVI is the presence of an unexplained 
or new neurologic deficit in the setting of otherwise normal (or unchanged) brain 
imaging. Trauma practitioners should be familiar with major risk factors for BCVI, both 
from the injury mechanism standpoint (i.e., cervical seat belt sign, blunt assault to 
craniofacial area with LeFort III fracture pattern, cervical spine fracture) and from the 
clinical presentation standpoint (i.e., high-speed motor vehicle crash, flexion-extension 
neck injury).57 
10. Missed injuries and diagnostic delays 
Important in the context of multiple trauma patient with concomitant brain injury are the 
concepts of missed injury and delayed diagnosis. Delay in diagnosis occurs when an 
injury is identified after the usually accepted initial phases of trauma evaluation (i.e., 
primary, secondary, or tertiary surveys) but before the injury manifests as an overt clinical 
problem.58 Missed injury can be defined as a delay in diagnosis that is associated  
with clinical symptoms and/or is not identified until after discharge from hospital.58 
Although the incidence goal for missed injuries and diagnostic delays should be “zero”, 
this target remains elusive. Major series cite missed injury rates between 0.5% and  
65%, with anywhere between 1 and 2.3 missed injuries per patient, depending  
on population under study, type of study (prospective versus retrospective), and 
diagnostic definitions (missed injury versus delayed diagnosis).58 Among missed injuries, 
over 10% are clinically significant and, of those, 14% to 50% can be associated directly 
with patient mortality.1, 58, 59  
The importance of this topic to the brain injured trauma population becomes obvious when 
one considers the most common contributing factors to missed injury: (a) altered mental 
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status; (b) presence of distracting injury; (c) administration of analgesia and sedation; and 
(d) overwhelming or multiple simultaneous injuries.58 Whenever the patient’s sensorium is 
diminished, it becomes more difficult to identify injuries as the patient loses the ability to 
effectively express complaints related to pain and discomfort. Alterations in pain processing 
may occur with traumatic brain injury, spinal cord injury, hypoxia, shock, 
intoxication/substance abuse, and administration of sedation for various reasons (i.e., 
combative patient). The pain response can be altered after a major injury and the patient 
may not be able to process pain from all injuries equally. For example, a non-displaced ankle 
fracture may not be readily evident with a concurrent presence of an open femur fracture. 
Often direct palpation over a specific injury site will elicit a pain response. Therefore, 
comprehensive repetitive physical examinations may be required in order to effectively 
identify the complete injury list in the presence of distracting pain. However, even the most 
detailed physical examination may fail to detect traumatic injuries in the multiply injured 
patient with concomitant moderate to severe brain trauma. Moreover, concurrent 
administration of analgesia and sedation may additionally affect the practitioner’s ability to 
reliably detect various types of injuries, from minor to life threatening.58 It is important to 
note that cranio-facial injuries constitute as many as 5%-30% of missed injuries, depending 
on study cited.1, 59, 60 
11. Pitfalls and controversies 
This section highlights important pitfalls and controversies associated with management of 
the multiply injured patients with concurrent brain trauma. We emphasize the need for 
continuous reassessment of competing priorities and need for centralized team 
coordination. Because many of the topics mentioned are beyond the scope of this chapter, 
the reader is referred to other sources as referenced herein. Practitioners should always be 
aware of potential complications related to massive fluid resuscitation, up to and including 
the abdominal compartment syndrome.61 On the opposite end of the hemodynamic 
spectrum, one should always be cognizant of complications related to use of escalating 
doses of vasoactive agents, including phenomena such as tachyphylaxis 62 and the 
possibility of skin/limb ischemia due to high-dose vasopressor use.63 Although the authors 
encourage the use of advanced hemodynamic monitoring (both invasive and non-invasive), 
there are many potential complications associated with both errors in hemodynamic data 
interpretation and iatrogenic injury related to invasive line placement.64  
Intra-hospital patient transfers (i.e., transport to operating room or imaging suite) carry its 
own set of complications, with serious adverse outcomes attributed to such transfers in over 
30% of critically ill patients.65 Use of any therapies or diagnostic tests that could potentially 
contribute to additional complications should always be considered in the context of risk-
benefit ratio.66 For example, although still controversial, evidence suggests that early use of 
prophylactic anticoagulation is more beneficial than withholding this therapy in the TBI 
population.67, 68  
Additional considerations include the effect of sedative agents on both hemodynamic and 
metabolic aspects of patient management. For example, the use of propofol for sedation may 
be associated with complications such as hypotension 69, pancreatitis 70, and propofol 
infusion syndrome.71 In addition, adjunctive approaches such as therapeutic hypothermia 
and chemically induced coma are mentioned and referenced for the reader.72, 73 These  
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Provider- and Team-related considerations 
 Skilled team management, leadership, and effective communication are of critical 
importance. 
 Coordinated care planning, including multi-disciplinary conferences and open dialogue 
between various clinical specialties, is important to optimizing patient care. 
 Trauma teams should work efficiently, utilizing protocolized care as well as well-
functioning clinical management / surveillance systems. 
 The overall goal of the trauma team is to reconcile conflicting priorities with the overarching 
goal of maximizing the outcome from the perspective of the “whole patient”. 
 
Injury-related considerations 
 Knowledge of injury patterns is useful in determining the likelihood of any potential 
associated non-TBI injuries, especially in the setting of concurrent neurological impairment. 
 The very presence of associated injuries in the setting of concurrent brain trauma is 
associated with significantly increased mortality. Among such associated injuries, those that 
carry highest mortality usually involve risks of hypotension, hemorrhage and/or hypoxia. 
 Familiarity with acceptable physiologic parameter ranges inherent to the management of 
each injured anatomic area or organ system is important to patient care optimization and 
reconciliation of potentially conflicting therapeutic priorities. 
 Non-conventional measures, including various “damage control” approaches permit the 
most critical injuries to be given higher priority while adequately temporizing other, less 
critical injuries. 
 
Patient care-related considerations 
 The overarching goal is to prevent secondary physiologic insults that have been shown to 
adversely affect outcomes. 
 Maintenance of adequate cerebral perfusion pressure while minimizing hypotensive and 
hypoxic events is crucial. It is important to note that while these priorities do not change 
over time, the nature of inciting events may differ (i.e., hemorrhage causing early 
hypotension versus sepsis causing late hypotension). 
 Intra-hospital patient transfers (i.e., for procedural interventions or imaging studies) carry a 
significant risk, with nearly one-third of such transfers associated with some sort of adverse 
event (i.e., hypotension, hypoxia, etc). Therefore, such transfers should be undertaken only 
if absolutely indicated. 
 Lack of reliable physical examination in multiply injured patients with TBI predisposes this 
group to missed injuries and diagnostic delays. Although modern technolgical advances 
enable practitioners to partially “compensate” for the lack of adequate bedside assessment, 




 Use of any therapies or diagnostic tests that carry a defined potential for complications 
should always be considered in the context of careful risk-benefit determination. 
Providers should be familiar with potential complications associated with each and every 
therapeutic agent and procedure. Early recognition of such complications can be life-saving. 
 
Table 1. Important points in management of multiply injured patients with concurrent 
traumatic brain injury 
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status; (b) presence of distracting injury; (c) administration of analgesia and sedation; and 
(d) overwhelming or multiple simultaneous injuries.58 Whenever the patient’s sensorium is 
diminished, it becomes more difficult to identify injuries as the patient loses the ability to 
effectively express complaints related to pain and discomfort. Alterations in pain processing 
may occur with traumatic brain injury, spinal cord injury, hypoxia, shock, 
intoxication/substance abuse, and administration of sedation for various reasons (i.e., 
combative patient). The pain response can be altered after a major injury and the patient 
may not be able to process pain from all injuries equally. For example, a non-displaced ankle 
fracture may not be readily evident with a concurrent presence of an open femur fracture. 
Often direct palpation over a specific injury site will elicit a pain response. Therefore, 
comprehensive repetitive physical examinations may be required in order to effectively 
identify the complete injury list in the presence of distracting pain. However, even the most 
detailed physical examination may fail to detect traumatic injuries in the multiply injured 
patient with concomitant moderate to severe brain trauma. Moreover, concurrent 
administration of analgesia and sedation may additionally affect the practitioner’s ability to 
reliably detect various types of injuries, from minor to life threatening.58 It is important to 
note that cranio-facial injuries constitute as many as 5%-30% of missed injuries, depending 
on study cited.1, 59, 60 
11. Pitfalls and controversies 
This section highlights important pitfalls and controversies associated with management of 
the multiply injured patients with concurrent brain trauma. We emphasize the need for 
continuous reassessment of competing priorities and need for centralized team 
coordination. Because many of the topics mentioned are beyond the scope of this chapter, 
the reader is referred to other sources as referenced herein. Practitioners should always be 
aware of potential complications related to massive fluid resuscitation, up to and including 
the abdominal compartment syndrome.61 On the opposite end of the hemodynamic 
spectrum, one should always be cognizant of complications related to use of escalating 
doses of vasoactive agents, including phenomena such as tachyphylaxis 62 and the 
possibility of skin/limb ischemia due to high-dose vasopressor use.63 Although the authors 
encourage the use of advanced hemodynamic monitoring (both invasive and non-invasive), 
there are many potential complications associated with both errors in hemodynamic data 
interpretation and iatrogenic injury related to invasive line placement.64  
Intra-hospital patient transfers (i.e., transport to operating room or imaging suite) carry its 
own set of complications, with serious adverse outcomes attributed to such transfers in over 
30% of critically ill patients.65 Use of any therapies or diagnostic tests that could potentially 
contribute to additional complications should always be considered in the context of risk-
benefit ratio.66 For example, although still controversial, evidence suggests that early use of 
prophylactic anticoagulation is more beneficial than withholding this therapy in the TBI 
population.67, 68  
Additional considerations include the effect of sedative agents on both hemodynamic and 
metabolic aspects of patient management. For example, the use of propofol for sedation may 
be associated with complications such as hypotension 69, pancreatitis 70, and propofol 
infusion syndrome.71 In addition, adjunctive approaches such as therapeutic hypothermia 
and chemically induced coma are mentioned and referenced for the reader.72, 73 These  
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Provider- and Team-related considerations 
 Skilled team management, leadership, and effective communication are of critical 
importance. 
 Coordinated care planning, including multi-disciplinary conferences and open dialogue 
between various clinical specialties, is important to optimizing patient care. 
 Trauma teams should work efficiently, utilizing protocolized care as well as well-
functioning clinical management / surveillance systems. 
 The overall goal of the trauma team is to reconcile conflicting priorities with the overarching 
goal of maximizing the outcome from the perspective of the “whole patient”. 
 
Injury-related considerations 
 Knowledge of injury patterns is useful in determining the likelihood of any potential 
associated non-TBI injuries, especially in the setting of concurrent neurological impairment. 
 The very presence of associated injuries in the setting of concurrent brain trauma is 
associated with significantly increased mortality. Among such associated injuries, those that 
carry highest mortality usually involve risks of hypotension, hemorrhage and/or hypoxia. 
 Familiarity with acceptable physiologic parameter ranges inherent to the management of 
each injured anatomic area or organ system is important to patient care optimization and 
reconciliation of potentially conflicting therapeutic priorities. 
 Non-conventional measures, including various “damage control” approaches permit the 
most critical injuries to be given higher priority while adequately temporizing other, less 
critical injuries. 
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 The overarching goal is to prevent secondary physiologic insults that have been shown to 
adversely affect outcomes. 
 Maintenance of adequate cerebral perfusion pressure while minimizing hypotensive and 
hypoxic events is crucial. It is important to note that while these priorities do not change 
over time, the nature of inciting events may differ (i.e., hemorrhage causing early 
hypotension versus sepsis causing late hypotension). 
 Intra-hospital patient transfers (i.e., for procedural interventions or imaging studies) carry a 
significant risk, with nearly one-third of such transfers associated with some sort of adverse 
event (i.e., hypotension, hypoxia, etc). Therefore, such transfers should be undertaken only 
if absolutely indicated. 
 Lack of reliable physical examination in multiply injured patients with TBI predisposes this 
group to missed injuries and diagnostic delays. Although modern technolgical advances 
enable practitioners to partially “compensate” for the lack of adequate bedside assessment, 
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therapeutic agent and procedure. Early recognition of such complications can be life-saving. 
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therapies are still controversial and further research is needed to better define their safety 
profiles and risk-benefit characteristics, especially in the setting of multiple trauma and 
competing clinical priorities. 
12. The multiply injured patient with TBI – Putting it all together 
Management of the multiply injured patient with TBI involves close collaboration of 
multiple specialties, including critical care, neurosurgery, orthopedic, and trauma experts. 
Practitioners must always be aware of all competing priorities, including cross-specialty 
considerations for specific injury patterns and associated pitfalls and complications. Life-
threatening injuries should be approached according to the magnitude of the most 
immediate mortality risk. At times, simultaneous management of multiple injuries may 
require the initiation of various “damage control” techniques. Complications related to 
the primary injuries as well as any secondary insults must be recognized and addressed 
promptly. Early rehabilitation is crucial in order to optimize long-term outcomes in this 
population. The achievement of these goals requires that trauma teams work efficiently, 
utilizing protocolized care and well-functioning clinical surveillance systems.74, 75 The 
overall goal of the trauma healthcare team is to reconcile any conflicting priorities with 
the goal of maximizing the outcome from the perspective of the “whole patient”. 
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therapies are still controversial and further research is needed to better define their safety 
profiles and risk-benefit characteristics, especially in the setting of multiple trauma and 
competing clinical priorities. 
12. The multiply injured patient with TBI – Putting it all together 
Management of the multiply injured patient with TBI involves close collaboration of 
multiple specialties, including critical care, neurosurgery, orthopedic, and trauma experts. 
Practitioners must always be aware of all competing priorities, including cross-specialty 
considerations for specific injury patterns and associated pitfalls and complications. Life-
threatening injuries should be approached according to the magnitude of the most 
immediate mortality risk. At times, simultaneous management of multiple injuries may 
require the initiation of various “damage control” techniques. Complications related to 
the primary injuries as well as any secondary insults must be recognized and addressed 
promptly. Early rehabilitation is crucial in order to optimize long-term outcomes in this 
population. The achievement of these goals requires that trauma teams work efficiently, 
utilizing protocolized care and well-functioning clinical surveillance systems.74, 75 The 
overall goal of the trauma healthcare team is to reconcile any conflicting priorities with 
the goal of maximizing the outcome from the perspective of the “whole patient”. 
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1. Introduction 
Traumatic brain injury (TBI) is a spectrum of pathological changes in the brain that result 
from application of external mechanical force(s) leading to temporary or permanent 
impairment of neurological function. TBI is a global health problem. In 1990, 9.5 million 
individuals worldwide sustained a TBI severe enough to warrant medical attention or result 
in death (Corrigan, Selassie, & Orman 2010). In the United States, the annual incidence of 
TBI is 506.4 per 100,000 population (Langlois JA 2006), in Europe it is 235 per 100,000 
population (Tagliaferri et al. 2006), and in Asia it is reported to range from 160 (Gururaj G 
2004) to 344 (Chiu et al. 1997) per 100,000 population (incidence rate from United States is 
inclusive of emergency department visits, hospital discharges and deaths, incidence rates 
from Europe and Asia are inclusive of hospital discharges and deaths only). Severe TBI has 
long term consequences for the individual and the society. In the United States, it is 
estimated that annually 43.1% (124,000) of the individuals discharged after acute 
hospitalization for TBI (Selassie et al. 2008) develop long term disability. The prevalence of 
individuals in the United States with disability secondary to TBI is estimated to be 3.2 
million (Zaloshnja et al. 2008). The total life time cost of treating TBI cases in the United 
States, including loss of productivity, is estimated to be $ 60.4 billion for the year 2000 
(Corrigan, Selassie, & Orman 2010).The enormous economic and social burden imposed by 
TBI demands aggressive measures to prevent and treat TBI.  
Technological developments and better understanding of brain physiology have resulted in 
a dramatic improvement in mortality related to TBI. Mortality rates declined precipitously 
between 1970 and 1990, likely related to the routine use of computed tomography (CT) scans 
and intracranial pressure (ICP) monitoring, as well as improvement in trauma resuscitation 
generally. However, despite more recent advances in neuromonitoring and neuroimaging, 
mortality has remained steady at approximately 35% since the 1990s (Stein et al. 2010). The 
reasons for this lack of progress are multifactorial; no doubt the increase in severe TBI 
among the elderly is a contributing factor (Colantonio et al. 2008). Nevertheless, the field of 
neurotrauma has suffered from the lack of well organized multicenter, randomized clinical 
trials designed to assess the efficacy of the newer techniques and interventions for the 
management of TBI. Efforts to design and conduct clinical trials in TBI have been 
challenging for many reasons including the heterogeneity of the disease, barriers to 
recruitment, and lack of standardized management protocols across centers (Narayan et al. 
2002). This chapter presents an overview of the pathophysiology and basic principals of 
management of TBI, and the challenges facing the scientific community in dealing with this 
debilitating disorder. 
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1. Introduction 
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TBI demands aggressive measures to prevent and treat TBI.  
Technological developments and better understanding of brain physiology have resulted in 
a dramatic improvement in mortality related to TBI. Mortality rates declined precipitously 
between 1970 and 1990, likely related to the routine use of computed tomography (CT) scans 
and intracranial pressure (ICP) monitoring, as well as improvement in trauma resuscitation 
generally. However, despite more recent advances in neuromonitoring and neuroimaging, 
mortality has remained steady at approximately 35% since the 1990s (Stein et al. 2010). The 
reasons for this lack of progress are multifactorial; no doubt the increase in severe TBI 
among the elderly is a contributing factor (Colantonio et al. 2008). Nevertheless, the field of 
neurotrauma has suffered from the lack of well organized multicenter, randomized clinical 
trials designed to assess the efficacy of the newer techniques and interventions for the 
management of TBI. Efforts to design and conduct clinical trials in TBI have been 
challenging for many reasons including the heterogeneity of the disease, barriers to 
recruitment, and lack of standardized management protocols across centers (Narayan et al. 
2002). This chapter presents an overview of the pathophysiology and basic principals of 
management of TBI, and the challenges facing the scientific community in dealing with this 
debilitating disorder. 
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2. Mechanism  
TBI results from the application of external force to cranium and its contents. The severity of 
injury is determined by the nature, magnitude and duration of load applied to cranium and 
the force vector (rotational, translational or angular) (Gennarelli 1993). Force applied to 
cranium can be static (delivered over more than 200 milliseconds) or dynamic (delivered 
over less than 200 milliseconds). Static loading is a less common cause of TBI in clinical 
situations, and usually leads to focal brain damage. Dynamic loading is a more common 
cause of TBI, and produces more complex and widespread brain damage. Dynamic loading 
itself results from direct blow to the cranium (contact load), or rapid acceleration or 
deceleration of the cranium (inertial load) that causes differential motion of the brain 
relative to the skull. Inertial loading can cause translational movement (linear motion of 
brain in the skull), rotational movement (shearing motion of different layers of brain in 
relation to one another), and angular movement (a combination of translational and 
rotational movements). In most clinical situations, severe TBI is initiated by impact to the 
head of a solid object at a high velocity, leading to brain damage by a combination of contact 
and inertial loading (Graham, Adams, & Gennarelli 1988). 
Traumatic brain injury can be focal or diffuse. Focal injury manifests as fractures, contusion or 
hematoma with mass effect. Contact loading, wherein a significant force is applied to cranium, 
can cause fracture at the site of impact with underlying contusion or epidural/subdural 
hematoma. If contact loading also produces translational acceleration or deceleration of the 
brain within the cranium, it can also cause focal damage by compression of brain under the 
site of impact (coup contusion) or remote from it (counter coup contusion). Diffuse brain 
injury results from rotational or angular acceleration or deceleration of the brain; the 
presentation can vary from transient loss of consciousness (concussion) to diffuse axonal injury 
(DAI) with prolonged coma. With increasing magnitude of inertial force progressively deeper 
structures in the brain suffer DAI (Adams et al. 1989).  In clinical situations focal lesions and 
DAI frequently coexist (Skandsen et al. 2010). 
3. Pathophysiology 
TBI is not a static event, but a constantly evolving dynamic process. The initial insult leads 
to instant brain damage known as primary brain injury. Primary brain injury triggers a 
cascade of events that cause brain edema, intracranial hypertension, and consequent 
ischemia, categorized as secondary brain damage (Enriquez & Bullock 2004). In diffuse 
injury the primary insult is at the cellular level and initiates events that lead to release of 
excitatory neurotransmitters, loss of ionic homeostasis, disruption of ATP production, 
toxicity from free radical production, loss of auto regulation and breakdown of blood brain 
barrier (BBB). These pathological changes lead to secondary injury. Similar secondary 
changes also occur in the region surrounding an area of contusion or traumatic hematoma, 
with a zone of ischemia and swelling developing around the focal injury. Tissue in this 
“ischemic penumbra” is at risk of dying but also salvageable (Schroder et al. 1995; Leker & 
Shohami 2002). Treatment of acute TBI is directed at minimizing secondary brain damage 
that follows focal as well as diffuse TBI. 
A good understanding of cellular and biochemical changes that follow brain trauma is 
required for the optimal management of brain injury, and for directing future research 
aimed at design of new therapies and protocols. A detailed discussion of these changes is 
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beyond the scope of this chapter; however, a brief summary is presented. Following trauma, 
the excitatory amino acid glutamate is released from the presynaptic neurons and activates 
both post synaptic neurons and glial cells. Under physiological conditions both glial cells 
and postsynaptic neurons actively remove glutamate from the synaptic space. Following 
trauma the high levels of glutamate activate receptors in the cell membranes of postsynaptic 
neurons and glial cells, resulting in Ca2+ influx into the cell with consequent free radical 
formation and increased oxidative stress. Calcium ions also accumulate in the mitochondria 
leading to mitochondrial membrane damage and disruption of energy cycle. These events 
eventually trigger necrosis and apoptosis in the cells (Enriquez & Bullock 2004; Shohami et 
al. 1997). 
TBI disrupts the BBB that allows fluid to move from intravascular compartment to 
extravascular compartment in the brain with resultant brain swelling and intracranial 
hypertension, which in turn leads to fall in cerebral perfusion thus further exacerbating 
brain ischemia. Aquaporins, matrix metalloproteinases and vasoactive inflammatory agents 
are potential mediators of BBB breakdown following trauma (Donkin & Vink 2010). A 
porous BBB allows infiltration of inflammatory cells into damaged brain. These cells 
(neutrophils and macrophages) release free radicals and cytokines into the brain tissue 
accentuating the damage (Soares et al. 1995).  
4. Initial management at the scene of injury 
Pre-hospital management is a critical step in the overall care of acute brain injury. Early 
institution of optimal care will minimize secondary injury while the patient is transported to 
a tertiary care facility. About half the deaths following TBI occur within first 2 hours of the 
injury (Badjatia, Carney et al. 2008) thereby signifying the importance of optimal pre-
hospital care. 
Pillars of pre-hospital care are restoring and maintaining airway, breathing and circulation 
(ABC) (Dewall 2010). The cervical spine must be immobilized as the patient is resuscitated, 
and spine precautions should be maintained till the patient is transferred to a trauma center. 
Intubation is indicated to secure the airway if the Glasgow Coma Scale (GCS) is less than 9, 
if the patient is hypoxic (SpO2 < 90%) despite supplemental oxygen, or if the patient is 
unable to maintain a patent airway (Gabriel et al. 2002). The SpO2 should be kept above 
95%, while maintaining eucapnea with an end tidal carbon dioxide (EtCO2) of 35 to 40 mm 
Hg (Badjatia, Carney et al. 2008). Hypotension accelerates secondary injury, and must be 
promptly recognized and treated. Systolic blood pressure below 90 mm Hg has been shown 
to increase mortality by two fold in TBI (Chesnut et al. 1993). Intravenous access should be 
promptly established, and normal saline is a reasonable choice for pre hospital fluid 
resuscitation (Dewall 2010). Intravenous dextrose should be administered only if blood 
glucose is less than 70 mg/dl (Badjatia, Carney et al. 2008). Persistent hypotension should 
prompt search for extracranial injury or spinal cord injury. Neurogenic hypotension 
presents with bradycardia and hypotension as opposed to hypovolemic shock that is 
characterized by tachycardia and hypotension. 
Glasgow coma scale (GCS) and pupillary response should be documented after the ABCs of 
resuscitation are complete, and if more than one provider is available, this can be done 
while the ABCs are being secured. Assessment of the GCS and pupillary response in pre-
hospital setting allows the emergency medical personnel to communicate to the receiving 
hospital the neurological status of the patient, screen for cerebral herniation and trend the 
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neurological status (Badjatia, Carney et al. 2008). A quick secondary survey for extracranial 
injuries should be performed prior to transport (Dewall 2010). 
Timely transport of these patients to tertiary care center is critical to a favorable outcome. 
Patients with severe TBI (GCS < 9) should be transported directly to a facility equipped with 
an immediately available CT scanner, prompt neurosurgical care and the ability to monitor 
intracranial pressure and treat intracranial hypertension (Badjatia, Carney et al. 2008), even 
if it is not the closest hospital (Hartl et al. 2006). Mortality can increase by 50%, if a severe 
TBI patient is not directly transported to such a facility (Hartl et al. 2006). Mode of transport 
(by road or air) should be chosen to minimize the transit time (Dewall 2010), as mortality 
following acute subdural hematoma has been shown to be directly linked to time to surgical 
intervention (Seelig et al. 1981). 
5. Medical management 
5.1 Principles of intensive care 
Management of the patient with traumatic brain injury is directed predominantly at 
minimizing and preventing secondary brain injury, which can result from intracranial or 
systemic causes. Although the mechanisms of secondary brain injury are incompletely 
understood, inadequate cerebral perfusion and oxygenation are integral factors. Systemic 
hypoxia and hypotension are significantly associated with increased morbidity and 
mortality. This effect was demonstrated in a data set from the Traumatic Coma Data Bank, 
in which a single episode of systemic hypotension was associated with double the risk of 
death (Chesnut et al. 1993; Bratton et al. 2007). This observation serves to demonstrate that 
good basic critical care is paramount. Current guidelines recommend a systolic blood 
pressure greater than 90 mmHg as a resuscitation end-point (Bratton et al. 2007). Adequate 
fluid resuscitation is important, but vasopressors should be used if fluids are insufficient to 
maintain adequate systemic blood pressures. Intubation and mechanical ventilation are 
necessary for patients presenting with severe brain injuries in order to ensure adequate 
oxygenation and ventilation, and to minimize the risk of aspiration (Valadka & Robertson 
2007). Admission to a dedicated neuroscience critical care unit, when available, may also 
result in improved outcomes (Patel et al. 2005). 
Ventilator management in patients with severe TBI presents some unique challenges 
because of the effect of PaCO2 on cerebrovascular autoregulation. Hyperventilation has long 
been recognized as an effective means for treating acutely elevated intracranial pressure. 
Hyperventilation results in a systemic respiratory alkalosis, which in turn lowers the pH of 
the cerebrospinal fluid. In patients with intact cerebral autoregulation, this change in pH 
results in constriction of cerebral arterioles, thereby decreasing the cerebral blood volume 
and lowering the intracranial pressure. As a result of this phenomenon, routine 
hyperventilation of TBI patients has been advocated in the past. However, experimental 
evidence has demonstrated that the vasoconstrictive effect is relatively short-lived, 
(Muizelaar et al. 1988) and there is concern that continued hyperventilation could potentiate 
cerebral ischemia (Bratton et al. 2007). Furthermore, subsequent efforts to correct an 
iatrogenic respiratory alkalosis sometimes precipitate rebound increases in intracranial 
pressure (Valadka & Robertson 2007). For these reasons, hyperventilation is usually 
employed only as a temporizing measure in patients suffering an acute neurological decline.  
The relationship between PaCO2 and cerebral blood flow becomes particularly problematic 
in TBI patients with co-morbid lung injury. Acute lung injury (ALI) and acute respiratory 
distress syndrome (ARDS) are not uncommon in the neurological critical care unit. Since the 
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publication of the ARDSnet trial in 2000, the mainstay of therapy for patients with ALI and 
ARDS has been lung-protective ventilation, which minimizes barotrauma to the lungs by 
employing lower tidal volumes ( The Acute Respiratory Distress Syndrome Network 2000). 
This strategy results in a moderate degree of hypercapnea and hypoxemia. While lung-
protective ventilation significantly improved mortality in the study population, the relative 
hypercarbia and hypoxemia may have deleterious effects in a patient who is at risk for 
cerebral edema, ischemia, or vasospasm. Randomized trials in TBI patients with ARDS are 
lacking. Monitoring of cerebral perfusion and oxygenation, which is discussed in 
subsequent sections, is particularly crucial in this scenario (Young et al. 2010). 
Because of the brain’s role in regulating metabolism, patients with severe traumatic brain 
injury demonstrate a number of metabolic derangements which ultimately result in systemic 
catabolism (Cook, Peppard, & Magnuson 2008). Adequate nutritional support is essential to 
forestall adverse consequences, including protein loss and immunocompromise (Sacks et al. 
1995). Early institution of nutritional support has a significant impact on mortality and 
decreases the rate of hospital-acquired infections (Hartl et al. 2008; Taylor et al. 1999). 
Patients with severe TBI will require replacement of approximately 140% of their resting 
energy expenditure, though this requirement will be decreased somewhat in the setting of 
pharmacological paralysis or deep sedation. Protein requirements are estimated at about 
1.5-2 grams/kg of protein (Cook, Peppard, & Magnuson 2008). Close monitoring is essential 
to ensure adequate supplementation and avoid complications such as hyperglycemia. Early 
hyperglycemia has been associated with poor outcome in TBI patients (Liu-DeRyke et al. 
2009), but intensive glycemic control may exacerbate metabolic stress in some patients 
(Vespa et al. 2006). Although the optimal glucose range for TBI patients has yet to be 
determined, our institution has chosen 140-180 mg/dL as a reasonable target range. 
Because of their increased sympathetic tone, severity of illness, and degree of immobility, 
TBI patients are at high risk of complications of critical illness including infection and 
thromboembolism. Long-term use of prophylactic antibiotics is discouraged, though there is 
some evidence that brief treatment at the time of endotracheal intubation reduces the 
incidence of ventilator-associated pneumonia (Sirvent et al. 1997). Fevers are common in 
patients with traumatic brain injury, and may represent an underlying infection, 
hypothalamic dysfunction, or other non-infectious cause. Hyperpyrexia must be 
investigated exhaustively in order to rule out the possibility of an infectious etiology; 
however, any fever in a patient with neurological injury must be treated aggressively. 
Increased temperature results in increased cerebral blood flow, which can exacerbate 
intracranial hypertension and reduce intracranial compliance (Segatore 1992). Furthermore, 
animal studies have indicated that hyperthermia can increase infarct size and potentiate 
cellular damage (Dietrich et al. 1996; Dietrich & Bramlett 2007). For these reasons, aggressive 
treatment of fever in brain-injured patients is warranted. First-line treatments generally 
include antipyretics such as acetaminophen; cooling blankets, fans, and chilled fluids have 
also been employed (Johnston et al. 2006). Control of shivering is also important, as 
shivering can increase metabolic demand and impede efforts to maintain normothermia 
(Badjatia, Strongilis et al. 2008).  
Prevention of thromboembolic events is a major consideration in patients with severe TBI, 
especially in poly-trauma patients. Mechanical prophylaxis with graduated compression 
stockings and/or pneumatic compression devices is recommended, though these 
interventions may be contraindicated in the presence of significant injury to the lower 
extremities (Bratton et al. 2007). Pharmacological prophylaxis with unfractionated (UH) or 
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distress syndrome (ARDS) are not uncommon in the neurological critical care unit. Since the 
 
Traumatic Brain Injury – Acute Care 
 
359 
publication of the ARDSnet trial in 2000, the mainstay of therapy for patients with ALI and 
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employing lower tidal volumes ( The Acute Respiratory Distress Syndrome Network 2000). 
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incidence of ventilator-associated pneumonia (Sirvent et al. 1997). Fevers are common in 
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animal studies have indicated that hyperthermia can increase infarct size and potentiate 
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shivering can increase metabolic demand and impede efforts to maintain normothermia 
(Badjatia, Strongilis et al. 2008).  
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especially in poly-trauma patients. Mechanical prophylaxis with graduated compression 
stockings and/or pneumatic compression devices is recommended, though these 
interventions may be contraindicated in the presence of significant injury to the lower 
extremities (Bratton et al. 2007). Pharmacological prophylaxis with unfractionated (UH) or 
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low-molecular weight heparin (LMWH) has been the subject of some debate. There is 
concern that use of pharmacological interventions could result in exacerbation of cerebral 
contusions, intracranial hemorrhage, and systemic bleeding. Evidence in a neurosurgical 
population indicates that pharmacological prophylaxis used in conjunction with mechanical 
devices is more effective than mechanical measures alone (Nurmohamed et al. 1996; Agnelli 
et al. 1998). Recent observational evidence suggests that initiation of prophylactic treatment 
with LMWH within 48 hours of injury or neurosurgical intervention is effective and 
associated with an acceptably low risk of complications (Norwood et al. 2008; Dudley et al. 
2010). Unfortunately, the most effective agent and dosing strategy is yet to be determined.  
5.2 Cerebral edema, intracranial hypertension and cerebral perfusion pressure 
The components of the intracranial compartment under normal circumstances consist of 
brain tissue, cerebrospinal fluid, and blood. Because the intracranial contents are contained 
within the rigid confines of the skull, any increase in volume—in the form of cerebral edema 
or a pathological mass lesion—must be met with a compensatory decrease in one of the 
other components, or the ICP will rise. Elevated ICP can result in cerebral ischemia, an 
important cause of secondary brain injury, by reducing cerebral perfusion pressure (CPP):  
CPP = MAP – ICP 
Where MAP is the mean arterial pressure.  
There is a considerable amount of debate regarding the relative importance of CPP and ICP 
thresholds. On one hand, observational data indicates that ICP > 20 mmHg is an 
independent predictor of morbidity and mortality (Helmy, Vizcaychipi, & Gupta 2007; 
Valadka & Robertson 2007; Robertson et al. 1999; Hiler et al. 2006; Czosnyka et al. 2005); 
however, good outcomes are possible even in the setting of exceptionally high ICPs, 
provided that cerebral perfusion is maintained. As a consequence, some centers advocate a 
CPP guided strategy, where as other clinical protocols focus predominantly on ICP and 
minimization of cerebral edema (Eker et al. 1998). Guidelines recommend ICP monitoring in 
patients with a Glasgow Coma Score (GCS) ≤ 8 who have abnormalities visible on computed 
tomography (CT). In the absence of CT abnormalities, ICP monitoring is indicated in 
comatose patients meeting 2 of the following criteria: age > 40 years, presence of motor 
posturing on exam, and/or SBP < 90 mmHg(Bratton et al. 2007). ICP values in excess of 20 
mmHg are considered pathological, though it is important to note that herniation can occur 
at lower ICPs, especially in the presence of intracranial mass lesions (Bratton et al. 2007). 
The situation is complicated by the fact that the relationship between ICP and CPP is 
affected by the integrity of cerebrovascular autoregulatory mechanisms. When cerebral 
autoregulation is intact, a fall in CPP is met with reflex cerebral vasodilation. This can 
precipitate an increase in ICP, thereby further diminishing cerebral perfusion (Robertson 
2001). In this setting, efforts to augment CPP artificially may abort a destructive cycle and 
arrest ongoing secondary brain injury. However, if CPP falls outside of the range of normal 
autoregulation, or if cerebral autoregulation is impaired, this relationship is reversed: ICP 
will rise in a linear fashion with increasing CPP, and artificial augmentation of cerebral 
blood flow may result in worsening cerebral edema and hyperemia. Initially, observational 
data using historical controls lead to the conclusion that CPP should be maintained at > 70 
mmHg. However, in a retrospective analysis of the Selfotel trial, Juul et al. found that there 
was no outcome benefit obtained by maintaining CPP > 60; interestingly, ICP ≥ 20 was the 
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most powerful predictor of outcome (Juul et al. 2000). The only randomized trial to date 
addressing the question of CPP vs. ICP was published by Robertson, et al. in 1999. In this 
trial, the CPP in one group was maintained at > 70 mmHg; in the other group, the ICP was 
maintained at ≤ 20 mmHg and CPPs as low as 50 mmHg were permitted. The investigators 
found no significant difference in outcome, but the CPP-targeted strategy carried five times 
the risk of ARDS (Robertson et al. 1999). An increasing appreciation of the role of 
cerebrovascular autoregulation in secondary brain injury has led some investigators to 
incorporate assessment of autoregulatory function into clinical protocols. The most readily 
available measure is the pressure reactivity index (PRx), which is a moving correlation 
coefficient calculated from measurements of ICP and MAP (Czosnyka et al. 1998). Centers 
that employ this measurement have reported that patients with intact autoregulation (PRx is 
low) have improved outcomes when managed according to a CPP guided paradigm, 
whereas those with impaired autoregulation (PRx is elevated) benefit from an ICP targeted 
strategy (Howells et al. 2005). Clearly, this observation warrants additional study. 
Interventions to control intracranial hypertension generally act to decrease the volume of one 
component of the intracranial compartment: blood, brain, or CSF. First line interventions 
include patient positioning, adequate sedation and analgesia, and maintenance of 
normothermia. The head of the bed should be elevated and any obstructions to jugular venous 
outflow, such as cervical collars, should be minimized. Adequate sedation and analgesia serve 
to minimize ventilator dyssynchrony, lower intrathoracic and intraabdominal pressure, and 
decrease agitation (Helmy, Vizcaychipi, & Gupta 2007). Treating systemic fever can mitigate 
the associated CNS hyperemia prevent shivering and rigors, which often result in increased 
ICP. If an external ventricular drain is present, diversion of cerebrospinal fluid can be helpful 
as well.  
Use of hyperosmolar substances is the mainstay of therapy for cerebral edema, with or 
without associated intracranial hypertension (Bhardwaj 2007). Infusion of a hyperosmolar 
substance serves to generate an osmotic gradient across the blood-brain-barrier, which 
reduces cerebral edema by drawing water out of the brain tissue. Mannitol and hypertonic 
saline (HTS) are the most commonly used agents in clinical practice. Mannitol is generally 
given as a bolus in doses ranging from 0.25-1.5 grams/kg. Hypertonic saline can be 
administered as a bolus or as a continuous infusion. For continuous use, concentrations 
ranging from 2% to 7.5% have been reported; boluses of 23.4% NaCl can be used in the 
setting of acute neurological decline. Use of either agent can result in rapid improvement in 
ICP; therefore, selection of the appropriate treatment will depend upon the clinical scenario. 
Mannitol can easily be infused through a peripheral intravenous line, whereas 
concentrations of HTS > 2% require central access. Mannitol acts as an osmotic diuretic, and 
can result in intravascular volume depletion, hypokalemia, and hypotension. There is 
concern that repeated dosing can result in renal impairment, especially if the drug is not 
adequately cleared by the kidneys; this can be monitored by calculating the osmolal gap. 
Hypertonic saline, on the other hand, acts as a volume expander and has been shown to be 
an effective means of reducing ICP even in patients who did not respond to mannitol 
(Ogden, Mayer, & E. Sander Connolly 2005; Vialet et al. 2003; Schwarz et al. 2002). Potential 
adverse events include congestive heart failure and hyperoncotic hemolysis; rapid 
administration of concentrated solutions may also result in transient hypotension. Either 
agent has the potential to accumulate in brain tissue in the presence of disruption of the 
blood-brain-barrier, Also, continued exposure to a hypertonic environment induces the 
generation of idiogenic osmoles within brain tissue, possibly setting the stage for rebound 
 
Brain Injury – Pathogenesis, Monitoring, Recovery and Management 
 
360 
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posturing on exam, and/or SBP < 90 mmHg(Bratton et al. 2007). ICP values in excess of 20 
mmHg are considered pathological, though it is important to note that herniation can occur 
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The situation is complicated by the fact that the relationship between ICP and CPP is 
affected by the integrity of cerebrovascular autoregulatory mechanisms. When cerebral 
autoregulation is intact, a fall in CPP is met with reflex cerebral vasodilation. This can 
precipitate an increase in ICP, thereby further diminishing cerebral perfusion (Robertson 
2001). In this setting, efforts to augment CPP artificially may abort a destructive cycle and 
arrest ongoing secondary brain injury. However, if CPP falls outside of the range of normal 
autoregulation, or if cerebral autoregulation is impaired, this relationship is reversed: ICP 
will rise in a linear fashion with increasing CPP, and artificial augmentation of cerebral 
blood flow may result in worsening cerebral edema and hyperemia. Initially, observational 
data using historical controls lead to the conclusion that CPP should be maintained at > 70 
mmHg. However, in a retrospective analysis of the Selfotel trial, Juul et al. found that there 
was no outcome benefit obtained by maintaining CPP > 60; interestingly, ICP ≥ 20 was the 
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found no significant difference in outcome, but the CPP-targeted strategy carried five times 
the risk of ARDS (Robertson et al. 1999). An increasing appreciation of the role of 
cerebrovascular autoregulation in secondary brain injury has led some investigators to 
incorporate assessment of autoregulatory function into clinical protocols. The most readily 
available measure is the pressure reactivity index (PRx), which is a moving correlation 
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that employ this measurement have reported that patients with intact autoregulation (PRx is 
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whereas those with impaired autoregulation (PRx is elevated) benefit from an ICP targeted 
strategy (Howells et al. 2005). Clearly, this observation warrants additional study. 
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component of the intracranial compartment: blood, brain, or CSF. First line interventions 
include patient positioning, adequate sedation and analgesia, and maintenance of 
normothermia. The head of the bed should be elevated and any obstructions to jugular venous 
outflow, such as cervical collars, should be minimized. Adequate sedation and analgesia serve 
to minimize ventilator dyssynchrony, lower intrathoracic and intraabdominal pressure, and 
decrease agitation (Helmy, Vizcaychipi, & Gupta 2007). Treating systemic fever can mitigate 
the associated CNS hyperemia prevent shivering and rigors, which often result in increased 
ICP. If an external ventricular drain is present, diversion of cerebrospinal fluid can be helpful 
as well.  
Use of hyperosmolar substances is the mainstay of therapy for cerebral edema, with or 
without associated intracranial hypertension (Bhardwaj 2007). Infusion of a hyperosmolar 
substance serves to generate an osmotic gradient across the blood-brain-barrier, which 
reduces cerebral edema by drawing water out of the brain tissue. Mannitol and hypertonic 
saline (HTS) are the most commonly used agents in clinical practice. Mannitol is generally 
given as a bolus in doses ranging from 0.25-1.5 grams/kg. Hypertonic saline can be 
administered as a bolus or as a continuous infusion. For continuous use, concentrations 
ranging from 2% to 7.5% have been reported; boluses of 23.4% NaCl can be used in the 
setting of acute neurological decline. Use of either agent can result in rapid improvement in 
ICP; therefore, selection of the appropriate treatment will depend upon the clinical scenario. 
Mannitol can easily be infused through a peripheral intravenous line, whereas 
concentrations of HTS > 2% require central access. Mannitol acts as an osmotic diuretic, and 
can result in intravascular volume depletion, hypokalemia, and hypotension. There is 
concern that repeated dosing can result in renal impairment, especially if the drug is not 
adequately cleared by the kidneys; this can be monitored by calculating the osmolal gap. 
Hypertonic saline, on the other hand, acts as a volume expander and has been shown to be 
an effective means of reducing ICP even in patients who did not respond to mannitol 
(Ogden, Mayer, & E. Sander Connolly 2005; Vialet et al. 2003; Schwarz et al. 2002). Potential 
adverse events include congestive heart failure and hyperoncotic hemolysis; rapid 
administration of concentrated solutions may also result in transient hypotension. Either 
agent has the potential to accumulate in brain tissue in the presence of disruption of the 
blood-brain-barrier, Also, continued exposure to a hypertonic environment induces the 
generation of idiogenic osmoles within brain tissue, possibly setting the stage for rebound 
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intracranial hypertension when the serum osmolarity begins to fall (Diringer & Zazulia 
2004). Consequently, close monitoring of the patients’ ICP, CPP, serum sodium, and serum 
osmolarity is required. Despite the lack of convincing evidence, general consensus it that 
driving the serum sodium above 160 mEq/L is rarely beneficial, and most clinicians try to 
maintain the serum osmolarity below 320 mOsm/L (Hays et al. 2011).  
When intracranial hypertension persists despite maximal osmotherapy, ICP may be 
controlled by interventions designed to decrease the cerebral blood volume. This can be 
accomplished by suppressing brain metabolism, either by inducing a pharmacological coma 
or with therapeutic hypothermia. Induction of a pharmacological coma is usually 
accomplished using barbiturates, such as pentobarbital. Barbiturates have been shown 
experimentally to mitigate the development of brain edema (Mishina & Yabuki 1994), 
decrease cerebral metabolism, and lower cerebral blood flow (Kassell, Hitchon et al. 1980). 
Early experimental data suggested a neuroprotective effect in models of focal cerebral 
ischemia (Smith et al. 1974); however, subsequent small-scale clinical trials were 
disappointing (Ward et al. 1985; Kassell, Peerless et al. 1980). Studies in brain injured 
patients indicate that barbiturates may be less effective than mannitol as an initial 
intervention, but nevertheless are useful in patients who have failed maximal osmotherapy 
(Eisenberg et al. 1988; Schwartz et al. 1984; Marshall et al. 2010). Pentobarbital has a number 
of undesireable side-effects including systemic hypotension, decreased gastric motility, and 
bone marrow suppression (Meyer et al. 2010). In addition, continuous infusion of 
pentobarbital results in delayed drug clearance, which can delay detection of neurological 
improvement or decline. Continuous electroencephalography allows the clinician to titrate 
to burst-suppression, thereby ensuring that the minimum effective dose is employed. 
Several other agents, including propofol and midazolam, can be used to suppress CNS 
metabolism and induce burst-suppression, though they do not appear to be as effective as 
barbiturates in the treatment of intracranial hypertension (Meyer et al. 2010; Stewart et al. 
1994). Unfortunately, no comparative trials are available. 
Induced hypothermia has been investigated as a neuroprotective strategy in many disease 
states, and is currently the standard of care for comatose patients following cardiac arrest 
(Bernard & Buist 2003; Mild therapeutic hypothermia to improve the neurologic outcome 
after cardiac arrest 2002; Bernard et al. 2002). Moderate hypothermia has been shown to 
decrease the cerebral metabolic rate considerably (Rosomoff & Holaday 1954). In models of 
ischemia, it serves to decrease the concentrations of lactate and excitotoxic neurotransmitters 
(Illievich et al. 1994). Although clinical trials have failed to demonstrate an outcome benefit 
for early hypothermia in traumatic brain injury (Clifton et al. 2001), there is ample evidence 
that moderate hypothermia is an effective intervention for intracranial hypertension (Meyer 
et al. 2010). Most investigators used a target temperature between 33-35oC, which can be 
achieved using a variety of cooling methods (Marion et al. 1993; Marion et al. 1997; Liu et al. 
2006; Qiu et al. 2007; Jiang, Yu, & Zhu 2000; Shiozaki et al. 1993). Complications of moderate 
hypothermia include an increased susceptibility to infection, cardiac arrhythmias, 
coagulopathy, and electrolyte disturbances. Iatrogenic hypothermia can also mask a fever, 
and potentially delay the diagnosis of an underlying infection; for that reason, the authors 
advocate following the white blood cell count and obtaining periodic cultures in all 
hypothermic patients. Shivering is often encountered during the induction and rewarming 
phases, and this can counteract the beneficial effects of hypothermia on ICP and cerebral 
metabolic rate. Pharmacological paralysis is often used to prevent shivering, but other 
interventions including magnesium, dexmedetomidine, and meperidine have also been 
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used successfully (Weant et al. 2010). Many of these complications of systemic hypothermia 
may be mitigated by the use of selective brain cooling devices, which are employed at some 
institutions (Qiu et al. 2006; Liu et al. 2006). 
The duration of hypothermia therapy can vary widely depending upon the clinical needs of 
the individual patient; reports in the literature range from 24 hours to 14 days (McIntyre et 
al. 2003). The rewarming phase of therapy is critical due to the risk of mitochondrial injury, 
vascular dysregulation, and rebound increases in ICP (Jiang, Yu, & Zhu 2000; Jiang & Yang 
2007; Povlishock & Wei 2009). Although the optimum rewarming rate has yet to be 
determined, most authors advocate rates of approximately 0.5-1o/hour (Bernard & Buist 
2003; Bernard et al. 2002; Alzaga, Cerdan, & Varon 2006). At our institution, cooling is 
generally performed for a minimum of 48 hours. If the patient’s ICP remains well-controlled 
during that period, rewarming is initiated at a rate of approximately 0.50/hr. In the event of 
recurrent intracranial hypertension, rewarming is halted for an additional 12-24 hours 
before repeating the attempt.  
5.3 Advanced neuromonitoring 
In an effort to elucidate the mechanisms of secondary brain injury in severe TBI and 
improve outcomes from this highly morbid condition, a number of technologies have been 
developed to provide information regarding brain function, oxygenation, and perfusion. 
Neurophysiologic techniques such as electroencephalography have been used intermittently 
in brain injured patients for decades; however, recent evidence suggests that continuous 
monitoring may provide considerable benefit. Similarly, recent technological advances have 
enabled the bedside assessment of cerebral perfusion and oxygenation at the bedside. These 
techniques will be discussed briefly in the following sections. 
5.3.1 Continuous electroencephalography 
Electroencephalography (EEG) is used for a variety of indications in brain injured 
patients. Continuous electroencephalography (cEEG) can be employed for the diagnosis 
and treatment of seizures, in order to titrate barbiturate therapy, as an indicator of 
cerebral ischemia, and to provide information regarding prognosis. Seizures are a well 
known complication of TBI, and can contribute to ongoing secondary brain injury 
(Claassen et al. 2004; Vespa et al. 1999). The incidence of electrographic seizures in 
severely head injured patients has been reported at 22-33%, with more than half of these 
events being clinically silent (Vespa et al. 1999; Ronne-Engstrom & Winkler 2006). 
Moreover, investigators utilizing intracortical electroencephalography report recording 
several seizures which were occult on simultaneous scalp EEG (Waziri et al. 2009). 
Seizures are both more likely and more difficult to detect in comatose patients, suggesting 
that these patients are most likely to benefit from continuous EEG (cEEG) monitoring 
(Claassen et al. 2004). Early post-traumatic seizures have been associated with adverse 
physiological events, including elevation of intracranial pressure and an increase in the 
lactate to pyruvate ratio (Vespa et al. 2007). There is no clear association between isolated 
post-traumatic seizures and increased mortality; however, case series suggest that post-
traumatic status epilepticus carries a high risk of death (Vespa et al. 1999; Bratton et al. 
2007). Although most investigators advocate treatment of early post-traumatic seizures as 
a means for reducing secondary brain injury, it remains to be determined if this 
intervention improves patient outcome. 
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5.3.2 Cerebral blood flow and brain tissue oxygenation 
The recognition of cerebral ischemia as a major contributing factor to secondary brain injury 
has generated considerable interest in measurement of cerebral perfusion in head injured 
patients. A number of imaging techniques, including transcranial Doppler ultrasound, 
xenon-enhanced CT, CT perfusion imaging, perfusion weighted MRI, and positron emitted 
tomography are available to evaluate cerebral perfusion. Using these techniques, 
investigators have demonstrated that cerebral blood flow following head trauma follows 
three distinct hemodynamic phases: initial hypoperfusion, accompanied by reduced cerebral 
metabolic rate of oxygen (CMRO2); subsequent hyperemia, without an associated increase in 
CMRO2, which may be associated with intracranial hypertension; followed by a period in 
which cerebral blood flow (CBF) may be reduced secondary to vasospasm (Martin et al. 
1997). However, the physiological and pathophysiological significance of these phases has 
been debated, and significant regional variation of cerebral perfusion is present 
(Wintermark et al. 2004). As discussed previously, cerebral perfusion can be significantly 
affected by systemic factors that impact the MAP and the CPP; the magnitude of this effect 
is dependent upon the individual’s autoregulatory status (Czosnyka et al. 1998; Howells et 
al. 2005). Furthermore, the reports of the incidence and significance of cerebral vasospasm 
after trauma are variable, and likely are affected by the mechanism of injury (Martin et al. 
1997; Zubkov et al. 2000). MR, CT, and PET based imaging techniques provide information 
regarding cerebral perfusion over large regions of the brain parenchyma, but for the most 
part the data obtained is useful only for a single time point. Transcranial Doppler can be 
performed for extended periods of time, but it is limited to the evaluation of the large 
vessels surrounding the Circle of Willis, and image quality is highly operator-dependent. 
More recently, parenchymal monitors have been used to provide a continuous measurement 
of cerebral blood flow in a specific, small region of tissue using thermal diffusion. This device 
is placed in the perilesional white matter via a burr hole in the skull. Use of CBF monitoring is 
currently employed in some centers and may provide a method for continuous assessment of 
cerebrovascular autoregulation in the future (Rosenthal et al. 2011).  
In addition to CBF, brain oxygenation is often used as an indicator of cerebral ischemia. For 
decades, brain oxygenation could be assessed only indirectly, by intermittent sampling of 
the jugular venous blood. However, in the 1990s, a fiber-optic catheter which permitted 
continuous assessment of jugular venous oxygen saturation (SjvO2) became available (Ritter 
et al. 1996). SjvO2 provides a global measure of cerebral oxygenation and can permit early 
detection of cerebral ischemia. Studies have shown that jugular venous desaturations (< 
50%) are correlated with poor outcome, especially if prolonged and/or recurrent (Gopinath 
et al. 1994). However, cerebral metabolism in TBI demonstrates regional heterogeneity, and 
a global measure such as SjvO2 may not permit detection of focal regions of ischemia 
(Valadka et al. 2000). More recently, intraparenchymal monitors have become available for 
the purpose of monitoring local brain tissue oxygen tension (PbrO2). These monitors are 
typically inserted in normal-appearing brain tissue adjacent to a focal lesion, or in the right 
frontal region in the setting of diffuse axonal injury. As with SjvO2 monitoring, episodes of 
desaturation detected by PbrO2 monitoring have been shown to correlate with increased 
mortality (Stiefel et al. 2005). The critical value appears to be approximately 15 mmHg, 
though some clinicians prefer a treatment threshold of 20 mmHg (Bratton et al. 2007). 
Various investigators have studied the relationships between PbrO2 and more conventional 
clinical parameters. In particular, positive correlations have been described between PbrO2 
and various determinants of oxygen supply to the CNS, including FiO2, PaO2, CPP, and 
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hemoglobin concentration (Stiefel et al. 2005). However, studies using PET imaging and 
monitoring of the arteriovenous oxygen tension difference have provided evidence that 
barriers to local oxygen diffusion, rather than determinants of oxygen supply, are significant 
determinants of PbrO2 (Rosenthal et al. 2008; Bratton et al. 2007). 
A drop in cerebral oxygenation (as measured by PbrO2 or SjvO2) should prompt an 
investigation for an underlying cause, such subclinical seizures; an expanding mass lesion; 
suboptimal CPP; or systemic derangements such as hypotension or worsening lung 
function. The two monitoring methods are often complementary. For instance, PbrO2 is 
more sensitive to changes in the arterial oxygen content, and would be more likely to signal 
the expansion of a nearby contusion (Valadka et al. 2000). Cerebral oxygen desaturation can 
be successfully treated using measures designed to augment oxygen delivery, such as 
optimizing the CPP, increasing the fraction of inspired oxygen (FiO2), and transfusion of red 
blood cells depending upon the patient’s specific clinical characteristics; however, these 
interventions carry some risk. Normobaric hyperoxia has been shown to improve PbrO2 as 
well as some other markers of brain metabolism, but prolonged use exposes the patient to 
the risk of oxygen toxicity (Tisdall et al. 2008). Similarly, the optimal transfusion threshold 
for brain injured patients has yet to be determined, and injudicious use of blood products 
carries the risk of transfusion related lung injury, as well as other potential complications. A 
recent trial of 70 patients reported that a group of patients with severe TBI who received 
PbrO2 guided therapy (goal > 20 mmHg) demonstrated improved mortality and better 
functional outcomes than those managed using traditional ICP (< 20 mmHg) and CPP goals 
(> 60 mmHg)(Spiotta et al. 2010). However, this trial relied on historical controls, and the 
authors did not report on the incidence of ARDS or other medical complications in either 
cohort. A multicenter randomized controlled trial addressing the use of PbrO2 monitoring in 
severe TBI is currently underway.   
6. Surgical management 
Surgical intervention is indicated in TBI for control of intracranial hypertension or restoring 
integrity of structures covering the brain as in compound injuries. High ICP, following TBI, 
can result from a focal intracranial hematoma or diffuse brain swelling. “Moderate” sized 
contusion hematomas can present the surgeon with a dilemma about whether to operate or 
observe the patient. Presence of alcohol or drugs on board can further compound the 
situation. Close clinical observation, ICP monitoring, and a follow-up head CT scan can help 
to guide the therapy, but ultimately surgeon’s experience and clinical judgment plays a 
crucial role in decision making. 
Evidence based guidelines are available to help with decision-making (Bullock et al. 2006, 
2006; Bullock et al. 2006, 2006, 2006). Any mass lesion with progressive neurological decline 
referable to the lesion should be operated upon. A supratentorial lesion with a midline shift 
of 5 mm or more and effacement of the basal cisterns, and a posterior fossa lesion with 
compression or distortion of fourth ventricle or effacement of basal cisterns or obstructive 
hydrocephalus in patients with GCS of 8 or less should be evacuated. Epidural hematomas 
(EDH) larger than 30 cm3 and subdural hematomas greater than 10mm in thickness or 
causing more than 5 mm of midline shift should be evacuated, independent of the GCS. An 
EDH less than 30 cm3, and less than 15mm in maximal thickness, and with less than 5 mm 
midline shift, in a patient with a GCS of 9 or more without a focal deficit, can be managed 
non-surgically with close monitoring and repeat CT scans. Frontal or temporal lobe 
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hemoglobin concentration (Stiefel et al. 2005). However, studies using PET imaging and 
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contusions greater than 20 cm3 associated with midline shift of 5 mm or more, in patients 
with GCS of 6 to 8 or any parenchymal lesion greater than 50 cm3 should be operated upon. 
An open (compound) cranial fracture depressed greater than the thickness of cranium 
should be operated upon to prevent infection. An open (compound) depressed fracture may 
be treated non surgically if it is not depressed more than 1 cm, there is no dural penetration, 
no intracranial mass lesion, no frontal sinus involvement, no pneumocephalus, no cosmetic 
deformity, and no wound contamination or infection. 
Decompressive craniectomy (DC) is being increasingly used for patients with severe  
diffuse TBI and medically refractory intracranial hypertension (Ahmad & Bullock 2011).  
DC is effective in reducing the ICP and increasing the survival, but has not been shown  
to improve long term neurological outcome(Li, Timofeev et al. 2010). In fact, there is strong 
evidence to suggest that DC in patients with severe TBI (GCS 3-8) with medically refractory 
intracranial hypertension is associated with a worse neurological outcome at 6 months  
after injury compared to similar patients who were treated with controlled ventilation, 
mannitol, hypertonic saline, external ventricular drainage, mild hypothermia  
and barbiturates(Cooper et al. 2011). DC for treatment of medically refractory intracranial 
hypertension, in severe diffuse TBI, is discouraged till parameters other than ICP control 
are available, to gauge the success of therapy (Marion 2011).This procedure can still  
be an effective therapy in very select group of patients such as those undergoing 
craniotomy for intracranial hematoma (particularly SDH) with significant brain swelling. 
Unwarranted use of DC may prove counterproductive in terms of neurological recovery 
in patients with severe TBI. 
7. Future directions 
7.1 Microdialysis 
Microdialysis is an invasive monitoring technique which allows sampling of the 
extracellular fluid within the brain parenchyma in order to test for a variety of substances. 
Although a wide variety of substances can be analyzed successfully, glucose, lactate, 
pyruvate, glycerol, and glutamate are the most commonly employed. Glycerol is monitored 
primarily as a marker of membrane breakdown, whereas glucose, lactate, pyruvate, and the 
lactate/pyruvate ratio are used as markers of cerebral energy metabolism. The 
lactate/pyruvate ratio, in particular, is often employed as an indicator of the brain redox 
state and an early sign of focal ischemia. Microdialysis probes are usually placed in the 
frontal white matter in patients with diffuse brain injury, or in the pericontusional tissue in 
patients with focal radiographic abnormalities (Bellander et al. 2004). Although cerebral 
microdialysis has been widely used in animal studies for more than 30 years, its use in 
clinical practice is limited primarily to large academic centers where it is generally used in 
conjunction with other monitoring devices to provide an early indicator of evolving 
secondary brain injury. For instance, in cases of cerebral ischemia, the lacate/pyruvate ratio 
increases markedly, whereas the glucose level declines to near zero. These findings have 
been shown to correlate with SjVO2 and PbrO2 measurements, as well as the oxygen 
extraction fraction as measured by PET (Robertson et al. 1995; Valadka et al. 1998; 
Hutchinson et al. 2002). When used in conjunction with CPP and ICP monitoring, 
microdialysis may have a role in early detection of focal (as opposed to global) pathological 
processes, such as vasospasm or expanding contusions (Valadka & Robertson 2007; 
Hillered, Vespa, & Hovda 2005). 
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The data acquired by centers that utilize microdialysis routinely provides considerable 
insight into the pathophysiology of secondary brain injury in this population. For instance, 
Vespa et al. have reported persistently low glucose levels in cerebral microdialysate in the 
first 50 hours following brain injury in patients with poor outcome, which was unrelated to 
cerebral ischemia (Vespa et al. 2003). This may reflect a disorder of energy metabolism 
related to ongoing brain injury in patients with severe TBI. Work from the same group has 
demonstrated that intensive insulin therapy, as practiced in many surgical ICUs, often 
results in evidence of metabolic stress in patients with TBI (Vespa et al. 2006). Investigators 
studying the relationship between CPP on cerebral glucose metabolism have noted 
significant increases in the lactate/pyruvate ratio at CPPs less than 50mmHg which were 
confined to perilesional tissue. This work would seem to support the contention that 
susceptibility to ischemic insult is greater in a region of “tissue at risk” adjacent to 
contused brain (Nordstrom et al. 2003). Data on hyperventilated patients have been 
conflicting, with some studies reporting no effect (Letarte et al. 1999). In contrast, another 
study demonstrated that increased glutamate and lactate/pyruvate ratio could be 
demonstrated in TBI patients hyperventilated within 36 hours of injury, though these 
changes were seen much less commonly at later time points (Marion et al. 2002). This 
observation reinforces the hypothesis that sustained hyperventilation is particularly 
detrimental in the early stages following TBI. 
Microdialysis data has also been used to investigate the physiological effects of various 
therapeutic interventions. Hyperbaric oxygen therapy has been shown to result in a 
reproducible decrease in lactate and lactate/pyruvate ratio, which was accompanied by 
improvements in cerebral blood flow, CMRO2, and ICP (Rockswold et al. 2010). Similarly, 
microdialysis has been used to investigate the effect of barbiturates and propofol on cerebral 
energy metabolism. Thiopental coma was shown to reduce lactate in a small number of TBI 
patients, suggesting reduced anaerobic metabolism (Goodman et al. 1996). In contrast, 
propofol was not shown to have any significant effect on lactate, pyruvate, or glucose 
concentrations even when titrated to burst suppression (Johnston et al. 2003). Although both 
studies involved small numbers of patients, this would seem to suggest that barbiturates are 
more effective for the prevention of secondary brain injury. 
7.2 Biomarkers 
One of the major goals of ongoing research in TBI is the identification of reliable biomarkers. 
The ideal biomarker would enable early diagnosis of underlying brain injury, provide an 
early indicator of secondary brain injury, and enable clinicians to monitor the patient’s 
response to therapy. Conceivably, use of a variety of biomarkers specific to different tissue 
types or mechanisms of injury may help to guide therapy and provide insight into ongoing 
pathophysiology. Over the past 40 years, a variety of candidate molecules have been 
evaluated in both clinical settings and in animal models. Perhaps the most widely studied is 
S100B, a calcium-binding protein that is found in astrocytes. S100B has a half-life of < 60 min 
in serum; consequently, elevated levels are unlikely to persist for more than 24 hours in the 
absence of severe TBI (Berger 2006).  This protein can be quantified in the serum and in the 
CSF; the peak serum levels appear to occur roughly 48 hours after the peak CSF 
concentration is reached (Petzold et al. 2003). Elevated levels of S100B have been shown to 
correlate with poor outcome, contusion volume, and (inversely) with certain quality of life 
measures (Raabe et al. 1998; Woertgen, Rothoerl, & Brawanski 2002). Unfortunately, the 
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time course of S100B release, the dynamics of transport across the blood-brain-barrier, and 
the patho- physiological implications of elevated S100B levels remain to be determined 
(Kleindienst et al. 2010). Other candidate biomarkers associated with outcome in TBI 
patients include neuron specific enlace, a cytoplasm protein found in neuronal tissue, and 
glial fibrillary acidic protein (GFAP), an intermediate filament protein found in astrocytes 
(Vos et al. 2004) GFAP, in particular, has been shown to correlate with CT findings and with 
outcome in trauma patients (Lumpkins et al. 2008; Nylen et al. 2006). Although no large 
scale studies are available, some investigators suggest that GFAP may prove to be more 
sensitive than neuron-specific enolase (NSE) or S100B, due to the lack of extracerebral 
sources (Honda et al. 2010). 
Whereas NSE, S100B, and GFAP are markers of cellular breakdown, certain other candidate 
biomarkers serve as indicators of ongoing pathophysiological processes. For instance, 
diffuse axonal injury is characterized pathologically by axonal degradation, which is 
associated with the breakdown of axonal microtubules. This results in the release of 
microtubule-associated protein tau, which is cleaved into fragments which are known as 
cleaved-tau (C-tau) (Li, Li et al. 2010). The presence of C-tau in the CSF has been found to be 
a sensitive indicator of diffuse axonal injury, and levels correlate inversely with clinical 
improvement (Zemlan et al. 1999).  Other putative biomarkers have the potential to allow 
investigators to differentiate between cell death related to apoptosis as opposed to necrosis. 
The alpha-II spectrin protein, for example, is a component of the axonal cytoskeleton which 
is cleaved by enzymes involved in both cellular necrosis (caspase-3) and apoptosis (calpain 1 
and 2). Western blot analysis of the alpha-II spectrin breakdown products present in a given 
sample can therefore provide insight into the predominant mechanism of cellular loss (Li, Li 
et al. 2010). Preliminary studies using alpha-II spectrin breakdown products in humans have 
demonstrated that necrosis, mediated by calpain, is the predominant mechanism involved 
in acute DAI, suggesting that calpain inhibitors may be a potential therapeutic target 
(Brophy et al. 2009).     
7.3 Pharmacotherapy 
A major factor contributing to intractable intracranial hypertension following severe TBI is 
cerebral edema. Both cytotoxic and vasogenic edema contribute to post traumatic cerebral 
edema (Barzo et al. 1997). Therapeutic interventions directed at mediators of cerebral edema 
offer potential treatment options for TBI. Aquaporins (AQPs) are integral membrane 
proteins that form pores in membranes of mammalian cells, and play an important role in 
development and resolution of cerebral edema (Pasantes-Morales & Cruz-Rangel 2010). 
AQPs modulation offers a potential therapeutic intervention to prevent or treat brain 
swelling (Manley et al. 2000; Papadopoulos & Verkman 2008; Taya et al. 2008). Matrix 
metalloproteinases (MMPs) are zinc dependent endopeptidases involved in the process of 
tissue remodeling following brain injury from stroke or trauma. MMPs are upregulated 
following TBI, causing disruption of BBB and cerebral edema in the early phase, followed by 
neurogenesis and neurovascular remodeling in the later stages of recovery. Thus selective 
therapeutic blocking of the detrimental effects in the early phase offers the possibility of 
preventing cerebral edema without disrupting the later reparative phase (Donkin & Vink 
2010). A group of neuropeptides released from sensory neurons have been implicated in 
neurogenic inflammation. Neurogenic inflammation that includes vasodilation, plasma 
extravasation and neuronal hypersensitivity, has been shown to play a role in the 
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development of post traumatic cerebral edema. Therapeutic inhibition of neurogenic 
inflammation offers another potential target to prevent cerebral edema after TBI (Donkin & 
Vink 2010). Progesterone is another agent with potential therapeutic role in the 
management of TBI. Progesterone receptors are distributed throughout the central 
nervous system, and the steroid has neuroprotective properties. Progesterone decreases 
brain edema, attenuates free radicals and reduces neuronal loss in TBI animal model. 
There is class II evidence to suggest it may improve neurologic outcome in patients with 
TBI (Junpeng, Huang, & Qin 2011). 
8. Conclusion 
TBI is a serious disorder with significant morbidity, mortality and economic implications. It 
is a dynamic process, and timely intervention can prevent progression of neurological 
decline. Foundation of acute care is built upon prompt resuscitation and transport from the 
site of accident to a tertiary care facility, appropriate imaging, and intensive monitoring 
focused on minimization and prevention of secondary damage. Considerable progress has 
been made in understanding the physiology of ICP and treatment of intracranial 
hypertension, but control of ICP does not always translate into good neurological outcome. 
Better understanding of pathophysiology, identification of newer parameters of brain 
function, and development of innovative therapeutic modalities is required to improve the 
outcome from TBI.  
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1. Introduction 
1.1 Understanding hypoxia tolerance and the challenge of clinical neuroprotection  
Most of the existing research on brain hypoxia mainly focused mainly on understanding the 
mechanisms of neuronal death as the means of identifying targets for therapy. This 
approach has not been helpful in understanding how the brain of humans can be made to 
resist tissue hypoxia. This is a major factor that leads to neuronal death during stroke, for 
example. Hypoxia tolerance is a robust fundamental adaptation to low oxygen supply and 
represents a novel neuroscience problem with significance to mammalian physiology as 
well as human health. Physiological and molecular changes during hypoxia are critical to 
the prevention, management, and treatment of many important health conditions, such as 
stroke and cardiac arrest. However, the initiation and maintenance of physiological changes 
during hypoxia tolerance can be very difficult, and even those interventions that succeed in 
laboratory animals and controlled clinical trials do not always translate into clinical therapy. 
Transformative advances in the science of mammalian physiology, especially those that can 
connect mammalian physiological, molecular changes and diseases are urgently needed. In 
this review, we discussed major molecular and physiological adaptations during hypoxia 
tolerance that can be developed for the induction of clinical neuroprotection to tissue 
hypoxia during brain injuries. 
2. Convergence between a specific neurotransmitter system and 
physiological mechanisms maybe critical for tissue hypoxia during brain 
injuries 
Comparative studies of adaptive physiology demonstrated that hypoxia tolerant animal 
species represent  potential sources of new strategies in our search for brain protection. This 
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is because studies on the neurons of these animals repeatedly reminded us that we are closer 
to understand  how cells and tissues develop resistance to hypoxia. Hypoxia tolerant species 
are very valuable models for understanding oxygen signaling processes simply because the 
responses to hypoxia are well developed. The possibility of separating adaptive signaling or 
defense responses from injury is a major benefit of studying hypoxia tolerant cells. They also 
serve as models for the slow adaptation of tissues to hypoxia, which humans are clearly 
capable of, and which might be enhanced to improve adaptation to diseases involving 
oxygen deficits. 
Studies on the pathophysiology of shock-induced disturbances in tissue homeostasis reveal 
that tissue hypoxia is a consequence of distressed microcirculation that worsens  
the diffusion geometry, such that tissue hypoxia induced significant physiological changes 
in brain cells. Measuring the targets that detect tissue hypoxia is known to reveal  
the immediate effect of the distressed microcirculation. Recent studies on hypoxia 
neurobiology research have advanced a considerable body of evidence supporting the 
hypothesis that convergence between neurotransmitter systems and physiological 
mechanisms is protective in hypoxia tolerant species. Establishing this protective phenotype 
in response to hypoxic stress depends on a convergence response at the genomic, molecular, 
and cellular and tissue levels (Singer, 2004, Jeffrey, 2006). At the cellular level, studies  
in mammalian hibernation that explore hypoxia tolerance capability reveal evidence of  
ion channel arrest, regulation of inhibitory neurotransmission and suppression of substrate 
oxidation as cellular physiological adaptations (Gentile et al., 1996, Wang et al., 2002). 
Furthermore, extracellular levels of GABA decline in the striatum during hibernation,  
while extracellular glutamate remains unchanged during steady-state torpor of hibernation 
when compared with euthermic animals (Zhou et al., 2001). A decrease in the tissue-specific 
depression of substrate oxidation is also thought to decrease oxygen consumption,  
and consequently attenuate cytotoxic events that lead to cell death (Barger et al., 2003). This 
effect was attributed to a decrease in ATP demand resulting in the maintenance of 
homeostasis of brain energy demand and supply. The central mechanism that underlies 
hypoxia preconditioning-induced tolerance, which maintains the homeostasis of brain 
energy demand and supply, remains unclear. Interestingly, a number of potential 
neurochemical induction pathways have been proposed to control hypoxia tolerance in 
natural genetic systems of hypoxia tolerance. Such pathways include neuroactive cytokines 
(Nawashiro et al., 1996), glutamate receptors (Ravid et al., 2007, Sivakumar et al., 2009), 
adenosine receptors (Perez-Pinzon et al., 2005), the ATP-sensitive potassium Channel 
(Reshef et al., 2000), nitric oxide (Gonzalez-Zulueta et al., 2000) and oxidative stress (Dalen et 
al., 2009).  
Taken together, findings from the aforementioned studies indicate that neuroprotective 
mechanisms against hypoxic insults in natural genetic systems of hypoxia or ischemic 
tolerance maybe be hinged on the convergence between a specific neurotransmitter system 
and physiological mechanisms. Although only few of the existing studies have been 
demonstrated in humans, one of these few studies indicates that elucidation of the central 
neurochemical mechanism of hypoxia tolerance is in this area of interest because  
the tolerance has been experimentally induced by clinically approved drugs (Konstantin et 
al., 2003). In another human study, it was found that adenosine plasma levels strikingly 
increased, such that the adenosine flow lasted days after transient ischemic or hypoxia 
attack and weeks after stroke (Moncayo et al., 2000, Pasini et al., 2000). Our view openly 
acknowledges the existence of hypoxia tolerance capacity in human brains and a possible 
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central endogenous neuroprotective mechanism for hypoxia brain injuries in humans.  
In this context, considering the roles of adenosine as a molecule, it is possible that adenosine 
might represent a potential central neurotransmitter system that modulates physiological 
mechanisms during hypoxia protection. It is also important to emphasize that hypoxia itself 
could be the driving force for the convergence between a specific neurotransmitter system 
such as adenosine and physiological mechanisms during protection in hypoxia tolerant 
species. Since extensive studies have been done on adenosine system in the context  
of hypoxia protection over the past twenty years, we will now summarize the  
existing knowledge of specific roles of adenosine (A1) receptor in inducing survival during 
hypoxia.  
3. Specific roles of A1 receptor during hypoxia tolerance 
Survival in a severe hypoxic stress during which arterial oxyhemoglobin saturation is equal 
to 35% or less is connected with the ability of the brain to adapt to low oxygen supply and 
demand, and is thought to be regulated by a specific neurotransmitter system, such as 
adenosine (Blood et al., 2002). Studies in young sheep and adult rats indicate that 
intracerebral A1 concentrations increased during hypoxia. The specific role of A1 was linked 
to its ability to inhibit neuronal activity (Fowler et al., 1999). In vitro studies on hippocampal 
slices indicate that elevation of A1 receptors is associated with hypoxia (Jin and Fredholm, 
1997), and severe asphyxia in vivo (Hunter et al., 2003c), following inhibition of neuronal 
activity. Studies in the fetal sheep further revealed that breathing movements can be 
inhibited by hypoxia and that such adaptation could be abolished by adenosine-receptor 
blockade at the level of the thalamus due to the inhibition of thalamic neurons (Chau and 
Koos, 1999). In a mouse knocked-out of A1 receptor, there is a significant decrease in 
tolerance to hypoxia (Johansson et al., 2001). Involvement of adenosine or adenosine 
triphosphate-sensitive potassium (KATP) channels in the development of tolerance has been 
suggested in global ischemia and hypoxia models (Kumral et al., 2010), cross-tolerance 
models (Xu et al., 2002) and in vitro studies (Perez-Pinzon et al., 2005). Activation of A1 
receptors directly accelerate neuritogenesis in the primary neuronal precursor cells of 
rats(Canals et al., 2005). This finding suggests that A1 receptors may play an important role 
in myelinization and neuronal differentiation with the potential for clinical management of 
neuronal repair in hypoxic-induced brain injury. 
By evaluating the action of hypoxia on synaptic transmission in hippocampal slices 
Sebastião and Ribeiro (2001) revealed that γ-aminobutyric acid (GABA), acetylcholine, and 
even glutamate may also have a neuroprotective role; however their action is evident only 
when activation of adenosine A1 receptors is impaired. This finding indicates that adenosine 
A1 receptors have a pivotal role of neuromodulating during hypoxia, though other 
substances can enhance adenosine actions when the nucleoside is not operative. A1 
receptors fine tuning neuromodulation is a very restrained change, similar to what e.g., a 
pianist does, modulating a tune through introduction of another tune to modify the 
characteristics of the previous tune. A1 receptors have specificity of interacting with 
receptors of other neurotransmitters and neuromodulators as well as with adenosine 
transport systems. A1 receptors and other cellular elements involved in brain insults act via 
interconnections between the cellular elements and their secretions, such as the immune 
system(Ribeiro, 2005). In this manner, the nervous system can be highly regulated in normal 
physiology to induce neuroprotection against hypoxia. The fact that chemical 
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neuromodulators such as A1 receptors are already part of normal physiology, either during 
embryonic development or adulthood, implies that their activity can be modified by specific 
pharmacological agonists and antagonists to restore homeostasis or to promote the safe 
pathways that can lead to tissue hypoxia protection. 
4. Cellular mechanisms that promote neuronal death can be manipulated to 
promote neuronal survival 
It is well known that neuronal death or apoptosis may result from continued activation of 
damaging molecular processes or pathways set in motion by a series of hypoxic insults, 
with the ultimate breakdown of the cell as a unit. According to Lipton (1999) such 
neuronal death is a morphological one, during which the cell cannot recover to perform 
its anatomical function. The idea is that the study of molecular processes of neuronal 
death at this point provides an understanding of what leads to these drastic structural 
changes and what needs to be done to promote neuronal survival. An interesting question 
in this regard is how can the molecular mechanisms or pathways that promote hypoxia-
induced neuronal death be manipulated to promote neuronal survival? By targeting the 
disruption of the mouse caspase 8 genes, it has been shown that caspase 8 can regulate the 
activities of death promoting receptor signaling within the TNFR superfamily. For 
example, the deletion of caspase 8 gene completely abrogated TNFR12 and Fas receptor-
induced apoptosis that was enacted via generation of reactive oxygen species during 
hypoxia (Cobelens et al., 2007). In other studies that explore the mechanisms of hypoxia-
induced cell death in primary cortical neurons, it was found that TNFalpha was 
responsible for inducing cell death in the cortical neurons of cultured rats (Reimann-
Philipp et al., 2001). These investigations established that TNF receptors are responsible 
for neuronal apoptosis because of the formation of an intracellular protein complex 
induced by hypoxia.  
Although TNFalpha is directly implicated in neuronal apoptosis, TNFalpha-induced 
neuronal death can be inhibited by nerve growth factors (Haviv and Stein, 1999). This 
finding indicates that  that hypoxia-associated apoptotic effects of TNFalpha can be 
converted by trophic factors (NGFs), and that the survival-promoting effect of NGF is 
mediated by a specific  pathway not shared by all tyrosine kinase receptors. This implies 
that the manipulation of caspases and NGFs during hypoxia-induced activation of 
TNFalpha in the cortical neurons can prevent apoptotic effect of TNFalpha during hypoxia. 
Phosphorylation networks regulating JNK activity have evolved to enable swift and 
accurate responses, even in the face of hypoxia-induced cellular perturbations (Bakal et al., 
2008). The JNK signaling network is thought to maintain cell and tissue integrity during 
hypoxia-induced cellular stress that involves stress-activated protein kinases (SAPKs), also 
known as JUN NH2-terminal kinases (JNKs). Hypoxia-induced activation of JNK is an early 
response to hypoxic stress (Antoniou et al., 2009). When treated with CEP-1347, which 
inhibits JNK activation, the increase of cellular JNK activity was blocked, such that 
sympathetic and cortical neurons were saved from hypoxia-induced stress (Qi et al., 2009). 
Hypoxia-induced cell death can be averted by inhibiting JNK activation(Wardle, 2009). The 
explanation for this is that C-jun, a transcription factor that controls genes involved in cell 
death, is a constituent of another transcription factor called AP-1, and when phosphorylated 
by JNK, c-jun becomes activated and induces apoptosis, by withdrawing survival signals 
but when inactivated, metabolically vulnerable neurons can be saved from apoptosis. 
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Apart from JNK, there are other molecular systems that are able to induce apoptosis or 
neuronal death when in an active form, yet in an inactive form fail to do so. Molecular 
factors such as CREN, NF-kB (238) and FKHRL1 (Obexer et al., 2006), must be in its 
inactive form in order to refrain from inducing the expression of death genes in cerebellar 
granule neurons during hypoxia. These factors (CREN, NF-kB and FKHRL1) can be 
activated by Akt (Akt is a protein family of the kinases B (PKB) that is involved in cellular 
signaling to support their continued existence in brain cells to promote apoptosis (Park et 
al., 2007). Akt can also inhibit the cellular machinery that functions in killing cells. This is 
possible by phosphorylation at sites both upstream (BAD) and downstream (Caspase 9) of 
mitochondrial cytochrome c release (Dashniani et al., 2009). Such phosphorylation has 
been previously suggested to regulate glucose metabolism, thus, helping cells to live 
rather than die following hypoxic insults (Zhou et al., 2001). In summary, most of the 
aforementioned studies have been done in rats, exploring similar studies in hypoxia 
tolerating species will provide an in-depth-understanding of the activities of these 
molecular mechanisms or pathways during neuronal survival in hypoxia tolerating 
conditions. 
Hormones are chemical substances produced by specialized glands with the primary 
function of regulating cellular activity. Levels of hormones in the brain demonstrate 
unique secretory characteristics that are linked to hypoxia. Leptin is a protein hormone 
with important effects in regulating metabolism functions. Most recent evidence has 
implicated leptin, the product of the obese gene derived from fat cells and placenta 
known to regulate body weight and food intake (Otukonyong et al., 2005), and synaptic 
plasticity during hypoxia neuroprotection (Shanley et al., 2001). More recently, the 
neuroprotective effects of leptin against tissue hypoxia have been explored (Perez-Pinzon 
and Born, 1999). This study revealed that leptin receptors are expressed in neurons of the 
hypothalamus. Another study (Guo et al., 2008),revealed the expression of leptin in the 
hippocampus and cerebral cortex. Endogenous synthesis and release of leptin by the brain 
may explain how localized leptin could protect neurons during hypoxia. For instance, 
cumulative evidence indicate that leptin could exert its neuroprotective effects to enhance 
neuronal survival both in vitro and in vivo by a mechanism involving stimulation of the 
Janus kinase (JAK)-signal transducers and activator of transcription (STAT) pathways. It 
has been shown that leptin protects neurons from neurotoxic 1-methyl-4-pyridinium 
(MPP+)-induced cell death in a dose dependent manner by activating the 
phosphatidylinositol 3-kinase (PI3-K)/Akt pathway; Jingnan et al., 2006). In mice model, 
systemic administration of leptin was shown to decrease infarct volume induced by focal 
cerebral hypoxia ischemia (Zhang et al., 2007). Apoptosis resulting from hypoxia or global 
ischemia is involved in the pathology of cerebral infarction and neuronal death. Leptin 
has been reported to inhibit apoptosis by removing growth factor from neuroblastoma 
cells utilizing JAK2-STAT3 and P13K/AKT signaling pathways (Guo et al., 2008). In 
seizures and epilepsy related hypoxia, leptin has been shown to protect hippocampal 
neurons against excitotoxicity in leptin deficient ob/ob mice, which are more prone to 
seizures (Erbayat-Atlay et al., 2006). Leptin has been reported as a hypoxic response gene 
whose transcription is induced by transcription factor HIF-1. Understanding the specific 
role of leptin in hypoxia conditioning can add leptin to the list of potential molecules for 
the treatment of hypoxia-associated brain injury. 
Ghrelin is another peptide hormone that has been implicated in regulating glucose 
homeostasis (Andrews, 2011). The discovery of ghrelin was based on its ability to stimulate 
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neuromodulators such as A1 receptors are already part of normal physiology, either during 
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with the ultimate breakdown of the cell as a unit. According to Lipton (1999) such 
neuronal death is a morphological one, during which the cell cannot recover to perform 
its anatomical function. The idea is that the study of molecular processes of neuronal 
death at this point provides an understanding of what leads to these drastic structural 
changes and what needs to be done to promote neuronal survival. An interesting question 
in this regard is how can the molecular mechanisms or pathways that promote hypoxia-
induced neuronal death be manipulated to promote neuronal survival? By targeting the 
disruption of the mouse caspase 8 genes, it has been shown that caspase 8 can regulate the 
activities of death promoting receptor signaling within the TNFR superfamily. For 
example, the deletion of caspase 8 gene completely abrogated TNFR12 and Fas receptor-
induced apoptosis that was enacted via generation of reactive oxygen species during 
hypoxia (Cobelens et al., 2007). In other studies that explore the mechanisms of hypoxia-
induced cell death in primary cortical neurons, it was found that TNFalpha was 
responsible for inducing cell death in the cortical neurons of cultured rats (Reimann-
Philipp et al., 2001). These investigations established that TNF receptors are responsible 
for neuronal apoptosis because of the formation of an intracellular protein complex 
induced by hypoxia.  
Although TNFalpha is directly implicated in neuronal apoptosis, TNFalpha-induced 
neuronal death can be inhibited by nerve growth factors (Haviv and Stein, 1999). This 
finding indicates that  that hypoxia-associated apoptotic effects of TNFalpha can be 
converted by trophic factors (NGFs), and that the survival-promoting effect of NGF is 
mediated by a specific  pathway not shared by all tyrosine kinase receptors. This implies 
that the manipulation of caspases and NGFs during hypoxia-induced activation of 
TNFalpha in the cortical neurons can prevent apoptotic effect of TNFalpha during hypoxia. 
Phosphorylation networks regulating JNK activity have evolved to enable swift and 
accurate responses, even in the face of hypoxia-induced cellular perturbations (Bakal et al., 
2008). The JNK signaling network is thought to maintain cell and tissue integrity during 
hypoxia-induced cellular stress that involves stress-activated protein kinases (SAPKs), also 
known as JUN NH2-terminal kinases (JNKs). Hypoxia-induced activation of JNK is an early 
response to hypoxic stress (Antoniou et al., 2009). When treated with CEP-1347, which 
inhibits JNK activation, the increase of cellular JNK activity was blocked, such that 
sympathetic and cortical neurons were saved from hypoxia-induced stress (Qi et al., 2009). 
Hypoxia-induced cell death can be averted by inhibiting JNK activation(Wardle, 2009). The 
explanation for this is that C-jun, a transcription factor that controls genes involved in cell 
death, is a constituent of another transcription factor called AP-1, and when phosphorylated 
by JNK, c-jun becomes activated and induces apoptosis, by withdrawing survival signals 
but when inactivated, metabolically vulnerable neurons can be saved from apoptosis. 
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Apart from JNK, there are other molecular systems that are able to induce apoptosis or 
neuronal death when in an active form, yet in an inactive form fail to do so. Molecular 
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mitochondrial cytochrome c release (Dashniani et al., 2009). Such phosphorylation has 
been previously suggested to regulate glucose metabolism, thus, helping cells to live 
rather than die following hypoxic insults (Zhou et al., 2001). In summary, most of the 
aforementioned studies have been done in rats, exploring similar studies in hypoxia 
tolerating species will provide an in-depth-understanding of the activities of these 
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neuroprotective effects of leptin against tissue hypoxia have been explored (Perez-Pinzon 
and Born, 1999). This study revealed that leptin receptors are expressed in neurons of the 
hypothalamus. Another study (Guo et al., 2008),revealed the expression of leptin in the 
hippocampus and cerebral cortex. Endogenous synthesis and release of leptin by the brain 
may explain how localized leptin could protect neurons during hypoxia. For instance, 
cumulative evidence indicate that leptin could exert its neuroprotective effects to enhance 
neuronal survival both in vitro and in vivo by a mechanism involving stimulation of the 
Janus kinase (JAK)-signal transducers and activator of transcription (STAT) pathways. It 
has been shown that leptin protects neurons from neurotoxic 1-methyl-4-pyridinium 
(MPP+)-induced cell death in a dose dependent manner by activating the 
phosphatidylinositol 3-kinase (PI3-K)/Akt pathway; Jingnan et al., 2006). In mice model, 
systemic administration of leptin was shown to decrease infarct volume induced by focal 
cerebral hypoxia ischemia (Zhang et al., 2007). Apoptosis resulting from hypoxia or global 
ischemia is involved in the pathology of cerebral infarction and neuronal death. Leptin 
has been reported to inhibit apoptosis by removing growth factor from neuroblastoma 
cells utilizing JAK2-STAT3 and P13K/AKT signaling pathways (Guo et al., 2008). In 
seizures and epilepsy related hypoxia, leptin has been shown to protect hippocampal 
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seizures (Erbayat-Atlay et al., 2006). Leptin has been reported as a hypoxic response gene 
whose transcription is induced by transcription factor HIF-1. Understanding the specific 
role of leptin in hypoxia conditioning can add leptin to the list of potential molecules for 
the treatment of hypoxia-associated brain injury. 
Ghrelin is another peptide hormone that has been implicated in regulating glucose 
homeostasis (Andrews, 2011). The discovery of ghrelin was based on its ability to stimulate 
 
Brain Injury – Pathogenesis, Monitoring, Recovery and Management 
 
388 
growth hormone (GH) release by activating the GH secretagogue receptor (GHSR1a) widely 
distributed in the hypothalamus and the pituitary gland. The neuroprotective effect of 
ghrelin has been demonstrated in many animal models of hypoxic-induced brain injury and 
stroke (Donnan et al., 2008). Injection of ghrelin intraperitonealy or intravenously in rats 
(both in vivo and in vitro) neuroprotects the forebrain by reducing infarct volume and  
cell death (Liu et al., 2009). Ghrelin has also been shown to attenuate CAI and CA3 
hippocampal neuronal loss by inhibiting casp 3 activation in the pilocarpine-model of 
epilepsy (Xu et al., 2009). It is also important to point out that the crosstalk in leptin and 
ghrelin secreting sites to contribute to neuroprotection during the period of hibernation. 
Precisely, during the winter months hibernating mammals, such as the Arctic ground 
squirrel undergo physiological and behavioral changes to cope with seasonal periods of 
food scarcity and high energy demand. Before going into hibernation, the Arctic ground 
squirrel eat a lot and accumulate body fat, such that leptin level increases resulting in the 
development of leptin resistance without which the process of adipose mass deposition will 
fail, and hibernation which is also characterized with hypoxia tolerance will be in jeopardy. 
When hibernating, the Arctic ground squirrels do not eat because food is scarce, body 
metabolism decreases and hypothermia sets in. Since ghrelin stimulates appetite, and the 
animals are able to eat after hibernation is over. Leptin resistance is known to allow fat to be 
stored in anticipation of another season. Therefore, we propose that the understanding of 
the interconnections between the leptin and ghrelin with the metabolic networks could open 
new windows on the treatment that identifies the role of leptin and ghrelin in the 
preservation of metabolically vulnerable neurons during tissue hypoxia following the onset 
of stroke. 
5. Conclusion 
Analysis of brain mechanisms that control hypoxia tolerance in natural systems indicate 
that the physiological and molecular mechanisms of hypoxia neuroprotection represent 
the core of our understanding of how the brain can be made to resist tissue hypoxic 
insults. Studies of mammalian hypoxia physiology revealed that hypoxia tolerating 
models have an intrinsic ability to resist hypoxia. The physiological and intracellular 
mechanisms underlying such protection are not fully understood. Transformative 
advances in the science of mammalian physiology, especially those that can connect 
mammalian physiological and molecular changes and diseases, such as stroke and cardiac 
arrest, are urgently needed. In this review, we suggest that the protective physiological 
and molecular mechanisms employed by hypoxia-tolerant species offer clues on strategies 
to adapt for the clinical management of brain injuries where oxygen demand fails to 
match the supply.  
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ghrelin has been demonstrated in many animal models of hypoxic-induced brain injury and 
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metabolism decreases and hypothermia sets in. Since ghrelin stimulates appetite, and the 
animals are able to eat after hibernation is over. Leptin resistance is known to allow fat to be 
stored in anticipation of another season. Therefore, we propose that the understanding of 
the interconnections between the leptin and ghrelin with the metabolic networks could open 
new windows on the treatment that identifies the role of leptin and ghrelin in the 
preservation of metabolically vulnerable neurons during tissue hypoxia following the onset 
of stroke. 
5. Conclusion 
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that the physiological and molecular mechanisms of hypoxia neuroprotection represent 
the core of our understanding of how the brain can be made to resist tissue hypoxic 
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models have an intrinsic ability to resist hypoxia. The physiological and intracellular 
mechanisms underlying such protection are not fully understood. Transformative 
advances in the science of mammalian physiology, especially those that can connect 
mammalian physiological and molecular changes and diseases, such as stroke and cardiac 
arrest, are urgently needed. In this review, we suggest that the protective physiological 
and molecular mechanisms employed by hypoxia-tolerant species offer clues on strategies 
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1. Introduction 
The aim of this chapter is to describe several studies which have attempted to 
measure/detect effects of antioxidant compounds (lipoic acid, ubiquinone, ascorbic acid and 
alpha-tocopherol) on behavioral alterations, neuronal damage and oxidative stress in 
hippocampus of rodents in epilepsy model induced by pilocarpine. 
Epilepsy can cause an uncomfortable impact on social, educational and emotional 
development of affected people, especially in childhood and adolescence, but its diagnosis 
has had great progress over the last years. Nevertheless, among the diagnostic details 
requiring research, the precise localization and lateralization of epileptogenic focus remains 
unclear, despite the fact that it has been demonstrated that removal of cerebral cortex region 
may result in a state free of seizures. Moreover, epilepsy is considered a risk factor for 
depression and other psychological problems, whereas cognitive impairment may be related 
to behavioral troubles, particularly of conduct and attention deficit, hyperactivity and 
psychiatric disorders.  
Neurotransmitter systems involved in the experimental model of epilepsy induced by 
pilocarpine are not fully defined yet. This seizure model in rodents is widely used to study 
the pathophysiology of convulsive process, since it reproduces behavioral, 
electroencephalographic (EEG) and neurochemical changes that are similar to those of the 
temporal lobe epilepsy in humans. The pilocarpine model is used to study the action 
mechanism of new drugs and antioxidant compounds during the installation and 
maintenance and/or propagation of epileptogenesis as well as to evaluate effects of new 
compounds isolated from medicinal plants on behavioral, histopathological, and other 
parameters relating neurochemical changes with epileptic activity (Costa Júnior et al, 2010).  
Histopathological studies using this model have demonstrated neuronal damage in various 
brain regions. Some specific brain areas revealed typical histopathological changes, mainly 
hippocampus, striatum and frontal cortex, suggesting the involvement of these different 
areas during the establishment of the epileptic process. Among those areas, the cellular and 
structural modifications seen in hippocampus and striatum may be significantly related  to 
the mechanisms of installation and propagation in epileptogenesis of limbic seizures. 
The temporal lobe epilepsy is the most common form of epilepsy. It is characterized by 
spontaneous recurrent seizures that are often blocked by treatment with antiepileptic drugs. 
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Seizures can be characterized as clinical manifestations resulting from abnormal neuronal 
discharges, producing an imbalance between the mechanisms of inhibitory and excitatory 
neurotransmission. The mechanisms of activation, propagation and maintenance of seizures 
are widely studied but little understood. Many studies have been performed using the 
pilocarpine model to clarify the effects of new drug modulators on brain mechanisms of 
seizures and status epilepticus (Santos et al, 2010). 
Status epilepticus is clinically defined as prolonged electrical and clinical seizure activity in 
which the patient does not regain consciousness to a normal alert state between repeated 
tonic-clonic attacks. The disorder is a neurological emergency associated with a mortality 
rate of 10-12% and an even greater morbidity. Status epilepticus can lead to permanent 
pathological damage and altered physiological function in certain brain regions and induces 
major changes in membrane phospholipids, massive increases in arachidonic acid 
concentrations, diacylglycerol-mediated activation of protein kinase C, calcium-mediated 
changes in calmodulin kinase II and possibly generation of free radicals that could play an 
essential role in mechanism of oxidative stress involved in neuronal damage. Status 
epilepticus can be characterized by a permanent change in neurotransmitter systems and 
oxidative stress that it is more facilitated in the brain rather than in other tissues because it 
contains large quantities of oxidizable lipids and metals (Freitas et al, 2010). Moreover, 
status epilepticus can produce considerable changes on the enzymatic activity of 
antioxidants systems according to the brain areas and the phase of the seizure studied.  
The role of monoamines, amino acid and oxidative stress in pilocarpine model was 
investigated in hippocampus, striatum and frontal cortex of adult rats. The status 
epilepticus was induced by pilocarpine and the results correspond to its acute phase. The 
data obtained suggest that pilocarpine induced neurotransmitters and oxidative stress 
changes in brain regions which are similar to those found in human temporal lobe epilepsy 
(El-Etri et al, 1993, Freitas et al, 2003, Ferreira et al, 2009).  
2. Pathophysiology of seizures in epilepsy model induced by pilocarpine  
Epilepsies are complex neurobehavioral disorders resulting from increased excitability of 
neurons in several brain regions involving various neurotransmitters (Rauca et al, 2004). The 
cholinergic system plays an important role in generating EEG activity as well as regulating 
the vigilance states. Pilocarpine is a cholinergic agonist with a moderate affinity with M1 
muscarinic receptors and high affinity with M5 ones. Muscarinic cholinergic agonists have 
effects on rapid eyes movement (REM) and slow wave sleep, playing a role in REM 
induction (MacGregor et al, 1997; Perlis et al, 2002). On the other hand, pilocarpine at a high 
dose (400 mg/kg, i.p.)  makes seizures progress to a long-lasting status epilepticus (SE) 
within 1-2 h and induces behavioral and EEG alterations in rodents, which are similar to 
human temporal lobe epilepsy (TLE) (Marinho et al, 1998).   
Pilocarpine-induced rodent models TLE might provide information regarding 
histopathological damage and oxidative stress consequences, as well as neurochemical 
changes associated with seizure activity in hippocampus of young and adult rats 
(Cavalheiro et al, 1991; Smith and Shibley, 2002, Freitas et al, 2003). TLE can be characterized 
by a permanent change in neurotransmitter systems and in development of the oxidative 
stress that is more facilitated in the brain rather than in other tissues because for several 
reasons, including a high consumption of oxygen, the presence of large quantities of 
oxidizable lipids and pro-oxidative metals, and its comparatively lower antioxidant capacity 
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(Frantseva et al, 2000; Naffah-Mazzacoratti et al, 2001). Neuronal cells continuously produce 
free radicals and reactive oxygen species (ROS) as part of their metabolic processes and 
during the establishment of convulsive process (Gilbert and Sawas, 1983; Halliwell and 
Gutteridge, 1999). The free radicals are very reactive and might produce oxidative damage 
in DNA, proteins and lipids (Peterson et al, 2002), leading to a sequence of outcomes that 
culminates in neuronal degeneration during the installation of seizures.  
ROS can affect the ion transport, proteins and channels, via protein oxidation or  
via membrane phospholipids peroxidation, resulting in a deleterious change on the ionic 
homeostasis and the neuronal transmission (Rong et al, 1999; Sah et al, 2002). The ROS 
increment induces oxidative stress, which is defined as the excessive production of free 
radicals, such as superoxide (O2-), hydroxyl radical (OH.), nitric oxide (NO) and their 
metabolites (nitrate and nitrite) and others that can dramatically alter the neuronal function. 
Therefore, some researches have correlated the overproduction of these compounds  
with seizure-induced neuronal death and status epilepticus (MacGregor et al, 1997; Ferrer et 
al, 2000).  
Several compounds can produce free radical such as H2O2, which in high concentration can 
react with O2- (Haber-Weiss reaction) or iron (Fenton reaction) producing highly reactive 
OH. The conversion of H2O2 to H2O and O2 is made by catalase and glutathione peroxidase 
(Michiels et al, 1994; Simonié et al, 2000). The formed OH. radical is likely to react with non-
radical molecules, transforming them into secondary free radicals. This reaction occurs 
during the lipid peroxidation producing hydroperoxides in brain epileptic (Vanhatalo and 
Riikonen, 1999). Nitric oxide (NO) can be estimated by their metabolites, which are 
associated with neurodegenerative diseases (Vanhatalo and Riikonen, 2001). Despite the fact 
that numerous studies clearly indicate the importance of antioxidant enzymatic activities in 
the epileptic phenomenon, the mechanisms by which these enzymes influence seizures and 
status epilepticus are not completely understood (Michiels et al, 1994; Simonié et al, 2000). 
Status epilepticus is a severe form of continuous seizure attacks and a medical emergency 
associated with brain damage and significant mortality (Aminoff and Simon, 1980). The 
common sequels of status epilepticus include continuing recurrent seizures, permanent 
neurological deficit and brain injury. The status epilepticus can be induced by the 
administration of pilocarpine or lithium-pilocarpine (Hirsh et al, 1982; Freitas et al, 2004). 
Pilocarpine administration induces seizures with three distinct phases: [A] an acute period, 
which lasts 1-2 days and is associated to repetitive seizures and status epilepticus; [B] a 
seizure-free (silent period) characterized by a progressive return to normal EEG and 
behavior, which lasts 4 to 44 days; [C] a chronic period characterized by spontaneous 
recurrent seizures (SRS) that starts 5 to 45 days after pilocarpine administration and persists 
until the animal dies. In addition, systemic injection of pilocarpine induces status epilepticus 
in rodents associated to histopathological alterations, which are most prominent in limbic 
structures (Cavalheiro et al, 1991), such as hippocampus, striatum, frontal cortex and others 
(Tomé et al, 2010). 
Pilocarpine is a muscarinic cholinergic agonist able to elicit seizures and status epilepticus in 
rodents, characterizing an experimental model frequently used to study SRS (Turski et al, 
1983; Freitas et al, 2005). This seizure model resembles several phenomenological features of 
human temporal lobe epilepsy, including a particular resistance to anticonvulsant 
medication (Browne and Holmes, 2001). Tissue accumulation of free radicals can occur in 
many metabolic disorders, such as seizures. Affected patients present a variable degree of 
neurological dysfunction, including mental retardation, cognitive decit and cerebral 
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edema. However, the exact mechanisms involved in these alterations remain poorly 
understood. 
It has been described that the impairments in learning, memory and behavior observed in 
patients with epilepsy are caused, at least in part, by changes in cholinergic system function 
(Bruce and Baudry, 1995), since there are consistent evidence that high levels of 
acetylcholine (ACh) in the brain are associated with cognitive dysfunction (Brozek et al, 
2000). Cholinergic transmission is mainly terminated after ACh hydrolysis cause by 
acetylcholinesterase enzyme (AChE).  
In the brain, the phenomena of excitotoxicity has been related to an over production of free 
radicals by the tissue during pilocarpine-induced seizures and status epilepticus (Simonié et 
al, 2000) and in human epilepsy (Vanhatalo and Riikonen, 1999). The increase in ROS levels 
can be responsible for this neuropathology and can activate apoptosis processes (Rong et al, 
1999). The free radicals in the convulsive process can be neutralized by an elaborate 
antioxidant defense system consisting of enzymes such as superoxide dismutase, 
glutathione peroxidase, catalase, and glutathione reductase, and numerous non-enzymatic 
antioxidants like reduced glutathione (GSH), indicating a neuronal response (Ferrer et al, 
2000). Status epilepticus induces ROS production by protein oxidation measured by tyrosine 
nitration (Rong et al, 1999). It can also be determined by both the end-product of lipid 
peroxidation, malondialdehyde (MDA) levels (Bruce and Baudry, 1995), and the 
effectiveness of the antioxidant enzymatic responses (Dal-Pizzol et al, 2000). The 
hippocampus is the most affected area by pilocarpine-induced seizures. Other authors also 
characterized the neuropathology associated with this convulsive process in striatum, 
frontal cortex, thalamus and amygdala (Perlis et al, 2002; Freitas et al, 2004).  
Seizures represent one of the most severe in vivo stimulatory stress that the brain is exposed 
to and generalized status epilepticus represents a very severe form of seizures. The 
international Classification of seizures has defined it as a condition characterized by an 
epileptic seizure that is so frequent or so prolonged as to create a fixed and lasting condition 
(Krug et al, 1981). Major motor status epilepticus can lead to permanent pathological 
damage and altered physiological function in certain brain regions. The pathophysiological 
changes seen in complex partial, simple partial and absence status epilepticus are much less 
clear (Freitas et al, 2005). SE can cause brain damage, but can also result from it, and it has 
been difficult to separate the two, particularly in humans (Lapin et al, 1998). 
Status epilepticus has been widely studied in animal models. In status epilepticus, 
glutamate, aspartate, serotonin, dopamine and acetylcholine play major roles as excitatory 
neurotransmitters, and GABA as the dominant inhibitory neurotransmitter (Hort et al, 2000; 
Costa-Lotufo et al, 2002). However, the relation among brain excitatory and inhibitory 
neurotransmitters and status epilepticus cannot be perfectly established yet and deserves 
further studies with the purpose to clarify the pathophysiology of seizures.  
The pathophysiology of epilepsy is not yet fully defined. The pilocarpine model of seizures 
in animals are widely used to study the pathophysiology of convulsive process (Ben-Ari et 
al, 1980), since it reproduces the behavioral and EEG changes that are similar to humans 
TLE (Ben-Ari et al, 1981). These models are used to study the involvement of 
neurotransmitter systems as modulators of epileptogenesis, but also to observe behavioral 
changes, histopathologic, and other neurochemical parameters related to seizure activity 
(Marinho et al, 1997; Costa- Lotufo et al, 2002, Freitas et al, 2006). 
In general, pilocarpine-induced seizures seem to depend on activation of muscarinic 
receptor, the enzymatic activity changes in some systems (Simonié et al, 2000; Naffah-
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Mazzacoratti et al, 2001; Liu et al, 2002), metabolism of fosfoinositídios (Marinho et al, 1998), 
as well as on the involvement of other neurotransmitter systems such as noradrenergic, 
dopamine (Kulkarni and George, 1996), serotonergic, GABAergic (Loup et al. 1999; Costa-
Lotufo et al, 2002) and glutamatergic (Massieu et al. 1994; Chamberlain et al, 2000). 
3. Behavioral alterations in epilepsy model  
Status epilepticus is an emergency situation which requires prompt medical atentem. If it is 
severe permanent brain damage or death has to be prevented with pretreatment with 
antioxidant compounds. Status epilepticus often occurs in individuals with a history of 
seizures, in whom there are neuronal substrates already predisposed towards supporting 
seizure activity. 
The pilocarpine model is an useful animal experimental to investigate the development of 
acute, silent and chronic phases (Cavalheiro et al, 1991). Immediately after pilocarpine 
administration, all animals persistently presented behavioral changes, including initial 
akinesia, ataxic lurching, peripheral cholinergic signs (miosis, piloerection, 
chromodacryorrhea, diarrhea and masticatory automatisms), stereotyped movements 
(continuous sniffing, paw licking, rearing and wet dog shakes that persisted for 10-15 min), 
clonic movements of forelimbs, head bobbing and tremors. 
These behavioral changes progressed to motor limbic seizures as previously described  
by Tursky et al. (1983a). Limbic seizures lasted for 30-50 min evolving to status epilepticus 
for a period longer than 30 min. During 1 h of acute phase of seizures, no case of fatality was 
observed between the adult rats. However, during the 24 h observation of this phase, 63%  
of adult animals died (Cavalheiro et al, 1994; Todorova et al, 2004). Similarly, these results 
for the behavioral alterations in pilocarpine model were described previously by Marinho et 
al. (1998).  
According to our previous studies (Freitas et al, 2004), few minutes after pilocarpine 
administration, the animals exhibited stereotyped oral and masticatory movements, 
hypokinesia, salivation, tremor and partial or generalized limbic seizures. Approximately 30 
min after pilocarpine injection, the seizures evolved to status epilepticus lasting 12-18 h. 
During this period, 40% of animals died due to SE. This acute phase was followed by a silent 
period varying from 4 to 44 days (mean of 15 days) during which the animals displayed 
normal behavior. A chronic period of spontaneous and recurrent seizures (SRS) (3-4 
seizures/week) was also observed and all animals which survived SE, displayed the chronic 
phase. During the interictal period, there were no behavioral alterations in the animals. 
In epilepsy model, pilocarpine induced the rst seizure to occur at 34.93 ± 0.70 min. All the 
animals that received pilocarpine injection (at a dose 400 mg/kg, i.p.) presented generalized 
tonic-clonic convulsions with status epilepticus, and 60% survived the seizures (Freitas et al, 
2004).  
4. Antioxidant compounds effects on behavioral alterations in epilepsy model 
The nervous system contains some antioxidant enzymes, including superoxide dismutase 
and glutathione peroxidase that are expressed in higher quantities than catalase 
(Shivakumar et al, 1991). This spectrum of enzymatic defense suggests that the brain may 
efficiently metabolize superoxide, but it may have difficulties in eliminating the hydrogen 
peroxide produced by this reaction. The accumulation of hydrogen peroxide is of major 
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edema. However, the exact mechanisms involved in these alterations remain poorly 
understood. 
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Mazzacoratti et al, 2001; Liu et al, 2002), metabolism of fosfoinositídios (Marinho et al, 1998), 
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seizures/week) was also observed and all animals which survived SE, displayed the chronic 
phase. During the interictal period, there were no behavioral alterations in the animals. 
In epilepsy model, pilocarpine induced the rst seizure to occur at 34.93 ± 0.70 min. All the 
animals that received pilocarpine injection (at a dose 400 mg/kg, i.p.) presented generalized 
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The nervous system contains some antioxidant enzymes, including superoxide dismutase 
and glutathione peroxidase that are expressed in higher quantities than catalase 
(Shivakumar et al, 1991). This spectrum of enzymatic defense suggests that the brain may 
efficiently metabolize superoxide, but it may have difficulties in eliminating the hydrogen 
peroxide produced by this reaction. The accumulation of hydrogen peroxide is of major 
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concern since the brain contains large quantity of iron and copper, which may catalyze the 
formation of hydroxil radical, which, in turn, can induce lipid peroxidation (Castagne et al, 
1999). 
The glutathione peroxidase is presented in large amounts during the Central Nervous 
System (CNS) development, but decreases in aged rats (Nanda et al, 1996). Nevertheless, 
other scavengers such as ascorbic acid and alpha-tocopherol also decrease the propagation 
of radical chain reaction. For these reasons, free radicals have been pointed as important 
molecules involved in the nervous system pathologies such as Huntington disease, 
Alzheimer, ischaemia and epilepsy (Jenner, 1998). 
In epilepsy model induced by pilocarpine administration, we found that superoxide 
dismutase and catalase activities in the hippocampus are not altered during the acute phase 
of seizures. On the other hand, according to several authors, the augment of these enzymatic 
activities could decrease the O2- and H2O2 levels. Taken together, these results show that 
during the acute phase, the hippocampus of the adult animals in pilocarpine model after 
seizures is more vulnerable to oxidative stress. 
In addition, high-levels of hydroperoxides were also observed in the same group of animals, 
which indicated that the lipid peroxidation could be dependent of disability of the 
antioxidant enzymatic (superoxide dismutase and catalase) activities. As the 
hydroperoxides are a class of compounds produced as the result of phospholipid 
peroxidation, its high concentration in the tissue suggests that the hippocampal cells are 
more vulnerable to damage during the acute period of seizures. Thus, the results described 
in literature about pilocarpine model suggest that the beneficial effects of antioxidants 
compounds in reducing the behavioral changes caused by seizures may be partly explained 
by their ability to remove free radicals, and prevent the formation of hydroperoxides in 
hippocampus of seized rats. 
The need for animal models of epilepsy is driven by the constraints of studying human 
epileptic brain. Although a great deal has been learned through the study of human 
epileptic brain tissue throughout the past 100 years, and particularly based in recent 
experiments  with pilocarpine model, our work was aimed at investigating the antioxidant 
effects of lipoic acid, ubiquinone, ascorbic acid and alpha-tocopherol in adult rats under 
pilocarpine-induced seizures. Our studies have demonstrated that all animals pretreated 
with the lipoic acid at the dose (10 or 20 mg/kg) during the first hour of acute phase of 
seizures induced by pilocarpine injection also manifested behavior alterations, such as 
peripheral cholinergic signs, tremors, staring spells, facial automatisms, wet dog shakes, 
rearing and motor seizures, which develop progressively within 1-2 h into a long-lasting 
status epilepticus. However, these behavioral changes occur at lower rates (Table 1). The 
findings also suggest that when administered 30 min before pilocarpine, lipoic acid reduces 
the percentage of animals that seized, increases latency to the rst seizure and the survival 
percentage (Table 1). 
Corroborating these data, other antioxidant compound evaluated in pilocarpine model 
when administered at the dose of 5 mg/kg before pilocarpine, ubiquinone had no effects on 
seized animals and survival percentage, but increased latency to the first seizure, when 
compared with the pilocarpine group (Table 1). On the other hand, at a dose of 10 or 20 
mg/kg ubiquinone produced a higher reduction of seizures percentage, and a higher 
increase to that produced by dose of 5 mg/kg in latency to the first seizure and survival rate 
in pilocarpine model (Table 1). 
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Drugs Dose (mg/kg) 
Cholinergic 
Reactions (%) 









Pilocarpine 400 100 35.00 ± 0.70 75 75 40 
Ascorbic acid 250 100 80.00 ± 1.30* 33a 33a 100a 
 500 100 189.19 ± 1.15*,** 25a,b 25a,b 100a,b 
Alpha-
tocopherol 200 100 103.00 ± 0.90* 32
a 32a 68a 
 400 100 158.10 ± 1.05*,** 16a,b 16a,b 70a,b 
Ubiquinone 5 100 69.00 ± 0.65* 60a 60a 60a 
 10 100 89.00 ± 0.83*,** 35a,b 35a,b 75a,b 
Lipoic acid 10 100 106.13 ± 1.05* 00a 00a 75a 
 20 100 119.00 ± 1.02* 10a 10a 90a 
Rats were acutely treated with the drug doses shown in the table above and 30 min afterwards they 
received pilocarpine (400 mg/kg). Following, the animals were observed for 24 h for assessment of 
cholinergic reactions, motor seizures which develop progressively within 1-2 h into a long-lasting status 
epilepticus and survival rate. Results of latency to first seizure and latency to installation of status 
epilepticus are expressed in minutes (min) as mean ± S.E.M of the number of experiments shown in the 
experimental groups and the others in percentages  *p<0.05, vs pilocarpine. **p<0.05 vs lower dose 
(ANOVA and t-Student Newman Keuls post hoc test);  ap<0.05, vs pilocapine. bp<0.05, vs lower dose  
(χ2 test). 
Table 1. Effect of pretreatment with antioxidant drugs on behavioral alterations in 
pilocarpine-induced seizures and lethality in adult rats. 
In preclinical practice, the animals pretreated with ascorbic acid (250 mg/kg) in pilocarpine 
model developed cholinergic reactions, 33% had seizures, 25% built up to status epilepticus 
and no animal died (Table 1). Ascorbic acid administration, 30 min before pilocarpine 
injections, increased the latency to the onset of the rst seizure in 129% and latency of the 
status epilepticus in 195% (Table 1). In pilocarpine model, it is also shown that when 
administered at the smaller dose (200 mg/kg), 30 min before pilocarpine injection, alpha-
tocopherol can be decrease by 43% the percentage of animals that seized, increased (194%) 
latency to the rst seizure, and increased survival (41%) (Table 1). 
Conversely, a higher dose (500 mg/kg) of the ascorbic acid in pilocarpine model, produced 
changes in behavior with lower intensity, such as peripheral cholinergic signs (100%), 
staring spells, facial automatisms, wet dog shakes, rearing and motor seizures (25%) were 
observed, which progressively developed (1-2 h) into long-lasting status epilepticus (25%), 
revealing a survival rate of 75% (Table 1). Other studies have revealed that alpha-tocopherol 
at a dose 400 mg/kg blocks all alterations in behavior, revealing only 16% of motor seizures, 
which progressively developed (1-2 h) into long-lasting status epilepticus in pilocarpine 
model and a survival rate of 84% from the seizures (Table 1). 
5. Histopathological alterations in epilepsy model  
Cholinergic mechanisms play an important role in the activation of limbic seizures, and 
dopaminergic, serotonergic, GABAergic and glutamatergic systems are responsible for the 
propagation and/or maintenance of seizures and status epilepticus induced by pilocarpine 
(Freitas et al, 2004). Previous studies have described a model of limbic seizures followed by 
brain damage produced by systemic injection of a high dose of pilocarpine in rats. The 
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concern since the brain contains large quantity of iron and copper, which may catalyze the 
formation of hydroxil radical, which, in turn, can induce lipid peroxidation (Castagne et al, 
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The glutathione peroxidase is presented in large amounts during the Central Nervous 
System (CNS) development, but decreases in aged rats (Nanda et al, 1996). Nevertheless, 
other scavengers such as ascorbic acid and alpha-tocopherol also decrease the propagation 
of radical chain reaction. For these reasons, free radicals have been pointed as important 
molecules involved in the nervous system pathologies such as Huntington disease, 
Alzheimer, ischaemia and epilepsy (Jenner, 1998). 
In epilepsy model induced by pilocarpine administration, we found that superoxide 
dismutase and catalase activities in the hippocampus are not altered during the acute phase 
of seizures. On the other hand, according to several authors, the augment of these enzymatic 
activities could decrease the O2- and H2O2 levels. Taken together, these results show that 
during the acute phase, the hippocampus of the adult animals in pilocarpine model after 
seizures is more vulnerable to oxidative stress. 
In addition, high-levels of hydroperoxides were also observed in the same group of animals, 
which indicated that the lipid peroxidation could be dependent of disability of the 
antioxidant enzymatic (superoxide dismutase and catalase) activities. As the 
hydroperoxides are a class of compounds produced as the result of phospholipid 
peroxidation, its high concentration in the tissue suggests that the hippocampal cells are 
more vulnerable to damage during the acute period of seizures. Thus, the results described 
in literature about pilocarpine model suggest that the beneficial effects of antioxidants 
compounds in reducing the behavioral changes caused by seizures may be partly explained 
by their ability to remove free radicals, and prevent the formation of hydroperoxides in 
hippocampus of seized rats. 
The need for animal models of epilepsy is driven by the constraints of studying human 
epileptic brain. Although a great deal has been learned through the study of human 
epileptic brain tissue throughout the past 100 years, and particularly based in recent 
experiments  with pilocarpine model, our work was aimed at investigating the antioxidant 
effects of lipoic acid, ubiquinone, ascorbic acid and alpha-tocopherol in adult rats under 
pilocarpine-induced seizures. Our studies have demonstrated that all animals pretreated 
with the lipoic acid at the dose (10 or 20 mg/kg) during the first hour of acute phase of 
seizures induced by pilocarpine injection also manifested behavior alterations, such as 
peripheral cholinergic signs, tremors, staring spells, facial automatisms, wet dog shakes, 
rearing and motor seizures, which develop progressively within 1-2 h into a long-lasting 
status epilepticus. However, these behavioral changes occur at lower rates (Table 1). The 
findings also suggest that when administered 30 min before pilocarpine, lipoic acid reduces 
the percentage of animals that seized, increases latency to the rst seizure and the survival 
percentage (Table 1). 
Corroborating these data, other antioxidant compound evaluated in pilocarpine model 
when administered at the dose of 5 mg/kg before pilocarpine, ubiquinone had no effects on 
seized animals and survival percentage, but increased latency to the first seizure, when 
compared with the pilocarpine group (Table 1). On the other hand, at a dose of 10 or 20 
mg/kg ubiquinone produced a higher reduction of seizures percentage, and a higher 
increase to that produced by dose of 5 mg/kg in latency to the first seizure and survival rate 
in pilocarpine model (Table 1). 
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Table 1. Effect of pretreatment with antioxidant drugs on behavioral alterations in 
pilocarpine-induced seizures and lethality in adult rats. 
In preclinical practice, the animals pretreated with ascorbic acid (250 mg/kg) in pilocarpine 
model developed cholinergic reactions, 33% had seizures, 25% built up to status epilepticus 
and no animal died (Table 1). Ascorbic acid administration, 30 min before pilocarpine 
injections, increased the latency to the onset of the rst seizure in 129% and latency of the 
status epilepticus in 195% (Table 1). In pilocarpine model, it is also shown that when 
administered at the smaller dose (200 mg/kg), 30 min before pilocarpine injection, alpha-
tocopherol can be decrease by 43% the percentage of animals that seized, increased (194%) 
latency to the rst seizure, and increased survival (41%) (Table 1). 
Conversely, a higher dose (500 mg/kg) of the ascorbic acid in pilocarpine model, produced 
changes in behavior with lower intensity, such as peripheral cholinergic signs (100%), 
staring spells, facial automatisms, wet dog shakes, rearing and motor seizures (25%) were 
observed, which progressively developed (1-2 h) into long-lasting status epilepticus (25%), 
revealing a survival rate of 75% (Table 1). Other studies have revealed that alpha-tocopherol 
at a dose 400 mg/kg blocks all alterations in behavior, revealing only 16% of motor seizures, 
which progressively developed (1-2 h) into long-lasting status epilepticus in pilocarpine 
model and a survival rate of 84% from the seizures (Table 1). 
5. Histopathological alterations in epilepsy model  
Cholinergic mechanisms play an important role in the activation of limbic seizures, and 
dopaminergic, serotonergic, GABAergic and glutamatergic systems are responsible for the 
propagation and/or maintenance of seizures and status epilepticus induced by pilocarpine 
(Freitas et al, 2004). Previous studies have described a model of limbic seizures followed by 
brain damage produced by systemic injection of a high dose of pilocarpine in rats. The 
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evidence included temporal correlation among free radical generation, development of 
seizures and neuroprotective effects of antioxidant drugs against neuronal damage caused 
by seizures (Kabuto et al, 1998).  
Other studies have shown pilocarpine-induced seizures and brain damage in various 
cerebral regions and a significant hippocampal injury in this epilepsy model (Turski et al, 
1991; Curia et al, 2008). The anticonvulsant effect in the absence of anticholinergic drugs 
subsequent to the seizure onset suggests that muscarinic receptor activation is involved 
directly in the beginning of seizures by pilocarpine.  
However, the oxidative stress might also play an essential role in the production of neuronal 
damage, which can be justified by neuroprotective actions of antioxidant compounds 
according to previous studies (Freitas et al, 2004; Xavier et al, 2007; Ayyildiz et al, 2007a). 
Previous research indicates that anticonvulsant effects of noradrenergic antagonist drugs have 
a fundamental role in the mechanisms responsible for beginning, severity and duration of 
seizure. In fact, the reduction of severity and duration of seizures are protective against 
neurotoxicity caused by seizures induced by chemical convulsants (e.g. pilocarpine, kainic acid 
and others). These data, in spite of confirming a pivotal role of anticonvulsant drugs in 
modulating seizure threshold and neuronal death, offer a novel target, which may be used to 
develop anticonvulsant and neuroprotective agents (Pizzanelli et al, 2009). 
There are several indications that free radical plays a role in epileptogenesis. During 
seizures, the ROS concentration and brain lipid peroxidation increase (Curia et al, 2008). It is 
currently hypothesized that any pathological process such as status epilepticus, which 
releases dopamine and glutamate, activates D2 and NMDA receptors.  
This may lead to neuronal necrosis by elevating intracellular calcium and activating 
potentially destructive calcium-dependent enzymes, augmenting the production of free 
radicals during seizures induced by pilocarpine (Michotte et al, 1997).  
The available experimental data suggest that convulsion generally accelerate brain damage. 
Limbic status epilepticus causes neuronal necrosis in hippocampus, amygdala, pyriform 
cortex, entorhinal cortex, thalamus, neocortex, striatum and substantia nigra (Ayyildiz et al, 
2007b). The neuronal damage depends on synaptic activation (Vanin et al, 2003), probably 
via a glutamatergic calcium-medited mechanism (Marinho et al, 1998).  
In the epilepsy model induced by a high dose of pilocarpine, we can observe neuronal loss 
in some brain areas, namely the hippocampus, striatum, amygdala, piriform cortex, 
entorhinal cortex, lateral septum, thalamus and substantia nigra, suggesting the 
involvement of these different areas during the establishment of the epileptic process 
(Honchar et al, 1983; Turski et al, 1983; Clifford et al, 1987; Marinho et al, 1997; Borelli et al, 
2002; Freitas et al, 2006). 
Among the areas in which neuronal damage occurs, the striatum and fronto-parietal cortex, 
besides being the most affected areas, may be related in important ways with the mechanism 
of propagation and/or maintenance (epileptogenesis) limbic seizures (Marinho et al, 1998). 
Barone and collaborators (1991) demonstrated that through intracerebral administration in the 
striatum of D2 dopamine agonists, there was a protection with respect to the development of 
seizures in adult rats, suggesting the participation of this brain region in limbic seizures. 
Histopathological examinations during the acute phase of seizures induced by pilocarpine 
show extensive hippocampal brain damage, pyriform, entorhinal, frontal, temporal and 
parietal cortices and in the  striatum and amygdaloid nucleus (Marinho et al, 1997). 
Cerebral lesions during the acute period are characterized by neuronal loss, gliosis and 
vacuolation, although there are contradictory data with respect to the severity and relative 
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distribution of brain damage (Mello et al, 1993). Brain necrosis is associated with the 
occurrence of seizures, although studies have demonstrated that this association is not 
obligatory, especially in the pilocarpine model (Peredery et al, 1992). The seizures induced 
by pilocarpine can be blocked by atropine, pointing towards involvement of the cholinergic 
system. On the other hand, atropine did not act after seizure onset, suggesting that others 
neurotransmitters and oxidative stress may participate in the maintenance and/or 
propagation of seizures and brain damage as well (Hirsh et al, 1982). Oxidative stress 
mediated by free radical produces lipid peroxidation, increases the nitrite content in the 
hippocampus, striatum and frontal cortex (Freitas et al, 2004) and may play a major role in 
the neuronal injury development after seizures induced by pilocarpine. 
6. Antioxidant compound effects on histopathological alterations in  
epilepsy model  
Hence, it could be expected that antioxidant drugs such as ascorbic acid and alpha-tocopherol, 
can be used as scavengers of free radicals, reducing brain injury induced by pilocarpine.  
In previous histopathological analyses, ascorbic acid and alpha-tocopherol antioxidants 
protected animals against seizures, status epilepticus and brain damage induced by 
pilocarpine (Figure 1) by decreasing the percentage of seizures, status epilepticus and death in 
relation to both doses tested.  
 
Fig. 1. Histopathological alterations in rat hippocampus treated with pilocarpine, ascorbic acid 
or their combinations. [A] Control group; [B] Pilocarpine group; [C] ascorbic acid 250 group; 
[D] ascorbic acid 250 plus Pilocarpine groups was treated with ascorbic acid (250 mg/kg) and 
30 min before Pilocarpine; [E] ascorbic acid 500 group; [F] ascorbic acid 500 plus Pilocarpine 
group was treated with ascorbic acid (500 mg/kg) and 30 min before Pilocarpine. Severity of 
lesion was expressed as mean ± S.E.M. of scores of damage based in a scale from zero (none) to 
100 (total) percent of structural involvement. Brain damage was considered positive if there 
was at least 50% hippocampal involvement. Hematoxylin & Eosin staining (H&E). 
Magnification, 100 X. One representative experiment with n=6 is shown. 
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evidence included temporal correlation among free radical generation, development of 
seizures and neuroprotective effects of antioxidant drugs against neuronal damage caused 
by seizures (Kabuto et al, 1998).  
Other studies have shown pilocarpine-induced seizures and brain damage in various 
cerebral regions and a significant hippocampal injury in this epilepsy model (Turski et al, 
1991; Curia et al, 2008). The anticonvulsant effect in the absence of anticholinergic drugs 
subsequent to the seizure onset suggests that muscarinic receptor activation is involved 
directly in the beginning of seizures by pilocarpine.  
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damage, which can be justified by neuroprotective actions of antioxidant compounds 
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a fundamental role in the mechanisms responsible for beginning, severity and duration of 
seizure. In fact, the reduction of severity and duration of seizures are protective against 
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Histopathological examinations during the acute phase of seizures induced by pilocarpine 
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parietal cortices and in the  striatum and amygdaloid nucleus (Marinho et al, 1997). 
Cerebral lesions during the acute period are characterized by neuronal loss, gliosis and 
vacuolation, although there are contradictory data with respect to the severity and relative 
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distribution of brain damage (Mello et al, 1993). Brain necrosis is associated with the 
occurrence of seizures, although studies have demonstrated that this association is not 
obligatory, especially in the pilocarpine model (Peredery et al, 1992). The seizures induced 
by pilocarpine can be blocked by atropine, pointing towards involvement of the cholinergic 
system. On the other hand, atropine did not act after seizure onset, suggesting that others 
neurotransmitters and oxidative stress may participate in the maintenance and/or 
propagation of seizures and brain damage as well (Hirsh et al, 1982). Oxidative stress 
mediated by free radical produces lipid peroxidation, increases the nitrite content in the 
hippocampus, striatum and frontal cortex (Freitas et al, 2004) and may play a major role in 
the neuronal injury development after seizures induced by pilocarpine. 
6. Antioxidant compound effects on histopathological alterations in  
epilepsy model  
Hence, it could be expected that antioxidant drugs such as ascorbic acid and alpha-tocopherol, 
can be used as scavengers of free radicals, reducing brain injury induced by pilocarpine.  
In previous histopathological analyses, ascorbic acid and alpha-tocopherol antioxidants 
protected animals against seizures, status epilepticus and brain damage induced by 
pilocarpine (Figure 1) by decreasing the percentage of seizures, status epilepticus and death in 
relation to both doses tested.  
 
Fig. 1. Histopathological alterations in rat hippocampus treated with pilocarpine, ascorbic acid 
or their combinations. [A] Control group; [B] Pilocarpine group; [C] ascorbic acid 250 group; 
[D] ascorbic acid 250 plus Pilocarpine groups was treated with ascorbic acid (250 mg/kg) and 
30 min before Pilocarpine; [E] ascorbic acid 500 group; [F] ascorbic acid 500 plus Pilocarpine 
group was treated with ascorbic acid (500 mg/kg) and 30 min before Pilocarpine. Severity of 
lesion was expressed as mean ± S.E.M. of scores of damage based in a scale from zero (none) to 
100 (total) percent of structural involvement. Brain damage was considered positive if there 
was at least 50% hippocampal involvement. Hematoxylin & Eosin staining (H&E). 
Magnification, 100 X. One representative experiment with n=6 is shown. 
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A variety of epilepsy models reflect the effects of acid ascorbic and alpha-tocopherol and 
specify their action (Koza et al, 2007; Gaby, 2007). Previously, it had been demonstrated that 
these compounds reduced the frequency of penicillin-induced epileptiform activity 
(Ayyildiz et al, 2006; Ayyildiz et al, 2007b). In recent years, many roles of alpha-tocopherol 
have been discovered, including not only an antioxidant function, but also pro-oxidant, cell 
signaling, and gene regulatory functions. Some studies have reported that alpha-tocopherol 
is considered to be the main antioxidant substance in the human body, interfering with the 
production of hydroxyl radical and also with the oxygen in cell membranes, thereby 
reducing lipid peroxidation (Barros et al, 2007).  
Our results demonstrated that seizure pattern and brain damage observed in pilocarpine-
treated animals differ from those pretreated with alpha-tocopherol (400 mg/kg) plus 
pilocarpine (400 mg/kg). The latter reproduced the syndrome with lower intensity  
of histopathological changes and mortality rate, in comparison with the alpha-tocopherol 
(200 mg/kg) plus pilocarpine, corroborating the outcomes obtained by Ribeiro and 
collaborators (2005) and Ayyildiz and collaborators (2006). The percentage of status 
epilepticus (75%) that was found further corroborated prior investigations (Clifford et al, 
1987; Marinho et al, 1997). 
Ascorbic acid is probably the most important water-soluble antioxidant in the brain 
extracellular fluid, and it is essential in regenerating reduced alpha-tocopherol in 
membranes (Niki, 1991). Despite the fact that ascorbic acid has an antioxidant role to 
counter oxidative stress, ascorbic acid also form reactive oxidants, especially in the presence 
of transition metals. The evidence suggests that ascorbic acid participates in pro-oxidant 
reactions under certain conditions (Layton et al, 1998).  
The outcomes confirm that ascorbic acid (250 or 500 mg/kg) decreased the frequency of 
pilocarpine-induced seizures, status epilepticus and brain lesions in rats. In addition, 
ascorbic acid decreases the severity of hippocampal lesions and mortality rate caused by 
pilocarpine. Yamamoto and collaborators (2002) demonstrated that the injection of 
ascorbate, 60 min before FeCl3 administration, prevented the occurrence of epileptic 
discharges. Since there are wide variations of alpha-tocopherol and ascorbic acid doses used 
in different models of seizure, more detailed investigations are necessary before an ultimate 
conclusion on the effects of those compounds on pilocarpine-induced seizures can be 
achieved. 
In conclusion, there is an accumulation of free radicals after status epilepticus induced by 
pilocarpine, and oxidative changes in other parameters during the acute phase. This finding 
suggests that seizures, status epilepticus and deaths induced by pilocarpine have a large 
participation in brain oxidative stress, which is closely related to the mechanism of 
propagation and/or maintenance of the epileptic focus by pilocarpine. These results suggest 
that free radicals as well as the muscarinic receptor activation seem to be involved in the 
genesis of seizures and brain damage obtained with pilocarpine. On the other hand, the 
muscarinic activation seems to play a major role in the neuronal damage produced by 
pilocarpine. Antioxidant compounds can exert neuroprotective function during acute phase 
of seizures, thereby decreasing the severity of hippocampal lesions. All these outcomes 
indicate the promising therapeutic potential of ascorbic acid and alpha-tocopherol in 
treatments for neurodegenerative diseases. 
Brain tissue examinations of the animals pretreated with ascorbic acid (250 or 500 mg/Kg; 
Figure 1), alpha-tocopherol (200 or 400 mg/kg Figure 2), lipoic acid (10 or 20 mg/kg, Figure 
3) or ubiquinone (5 or 10 mg/kg; Figure 4), did not reveal hippocampal and striatal 
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histopathological changes. Then again, pilocarpine-treated animals presented neuronal loss, 
gliosis, and typical vacuolar degeneration in hippocampus and striatum regions. 
Histopathological damage in hippocampus was observed in 50, 33, 33 and 17% of the 
animals co-administered with ascorbic acid (250 or 500 mg/kg) or alpha-tocopherol (200 or 
400 mg/kg), and that 30 min after pretreatment received pilocarpine (400 mg/kg), 
respectively (Table 2). In addition, the analyses of histopathological damage in 
hippocampus of rats pretreated with lipoic acid (10 or 20 mg/kg) or ubiquinone (5 or 10 
mg/kg), and that 30 min after pretreatment received pilocarpine (400 mg/kg) revealed a 
reduction of 52, 68, 52 and 100% in the number of animals with neuronal damage, 
respectively (Table 2). 
 
Drugs Dose (mg/kg) 
Rats with lesion 
(%) 
Severity of lesion 
(%) 
Number of animals 
with lesion per 
group 
Pilocarpine 400 83 59.92 ± 0.23 5 
Ascorbic acid 250 00 00 0 
 500 00 00 0 
Ascorbic acid plus P400 250 50a 20.00 ± 0.32a 3 
 500 33a,b 17.66 ± 0.33a,b 2 
Alpha-tocopherol 200 00 00 0 
 400 00 00 0 
Alpha-tocopherol plus P400 200 33a 13.66 ± 0.33a 2 
 400 17 a,b 5.97 1 
Ubiquinone 5 00 00 0 
 10 00 00 0 
Ubiquinone plus P400 5 33a 12.00 ± 0.25a 2 
 10 00 00 0 
Lipoic acid 10 00 00 0 
 20 00 00 0 
Lipoic acid plus P400 10 33a 11.96 ± 0.12a 2 
 20 17 a,b 5.97 1 
Pilocarpine was administered in a single dose (400 mg/kg, P400, n=6), ascorbic acid groups with 
ascorbic acid (250 or 500 mg/kg), alpha-tocopherol (200 or 400 mg/kg, n=6), ubiquinone (5 or 10 
mg/kg, n=6) and lipoic acid group with lipoic acid (10 or 20 mg/kg; n=6). The ascorbic plus P400 
groups were treated with ascorbic acid (250 or 500 mg/kg, n=6) and 30 min before P400. The alpha-
tocopherol plus P400 group was treated with alpha-tocopherol (200 or 400 mg/kg) and 30 min before 
P400. The ubiquinone plus P400 group was treated with ubiquinone (5 or 10 mg/kg) and 30 min before 
P400. The lipoic acid plus P400 group was treated with lipoic acid (10 or 20 mg/kg) and 30 min before 
P400. Severity of lesion was expressed as mean ± S.E.M. of scores of damage based on a scale from zero 
(none) to 100 (total) percent of structural involvement. Brain damage was defined as present if there 
was at least 50% hippocampal involvement. Results for % rats with brain lesion and % severity of lesion 
are expressed as percentages of the number of animals inside in parenthesis. ap<0.05 compared with 
P400 group (χ2 test). bp<0.05 compared with ascorbic acid 250 plus P400 group or alpha-tocopherol 200 
mg/kg plus P400 group or ubiquinone 5 mg/kg plus P400 group or lipoic acid 10 mg/kg plus P400 
group (χ2 test). 
Table 2. Histopathological alterations in hippocampus of rats pretreated with antioxidant 
compounds after 24 h of phase acute of pilocarpine-induced seizures. 
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histopathological changes. Then again, pilocarpine-treated animals presented neuronal loss, 
gliosis, and typical vacuolar degeneration in hippocampus and striatum regions. 
Histopathological damage in hippocampus was observed in 50, 33, 33 and 17% of the 
animals co-administered with ascorbic acid (250 or 500 mg/kg) or alpha-tocopherol (200 or 
400 mg/kg), and that 30 min after pretreatment received pilocarpine (400 mg/kg), 
respectively (Table 2). In addition, the analyses of histopathological damage in 
hippocampus of rats pretreated with lipoic acid (10 or 20 mg/kg) or ubiquinone (5 or 10 
mg/kg), and that 30 min after pretreatment received pilocarpine (400 mg/kg) revealed a 
reduction of 52, 68, 52 and 100% in the number of animals with neuronal damage, 
respectively (Table 2). 
 
Drugs Dose (mg/kg) 
Rats with lesion 
(%) 
Severity of lesion 
(%) 
Number of animals 
with lesion per 
group 
Pilocarpine 400 83 59.92 ± 0.23 5 
Ascorbic acid 250 00 00 0 
 500 00 00 0 
Ascorbic acid plus P400 250 50a 20.00 ± 0.32a 3 
 500 33a,b 17.66 ± 0.33a,b 2 
Alpha-tocopherol 200 00 00 0 
 400 00 00 0 
Alpha-tocopherol plus P400 200 33a 13.66 ± 0.33a 2 
 400 17 a,b 5.97 1 
Ubiquinone 5 00 00 0 
 10 00 00 0 
Ubiquinone plus P400 5 33a 12.00 ± 0.25a 2 
 10 00 00 0 
Lipoic acid 10 00 00 0 
 20 00 00 0 
Lipoic acid plus P400 10 33a 11.96 ± 0.12a 2 
 20 17 a,b 5.97 1 
Pilocarpine was administered in a single dose (400 mg/kg, P400, n=6), ascorbic acid groups with 
ascorbic acid (250 or 500 mg/kg), alpha-tocopherol (200 or 400 mg/kg, n=6), ubiquinone (5 or 10 
mg/kg, n=6) and lipoic acid group with lipoic acid (10 or 20 mg/kg; n=6). The ascorbic plus P400 
groups were treated with ascorbic acid (250 or 500 mg/kg, n=6) and 30 min before P400. The alpha-
tocopherol plus P400 group was treated with alpha-tocopherol (200 or 400 mg/kg) and 30 min before 
P400. The ubiquinone plus P400 group was treated with ubiquinone (5 or 10 mg/kg) and 30 min before 
P400. The lipoic acid plus P400 group was treated with lipoic acid (10 or 20 mg/kg) and 30 min before 
P400. Severity of lesion was expressed as mean ± S.E.M. of scores of damage based on a scale from zero 
(none) to 100 (total) percent of structural involvement. Brain damage was defined as present if there 
was at least 50% hippocampal involvement. Results for % rats with brain lesion and % severity of lesion 
are expressed as percentages of the number of animals inside in parenthesis. ap<0.05 compared with 
P400 group (χ2 test). bp<0.05 compared with ascorbic acid 250 plus P400 group or alpha-tocopherol 200 
mg/kg plus P400 group or ubiquinone 5 mg/kg plus P400 group or lipoic acid 10 mg/kg plus P400 
group (χ2 test). 
Table 2. Histopathological alterations in hippocampus of rats pretreated with antioxidant 
compounds after 24 h of phase acute of pilocarpine-induced seizures. 
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Histopathological damage in striatum was observed only in 33, 17, 17 and 17% of the 
animals co-administered with ascorbic acid (250 or 500 mg/kg), ubiquinone (5 mg/kg) and 
lipoic acid (10 mg/kg) and that 30 min after pretreatment received pilocarpine (400 mg/kg), 
respectively (Table 2). Moreover, the analyses of histopathological damage in striatum of 
rats pretreated with lipoic acid (20 mg/kg), alpha-tocopherol (200 or 400 mg/kg) or 
ubiquinone (10 mg/kg), and that 30 min after pretreatment received pilocarpine (400 
mg/kg) revealed no neuronal damage (Table 2). 
 
 
Fig. 2. Histopathological alterations in rat hippocampus treated with pilocarpine, atropine, 
alpha-tocopherol or their combinations. [A] Control group; [B] Pilocarpine group; [C] alpha-
tocopherol 200 group; [D] alpha-tocopherol 200 plus Pilocarpine group was treated with 
alpha-tocopherol (200 mg/kg) and 30 min before P400; [E] alpha-tocopherol 400 group; [F] 
alpha-tocopherol 400 plus Pilocarpine group was treated with alpha-tocopherol (400 
mg/kg) and 30 min before Pilocarpine. Severity of lesion was expressed as mean ± S.E.M. of 
scores of damage based in a scale from zero (none) to 100 (total) percent of structural 
involvement. Brain damage was considered positive if there was at least 50% hippocampal 
involvement. Hematoxylin & Eosin staining (H&E). Magnification, 100 X. One 
representative experiment with n=6 is shown. 
7. Oxidative stress in epilepsy model  
The lipid peroxidation level in the brain homogenates are increased in this model. During 
the acute phase of seizures induced by pilocarpine, increases in lipid peroxidation level, 
nitrite concentration and GSH content in striatum, frontal cortex and hippocampus have 
been verified in the same way (Freitas et al, 2004).  The improved review demonstrates that 
status epilepticus induces different changes in superoxide dismutase activity according to 
the brain region, as that enzymatic activity remained unaltered in striatum and 
hippocampus but increased in frontal cortex. After the first hour of acute phase of seizures 
an increase is detected in several regions (striatum, hippocampus and frontal cortex). In 
addition, catalase activity was increased in striatum, hippocampus and frontal cortex in this 
epilepsy model (Freitas et al, 2003).  
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Number of animals 
with lesion per group 
Pilocarpine 400 67 55.39 ± 0.52 4 
Ascorbic acid 250 00 00 0 
 500 00 00 0 
Ascorbic acid plus P400 250 33a 25.42 ± 0.25a 2 
 500 17a,b 13.46 1 
Alpha-tocopherol 200 00 00 0 
 400 00 00 0 
Alpha-tocopherol plus P400 200 00 00 0 
 400 00 00 0 
Ubiquinone 5 00 00 0 
 10 00 00 0 
Ubiquinone plus P400 5 17a 14.31 1 
 10 00 00 0 
Lipoic acid 10 00 00 0 
 20 00 00 0 
Lipoic acid plus P400 10 17a 12.96 ± 0.22a 1 
 20 00 00 0 
Pilocarpine was administered in a single dose (400 mg/kg, P400, n=6), ascorbic acid groups with 
ascorbic acid (250 or 500 mg/kg), alpha-tocopherol (200 or 400 mg/kg, n=6), ubiquinone (5 or 10 
mg/kg, n=6) and lipoic acid group with lipoic acid (10 or 20 mg/kg; n=6). The ascorbic plus P400 
groups were treated with ascorbic acid (250 or 500 mg/kg, n=6) and 30 min before P400. The alpha-
tocopherol plus P400 group was treated with alpha-tocopherol (200 or 400 mg/kg) and 30 min before 
P400. The ubiquinone plus P400 group was treated with ubiquinone (5 or 10 mg/kg) and 30 min before 
P400. The lipoic acid plus P400 group was treated with lipoic acid (10 or 20 mg/kg) and 30 min before 
P400. Severity of lesion was expressed as mean ± S.E.M. of scores of damage based on a scale from zero 
(none) to 100 (total) percent of structural involvement. Brain damage was defined as present if there 
was at least 50% straital involvement. Results for % rats with brain lesion and % severity of lesion are 
expressed as percentages of the number of animals inside in parenthesis. ap<0.05 compared with P400 
group (χ2 test). bp<0.05 compared with ascorbic acid 250 plus P400 group or alpha-tocopherol 200 
mg/kg plus P400 group or ubiquinone 5 mg/kg plus P400 group or lipoic acid 10 mg/kg plus P400 
group (χ2 test). 
Table 3. Histopathological alterations in striatum of rats pretreated with antioxidant 
compounds after 24 h of phase acute of pilocarpine-induced seizures. 
Lipid peroxidation in a tissue is an index of irreversible biological damage of the cell 
membrane phospholipid, which in turn leads to inhibition of most of the sulphydryl  
and some nonsulphydryl enzymes (Gilbert and Sawas, 1983). Lipid peroxidation level 
increase and reduce, whereas glutathione decrease can be induced by many chemicals (e.g. 
kainic acid and pilocarpine) and by many tissue injuries, and has been suggested as a 
possible mechanism for the neurotoxic effects of epileptic activity (Sah et al, 2002). Our 
findings demonstrated that lipid peroxidation levels increase after the first hour and during 
24 h of the acute phase of seizures induced by pilocarpine in hippocampus, striatum and 
frontal cortex.  
In normal conditions, there is a steady state balance between the production of ROS and their 
destruction by cellular antioxidant system. It is demonstrated that nitrite content in striatum 
and frontal cortex is augmented after seizures and status epilepticus in adult rats, suggesting a 
possible increase in ROS level, which can be involved in neuronal damage induced status 
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Histopathological damage in striatum was observed only in 33, 17, 17 and 17% of the 
animals co-administered with ascorbic acid (250 or 500 mg/kg), ubiquinone (5 mg/kg) and 
lipoic acid (10 mg/kg) and that 30 min after pretreatment received pilocarpine (400 mg/kg), 
respectively (Table 2). Moreover, the analyses of histopathological damage in striatum of 
rats pretreated with lipoic acid (20 mg/kg), alpha-tocopherol (200 or 400 mg/kg) or 
ubiquinone (10 mg/kg), and that 30 min after pretreatment received pilocarpine (400 
mg/kg) revealed no neuronal damage (Table 2). 
 
 
Fig. 2. Histopathological alterations in rat hippocampus treated with pilocarpine, atropine, 
alpha-tocopherol or their combinations. [A] Control group; [B] Pilocarpine group; [C] alpha-
tocopherol 200 group; [D] alpha-tocopherol 200 plus Pilocarpine group was treated with 
alpha-tocopherol (200 mg/kg) and 30 min before P400; [E] alpha-tocopherol 400 group; [F] 
alpha-tocopherol 400 plus Pilocarpine group was treated with alpha-tocopherol (400 
mg/kg) and 30 min before Pilocarpine. Severity of lesion was expressed as mean ± S.E.M. of 
scores of damage based in a scale from zero (none) to 100 (total) percent of structural 
involvement. Brain damage was considered positive if there was at least 50% hippocampal 
involvement. Hematoxylin & Eosin staining (H&E). Magnification, 100 X. One 
representative experiment with n=6 is shown. 
7. Oxidative stress in epilepsy model  
The lipid peroxidation level in the brain homogenates are increased in this model. During 
the acute phase of seizures induced by pilocarpine, increases in lipid peroxidation level, 
nitrite concentration and GSH content in striatum, frontal cortex and hippocampus have 
been verified in the same way (Freitas et al, 2004).  The improved review demonstrates that 
status epilepticus induces different changes in superoxide dismutase activity according to 
the brain region, as that enzymatic activity remained unaltered in striatum and 
hippocampus but increased in frontal cortex. After the first hour of acute phase of seizures 
an increase is detected in several regions (striatum, hippocampus and frontal cortex). In 
addition, catalase activity was increased in striatum, hippocampus and frontal cortex in this 
epilepsy model (Freitas et al, 2003).  
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kainic acid and pilocarpine) and by many tissue injuries, and has been suggested as a 
possible mechanism for the neurotoxic effects of epileptic activity (Sah et al, 2002). Our 
findings demonstrated that lipid peroxidation levels increase after the first hour and during 
24 h of the acute phase of seizures induced by pilocarpine in hippocampus, striatum and 
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In normal conditions, there is a steady state balance between the production of ROS and their 
destruction by cellular antioxidant system. It is demonstrated that nitrite content in striatum 
and frontal cortex is augmented after seizures and status epilepticus in adult rats, suggesting a 
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epilepticus. Other studies have shown that nitrite and nitrate levels were not elevated in 
patients with cryptogenic west syndrome (Vanhatalo and Riikonen, 2001), but it is tempting to 
speculate that the seizure activity per se did not account for the whole increment observed in 
nitrite and nitrate levels, and other mechanisms may be associated with this parameter in this 
epilepsy model, as well as neuronal degeneration observed in human beings. However, new 
studies using antioxidants drugs during status epilepticus induced by pilocarpine can indicate 
whether lipid peroxidation, nitrite and glutathione reduced (GSH) concentrations are involved 




Fig. 3. Histopathological alterations in rat hippocampus pretreated with lipoic acid prior to 
pilocarpine-induced seizures. Severity of lesion was expressed as a mean ± S.E.M. of scores 
of damage based in a scale from zero (none) to 100 (total) percentage of hippocampus 
involvement. Brain damage was considered positive if there was at least 50% hippocampal 
involvement showed by Hematoxylin & Eosin staining (HE). Pictures (100 X) shown are 
from one representative experiment of n=8. [A]: Control group; [B]: Pilocarpine group; [C]: 
lipoic acid 10 group; [D]: lipoic acid 10 plus pilocarpine group; [E]: lipoic acid 20 group; [F]: 
lipoic acid 20 plus pilocarpine group. 
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Fig. 4. Histopathological alterations in rat hippocampus pretreated with ubiquinone prior to 
pilocarpine-induced seizures. Severity of lesion was expressed as a mean ± S.E.M. of scores 
of damage based in a scale from zero (none) to 100 (total) percentage of hippocampus 
involvement. Brain damage was considered positive if there was at least 50% hippocampal 
involvement showed by Hematoxylin & Eosin staining (HE). Pictures (100 X) shown are 
from one representative experiment of n=8. [A]: Control group; [B]: Pilocarpine group; [C]: 
Ubiquinone 5 group; [D]: Ubiquinone 10 group; [E]: Ubiquinone 20 group; [F]: Ubiquinone 5 
plus P400 group [G]: Ubiquinone 10 plus P400; [H]: Ubiquinone 20 plus P400. 
Although there were no selective brain regions particularly vulnerable to oxidative stress, 
there were some regional variations in the amount of oxidative damage observed. In the 
regions studied, there were nearly equal elevations in lipid oxidative, nitrite content and 
GSH markers that persisted during the acute phase of seizures.  
All living organisms can suffer oxidative damage, yet the animal brain is often said to be 
especially sensitive (Gilbert and Sawas, 1983; Bruce and Baudry, 1995). The experimental 
data demonstrate that pilocarpine administration and its resulting status epilepticus 
produce significant alterations in hippocampus, striatum and frontal cortex. We recorded 
alterations in superoxide dismutase activity in frontal cortex during the seizures, however, 
no alterations were observed in striatal superoxide dismutase activity of rats under the same 
conditions. It is likely that the unaltered superoxide dismutase activity in striatum might not 
be related to the mechanisms involved in installation and propagation of seizures and status 
epilepticus induced by pilocarpine, which produces several changes in parameters related to 
generation and elimination of oxygen free radicals in adult rats (Sawas and Gilbert, 1985). 
An increase in free radical formation can be accompanied by an immediate compensatory 
increase of free radical scavenging enzymatic (superoxide dismutase and catalase) activities 
and this action was observed during status epilepticus in brain regions. Nevertheless, a 
similar compensatory mechanism of scavenging was observed in catalase activity after 
status epilepticus, suggesting that the enzymatic function of different systems can be 
modified either during the acute phase of seizures or according to cerebral area 
investigated. Literature reports the involvement of catalase activity in hippocampus, 
striatum and frontal cortex after status epilepticus. An increase in catalase activity in these 
brain areas can be related to a long-term compensatory mechanism including modulation 
activity of enzymes from the ROS catabolism.  
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Moreover, the catalase activity might be one of the mechanisms capable to avoid the 
development of neurotoxic effects mediated by SE, indicating that basal-oxygen radical 
production can damage the cell and that its control is necessary (McCord, 1989; Naffah-
Mazzacoratti, 2001).  
Evidences for the role of free radicals in seizures has been found by using exogenously 
administered enzymatic and non-enzymatic antioxidants for protection against seizures 
and status epilepticus-induced neuronal damage (Kulkarni and George, 1996; Freitas et al, 
2005). A steady state level of O2- and H2O2 is always present within cells as a result of a 
normal metabolism. Superoxide dismutase and catalase are responsible for degradation of 
O2- and H2O2, respectively. The balance between antioxidants enzymes, superoxide 
dismutase and catalase can be important during seizures and status epilepticus induced 
by pilocarpine. The present data indicate that pilocarpine treatment and its resulting 
status epilepticus induce neurochemical changes such as an increase in nitrite content and 
lipid peroxidation level, a decrease in GSH content as well as an activation of brain 
antioxidant mechanisms. The anatomic distribution of alterations observed in the 
enzymatic activities (superoxide dismutase and catalase) can suggest that the frontal 
cortex can be extensively involved in the propagation of epileptic activity and further 
studies should be carried out to ascertain that the catabolism of nitrite, ROS and GSH can 
be involved in the pathogenesis of status epilepticus.  
The pilocarpine model is essential to investigate the mechanisms for initiation and 
propagation of seizures and status epilepticus. Additionally, it may be assumed that the 
increased generation of nitrite and lipid peroxidation levels after status epilepticus is not 
primary caused by an exhaustion of both the enzymatic and non-enzymatic defense systems 
measured. Adaptative mechanisms, as the induction of catalase activity, may be taken into 
consideration to counteract oxidative stress mediated by status epilepticus. However, the 
relation among brain structures, antioxidant systems, lipid peroxidation, nitrite concentration 
and status epilepticus cannot be perfectly established and deserves further investigation. 
8. Antioxidant compound effects on oxidative stress in epilepsy model  
Neurochemical alterations are observed in pilocarpine-induced seizures (Freitas et al, 2005), 
whose physiopathology is still poorly understood. However, there is data in literature 
suggesting that elevated reactive oxygen species concentrations and/or its metabolites are 
potentially neurotoxic (Freitas et al, 2004). We have demonstrated that lipoic acid reduces 
brain oxidative metabolism (Militão et al, 2010) and cannot inhibit Na+, K+-ATPase activity 
in rat hippocampus. 
Animal models are useful to better understand the pathophysiology of seizures. In this 
context, the antioxidants compound effects in pilocarpine model were recently investigated 
(Mudd et al, 2001), revealing that they might produce a decrease in nitrite levels in rat 
hippocampus (Koçak et al, 2000; Augoustides-Savvopoulou et al, 2003). Animals exposed to 
lipoic acid treatment presented no differences in physical growth and brain, suggesting that 
lipoic acid ameliorates metabolic parameters in pilocarpine model (Mesulam et al, 2002). 
By using this model, we investigated the effect of lipoic acid on spatial navigation tasks in 
the Morris water maze. Results have shown that seized rats did not present performance 
impairment neither in the acquisition phase nor on the time spent in target quadrant and in 
platform location nor in the latency to cross over the platform location in the reference 
memory task session . However, lipoic acid signicantly impaired working memory 
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performance, since there was a signicant effect with the 9-day interaction group and 
signicant differences after days 2 and 5. 
The biological effects of free radicals are controlled in vivo by a wide range of antioxidants, 
such as alpha-tocopherol, ascorbic acid, vitamin A, and glutathione reduced (Halliwell and 
Gutteridge, 1990; Ayyildiz et al, 2006). Acid ascorbic and alpha-tocopherol have many 
functions in the brain and in the neuronal microenvironment. They work as 
neuromodulators as well as antioxidant/free radical scavengers (Koza et al, 2007; Devi et al, 
2008). It has been suggested that ascorbic acid and alpha-tocopherol have neuroprotective 
properties in some experimental models of excitotoxic neurological disorders, including 
seizure activity induced by pilocarpine (Gaby, 2007; Barros et al., 2007). 
Systemic injection of pilocarpine, a cholinergic muscarinic agonist, induces status 
epilepticus in rodents, which is associated to histopathological and neurochemical changes 
as well as oxidative stress (Turski et al, 1983; Cavalheiro et al, 1994; Freitas et al, 2005). 
Elevated free radical products were observed during the status epilepticus. Free radicals are 
highly reactive chemical compounds due to the tendency of electrons to pair, which are 
normally associated with oxidative damage (Castagne et al, 1999). 
Free radicals can be generated in the brain by several mechanisms such as inefficiency 
of the electron-carrying components of the mitochondrial transport chain, monoamines 
degradation, xanthine oxidase reaction or by metabolism of arachidonic acid. 
Nevertheless, the free radicals produced could be metabolized especially by antioxidant 
enzymes such as superoxide dismutases, catalase and glutathione peroxidase (Hussain 
et al, 1995; Meister, 1995; Frantseva et al, 2000; Ferreira et al, 2009). Then, the resulting 
free radicals are very likely to react with non-radical molecules and transform them into 
secondary free radicals, which are normally observed during the lipid peroxidation 
producing hydroperoxides (MacDonald et al, 1989). The lipid peroxidation and nitrite 
are increased in hippocampus rats during pilocarpine-induced seizures (Freitas, 2009; 
Militão et al, 2010). Thus, it is worthwhile assessing the role of antioxidant compounds 
in the prevention of these neurochemical alterations on oxidative stress during seizures. 
The excitotoxicity has been shown to be related to over-production of free radicals in 
hippocampus of adult rats. The excessive release of excitatory amino acids such as 
glutamate may kill neurons via excessive activation of their receptors facilitating the 
installation and/or propagation of seizures (MacDonald et al., 1989; Cavalheiro et al., 
1994; Meldrum, 1994). 
Depending on neuronal maturity, the glutamate may induce either apoptotic or necrotic 
types of death (Ferrer et al, 1995) by impairing the Ca2+ homeostasis and inducting the 
oxidative stress (Leite et al, 1990; Murphy and Baraban, 1990). Based on this fact, it is 
important to evaluate the role of ubiquinone on oxidative stress in rat hippocampus 
during seizures since ubiquinone is a powerful antioxidant that prevents oxidative 
damage caused by free radicals, including oxidation of lipids within the mitochondrial 
membrane (Geromel et al., 2002). 
Several antioxidant compounds, such as acid ascorbic (Xavier et al, 2007), lipoic acid 
(Freitas, 2009) and alpha-tocopherol (Barros et al, 2007) can protect the brain against 
oxidative stress in rat hippocampus caused by pilocarpine-induced seizures. Studies have 
suggested that ubiquinone (UQ) serves as an antioxidant by activating and increasing 
expression of mitochondrial uncoupling proteins which have antiapoptotic and antioxidant 
properties (Shults and Haas, 2005; Chaturvedi and Beal, 2008). Ubiquinol, a reduced form of 
ubiquinone, decreases lipid peroxidation directly by acting as a chain-breaking antioxidant 
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and indirectly by recycling alpha-tocopherol. Thus, it is important to investigate the 
neuroprotective effect of ubiquinone against hippocampal damage caused by oxidative 
stress observed during seizures.  
In addition to preventing lipid peroxidation, UQ, as an effective antioxidant, also reacts with 
ROS (James et al., 2004). This study implies that ubiquinone may alter the oxidative stress in 
rat hippocampus caused by the seizures. To further attest this hypothesis, this study was 
aimed at evaluating the effects of ubiquinone on superoxide dismutase, catalase and 
glutathione peroxidase activities as well as in hydroperoxide concentration in the rat 
hippocampus during acute phase of seizures induced by pilocarpine. 
The pilocarpine model could prove to be useful to delineate and understand the 
development of behavioral and neurochemical changes associated with temporal lobe 
epilepsy. Pilocarpine status may provide a model for studying the basic mechanisms 
responsible for refractory status epilepticus, amino acids and oxidative stress in humans and 
evaluating new drugs. The pilocarpine model may prove useful in the study of status 
epilepticus for number of reasons. First, these seizures accurately model human generalized 
epilepsy as it is seen from the anticonvulsant profile drugs. Secondly, the serve and 
refractory nature of this model indicates that it should be valuable in the development of 
new anticonvulsant agents. Finally, the prolonged and uniform degree of status epilepticus 
is useful for metabolic, neurochemical and neuroanatomical studies of the sequelae of 
prolonged seizure activity. 
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and indirectly by recycling alpha-tocopherol. Thus, it is important to investigate the 
neuroprotective effect of ubiquinone against hippocampal damage caused by oxidative 
stress observed during seizures.  
In addition to preventing lipid peroxidation, UQ, as an effective antioxidant, also reacts with 
ROS (James et al., 2004). This study implies that ubiquinone may alter the oxidative stress in 
rat hippocampus caused by the seizures. To further attest this hypothesis, this study was 
aimed at evaluating the effects of ubiquinone on superoxide dismutase, catalase and 
glutathione peroxidase activities as well as in hydroperoxide concentration in the rat 
hippocampus during acute phase of seizures induced by pilocarpine. 
The pilocarpine model could prove to be useful to delineate and understand the 
development of behavioral and neurochemical changes associated with temporal lobe 
epilepsy. Pilocarpine status may provide a model for studying the basic mechanisms 
responsible for refractory status epilepticus, amino acids and oxidative stress in humans and 
evaluating new drugs. The pilocarpine model may prove useful in the study of status 
epilepticus for number of reasons. First, these seizures accurately model human generalized 
epilepsy as it is seen from the anticonvulsant profile drugs. Secondly, the serve and 
refractory nature of this model indicates that it should be valuable in the development of 
new anticonvulsant agents. Finally, the prolonged and uniform degree of status epilepticus 
is useful for metabolic, neurochemical and neuroanatomical studies of the sequelae of 
prolonged seizure activity. 
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1. Introduction 
Acquired brain injury is a medical and social reality of growing magnitude and 
extraordinary severity requiring an increasingly specialised response to the extent permitted 
by technological advances and research. Although there are no accurate or reliable statistical 
data regarding the number of people affected by brain injury, scientific opinion maintains 
that brain injury represents one of the largest health problems in developed countries, both 
in terms of the number of deaths caused and the high number of people left suffering from 
some sort of functional and cognitive disability as a result of the sequelae caused by the 
damage occurred in the brain.  
The most frequent causes of acquired brain injury are pre/perinatal hypoxia/ischemia or 
post-natal infections (for example, meningitis), cranial traumas, stroke. One of the first 
consequences of acquired brain injury is the loss of consciousness; the duration and degree 
of it are one of the most significant indicators of the severity of the injury. After the 
progressive recovery of the level of consciousness and the spatial orientation, most patients 
suffer a wide range of cognitive and motor sequelae; the nature and severity of them depend 
on the location and extent of brain damage, and the age of the patient as well.  
The multiple functional and social impairments caused by the brain injury and the motor 
impairments affecting memory, speech or behaviour require a multi-disciplinary treatment 
approach from the critical-acute stage, calling for the highest level of specialisation until the 
patient can readjust back into the community. There is consensus among specialists regarding 
the damaged brain's ability to recover part of its functions spontaneously, a process that may 
take several months or even years. Experts also agree on the need for early neurorehabilitation 
to improve these natural mechanisms and achieve the best possible functional and social 
recovery, considering the complexity of the sequelae (motor, cognitive, emotional) caused in 
varying combinations by brain injury. However, access to rehabilitation facilities specialized in 
brain injury is marked by the shortage of public or private resources, with a huge difference in 
the availability of such facilities among the different countries. This shortage, scarcity or non-
existence of public or private rehabilitation facilities in many countries, together with the 
enormous cost of these services offered by private centres, make access to rehabilitation and 
recovery difficult or even impossible for many people. Therefore, as a result of not seeing the 
benefit of potential recovery and social integration, this leads to a greater dependence and 
burden on the family. Therefore, acquired brain injury is a major public health, and yet 
 
Brain Injury – Pathogenesis, Monitoring, Recovery and Management 
 
416 
concentration and antioxidant enzymatic activities in the rat hippocampus during 
pilocarpine-induced seizures, Brain Research 1315: 33-40. 
Sawas, A.H. & Gilbert, J.C. (1985). Lipid peroxidation as a possible mechanism for the 
neurotoxic and nephrotoxic effects of a combination of lithium carbonate and 
haloperidol, Archives internationales de pharmacodynamie et de thérapie 276: 301–312. 
Shivakumar, B.R., Ananndatheerthavarada, H.K. & Ravindranath, V. (1991). Free radical 
scavenging system in developing rat brain, International Journal of Developmental 
Neuroscience 9: 181-185. 
Shults, C.W. & Haas, R., 2005. Clinical trials of coenzyme Q10 in neurological disorders, 
Biofactors 25: 117–126. 
Simonié, A., Laginja, J., Varljen, J., Zupan, G. & Erakovié, V. (2000) Lithium plus pilocarpine 
induced status epilepticus – biochemical changes, Neuroscience Research 36: 157- 
166. 
Smith, B.N. & Shibley, H. (2002). Pilocarpine-induced status epilepticus results in mossy 
fiber sproutng and spontaneous seizures in C57BL6 and CD-1 mice, Epilepsy 
Research 49: 109-120. 
Todorova, V.K., Harms, S.A., Kaufmam, Y., Luo, S., Luo, K.Q., Babb, K. & Klimberg, V.S. 
(2004). Effect of dietary glutamine on tumor glutathione levels and apoptosis-
related proteins in DMBA-induced breast cancer of rats, Breast Cancer Research and 
Treatment 88: 247-256. 
Tomé, A.R., Ferreira, P.M.P. & Freitas, R.M. (2010). Inhibitory action of antioxidant (ascorbic 
acid or α-tocopherol) on seizures and brain damage induced by pilocarpine in rats, 
Arquivos de Neuropsiquiatria 68: 355-361. 
Turski, W.A., Cavalheiro, E.A., Schwarz, M., Czuczwar, S.J., Kleironk, Z. & Turski, L. (1983). 
Limbic seizures produced by pilocarpine in rats: behavioural, eletroencephalographic 
and neuropathological study, Behavioral Brain Research 9: 315–336. 
Turski, L., Cavalheiro, E.A., Leite, J.P., Bortolotto, Z.A., Turski, W.A. & Ikonomidou, C. 
(1991). Long-term effects of pilocarpine in rats: structural damage of the brain 
triggers kindling and spontaneous recurrent seizures, Epilepsia 32: 778-782. 
Vanhatalo, S. & Riikonen, R. (1999). Markedly elevated nitrate/nitrite levels in the 
cerebrospinal fluid of children with progressive encephalopathy with edema, 
hypsarrhythmia and optic atrophy (PEHO syndrome), Epilepsia 40: 210-212.  
Vanhatalo, S. & Riikonen, R. (2001). Nitric oxide metabolites, nitrates and nitrites in the 
cerebrospinal fluid in children with west syndrome, Epilepsy Research 46: 3-13. 
Vanin, A., Vitskova, G., Narkevich, V. & Bashkatova, V. (2003). The influence of 
anticonvulsant and antioxidant drugs on nitric oxide level and lipid peroxidation in 
the rat brain during penthylenetetrazole-induce epileptiform model seizures, Prog 
Neuro-Psychopaharm Biol Psychiatry 27: 487-492. 
Xavier, S.M.L., Barbosa, C.O., Barros, D.O., Silva, R.F., Oliveira, A.A. & Freitas, R.M. (2007). 
Vitamin C antioxidant in hippocampus of adult Wistar rats after seizures and status 
epilepticus induced by pilocarpine, Neuroscience Letters 420: 76-79. 
Yamamoto, N., Kabuto, H., Matsumoto, S., Ogawa, N. & Yokoi, I. (2002). α-tocopheryl-L-
ascorbate-2-O-phosphate diester, a hydroxyl radical scavenger, prevents the 
occurrence of epileptic foci in a rat model of post-traumatic epilepsy, 
Pathophysiology 8: 205-214. 
21 
Growth Hormone and Kynesitherapy  
for Brain Injury Recovery  
Jesús Devesa1,2, Pablo Devesa1,2, Pedro Reimunde2 and Víctor Arce1 
1Department of Physiology, School of Medicine, Santiago de Compostela   
2Medical Center "Proyecto Foltra", Teo 
Spain 
1. Introduction 
Acquired brain injury is a medical and social reality of growing magnitude and 
extraordinary severity requiring an increasingly specialised response to the extent permitted 
by technological advances and research. Although there are no accurate or reliable statistical 
data regarding the number of people affected by brain injury, scientific opinion maintains 
that brain injury represents one of the largest health problems in developed countries, both 
in terms of the number of deaths caused and the high number of people left suffering from 
some sort of functional and cognitive disability as a result of the sequelae caused by the 
damage occurred in the brain.  
The most frequent causes of acquired brain injury are pre/perinatal hypoxia/ischemia or 
post-natal infections (for example, meningitis), cranial traumas, stroke. One of the first 
consequences of acquired brain injury is the loss of consciousness; the duration and degree 
of it are one of the most significant indicators of the severity of the injury. After the 
progressive recovery of the level of consciousness and the spatial orientation, most patients 
suffer a wide range of cognitive and motor sequelae; the nature and severity of them depend 
on the location and extent of brain damage, and the age of the patient as well.  
The multiple functional and social impairments caused by the brain injury and the motor 
impairments affecting memory, speech or behaviour require a multi-disciplinary treatment 
approach from the critical-acute stage, calling for the highest level of specialisation until the 
patient can readjust back into the community. There is consensus among specialists regarding 
the damaged brain's ability to recover part of its functions spontaneously, a process that may 
take several months or even years. Experts also agree on the need for early neurorehabilitation 
to improve these natural mechanisms and achieve the best possible functional and social 
recovery, considering the complexity of the sequelae (motor, cognitive, emotional) caused in 
varying combinations by brain injury. However, access to rehabilitation facilities specialized in 
brain injury is marked by the shortage of public or private resources, with a huge difference in 
the availability of such facilities among the different countries. This shortage, scarcity or non-
existence of public or private rehabilitation facilities in many countries, together with the 
enormous cost of these services offered by private centres, make access to rehabilitation and 
recovery difficult or even impossible for many people. Therefore, as a result of not seeing the 
benefit of potential recovery and social integration, this leads to a greater dependence and 
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medical science has little to offer for the persistent symptoms that prevent many of these 
individuals from fully re-entering society.  
Until few years ago it was thought that recovery from a brain injury would occur through 
the reinforcement of the mechanisms of neural plasticity. Establishing new synaptic 
connections between surviving neurons would partially allow to recover lost functions. 
There are evidences that environmental enrichment induces epigenetic changes that 
facilitate synaptogenesis and memory in models of brain plasticity. On this basis special 
units for brain recovery should be the closest correpondence for an enriched environment 
for patients with brain injury. Anything that can be done to optimize the hospital and 
rehabilitation environment should be beneficial. No study was shown to what extent the 
beneficial effect is due to specific rehabilitation strategies, to the time spent in physiotherapy 
and occupational therapy, and a non-specific effect of a more stimulating environment with 
competent staff that can encourage and support the patients and family members, but all 
these factors are likely to be important. In all, it is likely that admission to an acute 
rehabilitation unit would benefit the recovery after a brain damage (Johansson, 2011).   
Today we know that appart of brain plasticity, the development of any brain injury quickly 
leads to enhanced proliferation of neural stem cells. From the damaged cerebral areas a 
number of cytokines would be released for activating the migration and differentiation of 
newborn cells. It has been recently identified a P2Y-like receptor GPR17 that is a sensor of 
brain damage and a new target for brain repair (Lecca et al., 2008). Upon brain injury, the 
extracellular concentrations of nucleotides and cysteinyl-leukotrienes (cysLTs), two families 
of endogenous signaling molecules, are markedly increased at the site of damage, 
suggesting that they may act as “danger signals” to alert responses to tissue damage and 
start repair. In brain telencephalon, GPR17, a recently deorphanized receptor for both uracil 
nucleotides and cysLTs (e.g., UDP-glucose and LTD4), is normally present on neurons and 
on a subset of parenchymal quiescent oligodendrocyte precursor cells. Induction of brain 
injury using an established focal ischemia model in the rodent induces profound 
spatiotemporal-dependent changes of GPR17. In the lesioned area, an early and transient 
up-regulation of GPR17 in neurons expressing the cellular stress marker Heat shock protein 70 
(Hsp70, Heat shock protein 70) is observed. Magnetic resonance imaging in living mice 
showed that the in vivo pharmacological or biotechnological knock down of GPR17 markedly 
prevents brain infarct evolution, suggesting GPR17 as a mediator of neuronal death at this 
early ischemic stage. At later times after ischemia, GPR17 immuno-labeling appeared on 
microglia/macrophages infiltrating the lesioned area to indicate that GPR17 may also acts as 
a player in the remodeling of brain circuitries by microglia. At this later stage, parenchymal 
GPR17+ oligodendrocyte progenitors started proliferating in the periinjured area, 
suggesting initiation of remyelination. The in vitro exposure of cortical pre-oligodendrocytes 
to the GPR17 endogenous ligands UDP-glucose and LTD4 promoted the expression of 
myelin basic protein, confirming progression toward mature oligodendrocytes. Thus, 
GPR17  may act as a "sensor" that is activated upon brain injury on several embrionic 
distinct cell types, and may play a key role in both inducing neural death inside the ischemic 
core and in orchestrating the local/remodeling repair response (Lecca et al., 2008). 
According to these concepts two different mechanisms are involved in trying to repair brain 
damage: 1) quick proliferation of neural precursors, and 2) development of neural plasticity. 
Both are independent but complementary of each other. Neural stem cells proliferation and 
brain plasticity require the intervention of neurotrophic factors. This concept is showed in 
Figure 1.  
 




Fig. 1. Physiological responses to a brain injury. After a brain injury adult neurogenesis 
starts in neurogenic niches. Later, adequate rehabilitation and rich environment facilitate the 
development of brain plasticity. Both responses require the intervention of neurotrophic 
factors.  
The knowledge of these and other events occurring after brain injury led to investigate how 
to enhance and improve mechanisms involved in brain repair.    
In this chapter we will analyze current concepts about brain stem cells proliferation for brain 
repair and the effect of administering a neurotrophic and neuroprotective agent, growth 
hormone together with specific kynesitherapy, on the recovery of different kind of patients 
with acquired brain injury. 
2. Adult neurogenesis  
The complexity and specialization of neural functions increase as animal species ascend in 
the zoological scale. It is clear that the degree of specialization achieved, with so many and 
so complex interactions and functions, requires a long period of time for morphogenesis, in 
which not only cell proliferation and differentiation occurs, but also apoptosis must take 
place in a perfectly scheduled sequential expression of many different genes; later, after 
birth, the morphogenetic development of central nervous system is modulated by learning 
phenomena and the environment. However, this classical concept about neural 
development establishing that no new neurons are formed after birth has been changed 
when it was reported that new neurons are produced daily in several niches of the adult 
brain in many mammal species, including humans (Kuhn et al., 1996; Eriksson et al., 1998; 
Kempermann et al., 2004). This production is particularly important in the subventricular 
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Fig. 1. Physiological responses to a brain injury. After a brain injury adult neurogenesis 
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development establishing that no new neurons are formed after birth has been changed 
when it was reported that new neurons are produced daily in several niches of the adult 
brain in many mammal species, including humans (Kuhn et al., 1996; Eriksson et al., 1998; 
Kempermann et al., 2004). This production is particularly important in the subventricular 
zone of the lateral ventricles and the subgranular zone of the dentate gyrus of the 
hippocampus, where neural progenitors reside primarily in the subgranular layers (Gould 
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The paradigm about a central nervous system unable to replace the daily loss of neurons 
began to be questioned in the mid-60's. However, the pioneer studies carried out in these 
years were not taken into account mainly due to technical and methodological issues 
(Altman & Gas, 1965; Kaplan & Hinds, 1977). Later, the notorious advance of the 
immunohistochemistry, cytology and molecular biology changed the dominant paradigm. 
Researchers, as Goldman (Goldman & Nottebohm, 1983) suggested that the generation of 
new neurons, neurogenesis, could be a normal phenomenon in the adult canary brain. The 
same group demonstrated later that the new formed neurons were incorporated into 
functional circuits (Paton et al., 1984). In the early 90's, cells with properties of neural 
precursors were isolated in the striatum of mice (Reynolds & Weiss, 1992). Soon the 
subventricular zone was identified as a niche were neural precursors were formed (Lois & 
Alvarez-Buylla, 1993). Lastly, at the end of 90's, it was described that adult neurogenesis is a 
phenomenon that also occurs in higher primates, including humans (Eriksson et al., 1998; 
Gould et al., 1999), a concept now widely accepted.  
2.1 Where adult neurogenesis occurs and what is its functional significance? 
Constitutive neurogenesis takes place in the rodent adult mammalian brain, and 
particularly in the subventricular zone.  This zone harbors a population of stem cells that 
proliferate and give rise to neurons and glial cells. Neuroblasts formed here migrate long 
distances along the rostral migratory stream toward the olfactory bulb, where they 
differentiate into GABA and dopaminergic interneurons, involved in odor discrimination 
(Betarbet el al. 1996; Gheusi et al., 2000). Following cerebral injuries, such as ischemia, 
epileptogenesis, or focal neuronal degeneration, neurogenesis increases in the 
subventricular zone and the newly formed neurons are able to repopulate damaged areas 
(Parent, 2002; Romanko et al., 2004; Zhang et al., 2004). Appart of the subventricular zone 
and the subgranular zone of the dentate gyrus, recent data indicate that adult neurogenesis 
can also occur in other brain areas. It is thought that in the adult mammal brain 
physiological anti-neurogenic influences can be removed in pathological conditions or after 
any specific injury. This has been recently demonstrated in a model of unilateral vestibular 
neurectomy (UVN) that mimics human pathology in adult cats (Dutheil et al., 2011). UVN 
promoted an intense reactive cell proliferation in the deafferented vestibular nuclei located 
in the brainstem. The new cells survived up to one month, differentiated into glial cells - 
microglia or astrocytes - or GABAergic neurons, so highlighting a GABAergic neurogenesis. 
Surprisingly, post-UVN reactive cell proliferation contributed successfully to fine 
restoration of vestibular posturo-locomotor functions. Moreover, following brain injury, glia 
outside known neurogenic niches acquire or reactivate stem cell potential as part of reactive 
gliosis (Robel et al., 2011). A comparison of molecular pathways activated after injury with 
those involved in the normal neural stem cell niches highlights strategies that could 
overcome the inhibition of neurogenesis outside the stem cell niche and instruct 
parenchymal glia towards a neurogenic fate. This new view on reactive glia therefore 
suggests a widespread endogenous source of cells with stem cell potential, which might 
potentially be harnessed for local repair strategies (Robel et al., 2011). 
Evenmore interesting is the fact that in the dentate gyrus of the adult hippocampus a 
continuous incorporation of new neurons exists. These new neurons slowly integrate into 
the existing dentate gyrus network: inmature adult-born neurons appear to function as 
pattern integrators of temporally adjacent events, thereby enhancing pattern separation for 
events separated in time; whereas maturing adult-born neurons it is likely that contribute to 
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pattern separation by being more amenable to learning new information, leading to 
dedicated groups of granule cells, the principal projection neurons of the dentate gyrus, that 
respond to experienced environments (Aimone et al., 2010). This continuous neurogenesis is 
important for hippocampal function. At different stages in its maturation, each new neuron 
has different properties and, at any given time, the dentate gyrus population consists of 
excitatory granule cells of many different ages. The youngest, apparently more excitable in 
the network, could complement the pattern separation function of matures by adding a 
degree of similarity between events experienced close in time. Several models suggest that 
directing plasticity towards maturing neurons can preserve the representations of old 
memories in the dentate gyrus while maintaining its capacity to learn new information 
(Aimone et al. 2010).  
Thus, although the role of this continuous adult neurogenesis remains to be fully 
established, a number of data suggest that it contributes to promote brain repair after 
injuries (Abdipranoto et al., 2008; Abdipranoto-Cowley et al., 2009). On the other side, it has 
been suggested that neurogenesis may be impaired in neurodegenerative disorders such as 
Parkinson's disease and Alzheimer's disease, and this might contribute to the pathogenesis 
of these chronic neurodegenerative disorders (Abdipranoto et al., 2008; Yu et al., 2008). 
2.2 How adult neurogenesis is regulated? 
The knowledge about how adult neurogenesis is regulated may provide adequate 
therapeutic tools for trying to repair the brain after an injury. However this is a difficult 
task, because many factors seem to be involved, directly or indirectly, in this process. We 
will analyze here the role of some of these putative neurogenic factors for trying later to 
establish then a relationship between them and the effects of growth hormone on 
neurogenesis.   
Since some years ago we know that adult neurogenesis can be modulated by several 
physiological processes including learning, exercise, environmental enrichment, or stress 
(Kempermann et al., 1997; Nilsson et al., 1999; van Praag et al., 1999; Trejo et al., 2001; Lledo 
et al., 2006; Zhao et al., 2008). Many, if not all, of these effects are related to signals mediated 
by hormones or growth factors.  
2.2.1 Gonadal steroids and adult neurogenesis  
In adult songbirds, integration and survival of new neurons in the vocal control nucleus is 
modulated by the gonadal steroids testosterone and estradiol (Nordeen EJ & Nordeen KW, 
1989; Rasika et al., 1994; Hidalgo et al., 1995; Johnson & Bottjer, 1995). In mammals, estrogen 
has been implicated in hippocampal function, with sex differences observed in long-term 
potentiation (Maren et al., 1994) and performance of hippocampal-dependent tasks (Roof & 
Havens, 1992; Roof et al., 1993; Galea et al., 1996). During proestrus, a time when estrogen 
levels are high, cell proliferation in the subgranular zone of the dentate gyrus increases, 
compared with estrus and diestrus, when estrogen levels are lower (Tanapat et al, 1999). 
Estradiol exerts extensive influence on brain development and is a powerful modulator of 
hippocampal structure and function. Surprisingly, the remarkable increase in ovarian 
hormones existing during the first and third trimester of pregnancy has no effect on cell 
proliferation in the subgranular zone of the dentate gyrus, suggesting that concomitants 
changes in oher factors, perhaps glucocorticoids, may counterbalance the positive regulation 
of cell proliferation by estradiol.  
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There is a sex difference in rates of cell genesis in the developping hippocampus of the 
laboratory rats, most likely occurrying because of the effects of estradiol on brain during 
critical periods of neural development (Bowers et al., 2010). Males generate more new cells 
than females. A recent study shows that exogenous estradiol treatment promotes cell 
proliferation and survival in the neonatal female but not the male hippocampus, whereas 
antagonizing endogenous estradiol synthesis or action reduces cell proliferation in the male 
but not in the female hippocampus (Bowers et al., 2010). Moreover, in the adult female 
hippocampus, estradiol stimulates cell proliferation and survival and increases dendritic 
synapse density, while the adult male hippocampus is insensitive to the spinogenesis or cell 
genesis inducing effects of estradiol treatment.  However, inhibiting aromatase activity or 
blocking estrogen receptor binding reduces cell proliferation in the developing male but not 
in the female hippocampus (Bowers et al., 2010). Both the amount of endogenous estradiol 
and aromatase activity in the developing hippocampus are very low compared to the 
hypothalamus and do not appear to be sexually dimorphic (Konkle & McCarthy, 2010), 
suggesting that hippocampal sensitivity to estradiol is high and differs between sexes.  
The possibility exists that the effects of estradiol are not mediated directly at the 
hippocampus but, instead, were secondary to changes in other brain areas projecting to the 
hippocampus (Bowers et al., 2010). Cholinergic neurons of the medial septum/diagonal 
band of Broca are essential for estradiol-induced spinogenesis in adult CA1 hippocampus 
(Lam & Leranth, 2003) and cholinergic input modulates maturation and integration of adult 
born dentate gyrus granule cells (Campbell et al., 2010). Gonadally intact males release more 
acetylcholine into the hippocampus than females during locomotor tasks and this sex 
difference is organized by estradiol during development (Mitsushima et al., 2009a; 
Mitsushima et al., 2009b). The cholinergic system matures relatively early and more new 
septal cholinergic neurons are born in males during a brief period of gestation but the sex 
difference does not persist into adulthood (Schaevitz & Berger-Sweeney, 2005). Nonetheless, 
it is possible that the effects observed in the study of Bowers et al. are the results of 
estradiol-induced acetylcholine release into the neonatal hippocampus during the early 
postnatal period. It is also possible that estradiol is acting outside the central nervous system 
(Bowers et al., 2010). At this time it is important to remark that acetylcholine is a powerful 
inducer of pituitary growth hormone release (Devesa et al., 1992).  
With regard to progesterone, it seems that enhances the survival of newborn neurons, rather 
than its proliferation, via the Src-ERK and PI3K pathways (Zhang et al., 2010). In fact, 
progesterone attenuates the estradiol-induced enhancement of cell proliferation (Galea et  
al., 2006).  
2.2.2 Adrenal steroids and adult neurogenesis  
Antidepressants increase adult hippocampal neurogenesis in animal models, an effect 
already described by Elizabeth Gould soon after discovering that adult neurogenesis occurs 
in non human primates (Gould et al. 1999); however, the underlying molecular mechanisms 
responsible for this effect of antidepressants were not known. Recent sudies have suggested 
that glucocorticoids are involved in the neurogenic action of antidepresssants (David et al., 
2009; Huang & Herbert 2006). Glucocorticoids release is the main response of the organism 
to acute and chronic stress. Chronic exposure to stress results in a reduction of hippocampal 
neurogenesis and of hippocampal volume.   
The antidepressant-induced changes in neurogenesis are dependent on the glucocorticoid 
receptor. Specifically, the selective serotonin reuptake inhibitor antidepressant, sertraline, 
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increases neuronal differentiation and promotes neuronal maturation of human 
hippocampal progenitor cells via a glucocorticoid receptor-dependent mechanism that is 
associated with glucorticoid receptor phosphorylation via protein kinase A signaling, 
therefore increasing cytosolic cAMP levels. Interestingly, this effect is only observed when 
sertraline is present during the proliferation phase, and it is accompanied by exit of cells 
from the cell cycle, as shown by reduced proliferation and increased glucocorticoid receptor-
dependent expression of the cyclin-dependent kinase 2 inhibitors, p27Kip1 and p57Kip2 
(Anacker et al., 2011). These effects of antidepressants are only seen in the presence of 
glucocorticoids; however, the molecular processes that lead to increased neuronal 
differentiation are activated directly by antidepressants alone and do not require 
glucocorticoids (Anacker at al., 2011). That is, regulation of neurogenesis by antidepressants 
is complex; it involves different glucocorticoid receptor-dependent mechanisms that lead to 
enhanced cell proliferation without changes in neuronal differentiation, or enhanced 
neuronal differentiation in the presence of decreased cell proliferation.  
The fact that antidepressants induce adult neurogenesis via glucocorticoid receptor-
dependent mechanism is not in contradiction with previous studies demonstrating that 
adrenal steroids inhibit adult neurogenesis by supressing cell proliferation in the 
hippocampal subgranular zone (Lennington et al., 2003). Aged rats and monkeys exhibit 
diminished cell proliferation in the subgranular zone as well as elevated levels of circulating 
glucocorticoids (Kuhn et al, 1996; Sapolsky, 1992). Removal of adrenal steroids by 
adrenalectomy increases cell proliferation in the subgranular zone in both aged and young 
adult (Cameron & McKay, 1999). Moreover, the number of new subgranular zone cells in 
adrenalectomized aged rats was threefold higher than the number in young control rats, 
indicating that adrenalectomized aged rats have rates of proliferation that surpass those 
normally found in young adults (Cameron & McKay, 1999). Moreover, a study on human 
post-mortem brain tissue has found that antidepressants increase the number of neural 
progenitor cells in patients with major depression to levels above those present in controls, 
and depressed patients are generally characterized by elevated endogenous levels of 
glucocorticoids (Boldrini et al., 2009). In the study of Anacker et al. (Anacker et al., 2011) the 
cell cycle-promoting genes, CCND1 and HDM2, were upregulated only by sertraline and 
dexamethasone co-treatment, the only condition which increases cell proliferation. In 
contrast, dexamethasone increased expression of the cell cycle-inhibiting genes, FOXO1 and 
GADD45B, which may explain the reduced cell proliferation and reduced neuronal 
differentiation with this treatment. 
Experience has shown that therapy using music for therapeutic purposes has certain 
effects on neuropsychiatric disorders (both functional and organic disorders). However, 
the mechanisms of action underlying music therapy remain unknown, and scientific 
clarification has not advanced. The results of past studies have clarified that music 
influences and affects cranial nerves in humans from fetus to adult. The effects of music at 
a cellular level have not been clarified, and the mechanisms of action for the effects of 
music on the brain have not been elucidated. It has been proposed that listening to music 
facilitates the neurogenesis, the regeneration and repair of cerebral nerves by adjusting 
the secretion of steroid hormones, ultimately leading to cerebral plasticity. Music affects 
levels of such steroids as cortisol, testosterone and oestradiol, and it is likely that music 
also affects the receptor genes related to these substances, and related proteins (Fukul & 
Toyoshima, 2008).  
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2.2.3 Pituitary hormones and adult neurogenesis 
Prolactin is a hormone that increases durig the pregnancy and also at postpartum, signaling 
lactation. The study of Shingo et al. (Shingo et al., 2003) showed that neurogenesis rates 
increase in the subventricular zone during pregnancy by 65% and again after delivery. In 
addition to observing cell proliferation, this study tracked integration of new neurons in the 
olfactory bulb, indicating that olfactory discrimination is critical for recognition and rearing 
of offspring. A doubling of olfactory interneurons may thereby enhance olfactory function 
following pregnancy, providing the mother with enhanced olfactory capability (Shingo et 
al., 2003). A similar mechanism has been recently described in male mice. Paternal-adult 
offspring recognition behavior in mice is dependent on postnatal offspring interaction and is 
associated with increased neurogenesis in the paternal olfactory bulb and hippocampus. 
Newly generated paternal olfactory interneurons are preferentially activated by adult 
offspring odors, but disrupting prolactin signaling aboslishes increased paternal 
neurogenesis and adult offspring recognition (Mak & Weiss, 2010).    
Prolactin is a regulator of the stress response and stimulator of neurogenesis in the 
subventricular zone, but also protects neurogenesis in the dentate gyrus of chronically 
stressed mice and promotes neuronal fate (Torner et al. 2009). Neural stem and progenitors 
cells express the prolactin receptor and prolactin signals in these cells via ERK 1/2, however 
in vitro studies did not observe any effect of prolactin on these neural precursors 
proliferation, differentiation or survival, suggesting that prolactin action on in vivo 
neurogenesis occurs via an indirect mechanism (Wagner et al. 2009).   
The effects of growth hormone on adult neurogenesis will be widely analyzed later in this 
chapter.  
Recently it has been described that Oxytocin, but not Vasopressin, stimulates adult 
neurogenesis in the hippocampus of rats, even in animals subjected to glucocorticoid 
administration or cold water swim stress, indicating that the hormone stimulates neuronal 
growth and may protect against the suppressive effects of stress hormones on hippocampal 
plasticity (Leuner et al., 2011).    
2.2.4 Growth factors and adult neurogenesis 
When dissociated from the adult subventricular zone, neural stem cells require either 
epidermal growth factor (EGF) or basic fibroblast growth factor (FGF2) for self-renewal and 
long-term survival in culture (Reynolds & Weiss, 1992; Kuhn et al., 1997). Analysis of EGF 
and FGF2 responsiveness in the developing telencephalon indicates that early growth factor 
choice is temporally regulated (Tropepe et al., 1999; Maric et al., 2003). In the adult, the vast 
majority of subventricular zone cells expressing EGFR also express FGFR1 supporting the 
finding that most EGF-responsive cells can also be stimulated by FGF2 (Gritti et al., 1999). 
However, EGF and FGF2 appear to differ in their mechanisms of support, with EGF 
promoting faster expansion of the stem cell-like pool (symmetric division) compared to 
FGF2 (Gritti et al., 1999). This may be the result of differential control of cell cycle length by 
each growth factor, with SVZ stem-like cells cycling faster in the presence of EGF (Gritti et 
al., 1999). Alternatively, since the subventricular zone has two subsets of mitotically active 
cells, the neural stem cells (a relatively quiescent population with a cell cycle length up to 28 
days) (Morshead & van der Kooy, 1992; Morshead et al., 1994), and the transitory 
amplifying progenitor (TAP) cells (cell cycle length approximately 12 h), these two growth 
factors may preferentially target one cell type. The latter appears to be supported by the 
work of Kuhn et al. (Kuhn et al., 1997) and Doetsch et al. (Doetsch et al., 2002). Kuhn et al. 
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(Kuhn et al., 1997) found that intracerebroventricular infusion of FGF2 into the lateral 
ventricle resulted in increased numbers of new neurons in the olfactory bulbe, while EGF 
infusion reduced the number of neurons reaching the olfactory bulbe, but substantially 
increased generation of astrocytes in the olfactory bulbe and the neighboring striatum. 
Extension of this study by Doetsch et al. (Doetsch et al., 2002) suggests that TAP cells are 
EGF receptive and these cells become invasive and glia-like, diverting neurogenesis to 
gliogenesis.  
Recent studies using long-term ventricular infusion of EGF demonstrate intense cell 
proliferation around the ventricular wall, implicating the presence of EGF-reactive cells also 
outside the classical neurogenic lateral niche. Intraventricular injection of EGF induces 
within minutes CREB and ERK phosphorylation in astrocyte-like progenitor cells (type B 
cells) and EGF receptor-expressing transit-amplifying progenitor cells-both in the striatal 
and septal ventricular walls (Gampe et al., 2011). EGF infusion for 6 days induced continued 
CREB and ERK activation in nestin+ cells paralleled by intense periventricular cell 
proliferation. In addition, the ependyma became EGF receptor-immunoreactive, revealed 
intense CREB phosphorylation and underwent partial de-differentiation. These results 
demonstrate that intraventricular application of EGF induces CREB and ERK 
phosphorylation along the entire ventricular walls and thus permits a direct identification of 
EGF-responsive cell types. They further support the notion that not only the striatal 
ventricular wall where the subependimal zone is located but also the septal ventricular wall 
carries latent potential for the formation of neurons and glial cells (Gampe et al., 2011). Basal 
activity of CREB is required for the mitogenic signaling of EGF in neural stem cells at a level 
between ERK activation and SRE-mediated transcriptional activation (SRE: serum response 
element, a promoter sequence regulating c-fos gene expression) (Iguchi et al., 2011).  
Interestingly, recent findings have shown that cells derived from subventricular zone Type-
B cells (neural stem cells in the subventricular zone) actively respond to EGF stimulation 
becoming highly migratory and proliferative. A subpopulation of these EGF-activated cells 
expresses markers of oligodendrocyte precursor cells (OPCs). When EGF administration is 
removed, subventricular zone-derived OPCs differentiate into myelinating and pre-
myelinating oligodendrocytes in the white matter tracts of corpus callosum, fimbria fornix 
and striatum. In the presence of a demyelinating lesion, OPCs derived from EGF-stimulated 
subventricular zone progenitors contribute to myelin repair. Given their high migratory 
potential and their ability to differentiate into myelin-forming cells, subventricular zone 
neural stem cells represent an important endogenous source of OPCs for preserving the 
oligodendrocyte population in the white matter and for the repair of demyelinating injuries 
(Gonzalez-Perez & Alvarez-Buylla, 2011). Of interest here is the fact that growth hormone 
induces EGF and EGFR expression in many territories (Pan et al., 2011) and activates EGFR 
by tyrosine phosphorilation as an essential element leading to MAP kinase activation and 
gene expression (Yamauchi et al., 1998).   
Another growth factor involved in neurogenesis is the hematopoietic growth factor 
erythropoietin (EPO). mRNA and protein of EPO and its receptor (EPOR) are detected in a 
number of brain areas during brain development as well as in vitro in neurons, astrocytes, 
oligodendrocytes, microglia and cerebral endothelial cells. Expression of EPO and EPOR in 
the adult brain is stress-reponsive and is regulated by oxygen supply; both are upregulated 
after hypoxia or ischemia. Other stimuli such as hypoglycemia and IGF-I activate hypoxia-
inducible factor and lead to increased expression of EPO (Byts & Sirén, 2009). The tissue 
protective functions EPO are independent of its action on erythropoiesis. Peripherally 
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protective functions EPO are independent of its action on erythropoiesis. Peripherally 
 
Brain Injury – Pathogenesis, Monitoring, Recovery and Management 
 
426 
administered EPO crosses the blood-brain barrier and activates in the brain anti-apoptotic, 
anti-oxidant and anti-inflammatory signaling in neurons, glial and cerebrovascular 
endothelial cells and stimulates angiogenesis and neurogenesis. These mechanisms underlie 
its potent tissue protective effects in experimental models of stroke, cerebral hemorrhage, 
traumatic brain injury, neuroinflammatory and neurodegenerative disease (Byts & Sirén, 
2009). Brain specific blockade of EPOR leads to deficits in neural cell proliferation and 
neuronal survival in the embryonic brain and in post-stroke neurogenesis in the adult brain 
(Chen et al., 2007; Tsai et al., 2006). Moreover, in vivo and in vitro data indicate hat EPO 
amplifies stroke-induced oligodendrogenesis that could facilitate axonal remyelination and 
lead to functional recovery after stroke (L. Zhang et al., 2010).  Of interest here is that growth 
hormone induces EPO release from kidneys.  
Brain injuries such as ischemia affect adult neurogenesis in adult rodents as both global and 
focal ischemic insults enhance the proliferation of progenitor cells residing in neurogenic 
niches. The ischemic insult increases the number of progenitor cells in monkey subgranular 
and subventricular zones, and causes gliogenesis in the ischemia prone hippocampal CA1 
sector (Tonchev, 2011). The analysis of the expression at protein level of a panel of potential 
regulatory molecules, including neurotrophic factors and their receptors revealed that a 
fraction of mitotic progenitors were positive for the neurotrophin receptor Tyrosine kinase B 
(TrkB), while immature neurons expressed the neurotrophin receptor Tyrosine kinase A 
(TrkA). Astroglia, ependymal cells and blood vessels in subventricular zone were positive 
for distinctive sets of ligands/receptors indicating that a network of neurotrophic signals 
operating in an autocrine or paracrine manner may regulate neurogenesis in adult primate 
subventricular zone (Tonchev, 2011). The analysis of microglial and astroglial proliferation 
in postischemic hippocampal CA1 sector showed that proliferating postischemic microglia 
in adult monkey CA1 sector express the neurotrophin receptor TrkA, while activated 
astrocytes were labeled for nerve growth factor (NGF), ligand for TrkA, and TrkB, a receptor 
for brain derived neurotrophic factor (BDNF). These results implicate NGF and BDNF as 
regulators of postischemic glial proliferation in adult primate hippocampus (Tonchev, 2011). 
Figure 2 summarizes how these hormones and growth factors act on adult neurogenesis.  
2.2.5 Growth hormone/IGF-I system and adult neurogenesis 
GH is a pleiotropic hormone expressed not only in the pituitary but in almost any tissue 
(Devesa et al., 2010b). Thus, far beyond of its classical actions on body growth and 
intermediate metabolism, GH exerts an important role in the regulation of cell proliferation 
and survival in several tissues, including the CNS (Costoya et al., 1999; Sanders et al., 2009; 
McLenachan et al., 2009; Aberg et al., 2009).  
The hypothesis that Growth Hormone (GH) and IGF-I play a role on brain repair after an 
injury has been postulated years ago. The existence of GH expression within the CNS has been 
reported by several authors, however its physiological role and, in particular, its possible 
contribution in the reparation of neurologic injuries remain poorly understood despite of that 
the positive effects of GH treatment on adult neurogenesis have been demonstrated in 
laboratory animals (McLenachan et al., 2009; Christophidis et al., 2009; Svensson et al., 2008; P. 
Devesa et al., 2011), and recent data from our group and others (Devesa et al., 2009; High et al., 
2010; Reimunde et al., 2010; Reimunde  et al., 2011; Devesa et al., 2011) suggest that the 
hormone may play a similar role in humans. GH-driven neurogenesis may also depend on the 
local production of GH (P. Devesa et al., 2011), the so called perypheral GH system that may 
be activated under both physiological and pathologic conditions (Devesa et al., 2010b). 
 




Blue lines indicate stimulation of neural precursors cells proliferation and/or survival, while red lines 
indicate inhibition.  
Fig. 2. Factors involved in adult neurogenesis control. 
In keeping with previous reports, we have found that hippocampal cells express GH under 
basal conditions and, more interestingly, the number of GH-expressing cells seems to increase 
after brain injury induced by kainate acid administration in rats (P. Devesa et al., 2011). 
Furthermore, using a double-labeling immunofluorescence we were able to notice that almost 
all GH-positive cells also showed BrdU immunoreactivity, thus suggesting the existence of a 
strong correlation between GH expression and cell proliferation (P. Devesa, 2011) (Figure 3). 
Interestingly, data from Katakowski et al. (Katakowski et al., 2003) demonstrate that the 
activation of PI3K/Akt signal transduction pathway mediates the migration of neuroblasts 
to damaged brain areas after stroke, most likely for inducing regeneration. PI3K/Akt is a 
key signaling pathway for the intracellular effects of GH (Costoya et al., 1999). Moreover, 
the group of Scheepens demonstrated that the expression of GH and its receptor is strongly 
upregulated after brain injury and specifically associated with stressed neurons and glia 
(Scheepens et al., 2000). More recently, the same group demonstrated that during recovery 
from an ischemic brain injury, a cerebral growth hormone axis is activated; the level of GHR 
immunoreactivity in the ipsilateral SVZ was significantly increased 5 days after injury vs. 
the contralateral SVZ, coinciding both spatially and temporally with injury-induced 
neurogenesis. The population of GHR immunopositive cells in the ipsilateral SVZ at this 
time was found to include proliferating cells, neural progenitor cells  and post-proliferative 
migratory neuroblasts (Christophidis et al., 2009).  
As indicated before, several lines of evidence support a role for GH in neurogenesis. The GH 
receptor is expressed in regions of the brain in which neurogenesis occurs during embryonic 
brain development (García-Aragón et al., 1992; Turnley et al., 2002) and in neurogenic 
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regions of the postnatal rat brain (Lobie et al., 1993). Growth hormone itself is also found in 
cells of the ventricular zone during embryonic neurogenesis (Turnley et al., 2002), and is 
produced endogenously within the postnatal hippocampus (Donahue et al., 2002; Donahue 
et al., 2006; Sun et al., 2005a; Sun et al., 2005b). Interestingly, GH gene expression within the 
hippocampus is increased by some factors known to increase neurogenesis (Parent, 2003), 
including learning (Donahue et al., 2002) and estrogen (Donahue et al., 2006). 
 
 
The detection of irBrDU in the nucleus of the cell (green) indicated by the arrow demonstrates that it is 
a newly born cell in rat hippocampal CA3 area showing irGH (brown), after brain injury induced by 
kainate acid administration and GH treatment, in its cytoplasm. Newly born neurons formed in the 
subgranular layer of the dentate gyrus migrate to the CA3 zone after commencing to maturate in the 
granular area. Thus, it is feasible that the detection of irGH in CA3 cells may be related to a trophic and 
survival role of the hormone. Taken from Pablo Devesa, Doctoral thesis, 2011. University of Santiago de 
Compostela, Spain. 
Fig. 3. Immunofluorescence (60x). Colocalization of GH and BrdU in a newly born 
hippocampal cell. 
However, the role of GH in the hippocampal dentate gyrus has been related to neuronal 
survival rather than generation, as altered hippocampal GH levels have no effect on cell 
proliferation but do affect the survival of immature neurons (Sun et al., 2005b; Sun et al., 
2007; Lichtenwalner et al., 2006). Studies of the effects of GH on embryonic rat cerebral 
cortical (Ajo et al., 2003) and hippocampal (Byts et al., 2008) neuronal cultures found that it 
induces the proliferation and differentiation of these cells. Overall, these findings indicate 
that GH may facilitate the proliferation, differentiation and survival of new neurons in 
response to brain injury. Further studies will reveal whether or not GH is "called" for brain 
repair after GPR17 activation. 
On these bases, we explored a potential role for GH and its receptor on the proliferation, 
differentiation and survival of neural stem cells (NSCs) in vitro. NSCs were isolated from the 
SGZ of the DG from 9 days old C57/BL6 mice and cultured as neurospheres. 
Western blot and immunofluorescence studies showed that neurospheres derived from 
these NSCs were demonstrated to express both GH and its receptor either in conditions of 
proliferation and differentiation showing colocalization with nestin (Figure 4) and SOX2 
(Figure 5), markers of undifferentiated cells or cells in development. Migrating cells from 
neurospheres also showed irGHR (Figure 6). In all, these results indicate that GH and its 
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Detection of irGHR (red dots) in different cells migrating from neurospheres formed from NSCs 
obtained from the dentate gyrus of 9days old mice. The detection of irGFAP (left, green) indicates that 
these cells are astrocytes, while the detection of irPSANCAM (right, green) indicates that this cell is a 
migrating neuron. Cells nuclei are stained in blue. Taken from Pablo Devesa, Doctoral thesis, 2011. 
University of Santiago de Compostela, Spain. 
Fig. 6. Confocal microscopy. Detection of GHR in cells migrating from mice neurospheres.  
However, from these studies we could not be able for establishing the exact role that the 
GH—GHR system plays on this mechanism. This is why we explored what would happen 
when adding the hormone to the culture media either in conditions of proliferation and 
differentiation. 
As reported in other studies (Christophidis et al., 2009) treating NSCs with GH in the 
presence of BrdU significantly increased the proportion of cells incorporating BrdU almost 
doubling it (Figure 7). That is, despite of the fact that NSCs express the hormone, the 
addition of exogenous GH increased stem cells proliferation. This effect is similar to that we 
observed in animals with kainate acid-induced brain injury (P. Devesa et al., 2011). 
It has been suggested that the GHR may actually play a greater role in the survival, 
migration or differentiation of neurons generated in response to hypoxia/ischemia than in 
proliferation (Christophidis et al., 2009). Consistent with a role for GHR in survival, GH 
protects both mature neurons (Möderscheim et al., 2007; Byts et al., 2008; Silva et al., 2003) 
and primary neurospheres derived from embryonic mouse NSCs (van Marle et al., 2005) 
from death in vitro. Also, the survival of newborn neurons in the subgranular zone of adult 
rat dentate gyrus is impaired as a result of GH deficiency (Lichtenwalner et al., 2006), and 
elevated GH levels within the hippocampus reduce apoptosis (Sun et al., 2007). A role for 
GH in neuronal differentiation is supported by a recent study that found that physiological 
concentrations of human GH stimulate neurite initiation and arborization of embryonic 
hippocampal neurons by activating the PI3K/Akt signalling pathway (Byts et al., 2008). 
Other studies have found that high concentrations of human GH reduce neuronal 
proliferation but enhance differentiation of these cells instead (Ajo et al., 2003; Lyuh et al., 
2007). Indeed, it appears that GH promotes proliferation of neural cells at the expense of 
their differentiation, as neurosphere cultures derived from GHR knockout mice proliferate 
less than those of wt mice due to their inability to respond to autocrine GH, yet they exhibit 
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accelerated neuronal differentiation (McLenachan et al., 2008). Interestingly, treatment of 
neurospheres derived from newborn or adult mouse neural stem cells with 100 ng/mL rat 
GH, which stimulates proliferation (Christophidis et al., 2009), significantly reduced 
neuronal differentiation (Turnley et al., 2002; Scott et al., 2006). 
 
 
GH treatment increased the number of proliferating stem cells in proliferation conditions, as irBrdU 
(red) shows. Left: control, saline treated cells. Right: GH treated cells. Taken from Pablo Devesa, 
Doctoral thesis, 2011. University of Santiago de Compostela, Spain.  
Fig. 7. In vitro effects of GH treatment on proliferating neural stem cells.  
Overall, it appears that the effect of GH on neuronal differentiation depends upon the 
concentration of GH and proliferative potential of the cells used. 
We also analyzed the role of GH on NSCs survival. In basal conditions there is a 
physiological rate of apoptosis that is significantly reduced by adding GH to the culture 
media in differentiation conditions. The antiapoptotic role of the hormone was clearly 
demonstrated by treating the cells with the GH agonist pegvisomant. This drug binds to the 
GHR but is unable to induce any kind of intracellular response because inhibits the 
dimerization of the GHR needed for intracellular signalling. In these conditions, basal 
apoptosis was significantly increased indicating that the autocrine interplay GH—GHR is 
key for NSCs survival. Moreover, treating the cells with GH did not modify the increased 
apoptosis elicited by pegvisomant (Figure 8). 
GH effects are mediated via the GHR, which is a member of the cytokine receptor 
superfamily. The critical step in initiating GH signaling is the activation of receptor-
associated Janus kinase 2 (JAK2), which induces cross-phosphorylation of tyrosine residues 
in the kinase domain of JAK2 and GHR. Phosphorylated residues on JAK2 and GHR form 
docking sites for the members of the STAT family of transcription factors (Perrini et al., 
2008). Phosphorylation of the STATs by JAK2 results in their dissociation from the receptor 
and translocation to the nucleus, with subsequent binding to DNA and regulation of gene 
expression. Among the target genes, GH regulates the expression of suppressor of cytokine 
signaling (SOCS), a family of negative regulators that terminate the GH signaling cascade 
(Hansen et al., 1999). SOCS proteins bind to phosphotyrosine residues on the GHR or JAK2 
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media in differentiation conditions. The antiapoptotic role of the hormone was clearly 
demonstrated by treating the cells with the GH agonist pegvisomant. This drug binds to the 
GHR but is unable to induce any kind of intracellular response because inhibits the 
dimerization of the GHR needed for intracellular signalling. In these conditions, basal 
apoptosis was significantly increased indicating that the autocrine interplay GH—GHR is 
key for NSCs survival. Moreover, treating the cells with GH did not modify the increased 
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GH effects are mediated via the GHR, which is a member of the cytokine receptor 
superfamily. The critical step in initiating GH signaling is the activation of receptor-
associated Janus kinase 2 (JAK2), which induces cross-phosphorylation of tyrosine residues 
in the kinase domain of JAK2 and GHR. Phosphorylated residues on JAK2 and GHR form 
docking sites for the members of the STAT family of transcription factors (Perrini et al., 
2008). Phosphorylation of the STATs by JAK2 results in their dissociation from the receptor 
and translocation to the nucleus, with subsequent binding to DNA and regulation of gene 
expression. Among the target genes, GH regulates the expression of suppressor of cytokine 
signaling (SOCS), a family of negative regulators that terminate the GH signaling cascade 
(Hansen et al., 1999). SOCS proteins bind to phosphotyrosine residues on the GHR or JAK2 
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and suppress GH signaling by inhibiting JAK2 activity, competing with STATs for binding 
to the GHR, or inducing degradation of the GHR complex. 
 
 
GH administration significantly reduced basal apoptosis in cultured NSCs cells (*p < 0.01 vs. control). 
Treatment with pegvisomant abolished the antiapoptotic effect of GH. C: control; P: pegvisomant. 
Taken from Pablo Devesa, Doctoral thesis, 2011. University of Santiago de Compostela, Spain.  
Fig. 8. In vitro effects of GH treatment on the survival of mice neural stem cells.  
The RAS/mitogen-activated protein kinase (MAPK) pathway has also been shown to be 
activated by GH. The GHR–JAK2 complex has been shown to recruit the adapter protein 
SHC, resulting in SHC tyrosine phosphorylation and binding to GRB2, and activation of 
RAS, RAF, MAPK/extracellular-regulated protein kinase (MEK), and ERK-1/2 (Vanderkuur 
et al., 1997). Alternatively, it has been suggested that GH might also regulate the activation 
of ERK by a SRC-dependent, JAK2-independent mechanism which involves phopholipase D 
(Zhu et al., 2002). This JAK2- independent mechanism has been recently demonstrated in 
vivo (Barclay et al., 2010). Tyrosine phosphorylation of a GRB2-binding site in the epidermal 
growth factor receptor could also be involved in GH-mediated MAPK activation (Yamauchi 
et al., 1997).  
GH signaling via SHC and ERK can be interrupted after blocking insulin receptor substrate-
1 (IRS-1) (Wang et al., 2009). IRS-1 is a docking protein tyrosine phosphorylated in response 
to insulin, IGF-I, GH, and other cytokines. IRS-1 greatly enhances GH-induced ERK. 
GH has also been shown to stimulate the PI3K pathway through JAK2-mediated tyrosine 
phosphorylation of the insulin receptor substrates (IRS-1 to IRS-3), leading to their 
association with PI3K regulatory subunits (Zhu et al., 2001). In addition, direct binding of 
the p85 and p85β subunits to phosphotyrosine residues in the carboxyl terminus domain of 
the GHR has also been demonstrated (Moutoussamy et al., 1998). 
As stated before, GH stimulation of PI3K is linked to the stimulation of the antiapoptotic 
serine protein kinase B or Akt (Costoya et al., 1999). Akt activation has been shown to be 
dependent on the presence of the JAK2-binding region of GHR, and to promote cell survival 
through the inhibition of the proapoptotic protein caspase 3 (Sanders et al., 2006). The role of 
PI3K/Akt on cell survival is well known after the pioneer study of our group (Costoya et al., 
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1999). Inhibiting PI3K/Akt with a potent inibitor of phosphoinositide 3-kinases led to a 
significant increase in apoptosis in NSCs, however GH treatment was able to clearly 
decrease the rate of apoptosis observed by blocking PI3K/Akt signaling. This indicates that 
the hormone is able for signaling through other different pathways acting on cell survival 
(P. Devesa, 2011). We then studied the effects of inhibiting another cell survival pathway 
such as ERK. Inhibiting ERK phosphorylation significantly increased NSCs apoptosis in 
differentiation conditions, but again the treatment with GH was able to revert the 
proapoptotic effect of blocking ERK signaling.  
Since GH was able to revert the propapoptotic effects of the inhibition of both PI3K/Akt and 
ERK, we decided to study signalling pathways located upstream, specifically mTOR. This is 
a master regulator of cell mass and metabolism, which is in part regulated by growth factor 
signalling through the canonical RTK (receptor tyrosine kinase)-PI3K/Akt axis and by 
nutrient (through class III PI3Ks), hypoxia or AMP. 
Rapamycin is an allosteric mTOR inhibitor. As expected, treating NSCs with rapamycin led 
to a significant increase in apoptosis, but once more this effect on cellular death was 
reverted when GH was added together with rapamycin. This seems to be surprising given 
the importance of mTOR in signalling cell survival, and again indicated that the hormone 
uses different pathways for promoting cell survival. However, evidence exists showing that 
mTOR inhibition can lead to pathway reactivation: abrogation of the negative-feedback loop 
which is normally initiated by the direct substrate p70S6K (p70 S6 kinase) on insulin 
receptor substrate proteins can lead to strong PI3K/Akt pathway reactivation, most likely 
producing ERK pathway reactivation in a PI3K/Akt dependent manner (Carracedo et al., 
2008). For a better understanding of such a concept see the scheme shown in Figure 9.    
Thus, while PI3K/Akt inhibition would allow GH to act through ERK pathway, ERK 
inhibition would not impede PI3K/Akt to be the survival-signalling pathway. Of interest 
here is the fact that both kind of inhibitions only were reverted when exogenous GH was 
added. This means that the autocrine production of the hormone by NSCs is not enough for 
blocking intense cell death signals. 
We then blocked simultaneously ERK and mTOR activation. Once more the intense 
apoptosis observed after pharmachological blockade of these pathways was reverted when 
GH was added together with them. The only explanations for this result is that the hormone 
may act directly at a upper level in the stream of signaling pathways for cell survival or the 
effect is due to the overactivation of PI3K occurred as a result of blocking those two other 
signaling pathways. To test the first possibility we used SP600125, an anthrapyrazolone 
inhibitor of Jun N-terminal kinase (Bennett et al., 2001). That is we were acting at the 
terminal level in the stream. In this case the clear increase in apoptosis produced by the 
inhibitor could not be reverted by administering GH together with the drug. It suggests 
either a direct effect of the hormone on JNK activation for cell survival or a direct effect of 
overactivated PI3K on JNK (as postulated by Zhu et al., 1998). 
In summary, our results (P. Devesa, 2011), together with other studies previously described, 
demonstrate that GH is able for promoting NSCs proliferation, and also plays a key role on the 
survival of these cells. With regard to the antiapoptotic role of GH, it seems to be exerted 
trough different signaling pathways: PI3K/Akt, ERK and pJNK (Figure 10). Since culture 
media contain insulin our results do not allow us to conclude whether the effect of GH on 
pJNK is a direct effect or it results from the known crosstalk between GH and insulin at the 
cellular level (Xu & Messina, 2009) or from the overactivation of PI3K directly enhancing JNK 
activity (Zhu et al., 1998). In any case GH effects a very strong effect on the survival of NSCs.  
 
Brain Injury – Pathogenesis, Monitoring, Recovery and Management 
 
432 
and suppress GH signaling by inhibiting JAK2 activity, competing with STATs for binding 
to the GHR, or inducing degradation of the GHR complex. 
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As showed in the scheme, rapamycin treatment inhibits mTOR, thus leading to a feedback activation of 
the PI3K/Akt pathway [2]. Physiologically this would lead to increased ERK activation [3], but this not 
occurs unless exogenous GH is given together with rapamycin [1]. Red lines indicate inhibition; blue 
lines indicate activation. Taken from Pablo Devesa, Doctoral thesis, 2011. University of Santiago de 
Compostela, Spain.  
Fig. 9. Schematic representation of the cell survival signaling pathways studied.  
 
 
The scheme shows how GH may act on cell survival in NSCs according to the results we obtained. The 
possibility of a direct effect of the hormone on JNK phosphorylation could not be demonstrated here; 
another possibility is that the activation of JNK occurs because of overactivation of PI3K after mTOR 
and ERK blockade. Red line indicates inhibition; blue lines indicate activation. Taken from Pablo 
Devesa, Doctoral thesis, 2011. University of Santiago de Compostela, Spain. 
Fig. 10. Schematic representation about the putative role of GH in NSCs survival.  
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A number of studies indicate that the neurobiological consequences of the decline in 
GH/IGF-I, that occurs physiologically during aging, include decreased neurogenesis in the 
dentate gyrus of the hippocampus (Lichtenwalner et al., 2001; Lichtenwalner et al., 2006), 
where IGF-I appears to affect primarily the survival of newborn neurons, but also may 
influence the maturation and differentiation of newborn cells (Aberg et al., 2000; 
Darnaudery et al., 2006).  
Despite that neurogenesis is dramatically reduced during senescence, newborn granule cells 
in the aged dentate gyrus retain the capacity for participation in functional hippocampal 
networks (Marrone et al., 2011); this is in agreement with the aforementioned hypothesis, 
suggesting that it is the age-associated lack of neurotrophic factors (GH/IGF-I?) the cause of 
decreased neurogenesis. In fact, growth hormone prevents neuronal loss in the aged rat 
hippocampus (Azcoitia et al., 2005).   
GH induces IGF-I expression in liver and other tissues; however it is not the only factor 
responsible for it. In fact, there are a number of pathological situations in which a clear 
divergence exists between GH production and plasma levels of IGF-I. This is the case, for 
instance, of Anorexia Nervosa; in these patients, while large burst of pituitary GH are 
released into the blood, IGF-I plasma levels are consistently lower than normal. The 
opposite situation can be observed in obese children; GH secretion is deficient in these 
children, but plasma IGF-I levels are normal and growth velocity is above the mean for age 
(Devesa et al., 1992). The common link between these two situations seems to be plasma 
glucose levels, low in Anorexia Nervosa and showing a tendency to hyperglycemia in 
obesity. Thus, it has been postulated that glucose is needed for the hepatic production of 
IGF-I; more particularly a product of intracellular metabolism of glucose, since 2-
deoxiglucose (who can not be metabolized) is unable to induce hepatic IGF-I expression. 
Therefore, although GH usually is the factor responsible for the hepatic production of IGF-I, 
in terms of neural effects both hormones may follow different paths. In fact, studies in rats 
submitted to moderate and severe hypoxia showed that the spatial distribution of the 
neuroprotection conveyed by growth hormone correlates with the spatial distribution of the 
constitutive neural growth hormone receptor, but not with the neuroprotection offered by 
IGF-I treatment in this model. These results suggest that some of the neuroprotective effects 
of growth hormone are mediated directly through the growth hormone receptor and do not 
involve IGF-I induction (Scheepens et al., 2001).  
The effects of the GH/IGF-I axis on cell turnover in the adult brain probably are not limited 
to neuronal progenitors, since IGF-I can promote proliferation of oligodendrocyte 
progenitor cells (OPCs) and differentiation and survival of oligodendrocytes (McMorris & 
McKinnon, 1996; Mason et al., 2000; Aberg et al., 2007; Pang et al., 2007), an effect also 
induced by EGF (Gonzalez-Perez & Alvarez-Buylla, 2011) whose expression and that of its 
receptor may also be induced by GH (Pan et al., 2011). Thus, it is likely that the aging-
related decline in GH/IGF-I and dependent changes in oligodendrocyte genesis and/or 
maturation may contribute to impaired remyelination in the central nervous system of aged 
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It is likely that some of the positive effects of GH at central level are not directly exerted by 
the hormone but they are mediated trough the induction and release of a number of 
neurotrophic factors, as shown in Figure 11.  
 
 
Some of the neurotrophic effects of GH in vivo could be mediated and/or enhanced through the 
induction of the expression and release of a number of neurotrophic factors. GH induces the expression 
of IGF-I, EGF, EPO; VEGF and FGF. The GH-effects on the induction of BDNF expression have not been 
tested yet but it is likely that they occur, directly or indirectly. GH induces an acute and strong release 
of neutrophiles from the bone marrow, then allowing the release of neurotrophic cytokines. GH has 
trophic effects on the gonads, thus facilitating estradiol and testosterone production. In turn, it is likely 
that the neurotrophic effects of these sexual steroids may be partially due to a positive effect on the 
pituitary GH release mediated by Ach and noradrenaline (Devesa et al., 1992).    
Fig. 11. GH induction of the expression and/or release of a number of factors with known 
neurotrophic activity. 
3. Effects of GH treatment combined with kynesitherapy on the recovery of 
patients with brain injuries  
3.1 Cerebral palsy children 
Cerebral palsy (CP) is a catastrophic acquired disease, occurring during development of the 
fetal or infant brain. It mainly affects the motor control centres of the developing brain, but 
can also affect cognitive functions, and is usually accompanied by a cohort of symptoms 
including lack of communication, epilepsy, and alterations in behavior. 
Major causes for CP include abnormal intrauterine developments, due to fetal-maternal 
infections, asphyxia before birth, hypoxia during delivery, brain trauma during labor and 
delivery, and complications in the perinatal period. Apart from these, prematurity is 
responsible for 40%–50% of cases of CP. Periventricular leucomalacia (PVL) and 
parenchymal venous infarction complicating germinal matrix/intraventricular hemorrhage 
have long been recognized as the two significant white matter diseases responsible for the 
majority of cases of cerebral palsy in survivors of preterm birth. 
However, in more recent studies using magnetic resonance imaging to assess the preterm 
brain, two new appearances have been documented, adding to the spectrum of white matter 
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disease of prematurity: punctate white matter lesions, and diffuse excessive high signal 
intensity. These appear to be more common than PVL but less significant in terms of their 
impact on individual neurodevelopment. They may, however, be associated with later 
cognitive and behavioral disorders known to be common following preterm birth. 
Most CP children often have poor linear growth during childhood, resulting in a diminished 
final adult height. However the number of studies in which it has been reported whether or 
not GH secretion is impaired in CP is quite limited. These studies reflect that GH 
provocative testing induced a GH deficient secretion. In a recent study it was indicated that 
diminished circulating IGF-1 and GH concentrations may explain why children with CP are 
smaller than normally growing children (Ali et al., 2007a). On the other hand, osteopenia is 
a common finding in children with CP, and seems to be associated with decreased IGF-1 
and IGFBP3 plasma levels, usual markers of deficient GH secretion. The large percentage of 
CP children with GH deficiency (GHD) has been reported to be noteworthy. However, 
given the complexity of GH neurorregulation (Devesa et al., 1992) it seems to be logical that 
severe brain damage may affect a number of neurotransmitter pathways involved in GH 
control, thus affecting the normal secretion of the hormone.  
Other possible causes of decreased growth in CP include psychosocial deprivation and 
suboptimal nutritional status, but these are also involved in subnormal GH secretion 
(Devesa et al., 1992). 
We studied whether GH secretion was affected in 46 CP children (28 males, 18 females; aged 
3 to 11 years old). Our results indicated that 70% of the patients seemed to have deficient 
GH secretion (Devesa et al, 2010a), therefore they were candidates to benefit from GH 
replacement therapy.  
In few studies have the benefits of GH-replacement therapy in children with CP been 
reported, and most of these studies only reflect the increased growth observed during the 
treatment period with the hormone (Coniglio & Stevenson, 1995; Shim et al., 2004; Ali et al., 
2007b).  
Neuropsychological assessments have demonstrated that GHD is associated with reduced 
cognitive performance; specifically, in the majority of studies it has been found that GHD 
can lead to clinically relevant changes in memory, processing speed, attention, vocabulary, 
perceptual speed, spatial learning, and in reaction time tests. Cognitive dysfunction appears 
to be specifically related to GH deficiency; this hypothesis is supported by the positive 
correlations between serum IGF-I concentration and IQ, whereas poorer emotional well-
being and reduced perceptual-motor performance are attributed to other pituitary hormone 
deficiencies. 
In a recent study we described (Devesa et al., 2011) the positive effects of GH therapy 
together with psychomotor and cognitive stimulation in 11 children (7 males, 4 females; 
aged 3 to 7 years old) with CP and GHD. Cognitive performances in the children studied 
were assessed by using the Battelle Developmental Inventory Screenning Test (BDIST) 
(Newborg et al., 1988). Tests were performed at admission, two months after commencing 
psychomotor and cognitive stimulation and two months after adding GH replacement 
therapy to psychomotor and cognitive stimulation. Before admission all these CP children 
had been intensively stimulated, most of them since they were 1 year old. Psychomotor and 
cognitive stimulation were adapted to the specific needs of each patient. Psychomotor 
stimulation involved tasks aimed at improving tonic–postural control, laterality, breathing 
and relaxation, static and dynamic balance, motor coordination and dissociation, body 
image, oculomotor coordination, spatial and temporal orientation, and gross and fine motor 
 
Brain Injury – Pathogenesis, Monitoring, Recovery and Management 
 
436 
It is likely that some of the positive effects of GH at central level are not directly exerted by 
the hormone but they are mediated trough the induction and release of a number of 
neurotrophic factors, as shown in Figure 11.  
 
 
Some of the neurotrophic effects of GH in vivo could be mediated and/or enhanced through the 
induction of the expression and release of a number of neurotrophic factors. GH induces the expression 
of IGF-I, EGF, EPO; VEGF and FGF. The GH-effects on the induction of BDNF expression have not been 
tested yet but it is likely that they occur, directly or indirectly. GH induces an acute and strong release 
of neutrophiles from the bone marrow, then allowing the release of neurotrophic cytokines. GH has 
trophic effects on the gonads, thus facilitating estradiol and testosterone production. In turn, it is likely 
that the neurotrophic effects of these sexual steroids may be partially due to a positive effect on the 
pituitary GH release mediated by Ach and noradrenaline (Devesa et al., 1992).    
Fig. 11. GH induction of the expression and/or release of a number of factors with known 
neurotrophic activity. 
3. Effects of GH treatment combined with kynesitherapy on the recovery of 
patients with brain injuries  
3.1 Cerebral palsy children 
Cerebral palsy (CP) is a catastrophic acquired disease, occurring during development of the 
fetal or infant brain. It mainly affects the motor control centres of the developing brain, but 
can also affect cognitive functions, and is usually accompanied by a cohort of symptoms 
including lack of communication, epilepsy, and alterations in behavior. 
Major causes for CP include abnormal intrauterine developments, due to fetal-maternal 
infections, asphyxia before birth, hypoxia during delivery, brain trauma during labor and 
delivery, and complications in the perinatal period. Apart from these, prematurity is 
responsible for 40%–50% of cases of CP. Periventricular leucomalacia (PVL) and 
parenchymal venous infarction complicating germinal matrix/intraventricular hemorrhage 
have long been recognized as the two significant white matter diseases responsible for the 
majority of cases of cerebral palsy in survivors of preterm birth. 
However, in more recent studies using magnetic resonance imaging to assess the preterm 
brain, two new appearances have been documented, adding to the spectrum of white matter 
 
Growth Hormone and Kynesitherapy for Brain Injury Recovery 
 
437 
disease of prematurity: punctate white matter lesions, and diffuse excessive high signal 
intensity. These appear to be more common than PVL but less significant in terms of their 
impact on individual neurodevelopment. They may, however, be associated with later 
cognitive and behavioral disorders known to be common following preterm birth. 
Most CP children often have poor linear growth during childhood, resulting in a diminished 
final adult height. However the number of studies in which it has been reported whether or 
not GH secretion is impaired in CP is quite limited. These studies reflect that GH 
provocative testing induced a GH deficient secretion. In a recent study it was indicated that 
diminished circulating IGF-1 and GH concentrations may explain why children with CP are 
smaller than normally growing children (Ali et al., 2007a). On the other hand, osteopenia is 
a common finding in children with CP, and seems to be associated with decreased IGF-1 
and IGFBP3 plasma levels, usual markers of deficient GH secretion. The large percentage of 
CP children with GH deficiency (GHD) has been reported to be noteworthy. However, 
given the complexity of GH neurorregulation (Devesa et al., 1992) it seems to be logical that 
severe brain damage may affect a number of neurotransmitter pathways involved in GH 
control, thus affecting the normal secretion of the hormone.  
Other possible causes of decreased growth in CP include psychosocial deprivation and 
suboptimal nutritional status, but these are also involved in subnormal GH secretion 
(Devesa et al., 1992). 
We studied whether GH secretion was affected in 46 CP children (28 males, 18 females; aged 
3 to 11 years old). Our results indicated that 70% of the patients seemed to have deficient 
GH secretion (Devesa et al, 2010a), therefore they were candidates to benefit from GH 
replacement therapy.  
In few studies have the benefits of GH-replacement therapy in children with CP been 
reported, and most of these studies only reflect the increased growth observed during the 
treatment period with the hormone (Coniglio & Stevenson, 1995; Shim et al., 2004; Ali et al., 
2007b).  
Neuropsychological assessments have demonstrated that GHD is associated with reduced 
cognitive performance; specifically, in the majority of studies it has been found that GHD 
can lead to clinically relevant changes in memory, processing speed, attention, vocabulary, 
perceptual speed, spatial learning, and in reaction time tests. Cognitive dysfunction appears 
to be specifically related to GH deficiency; this hypothesis is supported by the positive 
correlations between serum IGF-I concentration and IQ, whereas poorer emotional well-
being and reduced perceptual-motor performance are attributed to other pituitary hormone 
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skills. Cognitive stimulation involved tasks directed at improving interaction with the 
environment, communication, attention, perception, memory, reasoning, and concept 
learning. These therapies were carried out for 45 minutes per day, 5 days per week during 4 
months. Recombinant human GH was given subcutaneously, 30 µg/kg/day, 5 days/week, 
during 2 months (after 2 months of psychomotor and cognitive stimulation).  
Patients did not improve their psychomotor and cognitive status during the pretreatment 
period, during which only psychomotor and cognitive stimulation were performed. 
However, significant improvements in all BDIST domains were observed when GH was 
administered together with psychomotor and cognitive stimulation; specifically, patients 
improved in personal and social skills, adaptive behavior, gross motor skills and total 
psychomotor abilities, receptive and total communication, cognitive skills, and in the total 
score of the scale (p < 0.01), and in fine motor skills and expressive communication (p < 
0.02). As expected, plasma IGF-1 and IGFBP3 significantly increased after GH treatment. 
These results led us to conclude that the combined therapy involving GH replacement and 
psychomotor and cognitive stimulation is useful for the appropriate neurodevelopment of 
children with CP and GHD (Devesa et al., 2011). Since these children had received an 
intensive neurostimulation without significant improvements before being treated with GH, 
it seems to be clear that the hormone, and/or IGF-1 was the main factor responsible for the 
results obtained. Moreover,  since exogenous GH combines with locally produced GH for 
repairing brain injuries (P. Devesa et al., 2011) it is feasible to assume that GH treatment 
may be used too in CP children without GHD. 
In another study (Reimunde et al., 2011), we assessed the effects of growth hormone 
treatment (30 μg/kg/day) combined with physical rehabilitation in the recovery of gross 
motor function in children with GHD and CP (four males and six females, mean age 5.63 ± 
2.32 years) as compared with that observed in a similar population of CP children (five 
males, five females, mean age 5.9 ± 2.18 years) without growth hormone deficiency treated 
only with physical rehabilitation for two months. The Gross Motor Function Measure 
(GMFM-88) and Modified Ashworth Scale were performed before commencing the 
treatment and after completion thereof. The GMFM-88 is a scale constructed for evaluation 
of change in gross motor function in children with cerebral palsy and consists of 88 items 
grouped into five dimensions, ie, dimension A (lying and rolling, 17 items), dimension B 
(sitting, 20 items), dimension C (crawling and kneeling, 14 items), dimension D (standing, 13 
items) and dimension E (walking, running, and jumping, 24 items). 
Scores for each dimension are expressed as a percentage of the maximum score for that 
dimension, adding the scores for all dimensions, and dividing by 5 to obtain the total score. 
The reliability, validity, and responsiveness of the GMFM-88 scores are documented for 
children with cerebral palsy (Palisano et al., 2000).	The Modified Ashworth Scale is used for 
measuring spasticity in spastic patients (Bohannon & Smith MB, 1987).	
In children with CP and GHD, Dimension A (p < 0.02), dimension B (p < 0.02), and 
dimension C (p < 0.02) of the GMFM-88, and the total score of the test (p < 0.01) significantly 
improved after the treatment; dimension D and dimension E did not increase, and four of 
five spastic patients showed a reduction in spasticity. However, in children with cerebral 
palsy and without growth hormone deficiency, only the total score of the test improved 
significantly after the treatment period. Plasma IGF-I values (previously low in GHD CP 
children) were similar in both groups at the end of the treatment period, indicating that 
growth hormone replacement therapy was responsible for the large differences observed 
between both groups in response to physical rehabilitation. 
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According to these results it is likely that GH administration plays a key role in recovering 
from a brain injury, independently or not that a GH deficiency exists. In this regard, 
voluntary physical exercise is known to be a factor increasing neurogenesis and also 
enhancing learning and memory (Beckinstein et al., 2011). However few positive effects are 
obtained in CP chidren undergoing exhaustive daily physical work, as our data also reflect. 
Exercise is a powerful stimulus for endogenous growth hormone release, most likely 
through enhanced central NA tone (Devesa et al., 1992). It has been demonstrated that 
inhibiting PI3K/Akt signaling, one of the pathways by which GH acts (Costoya et al., 1999), 
blocks exercise-mediated enhancement of adult neurogenesis and synaptic plasticity in rats 
(Bruel-Jungerman et al., 2009). The possibility exists that the lack of significant 
improvements in CP children submitted to intensive physical work is due to an impaired 
GH secretion, as it seems to occur whenever a brain injury exists, independently that current 
provocative tests do not reflect the existence of a GH deficiency.   
As described before, blindness is a common finding in CP children. We studied 20 children 
with CP occurring as a consequence of prematurity leading to Periventricular Leukomalacia 
(11 males, 9 females, aged 2,05 ± 1,43 years; mean ± SD of the mean) with critical impairment 
of vision and marked pallor of the optic nerve. They were treated with GH and visual 
stimulation performed with a tachistoscope (repetitive white light flashes, 100-150 ms, 
carried out in 10 phases lasting 1 min each one, 80 flashes/min; 5 days/week). Stimulation 
was performed in a dark isolated room. Visual evoked potentials (VEP) were recorded 
before commencing the treatment and after finishing it. Treatment lasted for 5 ± 2.65 
months. The rationale for interrupting visual stimulation and GH treatment was based on 
clinical observations (for example, visual interaction with the environment, looking at 
objects or relatives, taking objects with the hands...).  
Results from this study (unpublished data) show that the children we studied presented 
severe visual deficiencies, characterized by a delayed conduction from the retina to the 
occipital cortex, as VEP showed, but these were corrected at the end of treatment period, as 
Figure 12 shows. Latencies were significatly decreased, while no significant changes were 
observed in amplitudes.   
Delayed conduction from the retina to the occipital cortex means a deficient myelination. 
This may be related to a delayed maturation of the CNS, but it is unlikely that this was the 
reason in these CP children since they suffered brain injuries produced by prematurity 
leading to Periventricular Leukomalacia in which cerebral white matter is consistently 
affected. Moreover, some of these children were older than 2 years old, a period of time 
from which it is considered that a brain damage is already established and significant 
improvements are unlikely to appear. Injuries involving the optic radiations, such as it 
happens in Periventricular Leukomalacia, have a bad prognosis (Hoyt, 2003) and most of 
these children are expected to remain visually handicapped.   
We utilized a tachistoscope as a stimulation method of both visual hemifields, but it is 
unlikely that visual stimulation alone could be responsible for the clinical and VEP changes 
observed after the treatment. Despite the fact that there was not a control group in our study 
and this could lead to missinterpretating the results obtained, most of these children had 
been receiving intense stimulation previously without achieving significant results.  
A recent study describe that plasma levels of GH/IGF-I influence glial turnover in the white 
matter (Hua et al., 2009). It is not clear whether the maintenance of Oligodendrocyte 
Precursor Cells (OPCs) and oligodendrocyte turnover in the adult brain serves normal 
function or only provides a rapidly recruitable population of cells for myelin repair 
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following damage. Proliferation of oligodendrocyte precursors and recruitment of new, 
myelinating oligodendrocytes from immature precursors contribute to myelin repair 
following demyelinating lesions. Following demyelination, proliferation of OPCs and 
commitment, differentiation and survival of adult-born oligodendrocytes all appear to be 
targets of regulation by inflammatory cytokines and growth factors. 
 
 
The figure shows changes observed in the latencies of Visual Evoked Potential waves registered in CP 
children before (black bars) and after (white bars) the treatment with GH and visual stimulation. * p < 
0.005 vs. pretreatment.  
Fig. 12. Latencies of Visual Evoked Potential waves in blind CP children.  
The GH/IGF-I system appears to play a particularly critical role in myelin repair. IGF 
expression is induced in multiple models of demyelination and is increased during 
remyelination (Fushimi & Sharabe, 2004). Treatment with IGF-I or overexpression of IGF-I 
in transgenic mice inhibits oligodendrocyte death during demyelination and/or enhances 
remyelination following demyelinating lesions (McMorris & McKinnon, 1996; Mason et al., 
2000; Kumar et al., 2007). 
The possibility exists that remyelination observed in our study, as showed by the 
improvements in VEPs latencies, might be due to increased plasma IGF-I values. This does 
not exclude a direct effect of GH on myelination. As described before, GH induces EGF and 
EGF-R expression, factors recently involved on central nervous system remyelination 
(Gonzalez-Perez & Alvarez-Buylla, 2011).  
Thus, it is feasible to assume that GH treatment played a significant role in the visual 
recovery elicited by specific visual stimulation.  
Case report  
At age 3 weeks a CP baby was admitted for rehabilitation in our Center. He suffered a 
massive bleeding in utero that produced a 20-minute cardiac arrest. A MRI carried out at age 
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2 weeks showed a severe encephalopathy with cystic cavities in both occipital lobes. VEP 
and auditory evoked potentials were isoelectric without any signs of conduction. Prognosis 
could not be worst: blind, deaf, dumb and spastic tetraparesia.  
After obtaining signed informed consent from the parents we commenced an intensive 
rehabilitation with him. Visual stimulation, auditory stimulation, sensorial and physical 
stimulation and GH treatment (0.04 mg/kg/day). Three months later the child was showing 
signs of positive evolution. There was electrical conduction from the retina to the cortex, he 
responded to auditory stimuli and spasticity was decreased. GH treatment lasted for 4 
months, but physical and sensorial stimulation continued for 12 months. At this time the 
child was absolutely normal as functional physical and cognitive tests revealed. Currently, 
at age 17 months, he walks, he speaks, he laughs, he plays, he is like any other child of his 
age. No sequelae have been observed and the treatment did not produce any kind of 
adverse effects.  
A new MRI taken when he was 1 year old showed that the brain was completely 
regenerated. Cystic cavities disappeared and occipital lobes were fully functional. Voxels 
based morphometry comparing both MRI indicated that a number of brain areas 
experienced a significant regeneration; this was particularly significant in thalamus.  




Upper images were taken at age 2-weeks. Notice the cavities affecting occipital lobes. Lower images 
were taken at age 1-year; no occipital cysts exist.  
Fig. 13. Some images of MRI studies in the child described as a Case report. 
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These images were obtained after comparing MRI studies carried out at 1-year interval in the child 
described as a Case report. The intensity of red colours is associated to greater regeneration.   
Fig. 14. Voxels based morphometry.  
To our knowledge this is the first description about complete human brain regeneration 
demonstrated with brain images. Brain plasticity may be responsible for achieving 
important functional recoveries in patients after a brain injury. In our case these 
recoveries were found not only by clinical and specific physical and cognitive tests, but 
they have been demonstrated with brain images. It is clear that the age at which we 
commenced the treatment of this child had a significant influence on the results obtained; 
brain development continues for 1 year after birth, approximately, but it also clear that 
physical and cognitive stimulation alone are not able for achieving a complete and 
functional recovery of the brain. Since the system GH/IGF-I has been involved in playing 
a very important role during embryonic brain development it seems that the treatment 
with the hormone was the main factor responsible for results achieved in this study. This 
supports our previous postulate about commencing GH treatments as soon as possible 
after a brain injury (Devesa et al., 2010a).    
3.2 Traumatic brain injury 
Traumatic brain injury (TBI) is an important health problem and a leading cause of death 
and disability worldwide, mainly in people under 40. Specifically, TBI is an important 
identified risk factor for cognitive deficits, such as attention, concentration, learning, 
memory, conceptual thinking, problem-solving or language (Vogenthaler, 1987). Recent 
studies have demonstrated that hypopituitarism, and particularly growth hormone 
deficiency (GHD), is common among survivors of TBI tested several months or years 
following head trauma (Popovic, 2005a; Popovic et al., 2005b). The subjects at risk are those 
who have suffered moderate-to-severe head trauma, although mild intensity trauma or even 
minor head injuries may precede hypopituitarism (Popovic et al., 2005b). Complex pituitary 
deficits are found in 35–40% of TBI patients; severe GHD occurs in 10–15% and partial GHD 
in 15% of TBI patients (Popovic et al., 2005b). 
Neuropsychological assessments have demonstrated that GHD is associated with reduced 
cognitive performance; specifically, most of the studies indicate that GHD can lead to 
clinically relevant changes in memory, processing speed, attention, vocabulary, perceptual 
speed, spatial learning and in reaction time tests as well (van Dam, 2006; Falletti et al., 2006; 
Nieves-Martinez et al., 2010). 
Cognitive dysfunction appears to be specifically related to GH deficiency; this hypothesis is 
supported by the positive correlations between serum IGF-I concentration and IQ. Thus, it 
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has been shown that cognitive disorders secondary to GHD may be reversed by GH 
replacement (Maruff &  Falletti, 2005).  
We studied (Reimunde et al., 2010) 20 male adult patients with TBI suffered in the previous 
10 years. Main brain injuries occurred because of frontal contusions affecting brain frontal 
lobes. Eleven of them presented GHD (mean age: 53.36 ± 17.35 years), while GH secretion 
seemed to be normal in the other nine patients (mean age: 47.12 ± 14.55 years).  
All patients received daily cognitive rehabilitation, 1 hour per day, 5 days per week during 3 
months. The contents of cognitive rehabilitation were aimed to improve the spatial, 
temporal and personal orientation, visual, auditory and tactile discrimination and 
perception, body recognition, planning and execution of motor acts, all memory types and 
processes, oral and writing language, calculation and executive function tasks. GHD 
patients were given human GH (0.5 mg/day during 20 days and then 1 mg/day, 5 days per 
week, for 3 months). Control patients were given placebo.  
To assess different cognitive abilities we used a widely recognized neuropsychological test 
battery, the Wechsler Adults Intelligence Scale (WAIS) (Wechsler, 1990). This assessment 
battery involves several sections that specifically measure multiple cognitive functions. 
WAIS test was performed before commencing the treatment and after 3 months of treatment 
in all patients. 
Results from our study demonstrate that individuals treated only with cognitive 
rehabilitation improved, specifically, their attentional functioning. However, the group 
treated with GH and cognitive rehabilitation improved their attentional functioning too, but 
moreover showed specific improvements in memory, understanding, associative thinking 
skills, information management and storing, learning, visual-motor dexterity and speed of 
execution. 
In addition, the GHD group reached greater improvements in aspects related with memory, 
understanding, associative thinking skills and information management and storing 
information than the control patients. 
These data correlated with previous results showing that GH-deficient subjects treated with 
GH experience significant improvements in concentration and attention, different memory 
modalities and learning.  
It has been described that memory performance is weakly related to the mean daily GH 
dose, but there was a stronger positive correlation between the increase in mental 
performance and the GH-induced rise in serum IGF-I; this phenomenon can be explained by 
the large inter-individual differences in GH sensitivity (Deijen et al., 1998). However, in our 
study, no significant differences between plasma IGF-I levels in both groups of patients 
were observed at the end of the treatment period. Thus, it is unlikely that the IGF-I rise 
could be responsible for the results here obtained. 
In conclusion, our study demonstrated, for the first time, the utility of a combination 
therapy involving GH replacement and cognitive rehabilitation in the recovery of cognitive 
impairments in patients who had suffered a TBI and a subsequent GHD. Our data show that 
the combination therapy has significantly greater effects than those achieved by carrying out 
only cognitive rehabilitation in patients with cognitive impairments secondary to a TBI 
without GHD. GH administration seems to be responsible for the results obtained. On these 
bases, we concluded that it woud be interesting to test whether GH administration to no 
GHD patients would improve cognitive functions in a number of neurological disorders 
(Reimunde et al., 2010).     
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Throughout this chapter we have reviewed the evidence showing that adult neurogenesis is 
a physiological mechanism to repair brain damage. We analyzed a number of factors 
directly involved in this process.  
We demonstrated that both GH and its receptor are expressed in neural precursors in mice, 
and we showed that after a brain injury, in rats, the treatment with the hormone increases 
the number of newly born stem cells produced in response to the damage. We demonstrated 
that GH is present in the cytoplasm of these newly born cells, most likely for facilitating 
their migration from neurogenic niches. Our data in cell cultures obtained from mice stem 
cells demonstrate that the hormone plays a key role for neural cells survival.  
In human patients with brain injury and GH-deficiency, we demonstrated that GH 
treatment together with physical and cognitive stimulation is responsible for the recovery of 
motor and cognitive abilities. GH treatment also appears to play a key role for remyelination 
of the visual pathways in children with cerebral palsy. 
For the first time we showed here that an early treatment with the hormone can recover a 
brain injury in the first months of the life. 
Although not presented here, GH treatment may repair central neurogenic dysphagias 
(Devesa et al., 2009; Reimunde et al., 2011, submitted for publication).  
By analyzing the role of many factors positively involved on adult neurogenesis, we 
postulate that some of the positive effects of GH at the central level may be due to GH-
induced expression of a number of neurotrophic factors and/or to enhanced release of some 
of them. 
We conclude that GH treatment is a powerful tool for being used in a number of brain 
injuries, including neurodegenerative non-genetical diseases (for example, multiple 
sclerosis, Alzheimer, etc). It seems that there is no need that GH-deficiency exists for the 
hormone being useful.  
GH treatments have to be well scheduled and short in time. The positive effects of the 
hormone remain in the time.    
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1. Introduction  
The proposed chapter outlines novel approaches that provide an infrastructure for 
discovery and validation of new biomarkers of acute brain injury. Approaches to validation 
can be also applied to existing biomarkers of brain injury in order to provide more rigorous 
assessment of their clinical utility. Importantly, there are currently no biomarkers of brain 
injury approved by Food and Drug Administration (FDA). The chapter reviews approaches 
critical for securing FDA approval of biomarkers of brain injury and disease, focusing on 
traumatic brain injury (TBI).  
The chapter reviews proteomics techniques applied for the first time to discovery of 
biomarkers of central nervous system (CNS). These techniques include refined mass 
spectrometry technology and high throughput immunoblot techniques.  Output from these 
approaches can identify potential candidate biomarkers employing systems biology and 
data mining methods that will also be described. 
Once potential biomarkers have been identified, it is important to provide information on 
their clinical utility for diagnosis, management and prognosis of patients exposed to brain 
injuries. This section of the chapter will review both preclinical and clinical methods for 
biomarker validation. Preclinical models discussed include rodent models of closed head 
injury such as the controlled cortical impact (CCI) device. Consideration will also be given 
to the design and results from human clinical trials validating biomarkers of mild, moderate 
and severe traumatic brain injury (TBI). Human studies will include detailed analyses of the 
biokinetics of different biomarkers in order to understand their utility in acute, subacute and 
chronic phases of TBI. Consideration will also be given to relationships between levels of 
biomarkers and magnitude of acute injury, CT imaging profiles, occurrence of secondary 
insults and long term outcome.   
To achieve practical clinical utility, it is important to develop highly sensitive and specific 
assays for individual biomarkers. Enzyme-linked immunosorbent assays (ELISAs) are the 
current choice for clinical use, since this assay technology provides reliable, quantitative and 
accurate data. ELISA technologies relevant to biomarker measurement will be discussed. 
Once ELISA assays for individual biomarkers have been developed, these assays need to be 
transferred to devices that are appropriate for the clinical application and medical 
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environment in which biomarker analyses will be conducted. We will review devices for use 
in clinical laboratories, emergency rooms (ERs), intensive care units (ICUs) and austere 
medical environment. In addition, this section will include review developing technologies 
allowing concurrent assessment of multiple biomarkers (multiplex). 
To date, studies of biomarkers for brain injury have been restricted to research applications 
only. Although there is broad recognition of clinical utility of biomarkers, the FDA has yet to 
approve any biomarkers of CNS injury of disease. This section of the chapter provides a 
detailed outline of the regulatory consideration necessary for a biomarker to file for approval 
by FDA. Importantly, many of these considerations need to be integrated into relatively early 
stages of biomarker validation, assay development and device selection. 
2. Biomarker discovery: Methods and results 
2.1 Proteomics/systems biology in the area of neurotrauma 
The application of neuroproteomics/neurogenomics has revolutionized the 
characterization of protein/gene dynamics, leading to a greater understanding of post-
injury biochemistry. Neuroproteomics and neurogenomics fields have undertaken major 
advances in the area of neurotrauma research focusing on biomarker identification. 
Several candidate markers have been identified and are being evaluated for their efficacy 
as biological biomarkers utilizing these “omics approaches”. The identification of these 
differentially expressed candidate markers using these techniques is proving to be only 
the first step in the biomarker development process. However, to translate these findings 
into the clinic, data-driven development cycle incorporating data-mining steps for 
discovery, qualification, verification, and clinical validation is needed. Data mining steps 
extend beyond the collected data level into an integrated scheme of animal modeling, 
instrumentation, and functional data analysis.  
Proteomics is the identification and quantification of all expressed proteins of a cell type, 
tissue or organism. The advancement in the field of proteomics has coincided with the 
completion of the human genome sequencing project (Fenn et al. 1989, Tanaka 1988, Karas & 
Hillenkamp 1988). In recent years, the term proteomics is often mentioned together with 
biomarker discovery, as proteomic studies have the capability of identifying sensitive and 
unique signature protein biomarkers from tissues or biofluids derived from animal models 
or human clinical samples inflicted with various diseases. Neuroproteomics and 
neurogenomics, the application of proteomics and genomics in the field of neuronal injury, 
have been identified as a potential means for biomarker discovery, with the ability to 
identify proteome dynamics in response to brain injury (Guingab-Cagmat 2009, Haskins et 
al. 2005, Davidsson & Sjogren 2005, Shin et al. 2002, Celis et al. 2004).  
In the area of brain injury, several studies have demonstrated the role of proteomics 
(Denslow et al. 2003, Katano et al. 2006) and genomics (Redell et al. 2009, Ding et al. 2006) in 
providing significant insight into understanding changes, modifications and functions in 
certain proteins post TBI. In addition, genomics and proteomics are powerful, 
complementary tools that play an important role in the area of biomarker identification. 
Over the past few years, advances in the fields of neuroproteomics and neurogenomics have 
led to the discovery of many candidate biomarkers and are becoming the primary methods 
for initial candidate marker selection (Kobeissy et al. 2008, Wang et al. 2006, Ottens et al. 
2007, Nogoy 2007, Ottens et al. 2006). The identification of differentially expressed candidate 
markers using these techniques is proving to be only the first step in the biomarker 
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development process. However, to translate these into the clinic, these novel assays require 
a data-driven development cycle that incorporates data-mining steps for discovery, 
qualification, verification, and clinical validation (Rifai et al. 2006). 
TBI neuroproteomics studies have utilized biofluids such as blood/serum in addition to 
injured tissue to identify clinical markers that may correlate with injury severity. One of the 
studies by Burgess et al, evaluated altered differential proteins in normal human post 
mortem cerebrospinal fluid (CSF) (Burgess et al. 2006). The rationale of using post-mortem 
CSF is that it resembles a model of massive brain injury and cell death which post-mortem, 
thus comparing protein profile of post-mortem CSF with brain injury CSF would be ideal 
for identifying protein markers of injury. Of the 229 proteins identified, a total of 172 were 
novel and not previously described. The findings showed that the use of post mortem CSF 
(non-TBI samples) to evaluate altered protein levels mimicked the changes occurring in the 
brain following a traumatic insult. Furthermore, the identification of differential proteins of 
intracellular origin in the CSF corroborates the suggestion that there is protein leakage into 
the CSF following brain injury (Dumont et al. 2004, Hammack et al. 2004). This is a key step 
in identifying protein markers since, neuronal specific proteins leak from injured brain 
directly to the CSF.  
In one of the TBI studies conducted in our laboratory, 1D-differential gel electrophoresis 
(DIGE) protein separation in series with mass spectrometry analysis was used to discover 
putative TBI biomarkers in brain tissues from a rat model (Haskins et al. 2005). These included 
57 downregulated and 74 upregulated proteins; however data were not so informative due to 
limited separation capability. In an advanced study, we utilized a multidimensional separation 
platform called (CAX-PAGE/RPLC-MSMS) which consisted of different levels of separation 
including ion chromatography, 1-D gel electrophoresis and mass spectrometry as a novel 
approach for identifying biomarkers and protein breakdown products (degradomes); for 
detailed reviews, refer to (Svetlov et al. 2006, Kobeissy et al. 2006). As an application, the 
CAX/neuroproteomic analysis was employed on cortical samples of rat subjected to 
controlled cortical impact (CCI) model of experimental TBI (48 hrs post injury). Of interest, our 
neuroproteomic analysis identified 59 differential protein components of which 21 decreased 
and 38 increased in levels after TBI. One main advantage of this technique is its ability to 
elucidate degradomic substrates of different protease systems; thus our data identified the 
elevated levels of the breakdown products of several proteins (Kobeissy et al. 2006). Several of 
these are now being investigated as potential biomarkers specific for TBI to assess severity and 
recovery by evaluating their levels at different time points post TBI.  
2.1.1 Data mining coupled neurosystems biology analysis in brain Injury 
Coupled to data-mining steps, systems biology (SB) represents a mathematical model capable 
of predicting the altered processes or functions of a complex system under normal and 
perturbed conditions. It combines experimental, basic science data sets, proteomic and genetic 
data sets, literature and text mining, integration with computational modeling, bioinformatics 
and pathway/interaction mapping methods. When constructed properly, SB databases can 
provided a context or framework for understanding biological responses within physiological 
networks at the organism level, rather than in isolation (Chen et al. 2007). 
In this regard, “omics” output constitutes one key component of neurosystems biology. It 
discusses the global changes involved in neurological perturbations integrating the final 
outcomes into a global functional network map which incorporates potential biomarkers 
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identified (Grant 2003, Grant & Blackstock 2001). In the area of brain injury, neurosystems 
biology platform harnesses data sets that, by themselves, would be overwhelming, into an 
organized, interlinked database that can be queried to identify non-redundant brain injury 
pathways or convert hot spots. These can be exploited to determine their utilities as 
diagnostic biomarkers and/or therapeutic targets. The ultimate goals of system biology are: 
first by exploring the systems component (gene, protein, small molecule, metabolite etc.), 
help biologist, pharmaceutical companies and doctors to better understand the mechanisms 
underlying the disease components. Thus, it allows for suitable targets for treatment. 
Secondly, the systems biology approach enables one to be able to predict the functions and 
behavior of various components of the system upon varying any on the interconnected 
component since the whole system will be viewed globally rather than on micro, individual 
component level (Beltrao et al. 2007).  
 
 
Fig. 1. Systems biology–based therapeutic target identification and target-specific biomarker 
selection. 
In the field of neurotrauma, identifying and analyzing brain injury-related networks plays 
important and practical clues relating to biological pathways relevant to disease processes. 
However, the more important underlying goal in this analysis is to provide important clues 
that may suggest radically new approaches to therapeutics. Systems modeling and 
simulation is now considered fundamental to the future development of effective therapies. 
In the brain injury for example, it has been shown that calpain and caspase proteases are 
major components in cell death pathways taking part in two destructive proteolytic 
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pathways that not only contribute to key forms of cell death (necrosis and apoptosis), but 
also in the destruction of important structural components of the axons (alphaII-spectrin 
breakdown products (SBDPs) and tau), dendrites (MAP2) and myelin (MBP) (Figure. 1). 
Interestingly, two different forms of SBDPs reflect either neuronal necrosis (SBDP150 and 
SBDP145 cleaved by calpain) or neuronal apoptosis (SBDP120 cleaved by caspase-3) (Wang 
et al. 2005). These SBDPs and other similar neural protein breakdown products can serve as 
target pathway specific biomarkers as illustrated in Figure 1.  
Calpain and caspase proteases are used here as examples of therapeutic targets with 
proteolytic brain biomarkers representing non-redundant pathways relevant to the 
pathobiology of these therapeutic targets and the disease itself. TBI (traumatic brain injury); 
MAP2 (microtubule-associated protein 2); MBP (myelin basic protein); SBDP (spectrin 
breakdown product).  
3. Biomarker validation: Methods and results 
Traumatic injury to the brain results in a cellular activation and disintegration, leading to 
release of cell-type–specific proteins. Measurable amounts of these damage markers are 
present in cerebrospinal fluid (CSF) and blood. These markers not only indicate the 
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information about the pathophysiologic mechanisms which can be targeted by therapeutic 
interventions. Therefore, during the last decade, neurobiochemical markers for TBI have 
attracted increased attention, they can be used to screen for, diagnose or monitor the 
patients and to guide targeted therapy or assess therapeutic response (Etzioni et al. 2003, 
Vitzthum et al. 2005). (Figure. 2) Furthermore, biomarkers might be valuable tool in drug 
development (Blennow 2010).   
3.1 Clinical evaluation 
However, several studies have measured a variety of neurochemical substances in the CSF 
or blood, and a number of proteins synthesized in astroglial cells or neurons have been 
proposed as markers of cell damage in the CNS and after TBI, to date, none has been 
approved for clinical use. Critical criteria of the diagnostic performance of a clinically valid 
biomarker for TBI include its diagnostic accuracy and predictability. 
The diagnostic accuracy of a test is the proportion of correctly classified patients (the sum of 
true positive and true negative tests) and is determined by calculating the test’s sensitivity, 
specificity, likelihood ratio and receiver operating characteristic (ROC) curve (Bossuyt et al. 
2003).  Sensitivity is the ability to detect a disease in subjects in whom the disease is truly 
present (i.e., a true positive), and specificity is the ability to rule out the disease in subjects in 
whom the disease is truly absent (i.e., a true negative). Likelihood ratio (LHR), used to assess 
diagnostic value of a test, is the likelihood that a given test result would be expected in a 
patient with the specific disease compared to the likelihood that that same result would be 
expected in a patient without the target disorder. Two dimensions of accuracy might be 
considered, the LHR for a positive test (positive LHR) and the LHR for a negative test 
(negative LHR) (Albert 1982, Altman 1991). ROC curve is the graphical way of presenting the 
sensitivity (true positive rate) versus false positive rate (1 − specificity). A ROC curve enables 
the determination of appropriate cut-points, depending on the intended clinical utility of the 
test (Zweig& Campbell 1993). The area under the curve (AUC) is a measure of predictive 
discrimination: 50% is equivalent to random guessing and 100% is perfect prediction. 
Although sensitivity and specificity are the most commonly provided variables in 
diagnostic studies, they do not directly apply to many clinical situations because the 
physician would rather know the probability that the disease is truly present or absent if the 
diagnostic test is positive or negative rather than probability of a positive test given the 
presence of the disease (sensitivity). This information is provided by the diagnostic 
predictability. Diagnostic predictability establishes the ability of the test to predict the 
presence or absence of disease for a given test result and is determined by calculating the 
positive and negative predictive values. The positive predictive value denotes the 
proportion of patients with positive test results who have the disease, and the negative 
predictive value defines the proportion of patients with a negative test who do not have the 
disease. The predictive values of a test vary with the prevalence of the disease in the 
population examined. Bayes’ theorem allows calculation of the predictive values for any 
prevalence of disease using the prevalence and the sensitivity and specificity measures 
derived from previous studies (Altman 1991). 
To demonstrate its clinical utility, a novel biomarker needs to be evaluated in a series of 
human studies (phase 1–4 trials) in order to establish the performance characteristics. The 
phase 1 examines whether the biomarker is significantly different for diseased patients as 
compared to those known not to have the disease. If a satisfactory discrimination between 
patients and controls is proven, the following step is to determine diagnostic accuracy 
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(phase 2). Phase 3 evaluates the performance of the test in the target population (Sackett & 
Haynes 2002). Phase 3 assesses whether the measurement of the biomarkers modifies 
outcome and influence therapeutic interventions and the subsequent effect on health 
outcome (intervention studies) (Sackett & Haynes 2002). Phase 4 trial is also known as post-
marketing surveillance trial because this phase can be done after the marker has been made 
commercially available. 
3.2 Novel candidate biomarkers 
Many publications can be found for candidate biomarkers, although the initially promising 
results have often not been confirmed. Here, we review novel biomarkers that have shown 
high sensitivity and specificity in at least two independent studies. Biomarkers reflect damage 
and release from each of the major cell types/structures in brain parenchyma, therefore they 
can be divided into neuronal/synaptic and glial biomarkers (Table 1). We also discuss selected 
candidate biomarkers related to cellular and subcellular origins. 
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3.2.2 Neuronal and axonal markers 
Neuronal and axonal proteins could prove to be valuable biomarkers as these molecules 
might correlate with cognitive function and long term outcome. 
3.2.2.1 Neuron-specific enolase 
Neuron-specific enolase (NSE) is a glycolytic pathway enzyme, localized predominantly in 
neuronal cytoplasm. Several studies demonstrated that NSE is a sensitive and specific 
indicator of neuronal cell death (Selakovic et al. 2005, Oertel et al. 2006). In addition, studies 
have been conducted examining CSF and serum NSE levels from adults with severe TBI, 
and their relationship with severity of injury and clinical outcome. Increased CSF and serum 
levels of NSE have been reported after TBI. NSE concentrations were also associated with 
severity of injury, CT scan findings and outcome (Selakovic et al. 2005, Herrmann et al.  
2000, Ross et al. 1996). Although, NSE was originally identified in neurons, further studies 
have shown the protein in erythrocytes and platelets. False positive values have been 
reported in the setting of combined CNS injury plus shock and in the setting of hemolysis 
(Piazza et al. 2005). 
3.2.2.2 Ubiquitin C-terminal hydrolase 
Ubiquitin C-terminal hydrolase (UCH-L1), a neuron-specific cytoplasmic enzyme, is highly 
enriched in neurons representing between 1 and 5% of total soluble brain protein (Lincoln et 
al. 1999). This protein is involved in either the addition or removal of ubiquitin from 
proteins that are destined for metabolism (via the ATP-dependent proteosome pathway) 
(Laser et al. 2003), thus playing an important role in the removal of excessive, oxidized or 
misfolded proteins during both normal and neuropathological conditions, such as 
neurodegenerative disorders (Kobeissy et al. 2006). Because of the important function and 
its high brain specificity, UCH-L1 has been proposed as a novel biomarker for TBI. CSF 
levels of UCH-L1 in CSF have been found significantly increased in severe TBI patients 
compared with uninjured patients, with significant associations observed between levels of 
UCH-L1 in CSF, injury severity and clinical outcome (Papa et al. 2010). A study has been 
conducted investigating the exposure and kinetic metrics of UCH-L1 in adults with severe 
TBI, and their relationship with severity of injury and clinical outcome (Brophy et al. 2010). A 
strong correlation between CSF and serum median concentrations and biokinetics, especially 
during the acute period, and relationships with clinical outcome were observed (Brophy et al. 
2011). Furthermore, a recent study reported that serum concentrations of UCHL1 were 
associated with abnormal blood brain barrier (BBB) permeability, suggesting that UCH-L1 
might be used to monitor BBB disruption in patients with TBI (Blyth et al. 2011). 
3.2.2.3 Spectrin Breakdown Products (SBDPs) 
Alpha II-spectrin is primarily found in neurons and is abundant in axons and presynaptic 
terminals (Riederer et al. 1986). The protein is processed to breakdown products (SBDPs) of 
molecular weights 150 kDa (SBDP150) and 145 kDa (SBDP145) by calpain and is also 
cleaved to a 120-kDa product (SBDP120) by caspase-3. Calpain and caspase-3 are major 
executioners of necrotic and apoptotic cell death, respectively, during ischemia or TBI 
(Ringger et al. 2004, Pineda et al. 2007, Mondello et al. 2010). Thus, a unique feature of this 
technique is the ability to concurrently detect calpain and caspase-3 proteolysis of aII-
spectrin, providing crucial information on the underlying cell death mechanisms. In 
addition, distinct temporal release patterns of CSF SBDP145 and SBDP120 were reported to 
reflect different temporal characteristics of protease activation (Mondello et al. 2010). Pineda 
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et al., employing Western blot analyses, reported elevated levels of SBDPs in CSF from 
adults with severe TBI and their significant relationships with severity of injury and 
outcome (Pineda et al. 2007). Increased CSF SBDP levels were found to be significantly 
associated with mortality in patients with severe TBI. In addition, the temporal profile of 
SBDPs in nonsurvivors also differed from survivors (Mondello et al. 2010).These data 
suggest that SBDPs may provide crucial information not only on severity of brain injury, but 
also on underlying pathophysiological mechanisms associated with necrotic and apoptotic 
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and GFAP, which are the most extensively examined glial markers in TBI.  
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astrocytes (Xiong et al., 2000). The biological function of S100B is still somewhat unclear. 
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Intracellularly, this protein is involved in in the regulation of a large variety of cell 
activities and in the regulation of cell morphology (Goncalves et al., 2008, Kleindienst & 
Bullock 2006). S100B is also released into the extracellular space where seems to have both 
toxic/degenerative and trophic/reparative roles depending on the concentration 
(Goncalves et al., 2008). S100B found in low levels in healthy individuals, rises rapidly 
after head injury. The serum half-life of s100 is about 30 to 90 minutes and can be detected 
soon after injury (Jonsson et al., 2000). Several studies have demonstrated effectiveness of 
S100B as a diagnostic marker in the setting of TBI (Romner et al. 2000, Raabe et al. 1999). 
Increased levels of this protein marker have been shown to correlate with injury severity, 
mortality, and poor neurologic outcome following severe TBI (Vos et al. 2004). In 
addition, since 1995 several studies have investigated the clinical utility of this biomarker 
to predict normal CT findings after minor head injury in adults (Ingebrigtsen et al. 1995, 
Biberthaler et al. 2006). However, several observations concerning S100B have tempered 
the original enthusiasm regarding the usefulness of this protein as brain damage 
biomarker.  One of the limitations to the use of S100B as a potential screening agent for 
brain injury is the lack of specificity. Indeed, S-100b, originally considered specific to 
astroglia in the central nervous system, is present in other extracerebral tissues such as 
adipocytes, chondrocytes and bone marrow cells (Donato 2001). High serum S-100b levels 
have been observed after extracranial trauma and burns (Anderson et al. 2001, Romner 
&Ingebritsen 2001). In addition, increased S100B may reflect either glial damage or 
astrocytic reactions to neural injury, referred to as reactive astrogliosis, which might have 
beneficial or detrimental physiological purposes (Herrmann et al. 2003, Kleindienst et al. 
2007). This has raised concerns as to whether the serum levels of this protein actually 
correlate with the degree of brain damage or are more reflective of other processes. 
Finally, because of the high normative values in the pediatric population, S100B is not a 
useful marker in children (Piazza et al. 2007, Berger et al. 2006). 
3.2.3.2 Glial fibrillary acidic protein 
Glial fibrillary acidic protein (GFAP), a monomeric intermediate filament protein found in 
the astroglial skeleton, is not found outside the central nervous system and is thus 
considered a marker worth focusing upon in the search for brain specificity (Vos et al. 2004, 
Missler et al. 1999). In addition GFAP can be measured in peripheral blood (van Geel et al. 
2002, Missler et al. 1999). 
Recent evidence indicates elevates serum GFAP levels in various types of brain damage, 
ranging from neurodegerative disorders (Baydas et al. 2003) and stroke (Herrmann et al. 
2000) to traumatic brain injury (TBI) (Vos et al. 2004, Nylen et al. 2006, Pelinka et al. 2004). 
Clinical studies have proposed that the serum GFAP level is a reliable marker of primary 
brain damage after TBI with the further advantage that it is not released in situations of 
multiple traumas without brain injury (Vos et al. 2004, Pelinka et al. 2004). GFAP has also 
been demonstrated to be a potential useful biomarker to predict clinical outcome. Recently, 
Vos and colleagues showed a high specificity of GFAP in predicting death or unfavorable 
outcome at 6 months (0.93– 0.95), with a falsepositive rate for unfavorable outcome below 
5% (Vos et al. 2010).   
4. Assay development and hand-held devices 
A variety of different analytical assay formats have been developed to measure biomarkers 
in biofluids such as cerebrospinal fluid (CSF) and plasma and serum (Mondello et al. 2011). 
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The most commonly used format is a two-sided enzyme-linked sandwich immunoassay 
(ELISA). This format is based on the coating of a solid surface in a plate to capture the 
biomarker/analyte of interest, followed by incubation with a directly or indirectly-labeled 
labeled detection antibody. In the ELISA, this label is of enzyme-based, but there are a 
variety of different surface structures, labels and detection methods available. These include 
fluorescence, chemiluminescence, optical (absorbance) and electro-chemiluminescence.  
Key elements in the consideration of the assay format are the analytical performance of the 
assay in terms of sensitivity and specificity, which assessed as specific assay parameters. The 
importance of these assay parameters and their assessment can be found in a recent paper 
by Mondello et al. (Mondello et al. 2011). Over the past few years, a practical iterative 
approach “fit-for-purpose” approach to biomarker assay development and validation has 
evolved, which centers around the “intended use” of the assay and the regulatory 
requirements associated with it (Lee et al. 2006). Assays “evolve” through different stages 
from the original assay development phase through an analytical qualification and 
validation phase. The underlying concept here is to fully understand the analytical 
performance of these assays for their intended use, before testing on clinical samples. 
Laboratories performing testing on human specimen for diagnosis, prevention or treatment 
of any disease are certified under the Clinical Laboratory Improvement Amendments 
(CLIA) of 1988 or have similar accreditation outside the US. These standard practices 
frequently required for CLIA certification were published by the Clinical and Laboratory 
Standard Institute (CLSI). In May 2001, the Food and Drug Administration (FDA) issued 
guidance for industry for bioanalytical method validation of assay to support 
pharmacokinetic (PK) assessment of small molecule drugs (Guidance for Industry on 
Bioanalytical Method Validation: availability. Fed. Regist. 66, 28526-28527, 2001).  
In view of the diverse of biomarker assays for either PK , drug development or diagnostic 
purposes, neither the FDA bioanalytical validation nor the CLSI guidelines fully meet the 
needs of drug development and diagnostic applications of biomarker assays, which has 
resulted in additional recommendations for  example by the American Association of 
Pharmaceutical Scientists (AAPS). A more comprehensive overview can be found in Lee et 
al, 2006. While it is important to develop “fit-for purpose” biomarker assays and analytically 
define and understand their performance, this procedure should be mirrored in the 
standardized collection of biofluids to be analyzed. For example, the Alzheimer Disease 
Neuroimaging initiative (ADNI) has identified the crucial parameters in the collection and 
storage primarily of CSF, which has resulted in the formulation of standard operating 
procedures (SOPs) and the quality-control assessment of collected samples. This has also led 
to the formation of a global CSF consortium, which based on the availability of biofluids 
such as CSF collected under standardized conditions allowed the identification of the 
variability when performing biomarker assessment at multiple sites (Mattson et al. 2011).  
The translation of a “fit-for-purpose assay into a clinically useful and commercially viable 
diagnostic product requires the transfer of such an assay onto an appropriate platform, 
suitable for its intended use. While the laboratory assays described above are typically 
performed in a clinical reference laboratory setting over a course of hours, it is desirable to 
perform the measurement of acute biomarkers of brain injury in point-of-care (POC) type 
setting, outside the clinical laboratory. This includes the accident site, emergency room, 
sidelines of a sports field and military field. Rather than performing the biomarker assay in 
a benchtop multiwell plate format, in these setting a smaller and portable POC system is 
desirable, which requires little to no sample preparation and can performed as a rapid 
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The most commonly used format is a two-sided enzyme-linked sandwich immunoassay 
(ELISA). This format is based on the coating of a solid surface in a plate to capture the 
biomarker/analyte of interest, followed by incubation with a directly or indirectly-labeled 
labeled detection antibody. In the ELISA, this label is of enzyme-based, but there are a 
variety of different surface structures, labels and detection methods available. These include 
fluorescence, chemiluminescence, optical (absorbance) and electro-chemiluminescence.  
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performance of these assays for their intended use, before testing on clinical samples. 
Laboratories performing testing on human specimen for diagnosis, prevention or treatment 
of any disease are certified under the Clinical Laboratory Improvement Amendments 
(CLIA) of 1988 or have similar accreditation outside the US. These standard practices 
frequently required for CLIA certification were published by the Clinical and Laboratory 
Standard Institute (CLSI). In May 2001, the Food and Drug Administration (FDA) issued 
guidance for industry for bioanalytical method validation of assay to support 
pharmacokinetic (PK) assessment of small molecule drugs (Guidance for Industry on 
Bioanalytical Method Validation: availability. Fed. Regist. 66, 28526-28527, 2001).  
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purposes, neither the FDA bioanalytical validation nor the CLSI guidelines fully meet the 
needs of drug development and diagnostic applications of biomarker assays, which has 
resulted in additional recommendations for  example by the American Association of 
Pharmaceutical Scientists (AAPS). A more comprehensive overview can be found in Lee et 
al, 2006. While it is important to develop “fit-for purpose” biomarker assays and analytically 
define and understand their performance, this procedure should be mirrored in the 
standardized collection of biofluids to be analyzed. For example, the Alzheimer Disease 
Neuroimaging initiative (ADNI) has identified the crucial parameters in the collection and 
storage primarily of CSF, which has resulted in the formulation of standard operating 
procedures (SOPs) and the quality-control assessment of collected samples. This has also led 
to the formation of a global CSF consortium, which based on the availability of biofluids 
such as CSF collected under standardized conditions allowed the identification of the 
variability when performing biomarker assessment at multiple sites (Mattson et al. 2011).  
The translation of a “fit-for-purpose assay into a clinically useful and commercially viable 
diagnostic product requires the transfer of such an assay onto an appropriate platform, 
suitable for its intended use. While the laboratory assays described above are typically 
performed in a clinical reference laboratory setting over a course of hours, it is desirable to 
perform the measurement of acute biomarkers of brain injury in point-of-care (POC) type 
setting, outside the clinical laboratory. This includes the accident site, emergency room, 
sidelines of a sports field and military field. Rather than performing the biomarker assay in 
a benchtop multiwell plate format, in these setting a smaller and portable POC system is 
desirable, which requires little to no sample preparation and can performed as a rapid 
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diagnostic test in 30 min or less. In the battle field, these requirements are even more 
stringent in that the assay system should be carried around as handheld device, simple and 
lightweight and withstand extreme environments.  
Over the last couple of years a variety of different POC platforms have been developed 
(Price & Kricka 2007).  These POC assay platform comprise different design concepts and 
detection technologies based on their intended use. Glucose testing in diabetic patients is 
one of successful examples of POC test. The first blood glucose measurements were carried 
out with small paper strips invented and introduced by Ames in 1965. A measurement if 
performed by adding a drop of blood to a strip wherein the reaction of glucose in the blood 
results in the development of blue color and is compared to a color chart for analysis.  
For tests, which do not require quantification, but simply detect the presence of a biomarker 
such as pregnancy test, a lateral flow-strip design might be sufficient. These are membrane 
strips, through which a small volume of sample liquid is transported by capillary action. 
These lateral flow strips are based on the binding of labels in the presence of biomarker 
through an immunochemical reaction, typically, small gold particles.  
The assessment of biomarkers in the POC or handheld device format might require a more 
semi-quantitative assessment and here solutions have been developed, which mimic several 
of the assay steps a central laboratory test in a miniaturized format. One of the earliest 
examples is the i-STATR system (Abbott Laboratories, Abbott Park, IL) for measuring 
electrolyte, coagulation, glucose, cardiac markers such as troponin, and other tests. Wet 
assay reagents are stored in a cartridge and are actively pumped by the device through 
mechanical displacement to perform the various steps of the assays. Other examples such as 
AtolyzerR, originally developed by Atonomics, and the Roche cobas h232R exist and many 
more new technologies are being developed. A modification is the Philips MagnotechR 
system, which replace the liquid manipulation steps by magnetically controlled movement. 
The implementation of molecular-diagnostic-based POCs also shows promise for the future. 
These assays typically include a polymerase-chain reaction-based amplification step.  
All these implementations of the POC tests in a miniaturized cartridge-type format are 
designed to allow a high level of assay control. The overall assay performance is influenced 
by minor variation for example in timing of the individual assay steps and can results in 
large overall assay performance variability. The successful adaptation of any biomarker 
assay to a POC/handheld device is dependent on the requirement for sensitivity and 
precision in its intended use. The development of new POC technologies and solutions 
shows great promise for the adaptation of CNS biomarker assays in unmet medical needs.  
5. Strategy for regulatory approval by FDA 
Biomarkers, whether proteomic based or based on more traditional technologies, can be 
used for a variety of purposes. Generally speaking, the term ‘biomarker’ describes any 
measurable diagnostic indicator used to assess the presence or risk of disease. For the US 
Food and Drug Administration (FDA), the term ‘diagnostic’ includes the diagnosis, 
screening and prediction of disease. But it also encompass other uses such as staging or the 
prognosis of disease, monitoring patients and the effectiveness of a treatment and/or 
optimizing treatment outcomes by aiding health-care providers in medical and therapeutic 
decision making. 
The FDA has been involved in the regulation of medical devices, including in vitro 
diagnostic devices (IVDs) since 1976 when the US Congress established laws for the 
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regulation of medical devices under the Medical Device Amendments act (REF. 8). 
According to the Medical Device Amendments act, for an in vitro diagnostic (IVD) device to 
enter the US market it must comply with a set of rules and regulations in order to prove 
safety and effectiveness for its intended use. In 21 CFR 860.7(d)(1) device safety requires 
“the probable benefit to health from use of device for its intended use and conditions of use 
… outweigh any probable risk.” In 21 CFR 860.7(e)(1) device effectiveness requires “that in a 
significant portion of the target population, the use of the device for its intended use and 
conditions for use … will provide clinically significant results.” In addition, a new assay is 
required to demonstrate an adequate analytical performance (appropriate accuracy and 
precision) and clinical performance (sensitivity, specificity and some indication of clinical 
utility) (21 CFR 807; 21 CFR 814).  
In order to be commercialized in a kit, newly discovered biomarkers device must follow 
specific pathways. Investigational studies of diagnostic devices can be performed with 
various design configurations, but they must conform to FDA requirements. The 
researchers are required to apply for an investigational device exemption (IDE) before 
initiating the study, as described in Title 21 of the Code of Federal Regulations 812 (21 
CFR 812)(US Food and Drugs Administration [FDA], 2006). The IDE submission should 
describe the nature of the proposed study, include details of informed consent and ensure 
patient protection and that the risks associated with participation in the study will be 
clearly communicated to individuals.  
After the appropriate investigational studies have been completed, the FDA requires 
premarket submissions before a test can be approved for clinical use in the United States. 
Depending on the nature of the test and its classification, the product could be reviewed as a 
510(k) premarketing clearance with a 90-day timeline or Premarket Approval (PMA) with a 
180-day timeline (21 CFR 807; 21 CFR 814). FDA considers three classes of devices (class I, II, 
or III) (FDA, 2009, 2010).  
The 510(k) process is used when the new test measures an existing FDA classified analyte 
(class I or II) where there exists a commercially available predicate test method that has been 
cleared by the FDA or that was in commercial distribution before May 28, 1976 (21 CFR 
860.84). Premarket clearance requires the sponsor to provide information for the new 
product including its intended use and classification and ‘substantially equivalence’ to the 
predicate device. This ensures that a high level of safety and effectiveness is maintained. In 
addition the sponsor must show characterization of analytical capability of the test (e.g., 
specificity and accuracy, precision and linearity by correlating patient studies against the 
predicate device) (http://www. fda.gov/ oc/mdufma/coversheet.html).  
The PMA process is used when the test is classified as class III; that is, either it is associated 
with high risk (e.g., when the outcome determines cancer treatment or diagnosis) or the 
clinical utility of the marker or the technology of the measurement are novel and no 
predicate device can be identified (21 CFR 814). FDA requires the sponsor to submit the 
same data required for 510(k) as well as clinical outcomes data, where the level of the 
marker is related to disease status defined by clinical criteria (http://www.fda.gov/ 
oc/mdufma/coversheet.html).  
In 1997, since some new biomarkers have no obvious predicate devices and do not have 
safety concerns, FDA created a new hybrid ‘de novo’ or ‘risk-based’ classification (21 CFR 
814). This process allows a new biomarker to be regulated as in a 510(k), but requires the 
demonstration of clinical effectiveness.  
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Therefore, in the absence of a predicate device and depending on the intended use and 
clinical utility, either a PMA or a ‘de novo’ process will be required for a new protein of 
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Fig. 4. Regulatory Pathway for PMA Application 
6. Conclusion 
This chapter provides an introductory review of techniques that have been applied to 
biomarker identification and clinical validation. Demonstration of clinical utility and 
compliance with regulatory requirements is critical for the commercialization of novel 
biochemical markers but also formidable, uncertain and costly. 
At present, there are still many unanswered questions in this area of research, however, 
such as the best statistical methods to analyze the large volume of data generated, the role of 
potential demographic and clinical confounders, such as age, sex, and on the other hand the 
broad and complex spectrum of types and severities of brain injuries. In addition, issues 
such as sample integrity and preservation, normalization, and appropriate control data also 
must be given careful consideration. A multimarker strategy will probably be needed to 
provide a greatly expanded approach to the detection of brain injury, elucidating its 
pathogenesis and making it possible to guide and monitor the therapy in new ways and 
ultimately to improve outcome. 
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“If there’s no CSF pressure, but brain pressure exists, then pressure relief must be achieved 
by opening the skull” -Kocher 1901 
1. Introduction 
The management of increased intracranial pressure is a common clinical scenario 
encountered in a large portion of medicine. It is encountered more often in the practices of 
trauma, neurology and neurological surgery and as such is very common in intensive care 
settings. Treatment approaches remain one of the more controversial fields in medicine. In 
this chapter we will address the treatment approaches for elevated intracranial pressure. 
Indications for assessment, clinical considerations and approaches to proper management of 
elevated pressures focusing mainly on the decompressive craniectomy. We will address the 
role of the decompressive craniectomy in trauma stroke and address the option of lumbar 
drainage. 
2. Intracranial pressure 
Intracranial pressure is defined as the pressure within the cerebral vault that the systemic 
perfusion must overcome in order to adequately perfuse the brain. A mathematical 
expression of this relationship is that of CPP (Cerebral Perfusion Pressure) = MAP (Mean 
Arterial Pressure) - ICP (Intracranial Pressure). This relationship predicts that under settings 
where intracranial pressure approaches or surpasses mean arterial pressure the perfusion 
pressure declines resulting in hypoxic brain injury. The Monro-Kellie doctrine is often 
highlighted in illustrations of intracranial pressure. It holds that the adult cranial vault is a 
rigid structure composed of brain parenchyma, cerebrospinal fluid, and blood. The cranial 
vault being a rigid bony structure offers very little compliance and is not easily subject to 
shifts in space composition. As such, expansion in any of these compartments results in an 
increase in the amount of pressure contained within the rigid vault. There are inherent 
safeguards that allow for an element of expansion without excessive effects on the 
intracranial pressure. However once a certain a threshold is surpassed further expansion 
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results in marked elevation in intracranial pressure. As intracranial pressure rises beyond 
adequate perfusion, the resultant effect is reduced perfusion and oxygen availability to the 
cerebrum resulting in hypoxic injury and cell death. The autolytic cascade leads to an 
increase in cell volume as the cell membrane is unable to maintain the electrochemical 
gradient due to a break down of the ATP dependent Na/K ATPase pump. Water and 
calcium influx leads to the expansion in the cell volume and a feed-forward positive cycle 
where cell death causes more edema and swelling, which causes increased intracranial 
pressure, which in turn causes less brain perfusion and results in further cell death. CSF 
flow through normal pathways can also be obstructed resulting in further elevation in 
intracranial pressure. The end result is often herniation as pressure becomes greater than the 
resistance of surrounding structures and brain structures actively transgress the boundaries 
established by dura mater and bone. There exist several ways to manage the complication of 
elevated intracranial pressure. Most of these are subdivided into a step wise systematic 
approach. One of such divides ICP management into two categories. Category 1 involves 
volume reduction. This utilizes the principles of the Monroe-Kellie doctrine. Removal of 
volume either in the form of CSF drainage or hyperosmotic diuresis will allow for more 
expansion of the edematous parenchyma. Category 2 describes the removal of mechanical 
constraints. This category primarily relies on the decompressive craniectomy. Removal of 
the rigid limitations preventing brain expansion would allow for more swelling thereby 
limiting and or preventing herniation (Scmidek H 2006). The AANS guidelines approach the 
management of elevated ICP similarly. The treatment paradigm is divided into 2 Tiers. Tier 
1 involves the use of sedatives, paralytics, ventricular drainage, hyperosmolar therapy and 
mild hyperventilation. Tier 2 involves hypothermia, longer acting sedatives such as 
barbiturates, lumbar drainage via an intrathecal catheter and surgical decompression of the 
cranial vault. The decompressive craniectomy as we will discuss later allows for an outward 
herniation of brain structures as the limitations of the cranial vault are expanded 
theoretically minimizing any further injury the brain tissue would suffer by being forced 
into other compartments. 
3. Management of elevated intracranial pressure 
In this chapter we will focus primarily on the management of intracranial pressure in 
patients suffering from either stroke or traumatic brain injury. There remain other clinical 
scenarios where patients could suffer from elevated intracranial pressure. They include but 
are not limited to: infection, either meningeal or encephalitic, spontaneous intracerebral 
hemorrhage, and aneurysmal subarachnoid hemorrhage. Although decompressive 
craniectomy may play a role in these settings, it is beyond the scope of this chapter. The 
application of decompressive craniectomy in the posterior fossa will also not be addressed 
in this chapter. 
Various cutoff values are used at different centers above which treatment of elevated 
intracranial pressure is indicated. Levels of 15, 20 and 25 are quoted but most centers use 
ICP > 20-25mmHg as the upper limit (Bullock 1995). There is a high mortality and even 
higher morbidity in patients with ICP persistently above 20mmHg. The physician’s clinical 
discretion remains paramount in these settings. A 25 year-old trauma victim with an ICP of 
30 but is awake, not intubated and following commands briskly is not as concerning as a 45 
year-old with an ICP of 20 but has become acutely unresponsive. Several measurements can 
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be employed in the management of elevated intracranial pressure. 1. Ensure adequate 
patient head positioning. The position of the patient’s head can either optimize or hinder 
venous drainage. Venous congestion can lead to increased intracranial pressure. 2. Optimize 
the patient’s vitals, specifically avoiding hypercarbia and hyperthermia. 3. Osmotic diuretics 
such as mannitol and hypertonic saline can also be utilized. In settings where adequate 
control of elevated ICP remains difficult, another option that can be employed is lumbar 
drainage. Lumbar drainage plays a role after ventriculostomy drainage has proven 
insufficient. At our institution we ensure patency of the ventriculostomy catheter with 
adequate drainage. If ICP remains elevated at this point a lumbar drain is placed. Initially 
the lumbar drain is left clamped and in most cases ICP control improves. However in 
situations where ICP elevation persists the lumbar drain is unclamped and placed at the 
same level as the ventriculostomy drain to minimize risk of brainstem herniation. The 
placement of lumbar drain plays a very valuable role in the reduction of elevated 
intracranial pressure (Munch E 2001; Murad A 2008). 
4. Assessment of the trauma patient 
The initial assessment of the trauma patient often begins in the emergency department. The 
basics must not be forgotten. Obtain a thorough history paying particular attention to 
mechanism of injury. Enough emphasis cannot be placed on obtaining a good overview of 
the situation. Even in the presence of an experienced trauma team the alert neurosurgeon 
can still play an additive role in helping to ensure that all bases are covered. A trauma team 
focused on placing a chest tube may not initially notice a lack of movement in a patient’s 
lower extremities. The alert neurosurgeon would function well to inform the trauma team of 
this finding and help facilitate the appropriate imaging modality needed. Pay attention to 
the patient as a whole without focusing on the brain alone. In every trauma setting ensure 
that the ABC’s of trauma (airway, breathing and circulation) are addressed before moving 
on to secondary surveys. A thorough physical and neurologic exam is always paramount. 
Initial head CT is indicated in settings where there are any moderate or high risk factors 
including but not limited to unresponsiveness, amnesia, altered mental status, deteriorating 
mental status (including intoxication), signs of calvarial fracture, focal neurologic deficits, 
penetrating skull injury, progressive headache, posttraumatic seizure, unreliable or 
inadequate history, multi-system trauma, severe facial injury, and significant subgaleal 
swelling (Stein S C 1992). Follow up Head CT remains at the clinical discretion of the 
physician and in the context of the nature of the presenting injury. A non-surgical epidural 
hematoma may require earlier follow up head CT than a small focal contusion. There exist 
practice guidelines and indications for ICP monitoring in the trauma setting. For salvageable 
patients with severe traumatic brain injury (GCS<8 after cardiopulmonary resuscitation), 
level II evidence dictates a need for ICP monitoring in patients with an abnormal Head CT. 
Level III evidence states a need for ICP monitoring in patients with a normal Head CT but 
with risk factors of elevated intracranial pressure, such as: age > 40 years, SBP < 90 mmHg, 
flexor or extensor posturing(Bullock 1995). However the final decision remains at the clinical 
discretion of the physician. Radiographic information can be used as an adjunct in 
determining a need for ICP monitoring but should not be used as a sole determinant. In one 
study 13% of patients with a normal CT scan will have elevated ICP, however patients with 
a normal CT and risk factors for elevated ICP have a 60% chance of elevated ICP (Narayan R 
 
Brain Injury – Pathogenesis, Monitoring, Recovery and Management 
 
476 
results in marked elevation in intracranial pressure. As intracranial pressure rises beyond 
adequate perfusion, the resultant effect is reduced perfusion and oxygen availability to the 
cerebrum resulting in hypoxic injury and cell death. The autolytic cascade leads to an 
increase in cell volume as the cell membrane is unable to maintain the electrochemical 
gradient due to a break down of the ATP dependent Na/K ATPase pump. Water and 
calcium influx leads to the expansion in the cell volume and a feed-forward positive cycle 
where cell death causes more edema and swelling, which causes increased intracranial 
pressure, which in turn causes less brain perfusion and results in further cell death. CSF 
flow through normal pathways can also be obstructed resulting in further elevation in 
intracranial pressure. The end result is often herniation as pressure becomes greater than the 
resistance of surrounding structures and brain structures actively transgress the boundaries 
established by dura mater and bone. There exist several ways to manage the complication of 
elevated intracranial pressure. Most of these are subdivided into a step wise systematic 
approach. One of such divides ICP management into two categories. Category 1 involves 
volume reduction. This utilizes the principles of the Monroe-Kellie doctrine. Removal of 
volume either in the form of CSF drainage or hyperosmotic diuresis will allow for more 
expansion of the edematous parenchyma. Category 2 describes the removal of mechanical 
constraints. This category primarily relies on the decompressive craniectomy. Removal of 
the rigid limitations preventing brain expansion would allow for more swelling thereby 
limiting and or preventing herniation (Scmidek H 2006). The AANS guidelines approach the 
management of elevated ICP similarly. The treatment paradigm is divided into 2 Tiers. Tier 
1 involves the use of sedatives, paralytics, ventricular drainage, hyperosmolar therapy and 
mild hyperventilation. Tier 2 involves hypothermia, longer acting sedatives such as 
barbiturates, lumbar drainage via an intrathecal catheter and surgical decompression of the 
cranial vault. The decompressive craniectomy as we will discuss later allows for an outward 
herniation of brain structures as the limitations of the cranial vault are expanded 
theoretically minimizing any further injury the brain tissue would suffer by being forced 
into other compartments. 
3. Management of elevated intracranial pressure 
In this chapter we will focus primarily on the management of intracranial pressure in 
patients suffering from either stroke or traumatic brain injury. There remain other clinical 
scenarios where patients could suffer from elevated intracranial pressure. They include but 
are not limited to: infection, either meningeal or encephalitic, spontaneous intracerebral 
hemorrhage, and aneurysmal subarachnoid hemorrhage. Although decompressive 
craniectomy may play a role in these settings, it is beyond the scope of this chapter. The 
application of decompressive craniectomy in the posterior fossa will also not be addressed 
in this chapter. 
Various cutoff values are used at different centers above which treatment of elevated 
intracranial pressure is indicated. Levels of 15, 20 and 25 are quoted but most centers use 
ICP > 20-25mmHg as the upper limit (Bullock 1995). There is a high mortality and even 
higher morbidity in patients with ICP persistently above 20mmHg. The physician’s clinical 
discretion remains paramount in these settings. A 25 year-old trauma victim with an ICP of 
30 but is awake, not intubated and following commands briskly is not as concerning as a 45 
year-old with an ICP of 20 but has become acutely unresponsive. Several measurements can 
 
Decompressive Craniectomy: Surgical Indications, Clinical Considerations and Rationale 
 
477 
be employed in the management of elevated intracranial pressure. 1. Ensure adequate 
patient head positioning. The position of the patient’s head can either optimize or hinder 
venous drainage. Venous congestion can lead to increased intracranial pressure. 2. Optimize 
the patient’s vitals, specifically avoiding hypercarbia and hyperthermia. 3. Osmotic diuretics 
such as mannitol and hypertonic saline can also be utilized. In settings where adequate 
control of elevated ICP remains difficult, another option that can be employed is lumbar 
drainage. Lumbar drainage plays a role after ventriculostomy drainage has proven 
insufficient. At our institution we ensure patency of the ventriculostomy catheter with 
adequate drainage. If ICP remains elevated at this point a lumbar drain is placed. Initially 
the lumbar drain is left clamped and in most cases ICP control improves. However in 
situations where ICP elevation persists the lumbar drain is unclamped and placed at the 
same level as the ventriculostomy drain to minimize risk of brainstem herniation. The 
placement of lumbar drain plays a very valuable role in the reduction of elevated 
intracranial pressure (Munch E 2001; Murad A 2008). 
4. Assessment of the trauma patient 
The initial assessment of the trauma patient often begins in the emergency department. The 
basics must not be forgotten. Obtain a thorough history paying particular attention to 
mechanism of injury. Enough emphasis cannot be placed on obtaining a good overview of 
the situation. Even in the presence of an experienced trauma team the alert neurosurgeon 
can still play an additive role in helping to ensure that all bases are covered. A trauma team 
focused on placing a chest tube may not initially notice a lack of movement in a patient’s 
lower extremities. The alert neurosurgeon would function well to inform the trauma team of 
this finding and help facilitate the appropriate imaging modality needed. Pay attention to 
the patient as a whole without focusing on the brain alone. In every trauma setting ensure 
that the ABC’s of trauma (airway, breathing and circulation) are addressed before moving 
on to secondary surveys. A thorough physical and neurologic exam is always paramount. 
Initial head CT is indicated in settings where there are any moderate or high risk factors 
including but not limited to unresponsiveness, amnesia, altered mental status, deteriorating 
mental status (including intoxication), signs of calvarial fracture, focal neurologic deficits, 
penetrating skull injury, progressive headache, posttraumatic seizure, unreliable or 
inadequate history, multi-system trauma, severe facial injury, and significant subgaleal 
swelling (Stein S C 1992). Follow up Head CT remains at the clinical discretion of the 
physician and in the context of the nature of the presenting injury. A non-surgical epidural 
hematoma may require earlier follow up head CT than a small focal contusion. There exist 
practice guidelines and indications for ICP monitoring in the trauma setting. For salvageable 
patients with severe traumatic brain injury (GCS<8 after cardiopulmonary resuscitation), 
level II evidence dictates a need for ICP monitoring in patients with an abnormal Head CT. 
Level III evidence states a need for ICP monitoring in patients with a normal Head CT but 
with risk factors of elevated intracranial pressure, such as: age > 40 years, SBP < 90 mmHg, 
flexor or extensor posturing(Bullock 1995). However the final decision remains at the clinical 
discretion of the physician. Radiographic information can be used as an adjunct in 
determining a need for ICP monitoring but should not be used as a sole determinant. In one 
study 13% of patients with a normal CT scan will have elevated ICP, however patients with 
a normal CT and risk factors for elevated ICP have a 60% chance of elevated ICP (Narayan R 
 
Brain Injury – Pathogenesis, Monitoring, Recovery and Management 
 
478 
K 1082) . Decompressive craniectomy in trauma unlike in stroke remains controversial. In 
animal studies with artificially induced intracranial lesions, craniectomy has been linked to 
increased cerebral edema hemorrhagic infarcts and cortical necrosis (Moody R 1968; Cooper 
P 1979; Forsting M 1995). However decreased intracranial pressure, improved cerebral 
perfusion pressure and increased oxygen tension are also reported following craniectomy in 
trauma (Moody R 1968; Burkert W 1988). A review of more than 30 articles failed to 
demonstrate a clear benefit for craniectomy in the setting of trauma (Munch E 2000). A 
definitive answer to benefit of decompressive craniectomy still requires definitive 
randomized trials. At this point there does appear to be benefit especially in young patients 
with GCS >4.  
Until the recently published DECRA trial (Cooper D 2011) no class I evidence supporting or 
disputing decompressive craniectomy in trauma existed. All previous evidence is class III at 
best. One of the more cited articles supporting decompressive craniectomy is a study 
designed at the University of Virginia (Polin 1997). In this study 35 bifrontal decompressive 
craniectomies were performed on patients with post-traumatic edema but no mass lesions 
between 1984 and 1993. The results were matched to control patients from the Traumatic 
Coma Data Bank. Their results showed good recovery and moderate disability in 37% of 
patients with mortality in 23% of patients as opposed to 16% moderate disability and 34% 
mortality in the Traumatic Coma Data Bank control. Post operative ICP control was better 
than the preoperative group and the control group. The study also found that patients with 
ICP>40 who underwent surgery >48hrs after time of injury did poorly. 
A separate study published by the University of Maryland in Baltimore(Aarabi B 2006) 
discussed the findings of decompressive craniectomies performed between 2000-2004. 50 
decompressive craniectomies were performed to control elevated ICP. 10 of these were 
performed before ICP elevation and 40 performed after ICP elevation. They found that 
decompressive craniectomies lowered the ICP to lower than 20 in 85% of patients. 14 of 50 
patients died, 16 remained in a vegetative or severely disabled state, 20 had what was 
defined as a good outcome. Decompressive craniectomy was associated with a better than 
expected functional outcome in patients with medically uncontrollable ICP and or brain 
herniation compared with outcomes in other control cohorts reported in the literature. 
A study out of Italy (Chibbaro S 2007) retrospectively reviewed 48 decompressive 
craniectomies and compared their outcomes to the Traumatic Coma Data Bank. They found 
that decompressive craniectomy reduced the midline shift and ameliorated basal cistern 
effacement. Younger patients (mean age of 31 years) had a better outcome. They also found 
that patients with early surgery, less than 16hrs of injury had, a better outcome than late 
intervention. 
The DECRA trial as described earlier remains the only Class I evidence to date. The trial ran 
from December 2002 to April 2010. Eligibility criteria for inclusion in the study were patients 
between 15 and 59 years, patients with severe non-penetrating traumatic brain and patients 
with a GCS of 3 to 8. They excluded patients with dilated un-reactive pupils and those with 
mass lesions, including, but not limited to subdural and epidural hematomas. All patients 
had ICP monitoring and were treated medically if ICP was greater than 20. They defined 
early refractory ICP as a spontaneous elevation for more than 15 minutes continuously or 
intermittently within a 1 hour period despite first tier intervention. Patients were 
randomized within 72 hours to either surgery or standard care. The bifrontoparietal 
craniectomy technique used was based on the bifrontal craniectomy technique described by 
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Polin (Polin 1997). They randomly assigned 155 adults with severe traumatic brain injury 
and ICP refractory to first tier therapy to undergo either bifrontotemporoparietal 
decompressive craniectomy or standard medical care. 73 patients were enrolled in the 
surgical arm and 82 patients were enrolled in the medical arm. Patients in the the surgical 
group were found to have less time with elevated intracranial pressure, required fewer 
interventions for increased ICP post op and spent fewer days in the ICU. However patients 
undergoing craniectomy were found to have a worse outcome on the Glasgow outcome 
scale than those receiving standard care. The rates of death at 6 months were similar, 19% in 
the surgical arm and 18% in the medical arm.  
The DECRA trial came under a large amount of criticism primarily related to the study 
design. The greatest word of caution arises in defining refractory ICP elevation has having 
reached levels greater than 20 for 15 minutes continuously or intermittently. Most 
neurosurgeons, neurologists and neurointensivists would address this as being too low a 
threshold for aggressive management of raised ICP. Some centers advocate the use of 
hyperosmotics such as Mannitol as a drip over 30 minutes instead of a bolus.  Although 
“time is brain”, operating on a patient based on an ICP elevation of 15 minutes can be seen 
as being very rapid and somewhat rash. Another criticism lies in the screening of 3,478 
patients over a 7 year period to only enroll 155 patients. Finally the exclusion of patients 
with mass lesions is also a concern. Several of the patients involved in the DECRA trial with 
no mass lesion might fall into a category of diffuse axonal injury that did not require and 
would not be expected to benefit from a surgical decompression. 
The RESCUEicp trial is a currently ongoing international prospective multi-center 
randomized controlled trial comparing the efficacy of decompressive craniectomy versus 
optimal medical management for the treatment of refractory intracranial hypertension 
following brain trauma. This study differs from the DECRA trial in terms of ICP threshold 
(25 vs 20 mmHg), timing of surgery  (any time after injury vs within 72 hours post injury) 
and the acceptance of mass lesions. The RESCUEicp also holds a longer follow up period, 2 
years as opposed to 6 months with the DECRA trial and a larger patient population with a 
goal of 400 (300 enrolled as of April 2011).  
5. Assessment of the stroke patient 
Decompressive craniectomy plays a vital role in patients diagnosed with malignant cerebral 
infarction. Malignant cerebral infarction refers to large territorial parenchymal strokes with 
ischemic edema and associated herniation. They typically involve occlusion of the MCA or 
ICA distribution causing infarction of the supplied territory. They account for 
approximately 15% of all strokes but mortality ranges from 50-80%. Patients typically 
present with rapid neurologic deterioration , gaze preference towards the infarcted 
hemisphere, contralateral hemiplegia and progressive decline in level of consciousness. 
Patients can rapidly progress from a state of being awake, alert, oriented and following 
commands to an obtunded state. The validity of decompressive craniectomy in stroke patients 
has been better studied and thereby better accepted in stroke patients than in trauma patients. 
Decompressive craniectomy in stroke patients as been show to reduce mortality from 50% to 
as as low as 32% in non-dominant hemisphere strokes with reduction of hemiplegia and in 
dominant hemisphere strokes only a mild-moderate aphasia. Better results occur with earlier 
surgery (Carter BS 1997). In 2007, three key landmark articles were published that proposed 
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class I evidence supporting the use of decompressive craniectomy as valid treatment in the 
management of patients with malignant MCA infarction. The DECIMAL trial (Vahedi K 2007) 
was a study conducted in France after a poll of 47 neurology departments showed that only 2 
departments were convinced of the efficacy of the decompressive craniectomy. The 
decompressive craniectomy in malignant MCA infarction trial was a multi center prospective 
randomized open but with blind evaluation of the primary end point study comparing early 
decompressive craniectomy versus standard medical therapy. It was conducted in 13 selected 
stroke centers including a stroke unit and a neurosurgery department from 2001 to 2005. 
Patients selected were between the ages of 18 and 55.  
They included strokes as defined by an NIHSS > 16 within 24 hours of initial symptoms. The 
imaging criteria included head CTs that showed greater than a 50% MCA distribution 
involvement and MRI-DWI showing > 145 cm infarct volume. Exclusion criteria included 
patients with significant contralateral infarction, secondary hemorrhage of more than 50% of 
MCA territory pre-infarct significant disability, coagulopathy or use of tPA. For patients in 
the surgical arm of the study, decompressive craniectomy was performed less than 6hrs 
after randomization and up to 30hrs after initial onset of symptoms. 38 pts from 7 centers 
had been end enrolled when the study was prematurely ended (18 medical therapy, 20 
surgical therapy). The study was ended due to slow recruitment of patients, a high 
difference in mortality between the 2 groups and to organize pooled data from the other 
ongoing trials, the DESTINY(Juttler E 2007) and HAMLET(Hotmeijer J 2009) trials. With the 
results gathered it was noted that the early decompression increased by more than half the 
number of patients with moderate disability and reduced by more than half the mortality 
rate at 1 year (mRS <3 of 50% in surgical group and 22% in medical group). The DECIMAL 
trial was able to conclude that in young patients (55yrs or younger) with malignant MCA 
infarction, early decompressive craniectomy had a great benefit on survival and led to a 
better functional outcome. No patients remained bedridden or had severe residual 
disability. Young patients had a significantly better outcome after surgery. However no 
patient had a complete recovery. 
The DESTINY trial (Juttler E 2007)was a prospective, multi center, randomized, controlled 
clinical trial also based on a sequential design that used mortality after 30 days as the first 
end point. Although this trial was also ended prematurely it was able to show a statistically 
significant reduction in mortality after 32 patients had been enrolled. 15 of 17 patients 
randomized to the surgical group as opposed to 7 of 15 in the medical group survived after 
30 days. DESTINY showed that hemicraniectomy reduces mortality in large hemispheric 
stroke patients. With only 32 patients enrolled the study was unable to demonstrate 
statistical superiority in functional outcome however the trial was terminated in light of the 
results of its joint analysis of the 3 European hemicraniectomy trials. 
The HAMLET trial (Hotmeijer J 2009) was the third European trial and its aim was to assess 
the effect of decompressive surgery within 4 days of symptoms in patients with space-
occupying hemispheric infarction. It showed that surgical decompression reduces fatality 
and poor outcome in patients with space occupying infarctions who are treated within 48hrs 
of stroke onset. The results however, showed no evidence that functional outcome is 
improved when decompression is delayed for up to 96hrs after stroke onset. They stress that 
the decision to operate should depend on the emphasis patients and relatives attribute to 
survival and dependency. Patient’s lives can be saved but functional independence will 
either be severely impaired or completely lost. 
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A Meta-Analysis of the 3 randomized controlled trials found that hemicraniectomy within 
48hrs after stroke onset resulted in reduced mortality and more favorable functional 
outcome. The trials were ongoing when the pooled analysis was planned. DESTINY and 
DECIMAL were stopped due to a clear reduction in mortality. HAMLET was still ongoing. 
The goal was to obtain results as soon as possible to avoid ongoing randomization in 
unnecessary and unethical situations. Indications include age <60 years. Stronger 
consideration in right hemisphere strokes and radiographic evidence of acute ICA or MCA 
infarcts with signs of impending severe brain swelling (Vahedi K 2007). 93 patients were 
included in the pooled analysis, (DESTINY 32pts, DECIMAL 38pts and HAMLET 23pts). 
More patients in the surgery group than in the medical group had mRS <4 (78% vs 24%). 
Also more patients in the surgical group survived than in the medical group (78% vs 29%). 
Interestingly certain rehab centers describe better improvement in patients with dominant 
hemisphere infarctions than in non-dominant hemisphere infarctions.  
Perhaps this can be attributed to a retained capacity to learn activities of daily living. The most 
compelling argument for craniectomy in stroke patients regards the timing of surgery. This is 
supported by the 3 European trials as well as a retrospective study of 52 decompressions 
stratified by time of surgery into groups with intervention in under 6 hours from injury, 
intervention 6 hours after injury and no intervention. These showed mortality rates of 8%, 36% 
and 80% respectively. The average length of ICU stay was 12 days, 18 days and 7 days 
(shortened due to fatality)(Cho D 2003). A separate but similar study retrospectively stratified 
63 interventions into decompression within 24 hours (early, 31 patients) and after 24 hours 
(late, 32 patients) of initial injury. Mortality was 16% for early decompression and 34% for late 
decompression. The average length of intensive care stay was 7 days for early decompression 
and 13 days for late decompression (Schwab S 1998). However early detection is only capable 
and confirmatory with adequate radiographic evidence.  
MRI with DWI offers the best correlation to stroke severity and clinical outcome. The 90% 
sensitivity and 96% specificity of predictive value of malignant cerebral infarction with MRI-
DWI are superior to the 60% and 70 to 90% specificity reported with Head CT (Arenillas J 
2002; Manno E 2003). Given the limited availability of MRI either due to hospital constraints 
or patient co-morbidities, as well as the time restraints imposed by timely use of tPA in the 
setting of hyperacute stroke, the Head CT remains the most available and widely used 
radiographic reference tool. 
At our institution we have developed a standard protocol applied to patients with 
malignant MCA stroke to assess their eligibility for decompressive craniectomy: 
- LLUMC Protocol for Decompressive Craniectomy in Stroke 
- Patients < 60 years old 
- Large MCA stroke (greater than 145ml volume on DWI or greater than 50% MCA 
territory) 
- Presentation within 48hrs of initial symptoms 
- Exclude dilated un-reactive pupils  
- Exclude bleeding diathesis 
- Ventriculostomy placement ipsilateral to infarcted brain 
- Lumbar drain if ICP remains elevated 
- Cranioplasty between 6 weeks and 6 months  
These parameters although not standardized nationally take into consideration the findings 
of other institutions and several published works. The ubiquity of factors such as age and 
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timing of intervention are far reaching, as exhibited by the findings of Eghwrudjakpor and 
Allison (Eghwrudjakpor P 2010). They describe a glasgow coma core of 8 and above, age 
less than 50 years and early intervention as being the most significant determinants of 
prognosis. 
6. Surgical considerations 
A wide variety of surgical techniques have been reported for decompressive craniectomy. 
All approaches can be performed either unilaterally or bilaterally. The bone flap can be stored 
in various locations, the patients abdominal subcutaneous fat, cryopreservation and in situ 
using the hinge craniectomy method (Ko 2007). A standard trauma flap skin incision is made 
with the goal of exposing the following margins: anteriorly to the superior border of the orbital 
roof, avoiding entry into the frontal sinus, posteriorly to at least 2cm posterior to the external 
meatus, medially to a point 2cm lateral to the midline to avoid the sagittal sinus and inferiorly 
to the floor of the middle cranial fossa (Scmidek H 2006). The temporalis muscle is reflected 
anteriorly. Burrholes are placed at the keyhole, the root of the zygoma and as preferred along 
the planned craniotomy route. A high speed drill is used for the craniotomy. The lesser wing 
of the sphenoid is fractured and removed to the superior orbital fissure. The dural edges can 
be tacked up to the skull to minimize formation of epidural hematoma. Dura can be opened in 
several manners but typically is done in a stellate fashion. Dura closure is not mandatory at 
this point and can either be left open, with mild approximation of dural leaflets or replaced 
with dural substitute. The decompressive craniectomy alone without durotomy reduces the 
intracranial pressure by 15%. A duraplasty further reduces the intracranial pressure by an 
additional 55% (Scmidek H 2006). At our institution we rely more on the rapid closure 
technique as described by Guresir et al. This technique has been found to significantly shorten 
operation time without increased complication rates or additional complications (Guresir E 
2011). There have been incidences of CSF leak attributed to open dural leaflets but this has not 
been our experience. In the setting of trauma, evacuation of hematoma or contusion can 
proceed as indicated by the nature of the injury.  
The size of the craniectomy directly correlates with degree of expansion (Gaa M 1990; Yoo D 
1999). Small craniectomies are associated with further infarction and hemorrhage at the sites 
of the craniectomy margin. Mortality rates have also been reported as elevated in small 
diameter craniectomies (Wagner S 2001). This is due to the venous congestion that occurs in 
the herniated brain tissue as it is restricted and compressed by the bony boundary of the 
skull defect. Brain parenchyma herniates through the bony defect which in essence is the 
desired effect but compression of parenchyma adjacent to the bony boundary in a small 
craniectomy leads to venous congestion, venous infarction and further damage to brain 
tissue. This is more common in craniectomies smaller than 8cm in diameter.  
Doubling the diameter of a craniectomy from 6cm to 12cm increases the decompressed brain 
volume from 9ml to 86ml. A lower margin of craniectomy relative to the floor of the middle 
fossa has also been described with improved outcomes. This can be related to the state of 
decompression of the mesencephalic cisterns. Compression of the basal cisterns is known to 
impair clinical outcome, a larger craniectomy to the base of the brainstem could minimize 
brain stem compression (Toutant S 1984; Munch E 2000). The state of the mesencephalic 
cisterns correlates greatly with the distance of the craniectomy to the temporal cranial floor. 
As such decompression or out-fracturing of the temporal floor after removal of the bone flap 
remains exceedingly important. Compression of the cisterns impairs clinical outcome and a 
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large craniectomy to the base of the cranium could minimize brain stem compression. A 
mortality rate of 77%, 39% and 22% as been described in those with absent, compressed and 
normal cisterns respectively. Patients presenting with a GCS of 7-8 who were expected to 
fair well did not recover as expected if the basal cisterns were compressed or absent in 
studies evaluated within the first 48hrs of admission(Toutant S 1984). As such 
recommendations for craniectomy size are typically in the range of 10x15cm with the lower 
margin extending to less than 1cm from the floor of the middle cranial fossa. 
The frontal craniotomy is typically used in cases of frontal contusions or infarction. Bifrontal 
craniectomy is the most widely used. The surgical technique involves placing the patient 
supine. A bicoronal skin incision is planned posterior to the coronal suture. After incision 
the temporalis muscle is reflected inferiorly. Burr holes are made at the keyhole and at the 
root of the zygoma. Burr holes are also placed on either side of the sagittal sinus and along 
the planned craniectomy. Bilateral craniectomies are performed leaving a strip of bone 
covering the sagittal sinus.This strip of bone is then removed after freeing the sagittal sinus. 
A separate technique involves placing burrholes directly on the superior sagittal sinus and a 
burr hole at each key hole. The dura is then stripped from the bone, taking particular 
caution at the sinus. A bone flap is created connecting the keyhole burrholes with the most 
posterior burrhole at the sinus. Bilateral U shaped durotomies are created.  
If the sinus is to be ligated and sacrificed, tributary veins are coagulated as they drain into 
the sinus. The sinus is then ligated at the most anterior margin as dictated by the craniotomy 
margin and posteriorly to a maximum of 1/3 of the length of the entire superior sagittal 
sinus. The ligated sinus can then be separated from the falx as it dives into the intercerebral 
hemisphere. Further consideration and care must be taken in settings of trauma with frontal 
skull fractures and frontal contusions. Bony structures may serve a tamponade effect on a 
lacerated sinus and may need to be left in place or anterior portions of the sinus may need to 
be sacrificed for adequate decompression. Bilateral dural openings are made into U-shaped 
flaps extending to the anterior portion of the sagittal sinus followed by ligation of the sinus. 
Some authors advocate preservation of the strip of bone overlying the sagittal sinus, others 
argue that sacrificing the anterior 1/3 of the sinus could lead to increased venous pressure 
and worsening cerebral edema (Polin 1997). 
The removal of large areas of contused, infarcted or hemorrhagic theoretically further 
enhances the decompression. It also removes regions of disrupted blood brain barrier that 
could lead to further edema. Temporal lobectomy can be performed with removal of no 
more than 4-5cm of brain from the temporal tip on the dominant side and 6-7cm on the non-
dominant side. Frontal lobectomy has also been described but neither has shown great 
therapeutic promise (Nussbaum E S 1991). 
7. Recovery after hemicraniectomy 
Decompressive hemicraniectomy, although life saving typically leaves survivors with severe 
disability. The alternative to this however being death. Most patients fail to ever re-attain 
functional independence. Patients typically have their bone flap replaced 6 weeks to 6 months 
after the initial injury to ensure resolution of the initial insult. Patients suffering from the post 
craniectomy syndrome may have their bone flap replaced sooner rather than latter. 
Complications include but are not limited to intracerebral hematoma formation, extra-axial 
collections, cerebrospinal fluid leakage and cranioplasty failure. Post craniectomy 
hematoma formation primarily occurs due to inadequate surgical hemostasis or rupture of 
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friable vessels as herniating brain tissue is compressed along the craniotomy margin. This is 
seen more often in small hemicraniectomies (Wagner S 2001).. The vast majority of these are 
clinically silent. Extra axial fluid accumulations occur as a result of CSF leakage through the 
dural leaflets or secondary to post traumatic extra axial hydrocephalus. Some patients may 
require a ventricular or sub-dural shunt.  
CSF leak occurs in conjunction with open dura and inadequate closure of galea and skin. 
The incidence of this is in the range of 3% to 5% (Polin 1997; Wagner S 2001). Cranioplasty 
failure occurs as a result of bone flap resorption or infection. This occurs in 2% to 6% of 
cases. Poor graft fixation and approximation, excessive use of bone wax and a poorly 
vascularized or infected scalp can lead to this (Polin 1997). Patients with a compromised flap 
could subsequently require an acrylic bone flap. Postoperative seizure disorder are also 
reported in the range of 5% to 30%. The etiology of these remain unclear but can be 
attributed to the initial injury, resultant decompression, and a complicated hospital course. 
8. Non-traumatic brain injury 
In the setting of non-traumatic brain injury, the role of decompressive craniectomy remains 
unclear similar to traumatic brain injury. These include patients in categories including but 
not limited to subarachnoid hemorrhage secondary to ruptured aneurysm, intracerebral 
hemorrhage (ICH), and infectious processes. Kim et al (Ki-Tae Kim 2008) describe a series in 
which 75 patients underwent decompressive craniectomy and were analyzed 
retrospectively. In this group 28 patients were classified as traumatic brain injury, 24 as 
intracerebral hemorrhage and 23 with major infarction. Patients with a GCS score less than 8 
and midline shift on head CT greater than 6mm were considered surgical candidates. 
Patients outcomes at 6 months revealed a mortality rate of 21.4% in TBI, 25% in ICH and 
60.9% in major infarction.  
Favorable outcomes defined by glasgow outcome score of 4-5 (moderate disability or better) 
were observed in 57.1% of patients with TBI, 50% with ICH and 30.4% with major infarction. 
They also describe changes in intracranial pressure that were further increased with dural 
opening regardless of the disease group. Although this study describes the decompressive 
craniectomy as being more effective in ICH and TBI patients, we would encourage the 
reader to bear in mind these findings relate to retrospective studies. As described earlier in 
the chapter there exists class I evidence supporting the use of decompressive craniectomy in 
major infarction or stroke patients provided certain parameters are met. 
Hitchings and Delaney further describe a series of patients who underwent decompressive 
craniectomy for non trauma related conditions (Hitchings L 2010). They describe 54 patients 
who underwent 56 procedures. They noted that although intracranial pressure was reduced 
by the procedure. patients had long hospital stays and consumed a very significant amount 
of resources. Among survivors, two-thirds sustained a good outcome however most 
patients suffered residual deficits. They noted a mortality rate of 39%. These findings remain 
in concordance with the general concordance regarding decompressive craniectomies in that 
patients lives typically can be saved but functionality and quality of life suffer greatly. 
9. Conclusion 
Intracranial hypertension is a common sequelae of several illnesses and traumatic injury. 
Decompressive craniectomy provides an effective means of reducing and managing 
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intracranial pressure. Lumbar drainage is also a useful adjunct in addition. Selection criteria 
remains in evolution primarily in the trauma setting but at the present time it appears the 
best outcomes are in young otherwise healthy patients. The decision to proceed with 
decompressive craniectomy should take into consideration several factors including family 
wishes and reasonable expectations of level of recovery. 
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1. Introduction 
Severe Traumatic Brain Injury (S-TBI) is the major cause of mortality, morbidity, and 
disability among people younger than 45 years old. It constitutes a major problem in 
developed countries, not only for the affected patients and their families but also for the 
society, with serious socio-economic ramifications. It cannot be overemphasized the 
society’s burden from S-TBIs, which may exhaust even the most developed health care 
systems. During the last 30 years, advances in pre-hospital treatment, novel imaging 
modalities, intensive care monitoring improvements, rehabilitation advances, as well as 
better understanding of the S-TBI pathophysiology have decreased the overall mortality rate 
from 70-80% in 1970’s to 30 % nowadays. Severe TBI is still associated with unfavorable 
outcome (death or severe disability) in up to 60%. Continuous efforts of the neurosurgical 
community focus not only on decreasing the S-TBI associated mortality, but also on 
improving the quality of life and the functional outcome of patients suffering S-TBIs 
[Danish, et al., 2009; Honeybul, et al., 2011]. 
It has been demonstrated by Marmarou and his colleagues [Marmarou et al., 1991] that 
increased intracranial pressure (ICP) is strongly associated with poor outcome in patients 
suffering S-TBIs, making thus intracranial hypertension the most frequent cause of death 
and disability. Moreover, it has been postulated that this association between increased ICP 
and poor outcome is linear.  Frequently, the greatest challenge for a neurosurgeon  treating a 
patient suffering a S-TBI is the management of increased ICP, which in a large number of 
cases overwhelms brain’s ability to regulate cerebral blood flow (CBF), resulting thus to 
cerebral ischemia and consequently to severe disability and/or death. Elevated ICP is 
usually defined as an ICP above a threshold of 20 mmHg, measured within any intracranial 
space (subdural, intraventricular, extradural or intraparenchymal compartments). The cause 
of increased ICP in patients with S-TBIs is the result of an increase in brain parenchyma 
volume at the expense of one or more of the other two intracranial components (cerebral 
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1. Introduction 
Severe Traumatic Brain Injury (S-TBI) is the major cause of mortality, morbidity, and 
disability among people younger than 45 years old. It constitutes a major problem in 
developed countries, not only for the affected patients and their families but also for the 
society, with serious socio-economic ramifications. It cannot be overemphasized the 
society’s burden from S-TBIs, which may exhaust even the most developed health care 
systems. During the last 30 years, advances in pre-hospital treatment, novel imaging 
modalities, intensive care monitoring improvements, rehabilitation advances, as well as 
better understanding of the S-TBI pathophysiology have decreased the overall mortality rate 
from 70-80% in 1970’s to 30 % nowadays. Severe TBI is still associated with unfavorable 
outcome (death or severe disability) in up to 60%. Continuous efforts of the neurosurgical 
community focus not only on decreasing the S-TBI associated mortality, but also on 
improving the quality of life and the functional outcome of patients suffering S-TBIs 
[Danish, et al., 2009; Honeybul, et al., 2011]. 
It has been demonstrated by Marmarou and his colleagues [Marmarou et al., 1991] that 
increased intracranial pressure (ICP) is strongly associated with poor outcome in patients 
suffering S-TBIs, making thus intracranial hypertension the most frequent cause of death 
and disability. Moreover, it has been postulated that this association between increased ICP 
and poor outcome is linear.  Frequently, the greatest challenge for a neurosurgeon  treating a 
patient suffering a S-TBI is the management of increased ICP, which in a large number of 
cases overwhelms brain’s ability to regulate cerebral blood flow (CBF), resulting thus to 
cerebral ischemia and consequently to severe disability and/or death. Elevated ICP is 
usually defined as an ICP above a threshold of 20 mmHg, measured within any intracranial 
space (subdural, intraventricular, extradural or intraparenchymal compartments). The cause 
of increased ICP in patients with S-TBIs is the result of an increase in brain parenchyma 
volume at the expense of one or more of the other two intracranial components (cerebral 
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blood volume, cerebral spinal fluid). An increase in brain water content (edema), increased 
cerebral blood volume, and /or the presence of hematomas contribute significantly to 
increases of ICP in patients with S-TBI. 
It has been proposed that the employment of DC may drastically lower the increased ICP by 
allowing expansion of the edematous cerebral hemispheres. Furthermore, it has been 
postulated that DC interrupts the vicious cycle of intracranial hypertension via the 
impairment of the cerebral perfusion pressure (CPP), which inevitably results into further 
ICP increasing and may eventually lead to cellular injury and death. In this chapter the 
historical evolution of the surgical technique of DC is presented along with a brief 
description of the various surgical types and techniques, which are currently utilized in 
clinical practice. Moreover, the current concepts and controversies, the ongoing clinical 
trials, and the procedure associated complications are presented and discussed. 
2. Decompressive craniectomy: Historical landmarks  
Decompressive craniectomy has been proposed for many years as a valid treatment option 
for severe medically refractory intracranial hypertension, caused by various pathological 
conditions such as, S-TBIs, extensive cerebral infraction, massive subarachnoid hemorrhage, 
large intraparenchymal hemorrhage, severe intracranial infections, and extensive venous 
sinus thrombosis. 
Hippocrates was the first who clearly described the indications for trephination in  
severe head injuries. Indeed, trephination remained for centuries the major surgical 
intervention for managing patients with severe closed head injuries. The concept of 
decompression (removal of a variable amount of calvaria) was introduced in the late 1890 by 
Annandale. Kocher in 1901 proposed the opening of the skull for relieving increased 
intracranial pressure, while Harvey Cushing [Cushing, 1905] performed a subtemporal 
decompressive craniectomy for treating moribund edema caused by an intracranial 
neoplastic disorder.  
The concept of large cranial and dural decompression along with the removal of any 
underlying masses was initially described by Miyazaki in 1966, while Kjellberr and Prieto 
refined this surgical technique in 1971. For decades, DC was known as an occasionally life 
saving procedure, associated however with numerous serious complications. Therefore, the 
vast majority of neurosurgeons were not very eager in incorporating DC in the trauma 
neurosurgical armamentarium. Characteristically, Clarke in 1968 stated that the only reason 
for reporting his experience from performing DCs in S-TBI patients was for warning other 
neurosurgeons to avoid performing similar surgery. 
Decompressive craniectomy in its current form was recently re-introduced by Guerra and 
his coworkers [Guerra et al., 1999], who reported favorable outcome in more than 50% of 
their cases, undergoing DC after suffering S-TBIs. Since then, many non-randomized, 
usually retrospective, and small size clinical studies have suggested that DC may be a 
valuable treatment option, when maximal medical treatment has failed to control increased 
ICP. It has to be pointed out that the number of the published articles in the medical 
literature regarding the role of DC in the management of patients with S-TBI has been 
geometrically increased during the last decade (Fig. 1). However, the pertinent literature 
demonstrates a wide variation in clinical outcomes, and ill-defined indications for 
performing DC in patients with S-TBIs [Aarabi et al., 2006; Howard et al., 2008; Jagannathan, 
et al., 2007; Morgalla et al., 2008; Münch et al., 2000]. 
The Role of Decompressive Craniectomy in the  




Fig. 1. Diagrammatic representation of the number of PubMed listed articles regarding the 
role of DC in S-TBI patients, during the decade 2000-2010.  
2.1 Types of surgical decompression and surgical procedures 
Historically, DC is defined as the removal of different parts and portions of the skull, with 
or without opening of the underlying dura, and augmentative duroplasty. A variety of 
operations have been proposed and different surgical techniques have been developed for 
brain decompression. These include: a) the classic and widely used fronto-temporo-parietal 
craniectomy (either unilateral or bilateral), b) the bifrontal (bicoronal) craniectomy, c) the 
subtemporal decompression or the recently modified temporal craniectomy, and d) the 
hinge (door-like) craniotomy. 
The fronto-temporo-parietal craniectomy (hemicraniectomy), theoretically consists of 
extensive bone resection, exposing practically almost the whole underlying cerebral 
hemisphere. The patient is placed in supine position, with his/her head turned towards the 
opposite direction. An extended reverse questionmark skin incision is performed starting 
one cm in front of the tragus, extending above and behind the ipsilateral ear (approximately 
to the posterior mastoid line) and then curving forward one or two cm laterally from the 
midline, ending at or just behind the frontal hair line. Key points of the procedure are the 
extension of the decompression to the floor of the middle cranial fossa (all the way to the 
zygomatic arch with preservation of the superficial temporal artery and the branches of the 
facial nerve), (Fig. 2), and adequate size decompression with at least 12cm in its largest 
diameter (Fig. 3).  Usually, the temporalis muscle is dissected in one plane (osteoplastic 
flap), by using monopolar cautery. According to another technique, the temporalis muscle 
may be mobilized separately, and its fascia may be dissected and harvested for the 
duraplasty. The pterion and the temporal bones have to be adequately exposed. Burr holes 
are placed to the pterion, temporal bone, posterior parietal and frontal regions, as close as 
possible to the scalp incision, taking advantage of the whole skin flap. Then, the underlying 
bulging dura is carefully stripped off the bone, in all the burr holes with the use of a fine 
dissector. The burr holes are connected by using a high-speed craniotome, and then the 
inferior rim of the temporal bone is carefully removed in pieces, by a large rongeur exposing 
thus the floor of the middle cranial fossa. At this point, the ipsilateral sphenoid wing can be 
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blood volume, cerebral spinal fluid). An increase in brain water content (edema), increased 
cerebral blood volume, and /or the presence of hematomas contribute significantly to 
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drilled off, by using a diamond burr, if the patient’s condition allows such a time-consuming 
maneuver. The bone flap may be preserved by implanting it in an abdominal subcutaneous 
pocket, or it can be freezed and appropriately stored. The underlying dura is incised and 
opened in a cruciate fashion (Fig. 4). Augmentative duraplasty is performed then by using 
either gallea aponeurotica, or temporal fascia, or commercially available dural substitutes. 
The importance of performing meticulous hemostasis cannot be overemphasized. The 
wound is closed in anatomical layers, avoiding any tension at the skin margins. The surgeon 
judges according to brain edema and ICP measurements, whether the temporal fascia is 
sutured back or just a few approximating sutures are placed to the temporalis muscle 
[Apuzzo, 1993; Huang & Wen, 2010; Valadka & Robertson, 2007].  
 
 
Fig. 2. Early postoperative CT scan showing adequate decompression of the middle cranial 
fossa in a patient undergoing decompressive craniectomy. 
 
 
Fig. 3. Early postoperative CT scan demonstrating a large size decompressive craniectomy. 
 
 
Fig. 4. Intraoperative picture showing cruciate opening of the dura. Please note the bulging, 
edematous brain, and the engorged cortical veins. 
In bilateral hemicraniectomy, a bone ridge of approximately 3-4 cm in width is preserved 
over the superior sagittal sinus (SSS) (Fig 5). In bifrontal DC, a bicoronal skin flap is 
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performed and bilateral frontal bones including the bone over the SSS are removed.  A key 
point of this procedure is the careful elevation of the bone flap, which requires careful 
dissection of the underlying SSS.  
 
 
Fig. 5. Delayed CT scan of a patient undergoing bilateral hemicraniectomy. Please note the 
preservation of the bone over the superior sagittal sinus. 
In the hinge craniotomy, the bone flap is repositioned in its place with the use of three 
titanium miniplates. A Y-shaped miniplate is placed just posterior to the coronal suture, a 
simple straight two-hole miniplate is placed at the sphenoid wing, and another miniplate at 
the posterior temporal region. It has to be emphasized, that only the Y-shaped miniplate is 
secured to the surrounding skull, while the other two miniplates are secured only at one 
side acting as buttress plates, preventing this way future bone flap settling, while allowing 
temporary expansion of the underlying edematous brain [Kenning, et al., 2009; Schmidt,  
et al., 2007]. 
In selected cases, DC can be combined with ipsilateral temporal lobectomy (anterior temporal 
lobectomy and uncusectomy), preventing thus the risk of transtentorial brain herniation. In 
this procedure the head of the patient should be turned 450 towards the contralateral side, and 
a fronto-temporo-parietal craniectomy is performed. After the dural incision and under 
microscopic magnification, an anterior temporal lobectomy is performed, sparing the superior 
temporal gyrus.  A sub-pial aspiration/resection technique is used for removing the anterior 4-
5 cm of the inferior and middle temporal gyri, as well as the fusiform gyrus, the uncus, the 
parahippocampal gyrus, and potentially the mesial temporal structures [Chibbaro, et al., 2008]. 
A decompressive craniectomy may be performed either for preventing or for treating severe 
brain swelling. Prophylactic or primary DC is defined as the surgical decompression 
performed primarily for evacuation of an underlying mass of any type, whenever the 
surgeon decides that removal of the bone flap along with the overlying bone flap will 
benefit the patient. According to the Congress of Neurological Surgeons’ guidelines, a 
prophylactic DC may be performed in: a) comatose patients with epidural hematoma, b) in 
patients with acute subdural hematoma with thickness greater than 10 mm, or midline shift 
greater than 5 mm,  c) in patients with admitting GCS score <8 and traumatic parenchymal 
lesions greater than 50 cm3 in volume, or greater than 20 cm3 with midline shift of at least 5 
mm and/or cisternal compression, and  d) in patients with  open (compound) depressed 
cranial fractures, greater in thickness than that of the adjacent cranium, or with underlying 
hematoma, dural penetration, pneumocephalus, infection, or frontal sinus involvement 
[Bullock, et al., 2006; Sahuquillo & Arikan, 2006]. Secondary DC or therapeutic 
decompression is defined as the surgical decompression performed in patients with massive 
unilateral or bilateral brain edema in order to control high ICP refractory to maximal 
medical therapy.   
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2.2 Current concepts and controversies   
Decompressive craniectomy has recently become a valid, widely-performed treatment 
option for managing patients with medically refractory intracranial hypertension. The Brain 
Trauma Foundation (BTF) and the Brain Injury Consortium (BIC) consider DC as a second- 
tier therapy for medically intractable intracranial hypertension. The algorithm of treating 
increased ICP of traumatic origin is based on a set of therapeutic maneuvers and first-line 
measures as head elevation, maintenance of adequate oxygen tension, maintenance of 
normovolemia and normal osmosis, normothermia, appropriate sedation and analgesia, 
avoiding pyrexia and seizures, adequate CSF draining via an external ventriculostomy, mild 
to moderate hypocapnia, administration of mannitol and hypertonic solutions, and 
neuromuscular blockade. When these first-level measures fail, only a few therapeutic 
options are available. These second-tier therapies are the administration of high dose 
barbiturates, induction of hypothermia, and DC. The BIC state that DC may be considered 
in exceptional situations, while Bullock et al suggest that DC may be   the procedure of 
choice in patients with post-traumatic edema, hemispheric swelling, or diffuse injury given 
the appropriate clinical context. This context however, remains to be defined [Brain Trauma 
Foundation [BTF], 2007; Bullock, et al., 2006; Maas, et al., 1997].  
Numerous experimental models have demonstrated that DC reduces secondary brain 
injury. These effects are thought to be the result of an increase in collateral cerebral 
circulation, reduction in tissue edema, and improvement in oxygenation and energy 
metabolism [Stiver, 2009; Weiner et al., 2010]. Furthermore, postoperative radiological 
evaluation in cases of DC shows amelioration of midline shift, and improvement of the 
preoperative compression of the basal cisterns [Laalo, et al., 2009].   
Despite the constantly increasing clinical employment of DC in the management of patients 
with S-TBIs, there are still several points of controversy, regarding its exact role in the 
treatment of these patients. The most important controversial points may be summarized to 
the following:  
 Lack of clear indications and guidelines, regarding the selection of candidates for DC. 
Cochrane data base analysis in 2007 [Sahuquillo & Arikan, 2006] concluded that there 
was no evidence to support the routine use of secondary DC to reduce unfavorable 
outcome in adults suffering S-TBIs and refractory intracranial hypertension. 
Contrariwise, it seems that there is more solid evidence in pediatric trauma patients, in 
whom DC seems to reduce the risk of death and unfavorable outcome [Sahuquillo & 
Arikan, 2006]. 
 The exact role of ICP measurements and the ICP waveform type in selecting patients for 
DC. Many investigators suggest that a single episode of ICP> 20 mmHg lasting at least 
for 5 minutes is  an indication for performing DC, while others suggest a higher ICP 
threshold of 25 to 30 mmHg.  
 Patient’s age. Most neurosurgeons are very reluctant to perform DC in patients over 60 
years old. Indeed, outcome seems to be worse in elderly patients. However, this issue 
remains to be addressed.   
 The presence of commorbitity.  It appears that multi systemic trauma patients have 
worse outcome. The presence of cardiological and other systemic underlying pathology, 
as well as the preoperative use of anti-platelet or anticoagulant medication should be 
seriously assessed before deciding to perform a DC.  
 Ideal timing for performing DC. The question of early versus late intervention remains 
still unanswered. It is apparent that surgical decompression needs to be performed 
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before irreversible brain stem compression and/or herniation occur [Ruf, et al., 2003; 
Timofeev, et al., 2008]. 
 Ideal size of decompression. It was previously mentioned that adequate decompression 
of the floor of the middle cranial fossa is essential for achieving optimal relaxation of 
the perimesencephalic cisterns. It has been also proven that small DCs and small dural 
openings may cause swollen brain tissue to herniate through the bony defect, causing 
strangulation, infarction and worsening of the brain swelling. The current trend is to 
perform large size DCs with a diameter larger than 12 cm. However, the issue of the 
appropriate size DC has to be addressed in a prospective, randomized study. 
 The exact role of other parameters of neuromonitoring, such as brain tissue oxygen, 
markers of anaerobic metabolism (microdialysis), transcranial Doppler ultrasonography 
measurements, and electroencephalographic monitoring may provide further 
information, making the selection of ideal surgical candidate for DC more accurate 
[Bor-Seng-Shu, et al., 2006; Weiner, et al., 2010]. 
 The effect of DC in the functional outcome of patients with S-TBIs remains to be proven. 
Does the performance of DC provide better functional outcome?  Several clinical studies 
have suggested that DC reduces ICP but the overall functional outcome remains 
essentially unchanged [Danish, et al., 2009; Howard, et al., 2008; Morgalla, et al., 2008]. 
During the last decade a systematic attempt was made to prospectively assess the role of DC 
in the management of patients suffering S-TBIs and/or presenting medically refractory 
intracranial hypertension [Ban, et al., 2010; Morgalla et al., 2008; Valadka & Robertson, 
2007].Two independent, parallel, multi-centric, prospective clinical studies (the DECRA and 
the Rescue ICP trials) were designed and are underway for evaluating the exact role of DC 
in the management of patients with S-TBIs. These studies are supposed to address the issue 
of the efficacy of DC but also may clarify other DC-associated controversial points.   
2.3 The DECRA clinical trial   
The early DEcompressive CRAniectomy (DECRA) in patients with severe traumatic brain 
injury is a multi-centric, prospective, randomized trial, coordinated by The National Trauma 
Research Institute, the National Health and Medical Research Council of Australia, the 
Victorian Trauma Foundation, the ANZICS Foundation, and the Western Australian 
Institute for Medical Research.  The primary objective of the trial is to determine whether 
early decompressive craniectomy compared to conventional management strategies in 
patients with severe diffuse traumatic brain injury and early refractory intracranial 
hypertension improves neurological outcomes, at six months post injury. The inclusion 
criteria are: severe diffuse traumatic brain injury defined as GCS<9 and CT-scan with 
evidence of brain swelling (Marshall score grade D2-4), or GCS score > 8 before intubation 
and Marshall score D3 or D4 on the obtained brain CT scan, age 15-60 years, ICP monitor 
insertion, decompression  within 72 hours from the injury, and medically refractory ICP 
(defined as ICP> 20mmHg for more than 15 minutes continuously or cumulative during one 
hour) [Cooper, et al., 2008]. 
The exclusion criteria are: intracranial hemorrhage>3cm in diameter, intracranial mixed 
hemorrhagic contusion>5cm in long axis, previous craniectomy, presence of epi-dural 
and/or sub-dural hematoma > 0.5 cm in thickness, co-existent spinal cord injury, 
penetrating brain injury, arrest at the scene, unreactive pupils >4mm in diameter, GCS  
score =3, general contraindications for neurosurgical intervention, or no change of survival 
after careful consideration of the obtained brain CT and the patient’s clinical examination. 
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score =3, general contraindications for neurosurgical intervention, or no change of survival 
after careful consideration of the obtained brain CT and the patient’s clinical examination. 
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The surgical technique used is the bifrontal decompressive craniectomy (as described by 
Polin and his coworkers) with a single fronto-temporal bone flap extending across the 
midline. The underlying dura could be opened either by making a bilateral cruciate incision 
or by employing a large L-shaped incision, with the lower corner of the L facing laterally. 
The dural openings are covered with dural or fascial patches [Polin, et al., 1997].        
DECRA trial investigators presented their initial results in April 2011.  They reported on 155 
randomly assigned cases (73 patients underwent DC while 82 had standard care). According 
to their results the investigators concluded that in adults with severe diffuse traumatic brain 
injury and refractory intracranial hypertension, early bifronto-temporo-parietal 
decompressive craniectomy decreased intracranial pressure and the length of stay in the 
ICU. However, they found that patients undergoing craniectomy had worse scores on the 
Extended Glasgow Outcome Scale than those receiving standard care (odds ratio for a worse 
score in the craniectomy group: 1.84).  Similarly, patients undergoing DC demonstrated a 
greater risk of an unfavorable outcome (odds ratio: 2.21). The observed death rates at six 
months were similar in the craniectomy group (19%) and the standard-care group (18%) 
[Cooper, et al., 2011]. 
It has to be emphasized however, that the DECRA study carries significant weaknesses and 
biases. It is of great interest that out of 3700 patients, who were potential candidates for 
participating in this study, only 155 were finally recruited. This may be a significant 
selection bias.   In addition, the small number of study participants significantly decreases 
the statistical strength of the DECRA study. Furthermore, the utilized ICP threshold of 20 
mmHg for assigning patients for DC may be considered too low for patients with S-TBIs. 
2.4 The rescue ICP trial   
The Randomized Evaluation of Surgery with Craniectomy for Uncontrollable Elevation of 
Intra-Cranial Pressure, is a multi-centric 48 (centers from 19 different countries) clinical 
study, organized as a collaborative research project between the university of Cambridge 
(Departments of Neurosurgery and Neurointensive Care), and the European Brain Injury 
Consortium. It is a randomized controlled trial comparing the efficacy of DC versus optimal 
medical management for the treatment of refractory intracranial hypertension following 
brain trauma. The inclusion criteria are: patients with S-TBI, age 10-65 y.o, with an abnormal 
CT-scan requiring ICP monitoring, and raised ICP > 25 mmHg for > 1 hour to 12 hours. 
Patients may have immediate operation for a mass lesion but not a decompressive 
craniectomy. Patients with immunological, hepatic, or renal compromise may be included in 
this study as long as there is a description of the type and the extent of their impairment. 
Contrariwise, patients with bilateral fixed and dilated pupils, bleeding diathesis, a 
devastating injury, inability to follow them, inability to monitor ICP, primary 
decompression, brainstem injury, or patients that were treated according to the Lund 
protocol, or have received barbiturates before their randomization, should be excluded from 
the study. The surgical treatment comprises of a large unilateral fronto-temporo-parietal 
craniectomy for unilateral brain edema or of large bilateral fronto-temporo-parietal 
craniectomies for diffuse bilateral hemisphere swelling. The craniectomy extends from the 
frontal sinus anteriorly to the coronal suture posteriorly, and to the pterion laterally. It is 
accompanied by a large dural opening (dural flap pedicles are based on the superior sagittal 
sinus medially, and also a division of the falx anteriorly is required). 
The primary endpoint of the Rescue-ICP study will be the outcome assessment at discharge 
(GOS score), and then at six months after injury (Extended GOS score), while secondary 
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endpoints will be: a) the assessment of outcome using the SF-36 and the SF-10 
questionnaires, b) assessment of ICP control, c) length of stay in the ICU, d) hospital length 
of stay, and e) a detailed health-economic analysis of the collected data [Hutchinson, et al., 
2006 ]. The results of the Rescue-ICP study are expected with great interest, and may greatly 
influence the future of DC and the overall management of patients suffering S-TBIs. 
3. Decompressive craniectomy complications 
Decompressive craniectomy has been associated with high mortality rates, mainly due to 
the severity of the underlying trauma, and also with numerous, and occasionally severe 
complications. Several factors have been identified as predisposing to the development of 
DC-associated complications. These include low GCS score upon admission, patient’s old 
age, the presence of commorbidity, and the systematic preoperative anti-coagulant 
administration. Yang et al [Yang, et al., 2008] reported that the frequency of DC associated 
complications was 62% for admitting GCS scores 3-5, 39% for GCS scores 6-9, and 36 % for 
GCS scores >9. In addition, older patients (> 60 y.o) tend to have higher complications rates 
and prolonged ICU stay. Likewise, preoperative administration of anti-coagulant or 
antiplatelet medication increases the risk of intraoperative and/or postoperative bleeding.   
The alterations in cerebral compliance, CBF autoregulation, and altered CSF dynamics 
associated with S-TBIs, are the main reason for developing DC-associated complications. 
Several theories suggesting that the sudden change from prolonged severe compression to a 
state of maximal vasolidation and hyperemia following DC may cause loss of 
autoregulation, and may be responsible for the occurrence of DC associated complications 
[Aarabi, et al., 2009; Yang, et al., 2008]. The most commonly occurred complications may be 
divided to:  
1. Perioperative complications  
a. Blossoming of pre-existing cerebral contusions. Expansion of pre-existing hemorrhagic 
contusions, as demonstrated on serial CT scans, has been reported as frequently as 40% 
of the cases, and may be considered inherent to the injury evolving process.  
b. Evolution and expansion of contralateral masses. The decompression provided by DC 
allows the expansion of contralateral masses (hematomas), which that were 
preoperatively tamponated by the swollen brain.  
c. External cerebral herniation. Expansion of the edematous brain through the bony defect 
may occur, especially during the first two postoperative weeks.  The compression of the 
cortical veins of the herniated cerebral tissue leads to infarction, and unfortunately to 
further swelling. In small size decompressions, a mushroom-like herniation of the 
swollen parenchyma may occur. Therefore, most surgeons propose large craniectomies 
and wide dural openings for protecting the underlying cortical veins and for 
minimizing the risk of external cerebral herniation. 
2. Early postoperative complications. 
a. Subdural effusions and hygromas are very often developed in cases of DC (Fig 6). Aarabi 
and his coworkers [Aarabi, et al., 2009] have reported subdural effusions and hygromas in 
50% of their cases. Alteration of CSF circulation after a DC may incite the development of 
hygromas, which may progressively expand in volume. However, the hygromas very 
rarely demand surgical evacuation, and they usually resolve spontaneously.  
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Fig. 6. Postoperative CT scan demonstrating the development of a subdural hygroma. 
b. Impaired wound healing and infection may complicate a DC, and prolong patient’s 
hospitalization.  The performance of an extensive DC may compromise the skin flap 
blood supply (especially in the occipital area), and thus may increase the possibility of 
postoperative wound healing problems. Therefore, it is of paramount importance to 
maintain adequate skin flap blood supply by preserving the superficial temporal artery, 
and by avoiding tight skin suturing during closure.  The observed high infection rate in 
patients undergoing DC may also be partially explained by the fact that the vast 
majority of these patients require prolonged ICU treatment and multiple interventions.  
c. Post-DC hydrocephalus incidence has been reported to be as high as 15 %, and is 
associated with poorer clinical outcome (Fig 7). The treatment of hydrocephalus with 
CSF shunting remains controversial, and the timing of intervention before or after 
cranioplasty is still disputable.   
 
 
Fig. 7. Delayed postoperative CT scan demonstrating severe ventriculomegaly in a patient 
undergoing bilateral hemicraniectomy. 
d. The syndrome of the trephined is a frequent delayed complication and its diagnosis is 
often overlooked. Occasionally it may be presented with delayed onset of focal 
neurological deficits. 
e. Paradoxical herniation with brain stem compression and neurological deterioration is a 
very rare complication and may be precipitated by a lumbar puncture in a craniectomized 
patient. 
3.1 Cranioplasty  
One of the drawbacks of DC is the fact that a second surgical intervention is required to 
repair the bone defect. Autologous bone grafts may be used, which are preserved 
subcutaneously, or stored freezed under specific conditions in storage bone-banks. Tailor-
made heterologous or synthetic bone grafts may also be used. The previous belief ofdelayed 
cranioplasty for minimizing the risk of infection, is seriously questioned nowadays, and an 
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increasing number of surgeons prefer early surgical skull reconstruction. Several surgeons 
support the idea of immediate cranioplasty even during the initial hospitalisation, as early 
as 2-4 weeks after trauma, when there is no suspicion of infection.  The possibility of a new 
head injury with the exposed brain unprotected must be taken into consideration. Moreover, 
the observation of better functional outcome after cranioplasty, may further increase the 
number of early cranioplasty cases [Beauchamp, et al., 2010; Morina, et al., 2011]. 
4. Conclusions  
The management of refractory post-traumatic intracranial hypertension remains a challenge 
for neurosurgeons, anesthesiologists, and neuro-intensivists. Cerebral ischemia leading to 
severe disability or death is unfortunately the only result expected. In order to deal with this 
dramatic situation only few treatment options exist.   The ultimate measure to relieve 
uncontrollable ICP is an extensive decompressive craniectomy. It is proven that DC 
increases the volumetric compensatory capacity and reduces ICP. However, the well-
documented risks and drastically complications of DC have to be seriously considered 
before performing a DC. In carefully selected cases these risks may be outweighted by the 
expected benefit. The results of the two ongoing prospective, randomized, controlled trials 
are expected to enlighten us on the exact role of DC in the management of patients with S-
TBIs, and its effect on their long-term functional outcome.  
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1. Introduction 
Brain concussion is unquestionably the most common form of traumatic brain injury (TBI) 
worldwide (Bruns & Hauser, 2003; Tagliaferri et al., 2006). In European countries, 
approximately 235 individual/100,000 people are admitted annually to the hospital 
following TBI, 80% of which receive a diagnosis of mild TBI (mTBI). (van der Naalt, 2001; 
Vos et al., 2002). It has been calculated that the ratio in the occurrence of mTBI to severe TBI 
(sTBI) is approximately 22 to 1, with mTBI accounting for at least 75% of patients who 
survive after TBI each year (Tagliaferri et al., 2006). These percentages are very similar to 
those recorded in the United States where it is estimated that approximately 1.5 – 8 million 
people per year suffer from TBI and, among those requiring hospitalization, a proportion 
ranging from 75% to 90% are classified as “mildly” injured or “concussed” (Bruns & Hauser, 
2003).  These wide ranges of annual incidence are probably due to the fact that an unknown 
proportion of mTBI victims do not seek any medical attention (McCrea et al., 2004) (HEADS 
UP) but it might also be due to the fact that there is still confusion and inconsistency among 
researchers and organizations in defining and understanding this type of trauma. (Cantu & 
Voy, 1995; Cantu, 1998, 2007).  
The above reported numbers give the evidence that albeit the incidence of mTBI is 
tremendously high, the mortality caused by this type of trauma appears to be rather low (6-
10 per 100,000/year). To reinforce this concept it has been reported that only 0.2% of all 
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patients attending the Emergency Departments (EDs) will die as a direct result of this head 
injury (Vos et al., 2002). 
With this in mind, it is evident that this situation represents a really serious public health 
concern of our time: in fact, the EDs are required to see a massive number of patients, with 
the most challenging task of identifying the small number of them that will progress to have 
serious acute intracranial complications. Statistics demonstrate that only 1-3% of all mTBI 
patients admitted to the hospital with a Glasgow Coma Scale (GCS) score of 14-15 will 
subsequently develop life-threatening intracranial pathology (the remaining 97-99% of them 
will be discharged home within 48 hours) (Livingston et al., 2000; Lloyd et al., 1997; 
Shackford et al., 1992; Swann et al., 1981; Taheri et al., 1993). Furthermore, when a mTBI 
patient is presenting with a GCS score of 15 and no additional associated risk factors the 
probability that he may suffer from intracranial hemorrhage, requiring neurosurgical 
intervention, is below  0.1% (Fabbri et al., 2010). 
As a consequence of this very low mortality rate, it is generally and widely accepted that 
mTBI represents a nosological entity with high frequency but that it does not represent a real 
serious injury. The common feeling that consequences of mTBI are only transient 
disturbances has slowly grown, mainly supported by the absence of structural lesions on 
traditional neuroimaging. Therefore, the general idea is that mTBI-affected patients need no 
intervention other than observation, with no additional clinical examinations nor specific 
recommendations for the post-injury period. However, a recent report revealed that the 
diagnosis of an intracranial hematoma in such patients was made with a median delay of 18 
hours (Yates et al., 2007), strongly suggesting that the quality of the “observation” that 
mildly-injured patients receive while in hospital is of utmost concern. If in the USA it has 
been established that only 50% of mildly head injured patients admitted to the hospital had 
documentation of neurological observations (Yates et al., 2007) in Europe the situation is 
even much worse, with mTBI patients who have historically been observed by non-specialist 
wards by nurses and doctors not experienced in neurological observations. The 
fundamental issues of whether to image, observe and discharge, each one of these endless 
patients, focused essentially on identifying those at risk for a hemorrhagic complications has 
completely obscured the real dilemma of the concussive injury, whose early and late 
symptoms and sequelae are continuously underreported, underinvestigated, 
underdiagnosed, and mainly underestimated by the majority of physicians.   
1.1 Background: Sports-related concussion 
If mTBI were as “mild” as we might think, it would be difficult to explain the actual 
complex management of these patients that may involve various health care professionals 
including family practice physicians, behavioral psychologists, clinical psychologists, 
neuropsychologists, neurologists, psychiatrists, neuro-ophthalmologists, neurosurgeons, 
physiatrists, nurses, occupational therapists, and physical therapists. Furthermore, long 
beyond the typical recovery interval of one week to three months, at least 15% of persons 
with a history of mTBI continue to see their primary care physician because of persistent 
problems (Alexander, 1995; Bigler, 2003; Gouvier et al., 1992; Kay et al., 1992; Ingebrigtsen et 
al., 2000). From the aforementioned picture and reminding that the majority of mTBIs are 
unreported, it is clearly evident how much difficult would be to select a homogeneous 
population for a study on mTBI, just on the basis of those who refer to the hospital.  
Although certainly blended in to the vast world of mTBI, by definition, brain concussion 
should be considered a discrete and distinct entity, since not all mTBI are truly 
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“concussive”; thus the two terms refer to different constructs and should not be used 
interchangeably (McCrory et al., 2009). Despite recent efforts, a unanimous definition of 
concussion has not yet been widely accepted (Cantu, 2007). It is possible to define 
concussion as a traumatic insult capable of provoking an acceleration-deceleration 
phenomenon within the skull (Barth et al., 2001). From a clinical point of view, concussion is 
not necessarily accompanied by loss of consciousness and is associated with various 
physical (headache, equilibrium, vision disturbances, etc.), cognitive (memory, 
concentration, etc.), emotional (behaviour) and sleep alterations (Gosselin et al., 2009; Hunt 
& Asplund, 2010; Randolph et al., 2009). These symptoms are included in the well known 
post-concussive syndrome and can affect, to various degrees, everyday life, resolving 
spontaneously within 7-10 days post-injury, in the majority of cases. In concussed subjects, 
the pathobiology of mTBI can not be defined by classical imaging techniques such as CT 
scan and MR (Kurca et al., 2006), as it occurs in all mTBI patients. This fact, coupled to the 
faintness and variability of symptoms, mainly assessed by the patient’s self-evaluation, is 
not certainly of help in diagnosing and monitoring concussed patients. 
It is generally accepted that at least 20% of all mTBI are sports-related injuries (concussions), 
of which 30-45% receives no medical care (McCrea et al., 2004). Athletes, therefore, represent 
a population at great risk of occurrence of concussive episodes and are, for several reasons, 
the population of choice with which to undertake trials to study the pathobiology of mTBI 
(Meehan & Bachur, 2009). It is well established that after the first traumatic episode the 
probability of recurrence of concussion in athletes increases by 3 times (Cantu, 2003), that 
currently, there is no agreement as to how many concussions are too many (Guskiewicz et 
al., 2003; Pellman et al., 2004), nor is there an unanimously approved diagnostic approach to 
monitor concussed athletes (Delaney et al., 2005; Kissick & Johnstone, 2005; Ponsford, 2005), 
consequently the criteria to assess a safe return of concussed athletes to play remain unclear 
(Guskiewicz et al., 2006; McClincy et al., 2006; Lovell et al., 2004). 
1.2 Background: Metabolic changes characterizing brain vulnerability following 
concussion 
An increasing number of studies on mTBI have focused attention on concussion-induced 
changes in brain metabolism (Bergsneider et al., 2000; Praticò et al., 2002) including those 
related to cerebral energy state (Vagnozzi et al., 1999). Hovda and colleagues first suggested 
the concept of metabolic vulnerability occurring in brain tissue after any concussive episode 
(Giza & Hovda, 2001; Hovda et al., 1993). During this transient period of altered brain 
metabolism and function, a second concussive episode of even modest entity may cause 
significantly addition and/or dramatic brain damage (Longhi et al., 2005), thereby 
underlying the so called second impact syndrome (SIS), encountered occasionally in sports 
medicine (Saunders & Harbaugh, 1984). In fact, the possibility of having a second 
concussive injury within a not yet defined period of time from the first (i.e., days or weeks) 
has been reported to be even fatal in some instances (Bowen, 2003; Cantu, 1998; Cobb & 
Battin, 2004; Logan et al., 2001; Mori et al., 2006; Saunders & Harbaugh, 1984). SIS is 
clinically characterized by untreatable malignant edema with devastating consequences for 
the patient up to death. Notwithstanding these reported cases, concerns still exist about the 
real occurrence of this peculiar pathological condition (McCrory, 2001; McCrory & Berkovic, 
2001; Nugent, 2006). 
By using a rodent model of closed diffuse mild head injury (Foda & Marmarou, 1994; 
Marmarou et al., 1994), data from our laboratories confirmed the concept of metabolic 
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“concussive”; thus the two terms refer to different constructs and should not be used 
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vulnerability (Tavazzi et al., 2007; Vagnozzi et al., 2007) and have also produced solid 
experimental evidence linking the severity of brain injury and recovery with the extent of 
ATP and N-acetylaspartate (NAA) decrease and recovery (Tavazzi et al., 2007; Vagnozzi et 
al., 2005, 2007). NAA is the most prominent compound detectable with proton Magnetic 
Resonance Spectroscopy (1H-MRS) in human brain, making it one of the most reliable 
molecular markers for brain 1H-MRS studies. Although an exact role of this compound 
remains to be established, brain NAA was found present in concentrations a hundred fold 
higher than in non-nervous system tissue and therefore considered a brain-specific 
metabolite (Miyake et al., 1981; Truckenmiller et al., 1985) and as an in vivo marker of 
neuronal density. NAA metabolism involves different brain compartments, with neuronal 
mitochondria taking care of its biosynthesis via the activity of aspartate N-acetyltransferase 
(ANAT) and oligodendrocytes contributing to its degradation via the activity of N-
acetylaspartate acylase (ASPA). NAA homeostasis is finely regulated by three different 
velocities: 1) rate of neuronal biosynthesis, 2) rate of neuronal outflow in the extracellular 
space, and 3) rate of oligodendrocyte uptake and degradation (Baslow, 2003a, 2003b). 
Furthermore, NAA biosynthesis is also strictly dependent on the neuronal energy state and 
therefore on the correct mitochondrial functioning. In fact, NAA synthesis necessarily 
requires the availability and the energy of hydrolysis of acetyl-CoA (∆G = -31.2 kJ/mol), 
working as the acetyl group and energy donor in the acetylation reaction of aspartate 
catalyzed by ANAT. It is fundamental to understand that when acetyl-CoA is used for NAA 
synthesis there is an indirect high energy cost to the cell. In fact, since in this case acetyl -
CoA will not enter the citric acid cycle (Krebs’ cycle) there will be a decrease in the 
production of reducing equivalents (3 NADH and 1 FADH2) as the fuel for the electron 
transport chain. Since the oxidative phosphorylation is stoichiometrically coupled to the 
amount of electron transferred to molecular oxygen by the electron transport chain, the final 
result will be a net loss of 11 ATP molecules for each NAA molecule newly synthesized. 
NAA concentration within neurons is comparable to that of glutamate (10 mmol/l brain 
water) but, notwithstanding such a relevant amount and in spite of NAA is known since late 
‘50s, there is no unanimity on the biochemical functions of this still enigmatic molecule. 
According to different studies, NAA may act as storage form for aspartate, protein synthesis 
regulator, shuttle of acetate and “amino-nitrogen” from the mitochondria to the cytoplasm, 
breakdown product or precursor of the neurotransmitter N-acetylaspartylglutamate 
(NAAG), metabolically inert pool regulating the anion deficit balance, metabolically active 
pool involved in the production of glutamate. Although NAA might play a marginal role in 
any of the aforementioned processes, recent studies have suggested that the potentially 
main roles of NAA might be to participates an acetyl group donor in brain lipid biosynthesis 
(production of myelin) (Moffett et al., 1991) and to act as a neuronal osmoregulator against 
cytotoxic swelling (molecular water pump) (Baslow, 2003a). Physiologically, NAA 
concentration is kept within a strict oscillation range even though NAA is regenerated 1.8 
times/24 hours (with a calculated turnover rate of approximately 0.75 mmol/l water/hour). 
It is therefore evident that a perfect  balance of the different velocities involved in NAA 
homeostasis, should exist. NAA decrease has been observed in association with many 
neurological diseases causing neuronal and axonal degeneration such as tumors, epilepsy, 
dementia, stroke, hypoxia, multiple sclerosis, and many leukoencephalopathies. Vice versa, 
the only known pathologic state characterized by a dramatic increase in cerebral NAA is the 
autosomic genetic leukodystrophy caused by the synthesis of a defective form of the 
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enzyme responsible for the NAA degradation (N-acetyl-asparto-acylase, ASPA), known as 
Canavan disease. Due to the enzymatic defect in the NAA degradation, Canavan-affected 
patients are also characterized by large urinary excretion of intact NAA, up to 2000-fold the 
normal physiologic excretion (Tavazzi et al., 2005). The morphological alterations in 
Canavan-affected patients, characterized at MRI by spongi degeneration and structurally 
defective myelin, can well account for the most accredited roles of NAA: the incapacity to 
degrade NAA would generate dramatic changes in water extrusion from the brain 
compartment with consequent spongi degeneration, as well as a drastic decrease in the 
availability of acetate groups for olygodendrocytes thereby causing deficits in lipid myelin 
biosynthesis.  
1.3 Background: NAA and 1H-MRS as a diagnostic tool to study in vivo brain 
vulnerability 
As already mentioned, the relevance of NAA as a biochemical marker of the metabolic 
neuronal “wealth” is related to the possibility to measure NAA concentration non-
invasively “in vivo” by 1H-MRS. When subtracting the spectral signal of 1H from water (the 
most abundant molecule containing an atom with an unpaired proton, which is a 
prerequisite to allow to detect a molecule by MRS), the 1H-NAA resonance returns one the 
best defined peaks at approximately 2 ppm. Using the clinically safe magnetic fields of the 
MRS apparatuses (1.5 or 3.0 Tesla) in the range 1.8 to 3.4 ppm to additional, well-resolved, 
resonance peaks are obtained, one at approximately 3.2 ppm referring to choline (Cho) and 
the other at approximately 2.9 ppm referring to creatine (Cr). It is worth recalling that the 
relatively low magnetic fields with no side effects (1.5-3.0 T) do not allow to discriminate in 
the multitude of compounds that are physiologically present within the brain tissue (acetyl-
choline, cytidinediphospho-choline, phospho-choline, glycerophospho-choline, 
phosphatidyl-choline, free-choline, etc.) having this quaternary ammonium derivative as a 
characterizing chemical group. The same can be applied either in the case of the creatine-
containing compounds (creatine and creatinephosphate) or in the case of the NAA-
containing compounds (NAA and NAAG). Actually, in a 1H-MRS the Cho peak represents 
the choline-containing compounds (with phosphatidyl-choline representing the 90% of the 
signal intensity), the Cr peak represents creatine-containing compounds (with creatine 
accounting for the 90% of the intensity signal) and the NAA peak the NAA-containing 
compounds (with NAA being 12 to 15 fold more concentrated than NAAG). Unless 
determining the water content within the voxel(s) for a calculation of the absolute 
concentrations of the different metabolites, it is necessary to quantify at the same time the 
peak areas of the spectroscopic intensity signals of both Cr and Cho-containing compounds 
and to then refer to the NAA/Cr and NAA/Cho ratios for the semi-quantitative NAA 
evaluation in physiopathological conditions (Barker et al., 1993; Brooks et al., 2001; 
Friedman et al., 1999; Garnett et al., 2000; Mitsumoto et al., 2007). This type of approach 
assumes Cr and Cho as two unvarying parameters to which relate the NAA changes. The 
results of a multicenter clinical trial (Vagnozzi et al., 2010) involving 40 concussed athletes 
and 30 healthy volunteers have been recently published, revealing that, despite different 
combinations of field strengths (1.5 or 3.0 T) and modes of spectrum acquisition (single- or 
multi-voxel) among the scanners currently in use in most neuroradiology centers, NAA 
determination represents a quick (15-minute), easy-to-perform, noninvasive tool to 
accurately measure changes in cerebral biochemical damage occurring after a concussion. 
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Patients exhibited the most significant alteration of metabolite ratios at day 3 post-injury, 
showing a gradual recovering, initially in a slow fashion and, following day 15, more 
rapidly. At 30 days post-injury, all subjects showed complete recovery, having metabolite 
ratios similar to values detected in controls. Interestingly, all these 40 patients self-declared 
symptom clearance between 3 and 15 days after concussion strongly demonstrating 
differential times of disappearance of clinical gross signs and of normalization of brain 
energy metabolism. In a previous pilot study carried out in a cohort of singly and doubly- 
concussed athletes, examined by 1H-MRS for their NAA cerebral content at different time 
points after concussive events, we demonstrated that the recovery of brain metabolism is 
not linearly related to time. In this study, two athletes experienced a second concussion 
between the 10th and the 13th day after the first insult. Although they were not affected by 
SIS nor showed signs of sTBI, they however had a significant delay in both symptom 
resolution and NAA normalization (Vagnozzi et al., 2008).  
According to the aforementioned data it is clear that concussion causes a reversible change 
of brain metabolism that can be monitored by 1H-MRS in terms of NAA variations. 
Furthermore, data recorded in the two doubly concussed athletes suggest that a second 
concussion might compromise rescue of cerebral metabolism and delaying its 
normalization. This would in turn cause delaying in return of athletes to play. In the present 
study, we report data referring to six concussed athletes who received a second concussion 
at different times during the period of alteration of brain metabolism. The time course 
changes in their cerebral NAA, evaluated by 1H-MRS up to complete normalization, are 
presented. 
2. Materials and methods 
Six non-professional male athletes from different sport disciplines who had suffered from a 
sport-related concussion, defined as a traumatically induced transient alteration in mental 
status, not necessarily accompanied with loss of consciousness, were considered in this 
study. At the clinical examinations they had a GCS greater or equal to 14, normal 
neurological objective signs and an age ranging between 20 and 33 years (mean age = 26 ± 5 
years). According to our previous observations (Vagnozzi et al., 2008, 2010), they were 
required to restrain from further physical activity during the entire observational period, 
which lasted until cerebral metabolic normalization. None of the patients had positive MRI 
for post-traumatic anatomical lesions (the presence of blood, etc.), or suffered from 
polytrauma, or presented with risk factors for subsequent complications (coagoulopathy, 
epilepsy, former neurosurgical interventions, alcohol or drug abuse, disabilities). The first 
clinical evaluation, MRI and MRS were carried out at 3 days post injury; follow-up MRI and 
MRS analyses, as well as clinical evaluation of concussion-associated symptoms, were 
performed at different times up to metabolic normalization (15, 22, 30, 45, 60, 90, 120 days 
post-injury). A group of 10 healthy male subjects matched for age (mean age = 25 ± 6 years) 
was subjected to MRS and used as the control group. 
In controls and athletes, semi-quantitative analysis of NAA relative to creatine (Cr) and 
choline containing compounds (Cho) was performed in the single voxel (SV) mode, after 
obtaining proton spectra using a 3.0 T system (Philips, Intera Achieva). For conventional 
MRI studies, T1 and T2 weighted TSE images were acquired in axial coronal and sagittal 
planes and, in order to rule out even the smallest amount of intra-cerebral blood, Fast Field 
Echo (FFE) T2* sequences were used. A multi channel coil (8 ch.) Sense-Head with 4 mm 
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slice thickness, 1 mm gap and a FOV of 230 mm, was used for all MRI sequences. Following 
localized shimming and water suppression, the spectroscopic examination was carried out 
using a PRESS (Point Resolved Spectroscopy Sequence) pulse sequence, with the following 
settings: TE = 144 msec; TR = 2,000 msec; Spectral Bandwidth = 2,000 Hz; acquisition  
cycles = 128. The optimal positioning of the voxel was determined using the MR images 
acquired on axial, coronal and sagittal planes to facilitate its three-dimensional placement, 
adjacent to the cortical-subcortical junction in order to include only the white matter of the 
frontal lobes, bilaterally and the choice of this location as the region of interest, was made to 
obtain the most homogeneous data as possible. To this end, a spectrum from a single voxel 
(SV) customized to sample a volume of interest (VOI) of 3.375 cm3 (1.5 x 1.5 x 1.5 cm), was 
obtained (acquisition time about 5 min for each voxel). In follow-up studies, the exact 
repositioning of the voxel on the same acquisition plane obtained in the previous MRI study 
was achieved by using dedicated software (SameScan, Philips Medical Systems). Metabolite 
intensity ratios (NAA-to-Cr and Cho-to-Cr) were automatically calculated at the end of each 
acquisition using dedicated software (SpectroView; Philips Medical Systems), by which 
gaussian-fitted peak areas relative to a baseline computed from a moving average of the 
noise regions of each spectrum were determined. Post-processing of spectral data, using a 
homemade computed program, allowed us to render uniform calculations of the area under 
the peaks of NAA, Cho and Cr, using common criteria for peak integration. In the case of a 
single, well-defined peak (typically the NAA peak), a valley-to-valley integration was 
performed to obtain the area under the peak. In the case of not fully resolved peaks 
(frequently the Cho and Cr peaks), a horizontal baseline between the start of the first peak to 
the end of the second peak was selected; the grouped peaks were then split by a vertical 
line, drawn from the median point of the common valley between peaks to the horizontal 
baseline and the area under the peaks calculated. These values were used to determine the 
metabolite ratios NAA/Cho, NAA/Cr and Cho/Cr. 
3. Results 
Table 1 summarizes the clinical features of the 6 doubly concussed athletes, including the 
time interval between concussion and the type and duration of the post-concussive self-
reported clinical symptoms after both the first and the second head injury.  
Table 1. Demographic data, sport activity and clinical features of 6 non professional athletes 
suffering from double concussion. 
None of these concussions was characterized by loss of consciousness. All athletes declared 
to suffer from headache following the first concussive episode and each of them suffered 
from at least one additional post-concussive disturbance. Disappearance of self-reported 
clinical symptoms after the first concussion ranged between 3 to 8 days (mean duration = 5.8 
± 2.1 days). In two athletes the second concussive event occurred between the first and 
second 1H-MRS (mean interval between the two concussions = 9.5 ± 0.7 days), whilst in the 
remaining 4 athletes the second concussion took place between the second and the third 
second 1H-MRS (mean interval between the two concussions = 18.5 ± 2.1 days). In athletes 1 
and 2, the second concussions were characterized by loss of consciousness (< 2 min). 
Following the second concussive episode, all athletes again declared to suffer from headache 
and each of them suffered from at least four additional post-concussive disturbances. Self-
reported clinical symptoms following the second concussion disappeared with a mean 
duration = 41.2 ± 13.0 days (p < 0.001 when compared to duration of symptoms observed 
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slice thickness, 1 mm gap and a FOV of 230 mm, was used for all MRI sequences. Following 
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time interval between concussion and the type and duration of the post-concussive self-
reported clinical symptoms after both the first and the second head injury.  
Table 1. Demographic data, sport activity and clinical features of 6 non professional athletes 
suffering from double concussion. 
None of these concussions was characterized by loss of consciousness. All athletes declared 
to suffer from headache following the first concussive episode and each of them suffered 
from at least one additional post-concussive disturbance. Disappearance of self-reported 
clinical symptoms after the first concussion ranged between 3 to 8 days (mean duration = 5.8 
± 2.1 days). In two athletes the second concussive event occurred between the first and 
second 1H-MRS (mean interval between the two concussions = 9.5 ± 0.7 days), whilst in the 
remaining 4 athletes the second concussion took place between the second and the third 
second 1H-MRS (mean interval between the two concussions = 18.5 ± 2.1 days). In athletes 1 
and 2, the second concussions were characterized by loss of consciousness (< 2 min). 
Following the second concussive episode, all athletes again declared to suffer from headache 
and each of them suffered from at least four additional post-concussive disturbances. Self-
reported clinical symptoms following the second concussion disappeared with a mean 
duration = 41.2 ± 13.0 days (p < 0.001 when compared to duration of symptoms observed 
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after the first concussion). Figures 1 and 2 illustrate the time course changes of NAA 
(reported in the Figures as the NAA/Cr ratio) in the two doubly concussed athletes 
(Patients 1 and 2) receiving the second head injury between the 1st and the 2nd 1H-MRS, both 
showing loss of consciousness < 2 min on field.  
 
 
Table 1. Clinical features of doubly  concussed athletes. The mean duration of symptom 
persistence lasted 5.8 ± 2.1 days after the 1st injury and 41.2 ± 13.0 days after the 2nd 
concussion (p < 0.001 when compared to duration of symptoms observed after the first 
concussion). In both cases, symptoms disappeared much earlier than the time needed for 
complete NAA restoration. 
At the time of the 1st resonance spectrum acquisition (3 days post-injury) both subjects 
showed a consistent decrease in the NAA/Cr ratio. When effecting the 2nd MRS, 
notwithstanding athletes were both initially advised to restrain from physical activity, they 
both declared to have started again their respective sport discipline because of symptom 
disappearance and to have received a second concussion few days later (mean value 
between repeat concussions = 9.5 ± 0.7). At this 2nd MRS analysis, the NAA/Cr ratio fell 
slightly below 1.6 (-23.6% with respect to value in controls), a value very close to that 
observed in patients suffering from sTBI (Signoretti et al., 2010). In both these athletes, the 
second concussive episode produced a prolonged loss of consciousness (< 2 min). Both 
subjects admitted to have experienced, from the beginning up to clinical healing, much more 
severe and prolonged post concussive symptoms (mean value of symptom persistence = 
55.5 days) than those lived following the first impact.  
Figures 3, 4, 5 and 6 illustrate the NAA/Cr ratio recorded in four athletes receiving the 
second concussion between the 2nd and the 3rd MRS.  
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Fig. 1. Change of NAA in doubly concussed athlete. NAA relative to Cr (NAA/Cr ratio) was 
measured by 1H-MRS in voxels properly positioned in the frontal lobes. The arrow indicates 
the approximate time of occurrence of the 2nd concussive episode (see Table 1). Dotted lines 
represent the range interval of the NAA/Cr ratio recorded in control healthy subjects. 
Notwithstanding prohibition to sustain physical activity, patient 1 restarted physical 
training immediately after symptom clearance (3 days after the 1st concussion), when 
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Fig. 2. Change of NAA in doubly concussed athlete. NAA relative to Cr (NAA/Cr ratio) was 
measured by 1H-MRS in voxels properly positioned in the frontal lobes. The arrow indicates 
the approximate time of occurrence of the 2nd concussive episode (see Table 1). Dotted lines 
represent the range interval of the NAA/Cr ratio recorded in control healthy subjects. 
Notwithstanding prohibition to sustain physical activity, patient 2 restarted physical 
training immediately after symptom clearance (4 days after the 1st concussion), when 
NAA/Cr was about 17% below the value recorded in controls. 
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Fig. 1. Change of NAA in doubly concussed athlete. NAA relative to Cr (NAA/Cr ratio) was 
measured by 1H-MRS in voxels properly positioned in the frontal lobes. The arrow indicates 
the approximate time of occurrence of the 2nd concussive episode (see Table 1). Dotted lines 
represent the range interval of the NAA/Cr ratio recorded in control healthy subjects. 
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Fig. 3. Change of NAA in doubly concussed athlete. NAA relative to Cr (NAA/Cr ratio) was 
measured by 1H-MRS in voxels properly positioned in the frontal lobes. The arrow indicates 
the approximate time of occurrence of the 2nd concussive episode (see Table 1). Dotted lines 
represent the range interval of the NAA/Cr ratio recorded in control healthy subjects. 
Notwithstanding prohibition to sustain physical activity, patient 3 restarted physical 
training immediately after symptom clearance (8 days after the 1st concussion), when 
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Fig. 4. Change of NAA in doubly concussed athlete. NAA relative to Cr (NAA/Cr ratio) was 
measured by 1H-MRS in voxels properly positioned in the frontal lobes. The arrow indicates 
the approximate time of occurrence of the 2nd concussive episode (see Table 1). Dotted lines 
represent the range interval of the NAA/Cr ratio recorded in control healthy subjects. 
Notwithstanding prohibition to sustain physical activity, patient 4 restarted physical 
training immediately after symptom clearance (7 days after the 1st concussion), when 
NAA/Cr was about 14% below the value recorded in controls. 
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Fig. 5. Change of NAA in doubly concussed athlete. NAA relative to Cr (NAA/Cr ratio) was 
measured by 1H-MRS in voxels properly positioned in the frontal lobes. The arrow indicates 
the approximate time of occurrence of the 2nd concussive episode (see Table 1). Dotted lines 
represent the range interval of the NAA/Cr ratio recorded in control healthy subjects. 
Notwithstanding prohibition to sustain physical activity, patient 5 restarted physical 
training immediately after symptom clearance (8 days after the 1st concussion), when 
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Fig. 6. Change of NAA in doubly concussed athlete. NAA relative to Cr (NAA/Cr ratio) was 
measured by 1H-MRS in voxels properly positioned in the frontal lobes. The arrow indicates 
the approximate time of occurrence of the 2nd concussive episode (see Table 1). Dotted lines 
represent the range interval of the NAA/Cr ratio recorded in control healthy subjects. 
Notwithstanding prohibition to sustain physical activity, patient 6 restarted physical 
training immediately after symptom clearance (5 days after the 1st concussion), when 
NAA/Cr was about 16% below the value recorded in controls. 
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At the time of the 2nd MRS, the four patients showed a recovery of NAA and affirmed to be 
symptomless. Both these phenomena allowed athletes to violate the ban on sports so that 
they started practicing their respective disciplines before completion of brain metabolic 
recovery. At 22 days post-impact, we found in these subjects a significant further decline in 
the NAA/Cr ratio, the value of which was even lower than that recorded 3 days post-injury 
(Figures 3, 4, 5, 6 and 8). During the clinical consult, the four patients declared to have 
suffered from a second concussion (mean interval between the two concussions = 18.5 ± 2.1 
days), interpreted on the field of minor relevance but being of surprisingly remarkable 
clinical severity and duration (mean value of symptom persistence = 34.0 days). It is worth 
underlining that in patient 5 completion of brain metabolic recovery was observed at the 
time of the 6th MRS, i.e. 39 days after the 2nd insult and 15 days after symptom 
disappearance.  
4. Discussion 
According to our opinion, data reported in the present study strongly demonstrate that the 
occurrence of repeat concussion produced a significant increase in the time of recovery of 
brain metabolism (as evaluated in terms of NAA/Cr variations determined by 1H-MRS), 
coupled to the appearance of clinical symptoms with increased severity and duration with 
those reported after a single concussive event (Vagnozzi et al., 2008, 2010). In sports 
medicine, this finding implies that it should be mandatory for concussed athletes to observe 
a period of restriction from physical activity until the process of normalization of brain 
metabolism is completed. Since also in these subjects the clearance of post-concussive 
clinical symptoms took place much before than the return of NAA to physiological values  
(Vagnozzi et al., 2008, 2010) it is our advise that monitoring alterations in the biochemistry 
of post-concussed neurons (NAA changes) by  1H-MRS should be considered a fundamental 
tool to evaluate recovery of post concussed athletes for their safe return to play.  
Supported by abundant literature, it is nowadays worldwide accepted that concussion 
triggers a cascade of molecular events that transiently alter the biochemistry of the post-
concussed neurons, with particular involvement for mitochondrial-dependent energy 
metabolism. This condition prompted Hovda and coll. to hypothesize the insurgence of a 
period of brain vulnerability during which a second concussive event may have fatal 
consequences for the neuronal vitality (Giza & Hovda, 2001; Hovda et al., 1993). Our 
previous researches in rats undergoing repeat mTBI, using the closed-head weight-drop 
model of diffuse injury set up by Marmarou and coll. (Foda & Marmarou 1994; Marmarou et 
al., 1994), clearly demonstrated that, depending on the time interval between injuries, two 
repeat concussions may cause metabolic cerebral irreversible alterations typical of single 
sTBI (3 days between concussions) (Tavazzi et al., 2007; Vagnozzi et al., 2007), i.e. 
cumulative effect of the two concussions. If the two repeat injuries were viceversa spaced by 
5 days the changes of brain metabolism are fully reversible and comparable to those 
recorded in single mTBI, i.e. the two concussions acted as separate events (Tavazzi et al.,  
2007; Vagnozzi et al., 2007). This strongly indicates the existence of a window of metabolic 
brain vulnerability during which neurons, when receiving a second insult of even very 
modest entity, can suffer from dramatic impairment of cell functions. This phenomenon, can 
be explained by hypothesizing that neurons, after the first mTBI, are deeply involved in the 
energy-consuming processes to restore cell homeostasis, therefore rendering cells more 
susceptible to injuries of even very modest entity. The duration for the completion of these  
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“repairing processes” corresponds to the window of brain vulnerability. In a pilot study in a 
restricted group of concussed athletes, we first monitored the time course of NAA decrease 
and recovery following concussion, thereby demonstrating the occurrence of the metabolic 
brain vulnerability status after an mTBI also in human beings (Vagnozzi et al., 2008). In the 
same study, we also described 2 cases of doubly concussed athletes who received a second 
impact during the period of energy metabolism recovery and who therefore underwent to a 
15 days delay in complete NAA restoration (Vagnozzi et al., 2008). Recently, we provided 
unquestionable evidences indicating that the determination of NAA by  1H-MRS is a reliable 
tool with which monitoring post-concussive periods in athletes. In this last study we 
demonstrated that results of the MRS analyses were independent on the MR apparatus 
(different MR suppliers), the field strength adopted (1.5 or 3.0 T) and the mode of spectra 
acquisition (Vagnozzi  et al., 2010). Furthermore, the number of athletes enrolled (n = 40) 
and serially analyzed allowed to demonstrate that it is possible to determine the period of 
metabolic brain vulnerability for a safe return of athletes to play. Recently, different research 
groups confirmed our findings and successfully applied NAA evaluation by MRS to 
monitor the metabolic recovery of mildly-injured patients (Henry, 2010; Gasparovic et al., 
2009; Sarmento et al., 2009; Yeo et al., 2011), thereby strongly corroborating the concept that 
methods capable of investigating at the molecular level are of great clinical relevance in the 
surveillance of post-concussed patients. On the other hand, the vast data in literature 
obtained in different models of mTBI (Barkhoudarian et al, 2011; Signoretti et al., 2010) 
clearly showed that post-concussive brain modifications are caused by a cascade of 
molecular events involving cerebral metabolism and, more in general, cerebral 
biochemistry. At present, in addition to the subjective indication of the patient, cognitive 
neuropsychological tests are widely used to assess the condition of mildly injured athletes. 
This type of monitoring has been considered one of the cornerstones for return to play after 
a concussion (Maroon et al, 2000; McClincy et al., 2006; McCrea et al., 2003; Schatz et al., 
2006), even though concerns have been raised, including the question of when they should 
be used in the management and assessment of concussion (Collie et al., 2006; Gosselin et al., 
2006; Randolph et al., 2005). Furthermore, none of the currently available diagnostic tests 
(Broglio et al., 2007; McCrea et al., 2003; Schatz et al., 2006; Register-Mihalik et al., 2008) are 
capable of measuring the unique, transient and potentially dangerous state of metabolic 
vulnerability experienced by the post-concussed brain tissue. Therefore, the need to find 
objective parameters to evaluate the extent of and recovery from concussion-induced 
cerebral damage has been stressed recently (Cantu, 2000). Our previous studies (Tavazzi et 
al., 2005; Vagnozzi et al., 2005, 2008, 2010) and the present research demonstrate that 1H-
MRS is capable of detecting significant neurochemical changes present in the injured brain 
despite the normal appearance of neuroimaging, absence of symptoms and normal 
neurological examination, i.e. we validated the use of a rapid, objective and sensitive 
diagnostic tool with which evaluating normalization of cerebral metabolism for a safe return 
of concussed athletes to play outside the window of metabolic brain vulnerability. 
Therefore, restraint from physical activity following concussion should be mandatory to 
avoid the risk of insurgence of SIS, with SIS being interpreted as an acute, fatal disease 
caused by uncontrolled brain swelling (Bowen, 2003; Cantu, 1998; Cobb & Battin, 2004; 
Logan et al., 2001; Mori et al., 2006; Saunders & Harbaugh, 2006). Results of the present 
study suggest that the concept of SIS might certainly be revised and could be broaden to any 
case of repeat concussion in which, after the second injury, a clear disproportion among the 
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entity of the concussive event, the post-concussive clinical symptoms and the cerebral 
metabolic recovery indeed exists. This restricted cohort of doubly concussed athletes could 
be included within the aforementioned definition of SIS. In fact, notwithstanding all athletes 
received two repeat concussions (for each athlete, both events were characterized by the 
same acute symptoms with no change in GCS and negative MRI), clinical symptoms after 
the 2nd impact lasted much longer than the 1st one, satisfying our first proposed criterium to 
diagnose SIS. Moreover, in our previous studies we showed that the time to return the 
NAA/Cr to normal cerebral levels in singly concussed athletes is within 30 days post-
impact. In the present cohort of doubly concussed athletes, the time required to measure 
values of the NAA/Cr ratio similar to those recorded in controls after the second concussion 
was of 81.2 ± 24.4 days. This much  longer time for NAA recovery satisfy the second 
criterium we proposed to diagnose SIS. Independently on the inclusion in the SIS category, 
these athletes definitely showed a prolonged time of clearance of clinical symptoms and 
brain metabolism normalization. In our opinion, monitoring of brain metabolism in singly 
concussed athletes should drive the timetable of return to physical activity, especially for 
those practicing sports at risk of recurrent concussions (American football, boxe, ice hockey, 
rugby, alpine skiing, martial arts, soccer, etc.), according to this possible steps: 1) if upon 
first examination, NAA is below the value of healthy controls, i.e. altered energy 
metabolism, the athlete should rest with no physical activity (approximate post-concussion 
time interval of 1–15 days); 2) if, at the second examination, MRS suggests an initiation of 
the process of NAA recovery (i.e. quasi-normal energy metabolism), it is advisable that the 
athlete begin physical activity of increasing intensity (approximate post-concussion time 
interval of 16–22 days); 3) if, at the third MRS, progressive NAA replenishment is observed 
(i.e. normalized energy metabolism), then physical activity might be intensified to a ‘return 
to play’ level of conditions (approximate post-concussion time interval of 23–30 days); 4) if, 
at the fourth MRS, normal NAA, i.e. normal energy metabolism, has been determined, it is 
suitable that athletes be permitted to return to play (approximate post-concussion time 
interval 30 days). Such a timetable could be adapted to any post-concussed, non-athlete 
patient and translated into recommendations differing on personal lifestyle during the 
recovery of NAA post-concussion: 1) NAA below control values (prolonged altered energy 
metabolism) would recommend rest, with no physical activity and sedentary lifestyle 
(approximate post-concussion time interval of 1–15 days); 2) signs of initiation of NAA 
recovery (i.e. quasi-normal energy metabolism) would suggest normal working activity and 
moderate physical activity (approximate post-concussion time interval of 16–22 days); 3) 
normal NAA at MRS (i.e. normal energy metabolism re-established) would implicate return 
to full normal lifestyle (approximate post-concussion time interval of 23–30 days). Results of 
this and of previous studies (Vagnozzi et al., 2008, 2010) indicated that the kinetic of NAA 
recovery, following a single concussion,  is non-linear, with a very slow phase of about 15-20 
days and a second faster period of 10-15 days. We have recently demonstrated that this non-
linear time-course of post-traumatic NAA recovery may be due to the cerebral energy 
imbalance, assessed by high-energy phosphate quantification (ATP, ADP, AMP, etc.), 
caused mainly by mitochondrial malfunctioning, as indicated by altered mitochondrial 
phosphorylating capacity (measured by the ATP/ADP ratio) (Signoretti et al., 2010; Tavazzi 
et al., 2005). Under these conditions, the remarkable decrease in cerebral NAA, which 
mirrors the changes in brain ATP, may possibly be attributed to the general energy 
depression consequent to impaired mitochondrial functions (Lifshitz et al., 2003; Robertson 
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et al., 2006). Incorporating the data obtained in preclinical studies on mTBI, demonstrating 
decreased ATP concentration for a given period of time post-injury (Tavazzi et al. 2007; 
Vagnozzi et al., 2005, 2007), it is conceivable that the process of NAA normalization is 
markedly hindered by an imbalance of neuronal energy metabolism induced by concussion.  
In fact, NAA synthesis necessarily requires the availability and the energy of hydrolysis of 
acetyl-CoA (∆G = -31.2 kJ/mol), working as the acetyl group and energy donor in the 
acetylation reaction of aspartate catalyzed by ANAT. It is fundamental to understand that 
when acetyl-CoA is used for NAA synthesis there is an indirect high energy cost to the cell. 
In fact, since in this case acetyl -CoA will not enter the citric acid cycle (Krebs’ cycle) there 
will be a decrease in the production of reducing equivalents (3 NADH and 1 FADH2) as the 
fuel for the electron transport chain. Since the oxidative phosphorylation is 
stoichiometrically coupled to the amount of electron transferred to molecular oxygen by the 
electron transport chain, the final result will be a net loss of 11 ATP molecules for each NAA 
molecule newly synthesized. Experimental studies (Signoretti et al., 2010) have shown that 
spontaneous re-synthesis of NAA occurs only after recovery of mitochondrial dysfunction 
with consequential return to normal ATP levels; therefore, it appears possible that 
normalization of NAA concentrations may occur only after the cerebral energy state has 
fully recovered. The slow normalization of the cell energetic could also be attributed to the 
drastic decrement of the nicotinic coenzyme pool that was observed in rat models of graded 
injury. In fact, previous studies (Tavazzi et al., 2005; Vagnozzi et al., 2007) showed the net 
diminution of the nicotinic coenzyme pool (NAD+ + NADH and NADP+ + NADPH) that 
certainly plays a pivotal role in the final result of general depression of cell energy 
metabolism. This depletion jeopardizes either the reducing equivalent supply to 
mitochondrial oxidative metabolism, or the catalytic activity of dehydrogenase-mediated 
oxidoreductive reactions. To date, possible mechanisms for this phenomenon are the 
hydroxyl radical-induced hydrolysis of the N-glycosidic bond of the reduced forms of the 
nicotinic coenzymes NADH and NADPH and the activation of the enzyme NAD-
glycohydrolase (Lautier et al., 1994). Both mechanisms cause the hydrolysis of these 
coenzymes and give rise to the same end products, i.e., ADP-ribose(P) and nicotinamide. 
Independently of the predominant mechanism, the final result is certainly deleterious for 
the correct functioning of cell metabolism. Finally, the augmentation of poly-ADP 
ribosylation reactions through the activation of the enzyme poly-ADP ribose polymerase 
(Du et al., 2003; Nanavaty et al., 2002; Pacher et al., 2002), has been demonstrated to trigger 
the mechanisms of apoptotic induction (Yu et al., 2002). The overall result should be to 
significantly contribute to the decrease in the rate of NAA recovery during the time period 
close to the head insult, when cells are more “metabolically vulnerable” and physical 
restriction is mandatory to avoid catastrophic consequences. 
5. Conclusion 
This and previous data (Vagnozzi et al., 2008, 2010) demonstrated that this process can be 
non-invasively followed in vivo by 1H-MRS giving clinically relevant information 
concerning the duration of the window of metabolic brain vulnerability. This time interval 
should be characterized by restriction of physical activity to avoid the occurrence of second 
concussion with unpredictable consequences, from the delay in cerebral metabolic 
normalization (such a delay being not yet defined in duration) to the onset of uncontrolled 
brain edema (i.e., the current definition of SIS). In our opinion, we again provided the 
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recovery, following a single concussion,  is non-linear, with a very slow phase of about 15-20 
days and a second faster period of 10-15 days. We have recently demonstrated that this non-
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concussion with unpredictable consequences, from the delay in cerebral metabolic 
normalization (such a delay being not yet defined in duration) to the onset of uncontrolled 
brain edema (i.e., the current definition of SIS). In our opinion, we again provided the 
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experimental evidence in the dramatic discrepancy between the time required for the 
clearance of post-concussive clinical symptoms and the time needed to restore concussion-
perturbed brain metabolism. Since 1H-MRS is the analytical method of choice and NAA the 
biochemical parameter indirectly representing the brain energy metabolism, it should be 
strongly suggest ed to determine healing of post-concussed athletes and patients using this 
potent diagnostic tool. In light of the consequences of a second concussive event during the 
window of brain vulnerability, potentially catastrophic, it should be strongly recommended 
that the restriction of physical activity is mandatory and that the removal of this restriction 
is submitted to the full recovery of the NAA physiological level. Due to the potential 
catastrophic consequences of repeat concussions and the need to have clear diagnostic tools 
and protocols to study recovery of the post-concussed brain it is fundamental to undertake 
further studies to better understand these topics. 
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